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Abstract 
The overall objective of this study is to promote the human rights to health of 
Nigerian women to have access essential medicines, to enhance their human 
capabilities for human development. This thesis argues for an improvement of 
women’s access to medicines within the context of patent law and rights in the 
international IP regime of the Trade Related Aspect of Intellectual Property 
(TRIPS) Agreement and Nigeria’s national patent system.  
Towards this goal, the thesis makes the point that patent law and its exclusive 
rights, both the TRIPS Agreement and national law of Nigeria, do not exist in a 
social welfare vacuum. The legal text of patent law, which confers rights on 
inventors when enforced, translates to many other things outside the sphere of 
property rights; indeed, it can be a matter of life and death. It is argued in this 
regard that patent right could, in effect, interfere with access to medicines and 
therefore, the right to health and prospects for human development. The thesis 
therefore argues that, in the construction, interpretation and enforcement of 
patent law in Nigeria, there is a need to take into consideration its impact on 
public health.  
It is against this backdrop that the research assesses the legal framework of 
pharmaceutical patents and the implications for women’s access to medicines, 
from a right to health and human development perspective. This 
interdisciplinary study is with a view to suggesting ways in which Nigeria’s 
patent system can be more human development and human rights friendly in 
the interest of public health, particularly, the use of the TRIPS flexibilities to 
enhance access to life-saving medicines in Nigeria.  
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Since Nigeria as a member of the World Trade Organisation, is bound by its 
treaty obligation to adopt the provisions of the TRIPS Agreement, the thesis 
makes proposals for ways in which the Nigerian government and law-makers, 
can adapt the patent rules and the flexibilities to suit development objectives 
and promote public health within the benchmark allowed in TRIPS. 
In this respect, this thesis critically investigates the practical implications of the 
available flexibilities and options in the TRIPS Agreement that can be used to 
address the effects of patents on access to medicines. While this thesis 
concedes the view that the hindrances to accessibility of essential drugs in 
Nigeria are multi-faceted and demand a multi-dimensional approach for a 
lasting solution, it is specifically argued that the TRIPS flexibilities are significant 
means for addressing the challenges of affordable access to important health 
treatments within the context of patent law.  However, it is emphasised that 
utilising the flexibilities will require that Nigeria’s patent system is strategically 
designed to take full advantage of the available safeguards and options. To this 
end, this study recommends ways to incorporate the flexibilities to enhance 
access to medicines in Nigeria while avoiding the technical and regulatory 
pitfalls that have trailed the enforcement of the flexibilities by other developing 
countries. 
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ENHANCING WOMEN’S ACCESS TO ESSENTIAL 
MEDICINES IN NIGERIA: 
A Reconsideration of the Patent Framework of the TRIPS 
Agreement to Improve Access to Medicines, as a Right to 
Health and a Means to Human Development in Nigeria  
1. Introduction 
Health is Wealth1 
If we did not have a patent system it would be irresponsible, on the basis of our 
present knowledge of its economic consequences, to recommend instituting one. 
But since we have had a patent system for a long time, it would be irresponsible, 
on the basis of our present knowledge, to recommend abolishing it.2 
1.1 Objective and Study Focus 
The objective of this study is to promote the right to health of Nigerian women to 
have access to life-saving medicines in order to enhance their capabilities for 
human development including leading long and healthy lives. In this respect, 
this thesis argues for women’s access to essential pharmaceuticals at an 
affordable cost within the scope of patent law and rights.  
To achieve this vision, this thesis appraises the public health implications of the 
patent protection of pharmaceuticals in the international intellectual property (IP) 
regime of the Agreement on Trade-Related Aspects of Intellectual Property 
Rights (TRIPS Agreement), and the existing flexibilities, with particular 
emphasis on the national patent system in Nigeria. This thesis argues that the 
                                                          
1 Anonymous. 
2 Fritz Machlup, An Economic Review of the Patent System: Study of the Subcommittee on Patents, Trademarks, and Copyrights of 
the Committee on the Judiciary, United States Senate, 85th Congress, Second Session, Study No 15 (U.S. Government Printing 
Office 1958) 80.  
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flexibilities in TRIPS provide a significant avenue for ensuring that the right to 
health is not compromised by the patent laws in Nigeria. Therefore, ways in 
which Nigeria can effectively utilise the legal exceptions, drawing on analysis 
and examples from other countries will be recommended.  
 
1.1.1 Why Women?  
In conducting the study in this thesis, the argument for increased access to 
medicines in Nigeria is considered within the socio-economic, traditional and 
cultural challenges that Nigerian women encounter. While it is acknowledged 
that the problem of access to medicines is one that affects everyone — males, 
females and children, particularly the poor in developing countries, — the 
central focus of this study is upon women in Nigeria.3 This is because women, 
especially those in developing countries face diverse social, economic and 
cultural challenges that often make access to healthcare and medicines 
particularly difficult for them.4 
The particular focus on women’s health and access to essential medicinal 
treatments in this thesis is not to say that men’s health is not as important as 
women’s health. In addition, the focus on women is not based solely on the fact 
that women have special needs over and above men’s but, because some fatal 
illnesses that affect women in many developing countries and their inabilities to 
access health treatments can also be traced to their subordinated social and 
                                                          
3 The word ‘women’ in this study signifies the female gender. The scope is wide enough to take into account young girls, however, 
the emphasis is on women of child bearing age. 
4 Gita Sen, Piroska Östlin and Asha George, Unequal, Unfair, Ineffective and Inefficient Gender Inequity in Health: Why It Exists and 
How We Can Change It: Final Report to the WHO Commission on Social Determinants of Health (World Health Organization 2007) 
119; Amrita Namasivayam and others, 'The Role of Gender Inequities in Women's Access to Reproductive Health Care: A 
Population-Level Study of Namibia, Kenya, Nepal, and India' (2012) 4 International Journal of Women's Health 351, 352-353; Sarah 
Gammage and others, 'Trade Impact Review: Framework for Gender Assessments of Trade and Investment Agreements' (The 
Coalition for Women’s Economic Development and Global Equality (Women’s Edge) 2002) iv-v; Durrenda Nash Ojanuga and Cathy 
Gilbert, 'Women's Access to Health Care in Developing Countries' (1992) 35 Social Science & Medicine 613, 613-617. 
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economic situation, gender-related barriers and biological predispositions.5 
Therefore, understanding the health-related experiences and social positions of 
men and women is fundamental to analysing the various ways which women 
may experience problems of accessing medicines within the context of trade 
rules in a different and sometimes more severe manner.6 However, this thesis 
does not focus solely on the socio-economic and cultural barriers women face 
in accessing medicines. Instead, the thesis advocates for a consideration of the 
ways which patent rights could also impact on their access, in the light of their 
social, economic and cultural circumstances.  
 In the assessment of access to medicines, discussions have focused on the 
disparity between developing and developed countries. Within states, however, 
social inequalities and discrimination on grounds of gender can further 
exacerbate the problem. Scholars have emphasised the social and cultural 
nature of the differences between men and women, particularly, their unequal 
power and status in society that should be included in health and development 
debates.7 Gehl Sampath, for example, argues that an adequate response to 
women’s health in the area of treatments should be sensitive to the various 
dimensions of the access problem.8  
The analysis in this thesis is relevant because it demonstrates the constituent 
reality of the access to medicine phenomenon, and exposes the issues taken 
for granted in examining the effects of patent rights on medicines, as well as 
                                                          
5 ibid; Cristina Puentes-Markides, ‘Women and Access to Health Care’ (1992) 35 Social Science and Medicine 619, 619-626; 
Jennifer G Cooke and Farha Tahir, 'Maternal Health in Nigeria: With Leadership, Progress is Possible’ (Center for Strategic and 
International Studies 2013) 4-5. 
6 Padmashree Gehl Sampath, ‘Gender and the Agreement on Trade Related Aspects of Intellectual Property Rights: Exploring Some 
Interlinkages’ in Anh-Nga Tran-Nguyen, Americo Beviglia Zampetti (eds), Trade and Gender: Opportunities and Challenges for 
Developing Countries (United Nations Publications 2004) 255-256. 
7 Gita Sen, Asha George and Piroska Östlin, 'Engendering Health Equality: A Review of Research and Policy' in Gita Sen, Asha 
George and Piroska Östlin, Engendering International Health: The Challenge of Equity (MIT Press 2002) 1-11; Sally Macintyre, Kate 
Hunt and Helen Sweeting, 'Gender Differences in Health: Are Things Really as Simple as They Seem?' in Michael Bury and Jonathan 
Gabe (eds), The Sociology of Health and Illness: A Reader (Routledge 2013) 161-170; Sarah Gammage and others (n 4) 1-12. 
8 Sampath (n 6) 258.  
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development at global and national levels. Thus this thesis, from a patent 
standpoint, will focus on and analyse the challenges that women face in 
accessing healthcare and medicines in order to make a case for their increased 
access, as a means of realising their rights to health in Nigeria.  
This thesis, however, makes a case for women’s rights to health, not only for 
their development but also for that of the Nigerian society as a whole. Hence 
the recommendations have wider implications for everyone in Nigeria—women, 
children and men. In the same way, although this study focuses on women, the 
TRIPS Agreement and Nigeria’s patent system, policies and practices, the 
result of the study can have a wider effect on the global IP framework and 
policy; hence other developing countries can draw on its recommendations. 
 
1.1.2 Study Focus on Nigeria 
It is appropriate to point out the rationale for the focus of this study on Nigeria.  
Patent rights are essentially national rights; the enforcement and interpretation 
are territorial.9 Thus, the barriers that pharmaceutical patents present to 
accessing medicines are largely jurisdictional.10 Also, though the international IP 
laws in TRIPS expanded the protection of intellectual property rights (IPRs) on a 
global scale, their impact and enforcement lie within the national jurisdiction of 
members of the World Trade Organization (WTO). This study will, therefore, 
focus on Nigeria as a developing country, although references and examples 
are frequently drawn from other developing and developed countries.  
According to the World Bank, with a population of an estimated 170 million 
people, Nigeria is the most populous country in Africa.11 In addition, Nigeria as a 
                                                          
9 However, in international trade matters, Members of the WTO can bring an action to the dispute settlement body (DSB) when 
one Member is alleged to have violated their obligations to the WTO. 
10 Although this problem can have a spill-over effect in countries that rely on imported medicines 
11 The World Bank, 'Nigeria: Data' (2015) <http://data.worldbank.org/country/nigeria.> accessed 15 June 2015. 
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country is the one of the richest nations in that continent with an estimated GDP 
of US$522.6 Billion.12 Because of its size, economic development and global 
participation, the country plays a significant role in influencing progress and 
development within the whole West Africa region and, indeed, the African 
continent.13  
The healthcare exigencies and the need for medicines in Nigeria also provide a 
contextual basis to argue for access to drugs as a right to health within the 
context of patent law and rights, and a broader interpretation of patent 
exceptions and TRIPS-related flexibilities to promote this access. Moreover, the 
country also offers a social context that is necessary for the gendered aspect of 
this study, being largely a patriarchal society. For instance, one scholar 
observes that the structure of social relations is based on the ‘system of social 
stratification and differentiation on the basis of sex, which provides material 
advantages to males while simultaneously placing severe constraints on the 
roles and activities of females.’14  
Furthermore, by adopting Nigeria as the case study, the thesis is approached 
from the basis of both personal and professional knowledge gathered from the 
experience of living and working there. Also, personal knowledge of the 
mitigating factors to women’s development resulting from their lack of access to 
quality health care has been garnered from years of living in Nigeria. 
In order to accomplish the foregoing study objective, the thesis considers 
Nigerian’s international patent law obligations and argues that in conforming to 
                                                          
12 ibid. As of 2015. 
13 For example, Nigeria was one of the ten developing countries that initially objected to the proposal presented by the US and 
some other developed countries to incorporate matters relating to IP, particularly patents, into the framework of GATT and the 
WTO. See Duncan N Matthews, 'Trade-Related Aspects of Intellectual Property Rights: Will the Uruguay Round Consensus Hold?' 
(2002) CSGR Working Paper No. 99/02, 9. Available at  
<http://dx.doi.org/10.2139/ssrn.319545> accessed 17 May 2015. 
14 Godiya Allanana Makama, ‘Patriarchy and Gender Inequality in Nigeria: The Way Forward' (2013) 9 European Scientific Journal 
115, 116.  
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the globalised IP standards in the TRIPS Agreement, Nigerian patent law 
should be designed to serve the country’s national health objectives. This study 
also makes proposals for ways of addressing the issues that have arisen in the 
context of the patent system and access to medicine by ensuring that the 
Nigerian government, in becoming TRIPS compliant, makes full use of all the 
legal exceptions and health-related options, including the flexibilities in the 
TRIPS Agreement in a development-oriented manner. Significantly, therefore, 
the result and recommendations of this research are expected to have policy 
implications in Nigeria. 
 
1.2  Methodological Framework and Approach 
This thesis adopts a doctrinal methodology to examine, analyse and evaluate 
the issues that have arisen in the context of patent protection of 
pharmaceuticals and its effect on women’s human right to access medicines 
and, consequently, their human development. To this end, this study employs a 
doctrinal approach to analyse the effect and role of patent law, particularly 
within the context of pharmaceuticals, health and development. In doctrinal 
research, the essential features of legal rules and case law are identified and 
critically examined, and the relevant aspects are synthesised to explain areas of 
difficulty, 'establish an arguably correct and complete statement of the law on 
the matter at hand' and predict areas for future development.15 The intention in 
this thesis is to gain an insight into the research questions, examine the 
significance of the law and analyse the issues that have arisen in respect of the 
international and national legal protection of pharmaceutical patents and the 
problem of access to medicines.  
                                                          
15 Terry Hutchinson, 'Doctrinal Research: Researching the Jury' in Dawn Watkins and Mandy Burton (eds), Research Methods in 
Law (Routledge 2013) 9-10.  
21 
 
The advantage of a doctrinal approach is that it provides a critical exposition of 
legal rules, norms, case law and precedent; it traces the discovery and 
development of the law and delineates the goals and objectives of the law.16 
That is, it centres around the question 'what is the law' and clarifies the nature 
of the law.17 This thesis analyses, compares and evaluates the legal regime of 
patents, including the exceptions, as contained in the TRIPS Agreement, 
Nigerian statutes, and also explores case law, court rules and legislative Draft 
Bills. The research also relies on the official text of international laws, 
conventions and international human rights instruments. Since the study is also 
based on a multilateral international agreement (the TRIPS Agreement), the 
thesis makes reference to the national legal statutes operating in other WTO 
members including India,18 the United Kingdom (UK) and the United States 
(US), and regional and national laws of other countries where the law and 
jurisprudence are more developed. UK laws and decided cases are particularly 
relevant to this study since Nigeria’s legal system, including patent law, is based 
on the English legal system and its customary traditions.19 In addition, the study 
takes into account the judicial decisions by the WTO Dispute Settlement Body.  
                                                          
16 ibid; Terry Hutchinson, 'The Doctrinal Method: Incorporating Interdisciplinary Methods In Reforming The Law' (2015) 3 Erasmus 
Law Review 130-138, 130. 
17 Monirul Azam, Intellectual Property And Public Health In The Developing World (Open Book Publishers 2016). 
18 India’s legal jurisprudence, judicial interpretations and implementation of the provisions of the TRIPS Agreement is particularly 
useful in suggesting ways that Nigeria can develop its own patent system as well as interpret and implement the patent law within 
the context of public interest and access to medicines. This is justified on the grounds of the similarity in legal history and socio-
economic environment as the two countries are both products of British colonial administration. The legal systems and patent 
laws of the two countries, therefore, have colonial origins in English jurisprudence. Coincidentally, they both enacted national 
Patents Acts in 1970. The two developing nations are members of the WTO. Equally, both countries govern in similar democratic 
political climates, face comparable HIV/AIDS and other health challenges and are inundated with development and poverty 
challenges. However, India has proactively amended its patent laws in accordance with the TRIPS Agreement’s IP standards and 
made important exceptions for the public interest whist doing so. The government and third parties have effectively utilised the 
flexibilities for public health purposes and the courts have elaborated on the importance of interpreting patent law in favour of 
public health, rights to health and access to medicines.  
19 This is by virtue of colonisation and the transplantation of the English legal system to Nigeria. 
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While primary sources provide the basis for the study, secondary sources such 
as law reports, scholarly analysis and empirical studies, books, journals, policy 
documents and reports, also provide rich sources of information and support.  
This research extends its focus beyond legal sources. The approach adopted is 
to consider the relationship of the law to other disciplines where relevant to the 
arguments including literature from economics, public health, gender studies, 
sociology, philosophy, and development theories.  In particular the study draws 
inspiration from the capabilities and human development principles20 to justify a 
broad and liberal interpretation of patent law and its legal exceptions in favour of 
access to essential drugs. This thesis also considers the effect of the law in a 
practical context, beyond the scope of the legal rules. Thus the thesis relies on 
research, information and literature in development and human rights sources, 
official reports of United Nations, human rights and other health organisations, 
healthcare laws and policies, writing and empirical research of scholars in the 
field of human development, gender/feminist studies, and international law.  
The choice of conducting a desk-based research is primarily based on the fact 
that most of the information required for this thesis is already contained in 
documented sources and official reports. The official documents and empirical 
research relied on provide reliable, broad and contextualised accounts of the 
problems and issues of access to medicines, particularly affordable drugs, in 
Nigeria. Empirical research has been conducted by the Nigerian Ministry of 
Health, World Health Organization, other scholars and international 
organisations which offer a broader approach and more data than I could have 
achieved within the scope of this thesis. The existing studies were conducted on 
                                                          
20 This human development approach relies considerably on the capabilities approach associated with Martha Nussbaum and the 
Nobel Laureate Amartya Sen’s description of development as the expansion of human capabilities and freedoms. 
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a large-scale, covering all the geopolitical zones in the country, and provide a 
representative report of the current state of affairs; they provide invaluable 
resources and insights into the healthcare system in Nigeria, women's state of 
health and the myriad issues that confront their quest to access important 
medical treatments, and its effect on their development priorities from a broader 
perspective. These data also provide statistical support for the implementation, 
enforcement and flexible use of the TRIPS-compliant flexibilities by the Nigerian 
legislative, judicial and executive authorities to address the challenges of 
access within the context of patent law.  
It was the original intention to combine the doctrinal analysis with an empirical 
investigation into the issues of access to medicines in Nigeria, using field 
research, survey instruments and interviews to explore the research questions. 
In particular, I considered conducting empirical research to ascertain the extent 
to which women in Nigeria face the difficulty of accessing medicines vis-à-vis 
patents. However, there were challenges due to the difficulty of conducting 
research in the volatile areas and conflict zones of the northern and middle belt 
regions of Nigeria, the challenge of getting ethics approval for research of this 
nature from the university and the resources that would be required as Nigeria 
is a large country in terms of land mass and is one of the most populated 
countries in Africa. Furthermore, conducting an alternative small scale study in 
few locations would not provide statistically representative data: my thesis could 
not rely on a small scale study to justify the national policy and legislative 
intervention, broad implementation, enforcement and interpretation of patents, 
including the flexibilities, in favour of access to medicine, the rights to health 
and human development, as such a finding would only reflect the situation in 
some segments of Nigerian communities.  It was therefore decided to rely on 
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existing studies as noted above.  I also encountered significant administrative 
and bureaucratic challenges when I tried to conduct interviews at the 
government ministries, the patents registry and other relevant organisations in 
Nigeria.21  
Notwithstanding, this research project is significantly doctrinal, critically 
appraising the law in a particular context and produces recommendations that 
are expected to have policy and legislative implications in Nigeria. 
 
1.3 Hypothesis / Theoretical Assumptions 
The fundamental premise of this research is that the patent law, rights and 
international IP system in the TRIPS Agreement and Nigeria should not be a 
hindrance to accessing important lifesaving medicines; rather, that the law and 
IP system can play a more active role in encouraging access to medicines in 
Nigeria and other developing countries. This thesis, therefore, hypothesises that 
within the patent system lie challenges and solutions to the problems of access 
to important lifesaving medicines. Indeed, it is acknowledged that patents can 
be tools for the enhancement of societal wellbeing and progress; however, 
unless the formulation, enforcement and interpretation of patents, the regulatory 
framework and legal exceptions are properly designed to take into account 
basic human considerations such as health, the adverse cost of patents will 
                                                          
21 I had frustrating encounters when I tried to carry out interviews in Nigeria. I visited Nigeria on three different occasions to 
conduct interviews (in 2013, 2014 and 2015). The purpose of the interviews was to elicit information on a broad range of 
questions such as the registration and administration of pharmaceutical patents, state of the ratification process for the 
implementation of the TRIPS Agreement in Nigeria administration, the reasons for the inadequate implementation of the 
flexibilities into the patent system and many others issues pertinent to the objective of this thesis. Many government officials 
were unwilling to grant interviews or were unavailable to grant the interviews. Some directed me to other government 
departments or ministries as the appropriate authorities to entertain my questions. The officials in the latter ministries redirected 
me back to the earlier visited ministries. In other instance, the appropriate authority to entertain the interview questions 
redirected me to other staff that were not very useful as interviewees. In the end, I had to rely on secondary sources as I had 
limited time to conduct the study in Nigeria.  
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obscure the benefits. In this respect, the flexibilities can play an important role in 
ensuring that patent rights do not constitute a barrier to the public function of the 
patent system and access to important pharmaceuticals. Nonetheless, the 
provisions of the legal remedies and flexibilities in national laws will not facilitate 
access unless they are effectively utilised and interpreted in the interests of 
public health. So conceived, this analysis proceeds on the hypothesis that an 
appropriately regulated patent system and flexibilities can contribute to, and 
facilitate, women’s access to medicines, leading to human development in 
Nigeria and other developing countries facing a comparable issue of access.  
 
1.4 Intellectual Contribution to Existing Knowledge 
 The impact of pharmaceutical patent rights on access to essential medicines is 
a global issue that has been extensively and widely debated. Much has been 
said on this issue, yet so much is left unsaid in this debate. Even the most 
ardent critics of the effect of patent rules do not fully engage with the social 
context in which these problems exist. For example, current literature on this 
issue offers limited engagement with the circumstances and events that shape 
how certain groups, such as women, encounter additional difficulties in 
accessing essential drugs in particular societies. This research departs from the 
dominant approach to the problems of access to medicines within the context of 
patent protection and offers a different approach to framing the debate. This 
research approaches the issue of access by examining the legal provisions of 
patents and the ways in which the patent protection of pharmaceuticals can 
have particular implications for women’s health and human development. This 
aspect of gender sensitivity, which examines women's social roles, exigencies 
and interests, is positioned to influence the content and enforcement of patents 
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in a way that reflects women's need to attain a good state of health and 
enhance their capacities for sustainable development. This premise is based on 
the assumption that women play a central role in society and the family; 22 
hence their health, welfare and wellbeing are of utmost importance to any 
development-oriented society.  
The thesis also contends that the problem of access to medicines in the context 
of patent raises human rights concerns especially the right to health, life and 
development. In particular, this study focuses on the connection between 
women’s human rights to health and the impact of global patent protection of 
pharmaceutical drugs on health. This study further argues that accessing 
essential medicine is relevant to the realisation of the right to health and pursuit 
of human development because medicine is a major determinant of good health 
and it is a vital element to human wellbeing and survival. 
In addition, most scholarship on the role and purpose of patents in national and 
international TRIPS regimes has focused on the positive effect of IP on 
innovation and economic development.23 It is widely assumed that the 
protection will encourage dissemination of the invention for technological 
progress which would, in turn, facilitate economic growth, and as an incentive 
mechanism, encourage additional inventions.24 Thus, the focus is on the role 
that the patent rights play in increasing innovation and economic growth rather 
than the distribution of the patented resources and human development benefits 
of patents.  
                                                          
22 OO Okwa, 'Tropical Parasitic Diseases and Women' (2007) 6(4) Annals of African Medicine 157, 157-163.  
23 Denis Borges Barbosa, Margaret Chon and Andrés Moncayo von Hase, 'Slouching Towards Development in International 
Intellectual Property' [2007] Michigan State Law Review 71, 75. (Arguing that the relationship between patents and development 
is often analysed from an economic development perspective and increase in gross national income). See also Kamil Idris, 
Intellectual Property: A Power Tool for Economic Growth (WIPO 2003) 24,134-137. (Arguing that IP is the ‘Cinderella’ or 
precipitator and ‘power tool’ for economic growth and development). 
24 Sigrid Sterckx, 'The Moral Justifiability of Patents' (2006) 13(2) Ethical Perspectives: Journal of the European Ethics Network 249, 
249-265. 
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This thesis contends that the fundamental purpose of the patent system and its 
rules in encouraging innovation is to promote public interest and advance social 
goals. Viewed from this angle, a patent, apart from being a right to an 
intellectual property, is a social instrument for human development. To this end, 
the thesis argues in terms of the social benefits to be derived from patent 
protection. Accordingly, the goal of IP protection is to promote social 
development, human needs and economic progress as per Articles 7 and 8 of 
the TRIPS Agreement. In this thesis, this development outcome is 
conceptualised in terms of building basic human health capabilities. This critical 
evaluation of access to medicines from a sustainable human development 
perspective, helps us to understand the role of patents in enhancing basic living 
standards, people’s quality of life and its far-reaching implications for the 
capability of women to be ‘able to have good health, including reproductive 
health.’25 In this sense, the granting, interpretation and enforcement of private 
intellectual patent rights vis-à-vis access to medicines, policymakers and the 
courts should take note of the social welfare and public interest of society as a 
whole.  
Ultimately, the goal of this study is to promote access to essential medical 
treatments, drugs, and other health commodities that are critical aspects of 
women’s right to health and human development.  
 
1.5 Research Question 
This thesis is motivated by one fundamental question: How can the 
reconsideration of the patent protection of essential medicines from a right to 
                                                          
25 Martha Nussbaum ‘Capabilities And Human Rights’ (1997) 66 Fordham Law Review 273, 287. 
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health perspective enhance women’s access to medicines and contribute to 
their capabilities for human development in Nigeria? 
 Other questions that guide this research are: 
1. How is patent law relevant to the issue of access to medicines? To what 
extent do patents give sufficient market power to introduce and maintain 
high prices? How is the effect of this on access to essential drugs?  
2. To what extent have women's experiences been included within the 
purview of mainstream discourse on access to essential drugs as a 
human rights entitlement? 
3. Do the provisions of human rights to health impose a duty on states to 
ensure that the granting and utilisation of patent rights do not impact 
adversely on public health, particularly access to medicines?  
4. How is the patent system linked to human development? How can the 
human capabilities approach reshape our imagination of the 
development goals of patents and the TRIPS Agreement to contribute to 
human development? 
5. How could the TRIPS flexibilities be interpreted and implemented in such 
a way that guarantees women's right to health and access to medicines 
in Nigeria? 
 
 
 
1.6 Overview of Chapters  
The introductory Chapter of this thesis provides a general overview and context 
in which it is set. This section outlines the focus, hypothesis and objectives of 
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the study. The chapter describes the significance of the study, research 
problems and gap in the literature. The chapter also further identifies the 
preliminary issues in the analysis and general framework of the study.  
Chapter II provides a general overview of the role and function of the patent 
system, with particular focus on the public welfare aspect, to reveal the social 
welfare purpose of patent law. It will further analyse and question underlying 
justifications and assumptions and the purpose of the patent system in both the 
TRIPS Agreement and Nigerian law to reconceptualise the links between 
pharmaceutical patents and access to medicines. 
Chapter III analyses in detail the literature on the effect of pharmaceutical 
patents on access to medicines. In particular, it identifies how patent law can 
affect prices, the cost of medicines and consequently, access. Also, the link to 
the unavailability of pharmaceuticals for diseases predominant in many 
developing countries is identified. The relevance of women’s health in the study 
is also presented. In so doing, the chapter considers the distinct needs, rights 
and experiences of women, particularly Nigerians, with regard to their health. 
The chapter argues for the inclusion of women’s distinct needs in finding a 
solution to the issue of accessing Overview of Chapters medicine in the 
international IP regime and Nigeria’s patent law.  
In Chapter IV, human rights principles and norms provide the underlying basis 
on which this thesis argues for women’s access to medicines. The proposals in 
this chapter set out a framework for a human rights approach to scaling up 
access to medicines in Nigeria and other developing countries. The chapter 
argues that states (particularly Nigeria) have a human rights duty to meet the 
basic healthcare needs of their people, including ensuring that patent rights do 
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not interfere with the accessibility to medicines. This analysis also aims to 
examine how human rights can influence the interpretation and enforcement of 
patents for broader access to medicines. The chapter also evaluates the 
intersection between private pharmaceutical patent rights and women’s rights to 
health. 
Chapter V is devoted to answering the question: what might a human 
development-oriented patent system, which aims to develop basic human 
capabilities to be healthy through access to medicines, look like? 
Fundamentally, how can the human capability approach to development change 
the current perception and approach to patents? Having made a case for the 
consideration of public health in the previous chapters, the research further 
argues for access to medicines by ‘rethinking’ patents as instruments for 
enhancing human capabilities and human development. Conversely, it is 
argued that patents could affect the accessibility to affordable medicines which 
is significant to human development.  
Chapter VI critically evaluates the current implementation status of TRIPS in 
Nigeria. The study principally examines the Nigerian pharmaceutical patents 
legal regime and the practical measures undertaken so far to maximise the 
benefits of TRIPS and its flexibilities. In doing so, it questions the effectiveness 
of the legal health-related solutions offered by the international TRIPS 
Agreement within the context of Nigeria and other developing societies. 
Thereafter, this chapter recommends ways in which the Nigerian government 
can utilise the flexibilities in the TRIPS Agreement to improve access to 
reasonably affordable medicines. 
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Chapter VIII draws some conclusions and recommends the way forward. In so 
doing, the final chapter of the study suggest ways in which Nigeria can promote 
women’s access to new pharmaceuticals and support rights to health and 
development in the context of its patent system, particularly through the 
proactive use of the TRIPS-compliant flexibilities. This chapter further suggests 
several other courses of action for the Nigerian government to adopt in order to 
promote access to medicines and address the public health challenges of its 
citizens.  
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CHAPTER II: EXAMINING PATENTS, THE TRIPS AGREEMENT 
AND NIGERIA’S PATENT SYSTEM FROM A PUBLIC WELFARE 
PERSPECTIVE  
 2.1 Introduction  
Before making a case for Nigerian women’s access to affordable and essential 
medicines within the context of the patent framework, it is pertinent to first 
identify what a patent is, the international and national laws for the protection of 
patents, and the basic underpinnings of the patent system, from a public welfare 
perspective. This study provides a background and context that is essential to 
understanding the key issues and laws that run through this thesis. 
A commonly perceived notion of a patent is that the protection is instrumental to 
promoting innovation, technological advancement and scientific progress for 
public benefit. From a pharmaceutical patent standpoint, a patent is also 
assumed to play an important role in encouraging pharmaceutical R&D, 
technology transfer (TT) and foreign direct investments (FDI) which, in turn, 
facilitate the availability of important medicinal resources to society. These 
assumptions are encapsulated in the theoretical justifications underpinning the 
patent system and the IP rights of inventors. This chapter assesses these 
philosophical supports of patent rights and argues instead for a need to focus 
on the public welfare benefit of having a patent system. This welfare-purpose-
driven approach to patents is to gain a contextual appreciation of the advantage 
that patent law and system offer to society from a user’s point of view. It is 
argued that approaching patents from a public welfare perspective would give 
the policymakers, the courts and other relevant authorities’ in Nigeria greater 
flexibility to formulate, implement and interpret pharmaceutical patents in the 
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interests of the public and also fulfil the objective of enhancing women’s access 
to essential health treatments. 
Since this study focuses on the effects of the international protection of patents 
on access to medicines in the localised setting of Nigeria, the chapter provides 
a descriptive overview of the international framework for patents. The study 
highlights the policy context, scope and objective for the existence and 
protection of patents at international level, specifically, the Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS Agreement). This 
exposition aims to provide a base for the contextual background to the 
subsequent analysis of the relationship between patents, the problem of access 
to medicines and the available health-related flexibilities that can be utilised to 
safeguard public health. 
As the case study for this thesis is primarily focused on Nigeria, this chapter 
critically evaluates the development of the patent system in Nigeria from a 
public interest and welfare perspective. Specifically, in view of a patent’s role in 
encouraging research and development (R&D) and the consequences of 
patents to women’s accessibility to medicines, the issue raised in this chapter is 
whether historically, the western-style patent system in Nigeria was suitably 
structured to enhance domestic technological and scientific growth, 
pharmaceuticals R&D and generally promote the public’s interest. The study 
also examines the reasons for any inadequacy and the current issues with the 
system with respect to public health.  
The argument made here is that the Nigerian patent regime originated as a 
colonial product, thus its regulation of intellectual knowledge and invention was 
shaped by foreign authorities that paid little attention to local contexts, socio-
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economic conditions and the technological state of development.1 This section 
also argues that following independence, Nigeria has relied on this unstructured 
system created during the colonial era, leading to inconsistencies in policy 
articulation, formulation and implementation of patent law, which can have 
significant implications for the accessibility to medicines. 
2.2 Defining Patents  
A patent is a legal protection or government-granted authority that confers its 
owner with certain, limited exclusive rights,2 namely, to exclude others from 
using, making and/or dealing with the patented invention/product without a 
licence or permission of the owner, for a specified limited period of time, within 
the territory it is granted.3 This exclusive and monopoly authority essentially 
permits the inventor to ‘exclude competitors from the marketplace’ and control 
unauthorised access to the patented invention.4 It is this exclusive right given to 
innovators that raises concerns with regards to accessing medicine as will be 
discussed in the next chapter.  
Patents are not granted for every invention. The invention must satisfy the pre-
determined conditions for the grant of a patent right to inventors, which dictate 
                                                          
1 Ikechi Mgbeoji, ‘African Indigenous Knowledge Systems and Patents: Is the Patent System Relevant to the Native Healers of 
Southern Nigeria?’ in Emmanuel K Boon and Luc Hens (eds), Indigenous Knowledge Systems and Sustainable Development: 
Relevance for Africa (Kamla-Raj Enterprises 2007) 78-81. (Stating that the patent system, as imposed on African peoples, was part 
of the colonial project to remodel non-Western peoples and cultures in the image of Europe on the hypothesis that indigenous 
peoples had no pre-existing institutions worthy of respect.) See also G Sipa-Adjah Yankey, International Patents and Technology 
Transfer to Less Developed Countries: The Case of Ghana and Nigeria (Avebury 1987) 98. 
2 Cynthia Ho, Access to Medicine in the Global Economy: International Agreements on Patents and Related Rights (Oxford 
University Press 2011) 17. 
3 Lionel Bently and Brad Sherman, Intellectual Property Law (Oxford University Press 2014) 375; Kieran Comerford, R&D and 
Licensing: Building Value through Intellectual Assets (Elsevier 2007) 97. 
4 Charlotte Waelde and others, Contemporary Intellectual Property: Law and Policy (Oxford University Press 2016) 519. 
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that the inventors or invention address an identifiable problem or provide a new 
and useful solution that is of high inventive quality.5 
To justify the existence of the patent system, it is commonly argued that a 
patent’s exclusivity and monopoly rights will not only encourage innovation and 
reward inventors; it also facilitates the availability of the invention and also spurs 
others to further invent around the disclosed invention.6 And in the international 
WTO trade platform, patents as well as other IPRs, would promote economic 
and social development, rapid technology transfer trade and the attraction of 
FDI.7 
However, among IP specialists, industry specialists and commentators, the 
widely unsubstantiated view that a patent is the ideal mechanism for 
encouraging innovation and technological development, is not universally 
accepted, especially considering the underlying adverse implication for 
competitions, incremental research and development (R&D), public health and 
consequently, the enhancement of human development.8  
2.3 Theoretical Justifications of the Patent System 
 2.3.1 The Natural Law and Labour Theory 
The natural law theory is rooted in the recognition of the inherent natural rights 
of inventors to their ideas and the products of their mental and intellectual 
                                                          
5 Specifically, these essential thresholds for the granting of patents are: ‘novelty’ (the invention must be new); utility or industrial 
applicability (i.e. it must be useful or have industrial relevance); and be an inventive step or non-obvious (above the current or 
existing state of art or science). John H Barton, 'Non-Obviousness' (2003) 43(3) IDEA 475, 476. 
6 See more at Waelde and others (n 4) 371; Robert P Merges, Justifying Intellectual Property (Harvard University Press 2011) 31-
102; Christine Greenhalgh and Mark Rogers, Innovation, Intellectual Property, and Economic Growth (Princeton University Press 
2010) 32-39. 
(It is worth noting that this thesis may not do justice to the entire debate considering the scope and space limit of this thesis.)  
7 Laurence Helfer, ‘Regime Shifting: The TRIPS Agreement and New Dynamics of International Intellectual Property Law Making’ 
(2004) 29(1) Yale Journal of International Law 1, 2-3. See also the Preamble of the Trade-Related Aspects of Intellectual Property 
Rights 1994 (Annex 1C of the Marrakesh Agreement establishing the World Trade Organization, signed in Marrakesh, Morocco on 
15 April 1994 U.N.T.S. 299, 33 I.L.M. 1197 (1994)) (Hereinafter referred to as the TRIPS Agreement.) 
This point is further discussed in the next chapter. 
8 The role of IP as an engine of innovation by providing the necessary incentives versus its adverse impact on public health and 
innovation has been debated extensively by scholars. Some of the arguments will be touched upon in the following chapters.  
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labour.9 Proponents therefore, argue for the moral right of an inventor to control 
their inventions and reap the results of their intellectual efforts.10  
The most influential argument for natural rights emerged from the writings of 
John Locke who believed in the natural entitlement to life, liberty and personal 
‘labour of property.’11 To the philosopher Locke, a human being is born with a 
set of natural rights which entitles him to the enjoyment of these rights including 
the preservation of his property.12 Locke’s main proposition is that every man 
has a natural right to the earth given by God ‘in common.’13 However, when a 
person appropriates a natural endowment by mixing his labour with it, he adds 
something of his own to it which ought to be protected from exploitation by 
others.14 Accordingly, therefore, man has a natural right to the products of his 
labour, a right which should be protected by society.15 Locke also argues in his 
labour theory that the right to property is justified because every man has a 
property in his own person.16 The natural law/labour principle is therefore 
premised on the ontological assumption that people have a right to property, to 
the exclusion of all others, to the extent that they have expended their labour to 
it. 
                                                          
9 Bently and Sherman (n 3) 379; Fritz Machlup and Edith Penrose, 'The Patent Controversy in the Nineteenth Century' (1950) 10 
Journal of Economic History 1, 10-17; See also Edwin Cameron, ‘Patents and Public Health Principles, Politics and Paradox in D 
Vaver, Intellectual Property Rights: Critical Concepts in Law, Volume 4 (Taylor & Francis 2006) 444. 
This point is further analysed in Chapter IV.  
10 Edwin C Hettinger, 'Justifying Intellectual Property' in David Vaver (ed) Intellectual Property Rights: Critical Concepts in Law, 
Volume 1 (Taylor & Francis 2006) 103; Lior Zemer, The Idea of Authorship in Copyright (Ashgate 2007) 11; Holger Hestermeyer, 
Human Rights and the WTO: The Case of Patents and Access to Medicines (Oxford University Press 2007) 30-31 
11 John Locke, Two treatises of Government (Whitmore and Fenn, and C. Brown 1821) 209-210. 
12 ibid; John Locke, ‘Two Treaties of Government’ extract in Michael DA Freeman, Lloyd's Introduction to Jurisprudence (9th edn, 
Sweet & Maxwell 2014) 132.  
13 Locke (n 11) paragraph 26. 
14 ibid paragraph 27. 
15 Sigrid Sterckx, 'The Moral Justifiability of Patents' (2006) 13 Ethical Perspectives 249, 250. 
16 Locke (n 11) paragraph 27. 
 Hettinger sums up John Locke’s justification of property rights thus:  
John Locke’s version of this labor justification for property derives property rights in the product of labor from prior 
property rights in one’s body. A person owns her body and hence she owns what it does, namely, its labor. A person’s 
labor and its product are inseparable, and so ownership of one can be secured only by owning the other. Hence, if a 
person is to own her body and thus its labor, she must also own what she joins her labor with – namely, the product of 
her labor.  
Hettinger (n 10) 100. 
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The proposition that a man owns a property right by removing something out of 
the state of nature and mixing his labour to it has been questioned by other 
commentators. Robert Nozick dismisses this labour premise by asking why a 
person acquires ownership by mixing his labour with something in common, 
instead of losing his labour. He uses an analogy of a person pouring a can of 
tomato juice into the ocean. He asks if a person, through the act of pouring the 
juice and ‘mixing one’s labor’ with the ocean, acquires the ocean or loses his 
can of tomato juice?17 The question essentially raises issues with the 
conceptualisation that a person owns a right to a property by mixing his labour 
with a common endowment.  
The labour and natural right argument has been extended to intellectual 
property rights (IPRs), including patents, as a consequence of intellectual 
labour. As a natural right, this theory presupposes that society, represented by 
the state, is duty bound to recognise, protect, and enforce the natural rights and 
interests of patentees.18 This argument is often canvassed with regards to the 
human rights entitlement of patent holders and other IPRs.19 
 Nevertheless, the notion that patent rights are the inherent rights of an inventor 
which the state recognises, finds strong opposition.20 The primary shortcoming 
in applying the ‘natural’ theory to patents is the nature of the protection itself. A 
patent, previously mentioned, is basically a statutory instrument granted by the 
state.21 A number of scholars reject this argument and criticise the inherent 
natural law postulate for failing to reflect the essential statutory creation and 
                                                          
17 Robert Nozick, Anarchy, State and Utopia (Basic Books 1947) 175. 
18 Ikechi Mgbeoji, Global Biopiracy: Patents, Plants, and Indigenous Knowledge (UBC Press 2006) 19. 
19 This justification is also at the root of the moral and material human rights prescription of IP as further discussed in Chapter IV. 
(See subsection 4.7.3.1.) 
20 Helen E Norman, Intellectual Property Law (Oxford University Press 2011) 16. 
21 See subsection 2.2 above. 
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nature of patents, which is fixed and limited to specific exclusive privileges.22 
For instance, the UN Secretary-General echoes the point that ‘patent legislation 
has never been based solely on the concept of the patent as the confirmation of 
an inherent, rather than the creation of a statutory, property right.’23 The 
Secretary-General further reasons that ‘such a concept would have left no room 
for statutory limitations on patent rights such as the fixed term of a patent, its 
forfeiture for failure to work them, its exclusion for inventions in certain fields.’24  
 2.3.2 The Contract and Incentive-to-disclosure Theory  
Another support for patents is the ‘Social Contract/Public Disclosure of Secret’ 
justification. As Waelde and others in Contemporary Intellectual Property: Law 
and Policy identify, a patent is often defined as ‘a form of social contract 
between the patentee and the state, whereby the award of a patent monopoly is 
given in return for public disclosure of the invention.’25 The contract theory 
therefore hypothesises that a patent is a contractual agreement, in which the 
state grants temporal property rights in exchange for securing the disclosure of 
the innovative knowledge and advantages of an intellectual endeavour.26 The 
crux of this quid pro quo social contract reasoning is that this public disclosure 
also presents an opportunity for others to invent further around the disclosed 
invention; thus a patent is presumed to be a catalyst for incremental 
technological scientific and industrial progress, as well as conferring a public 
benefit (the so-called ‘teaching function’).27  
                                                          
22 Mgbeoji, Global Biopiracy: Patents, Plants, and Indigenous Knowledge (n 18) 19-20. 
23 United Nations, The Role of Patents in the Transfer of Technology to Developing Countries: Report of the Secretary-General 
(Martinus Nijhoff 1964) 9.  
24 ibid 
25 Waelde and others (n 4) 371. 
26 ibid; Vincenzo Denicolò and Luigi Alberto Franzoni, 'The Contract Theory of Patents' (2004) 23 International Review of Law and 
Economics 365, 366.  
27 Waelde and others (n 4) 371; Alexandra Zaby, The Decision to Patent (Physica-Verlag 2010) 1-2; Hestermeyer (n 10) 30-31; 
Machlup and Penrose (n 9) 26. 
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There are, however, shortcomings in this theory. The theory erroneously 
assumes that patent protection is the only reason why inventors disclose their 
inventions to the public and consequently, the ideal mechanism for the 
encouragement of further innovations and ensuring public access. According to 
the observation by IP scholars, ‘the inventor discloses his secret only if he 
expects his profits from a temporary monopoly enforced by the state to be 
greater than those from an uncertain monopoly guarded by a tenuous 
secrecy.’28 Opponents of the disclosure theory, therefore, object to the incentive 
function the disclosure is presumed to present by suggesting that, without 
patent, important inventions and their benefits would remain a secret.29 
Pharmaceutical companies, for example, are mainly corporate entities whose 
‘disclosure’ of their medicinal products is driven by profit incentives.  
In another instance, the disclosure/contract rationale presupposes that 
innovations are products of a necessary infrastructure (patents) and the welfare 
cost of the monopoly is worth the increased benefit to a particular 
technical/scientific field.30 This assumption is however, called into question 
considering the long term detrimental welfare cost to health and human 
development in poorer countries.31 Also this assumption may ignore the fact 
                                                                                                                                                                          
The contract theory also finds support in case law. In the US for example, the US Supreme Court in the case of Universal Oil 
Products v. Globe Oil & Refining made the observation that:  
As a reward for inventions and to encourage their disclosure, the United States offers a seventeen-year 
monopoly to an inventor who refrains from keeping his invention a trade secret. But the quid pro quo is 
disclosure of a process or device in sufficient detail to enable one skilled in the art to practice the invention once 
the period of the monopoly has expired, and the same precision of disclosure is likewise essential to warn the 
industry concerned of the precise scope of the monopoly asserted.  
Universal Oil Products v Globe Oil & Refining [1944] 322 U. S. 484.  
28 Machlup and Penrose (n 9) 27. 
29 Luigi Alberto Franzoni, 'The Contract Theory of Patents in Perspective' in Thomas Eger,  Claus Ott and  Jochen Bigus (eds), 
Internationalization of the Law and its Economic Analysis (Springer-Verlag 2008) 106. 
30 Waelde and others (n 4) 371. 
31 ibid; Poku Adusei, Patenting of Pharmaceuticals and Development in Sub-Saharan Africa: Laws, Institutions, Practices, and 
Politics (Springer 2013) 119. 
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that a monopoly can be used to block competition and reduce access to the 
disclosed invention as expounded in the next chapter.32  
Irrespective of the inherent limitations of this theory of patents, the importance 
of public disclosure should not be underestimated.33 The disclosure and 
enablement requirements in patent applications lie at the heart of patent law 
and the hypothetical ‘bargain’ aspect of the patent system as protection-for-
disclosure.34 In this sense, the exclusive rights to exclude others from illegally 
appropriating a patented invention are not merely conferred as gifts; it is 
assumed that the right is in exchange for the disclosure of the invention and 
how it is practiced to the general public.35 From the point of view of society at 
large, the disclosure requirement is useful for securing the public returns of 
patent and innovations.36 It can be said that, from the public’s perspective that 
disclosure and statutory enablement conditions for patents require that society 
gains something from the disclosed invention. Ideally, the disclosure criterion is 
intended to benefit the public by encouraging improvements or follow-on 
designs around the patent; ‘thus bringing a flow of innovations to the 
marketplace.’37 Consumers should then benefit from the availability of useful 
technologies and products, such as essential pharmaceuticals, whose 
development was facilitated by the disclosed invention. 
However, many proponents of the disclosure theory seem to focus on the 
‘inventive’ or ‘teaching’ function of patent specification from the patentee’s 
                                                          
32 Waelde and others (n 4) 371; Wesley M Cohen, Richard R Nelson and John P Walsh, 'Protecting their Intellectual Assets: 
Appropriability Conditions and Why U.S. Manufacturing Firms Patent (Or Not) [2002] National Bureau of Economic Research 
Working Paper 7552, 25. 
33 Waelde and others (n 4) 372. 
34 ibid; Bently and Sherman (n 3) 406. 
35 Bently and Sherman (n 3) 537.  
36 However, whether or not the disclosure sufficiently enables and promotes societal welfare is a different matter. 
37 Peter K Yu, Intellectual Property and Information Wealth: Issues and Practices in the Digital Age (Greenwood Publishing Group 
2007) 115. 
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perspective rather than looking at the benefit that society can get from the 
disclosed invention. Beyond the theoretical foundations of the contract theory, it 
is important to recognise the importance of the disclosure from a public welfare 
standpoint. This thesis argues that users would derive better benefits from this 
patent advantage if they could access and use the products that have been 
disclosed.  
 2.3.3 The Best Incentive-to-Innovate Theory 
Another view of the patent system holds that patents present an opportunity for 
inventors to invest in innovative enterprises and, consequentially, disclose the 
knowledge and result for public benefit.38 The incentive theory, according to 
Machlup and Penrose, supposes that the patent system creates the necessary 
incentive for inducing an adequate amount of desirable inventions to society.39 
For his part, Adusei adds that the patent system is seen to provide an important 
inducement for inventors to make available to society, particular beneficial 
objects.40 In this manner, the inventive argument theorises that patents are 
fundamental incentives to encourage inventive undertakings, technology 
transfer, and facilitate R&D and economic development.41 
The underlying rationale for this utilitarian justification and economic incentive 
argument is straightforward: without patents, inventors — and, in the case of 
medicines and vaccines, pharmaceutical companies, — who invest time and 
ingenious efforts in medical R&D to produce efficacious drugs, will not get a 
                                                          
38 This literature is summarised in Machlup and Penrose (n 9) 10, 21-25; Fritz Machlup, An Economic Review of the Patent System: 
Study of the Subcommittee on Patents, Trademarks, and Copyrights of the Committee on the Judiciary, United States Senate, 85th 
Congress, Second Session, Study No 15 (U.S. Government Printing Office 1958) 33; Sigrid Sterckx ‘Patents and Access to Drugs in 
Developing Countries: An Ethical Analysis’ (2004) 4(1) Developing World Bioethics 58, 66-67. This discussion is further touched 
upon in subsections 3.6.2.1 of Chapters III and 5.3.1 of Chapter V 
39 Machlup and Penrose (n 9) 21-22; Hestermeyer (n 10) 31; Joo-Young Lee, A Human Rights Framework for Intellectual Property, 
Innovation and Access to Medicines (Ashgate Publishing Ltd 2015) 47. 
40 Adusei (n 31)121. 
41 Adusei (n 31) 121. 
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return on their investments.42 One scholar summarises the basic assumption of 
this ‘encouragement-to-invent’ argument thus: ‘[w]ithout the prospect of an 
exclusive right to use the invention, and hence a possibility of recouping the 
money invested in the development of the invention, too little inventing would be 
done.’43 From this perspective, increased profit from a patent’s exclusivity 
privilege is an incentive to innovate since inventors are most likely to invest in 
R&D and inventive enterprises because they are guaranteed a monopoly over 
the invention. A patent protection which guarantees profits on investments is 
therefore, a stimulus to the availability of new, innovative products.44 For 
example, studies indicate an increase in the use of patents as an investment 
strategy, and its importance in the decision to invest in a particular innovative 
activity such as pharmaceuticals R&D.45 As a corollary therefore, the patent 
system further encourages the patent owner to invest in the creation of 
additional inventions.46  
As with the public disclosure rationale, the incentive justification presumes that 
patent protection further stimulates innovation around the available invention 
which, in turn, provides a useful avenue for public utility.47 By linking a patent to 
                                                          
42 Adam B Jaffe and Joshua Lerner, Innovation and its Discontents: How Our Broken Patent System is Endangering Innovation and 
Progress, and What to Do About It (Princeton University Press 2004) 8.  
43 Sigrid Sterckx, 'The Moral Justifiability of Patents' (n 15) 259. 
44 Thomas Pogge, ‘The Health Impact Fund: Better Pharmaceutical Innovation at Much Lower Prices’ in Thomas Pogge, Matthew 
Rimmer and Kim Rubenstein (eds), Incentives for Global Public Health: Patent Law and Access to Essential Medicines (Cambridge 
University Press 2010) 136.  
45 Brownwyn H Hall, ‘Patents and Patent Policy’ (2007) 23 Oxford Review of Economic Policy 574; Edwin Mansfield, 'Patents and 
Innovation: An Empirical Study' (1986) 32(2) Management Science 173, 174; Richard C Levin and others, ‘Appropriating the 
Returns from Industrial Research and Development’ (1987) 3 Brookings Papers on Economic Activity 783-831. 
46 Lee (n 39) 47-50. 
47 The importance and effect of patents on inventiveness and creativity is best represented in the views by Professor JB Clark in 
his ‘Essentials of Economic Theory’ (ch. xxi) that the patent system is important because without the system, there would be little 
inventing, and that there would be very little adoption of the invention by other producers. Accordingly,  
If an invention became public property the moment that it was made, there would be small profit accruing to 
any one from the use of it and smaller ones from making it. Why should one entrepreneur incur the cost and risk 
of experimenting with a new machine if another can look on, ascertain whether the device works or not, and 
duplicate it if it is successful? […] The system which gave a man no control over the use of his inventions would 
result in a rivalry in waiting for others rather than an effort to distance others in originating improvements. This 
fact affords a justification for one variety of monopoly.  
He concludes that ‘[p]atents stimulate improvement, and the general practice of the nations indicates their recognition of this 
fact.’  
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its contribution to economic efficiency and technological progress, this utilitarian 
argument of the patent system tends to bring the benefit of a patent closer to 
the general social and public good.48 Within the narrow incentive view, 
therefore, patents are assumed to be the reason why people invest in 
innovation.49 Not surprisingly, proponents of patents argue that ‘without patent 
protection, the world would have been deprived of the innovative medicines 
which have saved countless of lives.’50 As Oguamanam also puts it, ‘the wheel 
of creativity will falter or ultimately grind to a halt’ without this incentive system.51  
 The ‘Encouragement-to-Innovate’ justification is however, questioned for failing 
to establish a clear evidential connection between the grant of patents and 
inventive progress.52 For example, Mgbeoji noted that:  
The most fundamental difficulty in making any rational claim for or against the 
alleged relationship between patents and inventiveness is the impossibility of 
separating out other factors contributing to technological inventiveness, such as 
‘local resource endowment, education of the labour force, availability of capital, 
and dynamism of the local market.’53 
As with the disclosure theory, ironically, patent protection, by building a 
monopoly fence around some core inventions, can create an obstacle to the 
improvement of the patented invention by others and the benefits that flow from 
                                                                                                                                                                          
John Bates Clark, Essentials of Economic Theory (The Macmillan Company 1907); Arnold Plant, ‘The Economic Theory Concerning 
Patents for Inventions’ in David Vaver (ed), Intellectual Property Rights: Critical Concepts in Law, Volume 3 (Routledge 2006) 50. 
48 For example, Pigout writes from a utilitarian perspective that:  
The patent laws aim, in effect, at bringing marginal private net product and marginal social net product more closely 
together. By offering the prospect of reward for certain types of invention they do not, indeed, appreciably stimulate 
inventive activity, which is, for the most part, spontaneous, but they do direct it into channels of general usefulness. 
AC Pigou, The Economics of Welfare (Palgrave Macmillan 2013) 185. 
49 Ikechi Mgbeoji, 'Beyond Patents: The Cultural Life of Native Healing and the Limitations of the Patent System as a Protective 
Mechanism for Indigenous Knowledge on the Medicinal Uses of Plants' (2006) 5(1) Canadian Journal of Law and Technology 1, 4.  
50 Ellen FM 't Hoen, The Global Politics of Pharmaceutical Monopoly Power: Drugs Access, Innovation and the Application of the 
WTO Doha Declaration on TRIPS and Public Health (AMB Publishers 2009) 79. 
51 Chidi Oguamanam, ‘Patents and Pharmaceutical R&D: Consolidating Private–Public Partnership Approach to Global Public 
Health Crises’ (2010) 13(4) The Journal of World Intellectual Property 556. 
52 Mgbeoji, 'Beyond Patents: The Cultural Life of Native Healing and the Limitations of the Patent System as a Protective 
Mechanism for Indigenous Knowledge on the Medicinal Uses of Plants' (n 49) 4. 
53 Mgbeoji, Global Biopiracy: Patents, Plants, and Indigenous Knowledge (n 18) 21; ibid 
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the widespread use of the patented article.54 This has led some scholars to 
argue that a patent’s monopoly right has stunted more innovations than it 
encouraged.55 Also, the exclusive privilege has ‘caused more brilliant schemes 
to be put aside than the want of them could ever have induced men to 
conceal.’56 On the contrary, advocates of the patent system argue that a patent 
comes at no cost to anybody since it does not deprive others of anything that 
they had before or anything that is not the property of the inventor.57 Rather, the 
patent system only delays the unlicenced use of the right holder’s invention to 
the public for a limited period of time, after which others are welcomed to use it 
as they deem fit.58 On the other hand, however, it is argued that, the patent 
system could actually deprive others of the opportunity to prospect, discover 
and use the same idea that the patent holder was fortunate enough to have 
conceived before others, or was the first to file for patent protection, as the case 
may be in some jurisdictions.59 Furthermore the argument is limited in assuming 
that the exclusive privilege will ‘cost nothing’ to society.60 A patent gives an 
exclusive privilege to the original inventor and so it can affect how others can 
use the patented invention. For example, inventors, who are mainly 
pharmaceutical companies in the case of pharmaceutical patents, might want to 
make the most of the monopoly privilege during the short period of the patent 
term, including charging high prices for the patented invention or licence. The 
exercise of this right can have an effect on accessibility to essential medicines, 
especially for the poor in developing countries.61  
                                                          
54 Machlup and Penrose (n 9) 23-24. 
55 ibid 24. 
56 ibid 24. 
57 ibid 
58 ibid 
59 ibid 
60 See Jeremy Bentham, The Rationale of Reward (R Heward 1830) 318. 
61 This will be examined in the next chapter.  
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 2.3.4 The Reward Theory 
In a similar argument to the inventive theory, a patent is seen to offer a reward 
for inventive enterprise by securing the proprietary rights and interests of the 
inventor to capture a return on their investment in the inventive activity.62 This 
‘reward theory’ maintains that a patent is a reward by government for creating a 
novel invention and disclosing a useful innovation that would otherwise remain 
a secret.63 This view essentially emphasises the bestowal of a patent as a 
reward or ‘prize’ for an inventor’s intellectual and creative genius effort,64 or as 
one commentator puts it, ‘[o]pportunities to gain a reward in the market-place.’65 
To the supporters of this reward approach, a patent is an important incentive for 
an inventor to apply human ingenuity and introduce a new solution to human 
problems. Conversely, without the ‘prize’ or ‘award’ incentive of patents, 
important inventions would not be made or offered to the public, as inventors 
only come forth with their inventions because they are guaranteed a reward.66 
That is, like the disclosure rationale, the reward theory reasons that, without the 
reward and incentive that a patent exclusive right confers, inventors would not 
carry out research or disclose the results for society’s benefit. As Bentham 
argues, ‘[a]n exclusive privilege is absolutely necessary in order that what is 
sowed, may be reaped.’67 Accordingly, without patents, anyone could easily 
                                                          
62 Edmund W Kitch, ‘The Nature and Function of the Patent System’ (1977) 20(2) Journal of Law and Economics 265, 266; A Samuel 
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(Professor Oddi identified two aspects of the reward theory: ‘patent-induced’ theory, which is based on an economic justification 
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63 Nuno Pires de Carvalho, 'The Primary Function of Patents' [2001] Journal of Law, Technology & Policy 27, 29. 
64 Adusei (n 31) 118. 
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imitate or duplicate other’s inventions and competition resulting from this 
imitation would reduce earnings on the investment. 68 
To further quote Jeremy Bentham on the issue,  
[…] that which one man has invented, all the world can imitate. Without the 
assistance of the laws, the inventor would almost always be driven out of the 
market by his rival, who finding himself, without any expense, in possession of a 
discovery which has cost the inventor much time and expense, would be able to 
deprive him of all the deserved advantages, by selling at a lower price.  
Bentham concludes that:  
An exclusive privilege is of all rewards the best proportioned, the most natural, and 
the least burdensome. It produces an infinite effect, and it costs nothing.69 
From a pharmaceutical patents standpoint, the strength of Bentham’s argument 
is that it advocates the granting of patent protection as a reward to innovators, 
which is a form of a return on their inventive activities, especially in cases where 
huge cost has been expended in, for example, the pharmaceutical R&D process 
for new medicines. This reward rationale justifies the granting of patents 
because it would be unfair to allow others, who have not invested the time, 
labour, money, ingenuity and effort to develop the invention, a ‘free ride’ on the 
invention.70 As revealed in the next section, this ‘freeriding’ and piracy concerns 
presented a compelling argument for the inclusion of IP rights within the 
multilateral trade fora and influenced the argument by developed countries, 
prominently as the US, for the adoption of the TRIPS Agreement.71 Besides 
                                                          
68 James Bessen and Eric Maskin ‘Sequential Innovation, Patents, and Imitation’ (2009) 40(4) RAND Journal of Economics 611.  
69 Bentham (n 60) 318. 
70 Sterckx, 'The Moral Justifiability of Patents' (n 15) 255. 
71 For example, the Preamble to the TRIPS Agreement highlights this objective by explicitly referring to the need to protect private 
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preventing others from unduly misappropriating the invention, this patent reward 
it is argued, provides a utilitarian avenue for society as a whole to benefit from 
the invention.72 
The reward theory has also been criticised for assuming that it is the profit 
award which drives innovation.73 It has been pointed out that several inventions 
and inventive activities have been and would be undertaken without the 
consideration of a patent ‘reward.’74 Another major critique of the reward and 
incentive-to-innovate approaches is that it does not give a complete view of the 
function of the patent system by assuming that a patent is a reward for an 
incentive for inventive activity.75 It is argue that patent does not exist solely as a 
reward mechanism to patentees or to confer rights to inventors. As will be 
shown below, the patent system essentially exists to confer a benefit on both 
inventors and the public. Equally, approaching patents from the right holder’s 
perspective gives greater weight to the instrumentality of the patent holders, 
and the sanctity of patent right to innovation to measure the appropriateness of 
the patent system. Adopting a concept of patents solely from the right holder’s 
point of view focuses attention on the need to prevent patent infringements and 
the appropriation of the right holder’s intellectual creations and inventions; this 
can obfuscate the importance of actually extracting the social benefit of the 
patent system to the public and consequently, to users and consumers.  
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2.4 Patent Law in a Social Welfare and Development Context  
While this thesis shares the view that the theoretical justifications for the patent 
system are not always satisfactory, it is not disputed that in its own terms, the 
patent system could provide an important utilitarian means for securing the 
dissemination of technological knowledge embedded in an invention and the 
availability of important technologies such as medicines.76 For example, Lord 
Oliver in the United Kingdom (UK) case of Asahi Kasei Kogyo KK’s Application 
aptly captured this objective thus:  
The underlying purpose of the patent system is the encouragement of 
improvements and innovation. In return for making known his improvement to the 
public the inventor receives the benefits of a period of monopoly during which he 
becomes entitled to prevent others from performing his invention except by his 
licence.77  
Along this line, patents and other IPRs are seen to protect the economic 
investment effort expended in the development of the invention; thus, a patent 
is a means to stimulating the innovation of essential products for society’s 
benefit.78 However, it is argued that there is a need to focus on the public 
advantage of the function of the patent system to society. 
Though the patent system and the economic incentive implications of 
guaranteeing protection may encourage innovation and promote the 
development of new and useful products, it is argued in this thesis that patent 
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essentially serves a larger societal purpose. In other words, the public and 
social benefit derivable from the patent system is not a mere incidental aspect 
of patent law. Broadly speaking, a patent aims to confer as much privilege and 
benefit to the public, including other inventors/researchers, users and 
consumers, as it does the patent right holders. The public policy and social 
development element of a patent system lie in the reasons and threshold 
principles for the grant of the patent and the requirement for disclosing the 
result of the innovation and technology in an enabling manner, in the patent 
claim. As mentioned in subsection 2.3.2, a patent is not merely granted in 
recognition of an inventor’s ingenuity and scientific/ technological progress. 
There is a belief that the scientific and technological advancement is original, 
useful and significant enough to be protected and that it contributes to the field 
of knowledge, thus patents aim to promote social goals.  
Apart from the public welfare and health benefits accruable from innovation 
such as essential medicines, the policies underpinning the novelty requirement, 
which aims to prevent others from monopolising matters already existing in the 
public domain, bears further emphasis. The underlying rationale for the novelty 
standard is to prevent the appropriation of ‘prior art,’ that is, knowledge that is 
already publicly available, patented, published or in use before a patent 
application was filed.79 It can be argued that this requirement takes into account 
public considerations. This patentable requirement illustrates that the patent 
system considers the public’s welfare and acknowledges the importance of 
ensuring that society is not prevented from having access to an existing public 
or common knowledge. In this sense, society is only willing to strike a bargain of 
granting monopoly rights to the inventor in exchange for disclosure after they 
                                                          
79 Waelde and others (n 4) 436-437; Bently and Sherman (n 3) 529, 532, 537; Bengt Domeij, Pharmaceutical Patents in Europe 
(Kluwer Law International 2000) 159.  
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determine that the invention is innovative ( i.e new or a significant improvement) 
and would not otherwise be publicly available more ‘quickly.’80 This point is 
important to understanding that the patent system contemplates the public and 
its welfare. Why then should the patent system be used to constitute a barrier to 
public welfare? 
Furthermore, the underlying basis of the inventive step is to determine whether 
the patentee makes a substantial contribution by advancing the state of art or 
field of technological and scientific knowledge, which would benefit society.81 
The requirement of the inventive step is significant to the argument in this thesis 
that patent is purpose-driven, the purpose being to encourage the development 
and availability of new and significant technologies and inventions. Thus, a 
patent, as aforementioned, is more than a reward or an incentive for inventive 
activity. The patent system anticipates that the invention itself must have a 
significant purpose and confer a substantial advantage to society. However, it is 
argued that the benefit accruable to the public would have a better development 
impact if the public were able to access the invention. For example, a ground-
breaking drug for the treatment of HIV/AIDS-related complications would no 
doubt, be useful to public health. An inventor who has brought about this new 
therapeutic treatment and seeks a patent in return for making it available will be 
offering a significant advantage to society. Its therapeutic benefit to society 
would, however, be better enhanced if patients were given the opportunity to 
access and use the drug to ameliorate their health. 
                                                          
80 Bently and Sherman (n 3) 530. The use of the word ‘quickly’ here is deliberate. It is assumed that an invention is a solution to a 
technical problem or a satisfaction of society’s needs posed by consumer demand. As ‘necessity is the mother of invention,’ it is 
conceivable that others would arrive at the same solution to the problem at a later time than the patentee did. However, having 
found a solution to the problem first (or indicated interest to seek patent protection first), the inventor promises to disclose his 
invention sooner rather than later, before others arrive at, or disclose the same result. Machlup and Penrose (n 9) 28. 
81 Waelde and others (n 4) 448-449. 
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From a public policy point of view, the industrial applicability criterion also 
establishes that patents should satisfy some social function and contribute to 
societal goals and welfare through its utility and industrial applicability purpose. 
This is a point supported by Kuanpoth, that, the requirement of industrial 
applicability aims to enhance industrial and economic progress from the 
application of new technologies to practical spheres of development in a 
manner that responds to the needs of society.82 In a related manner, the 
invention must indicate that it serves a useful and meaningful purpose.83 In the 
case of medicines, for example, a patent application for an HIV/AIDS medicinal 
treatment would indicate that the invention serves some curative or health 
sustenance purpose. Likewise, the invention must be capable of being 
replicated and reproduced through the same means. This requirement is 
fashioned to ensure that a patented invention not only indicates an important 
advancement but that it can also be made and used in at least one field of 
scientific, industrial, technical and agricultural activity.84 This means that 
innovators do not invent ‘in the dark.’85 The patent system expects that their 
inventions should have some public interest connotations and be a response to 
society’s welfare needs. 
Thus, a patent is another mechanism for guaranteeing the public access to a 
new and significantly useful invention. Rather than being seen as a mere 
system for conferring and recognition of patentee’s rights, as Bently and 
Sherman put it, the ‘patent registration should be seen as a process in which 
                                                          
82 Jakkrit Kuanpoth, Patent Rights in Pharmaceuticals in Developing Countries: Major Challenges for the Future (Edward Elgar 2010) 
77. 
83 Bently and Sherman (n 3) 440. 
84 Bently and Sherman (n 3) 440-441. 
85 de Carvalho (n 63) 27. 
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policy goals are implemented and enforced’86 This point has been articulated by 
the United States (US) Supreme Court the case of United States v Masonite 
Corp.87 The US Supreme Court took the view that ‘[t]he promotion of the 
progress of science and the useful arts [i.e technologies] is the “main object” [of 
the patent system]; reward of inventors is secondary and merely a means to 
that end.’88 In line with this assertion, the US Supreme Court in Motion Picture 
Patents Co. v Universal Film Mfg. Co. shared a similar view that ‘the primary 
purpose of our patent laws is not the creation of private fortunes for the owners 
of patents but is “to promote the progress of science and useful arts.'89 The 
court’s logic makes sense within the context of the public-related patents 
argument in this thesis.  
The requirement to work a patent further strengthens the social policy aspect of 
patent system. In some countries, patent law requires that the patented 
invention is worked or exploited although the consequence of not working or 
exploiting the patent varies from country to country. In some instances, non-
working of a patent may lead to a revocation of the patent licence and justify the 
grant of a non-voluntary licence to a third party wishing to exploit the invention 
or government non-commercial use in the public interest.90 In many instances, 
public interest (e.g health, environment, economic/technological and scientific 
development, defence and national security, development of vital sectors, 
                                                          
86 Bently and Sherman (n 3) 375. 
87 [1462] 316 U.S. 265 278, 62 S.Ct. 1070, 86 L.Ed. (Quoting from Pennock v Dialogue [1829] 27 U.S. 2 Pet. 1 19.)  
88 ibid  
89 [1917] 243 U.S. 502, 511. Article I, Section 8, Clause 8, of the United States Constitution in securing the limited exclusive rights of 
inventors to their inventions, directs that the aim is to ‘promote the progress of science and useful arts.’ In a similar fashion, the 
US Supreme court in reiterating this point, emphasised this public policy aspect of patent law and stated that ‘[t]he grant to the 
inventor of the special privilege of a patent monopoly carries out a public policy adopted by the Constitution and laws of the 
United States, "to promote the Progress of Science and useful Arts, by securing for limited times to inventors the exclusive Right " 
to their "new and useful" inventions.’ Morton Salt Co. v G. S. Suppiger Co. 314 U.S. 488 (1942) 492.  
90 This point is further considered in Chapter VI of this thesis when discussing compulsory licensing.  
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misuse of patent monopoly rights and dependent patents) is given paramount 
importance and primacy with regards to patent law and rights.  
In the case of compulsory licences, for example, society’s interest is taken into 
account to limit the exclusive rights of patent owners, even without the 
patentee’s permission, where it is expedient to do so. What this indicates is that 
the patent system does not exist solely in the interest of patent holders, in fact, 
where a patent is not serving its public purpose, the law can intervene to 
redirect it to ensure it does so. Therefore, public welfare is a necessary element 
of the patent system. As reiterated by the US Supreme Court in the anti-
competition related case of United States v Masonite Corp.91  
[w]hilst the remuneration of genius and useful ingenuity is a duty incumbent upon 
the public, the rights and welfare of the community must be fairly dealt with and 
effectually guarded. Considerations of individual emolument can never be 
permitted to operate to the injury of these.92  
The argument made here is not whether the patent system actually leads to 
technological, pharmaceutical or scientific progress, but to emphasise that the 
patent system is not intended to leave the public out of its consideration.93 
Consequently, since the material and objective nature of a patent indicates that 
the system exists within a certain public policy purpose, it is important for 
policymakers and the courts to take into account the public-driven aspect of the 
patent system in the design and interpretation of patent law and rights. From an 
access to medicines perspective, it should include the human and social 
                                                          
91 [1942] 316 U.S. 265, 278. 
92 ibid (quoting from Mr. Justice Deniel in Kendall v Winsor [1858] 21 How. 322, 329.  
93 In making this argument, this thesis is not oblivious to the criticism of the disclosure/enablement criterion. As pointed out by 
critics, despite the disclosure and enablement requirements, the actual disclosure in the patent claim may be incomplete, too 
technical and inadequate to enable others to utilise the disclosed knowledge. Luigi Alberto Franzoni (n 29) 112. Nonetheless, the 
arguments made here proceed on the assumption that, in a perfect world, the disclosed information in the patent application 
alone should be sufficient to facilitate the improvement and follow-on design as anticipated by patent law. Yu, Intellectual 
Property and Information Wealth: Issues and Practices in the Digital Age (n 37) 115. 
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development objectives of the system to users of the intellectual results and 
products.  
In sum, there is a need to redirect the focus of patents to the benefits that 
society stands to gain from them. In this thesis, the point is made that the public 
benefit of having a patent system would be better enhanced if people actually 
had access to the patented technology and medicines and that the protection 
does not stifle incremental innovations which would benefit the public.  
With this public perspective in mind, the next section examines the international 
system for the protection of patents, particularly, the TRIPS Agreement. This 
exposition also assesses the public nature of the system and its limitations. The 
introduction of the TRIPS Agreement and minimum IP standard in the 
Agreement has raised concerns with regards to patent rights and their effect on 
access to medicines; hence, the Agreement is significant to the analysis in this 
thesis.  
 
 2.5 The TRIPS Agreement from a Public Health and Access to Medicines 
Perspective 
States generally sign up to treaties and international agreements to increase the 
social and economic welfare of their citizens. Equally, these international 
treaties and agreements serve the overall goal of integrating global interests 
and interdependence for better technological, social, economic and human 
development. In the context of enhancing the public’s socio-economic and 
technological development, the international trade-related TRIPS Agreement 
also underlies a public objective. It is often argued that all IPRs, including 
patents, in the TRIPS Agreement can promote socio-economic development by 
encouraging innovative R&D of medicines, technology transfer, FDI and 
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economic growth, which could also enhance the availability of and access to the 
products of this increased development within an international trade context.94 
On the other hand however, the provisions of the Agreement have been the 
subject of criticism and debate on the grounds that they could restrict access to 
important life-saving health treatments, particularly for the poor in developing 
countries,95 or limit the obligations of governments to fulfil their national duty to 
safeguard public health, as was the case in South Africa,96 Thailand97 and 
Brazil.98 To increase understanding of the TRIPS Agreement and the debate on 
the role of its patent system in underpinning the problems of access to 
medicines, it is first necessary to briefly consider the scope and negotiating 
history of the Agreement.  
 
 2.5.1 The TRIPS Agreement Negotiations  
The TRIPS Agreement was negotiated as part of the Uruguay Round mandate 
within the General Agreement on Tariffs and Trade (GATT) framework of the 
WTO.99 Contrary to some opinions,100 IP rules were contained in some GATT 
Articles.101 These pre-TRIPS provisions set the scene for the emergence of the 
                                                          
94 The International Chamber of Commerce (ICC), 'Intellectual Property: Powerhouse for Innovation and Economic Growth' (2011) 
26. Available at <http://www.iccwbo.org/advocacy-codes-and-rules/bascap/value-of-ip/ip-and-economic-growth/> accessed 6 
August 2016; Ha-Joon Chang, Rethinking Development Economics (Anthem Press 2003) 269-272. 
95 International Center for Research on Women, Trade Liberalization Women’s Reproductive Health: Linkages and Pathways 
(International Center for Research on Women 2009). Also available at  
http://www.icrw.org/files/publications/Trade-Liberalization-and-Reproductive-Health.pdf; Jayashree Watal 'Access to Essential 
Medicines in Developing Countries: Does the WTO TRIPS Agreement Hinder It?' (2000) Science, Technology and Innovation 
Discussion Paper No. 8, Center for International Development, Harvard University, 2. 
96 The cases of South Africa and Brazil are further examined in subsection 6.4 of Chapter VI. 
97 In this case, the United States challenged the decision by the Thai Government to issue compulsory licence for patented 
HIV/AIDS drugs. 't Hoen (n 50) 23.  
98 In 2001, the United States instituted an action at the WTO Dispute Settlement Body (DSB) against the compulsory licensing 
provisions of Article 68 of the Brazilian Intellectual property law. ibid 24. (This case is further examined in Subsection 6.4 of 
Chapter VI.) 
99 For a comprehensive history of the negotiation see Daniel Gervais The TRIPS Agreement: Drafting History and Analysis (3nd edn, 
Sweet & Maxwell 2003). See also t’ Hoen (n 50) 9. 
100 Ho (n 2) 59. (stating that ‘IP norms were never been part of the GATT framework’)  
101 Article IX (6) of GATT, for instance, contained rules relating to marks of origin. See General Agreement on Tariffs and Trade 
(GATT) (1867 UNTS 187; 33 ILM 1153 1994) [Hereinafter GATT 1994]. 
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TRIPS Agreement.102 In Article XX (d) of GATT, contracting parties could adopt 
measures ‘necessary to secure the compliance with laws or regulations which 
are not inconsistent with the provisions of this Agreement including […] 
protection of patents, […] and the prevention of deceptive practices.’103 The 
Article adds that the measures should not ‘result in unjustifiable discrimination 
between countries or be a disguised restriction on international trade.’104 This 
way, IP was generally considered in the context of GATT ‘as an “acceptable 
obstacle” to free trade,’105 although the United States (US) had begun to 
perceive these “acceptable obstacles” as unacceptable in the 1970’s.106 
The international debate on the adoption and relevance of the TRIPS 
Agreement started when the more developed countries intensified efforts to 
include issues relating to IP into the global trading system and strengthen the 
standard of IP protection at the international trade level.107 At the Punta del Este 
Uruguay Round of multilateral trade negotiations in 1986, developed countries, 
prominently the US backed by Japan, presented a proposal to the Preparatory 
Committee appointed by GATT, to include aspects of IP on the agenda for the 
Round.108 The US justified the incorporation of IP on the trade agenda by 
putting forth the argument that developing countries were ‘free riding’ and 
                                                          
102 Gervais, The TRIPS Agreement: Drafting History and Analysis (n 99) 5 
103 ibid  
104 Article XX (d) of GATT 1994. 
105 Gervais, The TRIPS Agreement: Drafting History and Analysis (n 99) 8 
106 Christopher Scott Harrison, The Politics of the International Pricing of Prescription Drugs (Praeger 2004) 171. 
107 Laurence R Helfer and Graeme Austin, Human Rights and Intellectual Property: Mapping the Global Interface (Cambridge 
University Press 2011) 34. The historical account of the process leading up to negotiation and adoption of TRIPS is further 
expounded in Peter Drahos, 'Developing Countries and International Intellectual Property Standard-Setting' (2002) 5 The Journal 
of World Intellectual Property 765–789. Also available at  
<http://www.iprcommission.org/papers/pdfs/study_papers/sp8_drahos_study.pdf> accessed 15 July 2015; Laurence R Helfer, 
'Regime Shifting in the International Intellectual Property System' (2009) 7(1) Perspectives in Politics 42; Gervais, The TRIPS 
Agreement: Drafting History and Analysis (n 99) 10-27; Adusei (n 31) 79-88. 
108 Carolyn Deere, The Implementation Game: The TRIPS Agreement and the Global Politics of Intellectual Property Reform in 
Developing Countries (Oxford University Press 2009) 47.  
 According to Peter Drahos, other developed countries including Canada, Switzerland, European Communities (EC) and UN 
organisations such as WIPO, were also vocal in pushing for intellectual property provisions during the negotiations of the 
multilateral trade rules, but the US was the most influential player. Peter Drahos, 'Four Lessons for Developing Countries from the 
Trade Negotiations Over Access to Medicines' (2007) 28 Liverpool Law Review 15.  
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pirating technologies from developed countries, and that failure to enforce 
intellectual property standards was an unfair trade practice.109  
From the outset, the developing countries, mostly represented by the Group of 
Ten - Argentina, Brazil, Cuba, Nigeria, India, Egypt, Nicaragua, Peru, Tanzania 
and Yugoslavia - vehemently opposed the inclusion of IPRs in issues of 
international trade.110 In particular, Brazil and India were most vocal in opposing 
the widening of the scope of GATT by incorporating IP minimum standards in 
the trade forum and argued that it would undermine developing countries’ 
sovereignty in advancing their national development and health policies.111 
They also argued that matters relating to IPRs were outside the scope of 
GATT’s competence and should be left out of the negotiations.112 They 
contended that issues relating to IP and counterfeit goods were more suited to 
the exclusive jurisdiction of World Intellectual Property Organization (WIPO).113 
Moreover, it was contested that the IP system was not suited to stimulating 
developing countries’ innovative capacity.114 In a detailed paper elaborating the 
developing countries’ perspectives on the negotiation, India argued that:  
It would […] not be appropriate to establish within the framework of the General 
Agreement on Tariffs and Trade any new rules and disciplines pertaining to the 
standards and principles concerning the availability, scope and use of intellectual 
                                                          
109 Simon Walker, The TRIPS Agreement, Sustainable Development and the Public Interest: Discussion Paper (IUCN 2001) 8; 
Matthews (n 71) 5-6. 
This point is further mentioned in subsection 2.5.2. 
110 Drahos, 'Developing Countries and International Intellectual Property Standard-Setting' (n 107) 773; Preslava Stoeva, New 
Norms and Knowledge in World Politics: Protecting People, Intellectual Property and the Environment (Routledge 2010) 95-96. 
111 Drahos, 'Developing Countries and International Intellectual Property Standard-Setting' (n 107) 773; Walker (n 109) 8; Peter 
Drahos and John Braithwaite, Information Feudalism: Who Owns the Knowledge Economy (New Press 2003) 114. 
112 Stoeva (n 110) 95-96; Drahos and Braithwaite (n 111) 114-115. 
113 Simon Walker (n 109) 8; Peter Yu ‘The Objectives and Principles of the TRIPS Agreement’ (2009) 46 Houston Law Review 978, 
984. 
114 For a comprehensive view of these arguments, see J Michael Finger and Philip Schuler, 'Implementation of Uruguay Round 
Commitments: The Development Challenge' (2000) 23 The World Economy 511-526; Maskus, Intellectual Property Rights in the 
Global Economy (n 78); Joseph E Stiglitz, Making Globalization Work (WW Norton & Co 2006).  
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property rights. In our view, therefore, there can be no linkage between the basic 
principles relating to intellectual property rights and the GATT system.115 
The impending constraints to technological transfers and dissemination, the 
effect on generic competition and the increase in the cost of pharmaceutical and 
agricultural products in developing countries were also at the root of the 
resistance by the developing nations.116 India, particularly, expressed concern 
that the ‘monopolised and restrictive character’117 of exclusive IPRs ‘had wide 
implications’ for socio-economic and technological development, especially with 
regards to food production and healthcare.118 India further made the submission 
that developing countries should be allowed to exclude the patenting of 
pharmaceuticals, food, and chemical products from IP protection.119  
In spite of these objections, issues relating to the grant and protection of IPRs 
were included on the agenda of the Uruguay Round.120 At the end of a 
protracted period of negotiations, the TRIPS Agreement, with detailed rules for 
the general protection of IPRs, was adopted within the confines of multilateral 
trade rules at Marrakesh on April 1994 and entered into force on 1 January 
1995. Nonetheless, the perspectives and views of both developing and 
developed countries on the significance of IP, particularly within a trade forum, 
are still divided. 121  
The introduction of the TRIPS Agreement was a game changer for the 
international protection of IP, in that the Agreement for the first time introduced 
                                                          
115 ‘Communication from India, Applicability of the Basic Principles of the GATT and of Relevant International Intellectual Property 
Agreements or Conventions’ (MTN.GNG/NG11/W/39 1989) paragraph 2. See also Government of India, ‘Communication from 
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a uniform minimum standard for the creation and implementation of IP through 
the instrumentality of the WTO.122 Consequently, all WTO Members were 
required to implement the minimum patent standards in the Agreement, 
regardless of each member’s different level of economic and human 
development.123 The TRIPS Agreement contains substantive rules for the 
protection, availability and use of IPRs, as well as provisions for the 
administration and enforcement of IPRs.124 Patents granted to inventive 
products and processes that meet the conditions of newness, inventiveness 
(non-obviousness) and industrial applicability.125  
Although WIPO is a pre-TRIPS international organisation that promotes and 
regulates international IP,126 TRIPS introduced rules linking IP to trade, thus 
making private IP rights synonymous with trade issues. Furthermore, unlike the 
IP provisions in other international treaties and agreements, states can be 
sanctioned through the WTO’s Dispute Settlement Body (DSB) with respect to 
their obligation under the TRIPS Agreement.127 
 
 2.5.2 A Preliminary Critique of the TRIPS Agreement 
The negotiation background leading to the emergence of the TRIPS Agreement 
reveals why the scope and content of the Agreement is one of the most debated 
components of the WTO trading system. It also says a great deal about the 
reasons why the system, despite its public interest objectives and flexibilities, is 
                                                          
122 t’Hoen (n 50) 9. 
123As stated previously, some countries were given an extension of the deadline to comply with TRIPS’s implementation. 
124 Part III of the TRIPS Agreement.  
125 Article 27(2). For a further discussion of the negotiation of the TRIPS Agreement see Peter Drahos and Braithwaite (n 111)  
126 The organisation administers and regulates the Bern and Paris conventions respectively.  
127 Susan K Sell, Private Power, Public Law: The Globalization of Intellectual Property Rights (Cambridge University Press 2003) 9. 
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seen not to cater to the social development needs of people in developing 
countries, particularly the poor.  
A review of the negotiations leading to the emergence of the Agreement 
indicates that there was no consensus on the ways in which this system was 
relevant to the development priorities of all WTO Members, especially since 
many developing countries were mainly consumers rather than producers of 
IP.128 From a social and health policy perspective, developing countries 
expressed concern that the cost of the protection to crucial areas such as public 
health might be too high, yet the private interests of innovators, perceived 
benefits of FDI and technology transfer129 outweighed the development and 
healthcare concerns of people in developing countries.130  
Several scholars are in agreement that the introduction of IP into matters of 
global trade is at variance with the core purpose of opening up international 
borders for trade relations.131 Essentially, IP, as an exclusivity based system 
which creates monopolies, was protectionist in nature, hence it had little or no 
place in matters of trade. Indeed, t’Hoen asked ‘[w]hat was an agreement that 
created monopolies – which inherently restrict free trade and competition – 
doing in an institution whose main purpose was to encourage free trade and 
global competition?’132  
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129 Carlos M Correa, 'The TRIPS Agreement and Developing Countries' in International Trade Law Center, Arthur E Appleton 
and Michael G Plummer (eds), The World Trade Organization: Legal, Economic and Political Analysis (Springer Science & Business 
Media 2007) 420-423. 
130 Commenting on the negotiation leading up to the TRIPS Agreement and final text, Professor Gervais writes,  
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the entire area and adding enforcement, acquisition and most-favoured-nation obligations to new and existing 
rules and incorporating those rules in what could be considered the only truly effective and binding dispute 
settlement mechanism between states was negotiated on the basis of a limited initial mandate.  
Daniel J Gervais, ‘The TRIPS Agreement and the Doha Round: History and Impact on Economic’ in Peter K Yu (ed), Development in 
Intellectual Property and Information Wealth: Issues and Practices in the Digital Age (Greenwood Publishing Group 2007) 12. 
131 t’Hoen (n 50) 9; Jerome H Reichmann, ‘The TRIPS Component of the GATT’s Uruguay Round: Competitive Prospects for 
Intellectual Property Owners in an Integrated World Market’ (1993) 4 Fordham Intellectual Property, Media & Entertainment Law 
Journal 171, 175; Sell (n 127) 15; Stoeva (n 110) 94.  
132 t’Hoen (n 50) 9. 
61 
 
Other commenters note that developing countries conceded to the Agreement 
due to pressure from powerful, developed countries.133 The US, for example, 
threatened countries with trade sanctions and barriers using the so-called 
USTR ‘Special’ Section 301 provision of the Omnibus Trade and 
Competitiveness Act 1988, making it clear that the country would not hesitate to 
do same to other countries who were not IP compliant.134 The expectation was 
that the multilateral dispute settlement mechanism of the WTO would deter the 
US from taking unilateral action on the basis of the Trade Act.135 Despite this, 
however, the US has continued to arbitrarily use Section 301 to impose 
sanctions for 'non-compliance with adequate standards’ of IP.136 
It is also pertinent to note that the emergence of the TRIPS Agreement was 
facilitated by the support of pro-IP multinational businesses and corporations.137 
This group, led by large pharmaceutical and copyright industries, intensely 
lobbied the United States Trade Representative (USTR) to include issues 
relating to IPRs into the international trade framework.138 These patent and 
copyright-reliant industries and businesses were vocal in putting forth the 
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argument that third parties, particularly in developing countries were ‘free 
riding,’ imitating and pirating technologies from developed countries and these 
acts were creating an unfair disadvantage to inventors and creators in the more 
developed countries.139 Fearing further loss of profit from alleged piracy and 
IPRs infringement in developing countries, the group submitted a report to the 
USTR for the establishment of a conducive international trade environment, ‘in 
which intellectual property was respected and protected.’140 The role that this 
business group played greatly shaped the framework of TRIPS as an 
instrument for the protection of private rights within an international trade 
context.141 Providing critical insight into factors that informed the eventual 
outcome of the Agreement, Braithwaite and Drahos argue that perhaps TRIPS 
would have been more sympathetic to the developmental concerns of 
developing countries if the negotiators had not been influenced by the demands 
of the pro-IP lobbyists.142 Although the Preamble, and Articles 7 and 8 of TRIPS 
Agreement, as will be discussed in the next section, contain provisions that 
sought to promote the public interests and make the IP system development 
friendly, it can be said that the fate of TRIPS with regard to the protection of 
monopolistic private IP rights was sealed from its foundation. 
 The TRIPS Agreement was also actively promoted as a strategic instrument for 
FDI, technology transfer, and an avenue for market access and enhancement of 
international trade.143 Thus developing countries were lured by the potential 
benefits in textile, agricultural and access to other trade markets to accede to 
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and impose stronger IP standards than most had under their national laws.144 
Deere notes in this connection that some developing countries were swayed by 
promises of technological development and economic gains to accede to the 
TRIPS Agreement.145 However, whether the Agreement is sufficient to 
encourage the purported benefits and development, particularly to the 
developing or least developed world, is still open to debate.  
In spite of the claims that TRIPS was necessary for the technological and 
economic development of members, there was no empirical evidence to 
indicate that stringent IP rules alone would facilitate this development, 
especially in developing countries.146 In the case of FDI, for example, IP 
scholars and economists, including Carlos Primo Braga, Carsten Fink and Keith 
Maskus, demonstrate that stronger IP fosters foreign investment if the country 
has an effective industrial structure, competitive market and capacity to 
assimilate the foreign goods and technologies.147 As Fink and Maskus pointed 
out, ‘[a] poor country hoping to attract inward FDI would be advised to improve 
its overall investment climate and business infrastructure than to strengthen its 
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patent regime sharply, an action that would have little effect on its own.’148 With 
limited industrial infrastructures and weak technological structures, there was 
little to suggest that increased IP protection would facilitate the supposed 
technological development, FDI and technology transfer to developing 
countries.149 In the case of patent protection, for example, many developing 
countries may lack the necessary industrial, technical and manpower capacity 
to effectively draw on the benefits of a patent system. As Maskus argues, if 
stronger IP protection always led to more FDI, then ‘recent FDI flows to 
developing economies would have gone largely to sub-Saharan Africa and 
Eastern Europe […] [instead of] China, Brazil, and other high-growth, large-
market developing economies with weak IPRs.’150 
Moreover, increased technological development and social benefits are 
historically associated with flexible and weaker IP protection in developing 
countries.151 India, for example, relied on malleable IP laws to achieve a great 
level of technological advancement and develop its pharmaceutical sector.152 
Ironically, developed countries such as the US had lax IP laws until the early 
                                                          
148 Carsten Fink and Keith E Maskus ‘Why We Study Intellectual Property Rights and What We Have Learned’, in Carsten Fink and 
Keith E Maskus (eds), Intellectual Property and Development: Lessons from Recent Economic Research (World Bank and Oxford 
University Press 2005) 1–15. 
149 Correa, 'The TRIPS Agreement and Developing Countries' (n 129) 420. 
150 Maskus, ‘The Role of Intellectual Property Rights in Encouraging Foreign Direct Investment and Technology Transfer’ (n 147) 
129. 
151 Commission on Intellectual Property Rights, Integrating Intellectual Property Rights and Development Policy (n 146) 22. Scherer 
also observes that ‘[i]t is reasonably well established in the economics literature that, especially in a world of AIDS and resistant 
tuberculosis epidemics, low-income nations enjoy higher economic welfare when they can free-ride on pharmaceutical 
innovations made and patented in the first world than when they must pay monopolistic prices for the newest and most effective 
drugs.’ FM Scherer, 'A Note on Global Welfare in Pharmaceutical Patenting' (2004) 27(7) World Economy 1127, 1127. 
152 The Indian Patent Act of 1970 disallowed product patents for drugs. Only processes could be patented, and that too only for a 
period of five years. Sudip Chaudhuri, The WTO and India's Pharmaceuticals Industry: Patent Protection, TRIPS, and Developing 
Countries (Oxford University Press 2005) 37. This law was based on the recommendation of the Ayyanger Committee against 
product patents on the ground that monopoly rights over products limits access to vital products such as food and medicines by 
granting absolute powers to MNC at the expense of public interest. N Rajagopala Ayyangar, Report on the Revision of the Patents 
Law (Ministry of Commerce and Industry Manager of Publications, 1959). The absence of product patents enabled the industry to 
perfect the art of reverse engineering and copying of foreign patented products, which led to an increase in the local production of 
medicines. Furthermore, the Patents Act created a conducive environment for competition to thrive in the pharmaceutical market 
by eroding the monopoly powers of MNC to patent final products of innovative medicines. William J Bennett, ‘Indian 
Pharmaceutical Patent Law and the Effects of Novartis Ag v. Union of India’ (2014) 13 Washington University Global Studies Law 
Review 535, 541-542. 
65 
 
1980’s.153 Many European countries and the US were accused of violating the 
IPR of other countries right into the twentieth century.154 As Ta-hong Chang 
argues, developed countries were kicking away the ladder by ‘demanding from 
developing countries institutional standards that they themselves had never 
attained at comparative levels of development.’155 Indeed, one scholar observes 
that ‘the old era of IP was as much a consequence of intellectual capitalism as a 
cause of it, and […] was not a necessary condition for the emergence of the 
industries and technologies that fostered it.’156  
Equally, the Commission on Intellectual Property Rights (CIPR) observes that 
developing countries in their nascent stage of development require different IP 
policies according to their levels of development. The CIPR states in this 
respect that: 
[…] for most developing countries with weak technological capacity, the evidence 
on trade, foreign investment, and growth suggests IP protection will have little 
impact. Nor is it likely that the benefits of IP will outweigh the costs in foreseeable 
future. For more technologically advanced developing countries, the balance is 
finer. Dynamic gains may be achieved through IP protection, but at a cost to other 
industries and consumers.157 
It appears, therefore, that higher IPR provisions are more suitable for countries 
that have achieved a considerable level of industrial growth. That way, it 
supports the capacity for greater industrial, scientific and technological 
efficiency. For developing countries with insufficient manufacturing or 
technological capacity, the rules may not confer significant benefits, conversely, 
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the patent rules may also have the effect of restricting access to 
pharmaceuticals for the poor.  
Nevertheless, on the positive side, the goals, principles and objectives of the 
TRIPS Agreement contain provisions that take into account the needs of both 
producers and users of IP as well as some development concerns of developing 
countries. 
 
2.5.3 Goals of the TRIPS Agreement from a Public Interest Standpoint 
There are two ways of thinking about the goals and function of the TRIPS 
Agreement. First, it is a legal institution that provides rules for the protection and 
regulation of private proprietary rights of an innovation or invention. For this 
purpose, the Preamble recognises the need for ‘the provision of effective and 
appropriate means for the enforcement of trade-related intellectual property 
rights,’ and reiterates that IP rights are private rights.158 The provisions in the 
Agreement generally provide exclusive and time-specific IP-related rights and 
privileges. These IP rules and rights are, however, not devoid of public interest 
and welfare objectives.  
A second approach is to view the TRIPS as an instrument for promoting trade, 
scientifc and technological advancement, as well as human, social and 
economic development through the instrumentality of IP protection. For 
example, the Preamble to the Agreement highlights this objective by explicitly 
referring to the need to protect IPRs and promote international trade relations 
by reducing  
[…] distortions and impediments to international trade […] taking into account the 
need to promote effective and adequate protection of intellectual property rights, 
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and to ensure that measures and procedures to enforce intellectual property rights 
do not themselves become barriers to legitimate trade.159  
The TRIPS Agreement also aims to promote a developmental objective for IP to 
contribute to technological innovation, knowledge-based economic growth and 
technological diffusion. This intention is expressed in the Preamble to the 
Agreement which recognises ‘the underlying public policy objectives of national 
systems for the protection of intellectual property including development and 
technological objectives.’160 In the context of public health, it suggests that WTO 
members can take into consideration, the developmental needs of their citizens 
to have access to medicines under their national systems.161 It also means that 
members can implement the Agreement in a manner that promotes their 
national technological and R&D priorities, public interest and health objectives.  
This public welfare development goal of the TRIPS Agreement is consistent and 
can be read together with the WTO goals which state that:  
[…] relations in the field of trade and economic endeavour should be conducted 
with a view to raising standards of living, ensure full employment and a large and 
steadily growing volume of real income and effective demand and expanding the 
production of and trade in goods and services, while allowing for the optimal use of 
the world’s resources in accordance with the objective of sustainable development, 
[…] and to enhance the means for doing so in a manner consistent with their 
respective needs and concerns at different levels of economic development.162 
In this manner, while the WTO’s IP system has been framed as an instrumental 
institution for the creation and protection of IP, which includes patented 
                                                          
159 Preamble to the TRIPS Agreement. 
160 Preamble to the TRIPS Agreement. 
161 This argument is consistent with Article 1(1) of the TRIPS Agreement which states that ‘[m]embers shall be free to determine 
the appropriate method of implementing the provisions of this Agreement within their own legal system and practice.’ Sisule F 
Musungu, 'The TRIPS Agreement and Public Health' in Carlos María Correa and Abdulqawi Yusuf (eds), Intellectual Property and 
International Trade: The TRIPs Agreement (Kluwer Law International 2008) 427. 
162 (Emphasis added). First recital, Preamble to the Marrakesh Agreement Establishing the World Trade Organization, Apr. 15, 
1994, the Legal Texts: The Results of the Uruguay Round of Multilateral Trade Negotiations 4 (1867 U.N.T.S. 154, 33 I.L.M. 1144 
1994) (Hereinafter the WTO Agreement). Also Available at  
<https://www.wto.org/english/docs_e/legal_e/04-wto.pdf> accessed 15 January 2015. 
68 
 
pharmaceutical products and processes, its underlying objective lies in a 
broader development mandate.  
 
 2.5.4 The Public Interest Objectives and Principles of the TRIPS 
Agreement in Articles 7 and 8  
 Article 7 has been described as the balancing and ‘interpretive provision' of the 
TRIPS Agreement.163 It sets out the principal objective of the Agreement and 
plays a central role in the interpretation and enforcement of TRIPS.164 The 
provision states that IP protection and implementation should promote 
technological innovation and dissemination, and also links this protection to the 
promotion of social and economic development as follows: 
The protection and enforcement of intellectual property rights should contribute to 
the promotion of technological innovation and to the transfer and dissemination of 
technology, to the mutual advantage of producers and users of technological 
knowledge and in a manner conducive to social and economic welfare, and to a 
balance of rights and obligations. 
Significantly, this provision delineates the core public interest objectives of the 
TRIPS Agreement.  
The first objective envisages that the protection and recognition of IPRs should 
result in improvements in technology, knowledge and innovation. This supports 
the argument made earlier in subsection 2.4 that a patent, a form of IP, is not an 
end in itself. It can be said that this provision not only describes the 
technological purposes of the IP provisions in the TRIPS Agreement, it 
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encapsulates the public agenda behind the Agreement and defines IP 
protection as a means to an end.165 Thus, IP is an instrument for the 
advancement of technological dissemination, knowledge and innovation, which 
should also promote socio-economic development and public welfare. This 
point was made further by the submission of developing countries, including 
Nigeria, to the TRIPS Council before the Doha Ministerial Conference that, 
‘Article 7 […] clearly establishes that the protection and enforcement of 
intellectual property rights do not exist in a vacuum. They are supposed to 
benefit society as a whole and do not aim at the mere protection of private 
rights.’166  
The second objective seeks to protect and promote both the interests and 
contributions of authors/innovators as IP producers, at the same time as the 
interests of users of IP who, according to Correa, are ‘interpreted as 
encompassing final consumers as well as producers of goods and services that 
utilize technological knowledge.’167 Thus not only does IP in TRIPS grant rights 
to and impose obligations on innovators, it also acknowledges the ‘equal’ rights 
and obligations of public users to access and use intellectual products and 
technological knowledge.168 This objective can be invoked as a support for 
public health and access to medicines. From a public health perspective, it can 
be argued that it envisages that patients, as users, should gain some advantage 
from medicines which are products of intellectual creation. To gain this benefit, 
however, it is obvious that patients will need access to the drugs.  
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This second objective also reflects the need to find a balance between 
encouraging incremental creativity innovation and promoting users’ and 
society’s interests.169 The balance, according to Gervais, should be assessed 
using well-established IP legal principles and identified that the balance 
entails:170  
a) rewarding or compensating creators and inventors for innovation and; 
b) promoting the interest of businesses and the public at large in securing 
access to science, technology and culture.  
Gervais concludes that ‘[i]n order to stimulate innovation, this balance must be 
maintained.’171 
While it is argued that maintaining this balance is essential to stimulate 
incremental innovation,172 the question remains, how can this balance be 
achieved? Gervais provides insight into the outline of this ‘balance.’ At the 
policy level, it requires granting inventors rights in a manner that allows them to 
recoup investment costs without hindering competition or future innovation.173 In 
other words, inventors’ right must be weighed against the need for the public 
and users to access the products and information about the innovation.174 While 
this is ideal, in practice, finding a balance between protecting the short-term 
interests of IP owners whilst simultaneously promoting long-term investment in 
innovation and creativity and benefits to users is hard to achieve. Sometimes, 
the interests of IP producers and users might conflict. This is often the case 
where tension arises between the need to provide incentives for 
pharmaceuticals R&D and the need to access essential drugs.  
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The third objective, reflects the need to take into account ‘social and economic 
welfare,’ development and the advancement of both IP producers and the public 
in the protection, interpretation and enforcement of IP. In this manner, TRIPS 
seeks to strike a balance between the objectives of promoting IP as an 
incentive to encourage invention, and requiring the protection to contribute to 
social-economic, welfare and technological development goals. The emphasis 
is important because it positions the TRIPS Agreement not only as an 
instrument for the protection of IP rights but also as a means for promoting 
societal welfare and development as argued in the preceding section of this 
chapter. The provisions of Article 7 can be read together with Paragraph 19 of 
the Doha Ministerial Declaration which states that ‘[i]n undertaking this work, the 
TRIPS Council shall be guided by the objectives and principles set out in 
Articles 7 and 8 of the TRIPS Agreement and shall take fully into account the 
development dimension.’175 The Resource Book on TRIPS and Development 
also makes the point that Article 7 clearly indicates that the negotiators of 
TRIPS did not intend to ‘abandon a balanced perspective on the role of 
intellectual property in society.’176 Thus, the Agreement intends that patent rules 
should play a significant role in promoting, not hindering the public welfare and 
interests. 
Article 8 is another ‘interpretative or normative principle’ of the TRIPS 
Agreement that further state the public policy objective of patents and other 
IPRs in the Agreement.177 Its importance has been acknowledged by Professor 
Peter K Yu as a framework to limit the exclusive rights granted to IP holders in 
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the interests of the public.178 Provided it is consistent with the general standard 
in TRIPS, the provision of Article 8 permits members to promote the public 
interest in sectors of vital importance to their socio-economic development, with 
particular stress on nutrition and health. Article 8(1) provides that:  
Members may, in formulating or amending their laws and regulations, adopt 
measures necessary to protect public health and nutrition, and to promote the 
public interest in sectors of vital importance to their socio-economic and 
technological development, provided that such measures are consistent with the 
provisions of this Agreement. 
Thus, WTO members are allowed some flexibility to pursue their public policy 
objectives by incorporating and implementing measures, including policies, to 
safeguard the national public interest, health, nutrition and socio-development 
priorities in their domestic laws.179 According to Professor Correa,  
Article 8.1 broadly recognizes Members’ rights ‘in formulating or amending their 
laws and regulations’[…] [I]t does not only refer to laws and regulations on IPRs 
but to measures adopted in other fields, for instance, those that restrict the 
manufacture or commercialization of IPR-protected goods. Issues concerning the 
application of Article 8.1 may, hence, arise in two contexts, one fully within the IPR 
realm, and another one outside it, but with implications on the protection of 
IPRs.180  
Importantly, Article 8(2) adds support to the Article 8(1) by recognising the need 
to adopt appropriate measures to prevent the abuse of patent rights by 
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patentees, including practices that unduly restrain trade, or hamper technology 
transfer, in a TRIPS-consistent manner.181  
In summary, from a public health point of view, the Preamble, Articles 7 and 8 of 
the TRIPS Agreement outline the importance of the Agreement in the interests 
of society and importantly, the promotion and safeguarding of public health. It is 
imperative therefore, to approach this international IP system from this 
perspective.  
From the above public interest discussion of patents, the next section examines 
the Nigerian patent system. The section also inquires whether the patent 
framework in Nigeria is explicitly public welfare-friendly and reasons for any 
inconsistencies.  
 
2.6 THE ADAPTATION OF A WESTERN STYLE PATENT SYSTEM IN 
NIGERIA: AN ENQUIRY INTO THE EVOLUTION OF PATENT LAW AND ITS 
INADEQUACIES 
The development of the patent law and system in Nigeria can be best split into 
two key eras for analytical convenience: the colonial and post-colonial periods. 
 2.6.1 Colonial Development of Intellectual Property and Patent System  
It is plausible to say that the evolution of the patent law and system in Nigeria 
was devoid of underlying national or public interest considerations. Reasons 
may be traced to its colonial origins. The current patent system is a product of 
the British colonial administration. The introduction of the English Legal System 
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including patent laws was part of the administrative framework of the British 
colonial authorities in the colonies comprising present day Nigeria.182 The first 
national patent legislation in Nigeria was the Patents Ordinance No.17 of 1900 
of the Colony of Lagos.183 At the same time, the Patents Proclamation 
Ordinance No.27 of 1900 was made applicable to the Protectorate of Southern 
Nigeria184 and the Patents Proclamation Ordinance No.12 of 1902 was 
subsequently applied to the Protectorate of Northern Nigeria.185 The legal rules 
provided for the establishment of patents offices and an administrative system 
for the regulation, granting and control of patents in Nigeria.186 The 
administration of patents was under the control of a registrar and his deputy.187 
Applications were made to the patents office for the registration and granting of 
patents for inventions and appeals against decisions, if any, were made to the 
Attorney-General.188 Successful patents were thereafter granted in the name of 
the British Crown by the High Commissioner.189  
The Patent Ordinance and Patent Proclamation Ordinances of 1900 and 1902, 
with subsequent amendments, were repealed after the 1914 amalgamation of 
the Northern and Southern Protectorates into Nigeria.190 Following the 
unification of the Protectorates, the Patent Ordinance No. 30 of 1916 was made 
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to apply to all parts of the newly created Nigeria.191 The 1916 Ordinance with 
amendments was later renamed and re-enacted as the Registration of United 
Kingdom Patents Ordinance No. 6 of 1925.192  
The 1925 Ordinance was a radical departure from its predecessors.193 One of 
the fundamental changes was that a patent could no longer be granted in 
Nigeria.194 Effectively, it terminated the independent patent registration system 
in Nigeria, and instead, established a system of patent registration that was 
dependent on the granting of patents in the United Kingdom (UK).195 By this 
extension, patent rights granted in the United Kingdom were valid in Nigeria, 
provided the application to register the patent was made to the Registrar of 
patents in Nigeria within three years from the date of the patent in the UK.196 By 
way of illustration, an inventor, whether a Nigerian, or anyone who desired a 
Nigerian patent protection, could only procure one by first obtaining a UK patent 
before registering the same invention in Nigeria.197 The validity of the Nigerian 
patent remained in force as long as the patent was still active in the United 
Kingdom.198 
A possible explanation for terminating the autonomous system was that the 
colonial masters wanted to save the cost of maintaining an independent patent 
office and employing knowledgeable technical staff to evaluate patent 
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applications in Nigeria.199 It is also likely that the lack of local expertise on the 
patentability of inventions, and the required personnel with technical knowledge 
of the patent system necessitated the adoption of the UK dependent 
Ordinance.200 This is made obvious in the justification for adopting the 
Ordinance by the Attorney-General of the Colony of Nigeria in the report on the 
draft Patent Ordinance of 1916:  
It is frequently impossible to obtain locally that expert advice which is required by 
the authority responsible for deciding whether or not a patent should be granted, 
and in the circumstances it is submitted that persons desiring to obtain protection 
in Nigeria, for an alleged invention may probably be required to satisfy first the 
Patents Office in the United Kingdom that his invention is one for which a patent 
should be granted.201   
Thus, rather than train the required local officers at the patent office or employ 
additional technically knowledgeable staff to handle patent applications in 
Nigeria, the British authorities thought it best to simply alter the extant 
autonomous patent system and instead, align it with the UK’s. Another reason 
for this variance may simply be the administrative convenience of protecting the 
colonial territorial interest.202  
Besides the onerous time delay of obtaining a patent in this system, the most 
serious disadvantage of this dependency arrangement is that it took away the 
opportunity to build local expertise, train indigenous Nigerians to evaluate 
patent applications, or develop an IP culture that would cater for local needs.203 
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Gaius Ezejiofor observes that the imposed patent system also took away the 
sovereignty and independence of Nigeria as a state to order its domestic and 
local affairs.204 It also produced a cumbersome and inconvenient process for 
the registration of an invention.205 
From the historical description above, it is clear that patent law in Nigeria was 
introduced in order to entrench the dominance of the imperial power and not for 
the usual justification of increasing or supporting innovation and promoting the 
productivity of national inventions. The common rationale for the patent system 
is that it is a hallmark for technological/scientific development and economic 
growth, since it spurs inventiveness and R&D and technology transfer as 
suggested above.206 Also, historical analyses indicate that the IP and patent 
system of many industrialised countries evolved from the need to protect and 
encourage local inventors, promote the dissemination of inventions and develop 
national industries.207 However, the introduction of patent system in Nigeria, and 
neighbouring West African countries such as Ghana, that shared the same 
British law, did not rest on the usual technological development argument, 
neither was it meant to serve the national interest, nor support indigenous 
innovative growth, nor encourage the development of the relevant sectors in 
Nigeria.208 There is no evidence to indicate that the patent system was directed 
towards facilitating technological and economic development in Nigeria.  
From its functional and administrative structure, it appears that the patent 
system was enacted for the benefit of the colonial interest, to protect the 
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material base and mineral resources of the colonised regions.209 Many analysts 
agree that the strategy adopted by the colonial powers was mainly for purposes 
associated with imperialist interests and control of trading rights among the 
colonies.210 Ruth Gana provides a useful account of how Europe’s 
conceptualisation of law influenced the development of IP in developing 
countries during colonialisation.211 Reflecting on this process, Ruth Okediji 
Gana assesses that IP was more than a mere regulation; it was ‘a central 
technique in the commercial superiority sought by European powers in their 
interactions with each other beyond Europe.’212 Accordingly, it was 
‘characterised by efforts to secure national economic interest against other 
European countries in colonial territories.’213  
One great puzzle is how the foreign-dependent patent system could possibly 
function as an instrument for promoting national innovation and technological 
development in Nigeria when there was no framework that would ensure local 
benefits, such as the skills training of local patent agents or the education of 
inventors on the importance of a patent system for them.214 
Despite these shortcomings, the 1925 Ordinance in Nigeria remained in force 
until 1970, well after independence. 
 2.6.2 The Post-Colonial Patent System in Nigeria 
Following Nigeria’s independence in 1960, the independent Nigerian 
Government failed to redress the issue of patent registration’s dependency on 
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the Britain system until ten years after the country regained its right to 
sovereignty.215 In spite of the fact that some new industries were being set up 
that were exclusively or partly owned by Nigerians and foreign parties after 
independence, the IP laws were not amended accordingly to conveniently 
enable local inventors to register their patents.216 This national policy shortfall 
might have been a result of the fact that in a few years after independence, the 
commencement of a civil war disrupted the Government’s proposed national 
development plans and the military administration in power was preoccupied 
with other pressing national issues.217 
The case of Rhone-SA Poulenc and May & Baker v Lodeka Pharmacy in 1965 
set the pace for the revision of an independent patent system and 
administration in Nigeria.218 The facts of the case are as follows. The first 
claimant, in 1951, registered a patent in the UK for an ‘improvement in or the 
new phenothiazine derivatives.’219 In 1957, the patent was afterwards registered 
under the 1925 UK Patent Ordinance with the second plaintiff as a subsidiary 
and exclusive licensee of the first claimant. The second plaintiff, May and Baker 
commenced the sale and distribution of the product under the name ‘Largactil.’ 
In 1964, the Federal Ministry of Health, Nigeria engaged the services of the 
defendant, a local pharmaceutical firm, to supply the patented product in large 
quantities to the Ministry of Health. The claimants commenced actions against 
the defendant alleging an infringement of their patent rights. The defendant, 
whilst acknowledging the patent rights of the claimants, contended that the 
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supply was for public use by the Federal Ministry of Health and so the public 
interest use would override the infringement claim. The defendant consequently 
relied on the Government use provision in Section 46 (1) of the United Kingdom 
Patents Act 1949 which states that: 
Notwithstanding anything in this Act, any Government department, and any person 
authorised in writing by a Government department, may make, use, and exercise 
any patented invention for the service of the Crown in accordance with the [...] 
provision of this section.  
In the determination of the case, the trial judge held that the defendants could 
not rely on the public use provision as under the UK Patent Act. Although 
Ikpeazu J (as he then was) agreed that section 46(1) of the UK Patent Act was 
an express Act that specifically confers power to Government departments to 
override the patentee’s rights, his Lordship was of the view that the UK Patents 
Act 1945 did not apply in totality to Nigeria, and so Section 45(1) could not be 
relied on by the defendant. Furthermore, the only significant effect the UK 
Patent Act had was in respect to the rights and privileges that ensued from the 
issuance of a certificate after the registration of a UK patent in Nigeria pursuant 
to Section 6 of the 1925 Patents Registration Ordinance.  
It appears that the judge did not allow the application of the United Kingdom 
Patent 1949 Act in Nigeria because there was no clear indication that the UK’s 
Patent Act had entire applicability in Nigeria, and it was not expressly or 
implicitly stated that all its provisions had been extended to Nigeria by the 1925 
Registration Ordinance except with regards to a certificate of registration under 
Section 6 of that Ordinance.220 His Lordship further observed that to limit the 
patentee’s exclusive rights for public policy reasons, the Nigerian legislature 
                                                          
220 Yankey (n 1) 125.  
81 
 
had to expressly make provisions conferring powers to the government 
department to grant permission to unauthorised third parties who wished to 
supply the patented product. In the absence of this provision, section 46 (1) of 
the 1949 UK legislation could not grant such powers. The judge concluded that 
this had not been done in Nigeria; hence the legislature did not intend the power 
to exist.  
Significantly however, the outcome of the decision in the case led to the 
promulgation of the Patent (Limitation) Decree of 1968.221 Similarly to the 
provisions of section 46 (1) of the UK Patent Act, the Decree made provisions 
for the use of certain inventions in the public’s interest by the government and 
authorised third parties in Nigeria.222 The law also contains certain provisions 
for the use of a patented article in the event of emergencies to purchase, make, 
vend, use and exercise the patented invention for any purpose at the discretion 
of the Commissioner in the interest of the public.223 Unfortunately, under section 
5(1) and (2) of the Decree, the provisions and effect of the United Kingdom 
Patent Act of 1949 were fully extended to Nigeria.224 Effectively, the entire 
provisions of the UK patent laws were made to apply in Nigeria. There was 
absolutely no reasonable justification for this incorporation.225 The Nigerian 
legislative authority could have simply amended its laws to include the same 
provisions (including exceptions) as the UK Act if the intention had been to rely 
on similar provisions in the UK Patent Act.  
A review of the Patent (Limitation) Decree of 1968 shows that it was enacted 
out of necessity, therefore it merely adopted the United Kingdom’s Patents Act 
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of 1949 and the previous 1925 Ordinances as the statutory law regulating the 
patent system in Nigeria and made amendments thereof only subject to the 
minor modifications introduced in the Decree.226 In any case, there was no 
reason for Nigeria to adopt the same standards and provisions of UK patent 
law, considering the stage of its technological and economic development at 
that time. There was little to indicate that the Patent Decree showed an 
appreciation for indigenous inventive activity or set out to deliberately 
encourage local innovation or to spur further inventions to promote the public’s 
welfare.227 As Yankey noted, the Decree was not founded on any national 
planning consideration or a coherent and comprehensive national technology 
policy.228 It is little wonder that this Decree was also ill-suited to encourage the 
innovative progress of the new indigenous industries that were springing up 
after independence.229 For example, the grant of patents was still subject to a 
registration system in the UK.230 This process proved too cumbersome and 
inconvenient to the registration of new inventions.231 Thus ironically, the country 
was no longer under colonial administration, yet it sustained reliance on its 
former colonial authorities’ laws.  
 2.6.3 The Present State of the Law: the Patent and Designs (PDA) Act of 
1970 
In the light of the above noted inadequacy of the Patent Decree 1968, the 
Patents and Designs Decree of 1970232 (now the Patents and Designs Act 1970 
(PDA)) was enacted to set out provisions for a national statutory and 
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administrative patent regime.233 The PDA contains detailed provisions for the 
procurement of patents in Nigeria and sets out to facilitate inventive enterprise 
in the budding indigenous industries.234 Effectively, the PDA made provisions 
for the establishment of an independent national patent system to grant patents 
to new inventions or significant improvements that possesses high inventive 
qualities and are industrially inclined.235  
Nonetheless, at the time the legislation was passed, there was no national 
policy consideration or technology planning to ensure the practical public benefit 
of having a patent system, neither was the system designed to suit the 
economic structures and needs of the country at that time.236 For instance, the 
patent legislation provided an exclusive set of rights to the patent holder for a 
period of twenty years. While some developing countries such as India 
reviewed their patent laws to reduce the patent term and remove product patent 
protection to make it flexible and more responsive to the country’s development 
policy and industrial objectives, Nigeria’s patent law from the onset was 
stringent.237 Historically, the patent terms of the current industrialised and more 
developed countries was less than twenty years and they subsequently 
amended their laws as compelled by industrial needs.238 As observed by 
Shyllon, Nigeria was yet to formulate a national economic and development 
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policy for technological progress and growth of national industries at that time, 
thus there was no need for a stringent patent policy.239  
Perhaps, this legislative development is a reflection of the circumstances of its 
enactment. The PDA relied heavily on the draft International Bureau for the 
Protection of Intellectual Property (BIRPI)’s Model Law for Developing 
Countries.240 Nigerian IP scholars Professor Adewopo and Shyllon noted in this 
respect that the PDA, while relying heavily on the Model Law, did not proceed 
on the basis of any defined or underlying national policy consideration.241 
Though the Model Law supposedly emphasised innovation and technological 
development for developing countries, in practice it was influenced by pressure 
from industrialised countries for developing countries to join the international 
‘community of nations’, thereby subjecting them to the same patenting 
standards as the more developed and industrialised countries.242 Reflecting on 
the rationale for modelling the PDA according to the provisions of the Model 
Law, some scholars opine that Nigeria and some developing countries did so in 
the belief that it would afford the country an opportunity to gain increased 
access to trade, patented foreign technology and information from the 
industrialised countries.243 Accordingly, the then Acting Chief Registrar of 
Nigeria actively participated in the negotiations and the enactment of the draft 
Model Law; hence Nigeria simply adopted the provisions of the Model Law as 
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the blueprint for Nigeria’s patent system without an assessment of its benefits 
for the country, nor was it informed by any national policy consideration.244 
From an access to medicines perspective, although the PDA provides for 
compulsory licence and government use of patents and excludes certain 
inventions from patentable inventions,245 the flexibilities and patent exceptions 
in the PDA are inadequate for the purpose of sufficiently enhancing the 
availability and accessibility to affordable essential medicines in Nigeria, to be 
discussed in detail in Chapter V. Also, Nigeria is a member of the WTO and is 
thus bound to the terms and provisions of the TRIPS Agreement, however, the 
country is yet to incorporate and domesticate the Agreement including its health 
related flexibilities.246 
Although Nigeria enacted a law that had its foundation in a colonial creation, it 
now needs to be designed in a manner that will suit local needs and 
requirements in its traditional terrain to adequately encourage the inflow of 
important health-related technologies, stimulate innovative activities, and 
promote the circulation of knowledge in relevant sectors such as the 
pharmaceutical industry. As will be argued in Chapter VI, the system should 
also be flexible to promote access to affordable essential medicines.  
In addition, patent protection may have negative consequences for public 
health, diffusion and competition, especially when it limits access to essential 
knowledge and products of innovation at an affordable cost. It is, therefore, 
imperative to carefully strike a balance between promoting innovative 
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pharmaceutical R&D activities in Nigeria, promoting further innovations and 
facilitating the availability of cheaper generic drugs and also, promoting 
competition to facilitate better access to medicines. The key to striking this 
balance lies in the patent system through its patentable requirements and 
exclusions, its patentability criteria including the legal exceptions to patent 
rights, and the public interest related-flexibilities.247 In agreement, the 
Organisation for Economic Co-operation and Development (OCED) point out 
that appropriately suited patent subject matters, patentability threshold, and 
patent breadth or term of protection are basic tools within the patent systems 
that policy-makers and the government can use to enhance innovation and 
promote dissemination and diffusion of knowledge.248 
In sum, there is no evidence to indicate that patent law in Nigeria was 
developed based on a clear IP development-oriented policy or formulated to 
deliberately promote the public interest in Nigeria. Indeed, one scholar, 
commenting on the changes made from when patent law was initially introduced 
by the colonial administration to the post-independent patent law in many 
African countries, noted that their laws were based on mere aspirations of 
having an independent patent system, or to comply with international 
obligations.249 It is no wonder that patent law in Nigeria is not adequately 
structured to accommodate all the issues that arise within the context of patents 
and access to medicines such as the incorporation of all the available health-
related flexibilities.250  
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 2.7 Conclusion: Approaching the Patent System from a Public Health or 
User Perspective to Promote Women’s Access to Essential Medicines  
The point made in this chapter is that the statutory requirements of the patent 
framework indicate that the system does not completely disregard the public. 
This finds support in the observation by the UK Commission on Intellectual 
Property Rights that IPR privileges should not be considered as an end in 
theirselves, rather, they are a means to an end, ‘as instruments of public policy 
which confer economic privileges on individuals or institutions solely for the 
purposes of contributing to the greater public good’251 In this regard, it is argued 
that since one of the aims of the patent system is to promote the development 
goals of society, the exclusive control right which it confers upon inventors 
should not stand in the way of this fundamental objective. Thus, a patent right 
granted to innovators should promote, not hamper, public health. The system’s 
benefit to society’s interests must be evaluated in the light of this public interest 
goal.252 When the patent system is approached in the light of its public welfare 
objectives, it is expected that the interpretation and enforcement must take into 
account this basic social function and development purpose of the patent 
system. With this goal in mind, this thesis makes a case for Nigerian women’s 
access to medicines within the context of their socio-economic and cultural 
setting. In this connection, this thesis argues for ways to improving access to 
essential health treatments within the context of patent law, especially through 
the use of the TRIPS-compliant flexibilities and patent rights exemptions, where 
patent right threatens this access. 
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In closing, a patent, as an instrument for promoting better health, would require 
that people can actually derive the benefits, through access to the patented 
invention or medicine. The next chapter evaluates the debate on the adverse 
public health effect of patent rights on the accessibility to affordable life-saving 
treatments, particularly for poor women in Nigeria and other developing 
countries.  
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CHAPTER III: THE FRAMEWORK FOR THE INTERNATIONAL 
PROTECTION OF PATENTS, WOMEN’S HEALTH IN NIGERIA 
AND THE ISSUE OF ACCESS TO MEDICINES 
Health is not everything, but, without health, everything else is nothing.1 
 
 3. Introduction  
For the purpose of the study in thesis, access to affordable essential medicines 
is identified ‘as having medicines continuously available and affordable at public 
or private health facilities or medicine outlets that are within one hour’s walk 
from the homes of the population.’2 The concept of access to medicines 
generally encompasses the idea that everyone should have the equitable 
means, facilities and opportunities to have, obtain and use safe life-saving 
drugs for health treatment purposes.3 Access to a secure, affordable, regular, 
sustainable and good quality supply of life-saving essential medicines is, 
however, not adequate, especially in developing countries, including Nigeria.4 
Access to medicines is not only a public health conundrum; the problem of 
access also raises concerns with regards to the patenting of medicines. The 
patenting of pharmaceuticals is often at the forefront of the debate on the 
effects of patent rights on the availability of, and affordable access to, life-saving 
treatments, mainly for people living in developing countries.  
                                                          
1 Joseph Sutton (ed), Words of Wellness: A Treasury of Quotations for Well-Being (Hay House Inc 1991). 
2 United Nations, Millennium Development Goal 8: - Delivering on the Global Partnership for Achieving the Millennium 
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4 United Nations, Millennium Development Goal 8 - Delivering on the Global Partnership for Achieving the Millennium Development 
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(United Nations 2008). Available at  
<http://www.un.org/millenniumgoals/2008highlevel/pdf/newsroom/goal%208%20final.pdf> accessed 15 December 2015  
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Against this background, this chapter examines the problems of access to 
medicines within the context of patent rights in Nigeria and the international 
debate on the relevance of the Trade Related Aspect of Intellectual Property 
Rights (TRIPS) Agreement, particularly the ways in which the intellectual 
property (IP) rules in the Agreement could impact adversely on access to 
essential medicines. In conducting the analysis, the chapter particularly 
highlights the distinct public health needs and interests of women in their quest 
for access to essential medicines in Nigeria. This is borne out of a need to make 
a case for women’s right to health by pointing to a range of legal, socio-
economic and other factors, both in Nigeria and within the international trade 
system that can positively or negatively influence their health outcomes. 
Essentially, this chapter adds a gendered dimension to the problems of access 
to medicines within the scope of patent law.5 Principally, it surmises that, 
although the problems of access to medicines in Nigeria can be traced to socio-
economic, cultural and limited infrastructural factors, patent provisions can also 
potentially bear upon women’s access to important healthcare treatments.  
This chapter is divided into two parts. The first sets the tone for the study by 
outlining the general challenges of the Nigerian health care system and also the 
distinct health needs of its women. In addition, the general health condition and 
problems of access to medicines in Nigeria are discussed. This part argues 
that, although men and women face similar constraints and difficulties in relation 
to accessibility to medicines, due in part to socio-economic factors, harmful 
traditional, cultural and religious practices, the experience of women are 
exacerbated to varying degrees. It is therefore argued that on any national 
                                                          
5 This chapter does not claim to make an assessment of a gender-specific effect of TRIPS on access to medicines as there is no 
empirical basis to make such an assertion. Nonetheless, the chapter makes analogical analysis of the possible adverse effect of 
patents in TRIPS on women’s health, taking into account their socio-economic and cultural circumstances, in the absence of 
empirical evidence.  
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process to improve access to medicines requires multifaceted efforts. 
Specifically, in this thesis, it is argued that these should include a consideration 
of the ways in which patent rights could impede women’s accessibility to 
affordable essential medicines.  
The second part relates the problems of access to the widespread international 
debate on the ways in which patent rights could hinder accessibility to life-
saving medicines. This analysis also explores the unintended consequences 
and repercussions of patent rights on the cost of medicines and availability of 
drugs to women. In particular, the focus is on the patent provisions in the TRIPS 
Agreement which extend to pharmaceuticals and the consequential trickle-down 
effect on the price and the availability of medicines. Similarly, it outlines the 
problems associated with the patent system’s inadequacy on promoting 
investment in medicinal products for neglected diseases that affect women and 
the poor in many parts of the developing world. 
To put the research in context, this chapter starts with an examination of the 
health care system in Nigeria. 
 
PART I: THE NIGERIAN HEALTHCARE SYSTEM AND THE 
ISSUE OF ACCESS TO MEDICINES 
 
3.1 Essential Medicines: Improving Access to Life-saving and Important 
Pharmaceuticals 
While medicines are vital to maintaining, improving and restoring health, as well 
as for preventing and treating illnesses and diseases, essential medicines are 
important medicinal treatments that can save lives and improve health when 
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used appropriately, and available at affordable prices.6 The World Health 
Organization (WHO) defined essential medicines as 'those that satisfy the 
priority health care needs of the population.'7 Accordingly, these are 
medications that everyone should have appropriate access to, at all times to 
improve their health.  
             Essential medicines are intended to be available within the context of 
functioning health systems at all times in adequate amounts, in the appropriate 
dosage forms, with assured quality and adequate information, and at a price the 
individual and the community can afford.8  
In 1977, the WHO noted that essential medicines are 'of utmost importance, 
basic and indispensable, and necessary for the healthcare needs of the 
populations.'9 Importantly, access to essential drugs is recognised as 
fundamental to the realisation of the right to health.10    
Essential medicines are selected on the basis of certain criteria. They are 
selected with due regards to the 'disease prevalence, public health relevance, 
evidence of clinical efficacy and safety, and comparative costs and cost-
effectiveness.'11 There is no universal identification of all essential medicines; 
however, the definition of essential medicines by the WHO is widely adopted as 
the parameter for categorising essential medicines. The implementation of 
                                                          
6 World Health Organization, 'Equitable Access to Essential Medicines: A Framework for Collective Action' (WHO Policy 
Perspectives on Medicines No. 008, World Health Organization2004) 1. According to the Oxford Dictionary, Essential is defined as 
'absolutely necessary or extremely important.' Following this definition, essential medicines are medicines that are considered 
absolutely necessary, important and indispensable to good health and indeed, human survival. Angus Stevenson (ed), Oxford 
Dictionary of English (3rd edn Oxford University Press 2010) 
7 When the World Health Assembly convened in 1975, it introduced the concept of essential medicines and national drug policies. 
The WHO developed the first essential medicines list in 1977 and since then the list has been revised every 2 years. ibid 
8 ibid 
9 World Health Organization, The Selection and Use of Essential Medicines: Report of the WHO Expert Committee 2002 (including 
the 12th Model List of Essential Medicines) (WHO Technical Report Series, No. 914, World Health Organization 2003) 14.  
10 See Paragraph 12(a), 17 of the General Comment no 14. In paragraph 43(d) the provision of essential drugs, as from time to time 
defined under the WHO Action Programme on Essential Drugs is a minimum core obligation of the State to fulfil, respect and 
protect the right to health. Accessing essential medicines as a right to health is the central subject of chapter IV 
11  World Health Organization, 'Essential Medicines' (World Health Organization, 2017) available at 
<http://www.who.int/medicines/services/essmedicines_def/en/> accessed 1 March 2017.   
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which is intended to be flexible and adaptable to many different situations.12 The 
WHO states that which medicines are to be regarded as 'essential' is a matter 
of national responsibility; although further guidance is provided on how to 
determine and select essential medicines.13  
The WHO publishes a Model List of essential medicines although each country 
is encouraged to prepare and publish their own list by taking into account their 
development, health and national priorities.14 Though the list is not designed as 
a global standard, it is a guide for countries to adopt and adapt where 
necessary in the development of their national and institutional essential 
medicines list.15  
The first Model List of Essential Medicines was launched in 1977.16 It was 
designed to serve as a blueprint for the most effective, affordable and safe 
medicine to meet important healthcare needs and priorities.17 The most recent 
list is the 19th Model List of Essential Medicines, prepared by the WHO Expert 
Committee in April 2015. The WHO essential Model List contains a core list and 
a complementary list of essential drugs.18 The essential medicines list (EML) of 
a country is vital to improving and maintaining health as it gives priority status to 
safe and high-quality medicines that address a country’s public health 
                                                          
12 World Health Organization, 'Equitable Access to Essential Medicines: A Framework for Collective Action' (n 6) 
13 ibid 
14 Over 150 countries including 95% of developing nations have published an official essential medicines list. The essential 
medicines list enables health authorities, especially in developing countries, to optimise pharmaceutical resources. United 
Nations, Millennium Development Goal 8: Delivering on the Global Partnership for Achieving the Millennium Development Goals- 
MDG Gap Task Force Report 2008  (United Nations 2008) 36. 
15 World Health Organization, 'Essential Medicines' (n 11); World Health Organization, 'Equitable Access to Essential Medicines: A 
Framework for Collective Action' (n 6) 
16 ibid 
17 World Health Organization, 'Essential Medicines' (n 11); Sitanshu Sekhar Kar, Himanshu Sekhar Pradhan and Guru Prasad 
Mohanta 'Concept of Essential Medicines and Rational Use in Public Health' (2010) Indian J Community Med. Jan 35(1) 10–13, 10. 
18 According to the WHO, 'the core list presents a list of minimum medicine needs for a basic health-care system, listing the most 
efficacious, safe and cost–effective medicines for priority conditions. Priority conditions are selected on the basis of current and 
estimated future public health relevance, and potential for safe and cost-effective treatment. The complementary list presents 
essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, 
and/or specialist training are needed.' World Health Organisation, 'WHO Model List  of  Essential Medicines 19th List (April 2015)' 
(World Health Organization 2015). Also available at 
<http://www.who.int/selection_medicines/committees/expert/20/EML_2015_FINAL_amended_AUG2015.pdf> 
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challenges, whilst also taking into account the cost effectiveness of the 
medicinal treatment.19 
Most studies on access to essential medicines particularly with respect to 
pharmaceutical patents tend to focus on essential treatments for HIV/AIDS, TB, 
malaria and neglected tropical diseases in developing countries. While 
medicines for these diseases and illnesses are important and part of the 
argument in this study, the concept of essential medicines for this thesis is 
broader in scope. It also encompasses medicines for women's reproductive and 
sexual health problems, i.e. medicines to ensure healthy pregnancy and 
delivery, contraceptives and medicines for prevention and treatment of sexually 
transmitted infections (STIs), HIV/AIDS and pregnancy-related illness and 
death.20 Contraceptives are essential medicines to the extent that it is 
necessary to curtail early and unwanted childbearing, and prevent unplanned 
pregnancies, especially where the pregnancy can be damaging to the health, 
wellbeing and human development of women.21 Access to contraceptives can 
also limit the termination of unwanted pregnancies and the option of unsafe 
abortion. The WHO revealed that unsafe abortion poses a significant risk to 
health, particularly in poorer nations.22  
                                                          
19 Sophie Logez and others, 'Essential Medicines for Reproductive Health: Developing Evidence Based Interagency List' (2011) 
South Med Rev. 4(2): 62–68, 62. 
20 See Jane Cottingham and Marge Berer, 'Access to Essential Medicines for Sexual and Reproductive Health Care: The Role of the 
Pharmaceutical Industry and International Regulation' (2011) 19 Reproductive Health Matters 69–84. (Observing that the majority 
of research and development, manufacture and distribution of drugs including sexual and reproductive, is in the hands of private 
profit-making pharmaceutical companies that hold patent rights to their creations.) 
21 Contraceptive here refers to the medicinal contraceptive. However, it can still be argued that Condom, as a form of birth control 
and family planning, should be categorised as essential since it can offer protection against unplanned pregnancy and significantly 
protect against HIV or other sexually transmitted diseases (STDs). If HIV/AIDS and STD's can be prevented, accessing essential 
medicines for treatments of the diseases would be less of an issue. This analysis is outside the scope of this thesis.  
The WHO indicated that an estimated 225 million women in developing countries would like to delay or stop childbearing but are 
not using any method of contraception. World Health Organization, 'Family Planning/Contraception: Fact sheet' (World Health 
Organization 2017) <http://who.int/mediacentre/factsheets/fs351/en/> accessed 1 March 2017. 
22 World Health Organization, 'Reproductive Health Strategy to Accelerate Progress towards the Attainment of International 
Development Goals and Targets' (World Health Organization 2004) 14. Also available at 
<http://www.who.int/reproductive-health/strategy.htm>accessed 
on  February 2017;  World Health Organization, The World Health Report 2002: Reducing Risks. Chapter 3: Perceiving Risks (World 
Health Organization 2002). 
Also Available at <http://www.who.int/whr/2002/en/>  
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                   [u]nsafe abortions kill an estimated 68 000 women every year, representing 13% of 
all pregnancy-related deaths. In addition, they are associated with considerable 
morbidity; for instance, studies indicate that of every five women who have an unsafe 
abortion, at least one suffers a reproductive tract infection as a result; some of these 
infections are serious, leading to infertility.23 
In a similar manner, sexual and reproductive ill-health can result in sexual 
dysfunction and other gynaecological conditions such as severe menstrual 
problems, urinary and faecal incontinence due to obstetric fistulae, uterine 
prolapse, and pregnancy loss.24 This can lead to maternal and perinatal 
mortality. Consequently, this retards development, where the people affected 
are unable to make choices and exercise free will to make development 
choices.  
Studies also indicate that poor reproductive health and sexual health problems, 
including complications arising from early childbearing, HIV infection and 
sexually transmitted infections (STIs) are significant disease burdens in 
developing countries and also, essential medicines for reproductive health are 
often not available to the majority of women who need them.25 A survey further 
estimated that many couples who are at risk of unplanned or unintended 
pregnancy and would choose birth control using effective modern 
contraceptives are unable to do so.26 Also, reproductive and sexual health 
                                                                                                                                                                          
See also World health Organization, The World Health Report 2005 - Make Every Mother and child 
Count (World health Organization 2005). Also Available at <http://www.who.int/whr/2005/en/index.html>  
23 World Health Organization, 'Reproductive Health Strategy to Accelerate Progress towards the Attainment of International 
Development Goals and Targets' (n 22) 14. 
24 Sophie Logez and others (n 19); Véronique Filippi and others, 'Levels and Causes of Maternal Mortality and Morbidity' in Black 
RE and others (eds), Reproductive, Maternal, Newborn, and Child Health: Disease Control Priorities, Third Edition (Volume 2) (The 
International Bank for Reconstruction and Development / The World Bank 2016) 6. 
25 The World Bank, Reproductive Health at a Glance. (The World Bank 2001). Also available at http://info.worldbank 
org/etools/docs/library/122031/bangkokCD/BangkokMarch05/ 
Week1/4Thursday/S1BoundariesofRH/RHataGlance.pdf  
26 World Health Organization, 'Family Planning/Contraception: Fact sheet' (n 21) 11; Sophie Logez and others (n 19); World Health 
Organization, 'Reproductive Health Strategy to Accelerate Progress towards the Attainment of International Development Goals 
and Targets' (n 22)   
RHR_04_8/en/index.html> accessed on 19 February 2017]: International Conference on Population and Development (ICPD). 
Chapter VII, Reproductive Rights and Reproductive Health In: Summary of the ICPD Programme of Action. 
<http://www.unfpa.org/icpd/summary.htm#chapter7> accessed 2 March 2017; World Health Organization, 'Reproductive Health 
Strategy to Accelerate Progress towards the Attainment of International Development Goals and Targets' (n 22) 14. 
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problems such as maternal, perinatal mortality and gynaecological health-
related complications are said to be a significant disease burden for women of 
reproductive age.27  
Besides reducing the need and associated risk of abortion, contraceptive and 
medicinal resources for family planning will enable women to make informed 
decisions about their reproductive and sexual health. For instance, women can 
control childbearing until resources are available for adequate nutrition, health 
care and education.  
As will be discussed in Chapter IV, the right to health contains freedoms and 
entitlements. These freedoms include the right to control one's health and body 
including sexual and reproductive rights, and as such medicines for 
reproductive health and contraceptives are an essential part of a women's right 
to health.28 Thus it is argued that the right to access essential medicines, 
including contraceptives and pharmaceuticals for reproductive and sexual 
health, is not only a fundamental aspect of the human right to health and 
imperative to achieving good health, it is also a means by which individuals and 
women can build their health capabilities and enhance their human 
development. As will be discussed in detail in Chapter V, the capabilities 
approach to development, wellbeing and justice emphasises the importance of 
people's choices, freedoms and the opportunities to do and be what they term 
as valuable and lead the kind of lives they choose to lead.29 Thus Martha 
Nussbaum, a foremost capabilities scholar, argues that 'being able to have 
good health, including reproductive health' is one of the core capabilities that 
                                                          
27 World Health Organization, 'Reproductive Health Strategy to Accelerate Progress towards the Attainment of International 
Development Goals and Targets' (n 22) 11. 
28 Paul Hunt, 'The Right To Health: Key Objectives, Themes, and Interventions 
Questions for Reflection and Discussion' in Burns H Weston and Anna Grear (eds), Human Rights in the World Community: Issues 
and Action (University of Pennsylvania Press 2016) 189. 
29 Jocelyn Dejong  'Capabilities, Reproductive Health and Well-being' (2006) 42 The Journal Of Development Studies' 1151. 
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should be supported by all democracies.30 Therefore, reproductive health 
treatments, contraceptives and family planning medications as essential 
medicines that can enhance a woman’s ability to choose if and when to become 
pregnant, determine the number and spacing of children, and reduce the need 
for risky abortions, pregnancy-related complications and maternal mortality from 
early childbearing, enhances their capabilities and in so doing promotes human 
development.31  
There is thus a need to improve access to essential medicines that can give 
women the means to expand and improve their health capabilities and make 
health-related choices.32 These drugs can also present opportunities for women 
to be in good health and pursue other development goals.33  
Essential medicines are expected to be readily available and accessible within 
the context of a functional and viable healthcare system and services.34 The 
WHO identifies that provision of secure and sustainable access to essential 
medicines is dependent on four main factors: rational selection and use of 
medicines; affordable prices; sustainable financing; reliable health and supply 
systems.35 Rational selection and use reflects the importance of ensuring that 
essential medicines have the right balance of efficacy, safety, quality and are 
appropriate for use.36 Likewise, each individual should have and use this 
medication, in the most appropriate dosage, forms and strength, for an 
                                                          
30 Martha C Nussbaum, Creating Capabilities: The Human Development Approach (Harvard University Press 2011) 33. 
31 Dejong (n 29)1161.  
32 It is worth noting that this thesis does not focus only on the sexual and reproductive essential medicines.  
33 This argument covers drugs to prevent pregnancies (contraceptives), treat pregnancy related complications and protect or 
improve sexual and reproductive health.   
34 Ka, Pradhan and Mohanta (n 17) 10. 
35 World Health Organisation, 'WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy 2000 - 
2003' (WHO/EDM/2000.1, World Health Organization 2000) 33; World Health Organisation, 'Access to Medicines'  
<http://www.who.int/trade/glossary/story002/en/> accessed 6 April 2016; World Health Organization, How to Develop and 
Implement a National Drug Policy (2nd edn, World Health Organization, 2001) 7-8. 
36 ibid 
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adequate duration, with the suitable information and follow up treatment.37 The 
selection and rational use of essential medicines is the first steps towards 
improving access; these essential medicines should be cost-effective and 
available at affordable prices.38  In this thesis, it is argued that the State is under 
an obligation to ensure that the prices of patented essential medicines are not 
prohibitively beyond the reach of its populations. The flexibilities, as identified in 
Chapter VI, are important as a means to ensure that a patent does not 
constitute a challenge to accessing essential medicines. In addition to being 
available at a reasonable price, a reliable, regular and proper drug supply 
system, good pharmaceutical procurement practice and a suitable health 
system for distribution are vital in the quest to promote access to essential 
medicines.39 It is also important that there is sufficient research and 
development (R&D) for new and more effective drugs.40 The WHO also 
emphasises the need to ensure access through sustainable increased public 
funding for health and adequate health insurance especially for the poor.41 
This four-part framework is formulated to guide and coordinate actions to 
guarantee access to essential medicines. These four factors must be put in 
place if access to medicines is to be increased in Nigeria. It is within this context 
that this thesis argues for increased access to essential medicinal treatments in 
Nigeria. 
To further put the research in context, the next section examines the health care 
system in Nigeria. 
 
                                                          
37 Ka, Pradhan and Mohanta (n 17) 11.  
38 World Health Organisation, 'WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy 2000 - 
2003'  
39 ibid 
40 ibid 
41 ibid 
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 3.2 An Overview of the Nigerian Healthcare System 
Nigeria is estimated to be home to more than one-fifth of the entire population of 
sub-Saharan Africa.42 However, the general public healthcare system can best 
be described as struggling, underfunded, and in a ‘state of disarray’.43 Since its 
independence in 1960, the Nigerian authorities have made efforts to improve 
the life and livelihood of the citizens. While progress has been recorded in the 
education, financial and economic sectors, the provision of an adequate 
healthcare system remains a perennial problem in Nigeria.44 Factors such as 
inadequate medical infrastructures, services and health facilities, insufficient 
technological and medical equipment, and a shortage of highly skilled 
personnel, especially in the rural parts of the country, contribute to the poor 
state of the health care system.45 A report on the pharmaceutical market in 
Nigeria indicates that inadequate basic infrastructures and lack of access to 
affordable medicines are further challenges of the healthcare system.46 Low 
investment in, and underfunding of essential healthcare delivery services and 
facilities has also marred the health system’s operational effectiveness.47 In 
                                                          
42 The World Bank, 'Nigeria: Data' (2015) <http://data.worldbank.org/country/nigeria> accessed 18 July 2015; Thomas Magstadt, 
Nations and Government: Comparative Politics in Regional Perspective (6th edn, Cengage Learning 2010) 524. 
43 Oxford Business Group, The Report: Nigeria 2013 (Oxford Business Group 2013) 319-323. The World Health Organisation (WHO) 
for instance, ranked Nigeria’s overall health system’s performance as 187th out of 191 countries in 2000. World Health 
Organisation, The World Health Report 2000, Health System: Improving Performance (World Health Organisation 2000) 154. 
44 Remigius Nwabueze, ‘The Legal Protection and Enforcement of Health Rights in Nigeria’ in Colleen M Flood and Aeyal M Gross 
(eds), The Right to Health at the Public/Private Divide: A Global Comparative Study (Cambridge University Press 2014) 371-377.  
45 Menizibeya Osain Welcome, 'The Nigerian Health Care System: Need for Integrating Adequate Medical Intelligence and 
Surveillance Systems' (2011) 3(4) Journal of Pharmacy and Bioallied Sciences 470–478; Nwabueze (n 44) 371- 374; Federal Ministry 
of Health, Revised National Health Policy (Federal Ministry of Health 2004) 4. Also available at <http://cheld.org/wp-
content/uploads/2012/04/Nigeria-Revised-National-Health-Policy-2004.pdf> accessed 19 August 2015. 
46 Business Monitor International, Nigeria Pharmaceuticals & Healthcare Report Q3 2012 (Business Monitor International 2012) 
67. 
47 Oxford Business Group (n 43) 325.  
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2013, the amount spent on health per person by the Nigerian government was 
US$31 and although it varies by region, this is an estimated thirty six percent of 
the spending required to provide the necessary basic universal healthcare to 
the people.48 
 The health system’s ineffectiveness is compounded by the lack of an 
appropriate political and strategic approach to address the healthcare 
challenges of the population.49 The poor performance of the health system is 
worsened by the absence of a coordinated multi-sectoral approach to address 
the constraints, and a proactive effort to manage the many problems of access 
to adequate healthcare by the government.50 The WHO, in relating the 
problems of access to medicines to the structure and organisation of a health 
care system, observed that ‘ [w]ell performing health systems offer high levels 
of access, and poorly performing ones result in a large number of people being 
excluded from medicines as well as other forms of treatment, prevention and 
care.’51 This weak healthcare system and lack of other necessary 
infrastructures in Nigeria therefore, present a gloomy picture for the quest to 
access medicinal treatments.52  
The lack of an effective health system to facilitate the procurement of 
treatments for major diseases such as HIV/AIDS, tuberculosis (TB), malaria, 
                                                                                                                                                                          
The UNDP report, for example, revealed that Nigeria’s public health expenditure per percentage of gross national product (GNP) in 
2003 was 1.3%. See United Nations Development Programme (UNDP), Beyond Scarcity: Power, Poverty and the Global Water Crisis 
(Palgrave Macmillan 2006) 303. 
48 This is below the target of US$86 per person. Evidence for Action, ‘MamaYe Factsheet on Health Financing in Nigeria in 2015’ 
(Evidence for Action 2015) also available at  
http://www.mamaye.org/sites/default/files/evidence/NG%20HF%20Factsheet%202015.pdf 
49 World Health Organization 'Nigeria Still Searching for Right Formula' (2015)  
<http://www.who.int/bulletin/volumes/86/9/08-020908/en/> accessed 4 November 2014; Emmanuel Adeniran Alebiosu, 
'National Health System, Maternal Health and the Millennium Development Goals: A Review of Abiye Programme in Ondo State, 
Nigeria' (2014) 4(12) International Journal of Humanities and Social Science 213-214. 
50 Alebiosu (n 49) 213-214.  
51 World Health Organization, The World Medicines Situation (WHO/EDM/PAR/2004.5, World Health Organization 2004) 64 
52 The relevant Nigerian institutions essentially lack the necessary training and resources. See U.S. Department of State, '2013 
Investment Climate Statement: Nigeria’ (2015) <http://www.state.gov/e/eb/rls/othr/ics/2013/204707.htm> accessed 4 November 
2014. 
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etc., makes the health care situation even more daunting.53 Nigeria has 
recorded one of the highest levels of HIV/AIDS, malaria, and tuberculosis (TB) 
in the sub-Saharan African region.54 In 2013, the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) indicated that Nigeria had one of the 
largest numbers of HIV infections in the world.55 By this estimate, women in 
sub-Saharan Africa, including Nigeria, account for fifty eight percent of the total 
number of people living with HIV.56 Conversely, UNAIDS stated in 2014 that 
only twenty percent of people infected in Nigeria had access to the required 
antiretroviral therapy.57 Nigeria also records the fourth largest incidence of TB 
infection, with approximated 373,682 new cases annually.58 This is in addition to 
the prevalence of other tropical and communicable diseases.59 Most of these 
diseases are treatable with effective medications; however, accessibility and 
affordability of the necessary treatments pose a challenge.60  
The Federal Government of Nigeria has made commendable policy efforts to 
improve the healthcare needs of its people, yet the policies have not been 
effectively executed as a result of a low commitment by government and the 
relevant implementation authorities.61 To restructure and increase the 
                                                          
53 Kristin Peterson and Olatubosun Obileye, Access to Drugs for HIV/AIDS and Related Opportunistic Infections in Nigeria: A Status 
Report on the Sociopolitical, Economic, and Policy Climate on Drug Availability for People Living With HIV/AIDS (PLWHA) and 
Recommendations for Future Access (POLICY Project 2002) 1-13; O Oladepo and others, 'Malaria Treatment and Policy in Three 
Regions in Nigeria: The Role of Patent Medicine Vendors' (2007) Future Health Systems Working Paper 1 Nigeria Series, 26. 
Available at <http://r4d.dfid.gov.uk/Output/176843/> accessed 5 January 2015.  
54 James A Johnson and Carleen H Stoskopf, Comparative Health Systems: Global Perspectives (Jones and Bartlett Publishers 2010) 
313. 
55 Joint United Nations Programme on HIV/AIDS (UNAIDS), The Gap Report 2014 (UNAIDS 2014) 17. Also available at  
http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_rep
ort_en.pdf; Joint United Nations Programme on HIV/AIDS (UNAIDS), Global Report: UNAIDS Report on the Global AIDS Epidemic 
2010 (UNAIDS 2010) 25, 28.  
As of 2007, it was estimated that 2 million were living with HIV in Nigeria. See Joint United Nations Programme on HIV/AIDS 
(UNAIDS), 2008 Report on the Global AIDS Epidemic (UNAIDS 2008) 215, 219. 
56 UNIAIDS, The Gap Report 2014 (n 55) 26. 
57 ibid 19. 
58 United States Agency for International Development (USAID), ‘Nigeria: Tuberculosis Profile’ (2006) Available at 
<http://pdf.usaid.gov/pdf_docs/Pdaci545.pdf> accessed 17 July 2015.  
59 Kalu N Kalu, Chinelo Ogbuanu, and Ikechukwu Ogbuanu, ‘Nigeria’ in James Johnson and Carleen Stoskopf (eds), Comparative 
Health Systems: Global Perspectives (Jones & Bartlett Learning 2010 Sudbury) 313. 
60 Federal Ministry of Health, Revised National Health Policy 2004 (n 45) 3.  
61 World Health Organization ‘The Nigerian Health System’ 25. Available at  
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performance of the health care system, for example, the government adopted 
the National Health Policy (NHP) to improve the quality of health care delivery 
and services.62 The NHP contains some important provisions to strengthen the 
national health system and provide efficient health service delivery that can 
increase access to quality healthcare and medicines if strictly adhered to.63 
However, the current state of the healthcare system indicates poor 
implementation of the NHP. Among many other policy measures to improve 
health status, particularly funding of health care, the National Health Insurance 
Scheme (NHIS) Act was also set up in 1999 to reduce the cost burden and 
financing of health services.64 The impact of this insurance scheme has been 
limited by factors such as insufficient sustainable funding of the scheme, 
uncoordinated management and poor implementation.65  
Various other reforms have been put in place to address the state of healthcare 
in Nigeria.66 With the aim of controlling and treating the scourge of diseases 
                                                                                                                                                                          
<http://www.who.int/pmnch/countries/nigeria-plan-chapter-3.pdf> accessed 19 August 2015. 
(The largest responsibility for public healthcare falls on the Nigerian Federal Government through the Federal Ministry of Health 
(FMoH). The Federal Ministry is responsible for providing health services and medicines, policy guidance, planning and technical 
support to the overall health system in Nigeria, coordinating the implementation of the National Health Policy, as well as 
establishing health management information system in the Country.) ibid 21. 
62 With the aim of planning, promoting, organising and managing the health care of Nigerians, the first National Health and 
Strategy to Achieve Health for All Nigerians was promulgated in 1988. It was later revised in 2004 ‘[t]o reflect the new realities and 
trends in our national health situation.’ Federal Ministry of Health, Revised National Health Policy (n 45) 1-2.  
63 For example, the stated objective of the 2004 Revised Policy is ‘[t]o strengthen the national health system such that it will 
provide effective, efficient, quality, accessible and affordable health services that will improve the health status of Nigerians 
through the accelerated achievement of the health-related Millennium Development Goals.’ ibid 7-8. Progress related to this 
objective has however, been slow and there are challenges to fulfilling these objectives. 
The goal of the National Health Policy further sought to establish a comprehensive health care system, based on a primary health 
care that is promotive, protective, preventive, restorative and rehabilitative to all Nigerians. ibid 11.  
64 The NHIS was established under Act 35 of 1999 by the Federal Government of Nigeria. The NHIS seeks to provide easy access to 
healthcare for all Nigerians at an affordable cost through various prepayment systems. 'National Health Insurance Scheme' 
(Nhis.gov.ng) <http://www.nhis.gov.ng/> accessed 9 May 2015. 
65 Toyin Adefolaju, 'Repositioning Health Insurance in Nigeria: Prospects and Challenges’ (2014) 2(2) International Journal of Health 
Sciences 151, 159.  
66 Other relevant policies include the National Drug Policy (NDP) 2005 to improve the provision of drugs in the country and the 
National Strategic Health Development Plan (NSHDP) 2009-2015 which is aimed at strengthening the healthcare system, providing 
cost-effective healthcare interventions and improving the health status of all Nigerians, particularly the poorest and most 
vulnerable.  
Specifically aimed at safeguarding, providing the necessary facilities and improving women’s health, policy considerations are: 
National Reproductive Health Policy and Strategy to Achieve Quality Reproductive and Sexual Health for all Nigerians 2001; 
Maternal and Child Health Policy 1994; National Policy on the Elimination of Female Genital Mutilation 1988, among many others. 
While these policies are relevant to the promotion of women’s health, the lack of political will and absence of well-structured 
monitoring systems and implementation process have limited their effectiveness. 
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such as HIV for instance, the Federal Government established agencies and 
programmes such as the National AIDS Control and Prevention Programme 
(NASCPP), the National Action Committee on AIDS (NACA) and the National 
HIV/AIDS Strategic Framework, in addition to providing antiretroviral treatments 
at discounted prices.67 To address the problems of inadequate healthcare, 
services and health treatments, the National Health Act 2014 was enacted to 
provide a framework for the regulation, development and management of the 
Nigerian health system.68  
In light of the foregoing, it is obvious that the Nigerian government is aware of 
the need for an improved standard of health delivery system; nonetheless, the 
policy provisions to improve healthcare delivery must be put into practice to fulfil 
the policy intention of providing the best possible healthcare for all persons 
living in Nigeria ‘within the limits of available resources.’69 Enhancing access to 
adequate healthcare is an identifiable goal that goes beyond recognising the 
need for a viable healthcare system. Efforts to deliver this goal will require 
improvement in access to quality healthcare delivery, medical services and 
medicinal treatments, at an affordable rate. It also requires a proactive effort to 
practically facilitate access to good quality healthcare and medicinal treatments, 
expand the options for better access to health treatments and address all the 
impediments to accessibility.  
 
                                                          
67 The National Strategic framework replaced the HIV/AIDS Emergency Action Plan (HEAP). International donor assistance from 
other countries, organisations and donor groups to treat HIV, TB, and malaria has also enhanced the availability of healthcare 
services. For example, it was announced that the Global fund to fight AIDS approved about $68 million in grants to support the 
treatment and prevention of deadly diseases such as HIV/AIDS and TB in Nigeria. Ruby Leo, 'Nigeria: TB, HIV/Aids, Malaria Fund - 
Global Fund Warns Nigeria' The Daily Trust (4 May 2013) <http://allafrica.com/stories/201305061604.html> accessed 24 
September 2015.  
68 The Nigerian National Health Act 2014 was signed into law on the 9th Dec 2014. The Act is further discussed in the next chapter. 
69 See the objective of the Act in Section 1(1) of the Nigerian National Health Act 2014. 
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3.3 The Quest for Access to Medicines in Nigeria  
Access to drugs is a crucial component of a suitable health system. The 
significance of an available, affordable, accessible and good quality supply of 
important drugs for the treatment of diseases is indispensable. Indeed, it is the 
cornerstone of an effective health system. Gaining access to safe and efficient 
drugs for overall health care, however, remains difficult for some Nigerians.70 
With respect to HIV/AIDS treatments, for example, Médecins Sans Frontières 
(MSF) in 2001 conducted a survey in Lagos on behalf of the Coalition of Civil 
Society Groups on Access to Essential Medicines (COCSGAEM).71 The survey, 
which aimed to provide information on the availability and affordability of some 
antiretroviral (ARV) and medicines for opportunistic infection in the Lagos State, 
Nigeria, reported that there was generally little stock of the treatments in the 
facilities visited.72 MSF reported that drugs deemed expensive were deliberately 
kept out-of-stock due to low demand, and purchased only on request.73  
In addition, a 2002 Baseline Assessment of the Nigerian Pharmaceutical Sector 
by the Federal Ministry of Health (FMoH) and WHO illustrated that only forty six 
percent of the basket of twelve key medicines were available in public health 
facilities and seven percent of these medicines had expired.74 The study 
demonstrated that, despite the National Insurance Scheme (NIS), financing of 
medicines is mostly out-of-pocket.75 A survey of household use in the study 
                                                          
70 Oladepo and others (n 53) 26.  
71 In the study, public and private hospitals, community pharmacies, and drug companies were visited. Médecins Sans Frontières 
(MSF) and Coalition of Civil Society Groups on Access to Essential Medicines (COCSGAEM) ‘Coalition on Access to Essential 
Medicines Survey on Access to HIV/AIDS Drugs in Nigeria: Lagos’ (MSF and COCSGAEM 2001) as reported in Peterson and Obileye 
(n 53) 13.  
72 ibid 
73 In some cases, patients were sent directly to pharmaceutical companies to purchase the drugs. ibid 13. Another research report 
in 2002 came to a similar conclusion, that the cost of ARV medicines and treatments for HIV-related OI is expensive and out of 
reach for many Nigerians living with HIV/AIDS. See Peterson and Obileye (n 53) 3.  
74 Federal Ministry of Health and World Health Organisation, Baseline Assessment of the Nigerian Pharmaceutical Sector (Federal 
Ministry of Health 2002) 6, 24. The study also indicated that 58% of the basket of drugs was available at the public sector 
warehouse. ibid 
75 ibid 15. 
105 
 
further showed that most respondents (eighty nine percent) purchased their 
prescribed drugs.76 The survey further revealed that the main reason for the 
inability to purchase drugs was lack of funds (thirty six percent), while twenty 
eight percent of respondents claimed the relevant medicine was unavailable in 
public pharmacies.77 Furthermore, a reported twenty three percent of the 
average weekly expenditure of the respondents was on medicines for the 
treatment of an episode of illness for at least one member of the household.78 
The results of this study underscore the need to improve the availability and 
access to safe, high quality, and affordable efficacious medicines to the 
Nigerian populace.  
The status of access to available and affordable medicines in the studies above 
is consistent with a 2004 empirical study by the Nigerian Federal Ministry of 
Health (FMOH), WHO and Health Action International79 which revealed that 
innovator brands cost between two and seven times more than the lowest 
prices of generic equivalents.80 The results of the study also reveal that patients 
pay between two to sixty four times the international reference prices for drugs 
in both public and private facilities in Nigeria.81 One of the key findings to 
emerge from this study was that ‘[m]edicines are unaffordable to the majority of 
Nigerians (90.2%) who live below the income level of US$ 2 a day as well as 
the government worker that earns a minimum wage of US$1.4 per day.’82 The 
                                                          
76 ibid 6. 
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the six geopolitical zones in the country. The prices of a basket of 34 prescription medicines were measured. See also, Federal 
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81 ibid 5, 17, 27.  
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study also examined and rated the availability of a basket of thirty four 
medicines as low in all sectors, especially the public and private health clinics.83 
This study revealed that the high prices of pharmaceuticals could constitute a 
major hindrance to access to healthcare for women in the country since the 
burden of purchasing medicines mainly falls on households.  
In 2005, a research survey of 122 HIV/AIDS patients by MSF in Lagos also 
revealed that many are forced to pay for their own treatments, with a reported 
forty four per cent experiencing multiple treatment interruptions due to financial 
difficulties.84 Describing this deplorable situation, MSF reported that  
[t]o pay for their care, 39% of respondents reported borrowing or begging, while 
18% said they had been forced to sell property.85 Many patients reported erratic 
consumption of medicines, including skipping or sharing doses, which can lead to 
insufficient drug levels in the blood.86  
The study by MSF also corresponds with a study of Nigerians’ ‘Access to and 
Rational Use of Medicines at the Household Level’ by the FMoH in conjunction 
with the WHO in 2010.87 The objective of the study was to assess the extent to 
which households in Nigeria had access to medicines to treat acute and chronic 
diseases. The study was based on random samples from a representation of 
the six geopolitical zones in the country,88 as well as six health facilities in each 
zone of the six Local Government Authorities (LGAs) comprising three rural and 
three urban LGAs.89 Each location was randomly selected from a list of LGAs in 
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84 Médecins Sans Frontières (MSF) International, Forcing Patients to Pay for AIDS Care Endangers Treatment Success (Médecins 
Sans Frontières (MSF) International 2005)  
<http://www.msf.org/en/article/forcing-patients-pay-aids-care-endangers-treatment-success> accessed 14 November 2016. 
85 ibid 
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87 Federal Ministry of Health (FMoH) and World Health Organisation (WHO), Access to and Rational Use of Medicines at the 
Household Level (Federal Ministry of Health Nigeria 2010). Also available at  
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each of the six zones.90 A total of one thousand and eighty households were 
consulted using a newly revised WHO household survey.91  
A significant finding was that while geographical access to health facilities and 
availability of medicines in public and private facilities had improved, there is a 
concern for the financial burden of households in accessing medicines.92 The 
result of the research indicated that eight point nine percent of households have 
monthly medicines expenditure that represent more than twenty percent of their 
total expenditures93 and that the cost of medicines constituted a barrier to 
accessing medicines for almost half of all households.94 Key findings of the 
study were that less than one out of every five households claimed to have 
obtained medicines free or supported by any form of health insurance and most 
families pay for medicines out-of-pocket.95 In the study, a reported forty nine 
point four percent of the respondents claimed not to have taken prescribed 
medicines because the household could not afford to purchase it.96 
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92 ibid 1-3, 25-27. 
93 ibid 12. The study also reports that medicines account for an approximated three point five percent of total household 
expenditure. 
94 ibid 7. The study concludes that, ‘[a]ffordability of medicines constituted a barrier to access to medicines to about half of 
households.’ ibid 2.  
95 ibid 1-2. 
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Figure 3.1 Medicine Affordability Indicators 97  
The study demonstrates that about forty six point three percent of respondents 
claimed they had to borrow or sell things to afford payment for medicines.98 The 
study also revealed that the chronically ill were more affected than those with 
acute illness as most of them (seventy six percent) were not able to obtain thirty 
days' supply of prescribed medicines.99  
The results and statistics of this study indicate that there is a problem of 
affordability and access to medicines, especially for the chronically ill in Nigeria. 
This study also illustrates that safe, effective and affordable medicines may not 
reach poor people, especially women, who need them the most. This can be 
seen in the illness characteristics of households which reported that forty three 
point five percent of women suffered from chronic illnesses and a further forty 
eight point two percent had acute illnesses.100 While there is reasonable access 
to available healthcare facilities, an assessment of the availability of medicines 
showed that thirty seven percent of households stated that medicines were 
available at public healthcare facilities and fifty two percent agree that drugs 
were available at private pharmacies.101 Compared to the 2002 study by the 
FMoH and WHO, there appears to be a slight increase in access to medicines 
in the 2010 study. Nevertheless, with regards to affordability, this increase may 
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100 ibid 13-14. It is worth noting that a majority of the respondents in the study were men. (The main acute illnesses reported 
include fever and headaches (seventy seven percent), acute respiratory tract infections (ARI) (thirty nine percent), and sixty eight 
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be due to the fact that many are forced to take on loans or sell their property to 
purchase drugs.102  
This result of this study is not surprising considering the socio-economic and 
financial status of many people in Nigeria who are largely low or middle-income 
earners.103 The Human Development Report of 2013, for example, ranked 
Nigeria’s 153rd position as low on the Human Development Index.104 For 
women, who often earn less than their male counterparts, especially those in 
the rural areas where poverty is prevalent, affordability becomes a matter of life 
or death. Also, because women in Nigeria and many developing countries are 
confronted with adverse social, cultural and traditional-related practices, plus 
the financial and gender inequalities, as will be discussed, it is possible that 
they may face the problem of access to healthcare and medicines in a different 
or more severe way. Equally, drawing a link between the plight of women in 
Nigerian societies and the conundrum of access to medicines in Nigeria in the 
studies above, it is possible that the challenges of access to medicines for 
women in the studies is aggravated by adverse socio-cultural and traditional 
practices and barriers to accessing to health facilities, low income and 
unaffordable medicines.105 Consequently, any additional factor such as the high 
prices of patented pharmaceuticals could pose an added challenge to many 
people. With many patients in Nigeria financing the purchase of medicines out-
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104 United Nations Development Programme (UNDP), The Human Development Report 2013, The Rise of the South: Human 
Progress in a Diverse World (United Nations Development Programme (UNDP) 2013) 143. Also available at  
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of-pocket,106 the high cost of patented drugs and unavailability of cheaper 
generic substitutes could significantly constitute a major barrier to accessing 
basic and essential medicines.107 
It follows from the foregoing that interventions are needed to improve access 
and availability of affordable drugs in Nigeria. Among many other means to 
improve access, a price control policy must be developed and implemented in 
order to monitor and reduce drug prices, and also ensure that the marketing 
practices of patentees do not constitute a barrier to the accessibility of essential 
pharmaceuticals.108 As the study in this thesis is limited to patent law, the focus 
is on making a case for an increased access of women to medicines in light of 
patent rights. 
  
 3.3.1 The Nigerian National Drug Policy and its Shortfall in Addressing 
the Problems of Access to Medicines  
 Against the background of inadequacies in the availability, supply and effective 
distribution of high quality, efficacious drugs, including the high dependency on 
pharmaceutical raw materials and imported finished drugs from other countries, 
the Nigerian Government enacted the first National Drug Policy (NDP) in 
1990.109 To reduce reliance on foreign sources and imported health products, 
the 1990 Policy aimed to make the pharmaceutical sector self-sufficient by 
                                                          
106 Federal Ministry of Health and others, Medicine Prices in Nigeria: Prices People Pay for Medicines in Nigeria (n 79) 6. 
107 It is worth noting that the most important limitation of the preceding studies on the state of access to drugs in Nigeria lay in the 
fact that there is no specific assessment and report of the situation of women as a distinct group. Further work needs to be done 
to specifically reveal ways in which women experience the many dimensions of difficulty in access to medicines for a concerted 
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108 While price control is an option to lessen the excessive pricing of medicines, there is currently no legal or regulatory provision 
on pricing of medicines in Nigeria. Federal Ministry of Health and World Health Organization, Nigeria Pharmaceutical Country 
Profile (Federal Ministry of Health and World Health Organization 2011) 21. 
109 Federal Ministry of Health and World Health Organisation, National Drug Policy (Federal Ministry of Health and World Health 
Organisation 2005) 9; Charles Wambebe and Nelson Ochekpe, ‘Pharmaceutical Sector Profile: Nigeria’ (United Nations Industrial 
Development Organization (UNIDO) 2011) 53. The aims and objectives of the Policy set out to address the inadequate supply of 
drugs and to facilitate the availability and distribution of effective, good quality and safe medicines among many other goals. 
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promoting local drug research and development, training highly skilled scientists 
and research technicians in drug discovery activities, towards the objective of 
achieving full capacity in drug research, development and manufacturing.110 
Effectively, this policy yielded some successful results such as the publication of 
the Essential Drug List (EDL) and a National Drug Formulary (NDF) for the 
procurement and delivery of good quality essential medicines in Nigeria.111  
In spite of these laudable objectives, several lapses were observed in the 1990 
NDP.112 A post-13 year empirical report on the baseline assessment of the 
pharmaceutical sector stated that the 1990 NDP has had little effect in 
adequately improving access to medicines, spurring the national 
pharmaceutical industry to increase national production of pharmaceuticals and 
that gaps still exist despite the structures and processes put in place.113 Several 
factors are identified to explain the shortcomings. They include amongst others: 
the absence of an implementation plan; the lack of an equitable financing 
mechanism; a deficient budgetary allocation for drugs procurement and 
research; the absence of legislation to develop the pharmaceutical 
manufacturing sector and the huge taxes on drugs.114 In addition, the Policy did 
not contain provisions for intellectual property rights (IPRs) and the relevant 
exceptions and the flexibilities towards the aim of ensuring access to affordable 
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and safe medicines. Ultimately, however, the lack of political will and 
enforcement plans accounted for the failure to achieve its lofty goals.115  
In 2003, then 2005, the Nigerian National Drug Policy was revised to formulate 
effective ways of implementing the Drug Policy’s objectives to guarantee the 
availability and access to affordable essential medicines.116 To achieve this 
objective, the 2005 NDP sought to make the Nigerian Pharmaceutical industry 
self-sufficient by promoting and encouraging pharmaceuticals R&D including 
the research into and use of herbal and other traditional remedies to meet the 
healthcare needs of Nigerians.117 Furthermore, the 2005 Policy mandated the 
government to develop a strategy for the R&D of drugs; training high-level 
scientist and technicians;118 and developing local manufacturing capacity for 
this purpose.119 Importantly, the 2005 NDP, while recognising the importance of 
patents for research and development in Article 6(14), states that the Nigerian 
government should ensure that patent protection does not obstruct R&D and 
access to affordable medicines. The 2005 NDP further mandates the Nigerian 
authorities to monitor the impact of International trade agreements on access to 
essential medicines by Nigerians, and explore the existing health and safety 
measures in international agreements to ensure access to ‘affordable, good 
quality and essential drugs.’120 Further to this, the Health, Justice and Trade 
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Ministers are required to take into account public health considerations of 
Nigerians in international trade negotiations.121 The 2005 Drug Policy further 
obligates the government to make provisions for a drug distribution system, 
update other relevant drug and health policies and legislations, establish a 
pricing policy for procurement of cheap medicines and promote the rational use 
of drugs at all the levels of healthcare.122 Commendably, the Policy sought to 
guarantee the availability and affordability of drugs with the goal of building a 
dynamic national production industry. 
 3.3.2 To What Extent Has the Policy Objective for the Availability, Access 
to Affordable Medicines, Pharmaceutical R&D and Drug Production Been 
Met in Nigeria?  
An analysis of the pharmaceutical services efficiency and delivery of drugs 
indicate that positive changes have been recorded although more work needs 
to be done to fulfil its objective of facilitating increased access to safe, 
affordable and effective medicines, and improving the performance of the 
domestic pharmaceutical industry to cater for national medicinal needs.123 On 
the positive side, Nigeria’s pharmaceutical industry remains one of the biggest 
in West Africa and one of the fastest growing pharmaceutical sectors in the sub-
Saharan African region.124 Reports demonstrate, however, that despite the 
2005 NDP objectives and local production status, Nigeria is still relying heavily 
on imported high-value drugs from other countries to meet domestic 
demands.125 The local drug industry meets only about thirty to forty percent of 
the drugs needs in the country and it is estimated that the other sixty to seventy 
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percent are imported predominately from India, China, Europe and other 
industrialised countries.126 Besides, raw materials and active ingredients are still 
sourced from India, the USA, Germany and Indonesia and other foreign 
countries.127 To this end, the national Drug Policy in Nigeria has made 
commendable efforts; however, the policy alone cannot bring about a positive 
turnaround in the quest for increased accessibility to essential medicines in 
Nigeria. Supporting institutions, facilities and capacities should be developed, 
reformed and strengthened for this purpose. In this thesis, it is also argued that 
there is a need for the Nigerian authorities to critically look into the ways in 
which patents can add to the problems of access to pharmaceuticals and in this 
respect, incorporate and adapt the TRIPS-compliant flexibilities to ameliorate 
the accessibility issues associated with the IPRs.  
Having highlighted the state of the Nigerian health system and the challenges of 
access to medicines for everyone, the following section underlies other socio-
economic and cultural factors that can affect the state of women’s poor health 
and impinge their access to effective health treatments. The aim of the section 
is to argue for their improved access to effective healthcare services, facilities 
and medicines.  
 3.4 Women and Health: An Analysis of the Social System and Cultural or 
Traditional Factors that Impinge on Women’s Health in Nigeria  
Women have always played a central role in Nigeria, especially in caring for the 
healthcare needs of the family; however, gender or sex-role ascriptions, social 
expectations and traditional practices often lead to gender discrimination and 
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inequality that could have a trickle-down effect on women’s health and their 
ability to access healthcare treatments.  
Nigeria is largely a patriarchal society where most decision-making is in the 
hands of men and the choices of women, especially in rural areas, are 
limited.128 Discriminatory practices against women are primarily based on this 
patriarchy that defines the social roles of men and women in ways that relegate 
the latter to an inferior position in the home and society.129 These inequalities 
sometimes relate to issues of control in decision-making on where and how to 
access healthcare. At the household level, men and women tend to perform 
different roles in the provision of healthcare and control of resources.130 
Women, notably those in the rural areas, are traditionally care providers, 
whereas men are more often the financial decision makers on issues of 
healthcare. For example, a 2003 study by Nigeria’s National Population 
Commission (NPC) and ICF Macro indicates that men have the final say in 
major domestic issues such as household expenses and purchases and also 
they make the decisions regarding the survey respondents’ (women) own health 
care.131 Also in the study, men are often the sole decision makers in issues 
relating to children’s health and educational needs, while women are most likely 
to decide on issues relating to family welfare, such as cooking and household 
chores.132 Among unmarried women, the majority of the study’s respondents 
also indicated that, when applicable, someone else has the final say in the 
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decision-making concerning them.133 Thus social setting, in addition to other 
factors, can contribute to determining women’s state of health. In this manner, 
the underlying distribution of gender roles between men and women in society 
can limit women’s ability to access resources that could significantly enable 
them to respond to their healthcare needs. This is particularly where women 
have lower socio-economic status than their male counterparts, resulting in 
constraints that could influence their health outcomes.134 These gender 
inequalities can have far reaching consequences on women’s health and well-
being in Nigerian society.135  
 
 3.4.1 Women and their Health in the Context of Gender-based Barriers 
and Practices 
Gender barriers through cultural and traditional practices have been cited as 
additional factors that can affect women’s health and influence their access to 
healthcare services, facilities and medicines in Nigeria.136 These gender-related 
problems are prevalent in societies that subjugate the social status of women 
and subject them to crude traditional medical practices. Examples of adverse 
cultural practices are Female Genital Mutilation (FGM),137 preferential treatment 
of male children138 and differential access to and utilisation of healthcare 
facilities by men and women in many communities in Nigeria.139 The practice of 
FGM is largely prevalent in communities that believe the act is necessary to 
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reduce libido and prevent promiscuity.140 Apart from the psychological torture, 
this painful circumcision practice exposes women to infections such as 
HIV/AIDS, hepatitis B, as well as the danger of haemorrhage, shock and 
death.141 In recent times, several laws and public campaigns have condemned 
this dehumanising practice in Nigeria.142 Nonetheless, it subsists in many rural 
areas due to the fact that it is deep-rooted in religious beliefs and cultural 
norms.143 
Women are also subjected to other forms of degrading cultural practices such 
as early/forced marriage, wife inheritance and widowhood humiliation.144 Early 
marriage, especially in the northern part of the country, is a practice that is 
rooted in religious and traditional beliefs that justify it as necessary to prevent 
promiscuity, which, in turn, adversely affects women’s health.145 Sex and child 
bearing with an immature body causes many health problems, including Vesico 
Vaginal Fistula (VVF)146 and Recto-Vaginal Fistula (RVF),147 reproductive and 
sexual dysfunction and infertility including cases of chronic pelvic infections, and 
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death from childbirth.148 Scholars also note that religious and cultural practices, 
such as the purdah system of wife seclusion in the northern parts of the country, 
are also barriers to accessing healthcare by women.149 This practice can 
prevent women from seeking medical attention when necessary.  
Gender-based violence which includes intimate partner violence, rape and 
sexual violence, physical battery and psychological harm are also vices that 
affect women’s health and impinge their fundamental human rights. These 
violent practices, in turn, have far reaching consequences on women’s physical, 
sexual and psychological health and wellbeing.150 Researchers have associated 
violence and abuse of women with negative health outcomes including physical 
injuries, reproductive health disorders, HIV and sexual infections, unwanted 
pregnancy, emotional problems, depression and sleeping disorders.151 
Unfortunately, the inability to access healthcare resources to alleviate their 
health situation mean that they are severely restricted from regaining good 
health to pursue other productive activities.  
For these reasons and many others, this chapter makes a case for their access 
to medicines. The point being made here is that for women already confronted 
with these limiting factors, any additional constraint on access to essential 
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2015; Mary Ellsberg and others, 'Intimate Partner Violence and Women's Physical and Mental Health in the WHO Multi-Country 
Study on Women's Health and Domestic Violence: An Observational Study' (2008) 371(9619) The Lancet 1165, 1165-1166; 
Jacquelyn C Campbell, 'Health Consequences of Intimate Partner Violence' (2002) 359 The Lancet 1331, 1331-1332.  
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medicines will typically impose a greater challenge to their health outcomes.152 
The argument in the chapter does not lose sight of the fact that the most logical 
thing to do is address the socio-cultural and economic root cause of these 
problems and health concerns. Nonetheless, the problems associated with 
accessing drugs within the context of a patent right and the effect on their rights 
to health cannot be underestimated, hence the focus in this thesis. 153 
 3.4.2 Biological and Physiological Factors 
The specific healthcare needs of women, especially those infected with 
HIV/AIDS also offer an ethical base to argue for a consideration of women’s 
access to medicines in Nigeria.  
Studies indicate that HIV/AIDS incidence is higher for women than it is for men 
in the sub-Saharan African region.154 For various reasons relating to biological 
and cultural factors, lack of control over sexual interactions and economic 
hardship, women are more vulnerable to HIV infections.155 Several factors, 
including physiological disposition; sexual behaviour, social attitudes to the 
infection, cultural norms where women are less likely to negotiate condom use, 
domestic violence and rape, and so on, work to women’s disadvantage with 
                                                          
152 It is worthwhile noting that this is not to say that the problems of access are solely attributed to these socio-cultural, 
traditional, domestic and economic issues. In this thesis, these issues are raised to offer an additional basis to argue for women’s 
right to access medicines.  
153 For example, the Committee on Economic, Social and Cultural Rights (CESCR) has made the point […] there is a need to develop 
and implement a comprehensive national strategy for promoting women's right to health throughout their life span. Such a 
strategy should include interventions aimed at the prevention and treatment of diseases affecting women, as well as policies to 
provide access to a full range of high quality and affordable health care, including sexual and reproductive services. Consequently, 
‘[t]he realisation of women's right to health requires the removal of all barriers interfering with access to health services, 
education and information, including in the area of sexual and reproductive health. It is also important to undertake preventive, 
promotive and remedial action to shield women from the impact of harmful traditional cultural practices and norms that deny 
them their full reproductive rights.’ Committee on Economic, Social and Cultural Rights (CESCR), General Comment No 14, The 
Right to the Highest Attainable Standard of Health (Twenty-second session, E/C.12/2000/4, 2000) paragraph 21. Also available in 
United Nations International Human Rights Instruments, ‘Compilation of General Comments and General Recommendations 
Adopted by Human Rights Treaty Bodies’ (HRI/GEN/1/Rev.6, 2003) 85. (The right to health is the subject of the analysis in the next 
chapter.) 
154 Physicians for Human Rights, Futures Group International/POLICY Project and Center for the Right to Health, Nigeria: Access to 
Health Care for People Living with HIV and AIDS (Physicians for Human Rights 2006) 16.  
155 ibid; Pranitha Maharaj and Benjamin Roberts, ‘Tripping Up: AIDS, Pharmaceuticals and Intellectual property in South Africa’ in 
Caren Grown, Elissa Braunstein and Anju Malhotra (eds), Trading Women's Health and Rights: Trade Liberalization and 
Reproductive Health in Developing Economies (Zed Books 2006) 215; Tanja R Müller, HIV/AIDS, Gender and Rural Livelihoods in 
Sub-Saharan Africa: An Overview and Annotated Bibliography, Issue 2 (Wageningen Academic Publication 2005) 27. 
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regards to the infection.156 In most parts of the developing world, the increasing 
spread of the virus amongst younger and pregnant women is attributable to 
social and cultural practices that encourage older men to have sex with younger 
women and restrict women’s freedom in negotiating sexual practices.157  
In Nigeria, as in many other developing countries, mother-to-child transmission 
(MTCT) is another challenging issue of concern to women and their children.158 
MTCT transpires when HIV is passed on from an infected mother to child either 
during pregnancy, or delivery, or through breastfeeding. UNIADS indicate that 
many children living with HIV had been directly infected by their mothers, 
primarily in utero, during labour or while breastfeeding.159 Studies also illustrate 
that access to antiretroviral medicines can reduce the risk of MTCT to five 
percent.160 However, Joint United Nations Programme on HIV/AIDS (UNAIDS) 
in 2013 reports that less than fifty percent of pregnant women living with HIV in 
Nigeria have access to essential antiretroviral treatments.161 Without adequate 
                                                          
156 Research has also shown that in some sub-Saharan African societies, women are accused of being the source of infections, and 
often bear the brunt of promiscuity and immorality name calling, as well as facing countless acts of discrimination and 
stigmatisation due to their HIV status. Physicians for Human Rights, Futures Group International/POLICY Project and Center for the 
Right to Health (n 154) 16.  
157 Padmashree Gehl Sampath, ‘Gender and the Agreement on Trade related Aspects of Intellectual Property Rights: Exploring 
Some Interlinkages’ in Anh-Nga Tran-Nguyen and Americo Beviglia Zampetti (eds), Trade and Gender: Opportunities and 
Challenges for Developing Countries ( United Nations Publications 2004) 251–291. This is often for religious or cultural reasons. 
158 CO Agboghoroma, SA Sagay and JI Ikechebelu, ‘Nigerian Prevention of Mother to Child Transmission of Human 
Immunodeficiency Virus Program: The Journey so Far’ (2013) 1 Journal of HIV and Human Reproduction 1-7. 
159 For example, in 2009, an estimated 370 000 [230 000–510 000] children were directly infected with HIV through mother-to-
child transmission. UNAIDS, Global Report: UNAIDS Report on the Global AIDS Epidemic 2010 (n 55) 63. See also Scott Skinner-
Thompson, AIDS and the Law (Wolters Kluwer Law & Business 2015) 1-34. 
160 J McIntyre, ‘Antiretrovirals for Reducing the Risk of Mother-to-Child Transmission of HIV Infection: RHL Commentary’ (The WHO 
Reproductive Health Library, World Health Organization 2007) <http://apps.who.int/rhl/hiv_aids/jmicom/en/> accessed 24 
September 2015.  
For example, Zidovudine, administered within twenty eight weeks of pregnancy, can significantly reduce the viral loads, and 
Nevirapine treatment administered seventy two hours after delivery can also reduce the rate of MTCT transmission by forty seven 
percent in figures. Sampath (n 157) 265. 
UNAIDS report that as of 2009, proving access to the necessary antiretroviral medication to pregnant women living with HIV 
significantly averted the transmission of the infection to children. UNAIDS, Global Report: UNAIDS Report on the Global AIDS 
Epidemic 2010 (n 55) 9-10. See also Joint United Nations Programme on HIV/AIDS (UNAIDS), Global Report: UNAIDS Report on the 
Global AIDS Epidemic 2013 (UNAIDS 2013) 38-39. Also available at  
<http://www.unaids.org/sites/default/files/media_asset/unaids_global_report_2013_en_1.pdf> accessed 6 June 2015; World 
Health Organization, ‘Mother-to-child Transmission of HIV’ available at <http://www.who.int/hiv/topics/mtct/about/en/> 
accessed 15 June 3015. 
161 UNAIDS, Global Report: UNAIDS Report on the Global AIDS Epidemic 2013 (n 160) 40. UNAIDS also report in 2013 that women 
living with HIV in many countries still lack sufficient access to the HIV prevention, treatment care and support services, and 
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treatment, their babies’ chances of surviving to adulthood are reduced, thus 
access to and use of antiretroviral drugs to prevent transmission and safeguard 
children is paramount.162 For this reason and others, the UN general Assembly 
Special Session on HIV/AIDS made a case for a response to issues of HIV 
prevention and treatment in a multi-sectoral and gender-sensitive manner.163 
Apart from the difficulty posed by HIV/AIDS, studies and scholars have also 
shown that women are more prone than men to the risk of sexually transmitted 
diseases (STDs) such as chlamydia and gonorrhoea because of their 
anatomy.164 Poorer women may also be more susceptible to other diseases that 
affect their immune systems such as malaria or TB due to problems caused by 
anaemia and malnutrition.165  
Maternal mortality rate is another health related issue of concern in Nigeria.166 A 
status report by the Nigerian Demographic and Health Survey (NDHS) in 2013 
showed that the country has one of the highest maternal mortality rates, with a 
figure of 576 deaths per 100,000 live births.167 It was also estimated in 2015 
that Nigeria records about 58,000 maternal deaths per year as every ten 
minutes, one woman dies from pregnancy and childbirth, besides HIV/AIDS, 
malaria, and TB.168 In many maternal deaths, there are child-related deaths as 
                                                                                                                                                                          
reproductive health resources, which means that children are also at risk of the infection in utero, during labour or while 
breastfeeding. UNAIDS, The Gap Report (n 55) 232-233. 
162 Nandi Siegfried and others, ‘Antiretrovirals for Reducing the Risk of Mother-to-Child Transmission of HIV infection’ (2011) 11 
Cochrane Database of Systematic Reviews. 
163 Article 14, Declaration of Commitment on HIV/AIDS: United Nations General Assembly Special Session on HIV/AIDS 2001. Also 
available at <http://data.unaids.org/Publications/IRC-pub03/AIDSDeclaration_en.pdf> accessed 17 July 2015.  
164 Stuart Berman and Mary L Kamb, ‘Biomedical Interventions’ in Sevgi O. Aral, John M. Douglas and Judith A. Lipshutz (eds), 
Behavioral Interventions for Prevention and Control of Sexually Transmitted Diseases (Springer 2007) 75. 
165 Peter Katona and Judit Katona-Apte, 'The Interaction between Nutrition and Infection' (2008) 46 CLINICAL Infectious Diseases 
1582, 1584-1585. 
166 Olubunmi Akinsanya Alo, Gbadebo Babatunde and EK Odusina, 'Maternal Deaths in Southwest Nigeria' (2012) 1(6) Prime 
Journal of Social Science 104-112. 
167 National Population Commission (NPC) and ICF Macro, Nigeria Demographic and Health Survey 
2013 (National Population Commission (NPC) and ICF Macro 2013) 278.  
The WHO puts the maternal mortality ratio at 800 deaths per 100,000 live births as of 2007. World Health Organization, 'WHO 
Country Cooperation Strategy 2008–2013: Nigeria' (WHO Regional Office for Africa 2009) 4.  
168 World Health Organization and others, ‘Trends in Maternal Mortality: 1990 to 2015’ (World Health Organization 2015) 19. See 
also Federal Ministry of Health Nigeria, UNICEF and WHO, Mother, Newborn and Child Health and Mortality Status: Northern 
States in Nigeria (Federal Ministry of Health Nigeria 2008) The study puts this estimates at 53,000. 
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well.169 The timely availability of affordable health resources, services and 
medicines can and could have prevented many of these deaths.  
 
 
3.4.3 Assessing the Impediments to Women’s Access to Medicines and 
Healthcare in Nigeria  
A gender-based assessment of poverty and a review of the literature on social 
inequalities and health suggest that most women, especially in the rural parts of 
developing countries, experience limited access to health services and 
resources.170 In addition to the aforementioned general health system 
problems,171 the healthcare constraints for most women are in the areas of poor 
maternal care and inadequate access to medical services, health resources and 
medications.172  
In Nigeria, a majority of women, mainly in rural areas, are living in poverty.173 In 
2011, the Nigerian National Bureau of Statistics estimated that women 
constitute sixty five percent of the population living below poverty line.174 It has 
been noted that women are often faced with economic hardship, illiteracy and 
poverty, all of which create barriers to access to health services including 
                                                          
169 This is corroborated by a 2014 report which shows that two countries account for one third of global maternal deaths: Nigeria 
at fourteen percent (40,000) and India at nineteen percent (56,000). See World Health Organization, UNICEF, UNFPA and The 
World Bank, Trends in Maternal Mortality: 1990 to 2010 WHO, UNICEF, UNFPA And The World Bank Estimates (World Health 
Organization 2012) 22; Sulaimon Olanrewaju, 'MDGs: So Much Done, So Much More Undone' (Advocacy for Maternal and Infant 
Health in Nigeria (AMIHN) 4 August 2011) <http://amihin.blogspot.co.uk/> accessed 6 November 2014.  
170 Suzanne R Sicchia and Heather Maclean, ‘Globalization, Poverty and Women’s Health Mapping the Connections’ [2006] 
Canadian Journal of Public Health 70; John E Bennett, Raphael Dolin and Martin J Blaser, Principles and Practice of Infectious 
Diseases (Elsevier Health Sciences 2014) 1477-1479; Owen O'Donnell, 'Access to Health Care in Developing Countries: Breaking 
Down Demand Side Barriers' (2007) 23 Cadernos de Saúde Públication 2820, 2827.  
171 See subsection 3.2. 
172 Adedini and others (n 149) 3; O'Donnell (n 170) 2821. 
173 Ayanleye (n 141) 127-140, 135. 
174 National Bureau of Statistics, 'Women in Transforming Nigeria' Gender Statistics Newsletter (2011) 7 
<http://www.nigerianstat.gov.ng/> accessed 17 November 2014; British Council Nigeria, Gender in Nigeria Report 2012: Improving 
the Lives of Girls and Women in Nigeria, Issues, Policies, Action (British Council Nigeria 2012) 1-6. (The report reiterates the ranking 
of Nigeria as 118 of 134 out of countries in the Gender Equality Index) ibid 1. 
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medicines.175 The lack of economic resources to support the provision of 
essential health services could significantly contribute to the limited availability 
and access to quality healthcare and medicines by Nigerian women.176  
An empirical study by the NDHS in 2003, based on 7,000 households in a 
representative sample of women and men between the ages of fifteen to 
nineteen, revealed several impediments in different categories such as physical, 
social and economic barriers to women’s access to healthcare.177  
 
Figure 3.2 Problems in Accessing Healthcare for Women in Nigeria.178 
The survey, which also assessed the women’s social, economic and health 
status including their reproductive health, showed that many of the survey 
respondents cited finance as a problem in accessing medical treatments.179  
                                                          
175 Rebecca Holmes and others, Social Protection in Nigeria: Mapping Programmes and their Effectiveness (Overseas Development 
Institute 2012) 11. 
176 Ojanuga and Gilbert argued for example that many women’s health conditions would be treatable and preventable if health 
facilities were more easily accessible to women. Ojanuga and Gilbert (n 105) 614. 
177 National Population Commission (NPC) [Nigeria] and ORC Macro, Nigeria Demographic and Health Survey 2003 (n 131) 139-
140. (Access to healthcare is broadly construed in the study to cover access to health facilities, services and medicines. The 
National Population Commission periodically conducts this survey with technical and financial support from international bodies 
and organisations such as: ORC Macro, The US Agency for International Development (USAID), Nigerian government, United 
Nations Population Fund (UNFPA), the United Nations Children’s Fund (UNICEF), and Department for International Development 
(DFID). The most recent survey is the 2013 NDHS Report. Suffice to note that this thesis also relies considerably on data and 
information contained in the Nigerian Demographic and Health surveys of 2003, 2008 and 2013.) 
178 Adapted from ibid 141. 
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A 2008 version of the demographic survey assessed the healthcare situation in 
Nigeria and revealed that one-third of women had experienced at least one 
barrier to accessing basic healthcare.180 The 2008 survey identified several 
barriers women face when accessing quality healthcare and found, for example, 
that resource-related barriers constituted one of the most significant 
impediments.181 More specifically, the study reports that fifty six percent were 
constrained by a financial barrier, while forty one percent indicated a lack of 
drugs at the health facilities as a problem.182 Other challenging factors were: 
permission from the decision-maker (mostly men or heads of families) to go for 
treatment; incapacity, transportation and care-related impediments; illiteracy, 
and limited physical access to health facilities and medical services.183  
The most recent demographic survey, published in 2014, based its findings on 
quantitative and qualitative sampling to demonstrate a similar range of problems 
for women in accessing healthcare.184 Particularly, forty two percent of women 
identified finance as a major barrier to their health.185 The survey’s findings also 
demonstrated other impediments to women’s health and well-being, such as 
domestic violence, illiteracy, lack of good nutrition, cultural practices and other 
socio-cultural and environmental factors.186  
An assessment of these surveys suggests that many Nigerian women, 
predominantly the poor who are uneducated, and reside in the rural locations 
may not have the necessary access to medicines, especially for the prevention, 
management and treatment of life-threatening diseases and illnesses. Although 
                                                                                                                                                                          
179 ibid 141. 
180 National Population Commission (NPC) [Nigeria] and ICF Macro, Nigeria Demographic and Health Survey 2008 (Nigeria National 
Population Commission and ICF Macro 2009) 138. 
181 ibid 138. 
182 ibid 
183 ibid 137-138. 
184 National Population Commission (NPC) and ICF Macro, Nigeria Demographic and Health Survey 
2013 (National Population Commission (NPC) and ICF Macro 2013) 153.  
185 ibid 153. 
186 ibid 153, 303-328. 
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the poor access to healthcare services, facilities and medicines for women is 
not limited to resources and low income, inaccessibility due to finances and cost 
of drugs makes it even less likely for women to have access to adequate 
healthcare. As a result of the many factors that obstruct their access to health 
care, women will require specific attention in the efforts to scale up access to 
the necessary healthcare treatments and medicines in Nigeria.187 In addition to 
general healthcare services, goods and facilities, this access to health care 
specifically pertains to preventive and curative drug treatments including fertility 
control and reproductive health treatments, drugs that treat STDs, HIV/AIDS 
and the necessary maternity healthcare.188  
In light of the issues of accessibility to affordable medicines in Nigeria, the next 
part of this chapter considers the debate on the relevance of granting patent 
protection to pharmaceutical products and processes and the consequential 
effect on the availability and access to affordable medicines. This evaluation is 
conducted from an international patent perspective, particularly the effect of the 
patents provisions in the TRIPS Agreement on the accessibility of medicines for 
the poor in developing countries. As Nigeria is a member of the World Trade 
Organisation (WTO) and is obliged to incorporate and implement the patent 
provisions of the TRIPS Agreement, the access to life-saving medications and 
public health issues that have arisen in connection with the IP provisions in the 
Agreement are significant to the central argument of this thesis.  
 
 
                                                          
187 For example, the CESCR has stated that ‘a major goal [for states] should be reducing women's health risks, particularly lowering 
rates of maternal mortality and protecting women from domestic violence.’ CESCR, General Comment No 14 paragraph 21.  
188 Cottingham and Berer (n 20) 69–84. (Observing that the majority of research and development, manufacture and distribution 
of drugs including sexual and reproductive, is in the hands of private profit-making pharmaceutical companies that hold patent 
rights to their creations.)  
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Part II: PATENTS, THE TRIPS AGREEMENT AND ACCESS TO 
ESSENTIAL MEDICINES IN DEVELOPING COUNTRIES 
 
 3.6: The TRIPS Agreement and Access to Medicines: The International 
Debate  
In the preceding chapter, the relevance and advent of the TRIPS Agreement 
were discussed.189 The fact that the emergence of the global IP system has 
generated public debate on the effect of patents protection to pharmaceutical 
innovation and the far-reaching adverse on access to essential medicines was 
also introduced.190 These discussions have centred on whether the benefits of 
the TRIPS Agreement, which aims to promote technological innovations and 
investment in research for new and therapeutic drugs, outweighs the cost 
implications to public health, particularly, for poorer people in developing 
countries.191 Consequently, the patent provisions in the Agreement, which 
include the support for pharmaceutical innovation, raises an issue that Nigeria 
has to grapple with to address the challenges of access to medicines in the 
country.192  
                                                          
189 See the discussion in Chapter II, subsections 2.5.1, 2.5.2. 
190 Ellen FM ’t Hoen, 'TRIPS, Pharmaceutical Patents and Access to Essential Medicines: Seattle, Doha and Beyond' in Jean-Paul 
Moatti and others (eds), Economics of AIDS and Access to Care in Developing Countries; Issues and Challenges (ANRS 2003) 42. 
 Also available at http://www.who.int/intellectualproperty/topics/ip/tHoen.pdf accessed 16 May 2014. 
191 Patrick L Osewe, Yvonne K Nkrumah and Emmanuel K Sackey, Improving Access to HIV/AIDS Medicines in Africa: Trade-Related 
Aspects of Intellectual Property Rights (TRIPS) Flexibilities Utilization (World Bank 2008) 9-10; Emilie Cloatre, Pills for the Poorest: 
An Exploration of TRIPS and Access to Medication in Sub-Saharan Africa (Palgrave Macmillan 2013) 2-3. 
192 Okechukwu Timothy Umahi, 'Access to Medicines: The Colonial Impacts on Patent Law of Nigeria' SSRN Electronic Journal. 
available at <http://ssrn.com/abstract=1975928> accessed 14 June 2015.  
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 The following discussion highlights the ways in which patent law and rights 
interact with the campaign for access to medicines from an international 
standpoint.  
 
 
 3.6.1 Patents in TRIPS for Pharmaceutical Products and Processes  
The TRIPS Agreement contains provisions for the protection of products and 
innovative processes in all technological fields, including pharmaceutical 
products and processes, chemicals, and plant varieties with some patentability 
exceptions.193 Thus all members of the WTO are obligated to establish and 
enforce the same minimum standard of patent protection for pharmaceuticals — 
whether produced locally or by international multinational corporations — under 
their national laws, failing which they may be subject to a complaint before the 
WTO’s Dispute Settlement Body (DSB).194 In complying with TRIPS, members 
may, but are not required, to implement more extensive protection than is 
required by the Agreement, provided it is consistent with the general standard of 
the Agreement. Members are given latitude to adopt an appropriate method for 
implementing the Agreement provided it is in accordance with the national 
treatment (NT) and most favoured nation (MFN) treatment provisions in Articles 
3 and 4 respectively. 
                                                          
193 The TRIPS Agreement in Article 27. See also Jayashree Watal, 'Pharmaceutical Patents, Prices and Welfare Losses: Policy 
Options for India under the WTO TRIPS Agreement' (2000) 23(5) The World Economy 733–752, 733; Joo-Young Lee, A Human 
Rights Framework for Intellectual Property, Innovation and Access to Medicines (Ashgate Publishing 2015) 119.  
194 The TRIPS Agreement, Article 27(1). See Philippe Cullet, 'Patents and Medicines: The Relationship between TRIPS and the 
Human Right to Health' in Sofia Gruskin (ed), Perspectives on Health and Human Rights (Routledge 2005) 183; Pitman B Potter and 
Ljiljana Biukovic, Globalization and Local Adaptation in International Trade Law (UBC Press 2011) 106; Junaid Subhan, 'Scrutinized: 
The TRIPS Agreement and Public Health' (2015) 9(2) McGill Journal of Medicine 152, 152–159.  
Compared to the Paris Convention, several provisions of the Agreement such as Articles 27(1), 27(3) (b), 28, 30 and 31 (a)-(f) 
strengthened the minimum standards of patent rights for enforcement in Member countries. Sampath (n 157) 253; Germán 
Velásquez and Pascale Boulet, 'Globalization and Access to Drugs: Perspectives on the WTO/TRIPS Agreement' (World Health 
Organization Action Programme on Essential Drugs 2015) 21-22. 
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 A particular concern for some developing countries is the obligation to provide 
legal protection for pharmaceuticals and health products. Before TRIPS, states 
had the sovereign authority to design their laws governing pharmaceuticals in 
any manner best suited to their economic situation, technological activities and 
development priorities.195 In some countries, patents for pharmaceuticals were 
limited to process patents and generally favoured local production of generic 
drugs, hence medicines were generally less expensive than the original 
product.196 With the introduction of TRIPS, however, countries lost that 
sovereignty to craft their national laws in a more flexible way to promote 
innovation while allowing considerable room for generic competition, since all 
members were now obliged to adhere to the same minimum rules for products, 
including pharmaceuticals.197  
 
 3.6.2 An Inventor’s Right to a Patent in the TRIPS Agreement 
 To promote technological innovation and development, the TRIPS Agreement, 
in Articles 27 and 28, provides for the availability of a patent right to inventors. 
For a minimum period of twenty years, members are mandated to protect the 
term-specific interest of a patent holder to restrict others from using, making, 
offering for sale, selling or importing the patented invention without the 
permission and authority of the rights owner. This right is available without 
                                                          
195 Susan K Sell, Private Power, Public Law: The Globalization of Intellectual Property Rights (Cambridge University Press 2003) 12. 
196 For instance, t’Hoen observes that when the Uruguay Round of negotiations was launched in 1989, forty nine members out of 
the ninety eight signatories to the Paris Convention did not grant patent protection to pharmaceutical products. Ten members also 
excluded patenting of processes and twenty two disallowed chemical processes from patentability. Ellen FM 't Hoen, The Global 
Politics of Pharmaceutical Monopoly Power: Power Drugs Access, Innovation and the Application of the WTO Doha Declaration on 
TRIPS and Public (AMB Publishers 2009) 9. 
197 World Health Organization, World Intellectual Property Organization and World Trade Organization, Promoting Access to 
Medical Technologies and Innovation Intersections between Public Health, Intellectual Property and Trade (World Health 
Organization, World Intellectual Property Organization and World Trade Organization Publications 2013). These flexibilities 
provisions are the subject matter of Chapter VI in this thesis.  
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discrimination as to the place of origin of the invention, the field of technology 
and whether the invention is produced locally or imported.198  
With respect to pharmaceuticals and medicines, the patent right of inventors is 
often justified as particularly important in pharmaceuticals R&D. However, 
whether there is merit in the patent system for pharmaceuticals and, indeed, 
whether this advantage outweighs or justifies the associated cost is still open to 
debate and controversy. The justification is further examined.  
 3.6.2.1 Justifications of the Patent System for the Availability of, and 
Access to Medicines  
As previously discussed in Chapter II,199 IPRs, particularly patent rights, are 
perceived to be a mechanisms for innovation and technological development. 
Likewise the argument in favour of patent-as-incentive as an opportunity for 
increased innovation, R&D and economic reward for ingenuity, is largely 
supported in the case of patenting of pharmaceuticals, although this argument 
is still debatable.200  
In the pharmaceutical industry, it is widely argued that a patent provides an 
important incentive for the stimulation of R&D of new and highly therapeutic 
medicinal treatments and drugs.201 Because patents do appear to be important 
in facilitating new breakthrough drugs, the patent protection of pharmaceuticals, 
it is argued, is particularly relevant to increasing access to medicines.202 The 
International Federation for Pharmaceutical Manufacturers and Associations 
                                                          
198 The TRIPS Agreement, Article 27 
199 In subsection 2.3.1, 2.3.3 and 2.3.4 of Chapter II. 
200 Christine Greenhalgh and Mark Rogers, Innovation, Intellectual Property and Economic Growth (Princeton University Press 
2010) 32-39. (The role of IP as an engine of innovation by providing the necessary incentive and its adverse impact on public 
health and innovation has been debated extensively in the academic literature. It is however difficult to do justice to the entire 
debate considering the limited scope of this study.)  
201 Commission on Intellectual Property Rights (CIPR), Integrating Intellectual Property Rights and Development Policy: Report of 
the Commission on Intellectual Property Rights (Full Report) (Commission on Intellectual Property Rights 2002) 29. 
202 Cullet (n 194) 181. 
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(IFPMA) argue, for example, that ‘[t]he vast majority of medicines available 
today would not exist without the incentive provided by intellectual property 
rights.’203 
 For many reasons, a patent is seen to provide a desirable stimulus for 
pharmaceutical R&D. First, a patent is generally presumed to be essential to the 
pharmaceutical sector because it enables inventors to recoup the cost of 
expenditure on the research and production activities.204 Scholars and 
pharmaceutical industry specialists often paint a picture of drug development 
and production as a complex, unpredictable, long and risky undertaking.205 
Pharmaceutical industry specialists and commentators explain that the R&D 
process for a new drug (also known as a new molecular entity (NME) or new 
chemical entity (NCE)) is a capital intensive, time-consuming research process 
sometimes with uncertain results.206 In addition, they emphasise that the R&D 
process for a new drug is a very expensive venture.207 In 2016, for example, a 
                                                          
203 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), The Changing Landscape on Access to 
Medicines (International Federation of Pharmaceutical Manufacturers & Associations 2015) 50.  
204 CIPR (n 146) 29; Michele Boldrin and David K Levine, Against Intellectual Monopoly (Cambridge University Press 2008) 236-237; 
Thomas Pogge, ‘The Health Impact Fund: Boosting Innovation Without Obstructing Free Access’ (2009) 18(1) Cambridge Quarterly 
of Health Ethics 78, 79; IFPMA ibid 50. 
205 Cynthia Ho, Access to Medicine in the Global Economy: International Agreements on Patents and Related Rights (Oxford 
University Press 2011) 5; International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), The Pharmaceutical 
Industry and Global Health: Facts and Figures (International Federation of Pharmaceutical Manufacturers and Associations 
(IFPMA) 2011) 7-9. Also available at 
<www.ifpma.org/wp-content/uploads/2016/01/2011_The_Pharmaceutical_Industry_and_Global_Health_low_ver2.pdf> accessed 
18 June 2015; Elizabeth Siew Kuan Ng, ‘Global Health and Development: Patents and Public Interest’ in Thomas Pogge, Matthew 
Rimmer and Kim Rubenstein (eds), Incentives for Global Public Health: Patent Law and Access to Essential Medicines (Cambridge 
University Press 2010) 102-103; CT Taylor and Aubrey Silberston, The Economic Impact of the Patent System: A Study of the British 
Experience (University Press 1973) 252-254. 
206 IFPMA, The Pharmaceutical Industry and Global Health: Facts and Figures (n 205) 7-9; Pharmaceutical Research and 
Manufacturers of America (PHARMA), Biopharmaceutical Research & Development: The Process behind New Medicines (PHARMA 
2015) 5-6. Also available at <www.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf> accessed 18 June 2014; Ho (n 205) 
5-16; Holger Hestermeyer, Human Rights and the WTO: The Case of Patents and Access to Medicines (Oxford University Press 
2007) 159-160; Pharmaceutical Research and Manufacturers of America (PhRMA), 2016 Biopharmaceutical Research industry 
Profile (PhRMA 2016) 46. 
207 See also Pharmaceutical Research and Manufacturers of America (PhRMA), 2015 Biopharmaceutical Research Industry Profile 
(PhRMA 2015) 13; Ho (n 205) 7-8. 
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study estimated that it costs an average of US$2.6 billion to develop one new 
drug in the US.208 
Secondly, pharmaceutical companies argue that the granting of exclusive 
patent protection assures them of financial incentives to further invest funds into 
the discovery and development of other new medicines.209 Analysts are 
therefore quick to point out that the market advantage of patent exclusivity 
spurs pharmaceutical companies to invest further in other research ventures.210 
By conferring a temporal ‘exclusive market position,’211 inventors and investors 
can recover spending costs and also benefit through profits from sales which 
provide the capital to reinvest in other medicinal R&D undertakings.212 
Thirdly, having invested financially and undertaken the risk associated with the 
development and research of a new drug, a patent secures the inventor’s 
interest against imitation and commercial appropriation of inventive results, 
because new drugs can quickly be reverse engineered and reproduced in 
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bulk.213 This argument leads commentators to point out that a patent is 
significant to pharmaceutical firms because it is an effective tool to ward off and 
control competition.214  
Evidential empirical studies are often presented to demonstrate that a patent is 
a factor that influences the decisions of pharmaceutical companies to invest in 
the discovery and R&D of medicines and technological innovations.215 For 
instance, in a study of the British patent system, Taylor and Silberston identify 
that patent protection is relatively unimportant to many industries, with the 
notable exception of the pharmaceutical sector.216 In making the point that ‘[n]o 
other major industry approaches pharmaceuticals in its degree of attachment to 
patent protection,’ they report in their study that patents are influential in the 
operations and pharmaceutical R&D activities of the understudied 
pharmaceutical firms.217 Consequently, they conclude that ‘these operations 
would not have been created had effective patent protection not been available 
[…].’218 Consistent with this view, a study by Mansfield in 1986 revealed that 
patents are incentives for research-related drug firms to conduct R&D activities 
and to develop and market drugs.219 Through a random survey of 100 
manufacturing firms, the study shows that the pharmaceutical industry in the 
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United States was greatly influenced by the patent system in their R&D 
activities.220 In particular, the study demonstrates that sixty to sixty five percent 
of pharmaceutical products would not have been introduced or developed 
without the assurance of patent protection.221  
These studies make a compelling case for the argument that the 
pharmaceutical sector regards patents as particularly important to a high rate of 
drug research and production.222 However, one must be cautious in deducing a 
generalisation of the claim that patents induce inventiveness and R&D activities 
in the pharmaceutical sector. Other incentive mechanisms can play an 
important role in the innovation process and drug production decisions of 
pharmaceutical firms. A 2002 study of 1,478 R&D labs in the U.S. 
manufacturing sector in 1994 revealed that no industry relies exclusively on 
patents as an incentive.223 The study reports that firms generally employ a 
variety of other R&D incentives stemming from lead time advantage, selling 
complementary products and secrecy to protect their inventions. For instance, 
at different stages of the innovation process, firms may initially rely on secrecy 
prior to commercialisation, but maintain competitive advantage through a patent 
right, aggressive marketing and lead time.224 This also holds true for 
pharmaceutical firms. Although the study records a more significant effect of a 
patent on pharmaceutical R&D and product innovation of drugs relative to other 
sectors, the survey also observes that ‘pharmaceutical firms emphasise 
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complementary capabilities [such as secrecy] and being first to market in 
addition to patents.’225  
Moreover, even if a patent is sufficient to encourage innovation and research-
related activities, the current technological capacity and development reality of 
many developing countries suggest that the role of a patent as an inducement 
for innovation may be minimal. In sub-Saharan Africa for example, many 
countries (except South Africa), lack the required technological/scientific 
competence and manufacturing infrastructure to direct industrial and scientific 
activities towards research-intensive drug discovery and production activities.226 
This means that the ability of developing countries to respond to the incentive 
rationale of a patent is unlikely.227 WIPO recorded for instance that more than 
eighty percent of patent applications for pharmaceuticals, pharma-chemicals 
and biotechnology in the period 1995-2006 originated from six countries — the 
US, Japan, Germany, France, UK, and Switzerland.228 Clearly, then, patents 
are crucial policy instruments in guaranteeing the returns on investment in the 
pharmaceutical sector of the more industrial countries. Nonetheless, this is not 
to say that patents are irrelevant to the pharmaceutical sector whether directly 
or indirectly. 
 3.6.3 The Justification of Patents-as-incentives and the Neglected 
Diseases Argument  
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A pronounced area where the patent-as-incentive argument has failed to secure 
or facilitate innovation is in the area of R&D of diseases prevalent in developing 
countries.229 Even where treatments were initially researched and produced, 
there is the still the issue of the availability of appropriate new drugs to treat 
infectious diseases due to increasing resistance to existing treatments.230 The 
non-availability of medicinal treatments for infectious and tropical diseases 
predominantly affecting, or severe in, the developing parts of the world, is more 
commonly known as the issue of drug availability for ‘neglected’ tropical 
diseases (NTD).231 NTDs have been identified as diseases that ‘affect almost 
exclusively poor and powerless people living in rural parts of low-income 
countries.’232 Accordingly, ‘[w]hile they cause immense suffering and often life-
long disabilities, these diseases rarely kill and therefore do not receive the 
attention and funding of high-mortality diseases like AIDS, tuberculosis and 
malaria.’233  
Generally, disease burdens are categorised into three groups. Type I diseases 
such as Hepatitis B, liver diseases, diabetes and cancer, affect people in 
developing and developed countries in the same proportions.234 For these 
diseases, there is adequate funding and R&D for cures and treatment.235 Type 
II diseases like HIV/AIDS, and TB affect both developing and developing 
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countries; however, the incidence of infection is higher in developing 
countries.236 While there is funding for these types of diseases, especially in rich 
countries’ markets, the funding is not always proportionate to the disease 
burden or investment in treatments is insufficient, especially in developing 
countries.237 Type III diseases, such as leishmaniasis, onchocerciasis (river 
blindness), Chagas disease, leprosy schistosomiasis, lymphatic filariasis, 
sleeping sickness, TB and dengue fever amongst others, are neglected 
diseases that exclusively or overwhelmingly afflict people, especially the poor, 
in developing countries.238 For these diseases, there is generally limited funding 
and R&D for cures and treatments.239 Furthermore, because the disease 
incidence is predominantly in low and middle income countries, their 
governments may also lack the financial means to undertake or subsidise R&D 
expenditure for necessary treatments.240  
In Nigeria, studies also indicate that the country has one of the highest reported 
incidences of NTDs such as intestinal helminth infections, schistomiasis and 
lymphatic filariasis, especially in the rural areas.241 The country’s disease 
incidence ranks fourth or fifth globally behind the more populated Asian nations, 
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such as China, India and Indonesia.242 In terms of the incidence of vector-borne 
tropical diseases,243 Nigeria has one of the highest reported rates of lymphatic 
filariasis and onchocerciasis in Africa, with an estimated global ranking of third 
and first place respectively.244 Nigeria also has an estimated 18 million people 
at risk from trachoma, with nearly 1.3 million people living with trichiasis.245 The 
country also accounts for the third or fourth largest number of new cases of 
leprosy in Africa (behind Ethiopia and the Democratic Republic of Congo).246 
These diseases generally afflict the vulnerable poorest, living in rural 
communities with limited access to quality healthcare.247  
While not unique to women, the high burden of NTDs may be borne by women, 
particularly pregnant women and children under their care, because of their 
vulnerabilities resulting from social and gender determinants, biological and 
genetic factors, physical and environmental risk, economic, political and 
poverty-related factors.248 This high disease incidence could in turn, constitute 
serious impediments to women’s general well-being and severely affect their 
physical and reproductive health.249 Studies provide evidence to indicate that 
NTDs are factors that can significantly affect women’s reproductive health in 
developing countries and increase the chances of contracting sexually 
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transmitted diseases (STIs), as well as entrenching stigmatisation and gender 
inequalities.250 Women suffering from forms of neglected diseases such as 
female genital schistomiasis are particularly exposed to other severe health 
problems such as infertility, anaemia, preterm labour, menstrual disorders, 
painful sexual intercourse and pregnancy complications.251  
These neglected diseases further cripple economies in many poor communities 
of the third world.252 They leave in their wake significant physical and 
psychological burdens, in addition to economic hardships resulting from the loss 
of ‘productivity and high cost associated with long-term care, which in turn, 
contributes to the entrenched cycle of poverty and ill-health for neglected 
populations.’253 The lack of affordable and efficacious medications to treat these 
neglected diseases represents an enduring medical challenge to the healthcare 
needs of people, especially women, afflicted by these diseases in developing 
countries.  
 
 3.6.3.1 Patents and Research for the Development of Treatments for NTDs 
While pharmaceutical innovation is on the increase,254 this has not been 
followed by an increase in R&D for these diseases that predominately affect 
people in the developing world.255 For instance, studies indicate that tropical 
and other diseases concentrated among the poor in developing countries are 
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the most neglected in terms of research, development and drug production.256 
Of the 1,556 new drugs approved in the period 1975-2004 for instance, only 
twenty-one were for treatment of NTD.257 Eighteen were specifically designated 
for tropical diseases and only three were approved for treatment of TB (one 
point three percent), even though NTDs account for an estimated eleven point 
four percent of the global disease burden.258  
The low investment in the development of cures for these diseases is attributed 
to the insignificant pharmaceutical market of developing countries.259 The 
Commission on Intellectual Property Rights (CIPR) has stated in this regard that 
the current market conditions and healthcare needs of the poor in developing 
countries simply do not offer enough incentive to pharmaceutical companies to 
substantially invest in R&D for NTDs.260 CIPR further stated that less than five 
percent of global spending on pharmaceutical R&D is targeted at NTDs and 
infectious diseases prevalent in low-income countries.261 Even if pharmaceutical 
companies were to invest in the treatments for neglected diseases, the 
medicines cannot be sold at a price that would match their profit priorities or 
cover the R&D cost, given that many people in those countries are poor.262  
In reality, the research priorities of pharmaceutical firms and companies follow 
business and economic rationales as developing countries’ markets lack the 
economic capital to attract significant R&D, pharmaceutical companies would 
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rather invest in products that yield financial turnover.263 As such, their R&D 
focus is on products that potentially guarantee profit; thus the emphasis is on 
diseases that afflict the wealthiest in developed countries who can afford to pay 
for them.264 Other scholars including Kremer concur, observing that the 
healthcare needs of the poor in the developing world largely go unmet by 
pharmaceutical companies’ R&D investment priorities.265 According to Drahos 
and Braithwaite, ‘patent-based R&D is not responsive to demands, but ability to 
pay. The blockbuster mentality of the large pharmas takes them to those 
markets where there is the ability to pay.’266 Consequently, pharmaceutical 
corporations would rather focus on treatments for high profit yielding illnesses 
such as mental illnesses, hypertension and erectile dysfunction.267 It goes 
without saying that the health needs of the poor in developing countries are not 
necessarily being addressed by these pharmaceutical companies given the lack 
of profit inducements.268  
An illustration is the case of a drug called eflornithine which was designed to 
fight cancer.269 It was later discovered to be ineffective as an anti-cancer agent 
but effective as a treatment for African sleeping sickness (trypanosomiasis).270 
Subsequently, Hoechst Marion Roussel (HMR), the company that developed 
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this drug, stopped production in 1999 because it was a commercial failure, 
despite the fact that it could save thousands of lives in Africa.271 In 2000, HMR 
transferred the license for eflornithine to the WHO. Together with MSF, WHO 
began to search for a producer to continue the production of eflornithine for the 
treatment of sleeping sickness.272 At the same time, Bristol-Myers Squibb, in 
2000, announced the launch of Vaniqa, an eflornithine-based cream for the 
treatment of unwanted facial and chin hair in women.273 This profit-oriented 
venture sparked media attention, with many criticising the pharmaceutical 
industry of ignoring the poor and treatment for a disease that is killing millions in 
Africa and other developing countries in favour of a lifestyle treatment.274 In May 
2001, Aventis signed a deal with WHO275 and MSF to ensure sufficient 
production and donation of eflornithine by Bristol-Myers Squibb for the 
therapeutic needs of patients suffering from sleeping sickness.276 This is in 
addition to the commitment to support MSF in the supply of the treatment to 
patients, support continued research and a steady supply of sleeping sickness 
medicines, as well as surveillance of control programmes.277 Bayer also agreed 
to reproduce and support MSF in the supply of two other sleeping sickness 
drugs, nifurtimox and suramin, in 2001.278 The bifurcated development of the 
eflornithine, as a cure for sleeping sickness, with a second profitable use for the 
elimination of facial hair, highlights concerns about the prioritisation of lifestyle 
treatments for rich consumers in developing countries over cures for life-
threatening diseases affecting the poor in developing countries.  
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More recently, the spread of the Zika virus has drawn global attention and 
heightened the need to find a more sustainable and effective control 
mechanism to encourage R&D for vaccines and drug treatments for vector-
borne and neglected infectious diseases.279 As of 3 August, 2016, the WHO 
highlighted that Zika virus transmission has been reported in about sixty-five 
developing and developed countries since 2015.280 There is currently no 
vaccine for the prevention and control of the Zika virus infection which is linked 
to congenital abnormalities, including microcephaly associated with abnormal 
brain development in infants.281 As such, there is need to effectively respond to 
the vector-borne disease that affects not only the poor regions of developing 
countries, but also urban regions and developed countries as well. If and when 
effective vaccines and treatments are available for the virus, there is a need to 
ensure that the medicines and vaccines reach people living in poorer parts of 
developing countries at an affordable cost.  
Patent law is relevant to this discussion because available patent protection for 
pharmaceuticals has not resulted in substantial increased benefits in drug 
development and production of essential drugs to improve access to medicines 
for the treatment of ‘neglected diseases’ in developing countries.282 A large and 
                                                          
279 World Health Organization, 'Experts Lay Groundwork for New Global Response to Vector-Borne Diseases' (World Health 
Organization 2016) also available at  
<http://www.who.int/neglected_diseases/news/Experts_lay_groundwork_for_new_response_vector_borne_diseases/en/> 
accessed 7 August 2016.  
Emphasising the importance of a coordinated global effort to address the control of and R&D into neglected tropical and vector-
borne diseases and treatments, Dr Dirk Engel, Director of the Department of Control of Neglected Tropical Diseases observed, that 
‘[o]ver the decades, dengue and chikungunya showed us that an outbreak response is not enough. Now Zika further emphasises 
the need for more fundamental and sustained vector control interventions.’ ibid 
280 ibid; World Health Organization, 'Situation Report: Zika Virus, Microcephaly and Guillain-Barré Syndrome' (Apps.who.int, 2016) 
available at  
<http://apps.who.int/iris/bitstream/10665/247197/1/zikasitrep4Aug2016-eng.pdf?ua=1> accessed 7 August 2016. (The WHO 
(World Health Organization) declared Zika virus infections as a public-health emergency in February 2016, after Zika virus had 
been reported transmitted to humans in sixty-two countries worldwide.) 
281 World Health Organization, 'Zika Virus' (World Health Organization 2016)  
<http://www.who.int/mediacentre/factsheets/zika/en/> accessed 7 August 2016. (The Zika virus is transmitted through the bite of 
an infected Aedes specie mosquito (Ae.aegypti and Ae.albopictus. The virus causes serious brain defects in children that are born 
to women who are infected with it.)  
282 CIPR, Integrating Intellectual Property Rights and Development Policy: Full Report (n 166) 32.  
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growing body of literature points to the failure of the patent-based incentive to 
facilitate the availability of adequate medicines, particularly for diseases 
afflicting poorer parts of developing countries.283 For example, The WHO’s 
Commission on Intellectual Property Rights, Innovation and Public Health 
(CIPIH) explains that ‘[w]here the market has very limited purchasing power, as 
is the case for diseases affecting millions of poor people in developing 
countries, patents are not a relevant factor or effective in stimulating and 
bringing new products to market.’284 Assessing this economic reality further, the 
CIPIH concludes that [f]or developing countries, where the demand is weak — 
but not the need— there is little incentive to develop new or modified 
interventions appropriate to the disease burden and conditions of the 
country.’285  
The Special Rapporteur on human rights to health in his mission statement to 
the WTO further wrote:  
The commercial motivation of intellectual property rights encourages research, first and 
foremost, towards ‘profitable’ diseases, while diseases that predominantly affect people 
in poor countries—such as river blindness—remain under-researched.286  
                                                          
283 Maskus, Private Rights and Public Problems: The Global Economics of Intellectual Property in the 21st Century (n 237) 263-267; 
Frank Müller-Langer, Creating R&D Incentives for Medicines for Neglected Diseases: An Economic Analysis of Parallel Imports, 
Patents, and Alternative Mechanisms to Stimulate Pharmaceutical Research (Springer Science & Business Media 2009); Bradly J 
Condon and Tapen Sinha, Global Lessons from the AIDS Pandemic: Economic, Financial, Legal and Political Implications (Springer 
Science & Business Media 2008) 17-19; Jose M Zuniga, Stephen P Marks and Lawrence O Gostin, Advancing the Human Right to 
Health (Oxford University Press 2013) 314; Mueller-Langer, 'Neglected Infectious Diseases: Are Push and Pull Incentive 
Mechanisms Suitable for Promoting Drug Development Research?' (n 260) 185-189; P Chirac and E Torreele ‘Global framework on 
Essential Health R&D’ (2006) 367 (9522) The Lancet 1560, 1560–1561. (These scholars make the point that patents as market-
based incentives do not significantly address research for new diseases for the poor in developing countries); Médecins Sans 
Frontières (MSF), ‘R&D System is Failing to Meet Health Needs in Developing Countries’ (Médecins Sans Frontières 2005). 
 Available at <www.accessmed-msf.org/documents/MexicoR&Dbriefing.pdf> accessed 17 July 2015 (MSF argues that patent’s 
incentive relevance to pharmaceutical innovation is market-based and its incentive rationale has failed to adequately promote 
R&D in developing countries.)  
284 World Health Organization (WHO), Public Health, Innovation and Intellectual Property Rights: Report of the Commission on 
Intellectual Property Rights, Innovation and Public Health (World Health Organization 2006) 22. 
285 ibid 23. 
286 Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and 
Mental Health, Paul Hunt, on His Mission to the World Trade Organization: Addendum (E/CN.4/2004/49/Add.1 2004) paragraph 
42. Available at  
<www.unhchr.ch/Huridocda/Huridoca.nsf/(Symbol)/E.CN.4.2004.49.Add.1.En?Opendocument> accessed 15 July 2014. 
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The lack of research into specific diseases or appropriate medicines affecting 
women, with specific requirements such as reproductive or sexual health, has 
also been noted.287  
Drawing a similar observation as CIPIH, Oxfam stated that even the existing 
health treatments may not be appropriate for particular groups of patients such 
as women and children with special needs.288 For example, little research has 
been directed to the effects of antiretrovirals on women who are pregnant or 
lactating.289 Thus there is another issue of R&D of drugs to cater for the 
particular needs of women.  
A pertinent factor in the unavailability of treatments for NTDs is the role of the 
TRIPS Agreement as a means of encouraging innovation into diseases. 
Commonly argued, the extension of patent rights for pharmaceuticals in TRIPS 
has failed to boost research for drugs that satisfy the health needs of 
developing countries.290 Considering the current challenges for the availability 
and accessibility of drugs for neglected diseases, several authors and 
organisations have called into question the relevance of patents in the TRIPS 
Agreement on pharmaceutical R&D and global health.291 In 2006, CIPIH 
concluded that there was ‘no evidence that implementation of the TRIPS 
Agreement in developing countries will significantly boost R&D in 
pharmaceuticals’ and ‘insufficient market incentives’ in developing countries are 
                                                          
287 Malpani, Heineke and Kamal-Yanni (n 229) 16. 
288 ibid 1, 16. 
289 ibid 7. 
290 WHO, Public Health, Innovation and Intellectual Property Rights: Report of the Commission on Intellectual Property Rights, 
Innovation and Public Health (n 284) 22; Margaret Chon, ‘Intellectual Property and the Development Divide’ (2006) 27(6) Cardozo 
Law Review 2821, 2883-2884. 
291 See for example, Chidi Oguamanam ‘Patents and Pharmaceutical R&D: Consolidating Private–Public Partnership Approach to 
Global Public Health Crises’ (2010) 13(4) The Journal of World Intellectual Property 556 4-5; Tim Hubbard and James Love ‘A New 
Trade Framework for Global Healthcare R&D’ (2004) 2(2) PLoS Biology 0147-0148; Patrick Leoni and Alvaro Sandroni ‘Can Patent 
Duration Hinder Medical Innovation for Neglected Diseases?’ SSRN Electronic Journal 2-18. Available at 
<http://ssrn.com/abstract=1950700> accessed 15 August 2015. (Arguing that the current patent law has entrenched a system that 
deters investment in essential and innovative R&D for neglected diseases.); Mueller-Langer ‘Neglected Infectious Diseases: are 
Push and Pull Incentive Mechanisms Suitable for Promoting Drug Development Research?’ (n 260) 185-188. Likewise, Oxfarm 
observes that ‘R&D for neglected tropical diseases receives only $1 of every $100,000 spent worldwide on biomedical research 
and product development.’ Malpani, Heineke and Kamal-Yanni (n 229)1. 
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identified as factors for this conundrum.292 El Said and Kapczynski further argue 
that the world’s pharmaceutical market share in developing countries is low for 
increased marginal value resulting from stronger patent protection; hence the 
benefit of a patent is unlikely to outweigh the impact on access.293  
While it would be overstating the importance of a patent to expect that is the 
only factor that can spur the degree of necessary investment in R&D to address 
the disease problems of developing countries, the argument, as above, holds 
that it offers incentive for researchers and pharmaceutical companies to 
undertake important drug discovery ventures. Indeed, as noted in the Chapter 
II,294 there were reasons to believe that the introduction of patent law in 
developing countries would facilitate FDI, lead to an increase in innovation for 
the pharmaceutical companies and enlarge the incentive to undertake important 
research.295 The success of innovative efforts is thus greater when inventions 
are protected. However, the dearth of investment in products to tackle diseases 
predominately affecting people in developing countries calls into question the 
justification of the incentive argument for patent rights in developing countries. 
The current situation leads some scholars to argue that the welfare benefits of 
introducing a global regime of minimum patent law through the instrumentality 
of the TRIPS Agreement is negative or yet to materialise.296  
It also begs the question as to why developed countries and pharmaceutical 
companies strongly lobbied to ensure that patent rights were made available to 
pharmaceutical processes and products in developing countries. Hestermeyer 
                                                          
292 WHO, Public Health, Innovation and Intellectual Property Rights: Report of the Commission on Intellectual Property Rights, 
Innovation and Public Health (n 284) 85. 
293 Mohammed El Said and Amy Kapczynski, 'Access to Medicines: The Role of Intellectual Property Law and Policy' [2011] 
(Working Paper prepared for the Third Meeting of the Technical Advisory Group of the Global Commission on HIV and the Law, 7-9 
July)1-2.  
294 See subsection 2.5, 2.5.1 and 2.5.2. 
295 Hestermeyer (n 206) 162; Carlos Primo Braga and Carsten Fink, 'Reforming Intellectual Property Rights Regimes: Challenges for 
Developing Countries' (1998) 1 Journal of International Economic Law 538.  
296 Hestermeyer (n 206) 163. 
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pondered on this and suggests that, as a market strategy, the pharmaceutical 
industry wanted to prevent low ‘price leakage’ from developing countries to the 
markets of other developed countries through parallel imports.297 Also, as 
indicated in Chapter II, developed countries and their industries wanted to limit 
the imitation, ‘free-riding’ and generic re-engineering of their products and a 
global IP system appears to be the most appropriate mechanism.298  
While it is an undisputed fact that pharmaceutical companies are first and 
foremost, profit-making ventures with financial responsibilities to shareholders, 
they can facilitate the much needed availability of, and access to, medicines. 
Although the pharmaceutical industry is only one player in this scheme of 
research into NTDs (arguably, it is the government’s duty to ensure that there is 
investment in pharmaceutical R&D for the benefit of its people, particularly 
women), they could significantly contribute to the R&D of essential drugs 
including treatments for NTDs if more efforts are directed to address these 
diseases. For this reason, several proposals have been made for new, 
alternative or complementary mechanisms for directly incentivising and 
promoting the R&D of innovative treatments for NTDs.299  
In 2012, the Consultative Expert Working Group on Research and 
Development: Financing and Coordination (CEWG) examined proposals for 
new and innovative ways of financing and stimulating R&D, specifically for 
developing countries.300 They include amongst others: public-private 
partnerships (PPPs) to encourage private and public partnerships in drug 
                                                          
297 Hestermeyer (n 206) 165. 
298 See subsection 2.5.1.  
299 These proposals are generally grouped under two categories of ‘push’ and ‘pull’ mechanisms. While push programmes aim to 
finance or support a specific R&D project by a particular innovator, research institute or pharmaceutical firm, the pull programme 
is based on a pledge to reward several competitors for a valuable pharmaceutical R&D innovation. Thomas Pogge, ‘The Health 
Impact Fund: Better Pharmaceutical Innovations at Much Lower Prices’ in Thomas Pogge, Mathew Rimmer and Kim Rubenstein 
(eds), Incentives for Global Public Health: Patent Law and Access to Essential Medicines (Cambridge University Press 2010) 147.  
300 Details of the proposal can be found at Annex 3 of the 2012 CEWG Report. See Report of the Consultative Expert Working Group 
on Research and Development: Financing and Coordination Research and Development to Meet Health Needs in Developing 
Countries: Strengthening Global Financing and Coordination (World Health Organization 2012).  
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discovery, development or production programmes; Prize Funds for rewarding 
innovative R&D; Advanced Market Commitments (AMC) to assure 
pharmaceutical companies and researchers a return on their investment in R&D 
for treatments of diseases predominantly affecting developing countries; 
medicines patent pools for licensing of patents to members of a pool or third 
parties; patent buyout schemes and open source medicine initiatives.301 These 
avenues provide the means for pooling resources, data, and expertise to 
promote pharmaceutical R&D, licensing and drug production, towards the public 
health objectives of providing the necessary treatments, especially for 
populations afflicted by poverty.302 Importantly, these innovative approaches to 
promoting and incentivising R&D emphasise a network of collaboration and 
sharing of knowledge and data between various stakeholders such as 
governments, public sector, academia, scientists, donor groups, and 
international organisations as well as the pharmaceutical industry.303 Scholars 
and several organisations also promote the exploration of these multi-sectoral 
collaborative innovation models to promote R&D and access to medicines in 
response to the problems of the patent system, such as its implication on the 
cost of drugs and neglected diseases of the developing world.304 Developing 
                                                          
301 This list is in no way an exhaustive alternative or supplementary means to the current traditional patent law approach to 
incentivising innovation. Other schemes exist to stimulate innovation for the health needs of developing countries and promote 
access to medicines. They include the foreign filing approach, where patents right holders pledge not to enforce their rights in 
certain low-income countries, patent ‘buyouts’, international purchase agreements etc. For a general discussion on these, see 
WHO, Public Health, Innovation and Intellectual Property Rights: Report of the Commission on Intellectual Property Rights, 
Innovation and Public Health (n 284) 66-91; Michael Kremer ‘Patent Buyouts: A Mechanism for Encouraging Innovation’ (1998) The 
Quarterly Journal of Economics. 
302 Warren Kaplan and others, ‘Priority Medicines for Europe and the World Update Report, 2013’ (World Health Organisation 
2013) 184-192. Other government programmes such as the Orphan Drug Schemes, Tax credits and Transferable Intellectual 
Property Rights (TIPR) also promotes innovative R&D for medicines. WHO, Public Health, Innovation and Intellectual Property 
Rights: Report of the Commission on Intellectual Property Rights, Innovation and Public Health (n 284) 86-87. Developing countries 
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303 See more on this at WHO, Public Health, Innovation and Intellectual Property Rights: Report of the Commission on Intellectual 
Property Rights, Innovation and Public Health (n 284) 24-28. 
304 E Richard Gold and others, Toward a New Era of Intellectual Property: From Confrontation to Negotiation: A Report from the 
International Expert Group on Biotechnology, Innovation and Intellectual Property (International Expert Group on Biotechnology, 
Innovation and Intellectual Property 2008); T Bubela, GA FitzGerald and ER Gold, 'Recalibrating Intellectual Property Rights to 
Enhance Translational Research Collaborations' (2012) 4 Science Translational Medicine 1, 1-5. 
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countries such as Nigeria can explore these alternative/ complementary 
collaborative methods of stimulating innovation for R&D of essential medicines 
and vaccines as additional health-related safeguards.  
Recently, the scourge of the Ebola virus disease (EVD), and the effective 
response to treatment for the epidemic, is illustrative of how these 
collaborations and partnerships work to promote R&D for global health. To help 
combat the deadly Ebola virus in West Africa, several public-private 
partnerships and collaborative programmes were set up to support and 
significantly expedite the research, clinical testing, development, production and 
distribution of treatments for EVD. Through combined efforts, the clinical trial 
and research of treatments for EVD were undertaken with funding and technical 
expertise by the public and private sectors.305 For example, in 2014, the US 
Agency for International Development (USAID), the Broad Institute for MIT, and 
Harvard, and Illumina Inc, initiated a public-private partnership to train 
personnel, supply technological equipment and gather data that would expedite 
the development of diagnostic treatments, vaccines and medicines.306 The initial 
clinical study and manufacturing cost for the EVD Vaccine CAd3-ZEBOV was 
part financed by public bodies and research institutes.307 In 2014, Johnson and 
Johnson, in collaboration with the US-National Institute for Allergy and 
Infectious Diseases (NIAID), commenced research, development and clinical 
                                                          
305 Wellcome Trust ‘Recommendations for Accelerating the Development of Ebola Vaccines Report & Analysis’ (2015) available at  
<http://www.cidrap.umn.edu/sites/default/files/public/downloads/ebola_virus_team_b_report-final-021615.pdf> accessed 18 
December 2015. (The Recommendations for Accelerating the Development of Ebola Vaccines: Report & Analysis was made 
possible through a joint project of Wellcome Trust and the Center for Infectious Disease Research and Policy (CIDRAP) at the 
University of Minnesota).  
306 'USAID, Broad Institute and Illumina Form a Public Private Partnership Combating the Ebola Epidemic in West Africa’ 
(Broadinstitute.org) <https://www.broadinstitute.org/news/6209> accessed 13 May 2015. 
307 The vaccine by GlaxoSmithKlin was co-developed with the US-National Institute for Allergy and Infectious Diseases (NIAID) and 
Okairos. Daian Cheng, ‘Advancing the Ebola Pipeline Requires Continued Collaboration between Public and Private Stakeholders’ 
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Organization, WHO High-level meeting on Ebola Vaccines Access and Financing (WHO/EVD/Meet/EMP/14.2, World Health 
Organization 2014). Also available at 
http://apps.who.int/iris/bitstream/10665/137184/1/WHO_EVD_Meet_EMP_14.2_eng.pdf.  
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testing of vaccines for EVD.308 In 2015, Johnson and Johnson announced the 
formation of a consortium with other global research institutes and NGO’s to 
accelerate the R&D of EVD Vaccines.309 Funding for the project was supported 
by the Innovative Medicines Initiatives.310 Development of the vaccine ZMapp 
by Mapp Biopharmaceuticals received public funds from various government 
agencies and organisations.311 To fast-track research, trials, treatments and 
access to EVD vaccines and medicines, a consortium of government bodies, 
international NGOs and leading research institutions with a grant of $3.2 million 
from the Wellcome Trust was set up in 2014.312 Commendably, despite the low 
disease incidence (the recent outbreak was contained to a few countries) and 
obvious lack of financial incentive to research and develop treatments for EVD, 
there was a rapid response to combat the most recent Ebola outbreak from the 
onset.313 There was huge support from pharmaceutical companies in 
association with government and organisations who rallied together to share 
information, collaborate and mitigate the cost associated with the drug and 
vaccine R&D for EVD. Significantly, the traditional incentive argument of patents 
as an incentive was not relied on as a primary driver to stimulate the R&D.  
                                                          
308 'Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production | 
Johnson & Johnson' (Jnj.com) 
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include the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC), the University of Oxford, 
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313 PhRMA, 2016 Biopharmaceutical Research industry Profile (n 206) 40. 
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One of the biggest lessons to be learnt from the Ebola incident and subsequent 
coordinated attempt to diagnose, prevent, and find cures for the outbreak is that 
a more collaborative method of incentivising and promoting R&D also reshape 
the operational efficiency of medicinal R&D, particularly for NTDs. A 
convergence of interest and expertise from different parties may also lead to a 
better managed R&D performance and output; accelerate the discovery and 
development of effective and safe medicines and promote the availability and 
access to them.  
It is worth mentioning that international and donor organisations, public 
institutions, charities and private individuals are also supporting and funding the 
R&D of pharmaceuticals and vaccines, especially for neglected diseases 
pertinent to developing countries.314 The Bill and Melinda Gates Foundation, the 
Rockefeller Foundation, the Wellcome Trust, the William J Clinton Foundation, 
and Doctors Without Borders (Médecins Sans Frontières) are a few examples 
of non-governmental organisations (NGOs) and philanthropic donors that 
actively fund and support the R&D of drugs for diseases towards enabling the 
availability and access to essential drugs for the needy.315 Other examples are 
PATH Malaria Vaccine Initiative (MVI), an initiative set up to facilitate and speed 
up the R&D of medicines and vaccines for malaria treatments;316 the Roll Back 
Malaria (RBM) Partnership, a collaborative network fighting malaria;317 and the 
Foundation for Innovative New Diagnostic (FIND), a non-profit organisation 
devoted to developing and providing new and affordable diagnostic tests and 
                                                          
314 Cheri Grace, ‘Product Development Partnerships (PDPs): Lessons from PDPs Established to Develop New Health Technologies 
for neglected Diseases’ (DFID Human Resource Centre 2010) 2-3. 
315 It is pertinent to note that this list is merely symbolic of groups and organisations that actively seek alternative measures to 
encourage pharmaceutical innovation, R&D and availability of essential medicines.  
316 More information about the organisation’s activities can be found at the official website  
<http://www.malariavaccine.org/>. 
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other tools for poverty-related diseases such as sleeping sickness in developing 
countries.318 
From an IP perspective, this is not to say that patents are irrelevant to 
pharmaceutical R&D or should be discarded. Rather than work in isolation to 
incentivise the manufacturing and distribution of medicines based on financial 
remunerations and charging higher prices to recoup R&D investment cost, 
patent holders could also contribute to life-saving pharmaceutical R&D through 
partnership arrangements, collaborations, sharing of knowledge and many other 
ways. Pharmaceutical companies could also explore collaborative funding 
mechanisms to undertake the R&D of medicinal treatments for NTDs. 
To be fair to pharmaceutical companies, some have made commendable efforts 
to scale up access to cheaper drugs through discounted prices or drug 
donations in partnership with donor groups or organisations. Other 
pharmaceutical corporations have committed themselves not to acquire or 
enforce their patent rights in some developing countries. In Zambia, for 
instance, Novartis offered a discounted price for Coartem, an effective but 
expensive drug for the treatment of malaria, at cost price through the WHO.319 
In Uganda, drug donations have provided immense benefits in the treatment of 
leprosy, lymphatic filariasis, onchocerciasis sleeping sickness and HIV.320 
However, while drug donation is important to the affected communities, access 
through these means is at the discretion of the pharmaceutical companies or 
donor organisations that can elect to discontinue such discount/donor 
                                                          
318 ‘Foundation for Innovative New Diagnostics and WHO collaborate to Improve Diagnosis of Sleeping Sickness with a Gates 
Foundation Grant’ (WHO and FIND Press Release 2006). 
<http://www.who.int/mediacentre/news/releases/2006/pr08/en/> accessed 15 July 2015 
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and Zambia (The Initiative on Public-Private Partnerships for Health (IPPPH) 2004) 2.  
320 ibid 
152 
 
programmes at will. Caines and Lush, for example, express concerns that the 
discounts for drugs remain uncoordinated and fragmented, as companies 
exercise different approaches in making their donations and discount prices 
available.321 Another shortcoming of donation is that access to drugs may be 
unreliable and inconsistent, donation programmes may be short-term, for 
specific periods and reasons only. It is therefore argued that, for sustainable 
health benefits, it is essential that there is a consistent and reliable channel for 
the supply of effective drugs to meet the health challenges of developing 
countries.  
More recently, in 2016, GlaxoSmithKline announced their intention to facilitate 
better access to medicines by not filing, or even dropping its patents, in poor 
countries.322 GlaxoSmithKline made the decision not to file for patents in 50 low-
income countries.323 For lower-middle income countries, GlaxoSmithKline will 
continue to file for patents but grant licences to generic manufacturers for a 
‘small royalty.’324 In richer countries, however, patents will still be filed. The 
decision was made with the aim of allowing other independent manufacturers to 
make and sell generic versions in developing countries and thereby increase 
access to them.325  
This commendable move has been hailed as important for broadening access 
to essential drugs, one which other major pharmaceutical companies can 
emulate.326 Recognition of the effect that patents can have on accessibility, and 
taking steps to curtail the interference of patent right with this access, by the 
                                                          
321 ibid 37-38. 
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pharmaceutical industry, will greatly improve access to and use of essential 
drugs by the poor in developing countries. 
The contribution of this type of ‘corporate social responsibility’327 may, however, 
remain modest if developing countries do not have the facilities and 
pharmaceutical manufacturing infrastructures to take advantage of such 
opportunities, especially if the original price set by the pharmaceutical 
companies on their patented drug is still high. Moreover, access to medicines 
through this channel remains at the discretion of pharmaceutical companies, 
who can take out a patent on a dependent drug (e.g. cocktail of ARVs needed 
at different stages of HIV/AIDS treatment) or seek patent protection in major 
generic manufacturing countries such as India. This may still affect developing 
countries with little manufacturing capacity that rely on these cheaper drugs. 
There is also the issue of how to enforce pharmaceutical companies’ patents 
pledges should they choose to renege on it. Nonetheless, the importance of this 
voluntary means of ensuring access is commendable and should not be 
underestimated.  
Having considered the first aspect of the debate on the advantages and 
counter-arguments on the justification of patents, the consequential adverse 
effect on public health is further analysed. 
 
 3.7 ‘Tripping’ Women’s Health and Access to Medicines: The Case 
Against Patents in the TRIPS Agreement 
Despite the foregoing analysis of the beneficial effects of patents on 
pharmaceutical innovation, patent rights could nevertheless limit the access to, 
and use of, the patented medicinal resources or effectively reduce the 
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transformative potential (i.e ability to build upon existing innovation) of the 
patented invention.328 Scholars have noted that, although patents can contribute 
to increased innovation by encouraging invention and creativity, the protection 
may incur a social welfare cost and in some cases, obstruct the use and 
development of the patented invention by others.329 This point echoes the two 
conflicting perspectives to patent rights: on the one hand, a patent is justified by 
the claim that it provides the necessary incentive to spur pharmaceutical R&D, 
facilitate FDI and technology transfer and makes available important medicines 
leading to access.330 On the other hand, patent rights might impede access to 
important resources such as life-saving medicines and thus obstruct 
development goals. In this manner, reservations about the development 
benefits of patent rights in the TRIPS Agreement are often contrasted with 
potentially adverse effects on the affordable accessibility and availability of 
pharmaceuticals.331 This case against patent rights is based upon the exclusive 
rights granted to inventors and the nature of the protection which could limit 
poor women’s access to available, affordable and preventive essential 
medicines and reproductive health supplies. This argument essentially centres 
on the effects of a patent’s monopoly right on public health and consequently, 
social welfare and development. 
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existing invention. 
329 Haiyang Zhang, ‘Rethinking the Patent System from the Perspective of Economics’ in Frederick M Abbott, Carlos M Correa and 
Peter Drahos (eds,) Emerging Markets and the World Patent Order (Edward Elgar Publishing 2013) 61.  
330 As discussed earlier in 3.4.1.1. 
331 Amal Nagah Elbeshbishi, 'TRIPS And Public Health: What Should African Countries Do?' [2007] (African Trade Policy Centre 
(ATPC) Work in Progress No. 49. Economic Commission for Africa) 6-9.  
155 
 
 
 
Figure 3.3 Framework of the Debate and the Relationship between Patents, 
Access to Medicines and Development in the Context of the TRIPS 
Agreement.332 
 
 3.7.1 Arguments on Patents’ Exclusive and Monopoly Rights and Access 
to Pharmaceuticals 
It can be recalled333 that exclusivity and monopoly are inherent features of IP 
and patent law.334 Under patent law, no one can use a patented idea without the 
                                                          
332 This diagram is this thesis author’s representation of the debate. For a discussion of the conceptual framework in which the 
debate on patents, the TRIPS Agreement and access to medicines within the context of human rights is taking place, see Cullet (n 
194) 180-170.  
333 From subsection 2.2 in Chapter II.  
334 WR Cornish, Intellectual Property: Patents, Copyrights Trademarks and Allied rights (Sweet and Maxwell 1993) 47. 
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authorisation of the patent owner.335 It is this ‘monopoly rent to innovators’ that 
has generated controversy with regards to the effect of patents on the 
availability of, and access to, medicines.336 A study of the arguments against 
patents indicates that the exclusive right which fosters the monopoly and control 
of knowledge has been challenged by scholars and international organisations, 
particularly with regards to public health.337 Nobel laureate Joseph Stiglitz notes 
that: ‘the fundamental problem with the patent system is simple: it is based on 
restricting the use of knowledge.’338 In other words, a patent’s exclusivity is 
grounded in the concept of restriction which ‘involves constructing higher walls 
around knowledge and controlling it tightly.’339 When it comes to essential 
drugs, rights holders, who are usually pharmaceutical companies, can, through 
their IPRs, control who uses their patented inventions, when and in what 
circumstances.340 
With regards to follow-on medicinal R&D, critics have accused the patent 
system through patentees’ rights, of preventing the transformative use of a 
patented innovation by those who wish to leverage on the existing inventions.341 
They claim that, while a patent aims to encourage scientific and pharmaceutical 
R&D, an associated problem is that it can reduce the utilisation of the invention 
by other inventors, scientists and researchers.342 Two of the most outspoken 
critics of IP monopoly rights, economists Boldrin and Levine, also argue that 
                                                          
335 Boldrin and Levine (n 204) 8; Thomas Pogge, ‘The Health Impact Fund: Boosting Innovation Without Obstructing Free Access’ (n 
204) 79. 
336 M Trebilcock and R Howse, The Regulation of International Trade (Routledge 1995) 249.  
337 ‘t Hoen, The Global Politics of Pharmaceutical Monopoly Power: Drug Patents, Access, Innovation and the Application of the 
WTO Doha Declaration on TRIPS and Public Health (n 196) 79. (Stating that the temporal patent monopoly ‘comes at a cost to 
society.’) 
338 Joseph Stiglitz, 'Prizes, Not Patents' (Project Syndicate 2007). Available at <https://www.project-
syndicate.org/commentary/prizes--not-patents> accessed 17 June 2014.  
339 Gold and others, Toward a New Era of Intellectual Property: From Confrontation to Negotiation: A Report from the International 
Expert Group on Biotechnology, Innovation and Intellectual Property (n 304) 8. 
340 ibid 18. 
341 ibid  
342 Zhen Lei, Rakhi Juneja and Brian D Wright, ‘Patents versus Patenting: Implications of Intellectual Property Protection for 
Biological Research (2009) 27(1) Nature Biotechnology 36.  
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monopoly rights have an adverse effect on economic growth, science and 
technological progress.343  
Boldrin and Levine’s contention has some merit. Although, as discussed 
earlier344 a patent is essential to the pharmaceutical industry to encourage the 
creation of new medicines, it may affect the subsequent availability of, and 
access to, important follow-on products. Patent rights could act as a barrier to 
research and innovation when they preclude other pharmaceutical companies 
from either developing or commercialising new health products and drugs due 
to concerns over patent infringement or patent thickets. Edwin Cameron argues 
that patents paradoxically limit the ‘current use of existing inventions so as to 
increase the development and thus the future availability of new inventions.’345 
Thus the foremost objection to the justification of patent as an incentive-to-
innovate is that the monopoly right it creates can endanger further use and 
incremental innovation around the existing invention, rather that promoting it.346 
Scholars, such as Posner and Landes, while accepting that IP is instrumental to 
investment in innovation, also make a case for second-comers who might wish 
to adapt and improve existing inventions.347  
It may be argued that subsequent inventors seeking to improve an invention 
can negotiate a licence with the rights owner. This argument appears simple in 
principle; in practice, however, obtaining a licence is not always straightforward 
                                                          
343 They argue that: 
Intellectual monopoly is not a cause of innovation, but rather an unwelcome consequence of it. In a young, dynamic 
industry full of ideas and creativity, intellectual monopoly does not play a useful role. It is when ideas run out and new 
competitors come in with fresher ideas that those bereft of them turn to government intervention – and intellectual 
“property” – to protect their lucrative old ways of doing business 
Boldrin and Levine (n 204) 17. 
344 In subsection 3.6.2.1  
345 Edwin Cameron, ‘Patents and Public Health: Principle, Politics and Paradox’ in David Vaver (ed), Intellectual Property Rights: 
Critical Concepts in Law, Volume 4 (Taylor & Francis 2006) 442. 
346 ibid 
347 Williams M Lands and Richard A Posner ‘An Economic Analysis of Copyrights law’ (1989) 18 The Journal of Legal Studies 325. 
(While their argument is within the discourse of copyright, the general position on this relates to IP.) 
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or easy to negotiate. At the discretion of the originator, the request may be 
refused.348 Moreover, the royalty rate for pharmaceutical innovation tends to be 
high, especially in cases where multiple patent licences are required for R&D.349 
The higher cost of patent licences could, in turn, also increase the price of the 
product, resulting in limited access. The effect of the high cost of the product 
may be ameliorated where people are able and willing to pay the premium price 
for the products. But for poorer people, particularly women, in developing 
countries who cannot afford to pay the premium prices that ordinarily flow from 
patent exclusivity rights, access becomes a grave concern.350 With regards to 
this monopoly right, scholars and commentators have expressed mixed 
reactions to the suitability of patents for promoting scientific, technological and 
enhancing human development, especially in developing countries.351 
Another argument centres on the financial and welfare cost of obtaining the 
patented pharmaceutical products, especially for the poor in many parts of 
developing and in some cases, developed countries.352 This monopolistic effect 
of patents is more to do with the way it is used and implemented by rights 
holders within the legal privilege of patent law.353 While patents in theory only 
give the innovator a monopoly of rights to prevent others from practising the 
innovation, exercising this exclusionary right may, in many cases, control the 
actual access to the innovative resources. This results from the ‘right to exclude’ 
                                                          
348 Indeed, as will be examined in Chapter VI, many compulsory licences have been granted due to the refusal of patent holders to 
grant licences. 
349 Michael H Jester, Patents and Trademarks Plain & Simple (Career Press 200) 107 (Noting that, depending on the licencing 
arrangement, royalties charged for pharmaceuticals are as high as 20-60 percent.)  
350 Cameron (n 345) 442.  
351 Krishna Ravi Srinivas ‘Open Source Drug Discovery: Revolutionary Paradigm or a Utopian Model?’ in Thomas Pogge, Mathew 
Rimmer and Kim Rubenstein (eds), Incentives for Global Public Health: Patent Law and Access to Essential Medicines (Cambridge 
University Press 2010) 263. 
352 Aidan Hollis ‘An Efficient Reward System for Pharmaceutical Innovation’ (2005) Working Paper, The University of Calgary. 
Available at <http://keionline.org/misc-docs/drugprizes.pdf> accessed 15 August 2015; Eric von Hippel, Democratizing Innovation 
(MIT Press 2005) 89. 
353 Gold and others, Toward a New Era of Intellectual Property: From Confrontation to Negotiation: A Report from the International 
Expert Group on Biotechnology, Innovation and Intellectual Property (n 306) 13. 
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monopoly right which provides an opportunity for patent holders to restrict 
generic reproduction, control competition, and raise the prices of their 
innovative products as they deem fit.354 This temporary market exclusivity 
allows the rights owner discretion to set the price of the drugs, which they 
usually set much higher than the production costs.355 
In a competitive market, multiple companies will produce the same product and 
compete on price, thus driving the price down to a point near production cost.356 
However, during the subsistence of patents, patent holders (often large 
pharmaceutical companies), have a monopoly right over the production, 
distribution and price fixing of their patented products.357 This price control, 
therefore, raises issues about its effect in limiting access to affordable drugs 
required by people in developing countries to fight diseases and infections.358 
This is more so where one patent holder holds a patent right to an essential life-
saving drug with no therapeutic substitute, leaving consumers without a choice.             
                                                          
354 Abbe Elizabeth Lockhart Brown, Intellectual Property, Human Rights and Competition: Access to Essential Innovation and 
Technology (Edward Elgar Publishing 2011) 1; MSF, 'The Impact of Patents on Access to Medicines' 
<http://www.msfaccess.org/content/impact-patents-access-medicines> accessed 12 May 2016. 
355 Joachim Henkel and Robert Lutte, ‘Synthetic Biology: Solving the Pharmaceutical Industry Innovation Problems?’ in Iñigo de 
Miguel Beriain and Carlos María Romeo Casabona (eds), Synbio and Human Health: A Challenge to the Current IP Framework? 
(Springer 2014) 36. Describing how market monopoly power works, Schulz adds:  
[i]n a monopoly market, the sole producer of an item is free to set the price, in contrast to producers in competitive 
markets which have no individual influence in price and hence may be regarded as price takers rather than price setters. 
The monopolist has a considerable degree of market power, which will increase his profit as compared with that which he 
might expect to earn in a competitive market situation.  
Carl-Erik Schulz, ‘Prices and Access to Essential Medicines’ (2000) 13(1) International Journal of Risk and Safety in Medicine 143, 
145.  
356 ibid 145. These problems are not inherent in patent law, rather, they are a result of the manner in which patent right owners 
utilise and enforce their rights. E Richard Gold and others, 'Are Patents Impeding Medical Care and Innovation?' (2010) 7 PLoS 
Med 1, 3. 
357 Aida Caldera and Ziga Zarnic ‘Affordability of Pharmaceutical Drugs in Developing Countries’ Kiel Institute for World Economics 
Working paper No. 419. (Note, however, that even where drugs are patented, the patent owner only has monopoly rights over the 
chemical entities, and can only excluse others from making, selling, using or dealing with the patented invention. The right 
holder(s) still compete with other producers with therapeutic substitutes.) Carsten Fink ‘ How Stronger Patent Protection in India 
Might Affect the Behavior of Transnational Pharmaceutical Industries’ (1999) Policy Research Working Papers, 3; Haochen Sun, ‘A 
Wider Access to Patented Drugs under the TRIPS Agreement’ (2003) 21 Boston University International Law Journal 101, 106. 
358 Eric Noehrenberg, ‘The Realities of TRIP, Patents and Access to Medicines in Developing Countries’ in Meir Perez Pugatch (ed), 
The Intellectual Property Debate: Perspectives from Law, Economics and Political Economy (Edward Elgar Publishing 2006) 170-
175; Thomas Pogge ‘The Health Impact Fund: Boosting Pharmaceutical Innovation Without Obstructing Free Access’ (n 204) 79. 
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Commentators have expressed differing opinions on the anti-competitive effect 
of patent monopoly on accessing essential drugs.359 Some argue that the 
problem of access to medicines has little to do with patents. Putting forth a 
similar argument, Professor Adewopo states that ‘patent law, though a factor in 
the dynamics of promoting public health, is neither a determinant for nor a 
barrier to access.’360 Furthermore, it is argued, for example, that in countries 
with high rates of HIV/AIDS, patents for many antiretroviral are non-existent or 
rarely enforced.361 The basis of some of the contrary arguments is that patents 
do not confer sufficient monopoly control over ideas or market power to cause 
lack of access to medicines.362 This argument also hold the view that, actually, 
right holders in relation to pharmaceuticals have less than ten years to 
exclusively market their products as they wish, after which generic competitors 
can engage in price competition.363  
This argument is, however, insufficient considering that pharmaceutical 
companies can, and do, frustrate the generic availability of a drug by taking new 
patents to extend the life of pharmaceuticals through a process known as 
‘evergreening.’364  The effect of patents on price is further examined. 
                                                          
359 Jae Hun Park, Patents and Industry Standards (Edward Elgar Publishing 2010) 120. It is worth noting that the problem of access 
to medicines in developing countries is multifarious and not limited to patents alone. However, patent can be a factor. As a report 
indicated,  
The problem of access to essential medical products – diagnostics and vaccines as well as medicines – persists for 
reasons that are complex and often interlinked. They have to do with trade agreements, market size, drug 
pricing, intellectual property and competition within the pharmaceutical industry as well as with a progressively 
drying R&D pipeline, the financing of R&D and pharmaceutical production, procurement and supply issues, and 
the failures of health systems in many poor countries and regions. This complex situation calls for a 
comprehensive approach that will improve coherence among many players across different sectors. 
M Berger and others, Strengthening Pharmaceutical Innovation in Africa Designing Strategies for National Pharmaceutical 
Innovation: Choices For Decision Makers and Countries (Council on Health Research for Development (COHRED); New Partnership 
for Africa’s Development (NEPAD) 2010) 11. 
360 Adebambo Adewopo, 'Public Health, Access to Medicines and the Role of Patents System in Nigeria' [2011] NIALS Journal of 
Intellectual Property [NJIP] 165. 
361 Adewopo ibid 186. 
362 Adewopo ibid 186-187; HI Dutton, The Patent System and Inventive Activity during the Industrial Revolution, 1750-1852 
(Manchester University Press 1984) 22-24. 
363 Adewopo (n 360) 186-187. 
364 Oxfam reports for example, that ‘[i]nstead of promoting true innovation, pharmaceutical companies, due in part to the 
perverse incentives created by IP rules, have instead sought extensions on pharmaceutical patents (ever-greening), to pursue only 
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3.7.1.1 Examining the Literature on Patent’s Effect on the Price of 
Medicines 
So far, empirical evidence directly linking the prices of patented essential 
medicines to inaccessibility, and the degree to which patents specifically 
threatens access to new drugs, varies. Nonetheless, many empirical and 
scholarly investigations into several developing and developed countries make 
this connection by describing the effect of patents on prices, and then linking 
the increased price to the affordability of the products in association with other 
socio-economic, political and environmental factors.  
In Nigeria, there have been no specific empirical studies associating problems 
of accessing essential medicines with patent rights. However, a 2006 study by 
the Federal Ministry of Health, in conjunction with organisations which include 
the World Health Organization (WHO) and Health Action International (HAI), 
offers empirical evidence on price differences between the originator (innovator 
brands) and cheaper generic medicines.365 The study found that innovator 
brands of medicines for all treatments cost more than the equivalent generic 
version.366 By way of example, the study revealed that, while it would cost a 
worker one point four days’ wages to pay for the cheapest hypertension generic 
drug, atenolol, it would require ten point four days’ wages to pay for the branded 
equivalent of atenolol. The study thus concludes that the innovator brand of the 
                                                                                                                                                                          
blockbuster returns on medicines and to develop ‘me-too’ medicines in lieu of true innovation.’ Malpani, Heineke and Kamal-Yanni 
(n 229) 36. India and China who were the bulk suppliers of generic drugs are now subject to global regulation of patents under 
TRIPS. Thomas Faunce, ‘The Awful truth About Evergreening’ (2004) The Age. Available at  
<http://www.theage.com.au/articles/2004/08/06/1091732084185.html> accessed 15 June 2015. 
This point is further discussed in Chapter VI. For reasons of space and the scope of the study, this debate will not be sufficiently 
covered in this chapter. 
365 For a more comprehensive description of the results of the study, see Federal Ministry of Health and others, Medicine Prices in 
Nigeria: Prices People Pay for Medicines in Nigeria (n 79). 
366 ibid 27, 35-36. In comparison, this price ratio for medicines procurement in public facilities was above the international 
reference price and five times higher than seven other developing countries in Africa. Also, generics in Nigeria were comparatively 
825% more expensive than seven other countries. ibid 6, 38. 
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drug atenolol cost seven point three times more than the lowest priced 
generic.367 Furthermore, although the study indicated the low availability of 
medicines in public facilities368 compared to private facilities, it showed that 
generics were more available and affordable in all sectors than the originator 
brands.369  
In 2011, the situation report by the Federal Ministry of Health and the World 
Health Organization also illustrates that the median ratio price370 for public 
procurement of originator drugs was four point zero one and three point twenty 
nine for the generic equivalent.371 In the public sector, the median price for 
originator drug was seven point four and three point five for the generic, while 
the private sector had a considerable difference of fourteen point six for 
originator brand and four point five for the generic.372   
 
Figure 3.4 Representations of the Availability, Affordability and Price Difference 
between the Originator and Lowest Priced Generic Medicines in Nigeria.373 
 
                                                          
367 ibid 5-6. 
368 Only about 46% of a basket of key medicines were found in facilities. ibid 11. 
369 ibid 16, 22-25.  
370 In the study, prices of medicines were compared with standard international reference prices and expressed as a ratio of the 
national price to the international price. The Median Price Ration was selected to reflect the access to medicines situation in the 
country. For example, a price ratio of two will indicate that the price is twice the international reference price. Federal Ministry of 
Health and World Health Organization, Nigeria Pharmaceutical Country Profile (n 108) 22. 
371 ibid 22-23. 
372 ibid 
373 Adapted from Federal Ministry of Health and World Health Organization, Nigeria Pharmaceutical Country Profile (n 108) 22. 
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What these statistics portray is that prices of the original medicines are higher 
than the prices of similar generic sources in Nigeria.  
Other investigations in developing and developed countries have generated 
additional insight into the effect of a patent on price and access to medicines.374 
Much of the evidence linking patent prices and access to medicines have been 
highlighted in the case of HIV/AIDS.375 For instance, the result of a comparative 
study of patented and generic price differences of HIV/AIDS medicines in 
Thailand from 2001-2004 found that the patented drugs were one point five to 
three times more expensive than the equivalent generic version in 2001.376 In 
another example, the price of an important antiretroviral HIV drug, 3TC 
(Lamivudine, Epivir), was marketed and sold by Glaxo in the US for US$3,271 
while the generic version was sold for $190 and $98 by Cipla Ltd and Hetero 
Drugs Limited respectively.377 Furthermore, Schulz, citing examples of 
differences in the wholesale prices of several HIV drugs in three countries 
(South Africa, India and Thailand) under different patent regimes, illustrates a 
considerable price variation as follows:378 
 
                                                          
374 Cecilia Oh, 'TRIPS, Patents and Access to Medicines: Proposals for Clarification and Reform' [2001] Third World Network' 
available at <http://www.twn.my/title/drugs2.htm> accessed 6 May 2015; FM Scherer, 'Post-TRIPS Options for Access to Patented 
Medicines in Developing Nations' (2002) 5 Journal of International Economic Law 930-934. 
375 Joan-Ramon Borrell, 'Pricing and Patents of HIV/AIDS Drugs in Developing Countries' (2007) 39(4) Applied Economics 505. The 
effects of pharmaceutical patents on medicines is heavily debated within the context of HIV/AIDS vaccines and treatments due to 
the scourge of the disease in developing countries and the fact that, as a relatively recent infection, many of the medicines for 
HIV/AIDS treatment and control are still under patents. World Health Organization, 'Increasing Access to HIV Treatment in Middle-
Income Countries: Key Data on Prices, Regulatory Status, Tariffs and the Intellectual Property Situation' (World Health 
Organization 2014) 26. The International Intellectual Property Institute, Patent Protection and Access to HIV/AIDS Pharmaceuticals 
in Sub-Saharan Africa (The International Intellectual Property Institute 2000) 9.  
376 Inthira Yamabhai and Richard D Smith, ‘A Review of the Health and Economic Implications of Patent Protection, with a Specific 
Focus on Thailand’ (2012) 10(24) Health Research Policy and Systems 14. For the most recent available worldwide prices of 
antiretroviral, see World Health Organisation Global Price Reporting Mechanism, at <http://www.who.int/hiv/amds/gprm/en/> 
accessed 7 May 2016 
377 Oh, 'TRIPS, Patents and Access to Medicines: Proposals for Clarification and Reform' (n 374)  
378 Schulz (n 355) 147.  
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Figure 3.5 An illustration of the Price Variation of a Drug in South Africa, India 
and Thailand.379  
Comparatively, the study shows that the prices of generic drugs in India and 
Thailand were considerably less than their patented equivalents in South Africa. 
The study indicates that the reason for considerable price variation in Thailand 
and India is the difference in patent protection.380 While the patent law in South 
Africa offers considerable patent protection, India and Thailand, until recently, 
did not offer protection to pharmaceutical products. 
This point is further illustrated by MSF in a report on the wholesale price 
difference between the patented and generic versions of the ARV fluconazole in 
2000.381 MSF observed that, while the original drug sold by Pfizer cost 
US$11.84 in Guatemala,382 $10.50 in Kenya, and $8.25 in South Africa, the 
generic version by Cipla sold for $0.64 in India and $0.28 in Thailand.383 MSF 
estimated that, if South Africa imported the generic version from Thailand, it 
would reduce the cost of one year’s treatment from $2970 to $104, thereby 
increasing access to the medicine.384 Another comparative study by Lucchini 
                                                          
379 ibid 
380 ibid 147. 
381 Carmen Perez-Casas and others, 'Access to Fluconazole in Less-Developed Countries' (2000) 356 The Lancet 2102. Fluconazole is 
an essential drug for the treatment of meningitis, one of the main complications of AIDS, without which life expectancy is greatly 
reduced. Caroline Thomas, ‘Trade Policy and Access to Drugs’ (2002) 23(2) Third World Quarterly 253. 
382 The drug cost $27.60 for the non-negotiated price. ibid 
383 Perez-Casas and others (n 381) 2102.  
384 ibid  
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and others on the determinants of sources price of antiretroviral (ARV) drugs 
between 1998 and 2002 in Brazil and thirteen developing countries, including 
Nigeria,385 observes that patent policy can be linked to the price increases in 
drugs for HIV/AIDS treatment.386 In one of the cited examples, the study found a 
considerable price difference between the branded drugs Zidovudine 300mg, 
and lamivudine 150 mg, and the cheapest generic equivalent:387 
  
Figure 3.6 An illustration of the Price Difference between Branded Drugs and 
Generic Equivalents388 
In another example, a review of international and national empirical evidence of 
the impact of patents in Thailand in 2006, indicated that 200mg (100 capsules) 
of originator efavirenz HIV treatment cost 3,192 baht per bottle, while the 
generic version sold for 1,292 baht.389 The point being made here should not be 
lost on the reader. What these data reveal is that the prices of patented or 
branded medicinal treatments are prohibitive compared to the prices of similar 
generics sources or alternative medicines.  
                                                                                                                                                                          
It was claimed that Pfizer refused to lower the price of treatment or grant voluntary licence for the generic production of the drug 
in the less-developed countries where the treatment was patent protected.  
385 The data in the study was collected between 1996 and 2002, and the African countries considered include: Botswana, Congo, 
Gabon, Kenya, Nigeria and Senegal to ensure a good mix of varying purchasing powers and HIV rates. See Stephane Lucchini and 
others, ‘Decrease in Prices of Antiretroviral Drugs for Developing Countries: From Political "Philanthropy" to Regulated Markets?’ 
in JP Moatti, and others (eds), Economics of AIDS and Access to HIV/AIDS Care in Developing Countries: Issues and Challenges 
(ANRS 2003).  
386 ibid 169–211. (Although the study observed that pharmaceutical companies adopt different pricing strategies in developing 
countries.) ibid 201. 
387 ibid 198. 
388 Adapted from ibid. 
389 Yamabhai and Smith (n 376) 2. 
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Several other studies have focused on the difference between the price of 
patented medicines and generic versions after the expiration of the patent.390 
Many of these studies indicate that drug prices are lower amongst multiple 
competitors.391 For example, Suh and others studied the effect of generic drugs 
entry on the price of thirty-five chemical entities after the expiration of patents 
between the periods of 1984 and 1987 in the US.392 The study demonstrates 
the benefits of generics by indicating that, while the price of the original 
patented drug increased after patent expiration, the price had declined by the 
fourth year after patent expiration due to the availability of competing generic 
substitutes. The study, therefore, concludes that ‘[c]onsumers as a whole can 
gain from the entry of multiple-source drugs because the average price of the 
market continually declines after patent expiration.’393 Building on this 
perspective, in 2005, Boersma and others studied the price difference of three 
medicines: Enalapril, Fluoxetine and Ranitidine prior, to and after patents 
expiration from 1996 to 2001 in the Netherlands.394 Results of the study indicate 
a decrease in the cost of drugs after patent expiration.395   
 In other instances, the introduction of generics through compulsory licences 
successfully reduced the price of essential drugs. The case of Thailand offers a 
                                                          
390 Dong-Churl Suh and others, ‘Effect of Multiple-Source Entry on Price Competition after Patent Expiration in the Pharmaceutical 
Industry’ (2000) 35(2) Health Services Research (HSR) 543; Laura Magazzini, Fabio Pammolli and Massimo Riccaboni, 'Dynamic 
Competition In Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure' (2004) 5(2) The European Journal of 
Health Economics 175-182. (The study investigated how price is affected by the availability of generic competition after patent 
expiration in the pharmaceutical industry.)  
391 It has been indicated however that the presence of multiple local generic competitors does not necessary translate into lower 
prices of local drugs. Jayashree Watal, 'Workshop on Differential Pricing and Financing of Essential Drugs' [2001] available at  
https://www.wto.org/english/tratop_e/trips_e/wto_background_e.pdf> accessed 15 June 2015. 
392 Suh and others (n 390) 529. 
393 ibid 529, 543. 
394 Cornelis Boersma and others, 'Drug Costs Developments after Patent Expiry of Enalapril, Fluoxetine and Ranitidine' (2005)’ 4(3) 
Applied Health Economics and Health Policy 191, 191-193. 
395 ibid 195. Enalapril 61%, Fluoxetine 51%, and Ranitidine 65%. (The study noted that the reduced rate was due to availability of 
generic substitutes and competition.) Conversely, Grabowski and Vernon illustrate that the price of generics might actually 
increase when introduced after the expiration of the patented version Through a regression analysis, the study observed an 
increase in prices of original products one or two years after the introduction of generics. Henry G Grabowski and John M Vernon, 
'Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act' (1992) 35 The Journal of Law and 
Economics 339-341. 
(According to Borell, competition has the beneficial effect of reducing price discrimination in no-patent regime.) Borrell (n 375) 
506. 
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good example.396 A study by Yamabhai and others assessed the effect of 
compulsory licensing in facilitating the availability of cheaper generic medicines 
in Thailand.397 The licences granted for seven drugs showed a positive result in 
access to drugs and public benefits. The study estimated that an extra 84,158 
patients had access to the seven cheaper generic drugs over a period of five 
years after the compulsory licences were granted.398  
In contrast to the submission that the pricing of patented pharmaceuticals is a 
contributory factor to the inaccessibility of new and efficacious drugs,399 a study 
by Amir Attaran argues that other socio-economic factors, especially poverty 
and infrastructural incapacity, not patent policies, are responsible for the 
problems of access to medicines.400 Through surveys and statistical analysis, 
Attaran studied the relationship between patents and access to drugs by 
examining the status of essential medicines, as defined by the WHO Model List 
of Essential Medicines, and the frequency of patenting in sixty-five low and 
middle-income countries.401 The study showed that only seventeen out of the 
total 319 essential medicines on the WHO Essential Medicines list were 
patented. He concluded that patenting of essential medicines is rare in 
developing countries; hence patents are not a significant threat to the 
accessibility of relevant essential medicines in the developing world.402 His 
                                                          
396 For a review of the literature and price difference between generics and patented health products, see Yamabhai and Smith (n 
376) 1-18. 
397 Inthira Yamabhai and others, 'Government Use Licenses in Thailand: An Assessment of the Health and Economic Impacts' 
(2011) 7(28) Globalization and Health 1-12. 
398 Yamabhai and others (n 376) 1, 6-7. 
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400 Amir Attaran, ‘How Do Patents and Economic Policies Affect Access to Essential Medicines in Developing Countries?’ (2004) 
23(3) Health Affairs 156, 163. (The author further states that the market in developing countries does not offer significant 
incentives for investment.) 
(This thesis is mindful of the fact that the study published in 2004 is rather old. However, it is cited in this thesis to illustrate an 
objective view of the debate on the effect of patent on access to medicines and since the study is empirical, it offers a strong basis 
for one side of the debate.)  
401 ibid 155. 
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study further suggests that patents are not a hindrance because they do not 
exist ninety-eight point six percent of the time in many developing countries.403  
While the study stated that ‘patents are infrequent determinants of access to 
essential medicines,’404 it is noted that it did not report a zero frequency for 
patenting. With pharmaceuticals and essential medicines being fundamental to 
the life of an individual, the one point four percent patent incidence is significant 
enough and worth taking into account where patents threaten access to the 
means of treatment for survival.405 With little or no insurance provision and 
payment for medicines out-of-pocket in many developing countries, even a 
minor increase in the price of medicines can be prohibitive for many; thus the 
adverse effects of patenting, no matter how little, could constitute a life and 
death issue. Therefore, the role patents play in contributing to the problem of 
accessibility, however slight, is worth a policy response in making medicines 
more accessible to the poor in developing countries.  
In one way, the study by Attaran, which linked problems of access to 
inadequate economic, social and regulatory factors, supports the position taken 
in this thesis that, due to additional existing socio-economic, cultural practices 
and traditional factors, any incremental challenge to accessing medicines will 
escalate and entrench the problems for people, especially women, in Nigeria 
and other developing countries. Thus it is not to say that other factors cannot 
hinder access to medicines. Yet, the problems associated with patent monopoly 
and pricing control on accessibility to life-saving drugs should not be 
                                                          
403 ibid 159. It is worth noting that the study is based on medicines on the WHO Essential Model List. Since the cost effectiveness 
and affordability of overall treatment is a criterion for selecting essential medicines on the list, this may account for the absence of 
some expensive drugs under patents; hence the results of analysis may be limited. See selection criteria at Who ‘Essential 
medicines’ at 
 <http://www.who.int/medicines/services/essmedicines_def/en/> accessed 15 September 2015. (Although as Attaran stated, 
there is no evidence to suggest that expensive patented medicines were deliberately excluded.)  
404 Attaran (n 400) 164.  
405 According to the study, patents exist for one point four percent of essential medicines - that is ‘300 instances out of 20,735 
combinations of essential medicine and countries.’ ibid 158. 
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discounted. Currently, some important HIV medicines that can maintain and 
reduce viral loads in HIV patients are under patent protection in some 
countries.406 Important second-line or third-line ARV treatment regimen 
recommended by the WHO such as etravirine,407 Lopinavir408 rilpivirine409 and 
raltegravir410 are presently under patent protection in the national and regional 
patent laws of developed and developing countries.411 MSF made the 
observation that, because of patent barriers, there are no generic equivalents to 
the ARV treatments and the company discounted prices are not affordable to 
many in developing countries.412  
As mentioned earlier,413 poverty is prevalent in many parts of the developing 
world. The World Bank, for example, reports that extreme poverty in sub-
Saharan Africa was around forty seven percent and that an estimated three-
fifths of the world’s extreme poor are concentrated in just five countries which 
                                                          
406 See more on patent status for ARV treatments at Esteban Burrone and Karin Timmermans, 'Patents and Licences on 
Antiretrovirals: A Snapshot' (World Health Organization 2014).  
(It is worth noting that the study does not indicate the patent status of the ARV in Nigeria; however, the existence of patents on 
essential ARV in manufacturing countries such as Brazil, China, India, South Africa, Thailand may sufficiently confer exclusivity and 
affect Nigeria and other developing countries which rely on the production and export of medicines from these countries.)  
407 The compound patent on the third-line ARV treatment, etravirine, is set to expire in 2019. Patent is available for the treatment 
in Argentina, ARIPO member countries, Brazil, China, EAPO member countries, India, Malaysia, Mexico, OAPI member countries, 
Philippines, South Africa, Sri Lanka, Turkey, Ukraine and Vietnam. As of 2014, patents were pending in Indonesia and Pakistan. 
Also, patents on novel forms of etravirine expected to expire in 2026 are available in Albania, Mexico and Turkey and are pending 
in Brazil, China and India. Burrone and Timmermans (n 406) 14. 
408 Lopinavir, a second line treatment, whose patent is set to expire in 2017, is protected in Argentina, China, Colombia, Mexico, 
Philippines, South Africa and Thailand. ibid 16.  
409 The compound patent for rilpivirine, another second line treatment has the due date to expire in 2022 in many countries. The 
patent is available in Albania, Argentina, ARIPO member countries, China, EAPO member countries, India, Mexico, OAPI member 
countries, Panama, Philippines, South Africa, Sri Lanka, Turkey and Ukraine. As of 2014, patent application was pending in Brazil, 
Egypt, Jordan, Malaysia, Pakistan, Venezuela and Vietnam. A patent on the salt form, expiring in 2025 is also available in ARIPO 
member countries, EAPO member countries, Philippines, South Africa, Turkey and Ukraine. ibid 20. 
410 The compound patent on raltegravir, a third-line treatment, is set to expire in or around 2022 in developing countries. A review 
of patent status information by Esteban Burrone and Karin Timmermans indicates that patent has been granted in Albania, China, 
Colombia, Georgia, India, Mexico, Montenegro, Philippines, South Africa, Turkey, Ukraine, Uzbekistan and Vietnam, and is pending 
in Brazil as at 2014. The patent on the potassium salt which is expected to expire in 2025, is available in some developing countries 
including South Africa. ibid 19. 
411 ibid; Médecins Sans Frontières (MSF), Untangling the Web of Antiretroviral Price Reductions (14th edn, Médecins Sans 
Frontières’ 2011). 
412 ibid 
413 See subsections 3.3 and 3.4.3. 
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include Nigeria.414 The high cost of drugs in these countries means that many 
do not have access to medicines. Consequently, the problem of high prices for 
newer and more effective essential drugs under patent protection may be 
particularly disturbing for people in Nigeria and other developing countries 
because of the economic and financial burden it imposes on individuals who 
cannot afford to purchase these medicines. With women forming the bulk of 
poor people in most developing countries, this challenge poses a bigger threat 
to their general health well-being.415 In the UK, for example, the National Health 
Service (NHS) provides publicly funded healthcare services and hospital 
treatments for all UK residents.416 Unfortunately, such effective public 
healthcare services, treatments or health insurance do not exist or are 
ineffective in Nigeria and many developing countries. With access to health care 
treatments, as stated previously,417 dependent on out-of-pocket expenses, the 
high cost of patented medicines can be dire and debilitating to public health. 
 
 3.7.2 Revisiting the Debate on the TRIPS Agreement: Patent Rights, Price 
and Access to Medicines 
Although the impact of patents on access to affordable medicines predated the 
TRIPS Agreement, the introduction and requirements of the international IP 
system have generated controversy around the implications for price and 
access to essential medicines. As with the discussion above, the Agreement is 
considered a determining factor in the challenge of access to medicines 
                                                          
414 The countries are: Bangladesh, China, the Democratic Republic of Congo, India, and Nigeria. World Bank Group and the 
International Monetary Fund, Global Monitoring Report 2014/2015: Ending Poverty and Sharing Prosperity (International Bank for 
Reconstruction and Development and The World Bank 2015) 3. 
415 Lesley Doyal, ‘Putting Gender into Health and Globalisation Debates: New Perspectives and Old Challenges’ (2002) 23(2) Third 
World Quarterly 233–250. 
416 With the exceptions of some services and charges including prescriptions, optical and dental services. NHS, 'About the National 
Health Service (NHS) in England' (Nhs.uk)  
<http://www.nhs.uk/NHSEngland/thenhs/about/Pages/overview.aspx> accessed 12 May 2016.  
417 In subsections 3.2 and 3.3. 
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because it introduced the same minimum standard of patent rules for all WTO 
members to adopt and implement.418 Thus the Agreement has added impetus 
to the concern that the patent protection of processes and products can restrict 
generic competition and raise the transaction cost of accessing medicines 
which, in turn, limits the ability of users to purchase the product at a competitive 
price.419 Consequently, patent rights in the TRIPS Agreement, to the extent that 
it has broadened and lengthened the scope of the protection thereby increasing 
the market power conferred by patents, is seen to contribute to the problem of 
accessibility.420  
Before TRIPS came into being, some developing countries were able to avoid 
paying the high prices charged by pharmaceutical companies for purchasing 
branded medicines by acquiring the generic equivalents at a lower price from 
other countries whose patent laws did not cover pharmaceutical products, such 
as India.421 These generic medicines had the advantage of being less 
expensive when compared to patented equivalents because they did not have 
all the risks and costs associated with R&D for manufacturing new medicines.422 
With the introduction of the TRIPS Agreement, however, generic reproduction 
or imitation of patented drugs amounts to infringement in all WTO member 
                                                          
418 Pogge, Rimmer and Rubenstein, ‘Access to Essential Medicines, Public Health and International Law’ (n 255) 5-6; William W 
Fisher and Talha Syed, ‘A Prize system as a Partial Solution’ in Thomas Pogge, Matthew Rimmer and Kim Rubenstein (eds), 
Incentives for Global Public Health: Patent Law and Access to Essential Medicines (Cambridge University Press 2010) 183; ‘t Hoen, 
The Global Politics of Pharmaceutical Monopoly Power: Drug Patents, Access, Innovation and the Application of the WTO Doha 
Declaration on TRIPS and Public Health (n 196) 5. 
419 Pogge, ‘The Health Impact Fund: Better Pharmaceutical Innovations at Much Lower Prices’ (n 299) 137; FM Scherer and 
Jayashree Watal, ‘Post-TRIPS Options for Access to Patented Medicines in Developing Nations’ (2002) Journal of International 
Economic Law 914; Obijiofor Aginam and John Harrington, ‘Introduction’ in Obijiofor Aginam, John Harrington and Peter K Yu ( 
(eds), The Global Governance of HIV/AIDS: Intellectual Property and Access to Essential Medicines (Edward Elgar Publishing 2013) 
2. 
420 Sampath (n 157) 257. 
421 t’Hoen, The Global Politics of Pharmaceutical Monopoly Power Drugs Access, Innovation and the Application of the WTO Doha 
Declaration on TRIPS AND Public Health (n 196) 5-6. 
422 Fink (n 357) 2.  
Generic companies essentially focus on the reproduction of existing compounds when patent protection has expired rather than 
developing new medicines. Countries such as India which was the biggest supplier of cheap generic medicines to developing 
countries (with sixty seven of its exports going to the developing world) had to comply with the TRIPS.  
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countries, unless produced under the safeguard and flexibilities in TRIPS or 
produced under licence from the patent holder.423  
These structural conditions and mandate imposed by global patent law have 
reconfigured the landscape of countries that were prominent generic drug 
producers. For example, generic producing industries in Brazil and India had to 
conform to the mandatory twenty year term for product patents which was 
previously not part of their patent law.424 With many developing countries 
including Nigeria relying on cheaper generics from these countries for several 
reasons, including the inadequate or insufficient manufacturing capacity and 
expertise, the concern has been raised that patents for pharmaceuticals will 
affect the supply, availability and accessibility of the less expensive generics.425  
In spite of the access problems associated with the monopolistic and exclusive 
control of drugs, the TRIPS Agreement contains some flexible safeguards which 
members can incorporate into national law and take advantage of, in the 
interest of public health.426 These flexible exceptions are the focus of Chapter VI 
of this thesis.  
 3.8 Conclusion: Making a Case for Women’s Access to Medicines in 
TRIPS 
Trade regulations are generally perceived as gender-neutral.427 Nevertheless, 
Professors Elson, Cagatay and other foremost economists observe that 
seemingly neutral trading relations, market systems, economic policies and 
                                                          
423 Sampath (n 157) 260. (This is applicable where the national laws of a country so provides in accordance with the minimum 
standards of the TRIPS Agreement.) 
424 Before the current IP Law (No. 9.279 of May 14, 1996 (Industrial Property Law) which took effect in 1997), pharmaceutical 
patents could not be patented in Brazil. Brazil subsequently signed and incorporated the TRIPS Agreement into the national legal 
system, thus allowing patent protection for pharmaceuticals. World Bank, Innovation Policy: A Guide for Developing Countries 
(World Bank 2010) 113.  
425 Biswajit Dhar and KM Gopakumar, ‘The Case of the Generic Industry in India’ in Ricardo Meléndez-Ortiz and Pedro Roffe (eds), 
Intellectual Property and Sustainable Development Agendas in a Changing World (Elgar Edward Elgar 2009) 130. 
426 These flexibilities provide members with optional measures to foster competition, control prices and ensure equitable access to 
medicines. The flexibilities are discussed further in Chapter V of this thesis.  
427 Sarah Gammage and others, Trade Impact Review: Framework for Gender Assessments of Trade and Investment Agreements 
(The Coalition for Women’s Economic Development and Global Equality (Women’s Edge) 2002) iv. 
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programmes can bolster existing socio-economic inequalities and social 
biases.428 In the same vein, although the WTO trade rules, agreements and 
annexes make provisions via national laws that apply to men and women 
equally, the concern is that these trade arrangements may occasion adverse 
consequences for women.429 Within the ambit of TRIPS, gender issues are 
identified and traced to women’s access to healthcare and products that will 
improve their health.430 In assessing the impact of trade liberalisation on 
women’s reproductive health, Grown argues that ‘it can potentially compromise 
women’s access to affordable and quality reproductive care.’431 Specifically, she 
noted that the TRIPS Agreement is likely to lead to an increase in prices and 
limit women’s access to affordable reproductive health products.432 
In addition to the already mentioned effect of a patent right on access to 
medicines which would affect everyone, the effect may be greater on women as 
a result of other underlying factors, such as women’s vulnerable situations, 
roles in society, as well as their economic and social circumstances.433 In the 
case of Nigeria, because poverty increases or is especially prevalent among 
women, additional policies and laws that have adverse health implications mean 
that women will have little or no access to quality healthcare. Given that the 
higher cost implications of beneficial patented medicines affects those with less 
income and financial means, it is also likely that the high price of medicines will 
                                                          
428 ibid; Diane Elson, and Nilüfer Çağatay, ‘The Social Content of Macroeconomic Policies’ (2000) 28(7) World Development 1354-
1363; Nilüfer Çağatay and Korkuk Ertürk ‘Gender and Globalization: A Macroeconomic Perspective’ Policy Integration Department 
World Commission on the Social Dimension of Globalization International Labour Office Working Paper No. 19, 15-44. 
429 Sampath (n 157) 255-256. (Arguing that the effect of the trade rules in the TRIPS agreement could have greater adverse effect 
on women than men because of their vulnerable positions, especially, in many developing and least developed countries.)  
430 Doyal (n 415) 233–250. 
431 Caren Grown, 'Trade Liberalization and Reproductive Health: A Framework for Understanding THE Linkages' in Caren Grown, 
Elissa Braunstein and Anju Malhotra (eds), Trading Women's Health and Rights: Trade Liberalization and Reproductive Health in 
Developing Economies (Zed Books 2006) 31, 33. 
432 ibid 33. 
433 Sampath (n 157) 256.  
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be more severe on women.434 Therefore, to the extent that patent protection 
can result in changes that lead to price increases of drugs available to the poor, 
it can significantly reduce women’s access to medicines and pose a bigger 
threat to their general health, well-being and human development. This situation 
may be particularly daunting for pregnant women, resulting in incidental 
problems to babies and young children under women’s maternal care. The 
adverse cost effect of medicines on women in many poor countries is also likely 
to be substantially heavier on women that commonly take care of children, the 
sick and, at the same time, undertake primary responsibility for the provision of 
food and other basic household needs.435 This is more so in cases where the 
male head of the household is also sick or incapacitated.436 Consequently, while 
every person is subject to the same limitations and disproportionate access to 
health care services in developing countries, nonetheless, having unequal 
access to drugs and medicines based on several other factors may be an 
additional burden for most women in developing countries. 437  
For these reasons, this thesis makes a case for women’s access to medicines 
in subsequent chapters. This is not to say that men are not taken into account in 
the analysis. In the end, this study is structured to influence policy-making in a 
way that benefits both men and women. However, from a women’s perspective, 
this thesis urges the Nigerian policy makers to ensure that patent rights do not 
interfere with access to medicines and when it does, to effectively take out 
                                                          
434 Doyal (n 415) 242. (Arguing that, while men and women are affected by the effect of the TRIPS Agreement, ‘there are good 
reasons for assuming that the impact on women might be especially severe. In the first place, the high cost of potentially 
beneficial drugs will hit those with the fewest resources and the lowest social status hardest. In many situations this is likely to be 
women.’)  
435 Majaraj and Roberts (n 155) 218. 
436 ibid 218. 
437 Note that the use of the term ‘more’ is cautious in this instance. There is no empirical study to indicate that women suffer more 
in accessing medicines under patents and this thesis has not conducted any empirical study sufficient to draw this conclusion. 
However, the analogy in this study argues that compared to men, women may suffer the effect of inaccessibility more due to 
excessive increase in prices of medicines under patents. Other scholars make a similar point with regards to trade agreements and 
treaties. See Cottingham and Berer (n 20) 69-84; See also Gammage and others (n 427); Sampath (n 157) 256. 
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necessary measures to ameliorate the situation. In this manner, it argues for 
more proactive measures, including the use of the TRIPS-compliant flexibilities, 
to facilitate accessibility to life-saving drugs.  
Taking a human rights stance, the next chapter makes a moral and legal claim 
for women’s access to life-saving drugs as a human right. It also argues that 
there is no human rights basis for a patent right’s interference with access to 
medicines. 
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CHAPTER IV: ACCESS TO MEDICINES TO GUARANTEE 
WOMEN’S RIGHTS TO HEALTH IN NIGERIA: THE 
PHARMACEUTICAL PATENTS CONNECTION 
The state’s obligation with regard to the right to health […] encompasses not only 
the positive duty to ensure that its citizens have access to health care services and 
medication but must also encompass the negative duty not to do anything that 
would in any way affect access to such health care services and essential 
medicines. Any legislation that would render the cost of essential drugs 
unaffordable to citizens would thus be in violation of the state’s obligations […].1 
 
4.1 Introduction 
The preceding chapter discussed the proposition that the patent protection of 
pharmaceuticals and the exercise of this patent right raises concerns for health, 
particularly, access to medicines. In this chapter, access to medicines is 
identified as a fundamental human right to health, given that the right to health 
cannot be achieved without access to essential medicines for effective 
treatment of ailments and diseases. Health as a human right is enumerated in 
several human rights instruments. Article 25 of the United Nations Declaration 
of Human Rights identifies that: ‘[e]veryone has the right to a standard of living 
adequate for the health and wellbeing of himself and of his family, including 
food, clothing, housing and medical care and necessary social services.’ The 
1979 Convention on the Elimination of All Forms of Discrimination against 
Women (CEDAW) in Article 12(1) makes provisions for the consideration and 
protection of women’s right to health. In addition, health, and the importance of 
                                                          
1 Patricia Asero Ochieng, Maurine Atieno, Joseph Munyi, and AIDS Law Project v Attorney General Petition No. 409 of 2009 (High 
Court of Kenya) paragraph 66. 
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accessing essential medicines for adequate healthcare, are identified as 
significant to an adequate standard of living and connected to other human 
rights such as the rights to life, human dignity, education, development and the 
participation in civil and political life of society.  
It is against this background that this chapter situates the ongoing debate about 
pharmaceutical patents, access to medicines and public health within the 
framework of human rights. The chapter argues that the exercise and 
implementation of patent rights can raise human rights issues in the context of 
human health and access to essential and affordable life-saving 
pharmaceuticals. More specifically, human rights principles provide a strong 
moral support and useful framework within which this thesis argues for a 
consideration of women’s access to medicines in Nigeria, in view of the adverse 
impact of international and national patent law on public health. The chapter 
consequently argues for the consideration, interpretation, and implementation of 
patent rights to respond to the right to health and access to medicines.  
This chapter comprises three sections. The first examines the legal commitment 
to the rights of women to health in international legal instruments. It starts by 
examining the right to health and its medicinal component; implications for 
specific individuals or groups (women specifically); the obligation on states in 
respect of the right; and its connection to the accessibility of medicines. It also 
provides a brief introduction to the responsibilities of pharmaceutical companies 
to the right to health.  
The second part examines the intersection between patent rights and human 
rights, particularly the right to health and access to medicines. The last part 
makes a case for women’s access to medicines as a basic human right to 
health, specifically in Nigeria. As Nigeria has committed itself to protect, 
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safeguard and fulfil this right, the chapter argues that the state has a legal 
obligation to safeguard the health and wellbeing of everyone, including women, 
in the context of patent protection and its effect on access to life-saving 
treatments as discussed in the foregoing chapter.  
 
PART I: THE RELATIONSHIP BETWEEN ACCESS TO 
MEDICINES AND HUMAN RIGHTS: THE BASIC FRAMEWORK 
 
3.2.1 The Nature of Human Rights  
Before delving into the relationship between, and the normative content of the 
right to health and access to medicines, it is pertinent to ask: what is a human 
right?  
James Nickel identified human rights as: 
[B]asic moral guarantees that people in all countries and cultures allegedly have 
simply because they are people. Calling these guarantees ‘rights’ suggests that 
they attach to particular individuals who can invoke them, that they are of high 
priority, and that compliance with them is mandatory rather than discretionary. 
Human rights are frequently held to be universal in the sense that all people have 
and should enjoy them, and independent in the sense that they exist and are 
available as standards of justification and criticism whether or not they are 
recognized and implemented by the legal system or officials of a country.2 
This definition sums up the basic tenets as: natural and universal entitlements 
accruable to all humans; and moral or ethical rights and legal claims. The 
dualistic nature of human rights as both moral and legal claim means that they 
                                                          
2 James W Nickel, Making Sense of Human Rights (Blackwell Pub 2007) 561-562. 
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can exist outside of, or prior to, a legal recognition and at the same time exist 
within a defined positive law.3  
Human rights are frequently held to be universal, inalienable, equal and non-
discriminatory, indivisible and interdependent.4 As a universal right, a human 
right is a prerogative that is held by every human being solely by reason of their 
very existence. The United Nations5 in 1987 for example, defined human rights 
as ‘those rights which are inherent in our nature and without which we cannot 
function as human beings.’6 The concept of human rights is embedded in the 
notion that ‘human beings are born equal in dignity and respect. [Therefore], 
[t]hese rights are moral claims that are inalienable and inherent in all human 
individuals by virtue of humanity alone.’7  
The constitutive character of human rights is unassignable; it cannot be bought, 
sold or inherited; and it is indivisible, whether political, civil, cultural, social or 
economic.8 All human rights are interdependent and interrelated as such; each 
human right safeguards, guarantees and contributes to the fulfilment and 
actualisation of other human rights.9 Being a justifiable entitlement, a human 
right is not a gift or mere privilege.10 Human rights so construed find legal and 
moral expression in several international, regional and national human rights 
                                                          
3 Roger Brownsword and Morag Goodwin, Law and the Technologies of the Twenty-First Century: Text and Materials (Cambridge 
University Press 2012) 230. For example, Amartya Sen argues that human rights are principally ethical demands, that can and 
‘often do, inspire legislation [but] this is [not] a constitutive characteristic of human rights.’ See Michael DA Freeman, Lloyd's 
Introduction to Jurisprudence (9th edn, Sweet & Maxwell 2014) 1289. 
4 Martin H Birley, Health Impact Assessment: Principles and Practice (Routledge 2013)10; United Nations Office of the High 
Commissioner of Human Rights, 'What Are Human Rights' (2015)  
Available at <http://www.ohchr.org/EN/Issues/Pages/WhatareHumanRights.aspx> accessed 7 December 2015. 
5 On 10th December, 1948, the General Assembly of the UN adopted the Universal Declaration of Human Rights (UDHR). The UDHR 
is the basic statement of the inalienable and inviolable rights of the human family and it contains general principles and standards 
of human rights. Article 1 of the UDHR lays down the philosophy upon which the declaration is based and asserts that ‘[a]ll human 
beings are born free and equal in dignity and right […].’  
6 United Nations, Human Rights: Questions and Answers (United Nations 1987) 4. 
7 Leah Sarah Levin, Human Rights: Questions and Answers (UNESCO, 2012) 19.  
8 Ida Elisabeth Koch, Human Rights as Indivisible Rights: The Protection of Socio-Economic Demands Under the European 
Convention on Human Rights (Martinus Nijhoff Publishers 2009) 2; United Nations Population Fund (UNFPA), 'Human Rights 
Principles' (Unfpa.org) <http://www.unfpa.org/resources/human-rights-principles> accessed 6 May 2016. 
9 Koch ibid. 
10 Freeman (n 3) 1287. 
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laws, conventions and legal instruments that impose a degree of enforceable 
commitment on states and duty bearers to guarantee, safeguard, enforce and 
protect.  
Generally, scholars offer some philosophical theorisation of the nature of human 
rights as: a) ‘wills,’ or ‘choices’; and b) ‘entitlements,’ ‘interests,’ ‘benefits,’ 
‘claims to goods and services.’11 The first approach, ‘wills’ or ‘choices’ 
emphasises an individual’s personal liberty, freedom of choice and actions.12 
The ‘wills’ right advocates hold the view that the purpose of law is to give 
individuals the broadest possible means to assert and express themselves.13 
Essentially, this rights perspective is defined by people’s freedom to be and do 
something. Thus Hart the philosopher, speaks of rights as equal liberty of ‘all 
men to be free’14 and advances the concept of rights that are based on will, 
freedom and the capacity for autonomy.15  
The second approach views human rights as entitlements to have and to enjoy 
various freedoms, opportunities and benefits.16 Proponents of this right 
perspective argue that a right aims to protect and promote people’s interests to 
secure certain benefits.17 This ‘interests’ theory places an emphasis on the 
welfare and wellbeing of the right holder.18 Human Rights advocates further 
argue that rights regulate the way people relate to each other or impose an 
obligation on states to fulfil human being’s certain essential interest and 
needs.19 Professor Finnis argues, for example, that human rights are 
                                                          
11 ibid 335. 
12 ibid  
13 ibid  
14 HLA Hart, ‘Are There Any Natural Rights?’ (1955) 64 The Philosophical Review 175. 
15 Hart, ‘Are There Any Natural Rights?’ ibid 175; Freeman (n 3) 1305.  
16 Freeman (n 3) 335. 
17 Freeman (n 3) 336. 
18 Leif Wenar, ‘The Nature of Rights’ (2013) 33(3) Philosophy & Public Affairs 237, 240-241. 
19 Freeman (n 3) 1304; Andrew Fagan, 'Human Rights' The Internet Encyclopaedia of Philosophy (IEP) Available at 
 < http://www.iep.utm.edu/hum-rts/#SH4b> accessed 14 November 2015. 
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instrumental in securing the basic values and interest of human beings to live 
good lives.20  Within the context of social rights, Eide puts it thus, ‘the enjoyment 
of […] right requires, at a minimum, that everyone shall enjoy the necessary 
subsistence rights — adequate food, and nutrition rights, clothing, housing and 
the necessary conditions of care.’21 There are, however, difficulties with this 
‘interests’ view. Because human needs are boundless, the ‘interests’ theory 
raises questions as to whether there is a limit to the obligation on a state to fulfil 
this right.22 Nevertheless, the ‘interests’ approach provides a philosophical basis 
for the recognition and protection of economic, social and cultural human 
rights.23 As well as recognising a human’s basic ‘liberties,’ or ‘freedoms,’ these 
socio-economic and cultural rights such as the right to education, housing, an 
adequate standard of living, health and many others, are essential to the overall 
enjoyment of human rights.  
In sum, a human right is significant not only because it seeks to guarantee the 
moral and legal freedoms and entitlements of every individual, human rights 
also protect and promote the realisation of certain rights— usually in relation to 
the responsibilities of states to uphold and implement.  
 
4.2.2 Health and the Right to Health 
Good health is one of the many aspects of human wellbeing that is necessary 
for the enjoyment of human rights. Health,—a person’s state of physical and 
mental condition and wellbeing—also plays a pivotal role in empowering people 
                                                          
20 John Finnis, Natural Law and Natural Rights (Clarendon Press 1980) 81-92. (These basic human goods include life and its 
capacity for development; the acquisition of knowledge, as an end in itself; play and the capacity for recreation; aesthetic 
expression; sociability and friendship; practical reasonableness; the capacity for intelligent and reasonable thought process; 
religion or the capacity for spiritual experience and marriage. Finnis identified these interests or ‘basic forms of human good’ as 
essential factors for human well-being.)  
21 Asbjorn Eide, ‘Economic, Social and Cultural Rights as Human Rights’ in Richard Pierre Claude and Burns H Weston (eds), Human 
Rights in the World Community: Issues and Action (University of Pennsylvania Press 2006) 172. 
22 For a detailed discussion of the ‘interests’ theory of rights, see Paulos Z Eleutheriadēs, Legal Rights (Oxford University Press 
2008) 10-15. 
23 Nonetheless, for the purpose of this thesis, no distinction is drawn between the ‘interests’ and ‘wills’ theories of rights. 
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to pursue other activities that will enhance their welfare.24 For example, a 
person who is healthy is in a better position to practically engage in activities he 
or she find useful, improve their living standards, increase their life chances and 
also enjoy other human rights.25 Thus, as an essential state of wellbeing, health 
is also a means by which people can undertake social, economic and cultural 
activities as well partake in civil and political activities, and, as a basic human 
right, health is an essential, fundamental and indispensable state of wellbeing.26 
In this sense, health is both a human right in itself and an essential means for 
the realisation of other human rights.27 Consequently, the right to health is one 
of the cornerstones for the enhancement and improvement of overall social, 
cultural, economic and human development. The right to health, as with all 
human rights, contains ‘freedoms’ and ‘entitlements.’28 Freedom includes the 
right to make decisions and control one’s own health and body such as sexual 
and reproductive rights, while the entitlement aspect of the right to health 
pertains to the equal rights and opportunity for everyone to access an adequate 
healthcare system including health services, facilities and drugs.29 
These guarantees and articulation of human rights to health are acknowledged 
in several human rights laws and instruments.30 Significantly, Nigeria is a 
signatory to several of these international instruments that establish the right to 
                                                          
24 The WHO identified health as a state of complete physical, mental and social well-being and not merely the absence of disease 
or infirmity. However, the scope of this thesis focuses on health as a physical and mental condition. 
25 See the introduction of this chapter. 
26 Freeman (n 3) 1294. 
27 See Article 1, UN Committee on Economic, Social and Cultural Rights (CESCR), General Comment No 14: The Right to the Highest 
Attainable Standard of Health (Article 12 of the Covenant) (Adopted at the Twenty-second Session of the Committee on Economic, 
Social and Cultural Rights, on 11 August 2000 E/C.12/2000/4)  
28 Office of the United Nations High Commissioner for Human Rights and World Health Organization, The Right to Health: Fact 
Sheet No. 31 (Office of the United Nations High Commissioner for Human Rights and World Health Organization) 3.  
Freedoms include: the right to make decisions and control one’s own health and body which includes sexual and reproductive 
rights. 
29 ibid 
30 The convergence of these human rights laws indicates that every human being has a fundamental claim to the protection and 
enjoyment of their rights to an adequate state of health 
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health,31 thus the obligation to fulfil the human right to health may be binding on 
the government under certain conditions.32 
 
4.2.3 International Legal Commitments to the Right to Health 
The earliest articulation of health as a basic right is in the 1946 Constitution of 
the World Health organization (WHO) which states that ‘the enjoyment of the 
highest attainable standard of health is one of the fundamental rights of every 
human being [...].’33 This highest standard of physical and mental health as a 
right of individuals and a duty of the state is also accorded recognition in a 
number of human rights declarations and treaties.34 Implicit in the objective of 
the UN to ‘promote social progress’ and ‘better standards of life’ is the 
recognition that health is a right worth protecting, and a responsibility of states 
to recognise, enforce and safeguard in Article 25(1) of the UDHR.35 To 
emphasise the commitment to social security and other socio-economic and 
cultural rights, including the right to health, Article 22 of the UDHR requires 
State Parties to expend available resources and take steps individually and 
                                                          
31 Nigeria is a signatory to, and has ratified, several human rights international instruments such as the International Covenant on 
Civil and Political Rights (ICCPR), Ratified October, 29 1993; The International Covenant on Economic, Social and Cultural Rights 
(ICESCR), Ratified October 29, 1993. The International Convention on the Elimination of All Forms of Racial Discrimination (the 
ICERD) Ratified January 4, 1969; The Convention Against Torture and Other Cruel, Inhuman or Degrading Treatment or 
Punishment (CAT) Ratified July 28, 2001; The Convention on the Elimination of All Forms of Discrimination Against Women 
(CEDAW) Ratified July 13, 1985; and the Convention on the Rights of the Child (CRC) Ratified April 19, 1991. Nigeria has also signed 
the two optional protocols related to this Convention: The Optional Protocol to the Convention on the Rights of the Child on the 
involvement of Children in Armed Conflict and the Optional Protocol to the Convention on the Rights of the Child on the Sale of 
Children, Child Prostitution and Child Pornography, both signed on September 8, 2000. (The implementation conditions and 
binding status of these human rights instruments in Nigeria are further examined in the final section of this chapter.) 
32 The extent of Nigeria’s obligation to the right to health is further examined in the last section of this chapter.  
33 See Preamble of the Constitution of the World Health Organization in UN General Assembly, Constitution of the World Health 
Organization (17 November 1947, A/RES/131). Also available at  
<http://www.who.int/governance/eb/who_constitution_en.pdf> accessed 15 January 2014. 
34 Valentina Vadi, Public Health in International Investment Law and Arbitration (Routledge 2012) 28. 
35 For instance, the fifth recital of the Preamble to the Universal Declaration of Human Rights (UDHR) of 1948 states that  
[…] the peoples of the United Nations have in the Charter reaffirmed their faith in fundamental human rights, in 
the dignity and worth of the human person and in the equal rights of men and women and have determined to 
promote social progress and better standards of life in larger freedom. 
Article 25(1) further provides that 
Everyone has the right to a standard of living adequate for the health and well-being of himself and of his family, 
including food, clothing, housing and medical care and necessary social services, and the right to security in the 
event of unemployment, sickness, disability, widowhood, old age or other lack of livelihood in circumstances 
beyond his control.  
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through international and national cooperation, to facilitate the realisation of the 
rights of all citizens to ‘economic, social and cultural rights indispensable for his 
dignity […].’36  
Being a United Nations declaration rather than a treaty, the authority, legal and 
binding status of the Declaration on the state’s commitment to secure human 
rights, has been questioned.37 Nonetheless, the United Nations International 
Conference on Human Rights in 1968 established that the Declaration 
‘constitutes an obligation for the members of the international community.’38 Its 
provisions have influenced a significant number of national and international 
laws, treaties, conventions and judicial decisions.39 
The right to health is also acknowledged in other significant human rights 
frameworks such as Article 5 (e)(iv) of the 1965 International Convention on the 
Elimination of All Forms of Racial Discrimination;40 mentioned in Articles 3, 6, 
17, 23 and explicitly outlined in Article 24 of the Convention on the Rights of the 
Child.41 These conventions recognise the fundamental right of everyone to 
medical care, health facilities and access to treatments as constitutive 
                                                          
36 See also Paul Hunt and Rajat Khosla, 'The Human Right to Medicines' (2008) 5(8) Sur. Revista Internacional de Direitos Humanos 
99, 105. 
37 David Kinley and Junko Tadaki, ‘From Talk to Walk: The Emergence of Human Rights Responsibilities for Corporations at 
International Law’ (2004) 44(4) Virginia Journal of International Law 931, 949. 
38 United Nations, Human Rights: Questions and Answers (n 6) 4. 
39 ibid 4-5. For example, although not explicitly stated, the international Court of Justice touched upon the binding status of the 
UDHR in the context of state obligation in the Tehran Hostages Case. The Court considered the principles enshrined in the 
Declaration when examining the responsibility of Iran towards the United States for the detention of US diplomats and consular 
staff in Tehrah and stated thus:  
Wrongfully to deprive human beings of their freedom and to subject them to physical constraint in conditions of 
hardship is in itself manifestly incompatible with the principles of the Charter of the United Nations, as well as 
the fundamental principles enunciated in the Universal Declaration of Human Rights [UDHR].  
United States Diplomatic and Consular Staff in Tehran (United States of America v Iran) Judgments I.C.J. Reports 1980, 42, 
Paragraph. 91.  
40 The Article imposes an obligation on State Parties  
[t]o prohibit and to eliminate racial discrimination in all its forms and to guarantee the right of everyone […] to 
public health, medical care, social security and social services. 
41 The Convention was adopted and opened for signature, ratification and accession by General Assembly resolution 44/25 of 20 
November 1989. The Convention entered into force on September 1990. 
 The Convention in Article 24(1) states as follows:  
States Parties recognize the right of the child to the enjoyment of the highest attainable standard of health and 
to facilities for the treatment of illness and rehabilitation of health. States Parties shall strive to ensure that no 
child is deprived of his or her right of access to such health care services. 
185 
 
components of the right to the ‘highest standard’ of health. Specifically, the 
expansive provisions on the right to health in Article 24 of the Convention on 
Rights of the Child aim to address and reduce child mortality and ensure that 
every child is provided with, and has access to adequate healthcare services 
and facilities. It also includes the obligation on states to provide the necessary 
medical care and facilities for the reproductive, prenatal and postnatal care of 
mothers.  
The right to health, as an indispensable right to the enjoyment of the highest 
attainable state of physical and mental health and social wellbeing, is also 
contained in several regional legal instruments and national laws. For instance, 
the right to the highest possible standard and protection of health is recognised 
and promoted in Article 11 of the 1996 European Social Charter (Revised).42 
The African Charter on Human and People’s Rights of 1981 (African Charter) in 
Article 16(1) also provides that every person is entitled to the ‘best attainable 
state of physical and mental health.’43 The Article obligates states to take 
expedient measures to protect the health of their citizens and respond to their 
medical needs.44 The effect of the right to health in the African Charter was 
established in Purohit and Another v The Gambia.45  
In this case, the applicants alleged, amongst other things, that the legislative 
regime in The Gambia for mental health patients violated the right to enjoy the 
best attainable state of physical and mental health (Article 16) and the right of 
the disabled to special measures of protection in keeping with their physical and 
                                                          
42 The right to the standard of health and social wellbeing is recognised in the Additional Protocol to the American Convention on 
Human Rights in the Area of Economic, Social and Cultural Rights (Protocol of San Salvador) (San Salvador, 17 November 1988, 
entered into force 16 November 1999, OAS Treaty Series No 69 (1988), 28 ILM 156) Article 10. See Organization of American 
States (OAS), Additional Protocol to the American Convention on Human Rights in the Area of Economic, Social and Cultural Rights 
(A-52 16 November 1999) available at  
<http://www.refworld.org/docid/3ae6b3b90.html> accessed 30 September 2015. 
43 See Article 16(1) of the African Charter on Human and Peoples’ Rights (African Charter) (Nairobi, 27 June 1981, entered into 
force 21 October 1986, 1520 UNTS 217) (Banjul Charter) (Hereinafter African Charter) 
44 Article 16 (2), African Charter of 1981. 
45 (2003) AHRLR 96. 
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moral needs. Holding that The Gambia fell short of satisfying the requirements 
of Articles 16 and 18(4) of the African Charter, the African Commission stated 
that the enjoyment of the right to health is crucial to the realisation of other 
fundamental rights and freedoms and includes the right of all to health facilities, 
as well as access to goods and services, without discrimination of any kind. 
The right to health is also recognised as important and promoted in the 1993 
Vienna Declaration and Programme of Action.46 In Article 31, states are 
required to refrain from taking ‘any unilateral measure’ that impedes the full 
enjoyment of human rights, particularly, ‘the right of everyone to a standard of 
living adequate for their health and wellbeing’ including access to medical 
healthcare.47 Reiterating the same commitment, Article 41 specifically 
recognises the importance of women’s physical and mental health and reaffirms 
the obligation on states to promote their equal access to adequate healthcare 
and reproductive health services.  
 
4.2.4 The Right to Health in the International Covenant on Economic, 
Social and Cultural Rights (ICESCR) 
The ICESCR provides the most comprehensive provision on human rights to 
health as part of the socio-cultural and economic aspect of human rights. The 
right in Article 12(1) is in two parts as follows: the first gives a general 
recognition of the rights of everyone to ‘the highest attainable standard of 
physical and mental health.’ Having reaffirmed the rights of everyone to health, 
the second aspect of the right in Article 12(2) exhorts a duty on State Parties 
such as Nigeria, to take the necessary steps to guarantee and ensure the full 
                                                          
46 See Articles 18, 24, 31 and 41 of the Vienna Declaration and Programme of Action of 1993. (Adopted by the World Conference 
on Human Rights in Vienna on 25 June 1993)  
47 ibid 
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realisation of the rights by providing the necessary health-related resources 
(medicines), facilities, environment, information and conditions.48  
 
4.2.5 Approaching Women’s Health as a Human Right 
In addition to the above stated general entitlement of every person to the right 
to health and healthcare, the specific rights of women to health is recognised in 
several human rights instruments. The Protocol to the African Charter on 
Human and People’s Rights of Women in Africa is a significant human rights 
instrument that reaffirms and promotes women’s health and reproductive rights 
in Article 14.49 The Article particularly pays attention to the guarantee, protection 
and promotion of women’s reproductive health. Article 14(2)(a) requires the 
states, such as Nigeria, to undertake all necessary actions to ensure women’s 
access to adequate, affordable and accessible health services which will also 
include medicines. In addition, the 1995 Beijing Declaration and Platform for 
Action50 explicitly recognise women’s reproductive rights and also, the 
entitlement of all women to healthcare and access to adequate medicinal 
treatments as essential to their sustainable development and empowerment.51 
                                                          
48 The necessary steps to be taken include: 
(a) The provision for the reduction of the stillbirth-rate and of infant mortality and for the healthy development 
of the child; 
(b) The improvement of all aspects of environmental and industrial hygiene; 
(c) The prevention, treatment and control of epidemic, endemic, occupational and other diseases; 
(d) The creation of conditions which would assure to all medical service and medical attention in the event of 
sickness.  
United Nations General Assembly, International Covenant on Economic, Social and Cultural Rights (Adopted 16 December 1966, 
entry into force 3 January 1976, United Nations Treaty Series volume 993, 3) 
 
49 Article 13(i) also guarantees adequate and paid pre- and post-natal maternity leave in both the private and public sectors. 
50 The Beijing Declaration and Platform of Action was adopted at the Fourth World Conference on Women, convened by the UN in 
Beijing, China, in 1995. The Declaration and Platform of action is a commitment by governments and a global framework of action 
and blueprint for advancing women’s rights, promoting gender equality, and opportunities for the empowerment of all women. 
The Declaration and Platform of Action, reinforces the human rights provisions in CEDAW although the commitments and 
promises are not legally binding. See more at UN Women, Beijing Declaration and Platform for Action: Beijing+5 Political 
Declaration and Outcome (UN Women 2014). 
51 Paragraph 27 and 30 of the Beijing Declaration and Platform for Action Fourth World Conference on Women Beijing Declaration 
1995. 
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Furthermore, the Beijing Declaration obliges states to ‘[g]ive higher priority to 
women’s health and develop mechanisms for coordinating and implementing 
the health objectives of the Platform for Action and relevant international 
agreements to ensure progress.’52  
CEDAW is one of the most significant legal instrument guaranteeing women’s 
right to health.53 CEDAW is an international treaty that particularly set out to 
affirm the principles of fundamental human rights and equality for all women, 
including girls, around the world.54 Principally, CEDAW is concerned with 
promoting and protecting women’s rights by putting women’s issues at the 
centre of human rights.55 The Preamble to the Convention, having recognised 
that ‘in situations of poverty women have the least access to food, health, 
education, training and opportunities for employment and other needs,’ makes 
provisions for the guarantee and realisation of women’s fundamental rights 
including their rights to health.  
The protection of women’s human right to health in CEDAW is characterised in 
two aspects: the first addresses gender discrimination and equality between 
men and women; while the second part promotes the realisation of the specific, 
collective and individual rights of women in all areas of their lives including their 
rights to health and access to basic healthcare services and medicinal 
treatments in the interests of their human rights.56  
                                                                                                                                                                          
This commitment was also reaffirmed in the Beijing Declaration and Platform for Action Beijing, Political Declaration and Outcome 
in paragraph 55. See more discussions on this at Population Council, ‘World Conference on Women: The Beijing Declaration and 
the Platform for Action on Women and Health’ (1995) 21(4) Population and Development Review 910-911. 
52 Article 111(c) of The Beijing Declaration and Platform of Action, 1995. 
53 UN General Assembly, Convention on the Elimination of All Forms of Discrimination Against Women (Adopted 18 December 
1979, entry into force 3 September 1981 UNTS 1249, 13). Also available at  
<http://www.un.org/womenwatch/daw/cedaw/>accessed 17 July 2015. 
54 The Women's Intercultural Network, 'The Convention on the Elimination of All Forms of Discrimination Against Women - 
CEDAW' (The Women's Intercultural Network 2015); Mary Hallward-Driemeier and Tazeen Hasan, Empowering Women: Legal 
Rights and Economic Opportunities in Africa (World Bank Publications 2012) 43. 
55 Charlotte Abaka, ‘Framework for a Human Rights Approach to Women’s Health: The Work of the CEDAW’ available at  
<http://www.un.org/womenwatch/daw/csw/hrights.htm> accessed 27 Jan 2014;  
56 Rebecca J Cook, Women's Health and Human Rights (World Health Organization 1994) 19-20. 
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The recognition of women’s rights, including the right to health, in CEDAW, 
starts with their rights to be free from all forms of discriminations thus:  
[...] any distinction, exclusion or restriction made on the basis of sex which has the effect 
or purpose of impairing or nullifying the recognition, enjoyment or exercise by women, 
irrespective of their marital status, on a basis of equality of men and women, of human 
rights and fundamental freedoms in the political, economic, social, cultural, civil or any 
other field.57 
Implicit in this definition is the recognition that any ‘distinction, exclusion or 
restriction’ that compromises women’s rights— including their rights to 
healthcare systems and products—constitutes discrimination. Most importantly, 
it can be said that this provision aims to ensure their equal access to 
opportunities, health systems, medicinal products and facilities, and 
emphatically prohibits health-related violence against them.58 As further clarified 
by CEDAW General Recommendation No. 24 on Article 12 of the Convention 
(Women and Health), the elimination of discrimination against women requires 
the guarantee of their health, wellbeing and access to healthcare services to 
ensure the ‘attainment of highest standard of health.’59  
In recognising the important connection between women’s health and their 
developmental wellbeing, Article 12 of CEDAW specifically emphasises 
women’s right of access to adequate levels of healthcare systems in connection 
with their general, and specific reproductive and maternal health.  
Article 12 (1) explicitly directs as follows: 
                                                          
57 CEDAW 1979, Article 1.  
58 Committee on the Elimination of Discrimination Against Women, CEDAW General Recommendation No. 24: Article 12 of the 
Convention (Women and Health) (Committee on the Elimination of Discrimination Against Women 1999); United Nations Women, 
‘Convention on the Elimination of All Forms of Discrimination Against Women: Introduction’ available at  
 <http://www.un.org/womenwatch/daw/cedaw/text/econvention.htm> accessed 6 May 2016.  
59 ibid 
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        States Parties shall take all appropriate measures to eliminate discrimination against 
women in the field of health care in order to ensure, on a basis of equality of men and 
women, access to health care services, including those related to family planning.60  
This provision fundamentally reiterates the right of women to the enjoyment of 
the highest attainable standard of physical and mental health as set out in 
UDHR and ICECSR. However, while it is generally acknowledged that everyone 
has an equal right to health, CEDAW goes further, recognising that women may 
face additional challenges in accessing the relevant health-related goods, 
services and facilities, as considered in the preceding chapter.61 Thus 
specifically for women, the right to healthcare is linked to the elimination of 
discrimination.62  
It can be said that the provisions in CEDAW reflect the importance of health and 
the health system to women’s human rights and wellbeing by linking the issue 
of discrimination as another reason to ensure equal access healthcare. Indeed, 
one author, in noting the force of discrimination, argues that ‘discrimination is 
the most comprehensive, systematic and severe deprivation of human rights.’63 
Accordingly, women’s right to health is more than a requirement to guarantee 
their access to healthcare systems, resources and facilities, it is broadly 
construed as an ‘entitlement to an effective and integrated health system’64 
which also entails the removal of all forms of barriers and discriminations to 
accessibility.  
                                                          
60 Also, in the place of employment in Articles 11 (1) (f) of CEDAW 1979.  
61 See the analyses in the subsections of 3.4 in Chapter III. 
62 According to paragraph 13 of the CEDAW General Recommendation No 24,  
The duty of States parties to ensure, on a basis of equality of men and women, access to health-care services, 
information and education implies an obligation to respect, protect and fulfil women’s rights to health care. 
States parties have the responsibility to ensure that legislation and executive action and policy comply with these 
three obligations. They must also put in place a system that ensures effective judicial action. Failure to do so will 
constitute a violation of article 12.  
63 Martin Uzochukwu Gasiokwu, Human Rights: History, Ideology and Law (Mono Expressions 2001) 224. 
64 United Nations General Assembly, 'The Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and 
Mental Health' (A/61/338, United Nations 2006) paragraph 14. 
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The normative framework, the nature of the human rights to health and the 
obligations on states to guarantee the enjoyment of the right, is further 
examined. This subsection also explains the significance of accessing 
medicines, including patented pharmaceuticals, as a component of the right to 
health and the states’ duty to ensure affordable access to pharmaceuticals in 
this respect.  
 
4.3 Analysing the Theoretical Perspective and Normative Content of the 
Human Right to Health and Medicines  
The content and conditions necessary for the fulfilment of the right to health 
have been authoritatively expounded by the United Nation’s Committee on 
Economic, Social and Cultural Rights (CECSR). This is captured in General 
Comment No 14 on the Right to Health. The conceptual interpretation of the 
right to health in Article 12(1) of the ICESCR by the CECSR offers a useful 
clarification of the nature and scope of the right as well as the corresponding 
duty on states, including Nigeria, to realise the enjoyment of the right.  
 
4.3.1 The Content and Objectives of the Right to Health 
The entitlement to the right to health under human rights law is narrowed down 
to two health objectives: the right to healthcare and the right to healthy 
conditions.65 
 The right to healthcare aims to guarantee the availability of and access to an 
adequate system of healthcare. Inherent in this right is the assumption that 
everyone should have the means, facilities, products or drugs and services 
necessary for the realisation of the right to health in a timely and appropriate 
                                                          
65 Freeman (n 3) 1295.  
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manner.66 The CESCR has emphasised the role of states in providing the 
amenities, supplies, medical services and products necessary for the enjoyment 
of the right to health.67  
The right to healthy conditions places an obligation on states to provide 
reasonable conditions to enable people to attain and maintain good health such 
as a healthy working and living environment, and housing (essentially health-
related human rights).68 It also includes the underlying determinants of health 
such as nutrition, food, safe and potable water and sanitary conditions, and 
access to health-related information.69 This holistic approach to health includes 
the right to participate in all health-related decision-making in the community, 
and at national and international level.70 The right to healthcare and healthy 
conditions are also broadly conceived to include socio-economic factors, such 
as resource distribution, sensitivity to gender differences, and other traditional 
and cultural environments including socially-related events such as armed 
conflicts and violence which are so damaging to health.71 HIV/AIDS and other 
deadly diseases such as cancer are identified by the CECSR as diseases that 
require specific consideration in the right to health. 
It is worth noting that with regards to the duty of the state towards the right to 
health, the CESCR clarifies that the right to health is not synonymous with the 
unconditional right to be ‘healthy,’ in that being healthy is determined by several 
factors including unhealthy lifestyles, biological, genetic and physiological 
                                                          
66 ibid 
67 United Nations Committee on Economic, Social and Cultural Rights (CECSR), General Comment No. 14: The Right to the Highest 
Attainable Standard of Health (Art. 12 of the Covenant) (UN Doc E/C.12/2000/4 11 August 2000) Paragraph 8. (Hereafter CECSR, 
General Comment No. 14) 
68 Stephen P Marks, ‘The Emergence and Scope of the Human Right to Health’ in Jose M Zuniga, Stephen P Marks and Lawrence O 
Gostin (eds), Advancing The Human Right To Health (Oxford University Press 2013) 9. 
69 CECSR, General Comment No. 14, paragraphs 11, 15. 
70 ibid 
71 Freeman (n 3) 1296. 
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dispositions.72 The state is not expected to safeguard the good health of its 
citizens against all possible cases of sickness or every cause of ill-health and 
disability, rather the right to health embraces a wide range of factors necessary 
to lead a good life.73 Notwithstanding, the state is expected to take into account 
biological factors and socio-economic circumstances of individuals in addition to 
the available resources of the state in providing for the highest attainable health 
standards. Consequently, the CESCR reiterates that the right to health is 
conceived within the terms of the right to the enjoyment of medical care 
including ‘a variety of facilities, goods, services and conditions’ conducive to a 
standard of living adequate for basic health.74 
 
4.3.1.1 The Key Standards of the Right to Health 
The CECSR identifies that the realisation of the right to health and its 
usefulness in contributing to the enjoyment of other human rights broadly 
embodies four interrelated dimensions: Availability, Accessibility, Acceptability, 
and Quality.  
  
                                                          
72 Paragraph 8, CECSR, General Comment No. 14; World Health Organization and UN High Commissioner for Human Rights, Health 
and Human Rights: Fact sheet N°323 (World Health Organization 2015). Available at  
< http://www.who.int/mediacentre/factsheets/fs323_en.pdf > accessed 15 February 2015. 
73 Paragraph 4, CECSR, General Comment No. 14; Marks (n 68) 9. 
74 CECSR, General Comment No. 14, paragraph 9. 
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Figure 4.1 The Right to health according to the UN Comment No. 1475 
 
1) Availability in sufficient quantities: Availability includes adequate and 
functioning healthcare facilities (such as hospitals, medical 
professionals), goods (e.g medicines, vaccines and medical equipment), 
services (primary care, maternal and reproductive services, physical and 
mental care) and health-related programmes, as well as underlying 
healthy conditions (e.g safe environment, food, water).76 The healthcare 
facilities, supplies and conditions must be physically available when and 
where needed (for example, in both the rural and urban areas).  
2)  Accessibility to everyone without discrimination: the health 
infrastructures, medicines services and conditions must be equally 
accessible in a non-discriminatory manner in accordance with the 
general principles of human rights.77 Accessibility encompasses three 
aspects - physically accessible in safe reach for everyone; financially 
affordable; and with accessible health-related information in a clear and 
meaningful format. As will be discussed below, this accessibility is most 
relevant to the discussion on access to medicines in this chapter. 
Specifically, economic accessibility is important to the study as it touches 
upon the issue of drug pricing and pharmaceutical patent rights. 
3) Acceptable in the sense of respect for medical ethics and customs: the 
healthcare institutions, goods, medicines and services must be provided 
                                                          
75 Adapted from World Health Organisation ‘Right to Health Fact Sheet’ available at  
http://www.searo.who.int/entity/human_rights/Right_to_health-factsheet.pdf?ua=1 
76 CECSR, General Comment No. 14, paragraph 12(a). 
77 CECSR, General Comment No. 14, paragraph 12(b). 
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with regard to human dignity and medical ethics, in a culturally 
appropriate and acceptable manner.78  
4) ) Of good quality and scientifically appropriate: all healthcare delivery, 
services and drugs must be timely, of high standard that is medically and 
scientifically appropriate, efficacious and safe.79  
These key dimensions provide the basic framework of the interventions to 
achieve the objective of the right to health. These core standards generally refer 
to the idea that the enjoyment of the equal right of everyone to health should 
encompass all these dimensions. As a result, Nigeria and other State Parties to 
human rights laws must bear in mind these dimensions and standards in 
identifying and responding to the obligation to the right to health and the 
healthcare needs of their populations, including instances of negotiating 
multilateral and bilateral trade agreements, and formulating or interpreting 
patent rights.  
4.3.1.2 The Additional Framework of Women’s Right to Health  
Generally, the framework of the interventions necessary to guarantee the right 
to health in the human rights instruments including the ICESCR and the 
corresponding General Comment No 14, can be applied pari pasu in the context 
of women’s right to health in CEDAW and the Protocol to the African Charter on 
Human and People’s Rights of Women. However, in addition to the above, 
specific health consideration is given to women. For this purpose, the General 
Recommendation to CEDAW makes detailed requirements for the provision of 
healthcare services, goods (medicines) and facilities necessary for the 
prevention and treatment of women’s specific and general health conditions in a 
                                                          
78 CECSR, General Comment No. 14, paragraph 12(c). 
79 CECSR, General Comment No. 14, paragraph 12(d). 
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non-discriminatory and cost effective manner.80 In the interests of women’s right 
to health, this duty is reiterated in paragraph 21 of the General Comment No 14 
on women’s right to health. Accordingly, states such as Nigeria are required to 
provide healthcare in the following manner:  
a) Physical and financial accessibility: the CEDAW Committee, in noting 
that cultural, socio-economic barriers, including those of physical access, 
and the high cost of healthcare services can influence the decision of 
women to seek healthcare interventions, requires states to ensure that 
there is timely and affordable access to healthcare.81 The Committee 
further imposes a dual duty on states to promote access to healthcare 
systems and information, and also to remove every hindrance women 
encounter in accessing these basic healthcare facilities, services and 
goods including essential pharmaceuticals.82 Health service must be 
financially accessible to everyone within a reasonable and safe distance 
in a gender-sensitive manner that also takes into account the vulnerable, 
the old, children, the disabled and women.83  
b)  Reliable and available healthcare: Special attention is given to the health 
interventions that can prevent, detect and treat specific women’s 
diseases, or conditions that affect women differently from men.84  
c) Acceptable: the healthcare measures must be sensitive to women’s 
rights, dignity, interests and cultures of minorities and indigenous 
                                                          
80 CEDAW, General Recommendation No. 24, paragraph 9.  
81 CEDAW, General Recommendation No. 24, paragraph 21. The Committee adds that physical and economic access to health 
services is also part of this obligation on states in paragraphs 7 and 17.  
82 CEDAW, General Recommendation No. 24, paragraph 11 and 21. 
83 CECSR, General Comment No. 14, paragraph 12(b); Joo-Young Lee and Paul Hunt, 'Human Rights Responsibilities of 
Pharmaceutical Companies in Relation to Access to Medicines' (2012) 40 The Journal of Law, Medicine & Ethics 220, 225. (The 
authors write extensively on the responsibilities and obligations of pharmaceutical companies to the right to health and access to 
medicines.) 
84 CEDAW, General Recommendation No. 24, paragraphs 10, 11 and 12. 
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women, also taking into account the disadvantaged, vulnerable and 
disabled women.85 
d) Quality: the healthcare services and conditions must be of good and safe 
quality, tailored to meet the distinct features of women’s physiological 
and biological condition.86  
Thus, women are guaranteed the right to health in all facets of their lives. This 
right includes access to adequate healthcare facilities, services, goods, and 
living conditions necessary for the enhancement of their health and wellbeing. 
4.4 The Human Right to Medicines  
Medicine is a significant means for the realisation of the right to health. Where 
there are no drugs for essential medical treatments, it is hard to conceive the 
guarantee of the highest attainable standard of health, as it is a powerful 
resource for the realisation of the good health and wellbeing of humans. This 
opinion is shared by the UN Human Rights Council, reaffirming that access to 
medicines is ‘one of the fundamental elements in achieving progressively the 
full realisation’ of the right to the highest standard of health.87 For this reason, 
the right to medicines requires that medicinal resources are sufficiently 
available, accessible, culturally acceptable and of good quality and for women, 
without discrimination. With regards to affordability, the WHO further states that 
accessibility implies that the medicines are available at an affordable rate to 
all.88 This position coincides with the reasoning of other resolutions of the UN 
                                                          
85 CEDAW, General Recommendation No. 24, paragraph 22.  
86 CEDAW, General Recommendation No. 24, paragraph 22.  
87 Human Rights Council, Promotion and Protection of All Human Rights, Civil, Political, Economic, Social and Cultural Rights, 
Including the Right to Development: Access to Medicine in the Context of the Right of Everyone to the Enjoyment of the Highest 
Attainable Standard of Physical and Mental Health (A/HRC/RES/12/24 United Nations General Assembly 2009) paragraph 1. 
88 As well as rational selection and use of medicines; sustainable adequate financing; and a reliable health and supply system. 
World Health Organization, ‘Technical Cooperation Activities: Information from Other Intergovernmental Organizations’ (WHO 
Doc. IP/C/W/305/Add.3 2001) also available at  
<http://www.who.int/phi/WHO_Comm_TRIPS_implementation_activities_W305A3_2001a.pdf> accessed 18 October 2015. 
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and treaty monitoring bodies.89 The UN Office of the High Commissioner for 
Human Rights writes that ‘[f]rom a human rights perspective, access to 
medicines is intrinsically linked with the principles of equality and non-
discrimination, transparency, participation, and accountability.’90 While all 
medicines are important to health, the General Comment No 14 expressly 
acknowledges accessibility to health-related goods and essential medicines as 
defined by the WHO Action Programme on Essential Drugs as a central 
component of the right to health.91 The WHO identified essential medicines as 
‘those that satisfy the priority healthcare needs of the population. They are 
selected with due regard to public health relevance, evidence on efficacy and 
safety, and comparative cost-effectiveness.’92  
The link between access to medicines and human rights to health is significant 
to the argument in this thesis that it is the duty of the Nigerian state to improve 
and guarantee women’s access to essential medicines within the purview of 
patent rights. Accordingly, accessing good quality, affordable pharmaceuticals 
in a timely manner is not only significant to women’s health, development and 
wellbeing, there is an incumbent duty on Nigerian government as the primary 
duty bearer to protect, promote and sustain this access and remove of all 
obstacles to accessibility, including patent rights that could interfere with this 
access. The obligations on states with regards to accessing medicines, as a 
                                                          
89 See for instance, The UN Human Rights Council, Access to Medicines in the Context of the Right of Everyone to the Enjoyment of 
the Highest Attainable Standard of Physical and Mental Health (A/HRC/RES/23/14, 2013); The UN Human Rights Council, Report of 
the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental 
Health, Anand Grover, on Access to Medicines (1 UN Doc. A/RHC/23/42 2013) paragraph 3; Paul Hunt, Report of the First Special 
Rapporteur on the Right to Health (UN Doc. A/61/338, 2006).  
90 United Nations Human Rights Office of the High Commissioner for Human Rights ‘Access to Medicines: A Fundamental Element 
of the Right to Health’ (Ohchr.org)  
<http://www.ohchr.org/EN/Issues/Development/Pages/AccessToMedicines.aspx> 15 June 2015. 
91 CECSR, General Comment No. 14, paragraph 12(a) and paragraph 43(d).  
92 'WHO Essential Medicines' (Who.int).  
Available at <http://www.who.int/topics/essential_medicines/en/> accessed 6 May 2016. The WHO regularly reviews and updates 
the list of essential medicines. 
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human right entitlement have been examined by scholars and human rights 
advocates.93 For example, Yamin argues from a human rights perspective that 
access to medicines is not only a necessary component of health, but as a legal 
right, it emphasises the role that government, third parties and international 
organisations can play in facilitating and ensuring access.94 Consequently, 
accessing medicines as a human rights issue delineates the process, normative 
framework, policies and laws necessary for ensuring access and guarantying of 
the right.95 In this respect, it imposes a responsibility on duty-bearers to do all 
they can to ensure women’s access to the medicines in a manner 
commensurate with the right to health.  
Access to medicines from a human rights perspective implies several other 
obligations. First, it imposes a moral and humanitarian responsibility to 
undertake the necessary steps to ensure women’s access to medicinal and 
health treatments as will be further explored below.96 Secondly, there is a legal 
obligation to ensure women’s access to medication as a national legislative and 
policy priority which should be reflected in the health system including 
‘competition, pricing, licensing and other laws.’97 Thus, states are obliged to 
facilitate and enhance the means to accessing pharmaceuticals and drugs as a 
matter of human rights in their legislative and policy considerations. For 
example, since Article 8 of the TRIPS Agreement grants WTO members the 
flexible authority to ‘adopt necessary measures’ compatible with the general 
provisions of the Agreement to safeguard public health and promote the 
                                                          
93 Joo-Young Lee, A Human Rights Framework for Intellectual Property, Innovation and Access to Medicines (Ashgate Publishing Ltd 
2015); Alicia Yamin, ‘Not Just a Tragedy: Access to Medications as a Right Under International Law’ (2003) 21 Boston University 
International Law Journal 325, 336, 370; Danwood Mzikenge Chirwa, ‘The Right to Health in International Law: Its Implications for 
the Obligations of State and Non-State Actors in Ensuring Access to Essential Medicine’ (2003) 19 South African Journal on Human 
Rights 541, 548. 
94 Yamin (n 93) 329. 
95 ibid 
96 ibid 327. 
97 ibid 327. 
200 
 
interests of the public, states such as Nigeria, can adapt their IP regimes to take 
into account the accessibility of its people to adequate medicines, as a human 
right. Also, the human right to access medicines can be recognised as 
legitimate grounds for the design and implementation of the exceptions to 
TRIPS’ obligations and flexibilities regarding patents. Hestermeyer examines 
access to medicines as a human right within the framework of the WTO system 
and the TRIPS Agreement.98 His study indicates that access to medicines as a 
human right is essential to the interpretation of the objective and purpose of the 
Agreement within the context of public health.99 The study likewise illustrates 
that access to medicines as a right allows WTO members more discretion to 
take appropriate measures to guarantee accessibility.100 
Third, the legal responsibility of states to the right to medicines requires an 
accountability obligation to enhance accessibility.101 This will also include 
measures to ensure that accessing medicines as a right is not interfered with. 
Thus, accessing drugs as a central component of the right to health, should 
guide Nigeria’s actions and policies both at the international and national levels.  
A number of judicial decisions have shed more light on the central role of 
medicines as a prerequisite to the realisation of human rights in general and the 
right to health in particular. In Costa Rica, the applicant in International Ms Vera 
Salazar Navarro vs Caja Costarricense de Seguro,102 instituted an action 
against the Social Security Institution for refusing to repay the cost of prescribed 
                                                          
98 Holger Hestermeyer, Human Rights and the WTO: The Case of Patents and Access to Medicines (Oxford University Press 2008) 
78-136. 
99 ibid 207-224. 
100 ibid 229-254.  
101 Yamin (n 93) 327. 
102 Social Constitutional Court- File n°01-009007-CO, 26 September 2001. The analysis of the case is based upon the translation 
and details of the case in Hans V Hogerzeil, Melanie Samson and Jaume Vidal Casanova, ‘Ruling for Access Leading Court Cases in 
Developing Countries on Access to Essential Medicines as Part of the Fulfilment of the Right to Health’ (World Health Organization 
Department of Essential Drugs and Medicines Policy 2004) 27-28. 
201 
 
patented drugs. Instead the applicant alleged that she was offered a cheaper 
generic drug for her multiple sclerosis.103 The applicant therefore claimed that 
refusal to reimburse the branded drugs violated her right to health. The court 
held in favour of the applicant and ruled that the social security institution had a 
constitutional and internationally binding obligation to provide the exact 
patented drugs prescribed by her doctor and not the cheaper substitute on the 
Social Institutions Scheme. In that context, the court found that a denial of 
access to a certain drug can constitute a violation of the right to health.104  
Similarly the Costa Rican Supreme Court in Mr William García Álvarez vs Caja 
Costarricense de Seguro,105 ruled in favour of the plaintiff, an HIV-positive 
person who was refused antiretroviral treatment by the social security 
institution. Because the medicines were not considered essential at that time, 
they were not on the official national drugs list and thus were not freely available 
in public facilities.106 The plaintiffs argued that the treatments were expensive in 
the private sector and so refusal to provide them by the institution and 
inaccessibility was a violation of the right to life and health.107 The judge, in the 
ruling in favour of the plaintiff, decided that:  
If the right to life is especially protected in each modern State and with the right to 
health, any economic criteria that pretends to deny the exercise of those rights, has 
to be of second importance […] without right to life, all the remaining rights would 
be useless.108  
                                                          
103 The defendant's main argument was that the effects and composition of the generic drugs were the same as the branded ones. 
104 For a comprehensive discussion on other similar cases, see Hogerzeil, Samson and Casanova (n 102) 27. 
105 (1997) File 5778-V-97. Also available at 
<http://www.poderjudicial.go.cr/scij/index_pj.asp?url=busqueda/jurisprudencia/jur_ficha_completa_sentencia.asp?nBaseDatos=
1&nS entencia=15980> accessed 16 January 2015. 
106 ibid 
107 ibid 
108 ibid (As interpreted and cited in Hogerzeil, Samson and Casanova (n 102) 27). 
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Most importantly, although the court considered the economic rationale of not 
providing the necessary treatment, the court recognised the significance of 
accessing medicines as a part of the right to life and health. This progressive 
judicial interpretation of the right to access medicines as an intrinsic aspect of 
human right is worth emulation in Nigeria.  
It is important to note that Costa Rica, similarly to Nigeria, does not expressly 
recognise the right to health in its Constitution. However, there are provisions 
that seek to guarantee and safeguard the health of the citizens.109 For example, 
under the social rights and guarantees, Article 50 of the Costa Rican 
Constitution, recognises the right of every person to a healthy environment.110 
Article 73 provides for the establishment of a social security system for the 
protection of the citizens against illnesses to be managed by an institution 
known as the Caja Costarricense de Seguro Social (Costa Rican Social 
Security Administration) to offer health services.111 Costa Rica like Nigeria had 
also ratified a number of international human rights instruments and had even 
taken further steps by establishing institutions to give practical enforcement in 
the event of violations of the rights, such as the Constitutional Court and 
Ombudsman’s Office.112 The Constitutional Court has held in a number of cases 
that access to medicines plays an important role as an essential component of 
the rights to health and life.113                                                                                                                                                   
                                                          
109 For more details on the Costa Rican provision on health, see María del Rocío Sáenz, Juan Luis Bermúdez and Mónica Acosta, 
'Universal Coverage in a Middle Income Country: Costa Rica' (World Health Organization 2010). 
110 Political Constitution of the Republic of Costa Rica 1949 (as amended).  
111 ibid 
112 In making this comparison, it is important to acknowledge the constitutional and legislative variation in both countries as well 
as the international status of human rights law in their various domestic legal systems. In Nigeria, health is not a justiciable right 
under the Constitution. The Nigerian judicial authorities are also reluctant to cite international treaties and laws as the basis for 
their decision on human rights based on Section 12 of the Constitution as will be discussed. 
113 See for example the decision in Mrs Sidonia Vargas v Hospital San Juan de Dios Constitutional Court [1994] File 2390- C- 94. In 
this case, a woman suffering from acute leukaemia and diabetes was denied access to the necessary medication to self-administer 
at home. The reasons given for the refusal to provide the medicines were safety and administrative related. Also, the hospital 
alleged that its own query to the National Health system to allow the reimbursement of this sort of arrangement was refused. The 
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Another good example of a case where a state has been made accountable for 
its obligation to provide medicines in realisation of the right to health is a South 
African case by Treatment Action Campaign. The case of Treatment Action 
Campaign and others v Minister of Health and others114 and subsequent appeal 
to the Constitutional Court (Minister of Health and others v Treatment Action 
Campaign and others),115 illustrates the binding obligation of the state to provide 
essential medication as a right to health and life. At the time this case was 
decided in 2001, HIV/AIDS was a national epidemic in the country, with a high 
prevalence rate for women, particularly among pregnant women in rural 
areas.116 Approximately 70,000 children were infected through mother-to-child-
transmission (MTCT).117 The WHO reports that about 1,600 infants were 
exposed to the infection through birth every day, while others contracted the 
virus through pregnancy or breastfeeding, with many more children at risk.118 
AZT or nevirapine were considered significant in reducing chances of MTCT.119 
It is against this backdrop that some civil society groups and national health 
advocacy NGO’s challenged the decision of the South African government to 
                                                                                                                                                                          
plaintiff challenged the refusal on the grounds that it violates her rights to life and health respectively. The Constitutional court 
relied on the importance of upholding the constitutional provision on the right to life to rule that the rule on compulsory 
administration of such drugs in the hospital permits such an exception. The court linked the right to life with the right to health in 
its decision. Significantly, this case also illustrates the importance of having access to medicines as a constituent of human right. As 
interpreted and cited in Hogerzeil, Samson and Casanova (n 108) 25-26. 
114 (2001) High Court of South Africa, Transvaal Provincial Div., 12 December 2001 CASE NO: 21182/2001. Available at 
<http://www.tac.org.za/.> accessed 16 July 2016. In this case, the court decided in favour of the plaintiffs and stated that the 
restriction which affected the availability and accessibility of essential medicines for women and children violates the 
Constitutional human right provisions and constituted an ‘unjustifiable barrier to progressive realization of the right to health 
care.’ 
115 [2002] Constitutional Court of South Africa (CCT) 8/02, available at <http://www.tac.org.za/> accessed 15 July 2015.  
116 James R Hargreaves and others, ‘Explaining Continued High HIV Prevalence in South Africa: Socioeconomic Factors, HIV 
Incidence and Sexual Behaviour Change Among a Rural Cohort, 2001–2004’ (2007) 21 AIDS (suppl 7) S39, S39, S43, S46; AVERT, 
‘HIV and AIDS in South Africa’ available at <http://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/south-
africa> accessed 16 July 2015. 
A high incidence rate of an estimated twenty-four point eight percent was recorded among pregnant women attending antenatal 
clinics in 2001. Eyitope O Ogunbodede, ‘HIV/AIDS Situation in Africa’ (2004) 54 International Dental Journal 352, 354. 
117 Minister of Health v Treatment Action Campaign (n 115) paragraph 19. 
118 World Health Organization, ‘Mother-to-Child Transmission of HIV’ (June 26, 2006). <http://www.who.int> accessed 16 May 
2015.  
119 ibid 
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restrict the procurement and use of nevirapine,120 an effective drug for the 
prevention of mother-to-child HIV transmission, to specific pilot sites, through its 
Protocol Programme.121  
Most vocal in this case was an NGO, the Treatment Action Campaign (TAC), an 
HIV/AIDS campaign, lobbyist and advocacy group. The group and its allies 
claimed that the restriction by the South African government was a fundamental 
violation of women and children’s constitutional rights to health and equal 
access to medicines as guaranteed in section 27(1)(a)122 and 28(1)123 of the 
South African Bill of Rights,124 as well as the right to life and human dignity.125 
Furthermore, the absence of a programme to promote the use of the drug was a 
breach of its constitutional duty under section 27(2), and its international binding 
human rights obligations.126 The central argument was that the government’s 
programme affected the rights of mothers and their babies who cannot afford to 
access the private healthcare, research and training sites, hence it restricts their 
access to the medicine.127 The Ministry of Health counter-argued that the 
preventive efficacy and safety of the drug has not been conclusively proved, 
                                                          
120 Boehringer Ingelheim offered to supply the drug free of charge for five years but the offer was turned down by the 
government. 
121 The Protocol for Providing a Comprehensive Package of Care for the Prevention of Mother to Child Transmission of HIV in South 
Africa imposes restrictions on the availability of nevirapine in the public health sector to pilot sites in each of the Provinces. For 
more discussion and analyses of the case and role of the NGO’s, see Duncan Matthews, Intellectual Property, Human Rights and 
Development: The Role of NGOS and Social Movements (Edward Elgar 2011) 95-112. 
122 Section 27 provides that  
Everyone has the right to have access to – 
(a) health care services, including reproductive health care;  
(b) sufficient food and water; and  
(c) social security, including, if they are unable to support themselves and their dependents, appropriate social 
assistance.  
(2) The state must take reasonable legislative and other measures, within its available resources, to achieve the 
progressive realisation of each of these rights. 
123 Section 28(1) reads:  
Every child has the right – […]  
(c) to basic nutrition, shelter, basic health care services and social services 
124 Chapter Two of the Constitution of South Africa contains the Bill of Rights, a human rights charter that protects the civil, 
political and socio-economic rights of all people in South Africa. 
125 Minister of Health v Treatment Action Campaign (n 115) paragraph 44.  
126 ibid 
127 ibid paragraph 17. 
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and the state did not have sufficient resources to provide the relevant 
counselling and monitoring facilities and trained personnel to administer the 
treatment programme.128  
The court after a careful consideration of both arguments held that nevirapine 
was an efficacious drug that could significantly combat MTCT of HIV and the 
restrictive programme failed to take into account the need to provide access to 
the necessary health services to mothers and children who do not have access 
to the sites ‘particularly for those who cannot afford to pay for medical 
services.’129 The court held that, for children, the primary burden on the state to 
provide this access is irrespective of parental or family care.130 The court 
concluded that the cost of providing access to the drug was within the resources 
of the state and ‘it was not reasonable to restrict the use of nevirapine to the 
research and training sites.’131 The court therefore ordered the government and 
health authorities to progressively make the medicines accessible in all public 
health facilities and set up a programme to promote the use of nevirapine.132  
This South African case significantly establishes the conceptual and remedial 
framework for the provision and enforcement of the right to access medicine as 
a right to health. It points to the need to consider access to essential medicines 
within the broader context of the state’s obligation to respect and promote 
human rights. The court took the time to consider the legal obligation of the 
state to enforce socio-economic rights and stressed that the state is under a 
constitutional duty to take all necessary and reasonable actions to comply with 
the provision of the right to health. In this regard, the court decided that, while it 
                                                          
128 ibid paragraphs 48-57, 65. 
129 ibid paragraph 57, 60 and 67.  
130 ibid paragraph 79.  
131 ibid paragraph 71 and 95. (The court made orders for extensive access to nevirapine necessary to prevent MCT transmission of 
HIV in the pilot sites of all the health centres in the country.) 
132 ibid paragraph 135. 
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is practically impossible to give everyone access to a ‘care service immediately’ 
(according to the minimum core obligation), the state is under a duty to 
reasonably provide access to socio-economic rights on a progressive basis.133 
Although the delineation of this reasonable standard was not clearly defined by 
the court, it stated that that government is required to undertake all reasonable 
measures to eliminate or reduce the condition and ‘large areas of severe 
deprivation that afflict our society.’134 Notably the Court relied on international 
treaties (ICECSR) to interpret the state’s obligation to adopt ‘reasonable 
measures’ to implement the right to health.135  
All the aforementioned cases have one thing in common: the recognition that 
access to essential life-saving medicines is an important aspect of human 
rights, particularly life and health. Understanding the interpretation of access to 
medicines as a constituent of human rights leads to thinking about its centrality 
in the guarantee of all human rights. Since access to medicines as a human 
right is dependent on several factors, including affordability, availability and an 
efficient healthcare system, it is argued that the Nigerian government for 
example, has a duty to take proactive positive steps to strengthen its healthcare 
systems, prevent interference with the right to access medicines and generally 
fulfil the obligation to provide affordable, safe and timely access to treatments 
for the practical enjoyment of human rights. 
                                                          
133 ibid paragraph 35. 
134 ibid paragraph 36.  
The court considered the argument of the defendants as to whether section 27(1) (a) conferred a right to health care that was 
different from the content of the obligation of the state in section 27(2) and found that the two sections cannot be separately 
interpreted, accordingly, ‘section 27(1) of the Constitution does not give rise to a self-standing and independent positive right 
enforceable irrespective of the considerations mentioned in section 27(2).’ The court further concludes that  
Sections 27(1) and 27(2) must be read together as defining the scope of the positive rights that everyone has and 
the corresponding obligations on the state to “respect, protect, promote and fulfil” such rights. The rights 
conferred by sections 26(1) and 27(1) are to have “access” to the services that the state is obliged to provide in 
terms of sections 26(2) and 27(2). 
paragraph 39 ibid. 
135 ibid paragraph 26. (The court considered the minimum obligation of states in the General Comment No. 3: The Nature of States 
Parties' Obligations (Art. 2, Paragraph. 1, of the Covenant.)) 
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4.4.1 Linking Access to Medicines and the Human Right to Life 
As well as being quintessential to the right to health, accessibility to medicines 
is also an integral component of the right to life.136 As mentioned earlier,137 the 
right to health, is also interlinked with all human rights including the rights to life, 
development, social justice and human dignity.138 Access to medicines as a 
right to health is also paramount to the enjoyment of other basic human rights 
such as liberty, freedom, etc., since health is indispensable to living a 
meaningful and fulfilling life in dignity.139 Without access to essential life-saving 
medicines, the right to health, and indeed life, can be compromised.  
The right to life as a non-derogable right is enshrined in Articles 6 and 4 of the 
International Covenant on Civil and Political Rights (ICCPR).140 It is described 
as the ‘most basic, the most fundamental, the most primordial and supreme 
rights which human beings are entitled to have and without which the protection 
of all other human rights becomes either meaningless or less effective.’141 F 
Menghistu identifies two aspects of the deprivation of the human right to life as 
(a) execution, murder, torture and (b) ‘lack of fulfilment of basic needs such as 
                                                          
136 Lee (n 93) 122, 132.  
137 In subsection 4.1 of this chapter. 
138 Carmel Shalev, 'Rights to Sexual and Reproductive Health: The ICPD and the Convention on the Elimination of All Forms of 
Discrimination Against Women' (2000) 4(2) Health and Human Rights 38, 42. 
139 CECSR, General Comment No. 14, paragraph 1; Lee (n 93) 135.  
The Nigerian Constitution in Sections 33(1), 34 and 35 explicitly recognises the right of everyone to life, human dignity and liberty 
respectively. 
140 Article 6(1) states: 
 Every human being has the inherent right to life. This right shall be protected by law. No one shall be arbitrarily 
deprived of his life. 
UN General Assembly, International Covenant on Civil and Political Rights (Adopted 16 December 1966, United Nations, Treaty 
Series, volume 999, 171) 
 Article 3 of the UDHR also states that  
 Everyone has the right to life, liberty and security of person.  
The right to life is also enshrined in numerous regional human rights instruments such as: Article 4 of the African Charter; Article 2 
of the European Convention on Human Rights (ECHR); and Article 4 of the American Convention on Human Rights (ACHR). The 
right to life is also non-derogable under Article 4 of the ICCPR and Article 15 of the ECHR. 
141 F Menghistu, 'The Satisfaction of Survival Requirements' in Bertrand Ramcharan (ed), The Right to Life in International Law 
(Martinus Nijhoff 1985) 63. 
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food, basic health facilities and medical care’.142 Accordingly, the right to life is 
narrowly construed to include direct actions that cause death, and also broadly 
understood to include other aspects of human preservation that are necessary 
for nourishment, existence and human survival.143  
In the same vein, the Human Rights Committee, writing on Article 6 of ICCPR, 
states that 
[…] the right to life has often been narrowly interpreted. The expression “inherent 
right to life” cannot properly be understood in a restrictive manner, and the 
protection of this right requires that States adopt positive measures. In this 
connection, the Committee considers it would be desirable for States parties to 
take all possible measures to reduce infant mortality and to increase life 
expectancy, especially in adopting measures to eliminate malnutrition and 
epidemics.144  
Thus, the right to life imposes a duty on states to refrain from unlawfully or 
intentionally taking life, and also, a positive obligation to undertake appropriate 
actions to safeguard the right to life, which includes the provision of ‘adequate 
and appropriate’ healthcare facilities and treatments.145  
In Tavares v France, the European Commission on Human Rights (ECHR) 
reiterated this broad interpretation of right to life.146 In that case, the 
complainant instituted the action on behalf of a woman who died in childbirth, 
alleging that the death was a violation of the deceased’s right to life as 
contained in Article 2 of the European Convention (EC) on human rights. The 
case was subsequently dismissed on a legal technicality; however the court 
found that the right to life under the EC includes a duty on the state to take all 
                                                          
142 ibid  
143 ibid 66-67. 
144 UN Human Rights Committee (HRC), CCPR General Comment No.6: Article 6 (Right to Life), 1982. 
145 Menghistu (n 141) 67.  
146 Tavares v France [1991] Application No. 16593/90 European Commission of Human Rights.  
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necessary steps in preventing unintentional loss of life. By application of this 
judicial reasoning, it can be said that guaranteeing the right to life includes the 
duty to provide health-related goods, services and facilities including drugs that 
will prevent the unintentional deprivation of life.147 This extensive understanding 
of the right to life to ‘include necessary measures to protect and preserve the 
right to life’ was reaffirmed by the Inter-American Court of Human Rights in 
Villagran Morales v Guatemala.148 The court clarified that the right to life also 
includes a right that a person ‘[…] will not be prevented from having access to 
the conditions that guarantee a dignified existence.’149  
These judicial cases accentuate the interrelatedness, interconnectivity and 
indivisibility of the rights to life and right to health and the role of healthcare 
facilities, services, and goods including medicines in fulfilling the practical 
application of these rights.150 As the human rights scholar Lee also argues, 
access to essential medicines fundamentally constitutes a part of the minimum 
conditions necessary for survival and is thus a part of the right to life.151 
Following this line of argument, this thesis argues that Nigeria has a positive 
duty to ensure women’s equal access to medicines as a necessary condition 
and requirement of the right to life. This also entails a consideration of the ways 
which patents can interfere with this access to medicines. For without access to 
medicines, the rights to health, life and improving the quality of standards of 
living in Nigeria remains an illusion and a mere aspirational provision. A more 
                                                          
147 Ebenezer Durojaiye, 'Children and Adolescents Access to Reproductive and Sexual Healthcare' in Irehobhude O Iyioha and 
Remigius N Nwabueze (eds), Comparative Health Law and Policy: Critical Perspectives on Nigerian and Global Health Law (Ashgate 
Publishing Ltd 2015) 161.  
148 Villagran-Morales et al. v Guatemala (Street Children Case) [1999] Inter-American Court of Human Rights (IACrtHR), Joint 
Concurring Opinion of Judges in Paragraph 139. Also available at http://www.corteidh.or.cr/ 
docs/casos/articulos/seriec_63_ing.pdf, last accessed 11 April 2014.  
In this case, the Court was called upon to determine the kidnapping, torture and unlawful killing of Villagran and four others 
including minors by the Guatemalan National Police.  
149 ibid paragraph 144.  
150 Durojaiye, 'Children and Adolescents Access to Reproductive and Sexual Healthcare' (n 147) 161. 
151 Lee (n 93) 134. 
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detailed analysis of the duties of Nigeria and other human rights signatory 
states to the human right to access medicines, particularly in the context of 
patent law is further considered. 
4.5 The Obligation on States to Protect, Fulfil and Promote Human Rights 
to Health and Access to Medicines  
The right to health and medicines like other human rights imposes certain 
enforceable responsibilities on states. These obligations range from taking 
steps to facilitate the various means that will satisfy the right to health (active 
duty) and also refraining from interfering or violating the right to health (passive 
duty).152 Asbjørn Eide, the former Special Rapporteur to the UN Sub-
commission identified three levels of obligations: to respect, protect and fulfil.153 
In reiterating these obligations, the CECSR further clarified that ‘such steps 
must be deliberate, concrete and targeted towards the realisation of the right to 
health.’154  
The duties of states include: 
Respect: The obligation to respect human rights to health places a binding 
responsibility on all governments and its organs and duty bearers to desist from 
interfering directly or indirectly with the socio-cultural and economic rights of all 
citizens, including the right to access medicines and safe healthy conditions.155 
This obligation extends to the duty to refrain from entrenching any 
discriminatory, prejudicial and health practices that affect women’s health and 
                                                          
152 Ida Elisabeth Koch, 'Dichotomies, Trichotomies or Waves of Duties?' (2005) 5 Human Rights Law Review 81, 85. 
153 This is also contained in the CESCR, General Comment No. 14 Paragraph 33. States obligation towards human rights was earlier 
introduced by Henry Shua who wrote about the duty of states to ‘avoid depriving’, ‘to protect from deprivation’ and ‘to aid the 
deprived.’ Henry Shue, Basic Rights (2nd edn, Princeton University Press 1996) 52.  
See more cases and discussions of instances where the court has held states and their authorities accountable to the right to 
health and life at Hogerzeil, Samson and Casanova (n 102) 5-42.  
154 CECSR, General Comment No. 14, paragraph 2. 
155 Ida Elisabeth Koch, 'Dichotomies, Trichotomies or Waves of Duties?' (n 152) 81, 82; Hoferzeil, Samson and Casanova (n 102) 10-
11. 
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limit or deny them access to medicines.156 In particular, this would require 
Nigeria to abstain from limiting women’s right to reproductive, sexual and 
contraceptive health products and health-related information.157 Likewise, there 
is an additional duty to guarantee this right in a non-discriminatory and equal 
manner for women.158  
The state is also mandated to address the cultural impediments, social, 
infrastructural, economic and other challenges to women’s access to healthcare 
services, drugs and facilities. Article 3 of CEDAW for example, specifically 
prohibits discrimination against women in political, civil, economic, social and 
cultural context.159 This obligation is important because it focuses on crucial 
factors such as traditions, social norms, customs and cultural practices, 
including economic factors that impair the enjoyment of fundamental human 
rights including the right to health.160 This includes the harmful biases, practices 
and stereotypes at the root of women’s adverse health conditions such as 
Female Genital Mutilation (FGM).161 Women are therefore guaranteed a right to 
health and access to the healthcare services within the context of their social, 
cultural and economic circumstances. This way, the obligation on State Parties 
to CEDAW extends beyond the responsibility to respect, promote and fulfil the 
rights to health of women; it also implies that the provision of adequate 
healthcare systems, information, education and facilities, including medicines, is 
part of the measures and a state’s duty to eliminate discrimination and biases 
against women, on the basis of their equal rights.162 
                                                          
156 CECSR, General Comment No. 14, paragraph 34. 
157 ibid paragraph 34.  
158 ibid paragraph 34. 
159 It provides: ‘[t]o modify the social and cultural patterns of conduct of men and women, with a view to achieving the elimination 
of prejudices and customary and all other practices’ including stereotypes. Further, Article 5(a) obligates states to eliminate 
traditional and cultural practices and prejudice against women.  
160 See the Preamble to CEDAW 1979. 
161 See the discussion in subsection 3.4.1 of Chapter III. 
162 Article 10(h) and 14 (b) of CEDAW 1979.  
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It is also imperative to note that CEDAW explicitly prohibits actions by states 
and affiliated agencies that perpetuate direct and indirect discriminatory 
practices against women.163 Accordingly, countries that ratify or accede to the 
CEDAW not only commit themselves to taking measure towards ending 
women’s discrimination; they also are bound by an obligation to ensure that the 
fulfilment of the right is not impaired by national legislation or executive action or 
policy responsibility.164 Consequently, a state’s trade policies, laws and 
programmes must align with the human rights provisions to secure their 
enjoyment of the right to health. For example, this would include laws that could 
limit access to health facilities and medicines, whether directly or indirectly, 
such as patent laws. As the CESCR affirmed, it is a duty on states including 
Nigeria, to ensure that the right to health, including access to medicines, is not 
violated in a policy consideration context. This includes, for instance, the 
adoption of legislation or policies that are ‘manifestly incompatible with pre-
existing domestic or international legal obligations with regards to the right to 
health.’165 It follows that the obligation to respect the right to access medicines 
will be violated if the Nigerian state does not take into account its people’s rights 
to access medicines when signing and adopting bilateral or multilateral 
agreements and treaties such as the TRIPS Agreement.166 The CESCR 
specifically emphasises that any IP regime that encumbers and makes it difficult 
for states to comply with their core duties in relation to health as set out in the 
                                                          
163 For instance, Article 2(f) mandates the state ‘[t]o take all appropriate measures, including legislation, to modify or abolish 
existing laws, regulations, customs and practices which constitute discrimination against women.’ 
164 Article 2 (a)-(h) CEDAW 1979.  
165 CECSR, General Comment No. 14, paragraph 48. 
166 Several international organisations and human rights Committees have reported and highlighted that the IPR provisions of the 
TRIPS Agreement can have a profound effect on human rights, particularly, the right to health, life and guarantee of access to 
medicines. See for example, World Health Organization, Network for Monitoring the Impact of Globalization and TRIPS on Access 
to Medicines (Meeting Report, 19–21 February 2001 Chulalongkorn University Bangkok, Thailand 2002) 20-21; World Health 
Organization, ‘Globalization, TRIPS and Access to Pharmaceuticals’ (WHO Policy Perspectives on Medicines, No 3, 2001) (It was 
highlighted that accessing essential medicines is a human right and that patent protection, although an effective incentive for 
R&D, could likely affect accessibility, especially for the poor. The use of the TRIPS safeguards was promoted as an effective means 
for improving access.) 
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Covenant (ICESCR), is incompatible with the legally binding obligations of 
states. This understanding of the general provision of women’s right to health is 
important to the articulation in this thesis because it would require the Nigerian 
state to be aware of any health consequences in all its legislation and to ensure 
that laws or policies, agreements and treaties do not obstruct its obligation to 
guarantee and the enjoyment of the right to health.167 
Protect: To protect obligates two duties: to facilitate and enhance; and to 
prevent any obstruction to accessing healthcare facilities, services and 
medicines by third parties.168 This obligation not only requires states to protect 
and safeguard human rights to health, it mandates the state to facilitate access 
by preventing medical care providers (private and public) and third parties e.g. 
pharmaceutical companies, from violating the right to health.169 In Nigeria, this 
duty obliges the state to ensure that the rights granted to third parties,170 or 
private service providers in the provision of healthcare, do not interfere with the 
availability, acceptability and accessibility of high quality, affordable healthcare 
systems, services and medicinal resources.171 
                                                          
167 CEDAW 1979, Article 2. The World Health Assembly also established a body in 2003 to study and report on the effect of IPRs on 
public health. See one of the body’s reports on the role that IP plays in determining access to medicines in Commission on 
Intellectual Property Rights, Innovation and Public Health, Public Health ‘Innovation and Intellectual Property Rights (Commission 
on Intellectual Property Rights, Innovation and Public Health, Public Health 2006).  
The UN General Assembly has also discussed and reported on this issue in The Right of Everyone to the Enjoyment of the Highest 
Attainable Standard of Physical and Mental Health, (GA Res 58/173 UN Doc A/RES/58/173 (22 December 2003); Access to 
Medication in the Context of Pandemics such as HIV/AIDS, Tuberculosis and Malaria (GA Res, UN Doc A/RES/58/179, 22 December 
2003). (Recalling the importance of the Doha Declaration and World Trade Organization General Council decision of 30 August 
2003 on the implementation of Paragraph 6 of the Declaration in facilitating access to medicines). The United Nations High 
Commissioner for Human Rights also flagged this issue. See Access to Medication in the Context of Pandemics such as HIV/AIDS, 
Commission on Human Rights (Res 2001/33 23 April 2001) paragraph 3b; Access to Medication in the Context of Pandemics such as 
HIV/AIDS, Commission on Human Rights (Res 2002/32, 22 April 2002) paragraphs 7 and 8; UN Commission on Human Rights, 
Commission on Human Rights Resolution 2003/29: Access to Medication in the Context of Pandemics Such as HIV/AIDS, 
Tuberculosis and Malaria (Res 2003/29 22 April 2003) paragraph 5b; UN Commission on Human Rights, Commission on Human 
Rights Resolution 2004/26: Access to medication in the context of pandemics such as HIV/AIDS, tuberculosis and malaria, (Res 
2004/26 16 April 2004) paragraphs 6, 7, 11. (All these documents and resolutions exhort a duty on states to ensure that their 
actions with regards to their obligations to international organizations takes into account the right to health. states are also urged 
to safeguard access to medicines and ensure that the implementation of international agreements is supportive of public health 
policies to improve access to essential pharmaceuticals)  
168 Koch, 'Dichotomies, Trichotomies or Waves of Duties?’ (n 152) 88-89. 
169 Paul Hunt and others, Neglected Diseases: A Human Rights Analysis (World Health Organization 2007) 12; Koch ibid 82. 
170 CESCR, General Comment No. 14, paragraph 35. 
171 CESCR, General Comment No. 14, paragraph 42. 
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The significance of this obligation is relevant to the consideration of access to 
medicines in this thesis. As the CESCR expatiates, states are to ‘control the 
marketing of medical equipment and medicines by third parties’ and ensure that 
privatisation of the health sector does not threaten the right to health, provision 
of healthcare and access to medicines.172 The UN Norms for Corporations and 
Businesses further indicates that states have a general duty to ensure that 
corporations and business enterprises respect and promote human rights.173 
Likewise, State parties are required to prevent violations of women’s rights, 
including the right to health, by third parties, organisations and enterprises 
operating within the rights granted by states.174 It can, therefore, be argued that 
this responsibility places a duty on the Nigerian state to ensure that national 
patent legislation and patent rights granted to inventors do not constitute a 
hindrance to the availability and affordability of essential medicines, an 
important component of the right to health. Bearing this in mind, it is argued that 
this duty on states can be achieved by preventing pharmaceutical companies 
from introducing high prices for medicines, unreasonably restricting competition 
and follow – on R&D, thus limiting access, or by ensuring that the prices of 
patented medicines are at least affordable to the poor. In addition to other 
measures such as price control, the TRIPS flexibilities can be instrumental in 
this regard. 
Fulfil: Under this duty, the government is obligated to take appropriate 
legislative, regulatory, budgetary, administrative, judicial, and other necessary 
                                                          
172 CESCR, General Comment No. 14, paragraph 35. 
173 United Nations Sub-Commission Norms on Business and Human Rights, Norms on the Responsibilities of Transnational 
Corporations and Other Business Enterprises with Regard to Human Rights (U.N. Doc. E/CN.4/Sub.2/2003/12/Rev.2 2003) 
Preamble and paragraph 1. 
174 Article 2, CEDAW 1979.  
Article 2(e) reads:  
[t]o take all appropriate measures to eliminate discrimination against women by any person, organization or 
enterprise. 
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measures to progressively fulfil and ensure access to medicines and healthcare 
facilities for the realisation of the right to health.175 These measures are 
designed to guarantee the availability of, and equal access to, health facilities, 
healthy conditions and products for everyone.176 Specifically, signatories to the 
ICESCR are obliged to create the necessary conditions for health by providing 
‘equal and timely access to basic preventive, curative, rehabilitative health 
services […] and appropriate treatment of prevalent diseases, illnesses, injuries 
and disabilities, […] [including] the provision of essential drugs; and appropriate 
mental health treatment and care.’177 states, including Nigeria, are therefore 
required to ensure that the appropriate legislative and policy actions comply 
with the basic objectives of women’s right to health in line with the obligation.178 
While Nigeria can be constrained from providing the necessary healthcare 
system due to limited resources, there is still a responsibility on the government 
to use the available resources progressively to give the fullest attainable 
expression to the realisation of the rights to the highest standard of health and 
living for women and indeed, everyone in Nigeria.179  
 
 
                                                          
175 Article 2.1 of the ICECSR; Mary Dowell-Jones, Contextualising the International Covenant on Economic, Social and Cultural 
Rights: Assessing the Economic Deficit (Martinus Nijhoff Publishers 2004) 31-32; John Tobin, The Right to Health in International 
Law (OUP 2012) 194-195; Asbjorn Eide, ‘Economic, Social and Cultural Rights as Human Rights’ in Richard Pierre Claude and Burns 
H Weston (eds), Human Rights in the World Community: Issues and Action (University of Pennsylvania Press 2006)174-176. 
The Masstricht Guidelines in Guideline 6 also adopt a similar interpretation: [t]he obligation to fulfil requires States to take 
appropriate legislative, administrative, budgetary, judicial and other measures towards the full realization of such rights. Thus, the 
failure of States to provide essential primary health care to those in need may amount to a violation.’ Masstricht Guidelines on 
Violations of Economic, Social and Cultural Rights (January 22-26 1997)  
176 It is within this context that the CECSR expatiates that:  
The obligation to fulfil requires States parties, inter alia, to give sufficient recognition to the right to health in the 
national political and legal systems, preferably by way of legislative implementation, and to adopt a national 
health policy with a detailed plan for realizing the right to health. 
For this purpose also,  
States must ensure provision of health care […]. 
CECSR, General Comment No 14, paragraph 36. The framework of the legislation necessary for implementing the right to health at 
the national level is contained in paragraphs 53-16 of General Comment No. 14. 
177 CECSR, General Comment No. 14, paragraph 17. 
178 See generally CEDAW, General Recommendation No.24, paragraphs 13 -17. 
179 Sofia Gruskin, ‘Human Rights and Public Health: An Overview’ (1999) Canadian HIV/AIDS Newsletter available at 
<http://hivinsite.ucsf.edu/InSite?page=kb-08-01-07> accessed 9 March 2016. 
216 
 
4.6 Is there a Duty on Pharmaceutical Companies in Relation to the Rights 
to Health and Access to Medicines? 
While it is the duty of states to adopt all reasonable measures to realise the 
right to health, including the prevention of third parties from interfering with the 
right, a question that is receiving increasing attention is whether third persons or 
non-state actors and corporations have a duty towards the rights to health and 
access to medicines? Another question in this respect is whether states, as 
principal duty bearers, can compel third parties or corporations to protect and 
promote the right to health and enhance access to medicines. 
Within the specific sphere of pharmaceutical companies’ activities and 
influence, it has been suggested that they are obligated to respect and 
contribute to promoting human rights including the right to health.180 
Accordingly, within the scope of their business operations, business enterprises 
and corporations, and medical healthcare providers should respect, protect, 
fulfil and support the human rights of everyone.181 In this manner, the UN 
Norms for corporations in 2003 recognised the responsibilities of corporations 
and business enterprises to respect, promote and secure human rights 
including the right to health.182 The UN Norms make provisions covering a wide 
range of areas for corporations and businesses with regard to their human 
rights responsibilities in the exercise of their activities and influence.183 
Specifically concerning health, the UN Norms emphasise that transnational 
corporations and business enterprises should respect and contribute to the 
                                                          
180 Lee and Hunt (n 83) 231, 227.  
181 Jernej Letnar Cernic, 'Corporate Obligations under the Right to a Healthy Living Environment’ (2012) 3 Danube Law and 
Economics Review 21, 22, 31-34. 
182 United Nations Sub-Commission Norms on Business & Human Rights, Norms on the Responsibilities of Transnational 
Corporations and Other Business Enterprises with Regard to Human Rights (U.N. Doc. E/CN.4/Sub.2/2003/12/Rev.2, 2003) 
preamble and paragraph 1.  
183 Accordingly, ‘within their respective spheres of activity and influence, transnational corporations and other business 
enterprises have the obligation to promote, secure the fulfilment of, respect, ensure respect of and protect human rights 
recognized in international as well as national law, including the rights and interests of indigenous peoples and other vulnerable 
groups.’ ibid paragraph A(1).  
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realisation of the ‘highest standard of physical and mental health’ and also 
refrain from any action which limits or obstructs the realisation of the right.184  
In more recent times, the human rights responsibilities of third parties and 
corporations such as pharmaceutical companies have heightened. In 2011, the 
UN Human Rights Council adopted the human rights Guiding Principles for 
Businesses and Transnational Corporations on the Report of the Special 
Representative of the Secretary-General, John Ruggie. The Ruggie Report 
presented the Guiding Principles to clarify and differentiate the human rights 
responsibilities of states, business enterprises and transnational 
corporations.185 The ‘Protect, Respect and Remedy’ Framework centred on 
three core principles: (a) States’ existing obligations to respect, protect and fulfil 
human rights and fundamental freedoms; (b) the role of business enterprises as 
specialised organs of society performing specialised functions, required to 
comply with all applicable laws and to respect human rights; and (c) the need 
for rights and obligations to be matched to appropriate and effective remedies 
when breached.186 Significantly, the Guiding Principles reaffirmed the primary 
duty of states to protect human rights, provide effective remedies for abuses 
and also prevent third persons and non-state actors from abusing or impeding 
human rights. The guidelines add that business corporations and companies 
also have a duty to human rights.187 In the Guidelines, the corporate 
                                                          
184 ibid paragraph E(12).  
185 John Ruggie, Guiding Principles on Business and Human Rights: Implementing the United Nations “Protect, Respect And 
Remedy” Framework Report of the Special Representative of the Secretary General on the Issue of Human Rights and Transnational 
Corporations and other Business Enterprises (A/HRC/17/31, 2011) available at  
<http://www.ohchr.org/EN/Issues/TransnationalCorporations/Pages/Reports.aspx> accessed 14 July 2014. The Report is a result 
of consultations with many stakeholders including a review of several industrial sectors and practices.  
186 Suerie Moon, 'Respecting the Right to Access to Medicines: Implications of the UN Guiding Principles on Business and Human 
Rights for the Pharmaceutical Industry' (2013) 15(1) Health and Human rights 32; John Ruggie, Protect, Respect And Remedy: A 
Framework for Business and Human Rights’ Report of the Special Representative of the Secretary-General on the Issue of Human 
Rights and Transnational Corporations and other Business Enterprises (A/HRC/8/5, 2008). (Hereinafter known as the Ruggie 
Report). 
187 Ruggie Report ibid  
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responsibilities of businesses centre on the duty to respect human rights.188 
Ruggie expounds that the duty ‘[t]o respect rights essentially means not to 
infringe on the rights of others — put simply, to do no harm.’189 The UN Guiding 
Principle on Businesses and Human Rights also reaffirms that businesses and 
corporations are mandated to ‘respect human rights which mean they should 
avoid infringing on the human rights of others and should address adverse 
human rights impacts with which they are involved.’190 This duty exists 
irrespective of the state’s ability and willingness to fulfil its own human rights 
responsibility.191 What does this right to health duty of corporations imply for the 
pharmaceutical industry?  
This duty to respect — ‘does no harm to’ — human rights is relevant to the 
discussion on the duties of pharmaceutical companies towards access to 
medicines as a central component of human rights. This obligation to respect 
the right to medicines as an aspect of health, suggests that pharmaceutical 
companies are obligated to refrain from doing anything that will interfere with 
the enjoyment of the right to health, including access to life-saving drugs.192 In 
this regard, the UN’s Interpretive Guide on ‘The Corporate Responsibility to 
Respect Human Rights’ emphasises that ‘[f]or pharmaceutical companies, the 
right to health will be particularly salient.’193 For this purpose, it entails the 
responsibility to avoid and mitigate any adverse human rights impact that their 
business activities may cause or contribute to, and is linked to their operations, 
                                                          
188 Ruggie Report ibid paragraph 51-81. 
189 Ruggie Report ibid paragraph 21. 
190 United Nations, Guiding Principles on Business and Human Rights: Implementing the United Nations “Protect, Respect and 
Remedy” Framework (HR/PUB/11/04, United Nations 2011) 14.  
191 ibid 14.  
192 Cernic (n 181) 31-33. 
193 United Nations, The Corporate Responsibility to Respect Human Rights: An Interpretive Guide (HR/PUB/12/02, United Nations 
2012) 28. 
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products (including medicines) or services.194 Because access to medicines is 
one of the means to the realisation of the right to health, this duty implies that 
pharmaceutical corporations should ensure that their corporate activity does not 
violate or impair the realisation of the human right to health.  
In respect to the availability of, and accessibility of affordable medicines, it can 
be argued that pharmaceutical companies and their activities could positively 
and negatively impact access to medicines and the right to health.195 
Negatively, the monopoly and marketing practices of patent holding 
pharmaceutical companies can impact on accessing medicines.196 Hence the 
obligation on states to ensure that the right granted to pharmaceutical 
companies as patent holders does not interfere with the right to access 
medicines. Positively however, pharmaceutical companies can support the state 
to fulfil, respect and protect the right to health by providing the means for the 
realisation of the right to health.197 Through their pharmaceutical R&D and 
production undertakings, the drugs they produce can facilitate the availability of 
drugs for the realisation of the right to health. It is further argued, however, that 
their contribution to the human right to health goes beyond providing the 
                                                          
194 United Nations, Guiding Principles on Business and Human Rights: Implementing the United Nations “Protect, Respect and 
Remedy” Framework Guiding Principles on Business and Human Rights (n 46) 14-15. 
195 Paul Hunt, Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines’ (Annex) paragraph i. 
(Published in Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of 
Physical and Mental Health (A/63/263, 11 August 2008) 15. Also available at  
<http://www.who.int/medicines/areas/human_rights/A63_263.pdf> accessed 16 August 2015. 
196 See the discussion in subsection 3.7.1 of Chapter III. Paul Hunt, the first Special Rapporteur on the right to health, for instance, 
noted that the practices (pricing, research priority, marketing etc.) and policies of the pharmaceutical industry could hinder the 
state’s obligation to implement and fulfil the right to the highest standard of health. UN Human Rights Council, Report of the 
Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, 
Paul Hunt, annex: Mission to GlaxoSmithKline, (A/HRC/11/12/Add.2, 18 May 2009) paragraphs 4, 24. Also available at  
<http://www.who.int/medicines/areas/human_rights/A_HRC_11_12_Add_2.pdf> accessed 17 August 2015. 
197 Geralyn S Ritter, 'Are Drug Companies Living Up to their Human Rights Responsibilities? The Merck Perspective' (2010) 7 PLoS 
Med, 1. Analysing the special responsibility of pharmaceutical companies to the right to health, Hunt notes: 
Whether characterised as contract, licence or trust, the company holds the patent on express and implied terms. 
Society has legitimate expectations of a company holding the patent on a life-saving medicine. In relation to such 
a patent, the right-to-health framework helps to clarify what these terms, and expectations, are. Because of its 
critical social function, a patent on a life-saving medicine places important right-to-health responsibilities on the 
patent holder. These responsibilities are reinforced when the patented life-saving medicine benefited from 
research and development undertaken in publicly funded laboratories. 
ibid paragraph 36. 
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facilities and goods (medicines) necessary for the enjoyment of this right. This 
responsibility extends to refraining from any act or policy that will obstruct 
access to affordable and available medicines, given that their business and 
marketing practices could limit this access as discussed in Chapter III.198 
Whether they actually owe this responsibility as an enforceable legal duty and 
how to measure the responsibility of pharmaceutical companies in this regard 
may vary considerably, depending on where they operate and whether national 
laws imposes this duty on them. The UN Guidelines and reports are 
authoritative standards guiding the responsibilities of pharmaceutical companies 
and interested parties to human rights and are not binding on them. However, 
since states have the primary duty to enhance access to medicines through 
every necessary means, they could compel a binding legal duty to respect and 
remedy human rights on pharmaceutical companies and patent holders who are 
domiciled or registered within the territory of their states.199  
From an international human rights perspective, scholars have also argued that 
pharmaceutical companies indeed owe a duty to the right to health and access 
to medicines. Within the context of patent rights and access to drugs, scholars 
and experts have analysed the corporate responsibilities of pharmaceutical 
companies to the right to health.200 Lee and Hunt for example, argue that 
pharmaceutical companies may have certain additional ‘public function’ 
responsibilities beyond the duty to simply respect human rights.201 In view of 
                                                          
198 See subsection 3.7.1. 
199 The significant shared responsibility of pharmaceutical companies towards the right to access medicines recognised in the 
Millennium Development Goals (MDGs). The MDG goal 8.E is a target to provide access to affordable essential drugs in developing 
countries, in collaboration with pharmaceutical companies. 'Official Millennium Indicators' (Mdgs.un.org)  
<http://mdgs.un.org/unsd/mdg/Host.aspx?Content=Indicators/OfficialList.htm> accessed 11 August 2016. 
200 See for example, Lee and Hunt (n 83). (The authors argued that human rights can shape and influence the policies of 
pharmaceutical companies. Also, human rights provide a framework to hold pharmaceutical companies liable for human rights.) 
See also, Lisa Forman and Jillian Clare Kohler, Access to Medicines as a Human Right: Implications for Pharmaceutical Industry 
Responsibility (University of Toronto Press 2012). 
201 Lee and Hunt (n 83) 225. The argument mirrors Paul Hunt’s Report on the right to health framework of pharmaceutical 
companies, and the human rights guidelines for pharmaceutical companies. See Paul Hunt, Human Rights Guidelines for 
221 
 
pharmaceutical companies’ right-to-health obligations, Lee and Hunt argue that 
pharmaceutical companies should take reasonable actions to ensure that 
medicines are sufficiently available in countries where they are needed, 
including taking measures to address the issue of R&D of neglected 
diseases.202 They also suggest, for instance, that pharmaceutical companies 
‘should either provide in-house research and development for neglected 
diseases, or support external research and development for such diseases.’203  
In closing, the foregoing discussion argues that states (Nigeria) have an 
obligation to facilitate and make available affordably, safe and good quality 
medicines, in an acceptable manner. Pharmaceutical companies and patent 
owners can have a human right to health responsibility within the sphere of their 
business operations. This responsibility would pertain to the pricing of their 
drugs, testing and clinical trials, R&D, provision of safe and good quality 
medicines and the duty to ensure that their practices do not constitute an 
obstacle, especially to women’s enjoyment of human rights, and their right to 
medicines. Notwithstanding the obligations of pharmaceutical companies to the 
right to access medicines, states are ultimately the duty bearers accountable for 
the guarantees, and prevention of the violations of the rights to access 
medicines. It is their duty to monitor and also ensure that pharmaceutical firms 
do not impede the enjoyment of the right to health. Hence, if women’s access to 
                                                                                                                                                                          
Pharmaceutical Companies in Relation to Access to Medicines’ (n 195). In the Guidelines, Paul Hunt stresses that the 
pharmaceutical sector, especially patent holding companies besides their responsibilities to shareholders, has a commitment to 
contribute to the promotion of access to medicines and R&D of neglected diseases. ibid paragraph 23-25. See also, UN Human 
Rights Council, Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of 
Health, Paul Hunt, Annex: Mission to GlaxoSmithKline (n 196). (Reporting that the goal of enhancing access to medicines is a 
shared responsibility and pharmaceutical companies play a huge role in meeting this responsibility. The Report emphasises that 
while it is the core duty of the State to promote access to medicines and the right to health, pharmaceutical companies can 
equally play a supporting role in the quality production, acceptability, availability, and accessibility of medicines.)  
202 Lee and Hunt (n 83) 225, 228-229. See also UN Human Rights Council, Report of the Special Rapporteur on the Right of Everyone 
to the Enjoyment of the Highest Attainable Standard of Health, Paul Hunt, Annex: Mission to GlaxoSmithKline (n 196) paragraph 
22. 
203 Lee and Hunt (n 83) 225. In addition to making drugs available, they argue further that pharmaceutical companies have a 
human rights duty to ensure that the medicines are of good quality, acceptable, accessible and affordable and in this respect, the 
prices should be reasonably affordable to as many individuals and communities as possible. ibid 225-226. 
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medicines is to be enhanced, the Nigerian state must provide medicines and 
also guarantee the sustainable availability and accessibility of drugs through 
every avenue. 
Having examined the obligations and responsibilities to women’s rights to health 
and access to medicines, the next part focuses on the relationship between 
patent rights and the right to access drugs.  
 
PART II: RE-EVALUATING THE RELATIONSHIP BETWEEN 
PATENT RIGHTS AND HUMAN RIGHTS  
 
4.7 Patent Rights and Human Rights 
While the foregoing section analysed the link between the right to health and 
access to medicines, this part essentially analyses the relationship between 
patent rights and human rights with a view to making a case for broader access 
to medicines as a right to health. From a human rights perspective, this 
segment points to the issues and conflict that arise between patent and human 
rights. It is argued that patent rights in national laws and the TRIPS Agreement 
do not exist in a socio-economic and cultural vacuum; instead, they should be 
enforced and interpreted with regards to public interest and human rights. It is 
also argued that human rights to health, as expounded in the preceding part, 
provide a significant socio-economic and cultural framework for the 
consideration of patent rights and its effect on the right to access medicines. As 
such, there is a need to consider the effect of patent rights on the right of 
access to medicines and the state’s duty in this respect, particularly for Nigeria.  
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4.7.1 Is There Interconnectivity Between Patent Right and Human Rights? 
In recent years, scholars, courts and international organisations have devoted 
increasing attention to the connectivity between human rights and IP. As 
Professor Helfer remarks, ‘[h]uman rights and intellectual property, two bodies 
of law that were once strangers, are becoming increasingly intimate 
bedfellows.’204 The question that arises in this regard for the purpose of analysis 
in this chapter are: what is the exact nature of the relationship between a 
proprietary patent right and human rights? Does this relationship conflict or 
mutually coexist in a way that can reinforce each other for the common good of 
society? Are patent property rights human rights? If so, how far, and subject to 
what laws and limits, can human rights be relied upon by patent right holders? 
These questions are relevant to the examination of the impact of patent rights 
provisions in the TRIPS Agreement on access to medicines as a component of 
the right to health.  
4.7.1.1 Revisiting the Issue: Is a Patent a Property Right? 
Traditionally, a patent, as analysed in the last chapter,205 is viewed as an 
intangible private property right that is granted and protected by the state in 
exchange for a disclosure of an invention.206 However, the articulation of 
patents or intellectual property rights (IPRs) generally as ‘property rights’ has 
been the subject of heated debate, with some scholars arguing that ‘the 
expression of ‘intellectual property’ is actually a misnomer and that patents are 
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just privileges that have no claim to the full dignity of ordinary property rights’207 
or indeed human rights.208 Analysts frequently point to the difference between 
the general characteristics of IP in contrast to physical tangible properties.209 
For example, a patent right protects the intangible capital and expression of the 
innovation, not the tangible medium in which it is itself expressed. On the other 
hand, rights in physical properties are conferred in the tangible property itself.210 
Secondly, the duration of a patent right is limited to the legal term granted by 
the state and, on that score, is a limited monopoly right to restrict others from 
exploiting it,211 unlike many real property rights, for example, which are 
perpetual in nature.212 Thirdly, because the right is granted by the state on 
behalf of society in exchange for a disclosure, the character of the right has an 
element of public good and the state can override a patent right in the public 
interest.213 Fourthly, a patent right is territorial in nature, hence, the property 
right is limited to the jurisdiction within which it is granted.214 
Nevertheless, sharing similar attributes to physical property, patent rights allow 
the owner to share, assign, license, use, sell, transfer and exclude others from 
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doing these things.215 Therefore, to the extent which a patent grants control 
over an invention or product of innovation, and confers exclusive rights to 
prevent others from having unlicensed access to the products, patents can be 
regarded as a form of ‘property right.’216 However, the idea that all forms of 
intellectual proprietary rights, including a patent, should be viewed as a right 
within the realm of human rights may not find support from all scholars.217 The 
nature of the relationship between patent rights and human rights – including 
the right to health and medicines, is further analysed below.  
4.7.2 Examining the Relationship between a Patent Right and Human 
Rights 
The exact relationship between patent rights and human rights is the subject of 
diverse scholarly debate. Gold summarises the current views on the relationship 
between patent and human rights thus: the ‘subjugation approach,’ the 
‘coexistence approach’ and the ‘integrated approach.’ 218  
The ‘subjugation approach’ makes the point that patents, sometimes, comes 
into conflict with human rights.219 Analysing the subjugation approach, Helfer 
observes that IPRs — patent protection — are seen to be incompatible with 
human rights, by undermining the enjoyment and realisation of a broad 
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spectrum of human rights, especially socio-economic and cultural rights.220 
Where this conflict arises, scholars argue that human rights should be given 
priority and trump patent rights.221 One commentator in arguing that human 
rights considerations should prevail over rights granted to authors and 
inventions, writes that ‘[i]ntellectual property rights should be limited when 
necessary to protect the public health and to the degree necessary to guarantee 
the general welfare.’222 As will be further discussed shortly, this thesis is more 
inclined to analysing the relationship between patent rights and access to drugs 
within this context. 
With regards to the ‘coexistence approach,’ advocates assert that patent law 
and human rights law are two distinct areas of law; although they share the 
same fundamental goal of contributing to the common good and improvement 
of human welfare.223 Principally, this school of thought argues that rather than 
viewing patents and human rights laws as conflicting, they are compatible, 
mutually supporting each other to promote innovation and access.224 In his 
description of this approach, Helfer notes that the school of thought,  
[s]ees both areas of law as concerned with the same fundamental question: 
defining the appropriate scope of private monopoly power that gives authors and 
inventors a sufficient incentive to create and innovate, while ensuring that the 
consuming public has adequate access to the fruits of their effort.225 
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Proponents of this approach point to a number of human rights provisions that 
seek to assure creators and inventors a protection of their moral and material 
interest.226 This view may be totally hard to sustain in view of the effect of a 
patent right on the right to medicines. As recalled in Chapters III,227 a patent 
right can interfere with the right to access medicines under human rights law, 
thus the question is how to strike a balance between the incentive to innovate 
on the one hand and access on the other.228  
The ‘integrated approach’ views patents and other IPRs as human rights, with 
emphasis on property rights and the individual inventor’s rights under human 
rights instruments.229 Advocates of this approach argue that the provisions of 
tangible property rights should be extended to cover IPRs by assimilating the 
rights into human rights frameworks.230  
The conceptualisation of intellectual proprietary rights as a natural human right 
was articulated after the French Revolution.231 Article 17 of the 1789 
Declaration recognised property rights as an ‘inviolable and sacred right, no one 
shall be deprived thereof, except where public necessity, legally determined, 
shall clearly demand it.’232 This articulation of property rights sought to attach a 
sense of morality, equity and fairness to the right as an inherent human 
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entitlement.233 From this proprietary rights assertion, it has been argued that all 
IP rights are sacred and inviolable human rights entitlements, as set forth in 
Articles 2 and 17 of the Declaration.234 In this view, a patent right is perceived to 
extend beyond a mere licence or privilege granted by the state; it is seen to 
possess characteristics grounded in legal, social and ethical human rights 
entitlement.235  
Proponents of patents-as-human rights also rely on the rights to property in 
regional instruments such as the American Declaration of the Rights and Duties 
of Man236 and the EU Charter of Fundamental Rights to argue for the 
recognition of IP rights as property rights.237 The argument that IPRs as 
property rights are human rights finds some support in the judicial decisions of 
the European Commission of Human Right’s (ECHR). In Anheuser Busch Inc. v 
Portugal,238 for example, one of the main issues before the ECHR was whether 
the provision of Article 1 (1) of the Protocol No. 1 of ECHR was applicable to 
IP.239 In the instant case, the applicant alleged an infringement of its right to 
peaceful enjoyment of ‘possession’ of a trade mark.240 Accordingly, its trade 
mark constitutes ‘possession’ within the meaning of Article 1 (1) of the Protocol, 
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and a deprivation of the right to the ‘possession’ of the trade mark was clearly in 
breach of its human rights. Although the ECHR ruled that there was no violation 
of the trade mark and the applicants could only have relied on this right after 
registering the trade mark, the ECHR established that the provision of Article 1 
of Protocol 1 is definitively applicable to IP as such.241 Thus a trade mark was 
held to constitute a ‘possession’ within the human rights provisions of Article 
1.242 In this connection, the ECHR noted that ‘possession’ within the meaning of 
the Article 1 (1) of Protocol No. 1 is not limited to physical properties: certain 
rights and interest constituting assets, including IP can validly come within the 
purview of that Article.243  
The ECHR came to the same judicial conclusion namely, that a patent property 
right is a human right, in the case of Smith Kline and French Laboratories Ltd v 
Netherlands.244 In deciding whether there was an interference with the patent 
right of the applicant in the case, the Commission ruled that ‘that a patent 
accordingly falls within the scope of the term "possessions" in Article 1 (1) 
Protocol No. 1 (P1-1).’245 
Interestingly, both natural and legal persons are recognised as having the right 
to this ‘possession.’ This means that pharmaceutical corporations can lay a 
claim to their ‘human rights’. Viewed from this perspective, it would seem 
justifiable that pharmaceutical firms or innovators and researchers would want 
to draw on this ‘natural human right,’ commercially to capitalise on the fruits of 
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their labour through patents. Nonetheless, the question remains, are patent 
rights human rights within the purview of international human rights law? Put in 
another way, can the interference of patents with the right to access drugs be 
justified under human rights law?  
4.7.3 Human Rights Protection of an Inventor’s Moral and Material Interest  
It appears that the arguments that patent rights are human rights might find 
some support in human rights instruments such as the UDHR and ICECSR. 
Article 27(1) of the UDHR acknowledges the right of everyone to take part in the 
‘cultural life of the community.’246 Furthermore, the right to benefit from a 
creative work as a moral and material legal entitlement is accorded recognition 
in Article 27(2) of the UDHR which provides that ‘everyone has the right to the 
protection of the moral and material interests resulting from any scientific, 
literary or artistic production of which he is the author.’ This provision 
corresponds with the linguistic articulation and objectives of Article 15(1)(c) and 
15(2) of the ICESCR, which obligates the state to recognise an author’s rights 
to ‘benefit from the protection of the material and moral interest resulting from 
any scientific, literary or artistic production.’247  
                                                          
246 Article reads:  
Everyone has the right freely to participate in the cultural life of the community, to enjoy the arts and to share in 
scientific advancement and its benefits. 
247 Article 15(1)(c) ICESCR. (Emphasis added.)  
Article 15 states: 
1. The States Parties to the present Covenant recognize the right of everyone: 
 (a) To take part in cultural life; 
 (b) To enjoy the benefits of scientific progress and its applications; 
 (c) To benefit from the protection of the moral and material interests resulting from any scientific, literary or 
artistic production of which he is the author.  
 2. The steps to be taken by the States Parties to the present Covenant to achieve the full realization of this right 
shall include those necessary for the conservation, the development and the diffusion of science and culture. 
231 
 
These provisions are commonly identified as the basis for the right to the 
protection of creators and inventor’s interests in intellectual creations.248 It can 
be said that Article 27(2) of the UDHR and Article 15(1)(c) of the ICESCR 
underscore the protection of the interests of authors (or inventors or creators, as 
the case may be) and the result of their intellectual efforts. This protection is not 
only for the broader advantage of the public to enjoy the benefit of scientific 
progress and its application in Article 15(1)(b) of the ICESCR, but also because 
the creative interests and moral rights of the inventors are recognised as worthy 
of such protection.  
These human rights provisions raise questions relevant to the present 
discussion on the relationship between patent rights and human rights to health 
and life, particularly with regards to women’s access to medicines. Can it be 
said then that a patent as a proprietary right to the intellectual interest of 
inventors is a human right within the contemplation of UDHR and ICESR?  
4.7.3.1 The Moral and Material Rights of Creators/Inventors 
From the foregoing, the wording of Articles 15(1)(c) of the ICESCR and Article 
27(2) of the UDHR expressly seek the protection of an author’s ‘moral’ and 
‘material’ interest in his or her intellectual creation. The ‘moral interest’ in an 
invention, resonates with the natural rights postulations of the property rights 
argument.249 This right recognises that a person’s ingenious labour and effort to 
scientifically, artistically or literarily create a thing is to be protected. Moral 
rights, which are more relevant to the debate for authors of literary and 
copyrighted works, recognise and protect the non-material interest arising from 
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the intimate connections of an author to his/her work. Essentially, the Articles, 
by recognising moral interests, seek to protect the intrinsic personal character of 
an invention or creation of the human mind, including the integrity of an author 
or creator’s work.250 A moral right also acknowledges the right of an inventor to 
be so named and recognised as the ‘author’ of the invention.251 
The ‘material interest’ of inventors, on the other hand, protects his or her rights 
to deal with, enjoy, transact, and commercially utilise, reap and receive 
adequate remuneration from the fruit of their inventive labour and intellectual 
creations.252 It is often the material interest of the inventor that raises a number 
of questions on the interference of the right of patent holders to earn a living 
from their inventions and its effect on the right to access medicines.  
4.7.3.2 Is a Patent Right a Human Right? 
A first reading of the human rights provisions in ICECSR and UDHR may 
suggest that they equate IPRs with other types of human rights.253 This leads 
some authors, such as Stephen Marks, to argue that they provide a human 
rights justification for patent rights, as well as other forms of human rights.254 
That is, the recognition of the inherent human rights interests of creators in their 
inventions broadly extends to patent rights. Other IP scholars are, however, 
sceptical of this approach. Schermers argues, for example, that IPRs cannot be 
rightly categorised as fundamental rights since human rights are ‘of such 
importance that their international protection includes the right, perhaps even 
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the obligation, of international enforcement.’255 Schermers’ argument is 
premised on the fact that IPRs do not command the sort of protection and 
enforcement as other types of human rights which are so imperative to humans 
that ‘no legislative organ may lawfully take these rights away from the 
citizens.’256  
This thesis shares the opinion that a patent right arising from statute law is not a 
fundamental human right within the purview of human rights laws. By its very 
nature, a patent is a statutory creation, whereas other categories of human 
rights, such as the right to health, are derived from the inherent nature, dignity 
and worth of all human beings.257 A further distinction can be drawn from the 
regulatory structure of patent rights. The state, in recognising the rights of 
patent holders under a national statute, can withdraw or override that right in the 
interest of the public. The rights under the UDHR and ICESCR, however, 
accrue to inventors as inherent rights; hence they are independent of the state’s 
recognition and grant of exclusivity rights. Most importantly, patent rights exist 
within a fixed length of time, unlike human rights which are perpetually vested in 
human beings. Similarly, patent rights, being statutory creations, are 
assignable, transferable and revocable, an attribute that is not shared by any 
human right.258 The inherent nature of human rights, one that recognises the 
inalienable interdependence and indivisibility of all human rights to all human 
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beings, is, in short, fundamentally absent in patent rights.259 PN Bhagwati, in 
describing the character of human rights, maintains that they are:  
Not ephemeral, not alterable […] not the product of philosophical whim or political 
fashion. They have their origin in the fact of the human condition and because of 
this origin, they are fundamental […] constitutions, conventions or governments do 
not confer them. These are the instruments, the testaments of their recognition […] 
they do not give rise to human rights. Human rights were born not of humans but 
with humans.260  
Sganga, commenting on the assignable rights of IP, also observes that ‘IPRs 
belong to the realm of national policies and international trade, as proven by the 
fact that, contrary to human rights, they are limited in time, limited in scope 
and—with the exception of moral rights—revocable, forfeitable, licensable and 
assignable.’261 Stretching this argument further, the right to health is universal, 
whereas patent rights, as stated previously are territorial in character.262 
This opinion finds support in the clarification by the CECSR in paragraph 3 of 
the General Comment No 17 which categorically states that IPRs are not to be 
equated with the human rights provisions of Articles 15(1)(c). The CECSR 
stresses the point that the human rights recognised in Article 15 (1)(c) solely 
‘safeguards the personal link between authors and their creations […] as well as 
their basic material interests which are necessary to enable authors to enjoy an 
adequate standard of living.’ IPR regimes, on the other hand, ‘primarily protect 
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business and corporate interests and investments.’263 In other words, a patent 
right is not coterminous with human rights. To further underscore this point, the 
CECSR in paragraph 1 of the General Comment 17, clarifies that  
Human rights are fundamental as they are inherent to the human person as such, 
whereas intellectual property rights are first and foremost means by which States 
seek to provide incentives for inventiveness and creativity, encourage the 
dissemination of creative and innovative productions, as well as the development 
of cultural identities, and preserve the integrity of scientific, literary, and artistic 
productions for the benefit of society as a whole.264  
In terms of structure, patents for pharmaceuticals, by way of an example, are 
more concerned with the protection of the investors’ right than the right of 
inventors who, in most cases, are scientists and researchers whose laborious 
efforts lead to the intellectual production. In the case of a pharmaceutical 
patent, many people, and in some cases institutions, are involved in the 
research and production.265 In some cases, employees undertake the research, 
yet the ownership rights’ may be vested in an individual(s) or an institution who 
may not be the actual inventors. Indeed, patents, as has been discussed at 
length in Chapter II,266 are mainly used as economic and utilitarian instruments 
to advance the policy of the rights-owners.267 This character of patents is unlike 
the provisions on human rights which are more concerned with the inventor as a 
person.268  
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Moreover, human rights are applicable to individuals as humans and cannot be 
vested in legal entities.269 Patent rights on the other hand can be owned by 
companies, in fact, the bulk of pharmaceutical patents are actually owned by 
corporations.270 The CESCR has made it clear that the language of ICESCR is 
addressed to a natural person; hence the beneficiaries addressed are 
humans.271 To clarify this further, the CESCR adds that under the ‘existing 
international treaty protection regimes, legal entities are included among the 
holders of intellectual property rights. However, […] their entitlements, because 
of their different nature, are not protected at the level of human rights.’272 What 
this means is that legal personalities cannot derive benefits from the protection 
of their moral and material interest in an invention under the ICESCR.273  
Still on this point, some commentators argue that there is a conceptual 
difference between IP rights and the moral and material interest of the inventors 
under ICESCR and UDHR.274 The scope of IPRs, according to Hestermeyer, 
extends beyond the material and moral interest of the ‘author’ or inventor.275 He 
argues that, although the overall objective of patent protection is to serve a 
larger development goal for society’s benefit and thus shares a similar goal to 
human rights values, it is an instrumental right rather than a ‘fundamental’ 
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right.276 This is indicative in the temporal nature and transferable character of 
patent rights.277  
Perhaps a hybrid approach to the relationship between patent rights and human 
rights may be to argue that a patent right, one that necessarily prevents others 
from unlawfully appropriating or free riding on a patented invention in order to 
recoup the cost of investment in the inventive enterprise, recognises the human 
right i.e material interest of the inventor. From this IP-human rights dimension, 
the patent rights of inventors, and the moral and material interests of right-
holders in human rights law could overlap. That is, a patent holder’s rights 
under patent law can, at the same time, have human rights characteristics. The 
patent rights-holders can, within the specific limit of his proprietary interest in 
the creation, rely on the rights conferred in the human rights instruments to 
claim the moral and material ownership and benefit of an invention. Likewise, 
creators/inventors could rely on the patents right protection under statutory law 
to seek legal protection and draw material benefit from the invention.  
However, it is possible for one of the rights to exist without the other. Therefore, 
even when the patent term has elapsed, the right holder’s moral and material 
interest as a creator in the invention is not extinguished. In other words, it is 
possible to have a human rights entitlement to the protection of a scientific and 
material interest without a corresponding grant of patent right protection. In this 
manner, a patent protection is also an important medium through which the 
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government can promote the human rights of an inventor as contained in the 
ICESCR and UDHR.278  
This argument should, however, be treated with caution as human rights within 
the contemplation of the ICECSR and UDHR are clearly not to be equated with 
patent rights. Thus, to the extent that a patent under the law is a statutory 
instrument granted by the state within specific boundaries and conditions, it is 
erroneous to say that it is a human right in its entirety. In this respect a patent 
protection as a legal instrument under patent law, cannot be said to be a human 
right in itself. What this indicates is that an inventor’s right in a patent cannot be 
expected to carry the same weight of enforcement as other fundamental human 
rights such as the right to health. Thus to answer the question asked at the start 
of this section, human rights offers little justification for patent holders, and 
certainly pharmaceutical companies, to interfere with the public interest and the 
human right to access to medicines.279  
4.7.4 ‘Balancing’ the Rights of Inventors, and the Public’s Human Rights 
to Health and Access to Medicines 
On the issue of the human rights protection of an inventor’s interest on the one 
hand and the public’s access to the invention such as medicines on the other, 
the UDHR280 and ICESCR attempt to strike a balance. This is indicative in the 
provision of Article 15(1)(a) and 15(1)(b) of the ICESCR which recognises the 
right of everyone to enjoy and take part in ‘cultural life’ and to enjoy ‘the benefit 
of scientific progress and its applications.’ Fundamentally, these rights provide a 
moral and legal claim for users to access the fruits of scientific and 
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technological innovations. In this sense, access to the benefits of scientific R&D 
is placed on an equal standing with the protection of the rights of inventors 
under Article 15(1)(c). Commenting on this, Professor Okediji argues that the 
‘user’s interests are just as rights-based as the interests of owners.’281 On her 
part, Chapman observes from a human rights perspective that benefiting from 
the products of science and technology presupposes that everyone will have 
access to them.282  
Along this line, the CESCR relates the public policy goals of protecting the 
moral and material interest of creators to the realisation of other economic, 
social, and cultural rights. In paragraph 2, the right to benefit from the protection 
of a ‘scientific, literary and artistic production’ is described in the General 
Comment No 17 as a means through which creators are encouraged to 
contribute to ‘arts and sciences and to the progress of a society as a whole.’283 
It may be argued that Article 15 of the ICESCR as a whole tries to strike a 
balance between the recognition of a creator’s right to control his/her intellectual 
capital and derive benefit from its innovative value and the public’s right to 
access the products of the invention.284 In this manner, the objective of the 
protection of the inventor’s interest is to serve a broader societal goal as the 
right is intrinsically linked with other rights of users in Article 15 to ‘enjoy the 
benefits of scientific progress.’285 Other fundamental human rights, such as the 
right to access medicines, will also come under this public welfare benefit to 
society. Moreover, paragraph 35 of the General Comment No 17 emphasises 
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that the states’ obligation in the context of Article 15 has to take into account 
other rights recognised under the ICESCR. This mandate would require states, 
such as Nigeria, to strike a balance between protecting the private interests of 
inventors and promoting the larger socio-economic and cultural rights of society 
to have access to the products of creators. Accordingly,  
In striking this balance, the private interests of authors should not be unduly 
favoured and the public interest in enjoying broad access to their productions 
should be given due consideration.286 
Although there is no delineation of this balance, the clarification that the rights 
should be balanced with the right to access offers a platform to bolster the 
argument for a broader reliance on human rights to promote access to 
medicines in Nigeria and elsewhere, within the context of patent rights.  
This argument can best be understood within the context of the drafting 
background to Articles 15 of the ICECSR and 27 of the UDHR. A study of the 
original draft ESCR Covenant of 1954 reveals that Article 15(1)(c) was not 
included in the first draft.287 The original draft only contained provisions 
guaranteeing the rights of everyone to partake in cultural life and enjoy the fruits 
scientific progress (i.e Articles 15(1)(a)(b)).288 Likewise, in the original draft of 
Article 27 of the UDHR, Article 27(2) which seeks to protect the moral and 
material interest of authors and creators was not present.289 The Article only 
included provisions for participation in cultural development and enjoyment of 
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the benefits of scientific advances.290 It would therefore appear that Articles 15 
of the ICECSR and 27 of the UDHR were drafted and construed from an ‘end-
user’ perspective.291 This is to guarantee that users can derive benefits from 
scientific creations and inventions and also freely engage in the cultural 
development of the community. It follows that human rights values and places 
emphasis on social welfare and promotes society’s interest to have access to 
scientific developments.292 Thus the later addition of Article 15(1)(c) to the 
ICECSR cannot qualify the first two paragraphs of Article 15.293 With regards to 
IPRs and societal benefits (user’s rights), Professor Cullet argues that ‘[h]uman 
rights treaties require the balance to be attempted from the perspective of 
society at large.’294 
In addition, the CECSR stresses that the recognition of inventor’s or creators’ 
interest should not be at the risk of the state’s core obligation towards the 
realisation of the rights to health and access to medicines ‘as well as to take 
part in cultural life and to enjoy the benefits of scientific progress and its 
applications.’ The CECSR goes on to emphasise that State Parties have a duty 
to ensure that the protection of inventor’s rights under IP law does not occasion 
‘unreasonably high costs of access to medicines.’295 Furthermore, this rights-
based approach also implies that the obligation on states extends to the 
implementation of patent rights in a way that does not conflict with the right to 
access the products of the inventor’s scientific progress.296 Therefore, the moral 
                                                          
290 ibid 
291 Philippe Cullet, 'Patents and Medicines: The Relationship between TRIPS and the Human Right to Health' (2003) 79 
International Affairs 139, 150. 
292 ibid 
293 ibid 
294 ibid 152. 
295 CECSR, General Comment No. 17, Paragraph 35. 
296 ibid 
242 
 
and material interests of the inventors in patent law should not interfere with the 
right to access medicines.  
Moreover, Article 30 of the UDHR also stipulates that ‘[n]othing in this 
Declaration may be interpreted as implying for any state, group or person any 
right to engage in any activity or to perform any act aimed at the destruction of 
any of the rights and freedoms set forth herein.’ Clearly, the right given to 
inventors in Article 27(2) should not affect the human right to health as 
stipulated in Article 25, which will include the right to access medicines. What 
this means is that inventors have very little ground in human rights to stand on 
as justification for encroaching on the right to access drugs. One author notes 
that, if any of the socio-economic rights is at risk from the protection of the 
creator’s interest, the ‘pendulum swings towards supporting diffusion and 
access to the benefit of the new technology.’297  
To sum up, the analysis above highlights the interrelationship between patent 
rights, inventors’ rights, human rights and the human rights of end users to 
access scientific advancements. It has been argued that the rights of inventors, 
particularly their patent rights, should not constitute a hindrance to the 
fundamental right to health. If the rights of inventors lead to a reduction in the 
quest of women to obtain cost-effective medicines for better health, it may be in 
violation of women’s fundamental human rights. In particular, the Nigeria has a 
duty to ensure that patent rights, as a means to protecting the human rights and 
moral and material interests of inventors, does not negatively impact on the 
quest of women to obtain medicines, and indeed, other follow-on inventors. 
Having made the case for women’s access to medicines as a human right 
within the context of patent law, the next section specifically narrows down the 
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study to Nigeria to examine its obligation to human rights. More specifically, the 
country’s commitment to provide healthcare and the legislative measures to 
guarantee the right to health, including access to essential drugs. 
 
PART III: TOWARDS AN ENFORCEMENT OF WOMEN’S RIGHTS 
TO HEALTH AND ACCESS TO MEDICINES IN NIGERIA  
 
4.8 Constitutional Recognition of Healthcare in Nigeria 
In Nigeria, although the 1999 Constitution (as amended) does not expressly 
recognise the right to health, the country’s commitment to provide healthcare to 
its people is subsumed under the general provisions on health in the 
Fundamental Objectives and Directive Principles of State Policy in Chapter II of 
the Constitution. Section 17(3)(d) of the Constitution requires the state (Nigeria) 
to take appropriate measures and direct its policies towards ensuring an 
adequate standard of medical care for everyone, including the provision of 
medical and healthcare facilities.298 Under that section, the state shall also 
ensure that ‘the health, safety and welfare of all persons in employment are 
safeguarded and not endangered or abused.’299 It can be said that these 
Fundamental Objectives and Principles consider it a primary duty of the state to 
improve the healthcare and welfare of Nigerians.300 For this reason, it imposes 
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a liability on the state to secure the necessary facilities for the promotion of 
health and wellbeing of all Nigerians.301 
While this blanket provision does not effectively address the issues of rights to 
health and access to adequate medical treatments in Nigeria, it could be argued 
that the Constitution’s reference to ‘adequate medical and health facilities’ 
accords recognition to the appropriate health services and medicines as 
necessary for the improvement of the health and health-related conditions of 
Nigerians. Thus, the Nigerian government has a duty to promote the welfare of 
every individual, including the guarantee of their healthcare-related interests 
such as accessibility to medicines as part of medical care. This fundamental 
obligation of the government is supported by Section 14(1)(2) of the 
Constitution which enjoins the state to promote social justice, including the 
security and welfare of Nigerians, as a matter of public good. It could be argued 
that the obligation to promote the welfare and wellbeing of Nigerians could be 
discharged by providing adequate healthcare services and drugs for effective 
treatments of diseases and illness. A broad interpretation of this obligation also 
extends to ensuring that patents do not obstruct access to medicines or 
interfere with healthcare provision. 
 
4.8.1 Is Access to HealthCare and Medicines Legally Enforceable in 
Nigeria? 
Notwithstanding the provisions of Sections 17(3)(b) and (c) of the Constitution, 
there are two identifiable problems with the categorisation of the healthcare 
provision in Chapter II of the Nigerian Constitution. First, it is unenforceable by 
the courts; and secondly, the provision is not a ‘human right.’  
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The categorisation of healthcare as a Fundamental Objective and Directive 
Principle as contained in Chapter II of the 1999 Constitution has been 
characterised as ‘an aspirational or hortatory goal’ with no legally binding 
claim.302 This is because the duty on the state to provide adequate healthcare 
facilities including medicines, in accordance with section 17(1)(c)(d) in Chapter 
II of the Constitution, falls under one of the judicially unenforceable categories 
of duties and responsibilities within the contemplation of Section 6(6)(c) of the 
Nigerian 1999 Constitution.  
By virtue of Section 6(6)(c) of the Constitution, the courts lack jurisdiction to 
entertain issues emanating from the socio-economic and cultural aspirations 
and objectives in the Fundamental Objectives and Directive of Principles of 
State Policy in Chapter II of the Constitution. Under Section 6(6)(c), the judicial 
powers vested in accordance with the provisions of Chapter II in the 
Constitution,  
[...] shall not except as otherwise provided by this Constitution, extend to any issue 
or question as to whether any act of omission by any authority or person or as to 
whether any law or any judicial decision is in conformity with the Fundamental 
Objectives and Directive Principles of State Policy set out in Chapter II of this 
Constitution. 
Consequently, the justiciability of the socio-economic guarantees in the 
Constitution or any other law is clear.303 Accordingly, Section 6(6)(c) implies that 
an aggrieved person cannot take the government to court, or seek a judicial 
remedy for a violation of the provisions of Chapter II.304 As Section 17(1)(c)(d) 
falls within the provision of the Fundamental Directives in Chapter II, the 
restrictions on judicial enforceability apply to the duty to provide healthcare 
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facilities. In essence, a claim to medical and healthcare treatments in Nigeria 
has no judicial enforceable status under the Constitution. This means that in the 
Constitution, interference with access to healthcare services and medicines 
cannot be redressed through judicial channels by Nigerians. A further 
implication is that the government of Nigeria cannot legally be compelled to 
implement its obligations to provide medical and healthcare facilities under the 
Constitution.  
Although the necessity of directing state policies towards facilitating access to 
medical and healthcare facilities to further the material wellbeing of Nigerians 
was promoted in the Constitution, the status of this provision as a non-
justiciable entitlement robs the provisions of a judicial recourse to compel 
government compliance, action and enforcement. Thus as it stands, the 
provision is a mere political objective and goal, devoid of a concrete redress 
mechanism against the duty bearers to guarantee the enjoyment of these 
important provisions on health. This leads academicians and legal specialists to 
criticise the categorisation of the obligations to which the provision on 
healthcare in the Constitution belongs as a ‘toothless bulldog’ that barks but 
cannot bite because there are no concrete enforcement mechanisms attached 
to the health objective.305  
The Nigerian courts have generally adopted the same attitude to the non-
justiciability of the socio-economic provisions in Chapter II and have upheld the 
unenforceability of its provisions. For instance, the Nigerian Court in Archbishop 
Anthony Olubunmi Okogie (Trustee of Roman Catholic Schools) & Others vs 
Attorney General of Lagos State,306 reaffirmed the challenge that Section 
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6(6)(c) poses to the judicial application of the Chapter II provisions by the 
courts, thus raising the questions of how and whether the provisions are 
actually ‘fundamental’ since they cannot command judicial enforcement.307 In 
this case, the courts were invited to adjudicate on the question of the 
enforceability of the fundamental rights of the plaintiffs. The Lagos State 
Government issued circulars to abolish all private fee paying primary 
educational institutions. This was done ‘towards ensuring that there are equal 
and adequate educational opportunities at all levels’ as provided under Section 
18 of the 1979 Constitution (a non-justiciable provision in the 1979 
Constitution). The plaintiff claimed that the plan by the government to abolish 
private primary education was a threat to the freedom to hold and impart 
education under Section 36 of the Constitution. The Court of Appeal reaffirmed 
in its ruling pursuant to Section 6(6)(c), that the provisions of Chapter II were 
not enforceable in courts. The court proceeded on the general note that the 
provisions in Chapter II are not justiciable, and that ‘the arbiter for any breach of 
the Objectives and the Directive Principles of State policy is the legislature or 
the electorate.’308 Delivering the ruling, Justice Mamman Nasir (as he then was) 
acknowledged that the directive principles are the ultimate objectives of the 
nation and are policies which are expected to be pursued in the nation’s interest 
to realise its welfare objectives. He explained further that, 
[w]hile Section 13 of the Constitution makes it a duty and responsibility of the 
judiciary among other organs of government, to conform to and apply the 
provisions of Chapter II, Section 6(6)(c) of the same Constitution makes it clear that 
no Court has jurisdiction to pronounce any decision as to whether any organ of 
government has acted or is acting in conformity with the Fundamental Objectives 
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and Directive Principles. It is clear that Section 13 has not made Chapter II 
justiciable.309 
Ruling in favour of the plaintiff’s fundamental rights, the court further held that 
no legislation, pursuant to Section 16 or 18 of the Constitution can validly 
override the constitutionally guaranteed rights in Chapter IV of the Constitution. 
Likewise in Uzoukwu v Ezeonu II the Courts, per Nasir PCA, reiterated the non-
justiciability of Chapter II thus:  
There are other rights which may pertain to a person which are neither 
fundamental nor justiciable in the Court. These may include rights given by the 
Constitution under the Fundamental Objectives and Directive Principles of State 
Policy under Chapter II of the Constitution.310  
In this case, the appellants sought the enforcement of their fundamental rights, 
as guaranteed by Sections 31 and 39 of the 1979 Constitution. They alleged 
that the respondents treated and regarded them as slaves, in violation of their 
Constitutional guaranteed rights. The court in its ruling clarified that while the 
fundamentally ascribed rights in Chapter IV are justiciable in courts, the rights 
given by the Constitution in Chapter II are not fundamental or justiciable in 
Courts.311 It is unfortunate that despite the importance of the socio-economic 
and cultural provisions in Chapter II, their practical enforceability has been 
undermined by the same Constitution that pledged to promote the welfare and 
wellbeing of all persons in Nigeria. 
Another issue is that the provisions on health in the Constitution are not ‘human 
rights’; they are fundamental state objectives and principles which the Nigerian 
state aims to achieve for all its citizens. While the importance of protecting 
human rights in national constitutions is without doubt significant to 
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guaranteeing the enjoyment of the rights, the Nigerian Constitution has failed to 
accord the provisions in Chapter II with human rights status. Although the 
provisions embody socio-economic and cultural rights, the heading, focus, goals 
and procedural judicial embargo clearly indicate that the provisions are not 
guaranteed human rights. Indeed, while Chapter IV of the Constitution is 
entitled ‘Fundamental Rights, Chapter II has the heading ‘Fundamental 
Objectives and Directives of State Policy.’ If the intention of the legislature was 
to make the provisions in Chapter II human rights, it would have clearly stated 
so. Thus, despite the significance of access to medicines as a human right to 
health and the need to ensure that medical patents do not interfere with this 
access from a human rights perspective, the Constitution has failed to 
effectively reflect a human rights goal to the provision on health. 
It is argued that there is a need to guarantee the provisions in Chapter II as 
legally enforceable human rights. Under international law as analysed above312 
the provisions on human rights carry with them obligations for the state to 
respect, protect, fulfil and implement. This duty includes ensuring that policies 
and laws such as patents do not interfere with the enjoyment of the right. As 
justiciable human rights, the provisions on health would also avail Nigerians 
with the opportunity and legal recourse to measure the performance of the 
government, authorities and third parties who infringe on those rights. However, 
the failure to guarantee the provisions on health as human rights under the 
Constitution means that the provisions may not make full meaningful impact on 
all Nigerians, especially since the provisions are non-justiciable. 
Moreover, it is argued that the extant legislative provision on healthcare in the 
Constitution is inadequate to capture all the dimensions of the right to health. 
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The provision in Section 16(3)(d) simply obliges the state to direct its resources 
towards providing ‘adequate medical and health facilities for all persons.’ This 
language of the law does not guarantee all the dimensions of the right to health 
as discussed above in the subsections of 4.3.1 above. From the lens of access 
to medicines perspective, the text of the law with regards to health does not 
appear to clearly guarantee the availability and accessibility of affordable drugs 
that are acceptable and of good quality, in a gender sensitive and non-
discriminatory manner. Nevertheless, a broad interpretation of the measures to 
be undertaken to provide the medical and health facilities in the Constitution 
would require that health medicines are provided and any interference with 
accessing medicines is addressed by the Nigerian state. For the sake of brevity, 
however, the recognition of the provisions on adequate healthcare in the 
Constitution as human rights would ensure that all components of the right to 
health including access to medicines are guaranteed. 
 This suggestion is consistent with the preamble to the Constitution which 
pledges to promote the wellbeing of Nigerians. But without access to adequate 
healthcare and medicines, securing the wellbeing of the Nigerian women, and 
indeed all Nigerians will remain a pipe dream. Thus it is important that the 
healthcare of the citizens is given paramount importance as a matter of right in 
the country. 
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4.8.2 Making a Case for the Provision of Healthcare and Access to 
Medicines for Women under the Nigerian Constitution 
The Drafting Committee of the 1979 Constitution313 characterised the 
‘Fundamental Objectives’ as the ‘identification of the ultimate objective of the 
nation’. As such, they are the ‘ideals towards which the Nation is expected to 
strive’ to promote the security and welfare of the people.314 The ‘Directive 
Principles’, on the other hand, ‘lay down the policies which are expected to be 
pursued in the efforts of the Nation to realise the national ideals.’ 315 In other 
words, the Principles are identified as the guidelines which lead to the 
realisation of state ideals or goals; hence the state is expected to direct its 
policies to achieve these ideals. For this purpose, Section 13 of the 1999 
Constitution states: 
It shall be the duty and responsibility of all organs of government, and of all 
authorities and persons, exercising legislative, executive or judicial powers, to 
conform to, observe and apply the provisions of this Chapter [Chapter II].316  
This provision, however, leaves a myriad of questions open. Such as: what is 
the nature of duty and responsibility that the state is expected to adopt to 
comply with the requirement to fulfil the obligation to medical and healthcare 
facilities for women pursuant to Section 17(3)(c) and (d)? In other words, to 
what extent is the government expected to satisfy the duty to ‘conform to, 
observe and apply the provisions’ on guaranteeing their access to healthcare 
facilities including medicines? More specifically, if the state fails in its duty, how 
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can it be compelled to meet its responsibility and duty to healthcare, considering 
the fact that their recourse to a legal remedy has been foreclosed?  
 Where there is a duty, there is a corresponding obligation to fulfil that duty, and 
a remedy mechanism to enforce compliance with that duty; yet Section 6(6)(c) 
of the Constitution exempts this duty from judicial scrutiny. Can it be said then 
that there is no actual duty on the state to implement the provision on access to 
adequate medical care because it is not legally binding?  
Neither Section 13 nor any other section in the Constitution gives a clear 
answer to these questions. However, it is argued that, although the provision of 
access to adequate healthcare cannot compel judicial legal recourse, it does 
not affect the duty and responsibility of the Nigerian state to implement, apply 
and observe the statutory provisions of Section 17(3)(c) and (d) with regards to 
facilitating and protecting women’s access to adequate medical care. In other 
words, the absence of a justiciable statute does not divest the state of a duty to 
protect, promote and realise its duty to the provision of medical care. One 
scholar, commenting on the nature of the government’s duty, argues that the 
word ‘Directive’ in the title of Chapter II implies that this duty is mandatory and 
the provisions create an obligation on the government to fulfil and comply with 
the provisions on access to adequate health and medical facilities.317 
Accordingly, the term ‘Directive’ in Chapter II suggests that it is an order or 
command, meaning that the provisions of the Chapter are obligatory and create 
commitments for the government to comply.318 In agreement with the above 
suggestion, it appears that the duty with respect to adequate medical and health 
facilities, including access to medicines, is couched in an authoritative or 
mandatory term which requires the state to achieve the intended outcome. 
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Clearly, Section 6(6) (c) only purports to exclude the legal enforcement of a 
claim on this duty or a violation of the Fundamental Directives by foreclosing the 
possibility of subjecting the positive realisation of the provisions in Chapter II to 
judicial scrutiny.  
Notwithstanding this judicial bar, the state has a duty to direct its policies 
towards ensuring women’s access to adequate healthcare facilities and medical 
treatments. That is, the non-enforceability of the provision does not negate the 
fact that the state has a duty to ensure that its policies and laws guarantee 
women and indeed all Nigerians access to health facilities including medicines, 
even though this duty cannot command the force of law in a judicial proceeding. 
In addition, as Nwabueze observes, the provisions of Chapter II can be relied 
upon in the interpretation of constitutional debates.319 In this regard, it can be 
said that the provisions of Section 17(3)(c) can be relied upon to argue that the 
state direct its policies to ensuring that there is non-interference with women’s 
healthcare in view of patent rights, or utilise the patent-related flexibilities to 
guarantee their access to adequate medical care. India’s attitude to the 
constitutional provision on health offers a good example to support these 
arguments.  
The Fundamental Objectives and Directives in Chapter II of the extant Nigerian 
Constitution (including the provision on health and medical care) is borrowed 
from the Indian Constitution (1948) and was first included in the 1979 Nigerian 
Constitution.320 India’s present constitutional provision on the rights to health 
and healthcare is, however, extensive and covers a wider range of conditions 
                                                          
319 Remigius N Nwabueze, ‘The Legal Protection and Enforcement of the Health Rights in Nigeria’ in Colleen M Flood and Aeyal 
Gross (eds), The Right to Health at the Public/Private Divide: A Global Comparative Study (Cambridge University Press 2014) 381. 
320 ibid 381. The Fundamental objectives and directive principles first appeared in the Constitution of 1979, and are similar to Part 
IV of the Constitution of India 1949, as amended in 1951. J Akande, The Constitution of the Federal republic of Nigeria 1979 with 
Annotations (Sweet & Maxwell 1982) 13. 
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for public health and wellbeing of everyone.321 For example, the state in Article 
47 has a primary duty to secure the public health of the people by ‘raising the 
level of nutrition and standard of living […] and the improvement of public health 
[…]’ including control of substances that affect health and human conditions of 
work. Notably, Article 42 recognises the importance of women’s health and 
makes provisions to secure ‘maternity reliefs’ and benefits as being integral to 
health.322 Similarly to Nigeria, the provisions on health are not legally 
enforceable by the courts in India.323 Notwithstanding, the Indian courts have 
broadly construed the constitutional provisions on health to enforce the state’s 
obligation to improve the health and rights of the people to affordable 
healthcare, especially medicines.324  
In Samity v State of Bengal, for instance, access to timely healthcare necessary 
to preserve life was upheld by the Indian Supreme Court.325 Deciding on the 
basis of the right to life, the court held that the right includes an obligation to 
provide access to medical treatments to preserve human life as a ‘constitutional 
                                                          
321 The obligation on the state to ensure, create and sustain the necessary facilities and conditions congenial to good health is 
generally found in the Constitutional directives as contained in Articles 38, 39(e)(f), 41, 42, 47 and 48A in Part IV of the 
Constitution of India. For example, Article 41 states that the  
State shall, within the limits of its economic capacity and development, make effective provision for securing the 
right to work, to […] public assistance in cases of […] old age, sickness and disablement […]. 
322 Indrajit Khandekar, BH Tirpude and PN Murkey, 'Right to Health Care' (2012) 34 (2) Journal of Indian Academy of Forensic 
Medicine 160. 
323 Ebenezer Durojaiye, 'Litigating the Right to Health in Nigeria: Challenges and Prospects' in Magnus Killander (ed), International 
Law and Domestic Human Rights Litigation in Africa (PULP 2010) 166. The provisions guaranteeing healthcare and health 
conditions in India are found under the Directive Principle of State policy which is not justiciable in India. Article 37 of 
the Constitution declares that the  
[t]he provisions contained in this Part shall not be enforceable by any Court, but the principles therein laid down 
are nevertheless fundamental in the governance of the country and it shall be the duty of the State to apply 
these principles in making laws. 
324 See discussions and cases on this in Mihir Desai and Dipti Chand, ‘Fundamental Right to Health and Public Health Care’ in Mihir 
Desai and Kamayani Bali Mahabal (eds), Health Care Case Law in India (Centre for Enquiry into Health and Allied Themes (CEHAT) 
and India Centre for Human Rights & Law (ICHRL) 2007) 17-35.  
325 Paschim Banga Khet Samity v State of West Bengal, Case No. 169, Judgement of 6 May 1996 Writ Petn. (Civil) No. 796 of 1992 
(SC Agrawal, GT Nanavati JJ) (1996). In this case, Samity fell off a train and suffered serious head injuries. The necessary health 
facilities (including vacant bed) to treat him were not available in six hospitals. The Court held that ‘failure on the part of the 
government to provide timely medical care to a person in need of such treatment results in a violation of his right to life 
guaranteed in Article 21 of the Constitution. See paragraph 9 of the judgement.  
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obligation of the state to provide adequate medical services to the people.’326 
Perhaps, it is not out of place for Nigeria to follow this judicial activism and 
adopt a rights-based attitude to lay down the standards for the Nigerian state to 
comply with its obligations to women’s health.327  
Still on the issue, how then can an aggrieved person compel the enforcement of 
the duty to comply, enforce and observe the provisions of access to healthcare? 
The answer to this question remains unclear. However, despite the non-
enforceability and justiciability challenge of Chapter II, the Nigerian courts have 
begun to open up new windows to allow the enforcement of the constitutional 
provisions in Chapter II including the recognition of the health provisions as 
rights. The court generally relies on the justiciable fundamental rights in Chapter 
IV of the Constitution to interpret the non-justiciable provisions. For instance, in 
the case of Gbemre v Shell Petroleum Development Company Nigeria Limited 
and Others,328 the Nigerian Federal High Court delivered a landmark ruling for 
the protection of right to health and a healthy environment. In that case, the 
appellants sought an order to enforce their fundamental rights to life and dignity 
of person pursuant to Sections 33(1) and 34(1) of the Nigerian Constitution. The 
applicants supported their claim by relying on Articles 4, 16, and 24 of the 
African Charter.329 They claimed that the degradation of the environment by the 
respondents violated their human rights to a healthy environment. The 
respondents counter-argued that the African Charter and its provisions on 
health and healthy environment do not create justiciable and legally enforceable 
                                                          
326 Paragraphs 9, 15-16 ibid. Notably, the court held that this duty on the state is irrespective of financial and resource constraints 
and the state responsibility can be discharged in ‘whatever is necessary for this purpose.’ Paragraph 16 ibid. 
327 It should be noted that Nigeria shares a similar constitutional law and legal system with India hence the comparative study of 
Nigeria and India. This suggestion is made not only because Nigeria and India share a similar constitutional provision with regards 
to healthcare, but more so that both countries share a comparable socio-economic condition and political landscape. 
328 152 (2005) AHRLR 151 (NgHC 2005). 
329 Article 4 on the right to life, 16 on the right to health care and 24 on right to satisfactory environment in the African Charter. On 
the right to health provisions in African Charter, the appellant argued that they have a right to ‘enjoy the best attainable state pf 
physical and mental health as well as a right to a general satisfactory environment favourable to their development.’ 
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rights in regular Nigerian courts. The judge, Nwokorie J, rejected the arguments 
of the respondents and ruled that the provisions of the Charter are applicable in 
Nigeria.  
The Courts further held that:  
That section 3(2)(a) and (b) of the Associated Gas Re-Injection Act and section 1 
of the Associated Gas Re-Injection (Continued Flaring of Gas) Regulations section 
1.43 of 1984, under which gas flaring in Nigeria may be allowed are inconsistent 
with the applicant’s rights to life and/or dignity of human person enshrined in 
sections 33(1) and 34(1) of the Constitution of the Federal Republic of Nigeria, 
1999 and articles 4, 16 and 24 of the African Charter on Human and Peoples’ 
Rights (Ratification and Enforcement) Act, cap A9, Vol 1, Laws of the Federation of 
Nigeria, 2004) and are therefore unconstitutional, null and void by virtue of section 
1(3) of the same Constitution.330  
In this case, the judge relied on the guaranteed constitutional provisions on the 
rights to life and dignity of person and broadly construed the right to life as 
extending to the right to health and a healthy environment under the ratified 
African Charter.  
This case is a significant improvement in the judicial attitude to human rights, 
especially socio-economic provisions, for the following reasons. Firstly, the case 
was the first time a Nigerian court had made a pronouncement on the right to 
health and a healthy environment. Importantly, the court linked the right to a 
healthy environment (non-justiciable under Chapter II) with the justiciable right 
to life and human dignity provision in the 1999 Constitution. The right to life was 
thus broadly interpreted to include congenital factors such as a healthy living 
environment. Secondly, although the case was not decided exclusively on the 
human rights provisions in the African Charter, the court significantly relied on 
the right to health and healthy environment in the Charter to enforce socio-
                                                          
330 Paragraph 5(6). 
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economic rights in Nigeria. Thirdly, this case also illustrates the influence and 
application of human rights provisions in the African Charter to grant a human 
rights remedy. 
It follows that another way to secure the litigation of the provisions on health 
and access to medicines in Nigeria is by linking the enforcement of the 
provisions in Chapter II to the justiciable rights such as the right to life, dignity 
and liberty.331 This way, an action for the violation of the rights to health which 
will face the challenge of justiciability under the constitution can be based on the 
right to life as discussed above.332 The argument can be made when asserting 
these claims that, although the access to adequate medical care including 
medicines in Chapter II may not be a legally guaranteed right, nonetheless, it is 
essential to the enjoyment of other guaranteed rights in the Constitution.333 
 Most people would agree that the right to life in Section 33(1) of the Nigerian 
Constitution is more meaningful to a healthy person.334 Likewise, without 
essential medicines, it will be hard for the Nigerian government to guarantee 
health, life and other socio-economic objectives and political rights of Nigerian 
women and all its citizens. As stated above,335 access to essential medicines as 
a part of providing adequate medical and healthcare facilities has implications 
for the enjoyment and realisation of the civil and politically justiciable rights in 
the Constitution. In guaranteeing the right to life, therefore, the government has 
                                                          
331 For example, in Archbishop Anthony Olubunmi Okogie & Ors v Attorney General of Lagos State, (n 306), although the courts 
held that the Fundamental Directives and State Policy were non-justiciable, at the same time, the Court of Appeal held that the 
implementation of Chapter II could not be done in such a way as to infringe on the fundamental rights enunciated in Chapter IV of 
the Constitution (the freedom to hold opinion, receive and impart ideas under Section 36(1) of the Constitution). The court further 
found in favour of the plaintiffs on the basis that Sections 16(1)(c) and 18 of the Constitution guarantee their rights to participate 
in the economy and hindering them would amount to a violation of their fundamental rights under Section 36 - freedom to hold, 
receive and impart ideas. 
332 Durojaye (n 323) 166-167. 
333 Nnamuchi (n 302) 8; Agbakoba and others (n 303) 42. 
334 The Nigerian Constitution in Section 33(1), 34 and 35 explicitly recognises the right of everyone to life, human dignity and 
liberty.  
335 In subsection 4.4.1 above. 
258 
 
a duty to take appropriate measures to the provision of adequate healthcare 
system and medicines for women and children and all Nigerians. 
Other case studies also indicate that the non-justiciability status of Chapter II of 
the Constitution in Section 6(6)(c) of the Constitution may not be absolute and 
in some instances, the provisions in Chapter II can be made justiciable.336 The 
enforcement of Chapter II provisions is allowed where it is so provided under 
other sections of the Constitution. This argument is better explained in the case 
of Olafisoye v Federal Republic of Nigeria.337 In this case, the appellants were 
charged with offences under the Corrupt Practices and Other Related Offences 
Act, 2000. The Court was invited to determine the question of whether or not 
the National Assembly validly enacted the Corrupt Practices and Other Related 
Offences Act of 2000 in accordance with the powers conferred to the 
Government under Section 15(5)(2) of the Constitution. The Section, contained 
in Chapter II of the Constitution, grants powers to the National Assembly to 
make laws to prohibit and abolish corrupt practices and abuse of power. The 
Court in its ruling stated that Section 6(6)(c) does not completely foreclose the 
justiciability of Chapter II. In the words of Niki Tobi (JSC),  
In my humble view section 6 (6) (c) of the Constitution is neither total nor 
sacrosanct as the subsection provides a leeway by the use of the words “except as 
otherwise provided by this Constitution.” This mean that if the Constitution 
otherwise provides in another section, which makes a section or sections of 
Chapter 11 justiciable, it will be so interpreted by the Courts. 
The Supreme Court also based its decision on the provisions of Item 60(a) of 
the Exclusive legislative list of the Second Schedule to the Constitution which 
vests power in the National Assembly to promote and enforce the observance 
                                                          
336 GN Okeke, ‘The Justiciability of the Non-Justiciable Constitutional Policy of Governance in Nigeria’ (2013) 7 IOSR Journal of 
Humanities and Social Science 9, 11. 
337 (2004) 4 NWLR (Pt. 864) 580. 
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of Chapter II.338 Accordingly, the court ruled that the legislature validly exercised 
its rights in the exclusive list.  
In view of the foregoing, it appears that while Chapter II is non-justiciable, there 
are other ways which the provisions can be made justiciable. Pursuant to 
Section 4(2) of the 1999 Constitution, the National Assembly has the exclusive 
power to make laws for the peace, order and good government of the Nigerian 
Federation with regards to any matter in the Exclusive List. Equally, under Item 
60(a) of the Exclusive List of the Constitution, the legislature has the power to 
promote and enforce the realisation of the provisions of Chapter II (which 
contains provisions on Nigeria’s access to adequate healthcare facilities and 
medicines).339 This power extends to the establishment and regulation of the 
appropriate authorities for this purpose.340 The provisions of Section 4(2) and 
Item 60(a) essentially give teeth to the enforcement of Chapter II. As the matter 
of regulating Chapter II provisions falls under the Exclusive Legislative List, the 
National Assembly can make laws with respect to the implementation and 
enforcement of the provisions of Chapter II. Since the bar to the enforceability of 
Chapter II does not extend to matters in the Exclusive List, it can be argued that 
                                                          
338 The sub-item provides: 
The establishment and regulation of authorities for the Federation or any part thereof –  
(a) To promote and enforce the observance of the Fundamental Objectives and Directive Principles contained in 
this Constitution. 
339 Pursuant to Section 4(2) of the Constitution, the legislative power is vested in the National Assembly of the federal Republic of 
Nigeria, consisting of the Senate and Federal House of Representatives, with regards to matters in the Exclusive List. 
340 For example, Justice Mohammed L Uwais CJN (as he then was) succinctly emphasised the importance of Item 60(a) thus:  
Item 60 of the Exclusive Legislative List of the Constitution of the Federal Republic of Nigeria specifically 
empowers the National Assembly to establish and regulate authorities for the Federation to promote and 
enforce the observance of the Fundamental Objectives and Directive Principles, and to prescribe minimum 
standards of education at all levels, amongst others. The breath-taking possibilities created by this provision have 
sadly been obscured and negated by non-observance. This is definitely one avenue that could be meaningfully 
exploited by our legislature to assure the betterment of the lives of the masses of Nigerians, whose hope for 
survival and development in today’s Nigeria have remained bleak, and is continuously diminishing. The utilisation 
of this power would ensure the creation of requisite bodies to oversee the needs of the weak and often 
overlooked and neglected in our society. It would also provide a unique and potent opportunity to our legislators 
to monitor and regulate the functions of these bodies, where the Executive, for reasons best known to it, fails or 
neglects to prioritize and implement the provisions of Chapter II, and by extension, the welfare of all Nigerians. 
Mohammed L Uwais, ‘Fundamental Objectives and Directive Principles of State Policy: Possibility and Prospect’ in CC Nweze (ed), 
Justice in the Judicial Process: Essay in Honour of Honourable Justice Eugene Uba Ubaezonu (Fourth Dimension Publishing 
Company 2002) 179. 
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the legislature in Nigeria can make laws that permit the enforceability of the 
provisions of Chapter II, notwithstanding the bar in Section 6(6)(c). In this 
connection, Obilade noted with respect to the duties of the state to abolish 
corrupt practices and the abuse of power that  
[i]t is clear […] that although Section 15(5) [in Chapter II] of the Constitution is, 
generally not justiciable, as soon as the National Assembly exercised its powers 
under Section 4 of the Constitution with respect to Item 60(a) of the Exclusive 
Legislative List, the provisions of Section 15(5) of the Constitution becomes 
justiciable.341  
This argument also finds support in the case of Attorney General of Ondo State 
v Attorney General of the Federation & Others.342 The Supreme Court adopted 
a liberal interpretation which suggests the likelihood of the justiciability of 
Chapter II through relevant federal legislation. One of the main issues before 
the court for determination in that case was the question of whether or not the 
National Assembly was competent to enact the Corrupt Practices and Other 
Related Offences Act of 2000 in relation to Section 15(5) (under Chapter II) as 
empowered under Item 60(a) of the Second Schedule to the Exclusive 
Legislative list.343 The court upheld and justified the enactment of the Act based 
on the legislative authority of the National Assembly under Items 60(a), 67 and 
68 of the Exclusive Legislative List.344 On the non-justiciability of the 
                                                          
341 AO Obilade and others (eds), Contemporary Issues in the Administration of Justice: Essay in Honour of Justice Atinuke Ige 
(Treasure Hall Konsult 2002) 127.  
342 (2002) 9 NWLR (Pt 772) 222. 
343 The plaintiffs challenged the constitutionality and validity of the Corrupt Practices and Other Related Offences Act of 2000 
establishing the Independent Corrupt Practices and Other Related Offences Commission to prosecute alleged offenders in relation 
to Section 15(5) (under Chapter II) on the federalism principle. One of the questions before the Court was whether the National 
Assembly is constitutionally empowered to make laws with respect to ‘all corrupt practices and abuse of power’ in Section 15(5) 
under Item 60(a) of the Second Schedule to the Exclusive Legislative list.  
344 Similarly, in the case of Bamidele Aturu v Minister of Petroleum Resources and Others (2013) Suit No FHC/ABJ/CS/591/09, Aturu 
instituted an action challenging the incessant fuel price increases and the Nigerian government’s neo-liberal policy of deregulation 
of the downstream sector of the petroleum industry. He argued that the policy of deregulation was unconstitutional and illegal in 
view of Section 16(1) of the Constitution (under Chapter II) and Sections 6(1) and 4(1) of the Petroleum Act and the Price Control 
Act, respectively. The defendants counter-argued that the suit was not properly constituted on the grounds of locus standi and 
non-justiciability of section 16(1). On the substantive issue, the court ruled that the combined reading of the provisions of section 
16(1) of the Nigerian Constitution and sections 6(1) and 4(1) of the Petroleum Act and the Price Control Act respectively obliged 
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Fundamental Objectives and Directives of State Policy, Uwaifo S (JSC)345 adds 
as follows:  
While they remain mere declarations, they cannot be enforced by legal process but 
(it) would be seen as a failure of duty and responsibility of State organs if they 
acted in clear disregard of them […]. But the directive principles (or some of them) 
can be made justiciable by legislation.  
Uwaifo further expounded on this thus: 
The Constitution itself has placed the entire Chapter II [on Directive Principles] 
under the Exclusive Legislative List. By this, it simply means that all the Directive 
Principles need not remain mere or pious declarations. It is for the Executive and 
National Assembly, working together; to give expression to anyone of them through 
appropriate enactment as occasion may demand.346  
This view of the judge gives credence to the opinion in this thesis that provision 
of healthcare including medicines and the regulatory measures to ensure that 
women’s access to healthcare is not impeded is an obligation and possibly an 
enforceable duty on the Nigerian government. These judicial pronouncements 
significantly suggest that there are alternative and indirect means by which the 
provisions of Chapter II can be made justiciable by means of enacting and 
executing legislation to this effect.347 Thus it is possible that the provisions on 
access to adequate healthcare can be made justiciable through legislative 
provisions to bolster the effect of the provisions in Chapter II of the 
                                                                                                                                                                          
the government to regulate and fix, from time to time, the price of petroleum products in Nigeria in such a manner as to secure 
the maximum welfare, freedom and happiness of Nigerian citizens. On the issue of justiciability, the court relied on Attorney 
General of Ondo State v Attorney General of the Federation & Others (n 342) and held that the provisions of Chapter II of the 
Constitution can be made justiciable through legislation. The Court ruled that ‘by enacting the Price Control Act and Petroleum Act 
and providing in section 4 and 6 of those acts, for the control and regulation of prices of petroleum products, the National 
Assembly working in tandem with the government has made the economic objectives in section 16(i) (b) of the Constitution in 
Chapter II justiciable.’ See also Akinola E Akintayo, ‘A Good Thing from Nazareth? Stemming the Tide of Neo-Liberalism Against 
Socio-Economic Rights: Lessons from the Nigerian Case of Bamidele Aturu v Minister of Petroleum Resources and Others’ (2014) 
15(2) ESR Review. 
345 Not the leading judge in the case.  
346 Uwaifo S (JSC) 391 paragraph(s) G– H, 410 paragraph G.  
347 Nwabueze (n 219) 382. See also the case of Federal Republic of Nigeria v Anache and 3 ors. (2004) 17 NSCQR 140 where the 
court adopted the opinion that the phrase ‘save as otherwise provided by this constitution’ does not absolutely exclude matters in 
Chapter II from justiciability in the Constitution. 
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Constitution.348 However, the legislature has to make provisions to give 
applicability to them.349  
 
4.8.3 Current Measures to Promote the Right to Health in Nigeria  
Towards the promotion of the health and welfare of Nigerians, the National 
Health Act was signed into law in December 2014. The Act provides a policy 
framework for the enhancement, regulation and management of the national 
health system. Notably, it provides a framework to ‘protect, promote, and fulfil 
the rights of the people of Nigeria to have access to healthcare service.’350 Part 
of the healthcare services in the Act includes the duty to ‘promote availability of 
good quality, safe and affordable essential drugs, medical commodities, 
hygienic food and water.’351 It regulates both the private and public health 
service sectors and also creates a Basic Health Care Provision Fund to ensure 
access of every Nigerian citizen to healthcare services. The use of the word 
‘right’ to denote the entitlements of Nigerians to a healthcare system is 
illustrative of the legislators’ recognition of healthcare as an essential human 
right.352 It could be said that the Act imposes a human rights obligation on the 
state to provide healthcare to its citizens. Although not expressly stated in the 
                                                          
348 See for example, the National Health Act which recognises Nigerians to a right to healthcare and services.  
349 In a related manner, in the 1999 Constitution, health is listed in Schedule II, Part II, Item 17(a) of the Concurrent list; however 
the wording of the Item indicates that the National Assembly is charged with the responsibility of making laws with respect to 
matters and issues relating to health.  
Schedule II, Part II, Item 17(a) provides as follows that the National Assembly may make laws for the Federation or any part 
thereof with respect to: ‘[t]he health, safety and welfare of persons employed to work in factories, offices or other premises or in 
inter-State transportation and commerce including the training, supervision and qualification of such persons.’  
Under Schedule IV, Item 2(c), one of the functions of a local government authority (municipal) is to facilitate ‘provision and 
maintenance of health services’ in section 2(c).  
350 Emphasis added. Section 1(1) (e) of the National Health Act 2014. The Act provides a framework for the regulation, 
development and management of a national health system and sets standards for rendering health services in the federation.  
351 Section 2(1) (i) of the National Health Act. This duty is vested in the Ministry of Justice.  
352 Section 4(1) of the Constitution provides that ‘[t]he legislative powers of the Federal Republic of Nigeria shall be vested in a 
National Assembly for the Federation, which shall consist of a Senate and a House of Representatives.’ Under section 4(4)(a), the 
National Assembly shall have power to make laws with respect ‘any matter in the Concurrent Legislative List set out in the first 
column of Part II of the Second Schedule to this Constitution to the extent prescribed in the second column opposite thereto.’ 
What this provision seems to suggest is that the National Assembly can make laws with regards to issues relating to health as 
stated in Schedule II, Part II, Item 17(a). It can be argued that the National Assembly has exercised its right under the Constitution 
to make access to healthcare a matter of rights as opposed to merely stating that healthcare is an aspirational objective and 
directive principle of the Nigerian government.  
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Act, the obligation to provide healthcare and medicinal treatments will require 
the state to guarantee that its laws and policies, such as patent laws and the 
rights conferred on inventors do not hinder access to medicines or its duty as 
considered in the preceding parts of this chapter. The Act is still at its nascent 
stage; it remains to be seen if it will live up to its objective of promoting access 
to quality healthcare for women and everyone in Nigeria. 
 
4.9 Nigeria’s International Obligation to International Human Right 
Provisions Guaranteeing Rights to Health and Access to Medicines  
Nigeria, as mentioned in subsection 4.2.2, has committed itself to protect the 
rights to health and life under several international human rights instruments. 
This commitment to human rights imposes a duty on the state to fulfil its 
contractual obligation to respect, protect, enforce and promote the actualisation 
of human rights provisions including women’s right to health, life and access to 
medicines as earlier enumerated.353 Nonetheless, the applicability of human 
rights provisions in international laws and instruments is not absolute. The 
binding obligation on the state to give practical expressions to the right to health 
and access to medicines as a constituent of the right in the international human 
rights instrument raises numerous enforcement issues particularly with regards 
to Section 12(1) of the Nigerian Constitution. Nigeria is a dualistic state; thus 
treaties and laws do not automatically carry the force of law. The reason for this 
is that Section 12(1) of the Constitution expressly provides that before a treaty 
can be recognised as law in Nigeria, it must be incorporated into national law by 
the National Assembly for domestic validity. 354 At present, the UDHR, CEDAW, 
                                                          
353 See the analyses in subsections 4.2.3, 4.2.4, 4.2.5, 4.3 and 4.4 of this chapter. 
354 Section 12(1) provides that  
[n]o treaty between the Federation and any other country shall have the force of law to the extent to which any 
such treaty has been enacted into law by the National Assembly.  
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ICECSR and other international laws which contain significant human rights to 
health provision have not been enacted into the national laws of Nigeria. They 
will require domestication by the National Assembly to bear practical 
applicability and direct enforcement in Nigeria. The only binding human rights 
provision in Nigeria is the African Charter, which has been ratified and 
domesticated accordingly. 
 
4.9.1 Nigeria’s Commitment and Obligation to the Right to Health in the 
African Charter 
At the regional level, Nigeria is a State Party to the African Charter. The 
Nigerian National Assembly in March 1983 formally incorporated the African 
Charter (Ratification and Enforcement) Act into the domestic laws of Nigeria.355 
Section 1 of the Act states that the Charter  
[s]hall have the force of law in Nigeria and shall be given full recognition and effort 
and be applied by all authorities.356  
Thus the Act directly incorporates all the human rights provisions of the African 
Charter including the right to health.357 Furthermore, Article 18(3) of the Act 
specifically requires the state to take action to eliminate discrimination against 
women and ensure the protection of their rights as enumerated in international 
                                                                                                                                                                          
 What this means is that international law does not exist as law unless it is explicitly incorporated into national law as well. Section 
12(2)(3) of the Constitution further provides that where the subject matter of a treaty falls outside the Exclusive Legislative List, a 
bill for an Act of the National Assembly to give the treaty the force of law must be ratified by a majority of all the Houses of 
Assembly in the federation before it is enacted and assented to by the President. Hence, until a treaty has been domesticated in 
Nigeria, it cannot be applied within the country. 
355 This Charter is part of the Nigerian law in Chapter 10 Laws of the Federation 1990. (It is worth noting that, although the 
National Assembly enacted the Act in 1983, the president was entrusted with the power to set the commencement date for the 
Act. Before the date was set, the military Administration took over. Consequently, the Revised Edition of the Laws of the 
Federation of Nigeria backdates the Act and its commencement to 17 March 1983.) 
Nnamuchi (n 302) 16; U Umozuruike The African Charter on Human and Peoples’ Rights (Kluwer Law International 1997) 111. 
356 Section 1 of the Act. Paragraph 3(a) of the Preamble to the Fundamental Rights (Enforcement Procedure) Rules 2009 further 
clarified that ‘[t]he Constitution, especially Chapter IV, as well as the African Charter, shall be expansively and purposely 
interpreted and applied, with a view to advancing and realising the rights and freedoms contained in them and affording the 
protections intended by them.’ 
357 By virtue of Article 16 of the African Charter on Human and Peoples' Rights (Ratification and Enforcement) Act Chapter A9 
which states that:  
Every individual shall have the right to enjoy the best attainable state of physical and mental health.  
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Declarations and Conventions including CEDAW. By virtue of the Act, all human 
rights provisions in the African Charter are recognised in Nigeria, hence the 
right to health in the Charter constitutes a part of the domestic laws of 
Nigeria.358 The policy makers, judiciary and legislature are therefore duty bound 
to enforce and safeguard the rights of every Nigerian to health. In this regard, 
Nigeria has an obligation to undertake all reasonable measures to guarantee 
the enjoyment of all human rights including the right to access medicines.  
 
4.9.1.1 What does this Human Rights Commitment mean for Women’s 
Access to Medicines as a Right to Health in Nigeria?  
The explicit recognition of women’s fundamental right to health imposes a duty 
on the Nigerian state to give serious considerations to women’s state of health 
in Nigeria and also to promote, protect, and provide adequate, affordable 
medicines in this respect. The state has a duty to guarantee that there is no 
impediment to this access, including ensuring that its activities or those of third 
parties, laws and treaty obligations are not inconsistent with its human rights 
duties to health. The failure of the Nigerian state to promote, respect and fulfil 
its obligations to women’s rights means that it is in breach of its duty. The 
African Charter has played an important role in imposing a human rights 
responsibility on the Nigerian government to respect the right to health and 
provide medical care to its citizens. In Media Rights Agenda & Others v Nigeria, 
the Commission took the view that the denial of an incarcerated suspect’s 
                                                          
358 Furthermore, in Order 1 (2) of the Fundamental Rights (Enforcement Procedure) Rules, 2009 ‘Fundamental Right’ is defined as 
‘any of the rights provided for in Chapter IV of the Constitution, and includes any of the rights stipulated in the African Charter on 
Human and Peoples’ Rights (Ratification and Enforcement) Act.’  
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access to medical care while his health was deteriorating is a clear violation of 
the right to health under Article 16 of the Charter.359  
With specific regard to international human rights instruments such as ICECSR 
and CEDAW, containing important human rights obligations to health, the 
interpretative authority of the CECSR remains unclear since Nigeria is yet to 
incorporate the Covenants.360 Interestingly however, Article 60 of the African 
Charter provides that the Commission ‘shall draw inspiration from international 
law on human rights and people’s rights,’ including the provisions of ICESCR on 
rights to healthcare, and ‘specialised agencies of the United Nations’ such as 
the CECSR which has clearly stated that access to medicines is a constituent 
component of the right to health.361 In light of this provision, it appears that the 
provisions of the ICESCR and the accompanying General Comments and 
recommendations on the right to health can provide a conceptual interpretation 
and also guide the courts in the adjudication of rights of women and every 
Nigerian citizen’s to access medicines as a fundamental human right. Likewise 
General Comment No 2 on Article 14(1)(a)(b)(c) and (f) and Article 14(2)(a) and 
(c) of the Protocol to the African Charter on Human and Peoples’ Rights on the 
Rights of Women in Africa provides similar principles in relation to the right to 
health and the analogous state obligations as contained in CEDAW General 
Recommendation on Women’s Right to Health.362 It can be said, therefore, that 
                                                          
359 Media Rights Agenda and Others v Nigeria (2000) AHRLR 200 (ACHPR 1998) paragraphs 90, 91. Likewise, the Commission 
considered it a violation of the right to health under Article 16 to deprive prisoners of food, blankets and adequate hygiene as it 
affected their general state of health. See Thirteenth Annual Activity Report of the African Commission on Human and Peoples’ 
Rights 1999 – 2000 158.  
360 Nonetheless, the provisions of the African Charter and Protocol to the African Charter on Human and Peoples' Rights on the 
Rights of Women in Africa with respect to their right to health can be legitimately enforced by the courts in Nigeria.  
361 As articulated in subsection 4.2.4. 
362 And also, African Commission on Human and Peoples’ Rights, General Comment No. 3 on the African Charter on Human and 
Peoples’ Rights: The Right to Life (Article 4) (Adopted during the 57th Ordinary Session of the African Commission on Human and 
Peoples’ Rights held from 4 to 18 November 2015 in Banjul, The Gambia) Paragraphs 3, 42 and 43 where state’s obligation to the 
right to life is broadly construed to include adequate healthcare. In paragraph 42, the state has an obligation to prevent maternal 
mortality ‘by establishing functioning health systems and 
eliminating discriminatory laws and practices which impact on individuals’ and groups’ ability to seek healthcare.’ 
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attaining the best standards of health of women in Nigeria will require access to 
medicines to overcome illnesses and restore health. This also requires the state 
to address violations and safeguard against interference by patent right holders 
and pharmaceutical companies. Section 16(2) of the African Charter 
(Ratification and Enforcement) Act specifically mandates the state to protect the 
health of the people and ensure access to medical care. Access in this regard 
presupposes that the Nigerian government should take all necessary actions, 
including the use of patents exceptions and TRIPS-complaint flexibilities 
safeguards to provide essential medicines and also ensure that accessibility to 
the medicine is not hindered.363 
A question with regards to the African Charter, however, is whether it has 
domestic application in terms of the enforcement of its provisions by the courts 
in Nigeria. In a number of cases, the courts have held that the African Charter 
and all its provisions are indeed directly enforceable in Nigeria. In Ogugu & 
others v State,364 the Supreme Court held per Bello (CJN) that the African 
Charter is a part of Nigeria’s domestic law as ‘[…] the Charter has become part 
of our domestic laws, the enforcement of its provisions like our laws fall within 
the judicial powers of the Court as provided by the Constitution and all other 
laws relating thereto.’365 Accordingly, the rights in the African Charter are ‘[…] 
enforceable by the several High Courts depending on the circumstances of 
each case and in accordance with the rules, practice and procedure of each 
                                                          
363 Within the context of promoting the right to health, scholars have pointed out that compulsory licence and other public health 
exemptions are valuable tools for this purpose. See Lazzarini (n 222) 125; Haochen Sun, ‘A Wider Access to Patented Drugs under 
the TRIPS Agreement’ (2003) 21 Boston University International Law Journal 101. (Sun argues for the implementation and 
interpretation of the TRIPS flexibilities, Doha Declaration and the Paragraph 6 Solution in light of public policies and the right to 
health, particularly, accessibility, availability and affordability in a non-discriminatory manner, to secure access to medicines.) ibid 
112-113. 
364 Ogudu v State (1994) 9 NWLR (Pt.366) 1. (The case is also reported as Peter Nemi v A.G of Lagos [1994]1LRC 376 in some 
reports.) In this case, the 3rd appellant and four other persons were convicted of conspiracy to commit armed robbery and 
sentenced to death on 28th February 1986. In their appeal, they invoked the provisions of the African Charter and invited the 
court to assume jurisdiction in a question of complaint of "cruel, inhuman or degrading punishment and treatment" contrary to 
Article 5 of the African Charter on Human and Peoples Right. 
365 ibid 26-27, paragraph G-G ibid. 
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Court.’366 Thus all human rights provisions including the right to health in the 
African Charter are justiciable and applicable in all courts of law in the same 
manner as the Fundamental Rights in Chapter IV of the Constitution.367 This 
opinion is supported by Cui who notes that the Nigerians can rely on the African 
Charter as an enforceable legal instrument, to seek redress for their human 
rights.368 This position is also reiterated by the Supreme Court in General Sani 
Abacha & 3 others v Gani Fawehinmi.369 The Supreme Court held that the 
African Charter is a part of Nigerian laws and the provisions are enforceable by 
the courts as other laws in Nigeria. It follows that the right to the ‘best attainable 
standard of mental and physical health’ including access to medicines in the 
Charter can be enforced by the courts in Nigeria.370 Importantly therefore, the 
right to health in the African Charter complements the absence of an 
enforceable right to health in the Constitution.371  
This argument finds support in the seminal ruling by the African Commission on 
Human and People’s Rights in Social and Economic Rights Action Centre 
(SERAC) and another v Nigeria.372 The Commission broadly interpreted the 
African Charter to enforce the right to health provisions amongst others, and 
                                                          
366 27, paragraph G-G ibid. 
367 What this signifies is that all the provisions of the Charter will have similar effects to the Fundamental Rights under the 
Constitution. Olowu (n 307) 173. Although this was decided based on the enforcement of a civil and political right, undoubtedly, 
the application of the Court’s decision extends to the socio-economic rights in the Charter. 
368 Roberto Cui, Oil Multinationals in Nigeria: Human Rights, Sustainable Development and the Law (Anchor Academic Publishing 
(Aap Verlag) 2015) 54. 
369 (2000) Volume 4 Federation Weekly Law Reports 533. In this case, the respondents challenged their detention by the military 
government on the grounds that it violated their fundamental human rights under the Nigerian Constitution and Article 4, 5, 6, 12 
of the African Charter.  
370 Per Ogundare JSC (ibid 31-32, paragraph F-G). Notwithstanding this, the court held that the Constitution is supreme and 
overrides any other law or binding international treaties; hence in the event of a contravening provision in the Charter, the 
Constitution will prevail.  
371 In Socio-Economic Rights and Accountability Project (SERAP) v Federal Republic of Nigeria and Universal Basic Education 
Commission (2012) No. ECW/CCJ/APP/0808, the Economic Community of West African States (ECOWAS) Community Court of 
Justice also upheld the justiciability of the African Charter as a part of the domestic laws in Nigeria. In a case involving the right to 
education, the court held that it has the jurisdiction to entertain matters under the African Charter notwithstanding the fact that 
the educational objective in the Constitution of Nigeria is unenforceable by the court. The court ruled that ‘under article 9 (4) of 
the Supplementary Protocol, the Court clearly has jurisdiction to adjudicate on applications concerning the violation of human 
rights that occur in Member States of ECOWAS’ and that it ‘has jurisdiction over human rights enshrined in the African Charter and 
the fact that these rights are domesticated in the municipal law of Nigeria cannot oust the jurisdiction of the Court.’ 
372 (2001) Communication No 155/96 African Commission on Human and Rights (ACHPR).  
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found that the Federal Republic of Nigeria was in violation of Articles 2, 4, 14, 
16, 18 (1), 21 and 24 of the African Charter on Human and Peoples' Rights by 
allowing multi-national companies to carry out oil exploration operations that 
affected the environment and health of the people in that region.373 The 
Commission imposed a responsibility on the Nigerian government to respect the 
health and environmental rights of the people of Ogoniland, even though it was 
a non-justiciable right under the Nigerian Constitution. This decision opened up 
another avenue for the enforcement of the right to health in Nigeria. 
Fundamentally, this was a decision against acts committed by a corporation but 
the court held the Nigerian government liable for the acts of the third parties. 
Applying the current understanding of the obligations of pharmaceutical 
corporations to respect and promote rights to health and access to medicines, 
there is no reason barring the application of the court’s rationale in this case to 
determine the liabilities and responsibilities of pharmaceutical companies in 
cases on pharmaceutical patents and access to medicines.  
Nevertheless, Section 12(1) of the 1999 Constitution remains in force; hence 
CEDAW, ICECSR and UDHR which contain significant human rights to health 
provisions, will require domestication to bear meaningful practical applicability in 
Nigeria. In the meanwhile, the binding duty of responsibility on the Nigerian 
government to give reference to the provision of adequate healthcare and 
medicines in the African Charter and Constitution is sufficient to compel a 
binding duty. As Article 5(3) of the Protocol to the African Charter allows 
relevant NGO's with observers status and Individuals to institute cases directly 
to the African Commission with regards to their human rights, Nigerians and 
NGO's on their behalf can institute actions to mandate the government to foster 
                                                          
373 See ibid paragraph 70. 
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better access to medicines as a part of the people's legitimate human rights 
entitlements. Nigerians can also seek to compel the government to take into 
account the human rights aspirations and interests of the people in the 
negotiations, implementation and enforcement of its international trade 
obligations such as TRIPS. More specifically, the government can be mandated 
to consider the citizens' rights to health when designing, structuring and 
enforcing the rights and exceptions contained in its patent law. 
 
4.9.2 Adopting a Rights-Based Approach to Patent Right to Promote 
Women’s Right to Access Medicines in Nigeria 
The sum total of the arguments and analysis in this chapter indicates that 
human rights relate to health and that access to medicines is germane to the 
enjoyment of the right to health as well as the right to life. In this manner, 
human rights provide the basis to argue for the alleviation of problems inhibiting 
women’s access to healthcare in Nigeria. This rights approach to the issue of 
accessing medicine is relevant because it provides a guiding standard for 
national policies, laws and programmes to achieve the goal of fulfilling, 
protecting, respecting and generally securing their right to health. 
To secure women’s right to health and ensure that they can fully enjoy their 
human rights, it is submitted that there is a need to promote their access to 
affordable medicines. The preceding chapter highlighted the concern that the 
patent protection of pharmaceuticals could result in high prices or stifle 
incremental innovation which could have the effect of impeding the availability 
of and women’s access to affordable drugs for serious medical needs.374 In this 
event, one of the ways in which the Nigerian state can meet its obligation, as to 
                                                          
374 See the debate in subsection 3.7 and its sub-subsections in Chapter III. 
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the right to health is to make sure that pharmaceutical patents do not constitute 
an obstruction to the enjoyment of the rights of women to better healthcare.  
From a health perspective, however, patents cannot be discounted. As noted in 
the previous chapter,375 patent, as has been argued, could promote public 
health by facilitating increased medicinal R&D. Thus the human rights 
perspective in this thesis does not reject the importance of protecting the 
interests of the pharmaceuticals industry and patent right owners with regards 
to their pharmaceutical patent rights. However, there is a need for the Nigerian 
state to balance its responsibilities to women’s human rights and promoting 
scientific and medicinal R&D. One way of so doing is to limit the impact of 
patent rights on human rights in national laws. The state can do this by relying 
on public interest measures and flexibilities in the TRIPS Agreement to broadly 
give effect to the right to health and access to essential drugs.376 The right of 
WTO members to determine their appropriate level of protection in a given 
situation has been recognised by the WTO appellant body.377 
Another possibility open to the Nigerian government and the national courts is 
to strike a balance between the human rights-related interest of inventors on the 
one hand and promoting society’s welfare (which includes women’s rights) to 
access the fruits of pharmaceuticals R&D on the other. The need to strike a 
balance between the rights of the creators and the human right to access the 
products of technological innovation such as medicines also mirrors the debate 
about the balance of patent holders’ rights and user’s rights in IP systems.378 As 
                                                          
375 In subsection 3.6.2.1 of Chapter III. 
376 See the case of Novartis AG v Union of India. IPAB Order No 100/2009 available at <http://www.ipab.tn.nic.in/Orders/100-
2009.htm> accessed 22 October 2013; see also SC Civil Appeal Nos. 2706-2716 of 2013, paragraph 168.  
377 Accordingly, ‘WTO Members have a right to determine the level of protection of health that they consider appropriate in a 
given situation’. European Communities - Measures Affecting Asbestos and Asbestos-Containing Products: Appellate Body Report 
(WT/DS135/AB/R April 5 2001) 168. 
378 See subsection 2.5.4 of Chapter II. 
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identified in Chapters II and III, it is commonly argued that an objective of patent 
protection is to promote long-term public interest and social welfare by means of 
providing exclusive rights to right holders for a limited duration. 379 During the 
term of protection, there is potential for conflict between these private and public 
rights considerations, which can also mirror the differences between the 
interests of right holders and end users under human rights law. The challenge 
for national and international lawmakers is to find the optimal balance between 
the various competing interests with a view to maximising the benefit of the 
invention to the public, whilst also meeting the private interests of inventors.380  
One way in which this can be done is by properly delineating the nature and 
scope of public and private rights. For patents, the patentable subject matter, 
scope, limitations and term of protection, can be clearly defined and balanced 
against the socio-economic and cultural rights such as rights to health. Also, a 
way of finding this balance might be to clearly map out the purpose of patents, 
which is the promotion of technological and social development, and state that 
where private rights interfere with this goal, the fundamental human rights to 
health should prevail in the public interest. Human rights law does not provide a 
clear indication on how to strike the right balance between protecting the 
interests of inventors and promoting access to the products of intellectual 
activities, neither do international IP agreements offer an ideal balance. 
However, within the context of patent law, states can clearly delineate a way of 
addressing these two interests when they conflict. There is no Nigerian 
jurisprudence to support this point, however, by way of example, the case of 
Smith Kline and French Laboratories Ltd v Netherlands buttressed the point that 
public interest is given paramount importance where there is a conflict of 
                                                          
379 See subsections 2.3.2 and 2.3.3 of Chapter II and subsection 3.6.2.1 of Chapter III.  
380 As discussed in subsection 4.7.4 of this chapter. 
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interests.381 The ECHR stated that the granting of compulsory licensing for a 
patented drug was not an interference with the human rights entitlement under 
Article 1 of Protocol No 1 of the ECHR.382 Even when the patent holder’s right 
was recognised as a human right, the court gave primacy to the public interest.  
In that case, the applicant, a proprietor of a patented medicine cimetidine (for 
the treatment of gastric and duodenal ulcer), appealed against the granting of a 
compulsory license to a drug company, Centrafarm Bv, to use and work whose 
patented invention. Among other things, the applicant claimed that the 
compulsory licence was a violation of its right to peaceful enjoyment of its 
‘possession’ contrary to Article 1(1) Protocol 1, and that the licence interfered 
with the exclusive right to exploit the patented invention.383 The ECHR in its 
ruling found that, although the compulsory license ‘constitutes a control of the 
use of property,’ the grant was lawful in accordance with the general interest of 
the public.384 Notably, the general public interest was adopted as a yardstick by 
the courts to test whether the interference with the use and enjoyment of the 
proprietor’s right was lawful. In the end, the ECHR came to the conclusion that, 
‘the grant of the compulsory licence was lawful and pursued a legitimate aim of 
encouraging technological and economic development.’385 Since the applicant’s 
invention prevented the working of a patent that that was beneficial to society, 
the ECHR considered the long-term interest of the public to benefit from 
technological and scientific progress to decide in favour of the compulsory 
licence. 
                                                          
381 SmithKline and French Laboratories Ltd v Netherlands (n 244).  
382 ibid 
383 ibid paragraph 2. 
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It could be said that the interests of the patentee, in this case, were recognised; 
hence the ECHR found that the decision of the patent office to grant the licence 
constituted an interference with the inventor’s rights and use of its property. Yet, 
the ECHR took into account the broader development goal of the public (the 
dependent patent in this case) to access and use the patented invention since it 
was clear that the applicant’s patent limited the use and working of Centrafarm 
Bv’s invention. The ECHR attempted to strike a balance between two 
competing interests (SmithKline and French Laboratories Ltd and Centrafarm 
Bv) by recognising the overall objective of encouraging technological and 
economic development as a yardstick to measure their various interests.  
In another example, the Indian Supreme Court in 2014, dismissed a petition by 
Bayer to set aside the compulsory license on the anti-cancer drug ‘Sorafenib 
Tosylate’, otherwise marketed as ‘Nexavar.’386 In that case, Nacto Pharma 
Ltd.,387 a pharmaceutical drug producer, made a request for a voluntary licence 
to Bayer which was denied. Natco subsequently made an application for, and 
was granted, a compulsory licence to manufacture and market the patented 
drug in 2011. On appeal by Bayer against the decision to grant the compulsory 
licence, Natco argued in defence that Sorafenib tosylate, a crucial drug for 
patients living with kidney and liver cancer, was unreasonably expensive and 
unaffordable to patients in India. Moreover, Bayer had not worked its drug, 
Nexavar, in the territory of India. Bayer contended these claims, but the 
Controller General of Patents ruled in favour of Natco.388 In 2013, the 
                                                          
386 Further information is available at ‘Breaking News!! SC Dismisses Bayer’s SLP Against India’s First CL’ (Spicy IP) 
<http://spicyip.com/2014/12/breaking-news-sc-dismisses-bayers-slp-against-indias-first-cl.html> accessed April 23, 2016; 
'Supreme Court Says No to Bayer, Upholds Compulsory License on Nexavar' (Lawyerscollective.org)  
<http://www.lawyerscollective.org/updates/supreme-court-says-no-to-bayer-upholds-compulsory-license-on-nexavar.html> 
accessed 23 April 2016.  
387 This case was briefly mentioned in footnote of subsection 6.8. ( See footnote 287). 
388 See decision of the Controller at Natco Pharma Ltd v Bayer Corporation – Application for Compulsory License under Section 
84(1) of the Patents Act 1970 in respect of Patent No 215758 Controller General of Patents, Mumbai, CLA No 1 of 2011 
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Intellectual Property Appellate Board (IPAB) considered whether the licence can 
be granted to the applicant on the grounds that the drug was not ‘available to 
the public at a reasonable price’ in accordance with Section 84(1)(b) of Indian 
Patents Act. The IPAB after a careful deliberation, dismissed the appeal filed by 
Bayer and confirmed the compulsory licence given to Natco.389 The IPAB based 
its decision on the yardstick of the public in ruling that ‘[s]ection 84 […] is only 
concerned with the price at which the drug is made to the public.’390 
Significantly, the IPAB approached the appeal from the perspective of the public 
interest within the context of the right to life as guaranteed under Article 21 of 
the Constitution of India, 1950. Accordingly, 
[t]here we are not concerned with the interest of the compulsory licence applicant, 
but only the public interest. The grant of compulsory licence is not to favour the 
applicant, but only because the applicant has demonstrated that the invention has 
not reached the public in the manner envisaged under Section 84.391 
The ruling in this case upheld the primary importance of public health over 
private monopoly rights and gave impetus for the Indian Government to grant 
more compulsory licences in the interest of access to medicines. 
Commentators have also pointed to the persuasive effect of human rights 
rhetoric as a means to balance the rights in IP laws, mitigating the adverse 
impact of IP rights or adjusting IPRs to respond to essential human rights 
                                                                                                                                                                          
(unreported) also available at http://www.ipindia.nic.in/iponew/compulsory_license_12032012.pdf. After a careful consideration 
of evidence, the Controller General came to the conclusion that the patented invention was not ‘available to the public at a 
reasonably affordable price’ not locally manufactured in India, and that the patent rights holder has ‘failed to grant a voluntary 
license on reasonable terms to anyone,’ therefore, a compulsory licence was granted to Natco Pharma Ltd. The licence effectively 
authorises Natco Pharma Ltd to produce the drug in its own facilities and sell it. A royalty payment of six percent is to be paid to 
Bayer Corporation. Natco Pharma Ltd v Bayer Corporation Controller General of Patents, Mumbai, CLA No 1 of 2011. 35-61 
(unreported) 
See also Charles Lawson, ‘Accessing and Affording Drugs Despite the Patent Barrier: Compulsory Licensing and Like 
Arrangements?’ (2013) 24 AIPJ 94, 107-108; Mansi Sood, 'Natco Pharma Ltd. V. Bayer Corporation and the Compulsory Licensing 
Regime in India' [2013] NUJS Law Review, 104. 
389 Bayer Corporation v Natco Pharma Ltd., Order No. 45/2013 (Intellectual Property Appellate Board, Chennai). 
390 ibid paragraph 42.  
391 ibid paragraph 43.  
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needs.392 For example, Professor Correa points out the variety of ways that 
Human Rights Impacts Assessments (HRIAS) have been used to assess the 
direct and indirect impacts of agreements, treaties, and actions which affect the 
right to health.393 Likewise, he examined the role and use of human rights 
principles by the courts to mitigate the excessive effect of IP on access to 
medicines and rights to health and concludes that human rights values, when 
incorporated into national legal systems, can ‘provide national Courts with 
grounds for effectively circumscribing the substantive procedural rights 
conferred under different modalities of IPR.’394 Also, that there is ‘a lot of 
promise for the potential of human right [to health] arguments to play a key role 
in judicial decision-making.’395 
Furthermore, it is submitted that the courts can adopt a rights-based approach 
to interpret and enforce matters bordering on patents and rights to health, life 
and the dignity of the human person. In recent times, a number of national court 
decisions in other jurisdictions have provided clear reference points on the 
impact of, and relationship between access to medicines, human rights and 
IPRs in general. For example, adopting a rights-based approach, the Kenyan 
Courts recognised the precedence of public health and basics human health 
over private IP rights in Patricia Asero Ochieng, Maurine Atieno, Joseph Munyi, 
and AIDS Law Project v. Attorney General.396 The court stated that the ‘right to 
                                                          
392 Laurence R Helfer, 'Toward a Human Rights Framework For Intellectual Property' (2007) 40 972 University of California Davis 
Law review 971, 976. 
393 Carlos M Correa, ‘Mitigating the Impact of Intellectual Property in Developing Countries Through the Implementation of Human 
Rights’ in Christophe Geiger (ed), Research Handbook on Human Rights and Intellectual Property (Edward Elgar Publishing 2015) 
208-210. 
One example he gave was the assessment of the effect of IPRs on rights to health in the Central American Free Trade Agreement 
(CFTA) by the Defensoria de los Habitantes de la Republica of Costa. ibid 209.  
394 ibid 216. 
395 ibid 216. 
396 Petition No.409, 2009 paragraph 56. (The Judge ruled that the right to health, life and human dignity are inextricably bound; 
there can be no argument that ‘without health, the right to life is in jeopardy […].’  
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life, dignity and health of the petitioners must take precedence over the 
intellectual property rights of patent holders.’397 In that case, a group of 
individuals living with HIV/AIDS instituted an action, challenging the Kenya Anti-
Counterfeit Act on the grounds that the counterfeit provisions which included 
essential generic medications as counterfeit goods, violated their ability to 
access affordable and generic medicines and, therefore, their rights to health. 
The court, in ruling that IPRs should not override essential rights to life and 
health, found that the sections398 would negatively impact on the rights of the 
petitioners and others living with HIV and [AIDS] to access essential 
medicines.399 Thus, the Act was in ‘violation of their rights under the [Kenyan] 
constitution.’400 Although the public policy objective of the Act was to prohibit 
counterfeit goods, the court took into account the effect of the provisions on the 
petitioners’ access to available and affordable essential medicines, including 
generic drugs.401 Importantly, this case supports the position adopted in this 
thesis that the right to access affordable essential medicines is greater and 
more critical than the enforcement of IP rights.402  
The Indian case of F. Hoffmann-La Roche Ltd. and Anr. v Cipla Ltd, further 
illustrates the point that litigation can effectively be used to give consideration to 
the rights to access affordable essential life-saving drugs where patent rights 
adversely impact on rights to medicines.403 In this case, the plaintiff brought an 
                                                          
397 Paragraph 85 of the court’s decision ibid.  
398 Sections 2, (definition of counterfeiting) section 32 (offences) and section 34 (powers of commissioner to seize suspected 
counterfeit goods). 
399 For the full judgment, see <kelinkenya.org/wp-content/uploads/2010/10/Judgment-Petition-No-409-of-2009-Anti-counterfeit-
case.pdf> accessed 14 July 2015. 
400 The Court relied on the constitutional human rights of the petitioners to human dignity and highest standard of health as 
protected under Articles 26(1), 28 and 48 of the Constitution to make the order. Paragraph 52 of the decision.  
More discussions on the case at Allan Maleche and Emma Day, ‘Right to Health Encompasses Right to Access Essential Generic 
Medicines: Challenging the 2008 Anti-Counterfeit Act in Kenya’ (2014) 16(2) Health Human Rights 96. 
401 Paragraph 52 of the decision.  
402 Paragraph 85 of the decision.  
403 148 (2008) DLT 598, MIPR 2008 (2) 35. Judgment delivered by J Ravindra Bhat. 
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action against the generic producer, Cipla Ltd, to prevent the infringement of its 
patent rights to the cancer drug erlotinib hydrochloride (‘Tarceva’). In a 
landmark decision, the court, in refusing the interim order sought by the plaintiff, 
also based its decision on broader public interest, health and the right to access 
life-saving medicines.404 In this connection, the court ruled that although, 
India entered into the TRIPS regime, and amended her laws to fulfil her 
international obligations, […] the Court cannot be unmindful of the right of the 
general public to access lifesaving drugs which are available and for which such 
access would be denied if the injunction were granted. The degree of harm in such 
eventuality is absolute; the chances of improvement of life expectancy; even 
chances of recovery in some cases would be snuffed out altogether, if injunction 
were granted.405  
It is worth noting that the patent protected version of the drug in this case cost 
three times the price of the generic version by Cipla.406 Deciding in favour of the 
defendant meant that general public interest had a greater weight than private 
proprietary interest. In the end, the judicial decision was useful to safeguard the 
rights of the public to access essential drugs.407 
                                                          
404 Similarly, in the 2013 copyright related case of Ediciones de la Flor SA v. Fontanarrosa Franco s. Acción Mere Declarativa, file no. 
1420/08, the Court of First Instance on Civil and Commercial Matters No. 12 of Rosario, the co-heir of a deceased author, Roberto 
Fontanarrosa, opposed the publication of the deceased’s unpublished works (a moral right specifically recognized to the author) 
arguing subsidiary moral rights as co-heir. The Argentinian Court of First Instance in Civil and Commercial Matters (No. 12 of 
Rosario) held that the rights of the public or community interest to have access to the unpublished work will prevail over authorial 
economic and moral interest, thus ensuring that social interests superseded individual private IP rights. In its decision, the court 
relied on Article 21(1) of the American Convention of Human Rights (which states that ‘[e]veryone has the right to the use and 
enjoyment of his property. The law may subordinate such use and enjoyment to the interest of society.’), and Article 15(1) (a) of 
the International Covenant on Economic, Social and Cultural Rights. 
 See the translated report in Maximiliano Marzetti, ‘ Comments on Ediciones De La Flor v Fontanarrosa Franco’ (2013) 44(7) 
International Review of Industrial Property and Copyright Law  
405 Paragraph 85 of the decision. An appeal against this decision found that there was no infringement.  
406 Correa (n 393) 212. 
407 The obligation of the state to protect rights to health and life was also reiterated in the case of Eli Lilly and Company v 
Laboratorios Leti, S.A.V. y otra s/ Infracción de derechos (patente) (2011) Circunscripción Judicial of Caracas, Venezuela,Juzgado 
Superior Octavo en lo Civil, Mercantil, Tránsito y Bancario. [Judicial Circuit of Caracas, Venezuela, Eight High Tribunal on Civil, 
Commercial, Transit and Banking]. In that case, the defendant alleged that the act of granting marketing approval of the medicine 
raloxifen hydrochlorid, before the expiration of its patented term was an infringement of patent rights. The court stated that ‘the 
right to health as an integral part of the right to life, in keeping with the high aim of the Andean integration, represents an 
obligation for the state.’ (As interpreted and quoted in Correa (n 393) 214.) 
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The cases above lend credence to the point that national courts can adopt 
standards of interpretation to give significant effect to human rights to health in 
view of the public interest and welfare. To fully implement the right to health, 
and particularly women’s rights to access medicines with regards to patent 
rights, the Nigerian courts can play a major role. In actions bordering on health 
and access to medicines, the courts can interpret and lay down similar human 
rights standards for the guarantee and enforcement of health provisions. It has 
been argued that national courts can play a role in giving practical effect to 
human rights by preventing violation and interference.408 The courts can also 
encourage and where necessary, compel the fulfilment and realisation of 
human rights.409 Since human rights are part of the legal framework of Nigeria 
as per the African Charter, the courts could develop appropriate standards for 
enforcing the right to health and life, particularly where the issues concern the 
conflict between public health and patent rights. The principles of human rights 
and key dimensions of the right to health provide a fundamental jurisprudence 
to guide the court in this duty to enhance women’s rights to health in Nigeria.  
 
4.10 Conclusion: Making Human Rights Central to Promoting Women’s 
Access to Medicines within the Context of Patent Rights in Nigeria 
Indubitably, everyone is entitled to the right to a standard of health. While 
women’s rights to health and life are clearly established in legal instruments, 
having these laws without the fulfilling them will not serve the people they are 
meant to safeguard. For this reason, this chapter argues that the right to health 
and life includes the right to an effective access to available, good quality, safe, 
                                                          
408 Cnthia Soohoo and Jordan Goldberg, ‘The Full Realization of Our Rights: The Right to Health in State Constitutions' (2010) 60(4) 
Case Western Reserve Law Review 997, 1072. 
409 ibid 
280 
 
and effective medicines that are equally affordable to everyone. It is also 
submitted that ensuring this access to a choice of essential medicines at an 
affordable price requires the state to ensure that the granting of patent rights to 
inventors and pharmaceutical companies does not hinder access to essential 
drugs. 
More specifically, the argument based on human rights principles in this chapter 
is a consideration of women’s health needs in Nigerian regulations and policies 
to fulfil their demands of healthcare. Although the current effect of international 
human rights laws in Nigeria with regards to Section 12 of the 1999 Nigerian 
Constitution leaves many of questions open, the government is not absolved of 
its socio-economic and cultural obligations to promote, respect and fulfil the 
rights of women to have equal access to affordable, safe and effective 
medicines. This positive step in the right direction includes implementing the 
TRIPS Agreement in a manner that supports women’s rights to health. Such a 
trade agreement should be balanced against the right to health, especially 
where its patent rights interfere with health of women whether directly or 
indirectly.410 
To add to the justification for a consideration of women’s access to medicines 
within the context of patents, the next chapter also makes a case for access 
from a human development perspective.  
                                                          
410 As stated previously, Nigeria has not incorporated the Agreement as required under Section 12 of the Constitution. Chapter VI 
of this thesis suggests ways in which the Nigerian Government and legislators could promote innovation and the public interest in 
implementing the Agreement. It is worth noting that the human rights framework for implementing TRIPS offers only one of the 
many policy arguments for making health a focal point in foreign trade policy and patent rights. In essence, it complements other 
policy approaches geared at improving people’s welfare and wellbeing including economic and human development, and security. 
See Michelle l Gagnon and Ronald Labonte ‘Human Rights in Global Health Diplomacy: A Critical Assessment’ (2011) 10 Journal of 
Human Rights 189,189–213.  
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CHAPTER V: RECONCEPTUALISING PATENTS AS TOOLS FOR 
HEALTH AND HUMAN DEVELOPMENT: ENHANCING ACCESS 
TO MEDICINES IN NIGERIA 
The ends and means of development require examination and scrutiny for a fuller 
understanding of the development process; it is simply not adequate to take as our 
basic objective just the maximization of income or wealth, which is, as Aristotle 
noted, ‘merely useful and for the sake of something else.’ For the same reason, 
economic growth cannot sensibly be treated as an end in itself. Development has 
to be more concerned with enhancing the lives we lead and the freedoms we 
enjoy.1 
 5.1 Introduction  
As the analysis in the previous chapters reveal, the patent system underlies 
public policy and welfare objectives.2 From a development perspective, a patent 
is widely considered as integral to human well-being and economic growth. As 
demonstrated in Chapter II3 it is generally argued that the grant of patent rights 
to innovators, and protection of new and substantially useful innovations are 
instrumental in bringing about technological and scientific progress and 
consequently, economic, social and technological development. In many ways, 
a patent is also assumed to give rise to development by promoting medicinal 
research and development (R&D), and facilitating technological innovation for 
public benefit.4 Patents are also considered important policy instruments for 
technology transfer (TT), foreign direct investment (FDI), and the dissemination 
of technological knowledge and the results of innovation, which in turn, lead to 
                                                          
1 Amartya Sen, Development as Freedom (Oxford University Press 2001) 14.  
2 See subsection 2.4 and 2.5.6. 
3 See subsection 2.3 and sub subsections 2.3.2, 2.3., 2.3.4, 2.5.1 and 2.5.2 Chapter II.  
4 Tzen Wong, ‘Intellectual Property Through the Lens of Human Development’ in Tzen Wong and Graham Dutfield (eds), 
Intellectual Property and Human development: Current Trends and Future Scenarios (Cambridge University Press 2010) 3. 
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economic growth and other developmental advantages to the public.5 
Furthermore, this development policy in the interest of IP owners and users is a 
principal objective in Article 7 of the TRIPS Agreement.6  
From a health perspective, human development is construed as the yardstick 
for measuring the development objective of patents to the public. It is argued 
that the development objectives in TRIPS and the patent system in itself, cannot 
give rise to development if it is not properly positioned to enhance vital areas of 
human well-being such as health. In this regard, this chapter argues that the 
development element of patents should extend beyond the traditional analysis 
of patents as a conduit for promoting the availability of innovative products and 
prospects for economic growth. Particularly, this chapter explores the human-
centred dimension of patents by analysing the ways in which patents could 
potentially hinder women’s access to important medicines and consequently, 
human development; or confer benefits to their human development by 
enhancing their capabilities to be in good health.  
It has been acknowledged that there is an inextricable link between enhancing 
the basic health of individuals and improving their prospects for development.7 
As noted in Chapter IV, on human rights,8 the state of a person’s health is 
instrumental to their prospects for economic and human development. As such, 
there is a nexus between the right to health, as identified in the preceding 
chapter and women’s human development. The recognition of health as a 
human right which requires state action, therefore, entails the government and 
policy makers to take into account the importance of health to their people’s 
                                                          
5 Wong (n 4) 3. 
6 See the Preamble, Articles 7 and 8 of the TRIPS Agreement. This was discussed Chapter II of this thesis, subsection 2.5.6. 
7 William W Fisher and Talha Syed, 'Global Justice in Healthcare Developing Drugs for Developing World' (2006) 40 U.C. Davis Law 
Review 581, 589. 
8 See subsection 4.2.2. 
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human development and the factors that can influence this development 
outcome. The Organisation for Economic Co-Operation and Development and 
World Health Organization (WHO) has shown that ill-health, particularly among 
the poor, significantly undermines development.9 Thus, improving the health of 
the people is a prerequisite for governments to meet national development 
goals. Indeed, one of the key aspirational objectives of the United Nation’s 
Sustainable Development Goals (SDG’s) is the improvement of health and well-
being of everyone, including access to effective, safe quality and affordable 
essential medicines and vaccines.10 This development agenda affirms the 
intricate relationship between health and development.11  
In light of the above considerations, this chapter, using the capabilities 
approach, presents a critical analysis of the benefit or adverse effects of patents 
on women’s health and the consequential effects on their prospects for 
development with special focus on their access to medicines as a constituent 
component of the right to health. As the analyses in Chapter III subsection 3.7 
of this thesis have demonstrated, patent rights could impact on accessibility to 
medicines by limiting the options to accessing affordable medicines to enhance 
health outcomes and therefore prospects for human development. Set within 
                                                          
9 Organisation for Economic Co-Operation and Development and World Health Organization, Poverty and Health (DAC Guidelines 
and Reference Series, Organisation for Economic Co-Operation and Development and World Health Organization 2003) 14-22. The 
WHO also states that health as well as being an indicator for development, is an outcome of progress in sustainable development. 
World Health Organization (WHO), Positioning Health in the Post-2015 Development Agenda (WHO discussion paper 2012) 1. 
Available at  
<http://www.who.int/topics/millennium_development_goals/post2015/WHOdiscussionpaper_October2012.pdf> accessed 16 
November 2016. See also World Health Organization, Health in the post-2015 development agenda: Report by the Secretariat 
(Sixty-Sixth World Health Assembly, 1 May 2013 A66/47) paragraph 14.  
10 See Goal 3.3 in United Nations General Assembly, Report of the Open Working Group of the General Assembly on Sustainable 
Development Goals (A/68/970 United Nations General Assembly 2014) 12 available at <http://undocs.org/A/68/970> accessed 16 
August 2016.  
11 Goal 3.b pledges to  
[s]upport the research and development of vaccines and medicines for the communicable and non-
communicable diseases that primarily affect developing countries, provide access to affordable essential 
medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, 
which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-
Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, 
provide access to medicines for all. 
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the context of patent law and women’s right to health, this chapter relies on the 
concepts of human development and capabilities approach as expounded by 
Amartya Sen and Martha Nussbaum to characterise access to patented 
medicines as a means through which women can enhance their opportunities 
for human development, build their health capabilities, and achieve their 
potential to live long, normal and sustainable lives. The capabilities approach in 
the context of human development essentially focuses on the development of 
women’s quality of life – what they are actually able to do and be.12 It is also 
argued that the inability to access quality and affordable medicines can 
constitute a challenge to women’s human development.  
Questions raised in this chapter are: does the development goal of patent law 
extend further than the availability and production of innovative goods and the 
consequential technological/scientific and economic development outcome? If 
so, can the development objective extend to the development of human 
capabilities for sustainable human development? With these questions in mind, 
the welfare benefit of patents to health is analysed with a view to bringing out 
the relevance of the protection to human development in the context of the 
rights to health and access to medicines in Nigeria. Furthermore, the 
discussions in this chapter provide an additional basis to argue for the broad 
interpretation and implementation of the patent-related flexibilities to improve 
women’s access to medicines in Nigeria. 
To achieve this purpose, the first section of this chapter starts with an overview 
of the understanding of development, particularly, human development. The 
                                                          
12 Sandrine Berges, 'Why the Capability Approach is Justified' (2007) 24 Journal of Applied Philosophy 16, 16-7. According to Ingrid 
Robeyns, the capabilities approach is a people-centred evaluative framework that focuses on removing obstacles to people’s lives 
so ‘that they have the freedom to live the kind of lives, upon reflection, they find valuable.’ Ingrid Robeyns, 'The Capability 
Approach: A Theoretical Survey' (2005) 6(1) Journal of Human Development. 93, 94-95.  
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second part underscores the importance of health to development from a right 
to development and health perspective. The last part makes a case for access 
to patented drugs in Nigeria as a means to the expansion and human 
development of basic capabilities such as the capability to be healthy.  
 5.2 Advocating for a Human Development-Oriented Patent System 
This section argues for a pro-human development patent system that would 
take into account the public health and development needs of users.  
To analyse the correlation between IP and human development, it is expedient 
to discuss the definition of the term ‘development,’ to place the understanding of 
development in this chapter within a meaningful context. 
 5.2.1 The Concept of Human Development 
Development for the purposes of this thesis is construed in the context of a 
people – focused human development paradigm. Specifically, it is an 
exploration of the connection between the protection of pharmaceutical patents 
and access to essential medicines for the enhancement of human development 
and capabilities. The concept of development is examines in the following. 
 5.2.3 The Normative Framework of Human Development 
An understanding of development in the wider context of expanding people’s 
human capabilities has been advocated by scholars such as Sen, Nussbaum, 
ul Haq, Alkire and adopted by the United Nations (UN). The 1990 United 
Nations Development Programme (UNDP) Human Development Report 
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provides a clear and fundamental definition of human development.13 The first 
chapter of the report reads:  
Human development is a process of enlarging people’s choices. The most critical 
ones are to lead a long and healthy life, to be educated and to enjoy a decent 
standard of living. Additional choices include political freedom, guaranteed human 
rights and self-respect […].14 
The 1990 report further identifies that the fundamental objective of development 
is to: 
[…] create an enabling environment for people to live long healthy and creative 
lives. This is a simple truth, but it is often forgotten in the immediate concern with 
the accumulation of commodities and financial wealth.15  
Human development analysis essentially centres on three main aspects viz.: 
people, opportunity and choice.16 According to the 2015 report, human 
                                                          
13 The 1990 report is the first document to focus on human development as a measuring matrix for development, hence it contains 
a succinct understanding of what human development is. The structure of human development in this report is similar to 
subsequent reports with some variations although the general rationale for development is replicated in all reports. To illustrate, 
the 1991 Report reiterates that, ‘[t]he real objective of development is to increase people’s choices.’ United Nations Development 
Programme (UNDP), Human Development Report 1991 (Oxford University Press 1991) 13. Also, the definition of human 
development in the 1990 report is similar to subsequent reports with some adjustments and inclusion of other factors as key 
elements for human development. The 1994 Report for example, includes human security as an essential factor for human 
development. United Nations Development Programme (UNDP), Human Development Report 1994 (Oxford University Press 
1994).The 1995 report is focused on gender equality and human development. The report highlights the progress made in 
reducing gender disparity and explores the wide gap between women’s expanding capabilities and limited opportunities, under-
valuation and the non-recognition of women’s work. United Nations Development Programme (UNDP), Human Development 
Report 1995 (Oxford University Press 1995). The 1995 report further introduced two measures for ranking countries on a global 
scale by performance in gender equality (GEM) and (GDI). Essentially, four principles are identified as central to human 
development: Productivity, Equity, Sustainability and Empowerment. Sabina Alkire ‘Human Development: Definitions, Critiques, 
and Related Concepts’ (2010) OPHI Working Paper 36, 7. The 1999 report gave emphasisis to human agency. The Report states 
that ‘[t]he central concern of [the Human Development Report] has always been people as the purpose of development, and their 
empowerment as participants in the development process.’ United Nations Development Programme (UNDP), Human 
Development Report 1999 (Oxford University Press 1999) 18. The 2014 report focused on sustainable development and human 
vulnerability. The Report stressed that ‘the sustained enhancement of individuals’ and societies’ capabilities is necessary to reduce 
vulnerabilities-many of them structural and many of them tied to the life cycle.’ United Nations Development Programme (UNDP), 
Human Development Report 2014 (Oxford University Press 2014) 18.  
14 United Nations Development Programme (UNDP), Human Development Report 1990 (Human Development Report 1990) 10. 
The 1990 Report further clarifies that: ‘[t]he term human development here denotes both the process of widening people’s 
choices and the level of their achieved well-being.’ ibid 10. Mahbub ul Haq, Reflections on Human Development (Oxford University 
Press 1995) 14. 
15 ibid 9; UNDP, Human Development Report 1991 (n 13) 13. 
16 ibid; Alkire, 'Human Development: Definitions, Critiques, and Related Concepts' (n 13) 4. Mahbub ul Haq ‘The Human 
Development Paradigm’ in Sakiko Fukuda-Parr and AK Shiva Kuma (eds), Readings in Human Development: Concepts, Measures 
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development is fundamentally about people; it emphasises that the main 
concern or central goals of development should not be income or resources but 
enhancing people’s capabilities, freedoms and opportunities to improve their 
quality of lives.17 Principally, human development ‘emphasizes the importance 
of putting people – their needs, their aspirations, their choices – at the centre of 
the development effort.’18 Human development is therefore a people-focused 
measure of evaluating an individual’s quality of life and well-being; hence, the 
end objective of human development is the expansion of people’s welfare and 
their well-being.19  
 
Figure 5.1 The Dimensions of Human Development.20 
Human development in this view is concerned with expanding the choices, 
opportunities and full potential of people to live quality lives.21  
                                                                                                                                                                          
and Policies for a Development Paradigm (Oxford University Press 2004) 17-19. According to Mahbub ul Haq, human development 
encapsulates four essential pillars: equality, sustainability, productivity and empowerment. ibid 19. 
17 United Nations Development Programme, Human Development Report 2015: Work for Human Development (United Nations 
Development Programme 2015) 4. Also available at <http://hdr.undp.org/en/2015-report/download> accessed 11 March 2016. 
18 The 1996 Report on Economic Growth and Human Development for example, elucidates that human development extends 
beyond income and growth as measures for human progress. Accordingly, human development essentially covers ‘the full 
flourishing of all human capabilities.’ United Nations Development Programme (UNDP), Human Development Report 1996 (Oxford 
University Press 1996) 49.  
19 Sabina Alkire and Séverine Deneulin, 'The Human Development and Capability Approach' in Séverine Deneulin and Lila Shahani 
(eds), An Introduction to the Human Development and Capability Approach: Freedom and Agency (Earthscan 2009) 25-26. In this 
sense, human development ‘denotes both the process of widening people’s choices and the level of their achieved well-being.’ 
UNDP Human Development Report 1990 (n 14) 10; ul Haq Reflections on Human Development (n 14) 14. 
20 Adapted from United Nations Development Programme (UNDP), ‘What is Human Development?’ Available at 
<http://hdr.undp.org/en/content/what-human-development> accessed 14 March 2016. 
21 ibid 
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As a lens to assessing development, human development basically focuses on 
the state of people’s welfare.22 Consequently, apart from focusing on an 
individual’s freedom to live the lives he or she finds valuable, the human 
development paradigm also draws attention to social, economic and welfare 
factors in evaluating the impact of policies on people’s lives.23  
The human development paradigm is significant in directing the aims of 
development-oriented policies and laws because it covers all aspects of a 
human’s life – whether economic, political, social or cultural – as long as the 
development goals centre on improving people’s lives.24 Within the human 
development structure, the economic system is also important because it is a 
medium for the production and distribution of commodities that can improve and 
enhance the standards of human lives.25 The resources and products of the 
economic system can create the economic opportunities and facilitate the 
means to expanding people’s capability, as well as extending to people a 
variety of choices to use the products or resources to advance their own well-
being.26 However, economic growth focuses on external structures and 
economic progress to bring about developmental changes, thus it is only one of 
the means of ensuring human development,–albeit a very important one,–rather 
than an end in itself.27  
                                                          
22 Tzen Wong adds that development in this sense is about giving people the opportunities to live the lives they value, and 
enabling them to become actors in their own destinies. Wong (n 4) 27. 
23 Alkire and Deneulin (n 19) 19; Graham Dutfield and Uma Suthersanen, 'Innovation and Development’ in Uma Suthersanen, 
Graham Dutfield and Kit Boey Chow (eds), Innovation Without Patents: Harnessing the Creative Spirit in a Diverse World (Edward 
Elgar P.ublishing 2007) 3. 
24 Alkire and Deneulin (n 19) 27 
25 United Nations Development Programme (UNDP), Human Development Report 1993 (Oxford University Press 1993) 21.  
26 ibid 21-22.  
27 Sakiko Fukuda-Parr, 'The Human Development Paradigm: Operationalizing Sen's Ideas on Capabilities' (2003) 9 Feminist 
Economics 301, 304-305; ul Haq, Reflections on Human Development (n 14) 14-16; United Nations Development Programme 
(UNDP), Human Development Report 1993 (n 13) 22; United Nations Development Programme, ‘What is Human Development?’ (n 
20) 
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The focus on individuals, as opposed to income or commodities as central 
subjects of development, is grounded in the rationale that ‘people are the real 
wealth of a nation.’28 Thus, ‘the expansion of output and wealth is only a means’ 
to achieving development.29 As will be discussed,30 although improved 
economic conditions and increased innovative products are necessary for 
development, product output and economic growth may not necessarily lead to 
a rise in the actual standard and conditions of individual’s lives. 
With this understanding of human development in mind, this chapter and thesis 
advocates for the human development goal of expanding the provision of 
Nigerian’s basic health needs, to enhance their health capabilities and potential 
to live long, normal and healthy lives. This thesis engages the language of 
capabilities and freedom analysis to emphasis the welfare dimension of patents 
on human development, in line with the development objectives of patents, as 
also elaborated in Article 7 and 8 of the TRIPS Agreement. For this purpose a 
brief outline of the capabilities approach to human development, as expounded 
by Amartya Sen and Martha Nussbaum and other scholars is described in order 
to situate the arguments for access to medicines as a means to expanding the 
opportunities for people to enhance their health capabilities.31  
 5.2.4 The Capabilities Approach to Human Development 
Amartya Sen and Martha Nussbaum’s theoretical approach to development, 
which emphasises the enhancement of capabilities and people’s freedoms, 
choices and opportunities, has informed the insight into the concept of 
                                                          
28 The 1993 Report essentially made a case for people’s participation in the development process. According to the report, the 
participatory nature of development means that ‘people are closely involved in the economic, social, cultural and political 
processes that affect their lives.’ United Nations Development Programme (UNDP), Human Development Report 1993' (n 13) 21. 
29 UNDP, Human Development Report 1990 (n 14) 10. 
30 In subsection 5.3.1.1 and 5.6 below. 
31 The account of human development adopted in this chapter is brief, merely intended to highlight the relevant aspect of the 
approach within the context of access to patented medicines.  
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development by the UNDP in its Human Development Report.32 Similar to the 
earlier mentioned conceptualisation of development in the UNDP reports,33 the 
capabilities approach views the expansion of people’s freedoms or human 
capabilities as the primary goal of development.34 According to Sen, 
development should be seen ‘[…] as the process of expanding the real 
freedoms that people enjoy.’35 Sen’s model of development as freedom further 
recommends the enhancement of people’s capabilities through the provision of 
basic means to meet human needs such as education and healthcare.36 In his 
writing, Sen makes reference to the social opportunities and the health facilities 
necessary to promote an individual’s substantive freedom and opportunity to 
live a better life.37 In particular, Sen identifies five distinct instrumental freedoms 
‘that contribute, directly or indirectly, to the overall freedom people have to live 
the way they would like to live.’38 Among these are social ‘arrangements that 
society makes for education, health care and so on, which influence the 
individual’s substantive freedom to live better.’39 Accordingly, freedom or 
capability is dependent on socio-economic arrangements including the 
provisions of services and healthcare facilities, to allow human beings to 
function and live fuller lives.40 In this regard, the provision of some basic needs 
such as education and healthcare are elementary means to the development of 
                                                          
32 Margaret Chon, ‘Intellectual Property and the Development Divide’ (2006) 27(6) Cardozo Law Review 2821, 2866; Sen, 
Development as Freedom (n 1) 1-11, 73-74; Martha C Nussbaum, 'Capabilities and Human Rights' (1997) 66(2) Fordham Law 
Review 273, 285-287. 
33 See subsection 5.2.3 above. 
34 Nussbaum, 'Capabilities and Human Rights' (n 32) 288; Sen, Development as Freedom (n 1) 1. 
35 Sen, Development as Freedom (n 1) 1. Sen argues that:  
Development requires the removal of major sources of unfreedoms: poverty […] poor economic opportunities as 
well as systematic social deprivations, neglect of public facilities. 
 ibid 3-4, 17-20. 
36 ibid 11. He argued that ‘[s]ometimes the lack of substantive freedoms relates directly to economic poverty, which robs people of 
the freedom to satisfy hunger, or achieve sufficient nutrition, or obtain remedies for treatable illnesses.’ ibid 3-4, 17-20. 
37 ibid 39. 
38 ibid 38. 
39 ibid 39. Sen also highlights the vital role of economic, social and political institutions and organisations in enhancing people’s 
capabilities or eliminating ‘unfreedoms’ and obstacles to development. ibid 3-4, 17-20 
40 ibid 3-4. 
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freedoms and human capability.41 These health facilities and systems can 
constitute an instrumental means for enabling an individual to exercise his or 
her health capabilities and choices.  
Similarly to Sen, Martha Nussbaum espouses a human development paradigm 
that views the expansion of capabilities as an important goal of government, 
constitutional principles and development policies.42 This approach, 
fundamentally takes ‘each person as an end, asking not just about the total or 
average well-being but the opportunities available to each person.’43 The 
arguments of Sen and Nussbaum adopt the capabilities approach as a 
normative evaluation framework to measure people’s well-being, standard of 
living, social arrangements, development policies and proposals for social 
change in society.44  
The capabilities approach has influenced several development and public policy 
analyses and increasingly, the approach has been applied to the analysis of IP 
and health.45 IP scholars have employed the human development and 
capabilities approach as an alternative way to analyse and evaluate the 
relationship and consequential effect of IP on development.46 In his 
consideration of patents and human development in sub-Saharan Africa for 
                                                          
41 ibid 17-18. 
42 Martha Craven Nussbaum, Women and Human Development (Cambridge University Press 2000) 5, 12.  
43 Martha Craven Nussbaum, Creating Capabilities: The Human Development Approach (Harvard University Press 2011) 18. 
44 Robeyns (n 12) 94. (This thesis does not dwell on the distinction between Sen’s capability approach and Nussbaum’s work in its 
application of the capabilities approach. This thesis relies on both approaches of the scholars and uses their arguments 
interchangeably in this study.)  
45 ibid 4. See Poku Adusei, Patenting of Pharmaceuticals and Development in Sub-Saharan Africa: Laws, Institutions, Practices, and 
Politics (Springer 2013); Sridhar Venkatapuram, Health Justice: An Argument from the Capabilities Approach (Polity 2011); 
Christopher A Riddle, 'Well-Being and the Capability of Health' (2013) 32 Topoi; Jennifer Prah Ruger, 'Health, Capability, and 
Justice: Toward A New Paradigm of Health Ethics, Policy and Law' (2006) 15(2) Cornell Journal of Law and Public Policy 101.  
46 Similarly, several IP scholars have adopted the human development and capabilities approach in their analyses of IP rights. See 
for example, Olufunmilayo Arewa, ‘Freedom to Copy: Copyright, Creation and Context’ (2007) 41(2) UC Davis Law Review; Chon, 
‘Intellectual Property and the Development Divide’ (n 32) 2821, 2827-2828, 2869-2870; Denis Borges Barbosa, Margaret Chon and 
Andrés Moncayo von Hase, 'Slouching towards Development in International Intellectual Property' [2007] Michigan State Law 
Review; Julie E Cohen, Configuring the Networked Self: Law, Code, and the Play of Everyday Practice (Yale University Press 2012); 
Madhavi Sunder, From Goods to a Good Life: Intellectual Property and Global Justice (Yale University Press 2012).  
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example, Poku Adusei makes suggestions for the integration of human 
development norms into the activities and agenda of the national patent policies 
and WTO and TRIPS to promote access to medicines.47 This chapter adds to 
the debate on access to medicines by examining the extent to which the 
capabilities approach can provide a lens to view the benefit of patent law to 
human development by enhancing the capabilities of individual persons in 
Nigeria and women in particular, to be healthy.48 It also highlights that patent 
rights could interfere with women’s quest for human development hence the 
Nigerian government must be proactive in safeguarding the right to health of 
women, particularly, by incorporating, designing and using the TRIPS-compliant 
flexibilities.  
 5.3 The Importance of Development in the Context of International 
Intellectual Property Law 
‘Development’ in the sphere of IP discussions has, at its epicentre multiple 
issues of how IP influences prospects of development: as a means to improving 
technological progress; trading relations; knowledge disclosure; and stimulation 
of innovation (medicinal R&D) for public health.49 At the international trade fora, 
IP is also seen as having the potential to facilitate development, as well as the 
enhancement of trade prospects, economic progress and distribution of 
wealth.50  
Within the province of the World Trade Organization (WTO), development is a 
central component of the IP regime in the TRIPS Agreement. The Preamble of 
                                                          
47 Adusei (n 45) 261. 
48 It is worth noting that this thesis adopts the capabilities approach within a restricted context of health to boost the argument for 
access to medicines within IP and TRIPS context. It lays no claim to all aspects of health capabilities. 
49 Wong (n 4) 1.  
50 Keith E Maskus and Jerome H Reichman, ‘The Globalization of Private Knowledge Goods and the Privatization of Global Public 
Goods’ in Keith E Maskus & Jerome H Reichman (eds), International Public Goods and Transfer of Technology Under a Globalized 
Intellectual Property Regime (Cambridge University Press 2005) 3, 11-15.  
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the TRIPS Agreement, as discussed in Chapter II51 mirrors a development 
objective by setting up a socio-economic and technological development priority 
for IPR protection.52 Article 7 of the TRIPS Agreement echoes this objective in 
stating that the objective of TRIPS is to ensure that protection and enforcement 
of IP rights contributes to technological innovation, dissemination and progress, 
by recognising private rights interest of IP producers in a manner that also takes 
into account, socio-economic welfare of consumers. With this developmental 
objective in view, Article 8(1) of the TRIPS Agreement further allows Members 
to formulate their IP legal systems to protect social well-being ‘in sectors of vital 
importance to their socio-economic and technological development,’ including 
public health.53 It can be said that these provisions delineate a fundamental 
development-oriented objective and the principle of the TRIPS Agreement.54 
Although the Agreement is silent as to how the development objective can be 
achieved, the basic assumption is that IP is a factor for development; hence the 
TRIPS Agreement aims to strike a balance by promoting innovation while also 
underscoring the social and economic welfare objective of IP to society.  
It will be recalled from the argument in Chapter II,55 that the underlying objective 
of the patent system is public welfare-driven. The development for the public 
good flowing from a patent generally encompasses the dissemination of 
                                                          
51 See subsection 2.5.6.  
52 This recognition of development objectives corresponds with the development goal of the WTO, as identified in the Preamble of 
the Marrakesh Agreement Establishing the World Trade Organization, recognising that ‘trade and economic endeavour should be 
conducted with a view to raising standards of living, […] while allowing for the optimal use of the world’s resources in accordance 
with the objective of sustainable development […].’ Marrakesh Agreement Establishing the World Trade Organization, Apr. 15, 
1994, the Legal Texts: The Results of the Uruguay Round of Multilateral Trade Negotiations 4 (1999), 1867 UNTS 154, 33 ILM 1144 
(1994) (Hereinafter The WTO Agreement).  
See also, subsection 2.5.3 and 2.5.4 of Chapter II. 
53 Emphasis added. The Preamble of the Agreement also made reference to ‘the special needs of the least-developed countries 
members in respect of maximum flexibility in the domestic implementation laws.’ See Preamble to The TRIPS Agreement. 
54 United Nations Conference on Trade and Development (UNCTAD) and  International Centre for Trade and Sustainable 
Development (ICTSD), Resource Book on TRIPS and Development (Cambridge University Press 2005) 126, 130; Olasupo Ayodeji 
Owoeye, ‘Patents for Drugs and the Right to Development in International Law’ (2015) 8(1) Law and Development Review 82.  
55 See subsection 2.4. 
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innovative, increased technology from follow-on innovation, improvement of 
social welfare such as healthcare and knowledge through the availability of 
innovative results, and a long-term guarantee of access to the technology after 
the expiration of the patent term.56 From a development perspective therefore, it 
can be said that the TRIPS Agreement acknowledges the need to implement 
IPRs in a manner that promotes social welfare and human development. In this 
thesis, it is submitted that the full enjoyment of the human development 
opportunities that TRIPS aims to facilitate depends upon whether people are 
actually able to access and use the innovative technologies and products. It can 
be said therefore, that the health safeguards which gives countries greater 
flexibility in the implementation of patents in their national laws, recognise the 
need for states to take into account their people’s human development interests 
in the protection and implementation of IPRs, especially with regards to patent 
rights and access to medicines.57 The flexibilities in the Agreement and 
clarification thereof in the Doha Declaration58 adds credence to this 
development dimension of IP in TRIPS.59 
One issue that arises with regard to the significance of the development 
objective in the TRIPS Agreement, is the weight to be attached to Articles 7 and 
8 which reference the development goals of the Agreement. The fact that the 
Articles are not within the main body of the treaty has led commentators to 
                                                          
56 Simon Walker, The TRIPS Agreement, Sustainable Development and the Public Interest: Discussion Paper (IUCN 2001) 4. 
According to the United Nations Development Commission on Development Policy, for example, intellectual property rules and 
practices have a direct impact on health, education and access to knowledge, food security and rural livelihoods, the role of SMEs 
(including job creation and gender empowerment), international competitiveness and economic diversification. Committee for 
Development Policy, The United Nations Development Strategy Beyond 2015 (United Nations publication) 51. 
57 Chon ‘Intellectual Property and the Development Divide’ (n 32) 2834-2835; Owoeye (n 54) 82. 
58 (The Doha Declaration is discussed extensively in the next chapter.) Moreover, the Doha Ministerial Declaration specifically 
mentioned the development dimension of Articles 7 and 8 of the TRIPS Agreement as being particularly important in Paragraph 
19. The paragraph provides that  
In undertaking this work, the TRIPS Council shall be guided by the objectives and principles set out in Articles 7 
and 8 of the TRIPS Agreement and shall take fully into account the development dimension. 
Daniel Gervais The TRIPS Agreement: Drafting History and Analysis (3nd edn, Sweet & Maxwell 2003) 207. 
59 Chon ‘Intellectual Property and the Development Divide’ (n 32) 2834-2835. 
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argue that the provisions of Article 7 and 8 are hortatory, rather than 
mandatory.60 Another issue in this regard is the language of Article 7 which 
states that IP ‘should’ contribute to development, as opposed to ‘shall’ 
provisions in other articles.61 Others, however, argue that the position of the 
Articles of the Agreement and its importance should not be ignored, particularly 
its interpretative significance.62 The Vienna Convention on the Law of Treaties 
is also clear on this issue. Article 31(1) states that ‘[a] treaty shall be interpreted 
in good faith in accordance with the ordinary meaning to be given to the terms 
of the treaty in their context and in the light of the object and purpose.’63 
Paragraph 5(a) of the Doha Declaration reiterates that the provisions of TRIPS 
shall be considered with regards to the objectives and principles of the 
Agreement. The language referencing Articles 7 and 8 clearly state that the 
provisions are the objectives and principles of the TRIPS Agreement, hence, 
the development objectives contained therein are significant to the 
consideration and interpretation of IPRs. Moreover, in relying on Article 31 of 
the Vienna Convention, the WTO Appellant Body in the United States, 
Standards for Reformulated and Conventional Gasoline, emphasises that treaty 
interpreters should ‘take adequate account of the words actually used by [the 
treaty].’64 Thus the importance of the development objectives of TRIPS in 
Articles 7 and 8 should not be undermined; after all, the provisions are 
contained in the body of the Agreement not the Preamble.65 It follows that 
                                                          
60 ibid 2835; Owoeye (n 54) 82. 
61 Gervais, The TRIPS Agreement: Drafting History and Analysis (n 58) 203, 207; Peter Yu ‘The Objectives and Principles of the TRIPS 
Agreement’ (2009) 46 Houston Law Review 978, 1003. 
62 ibid. As Gervais argues, ‘[t]he fact that a provision of this nature is contained in the body of the Agreement and not in the 
preamble, would seem to heighten the status, as does the reference to this article [Article 7] and art.8 in the 2001 Doha 
Declaration.’ Gervais, The TRIPS Agreement: Drafting History and Analysis (n 58) 203. 
63 Vienna Convention on the Law of Treaties 1969. (1155 U.N.T.S. 331, 8 I.L.M. 679, entered into force January 27, 1980)  
64 United States—Standards for Reformulated and Conventional Gasoline: Report of the Appellate Body (WT/DS2/AB/R, 20 May 
1996) 17. Available at  
<https://www.wto.org/english/tratop_e/dispu_e/2-9.pdf> accessed 16 July 2016; Yu (n 61) 1003. 
65 Yu (n 61) 1004. 
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Nigeria and other developing countries can rely on the development objective of 
the TRIPS Agreement, in particular, Articles 7 and 8, to improve women’s 
access to medicines and enhance their human development opportunities, 
particularly through the use of the flexibilities. 
 5.3.1 Conceptualising the Development Paradigms of IP 
A study of the scholarship on IP and development indicates that, while 
commentators and studies generally identify IP as an important means to 
development and a tool for promoting human welfare, they differ in their 
articulations of how IP fosters development.66 Their approaches are divided 
along the lines of IP as a means of stimulating innovation and creativity 
efficiency for the public benefit, and its potential for facilitating economic growth 
to nations through TT and FDI on the one hand, and the social welfare benefits 
of IP law as a means to expand human capabilities and development on the 
other.67  
As an instrument for economic growth and innovation, a patent is seen to foster 
the transfer of innovations, and therefore increases the availability of the 
inventive product which, in turn, drives economic growth as a whole.68 Within 
this context, patent rights and similar IPRs, by stimulating economic growth 
through an increase in the supply of creative and innovative goods, FDI and TR, 
substantially contribute to overall economic performance and increase Gross 
                                                          
66 Wong (n 4) 23. Commission on Intellectual Property Rights (CIPR), Integrating Intellectual Property Rights and Development 
Policy (Commission on Intellectual Property Rights 2002) 20-24. (Hereinafter CIPR) 
67 Chon, 'Intellectual Property and the Development Divide’ (n 32) 2859-2860.  
This chapter is concerned with the latter; however, the former is mentioned for analytical convenience. It is worth stating here 
that it is beyond the scope of this chapter to consider in detail all the arguments concerning whether IP actually leads to economic 
development or not. 
68 CIPR (n 66) 11-12; Tú Thanh Nguyễn, Competition Law, Technology Transfer and the TRIPS Agreement (Edward Elgar 2010) 13; 
Commission on IP, Business Action to Stop Counterfeiting and Piracy (BASCAP) and Commission on Intellectual Property (ICC), 
Intellectual Property: Powerhouse for Innovation and Economic Growth (Business Action to Stop Counterfeiting and Piracy 
(BASCAP) and Commission on Intellectual Property (ICC)) 3-5. See subsections 2.5.2 and 2.5.3 of Chapter II. 
297 
 
297 
 
National Products (GDP) which leads to sustainable development in developing 
as well as developed countries.69 Primary attention is therefore paid to the ways 
in which patent rights and IPR in general, play a role in bringing about 
development through their contribution to economic growth and the facilitation 
of technological progress.70 Kamal Idris, the former director of WIPO, for 
example, emphasises that the recognition and award of IPRs is instrumental in 
incentivising creativity and inventive activities which in turn, stimulate economic 
growth.71 In this regard, the forms of IP—patent, trade marks, copyright etc. are 
often portrayed as ‘power tools’ and ‘engines’ for economic growth, leading to 
development.72  
While these economic development perspectives are important in describing the 
role that a patent as an IP plays in facilitating development, it is argued that this 
                                                          
69 Business Action to Stop Counterfeiting and Piracy (BASCAP) and Commission on Intellectual Property (ICC) (n 68) 2-5; Vinod V 
Sople, Managing Intellectual Property: The Strategic Imperative (PHI Learning Pvt. Ltd 2014) 4-9; Keith E Maskus, 'The Role of 
Intellectual Property Rights in Encouraging Foreign Direct Investment and Technology Transfer' (1998) 9 Duke Journal of 
Comparative & International Law; Organisation For Economic Co-Operation and Development (OCED), ‘Foreign Direct Investment 
for Development: Maximising Benefits, Minimising Costs’ (OECD 2002). 
70 Vinod V Sople (ibid) 6-9; Rami M Olwan, Intellectual Property and Development: Theory and Practice (Springer Science & 
Business Media) 348; Robert L Ostergard, ‘Economic Growth and Intellectual Property Rights Protection: A Reassessment of the 
Conventional Wisdom’ in Daniel Gervais (ed), Intellectual Property, Trade and Development (Oxford University Press 2014) 4; David 
M Gould and William C Gruben, ‘The Role of Intellectual Property Rights in Economic Growth’ (1996) 48 Journal of Development 
Economics 323-350; Jeremy de Beer, ‘Defining WIPO's Development Agenda’ in Jeremy de Beer (ed), Implementing the World 
Intellectual Property Organization’s Development Agenda ( Wilfrid Laurier University Press, 2009) 9. 
71 Kamil Idris, Intellectual Property: A Power Tool for Economic Growth: (2nd edn, WIPO, 2003) 2; de Beer (n 70) 3. This discussion 
was mentioned in Chapter II (subsection 2.5.2).  
This economic growth development rhetoric also dominates the development aspect of the TRIPS Agreement. Professor Daniel 
Gervais observes that the TRIPS Agreement was seen as a ‘poster child’ for development. Daniel Gervais, 'Current Issues in 
International Intellectual Property Norm-Making' in Josef Drexl, Henning Grosse Ruse-Khan and Souheir Nadde-Phlix (eds), EU 
Bilateral Trade Agreements and Intellectual Property: For Better or Worse? (Springer-Verlag 2014) 5. See also Carsten Fink and 
Carlos A Primo Braga, 'How Stronger Protection of Intellectual Property Rights Affects International Trade Flows' in Carsten Fink 
and Keith E Maskus (eds), Intellectual Property and Development Lessons from Recent Economic Research (World Bank and Oxford 
University Press 2005) 19-34; Carlos Correa, ‘Review of the TRIPS Agreement: Fostering the Transfer of Technology to Developing 
Countries’ (2005) 2(6) The Journal of World Intellectual Property 939. (Pointing out that the concept of IP is grounded in the 
rationale that high standards of protection lead to Foreign Direct Investment and technology transfer that would stimulate local 
innovation.) 
72 Kamil Idris (n 71) 5. The UK Commission on IP strikes a similar picture of the relationship between IP protection and its economic 
development benefit argument to developing countries thus: 
The contemporary evidence suggests that, because developing countries are large net importers of technology 
from the developed world, the globalisation of IP protection will result in very substantial additional net transfers 
from developing to developed countries. The benefits to developing countries from IP protection would have to 
come from an offsetting dynamic stimulus to trade, the development of technology, investment, and growth.  
Commission on Intellectual Property Rights, Integrating Intellectual Property Rights and Development Policy (Executive 
Summary) (Commission on Intellectual Property Rights 2002) 11-12.  
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view mirrors only a partial picture of the development advantages of IP and 
should not be the only focus of IP’s development paradigm.  
 5.3.1.1 Reconceptualising the Relationship between Patents and 
Development 
It is clear from the discussion above that the perception of IP, including patents, 
in terms of economic utility and development, has shaped the understanding of 
its development function as the conduit for technological innovation, economic 
growth and development. While this may be true in some circumstances,73 the 
development focus is on the role that patents play in increasing innovation for 
societal benefit rather than the actual development benefit of the resources to 
human lives. The focus of development on the growth-oriented economic angle 
of patents may not capture the social welfare and human dimension 
development because it stresses commodity output, as opposed to people, as 
the fundamental subject of development. It can be argued that, while patents 
can contribute to overall human development through the availability of goods 
which it stimulates, the growth and efficiency focus could also ignore the fact 
that the economic and product benefits generated as a result of patent rights do 
not necessarily mean that people can actually gain access to the innovative 
technologies and products.74 In other words, focusing on the innovation or R&D 
incentives conferred by patent rights as a measure for assessing development 
may not capture the central aspect of human development which is people-
                                                          
73 While it is often argued that patents encourage inventions when the socio-economic environment is conductive and the system 
is suited to innovations, the extent to which patents actually promotes innovation is still debatable and subject to varying analysis. 
(Note that this is however, not the focus of this chapter. It is not the intention of this study to analyse the economic argument and 
benefit of IP.) 
74 Carlos M Correa, 'Pro-Competitive Measures under the TRIPS Agreement to Promote Technology Diffusion in Developing 
Countries' in Peter Drahos and Ruth Mayne (eds), Global Intellectual Property Rights: Knowledge, Access and Development 
(Palgrave Macmillan 2002) 42.  
299 
 
299 
 
oriented.75 This observation coincides with the one drawn by the UNDP that ‘the 
recent decades show all too clearly that there is no automatic link between 
growth and human development.’76 The report concludes that while economic 
growth can enrich people’s lives, ‘more attention must go to the structure and 
quality of that growth—to ensure that it is directed to supporting human 
development.’77  
Consequently, it is argued that the economic development and productivity 
aspects of patents are not the only relevant factors when considering the 
development benefits of IP. Sunder observes for IP generally that: 
The traditional utilitarian understanding of intellectual property focuses on 
incentivizing the creation of more knowledge goods. Public-domain advocates 
would preserve a rich public domain in order to promote this goal. But utilitarianism 
does not ask who makes the goods or whether the goods are fairly distributed to all 
who need them. 78  
Sunder further recommends a wider understanding of IP beyond the importance 
of producing more knowledge goods.79 To capture the instrumentality of patent 
to development, it is argued that there is a need to consider the other ways in 
which patent rights can enhance people’s human development, as an 
instrumental means to improving healthy well-being. In particular, access to 
patented medicines to treat life-threatening diseases is identified as a means of 
improving people’s health capabilities and as a corollary, promoting human 
development. Approaching development in IP from the human development 
                                                          
75 Dutfield and Suthersanen (n 23) 4. 
76 United Nations Development Programme (UNDP) Human Development Report (United Nations Development Programme 
(UNDP) 1996) 1. Also available at  
<http://hdr.undp.org/sites/default/files/reports/257/hdr_1996_en_complete_nostats.pdf> accessed 17 July 2016.  
77 ibid  
78 Madhavi Sunder, 'Intellectual Property and Development as Freedom' in Neil Weinstock Netanel (ed), The Development Agenda: 
Global Intellectual Property and Developing Countries (Oxford University Press 2009) 470; Madhavi Sunder, 'The Invention of 
Traditional Knowledge' (2007) 70 Law and Contemporary Problems 122.  
79 ibid 
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paradigm in this thesis, finds support in a similar articulation by other scholars. 
Professor Margaret Chon and other IP scholars argue that IP should not only be 
considered in the narrow sense of technological efficiency, wealth maximisation, 
and economic growth or through a development paradigm that focuses on 
simple utilitarian measures of social welfare; rather, IP should be considered 
through the broader view of expanding human capabilities and freedom.80 In 
contrast to the economic growth or utility maximisation perspective of 
development in IP, Chon endorses a more comprehensive understanding of the 
human welfare and distributional-driven aspect and effect of IP on 
development.81 Approaching development in patent law from a human 
development perspective therefore, goes further to examine how individuals can 
actually benefit from the patent system and how it helps to build their 
capabilities. In corollary, approaching patents from a human development 
paradigm draws attention to the effect that patent rights could have on human 
wellbeing.  
It is noteworthy that the aim of this thesis is not to critique the economic growth 
and efficiency argument of patent rights. Indeed, it is acknowledged that techno-
                                                          
80 Sunder ‘Intellectual Property and Development as Freedom’ (n 78) 470 (arguing that intellectual property law is essential to 
development, not just in the narrow sense of efficiency but in this broader view of expanding capability for central freedoms); 
Chon, ‘Intellectual Property and the Development Divide’ (n 32) 2815, 2869-2870; Barbosa, von Hase and Chon (n 46) 77. 
Margaret Chon inclines to an understanding of development as a freedom model in contrast to the economic growth analysis. Her 
study essentially takes a human development-oriented goal analysis of IP within international intellectual property regimes 
through a substantive equality principle. See Margaret Chon ‘Substantive Equality in International Intellectual Property Norm-
Setting and Interpretation’ in Daniel Gervais (eds), Intellectual Property, Trade and Development: Strategies to Optimize Economic 
Development in a TRIPS-Plus Era (OUP Oxford 2007) 476. Likewise, Barbosa, Chon and Moncayo von Hase, make the case for the 
principles of substantive equality within the World Intellectual Property Organization (WIPO) to link IP and innovation to human 
development. Barbosa, von Hase and Chon (n 46) 73. See also Wong (n 4) 22-26. (Making the argument that the social impact of IP 
should be approached and evaluated more systematically through the human development and capabilities context. He also 
argues for example that ‘[w]hile conventional IP policies tend to approach IP-protected intangible works in terms of markets and 
commodities to which public access needs to be balanced with private proprietary rights, what matters for human development is 
whether such access is provided in a way that enhances human capabilities.’) ibid 26. 
81 Chon, ‘Intellectual Property and the Development Divide’ (n 32) 2823-2825, 2831. (Within the realm of development and IP, 
Chon challenges the assumption that wealth and utility maximisation, and economic growth are the ideal measures for social 
welfare and development. Instead, she contends that the normative goals and principles of global IP should also be measured by 
its distributional effects ‘—one that is responsive to development paradigms that have moved far beyond simple utilitarian 
measures of social welfare.’) ibid 2815, 2824-2825. 
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economic progress could be an instrumental means to enhance the capabilities 
approach adopted in this thesis. However this chapter draws attention to the 
less considered aspect of the development effect of patents on human 
development particularly, the improvement of human welfare and capabilities. In 
other words, although the importance of the economic growth development 
approach to patents in TRIPS cannot be disregarded since achieving economic 
growth has the potential to enhance people’s welfare and create the 
opportunities to expand their human capabilities, such a limited view may not 
capture all aspects of the development objectives in the Agreement. The 
expression ‘social development’ in Article 7 of the TRIPS Agreement is a useful 
reminder not to view patents only in terms of technological advancement or 
economic terms. With particular regards to women’s human development, a 
consideration of the advantages of patents through the human development 
paradigm– as ‘a process of expanding the real freedoms that people enjoy’82 – 
is necessary to direct a focus to ways which individuals can enhance their 
human development potential through access to medicines.  
Before making a case for access to patented medicines as a means to the 
enhancement of health well-being and human development, an overview of the 
right to development is made to highlight the importance of development from a 
people-centred human rights perspective.  
 5.4 Approaching Access to Essential Drugs as a Right to Development 
Development is not only central to general human well-being; it is recognised as 
a human right entitlement in international human rights instruments.83 Article 1 
                                                          
82 Sen, Development as Freedom (n 1) 3. 
83 In the 1993 Vienna Declaration and Programme of Action, the right to development is described as ‘[..] a universal and 
inalienable right and an integral part of fundamental human rights.’ Vienna Declaration and Programme of Action of 1993 
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of the International Covenant on Economic, Social and Cultural Rights 
(ICESCR) recognises the rights of everyone to self-determination. This right to 
self-determination is linked to people’s development thus Article 1 adds that 
‘[b]y virtue of that right they freely determine their political status and freely 
pursue their economic, social and cultural development.’84 The right to social, 
economic and cultural development is also articulated in Article 22 (1) of the 
1981 African Charter on Human and People’s Rights (African Charter), with 
regards to people’s ‘freedom and identity and in the equal enjoyment of the 
common heritage of mankind.’85 Of equal importance is the reaffirmation of the 
right to development in the Vienna Convention as an integral part of human 
rights.86 The duty of Contracting States with respect to this right to development 
is to collectively and individually guarantee the exercise of the right to 
development.87  
Likewise, development as a component of human rights is acknowledged by the 
United Nations Declaration on the Right to Development (hereafter UNDRD).88 
Article 1 states that:  
                                                                                                                                                                          
(Adopted by the World Conference on Human Rights in Vienna on 25 June 1993) Article 10. The Vienna Declaration adds that the 
right ‘should be fulfilled so as to meet equitably the developmental […] needs of present and future generations.’ ibid. 
It is worth noting that there are several debates on whether the development should be recognised as an international human 
right and how to implement the right. For more discourse on the categorisation of the right to development, political debate and 
objection, and challenges to the realisation of the right, see Stephen P Marks, ‘The Human Right to Development: Between 
Rhetoric and Reality Obstacles to the Realization of the RTD’ (2004) 17 Harvard Human Rights Journal 137–168. 
84 Emphasis added. UN General Assembly, International Covenant on Economic, Social and Cultural Rights (16 December 1966, 
United Nations, Treaty Series, volume 993, 3) 
85 The Preamble to the African Charter gives special emphasis to the right to development and duty of states thus: 
Considering that the enjoyment of rights and freedoms also implies the performance of duties on the part of 
everyone; convinced that it is henceforth essential to pay a particular attention to the right to development and 
that civil and political rights cannot be dissociated from economic, social and cultural rights in their conception 
as well as universality and that the satisfaction of economic, social and cultural rights is a guarantee for the 
enjoyment of civil and political rights. 
African Charter on Human and People’s Rights of 1981 (Banjul Charter) (Adopted 27 June 1981, OAU Doc. CAB/LEG/67/3 
rev. 5, 21 I.L.M. 58 (1982), entered into force 21 October 1986) (Hereinafter ‘African Charter’) 
86 Articles 10 and 11, Vienna Declaration and Programme of Action (n 83). 
87 Article 22 (1) of the 1981 African Charter. 
88 Declaration on the Right to Development Adopted by General Assembly Resolution 41/128 of 4 December 1986. Available at  
<http://www.un.org/documents/ga/res/41/a41r128.htm> accessed 12 August 2014. (Hereinafter known as UNDRD) 
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The right to development is an inalienable human right by virtue of which every 
human person and all peoples are entitled to participate in, contribute to, and enjoy 
economic, social, cultural and political development, in which all human rights and 
fundamental freedoms can be fully realized.89 
Although the UNDRD, as a UN resolution, has no binding legal status 
under international law, the provisions are significant in explaining the 
importance and obligations to the right to development identified in the 
above mentioned binding human rights instruments (ICECSR and African 
Charter) in signatory states.90 Moreover, the provisions are persuasive in 
compelling a duty on states towards their citizen’s right to development.91 
The UNDRD, in Article 8, expatiates that the State is obliged to undertake all 
necessary measures for the realisation of the right to development including 
‘inter alia, equality of opportunity for all in their access to basic resources, 
education, health services, food, housing, employment and the fair distribution 
of income.’92 Consequently, this provision confirms that effective means for 
development require that the state should undertake the necessary measures to 
ensure that every individual has access to medicines as a way of enhancing 
development.93 Moreover, and just as importantly, Article 8 of the Declaration 
specifically spells out a woman’s right to development and places a duty on the 
                                                          
89 ibid  
90 Office of the High Commissioner for Human Rights, Frequently Asked Questions on the Right to Development: Fact Sheet No. 37 
(United Nations 2016) 5. 
91 ibid 5. 
92 Article 8 (emphasis added).  
93 The Preamble of the Declaration on the Right to Development states that ‘[d]evelopment is a comprehensive economic, social, 
cultural and political process, which aims at the constant improvement of the well-being of the entire population and of all 
individuals on the basis of their active, free and meaningful participation in development and in the fair distribution of benefits 
resulting therefrom.’ Article 8 of UNDRD. 
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State to effectively ensure that every woman has an active role in the 
development process.94 
The articulation of development as a human right is significant in enriching the 
argument for access to essential medicines as a human right to health in this 
thesis. Since all human rights are universal, interrelated, interdependent, and 
indivisible as stated in Paragraph 5 of the Vienna Declaration and Programme 
of Action,95 it can be said that the right to health and the right to development 
are related and both rights underlie a similar objective.96 This common objective 
is to promote the improvement of quality of life, create opportunities and 
enhance everyone’s standard of living, as a matter of right. The Preamble of the 
Universal Declaration of Human Rights (UDHR) which recognises that the 
peoples of the United Nations have reaffirmed ‘[…] the equal rights of men and 
women and have determined to promote social progress and better standards 
of life in larger freedom,’ supports this argument.97 The right to health, as 
discussed previously in Chapter III,98 mandates the state to guarantee, 
safeguard, respect, and enforce. For this reason, the right to development, like 
the right to health, requires State Parties to strive to improve their people’s 
human welfare, provide the resources and to create the necessary enabling 
environments for development.99 Given that health is linked to a person’s 
development prospects,100 it can be argued that the right to development would 
require the state to take all feasible measures to guarantee access to the 
                                                          
94 Consequently, ‘[a]ppropriate economic and social reforms should be carried out with a view to eradicating all social injustices.’ 
Article 8 of UNDRD. 
95 The paragraph provides that  
All human rights are universal, indivisible and interdependent and interrelated. The international community 
must treat human rights globally in a fair and equal manner, on the same footing, and with the same emphasis.  
This was also discussed earlier in Chapter III subsection 3.2.1.  
96 Office of the High Commissioner for Human Rights (n 90) 2. 
97 See Preamble to the UDHR. 
98 In subsection 4.5. 
99 Office of the High Commissioner for Human Rights (n 90) 10. 
100 Owoeye (n 54) 93. 
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important healthcare facilities, services and resources such as medicines, to 
achieve the full realisation of the right. 
Furthermore, the reflection that the right to development includes the right of 
individuals to have access to basic resources, as well as equal opportunities for 
development, would also entail the removal of obstacles to achieving this 
development objective. It goes without saying that multilateral trading 
commitment in multilateral or bilateral agreements or treaties, and patent rights 
should not be allowed or implemented in a manner that limits the ability of 
people to enjoy the right to development and health. This important duty of the 
state to eliminate obstacles to development is emphasised in Article 3(1) of the 
UNDRD.101 To reiterate this point, the UN Intergovernmental Working Group on 
the Right to Development observed that, whilst IP is pivotal to development by 
stimulating innovative R&D and TR, the protection of IP should not limit the 
enjoyment of the right to health or undermine access to essential medicines.102 
On this point, the utilisation of the TRIPS flexibilities, as reaffirmed in the Doha 
Declaration, is significant as states can utilise the health-related safeguards to 
address the access issues that arise from the application of pharmaceutical 
patent rights in the context of the right to development.103 
The UNDRD further directs states to create favourable international and 
national conditions for the realisation of the right to development.104 The duty to 
realise the right to development also requires that the state formulates 
appropriate national development policies aimed at constantly improving the 
                                                          
101 Article 3(3) of UNDRD. 
102 UN General Assembly, The Right to Development: Report of the Secretary General (UN Doc A/66/216, 1 August 2011) 
paragraphs 51, 58 and 59. Also available at  
http://www.ohchr.org/Documents/Issues/Development/A.66.216_en.pdf. (The Working Group was created to oversee the 
implementation of the right to development.)  
103 Paragraph 58 ibid. 
104 Article 3(1) of UNDRD. 
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well-being of the entire population and every individual, including the promotion 
of its citizens’ freedom to participate meaningfully in development processes 
and ‘the fair distribution of the benefits resulting therefrom.’105 It stands to 
reason that the right to development also recognises the rights of individual 
inventors to legitimately pursue their innovative and research related activities 
according to their developmental goals: in like manner, patent law and policy 
can improve the capacity for participating in the ‘processes of knowledge 
creation.’106 However, approaching the patent system and law from a human 
development paradigm requires not only enhancing the inventor’s rights and 
facilitating the process of producing innovative products and medicines but also 
promoting access to the benefits of these innovative products.107  
Significantly, Article 2(2) of the UNDRD places the responsibility for 
development on all human beings to ‘promote and protect an appropriate 
political, social and economic order for development.’ This responsibility is 
individually and collectively shared by every person and every organ of society, 
including civil society and private actors.108 As the United Nation Office of the 
High Commissioner for Human Rights, elaborates, businesses and 
corporations, which includes pharmaceutical companies, also have a 
responsibility to respect the right to development in accordance with their 
                                                          
105 Preamble, Articles 1 and 2(2) of UNDRD. 
106 Sunder, 'Intellectual Property and Development as Freedom', (n 78) 470. See also Article 1 of UNDRD. It can also be argued that 
this development objective is recognised in Article 7 of the TRIPS Agreement. This Inventor’s right to development argument 
corresponds with the recognition of the rights of inventors and creators’ right to participate in cultural life and derive benefits 
from the protection of their moral and material interest resulting from any scientific, literary or artistic production in Article 27 
UDHR and Article 15(1) (a) and (c) of the ICECSR. For example, Madvi made the case for a broader understanding of IP to recognise 
the importance of producing more knowledge goods as well as participation in the process of knowledge creation. This view is 
however, not the central subject of this chapter.  
It is doubtful whether companies and firms can enjoy this right to development privilege as the human person is the central 
subject of the right to development. Article 2(1) UNDRD. 
107 It is noteworthy that the focus of this thesis is not on the development aspect of an inventor’s right within the context of patent 
hence it will not be analysed in detail. It is merely highlighted for analytical purposes.  
108 Office of the High Commissioner for Human Rights (n 90) 4. See the previous discussion on the responsibilities of 
pharmaceutical companies in subsection 4.6. 
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human rights obligations in the Guiding Principles on Business and Human 
Rights.109 Accordingly, non-state actors, namely, the private sector and 
individuals, can also contribute to the realisation of the right to development by 
creating favourable conditions.110 Linking this to the earlier discussion in the last 
chapter,111 pharmaceutical companies and patent holders can promote and 
facilitate the practical realisation of the right to development through the 
availability of medicines.  
 5.4.1 The Right to Development and Access to Life-saving Medicines and 
Patents 
The right to development relates to the debate on patent protection of 
pharmaceuticals and access to essential medicines in a number of ways. As 
examined in Chapter III,112 the first issue is the widespread concern that patents 
can pose a barrier to accessing life-saving drugs for life-threatening sicknesses 
such as HIV/AIDS, malaria and other diseases, particularly in developing 
countries.113 Besides the human cost, HIV/AIDS epidemics for example, 
significantly disrupt the smooth functioning of economic and social systems in 
ways that also affect sustainable growth and human development, especially in 
sub-Saharan Africa.114 To address the development concerns that the health 
epidemic raises, there is the need for people to have access to newer 
antiretroviral treatments. As novel and more effective antiretroviral treatments 
                                                          
109 ibid 
110 ibid 4-5. 
111 See the discussion on the responsibilities of pharmaceutical companies in Chapter III, subsection 4.6 
112 In subsection 3.7. 
113 Bhaven N Sampat, 'Academic Patents and Access to Medicines in Developing Countries' (2009) 99(1) American Journal of Public 
Health 9, 9-10. 
114 Franklyn Lisk and Desmond Cohen, 'Regional Responses to HIV/AIDS: A Global Public Goods Approach’ in Nana Poku, Alan 
Whiteside and Bjorg Sandkjaer (eds), AIDS and Governance (Ashgate Publishing Group 2007) 248-249, 253; S Dixon, 'The Impact of 
HIV and AIDS on Africa's Economic Development' (2002) 324 (7331) British Medical Journal, 232-234. 
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are more likely to be patented in developing countries,115 it is necessary for 
states to think more carefully about the delivery of and access to essential 
drugs in the regulation of their national patent law. This is because achieving 
the right to development as mentioned in subsection 5.4.1, entails the state 
taking proactive steps to improve the well-being of every individual including the 
provision of health care facilities, services and medicines as a matter of 
guaranteeing the right. Arguing in support, Adusei, highlights that guaranteeing 
the right to development requires that the state pursues ‘a comprehensive 
social, economic, legal, cultural and political process’ and policy.116  
The recognition of development as a human right in the African Charter is also 
significant to the arguments in this chapter. Accordingly, Nigeria, having ratified 
and incorporated the African Charter as noted in the last chapter,117 is bound by 
its treaty obligation to fulfil, respect and promote the right of every woman in 
Nigeria to be developed. The decision of the African Commission on Human 
and People’s rights in the case of Centre for Minority Rights Development 
(Kenya) and Minority Rights Group International on behalf of Endorois Welfare 
Council v Kenya (Endorois case) is illustrative of the duty of states to the right to 
development. In this case, the African Commission found that the state (Kenya) 
has a duty to create conditions favourable to the people’s development.118 In 
1973 and 1978, the Kenyan government dispossessed the Endorois Community 
of their lands to create Lake Hannington Game Reserve and Lake Bogoria 
Game Reserve.119 The Endorois community, an indigenous people, alleged that 
                                                          
115 Ellen FM 't Hoen and others, 'Driving a Decade of Change: HIV/AIDS, Patents and Access to Medicines for All' (2011) 14 Journal 
of the International AIDS Society 1-3. 
116 Adusei (n 45) 240.  
117 Subsection 4.9.1. 
118 Centre for Minority Rights Development (Kenya) and Minority Rights Group International on behalf of Endorois Welfare Council 
v Kenya (2010) 276/2003, African Commission on Human and Peoples' Rights, paragraph 298. 
119 ibid paragraph 1-12. 
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the government violated their rights to development as contained in the African 
Charter by forcibly removing them from their ancestral home, failing to 
compensate them for the loss of their properties, not involving them in the 
decision-making in the development process and the disregard for their well-
being and continued development.120 The Endorois people also argued that the 
eviction from the game reserve limited the choices and capabilities open to 
them and affected their livelihoods as their cattle died from lack of access to the 
lake, usual pastures and salt licks.121 The African Commission, making 
reference to the right to development in the African Charter, took the view that 
the dispossession and disruption of the community’s pastoral enterprise was a 
violation of their human rights to development, contrary to Article 22 of the 
African Charter.122 According to the Commission on the state’s duty, ‘[t]he result 
of development should be empowerment of the Endorois community. […] The 
capabilities and choices of the Endorois must improve in order for the right to 
development to be realised.’123 This case is significantly an example of the 
nature of the duty that states are expected to adhere to, or refrain from to 
realise the right to development. 
On the basis of the Nigerian government's duty to women’s right to 
development, it is argued that the state should aim at constantly improving their 
living standards and well-being. Since improved health is a central component 
of development and women’s well-being, the Nigerian authorities and policy 
makers have an obligation to provide the necessary healthcare facilities along 
with access to necessary medicines and services to improve or maintain 
women’s health including the promotion of public health in its laws. The state’s 
                                                          
120 ibid 
121 ibid paragraph 126. 
122 ibid paragraph 297-298. 
123 ibid paragraph 283. 
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duty to fulfil the right to development implies, like the right to health, that 
measures should be taken to prevent direct or indirect interference with the right 
by third parties including multinational corporations.124 It is therefore important 
that the Nigerian government adopts a people-driven development approach to 
its patent law and policy to guarantee women and everyone in Nigeria access to 
affordable essential medicines.  
It will be recalled125 that an important feature of the right to development is that 
it emphasises that every human being is a central subject of development.126 
The identification of humans as the central subjects of development in the 
Article 2(1) of the UNDRD corresponds to the definition of development by the 
UNDP as a ‘process of enhancing human capabilities—to expand choices and 
opportunities so that each person can lead a life of respect and value.’127 This 
view, applied to patent law, captures the development-enhancing aspect of a 
patent policy and system, not only in the narrow sense of promoting 
technological innovation and pharmaceutical R&D, but also viewing the public 
benefit of patents as an important instrument for human development by 
enhancing basic human health capabilities.128 It is in light of this understanding 
that this chapter makes a case that wider access to patented medicines will 
expand and improve the health capabilities of women and every individual in 
Nigeria.  
The second related issue is to do with the international obligation of Nigeria to 
implement a minimum standard of patents in the TRIPS Agreement under its 
                                                          
124 Office of the High Commissioner for Human Rights (n 90) 4. 
125 From the discussion in subsection 5.2.3 and 5.2.4. 
126 Article 2(1) of UNDRD. 
127 United Nations Development Programme (UNDP), Human Development Report 2000: Human Rights and Human Development 
(United Nations Development Programme (UNDP) 2000) 2. Relating human development to human rights, the UNDP notes that 
‘[w]hen human development and human rights advance together, they reinforce one another—expanding people’s capabilities 
and protecting their rights and fundamental freedoms.’ ibid 
128 Adusei (n 45) 240; Sunder, 'Intellectual Property and Development as Freedom' (n 78) 470.  
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domestic law. In the light of the potential effect of patent rules on access to 
affordable essential medicines and adverse consequences for the availability of 
medicinal treatment, the issue for the state and lawmakers to consider is how 
Nigeria can meet the WTO international obligation and also safeguard the 
health and well-being of its people in the interests of their rights to development. 
While the TRIPS Agreement and Doha Declaration confirmed that countries can 
interpret and implement national patent laws and flexibilities to protect public 
health by taking into account its population’s socio-economic welfare, a related 
issue to consider is whether the country can exercise a greater policy space to 
enhance the citizens’ development needs and expand their capabilities in light 
of patent rights and the protection of pharmaceuticals. These issues will be 
further considered in the following sections. But first, the importance of the 
health capabilities for this purpose is highlighted. 
5.5 The Human Capabilities Approach to Health: An Evaluative Framework  
In analysing the significance of health to general welfare and well-being, Henry 
Sigerist writes:  
A healthy individual is a man [woman] who is well balanced bodily and mentally, 
and well adjusted to his physical and social environment. He is in full control of his 
physical and mental faculties, can adapt to environmental changes, so long as they 
do not exceed normal limits, and contributes to the welfare of society according to 
his ability. Health therefore is not simply the absence of disease; it is something 
positive, a joyful attitude towards life, and a cheerful acceptance of the 
responsibilities that life puts upon the individual.129 
                                                          
129 Henry E Sigerist, Medicine and Human Welfare (Yale University press 1941) 100. The WHO also depicts health as a complete 
welfare condition besides the absence of diseases, and infirmity. 
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This depiction of health draws attention to the importance of health as an 
essential aspect of a human’s well-being and life. Sen observes that ‘health is 
among the most important conditions of human life and a critically significant 
constituent of human capabilities which we have reason to value’.130 From a 
health perspective, the human development framework and health capabilities 
approach draws focus to ‘the process of generating health.’131 In this vein, the 
capabilities approach offers a method for assessing whether individuals have 
the capability to be healthy. Therefore, Jennifer Prah Ruger describes health 
capabilities thus: [h]ealth capability constitutes a person's ability to be healthy; it 
includes health functioning and health agency.'132 In conceptualising health 
capability, Ruger adds that health capability creates an understanding of the 
conditions and barriers that could hamper health and the ability to make health 
choices.133  
Health plays a special role in the promotion of well-being within the capabilities 
approach framework. This is because health is not only intrinsically important to 
personal well-being; it can affect the mental and physical capability to achieve 
other development goals. Better health is a tool for other development 
prospects; the health capability of an individual to a large extent determines the 
level of opportunities, freedoms and choices to develop their capabilities in 
other areas of their lives. As such an individual’s health capability is 
fundamental in securing the viability of other capabilities. When individuals are 
                                                          
130 Amartya Sen, 'Why Health Equity?' (2002) 11 Health Economics 659, 660. 
131 Proochista Ariana and Arif Naveed, ‘Health’ in Severine Deneulin and Lila Shahani (eds), An Introduction to the Human 
Development and Capability Approach (Earthscan and IDRC 2010) 234. 
132 Ruger, ‘Health, Capability, and Justice: Toward a New Paradigm of Health Ethics, Policy and Law’ (n 45) 106. Ruger writes that 
‘[a]gency is important for public policy because it supports individuals' direct participation in "economic, social and political 
actions" and enables individuals to make decisions" as active agents of change.’ ibid 158. 
133 Jennifer Prah Ruger, 'Health Capability: Conceptualization and Operationalization' (2010) 100 American Journal of Public Health 
42. From the same point of view, Venkatapuram highlights that an individual’s health capabilities include the ‘ability to achieve a 
basic cluster of beings and doings-or having the overarching capability, a meta-capability, to achieve a set of basic inter-related 
capabilities and functionings.’ Venkatapuram, Health Justice: An Argument from the Capabilities Approach (n 45) 20; Sridhar S 
Venkatapuram, ‘Health, Vital Goals, and Central Human Capabilities’ (2013) 27(5) Bioethics 271, 279. 
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in good health, they contribute effectively to the development of themselves and 
society at large. Gostin and Wiley, on the significance of health to the 
empowerment of populations and their socio-economic development, observe: 
[…] health is also essential for the functioning of populations. Without minimum levels of 
health, people cannot fully engage in social interactions, participate in the political process, 
exercise rights of citizenship, generate wealth, create art, and provide for the common 
security. A safe and healthy population provides the basis for a country’s government 
structures, social organizations, cultural endowment, economic prosperity, and national 
defense. Population health becomes a transcendent value because a certain level of human 
functioning is a prerequisite for activities that are critical to the public's welfare--social, 
political, and economic.134 
In addition, the current 2015 UNDP Report stresses that an individual’s 
capability to live a long and healthy life is not only central to enhancing their 
overall capabilities; it is also fundamental to creating the necessary conditions 
to achieve other aspects of development.135 It follows that the capability to be 
healthy is also a nucleus of development in itself and a means to the 
development of other capabilities. In retrospect, a healthy person is better 
placed to develop society and also enjoy the technological and developmental 
benefits conferred by patent law to users as espoused in the TRIPS Agreement.  
As Ariana and Naveed point out, it is important to recognise that the health of 
an individual is a multi-dimensional phenomenon that cannot be assessed by a 
single indicator.136 In this sense, while there are several factors that influence 
the ability of an individual to be in good health, including a person’s biological 
make-up, physical environment, social-economic conditions and personal 
                                                          
134 Lawrence O Gostin and Lindsay F Wiley Public Health Law: Power, Duty, Restraint (3rd edn, University of California Press 2016) 8; 
LO Gostin, ‘Meeting Basic Survival Needs of the World’s Least Healthy People: Towards a Framework on Global Health’ (2008) 96 
George Town Law Journal 331, 344.  
135 UNDP, Human Development Report 2015: Work for Human Development (n 17) 3. The WHO in a 2013 report also reiterates the 
importance of good health by stating that health is ‘a critical contributor to and outcome of sustainable development and human 
well-being’ World Health Organization, Health in the post-2015 development agenda: Report by the Secretariat (n 9) paragraph 18. 
136 Ariana and Naveed ‘Health’ (n 131) 228, 230. 
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choices,137 from a capabilities perspective, an individual should also have the 
freedom, opportunities and choice to achieve a valued state of better health and 
well-being. Central to Nussbaum’s capabilities approach for example, is the 
idea that people should have the freedoms, choices and opportunities to live a 
life that is worthy of human dignity which they value.138 Nussbaum’s version of 
capabilities also analyses the choices and opportunities that an individual has to 
undertake a capability action based on their political, social and economic 
circumstances and further notes that it is the duty of the state or society to build 
and promote these basic human capabilities.139  
It can be said that a way of enhancing or supporting the development of health 
capabilities can be through access to health care services and sufficient, 
affordable and safe medicines for treatment of illnesses and diseases. Since 
health is central to a person’s capabilities, Nigerian authorities can strive 
improve the health capabilities of all its citizens by facilitating access to 
medicines, in a manner that takes into account everyone’s level of access—
men, women and children. By making available the necessary medicines and 
providing the avenues through which individuals can have the opportunity to 
increase and sustain their health capabilities, the state can support, protect and 
guarantee the basic capabilities of individuals ‘to be and do what they have 
reasons to value.’140 Applying this reasoning to the patent system, while 
innovation fostered by patent law may improve human well-being and/or 
                                                          
137 Venkatapuram, Health Justice: An Argument from the Capabilities Approach (n 45) 18. (The biological and medical factors that 
influence health and well-being are not the focus of this thesis.)  
138 Nussbaum, Creating Capabilities: the Human Development Approach (n 43) 21. According to Nussbaum, the concept of dignity 
has no precise definition and can be given different interpretations by people. Nonetheless, Nussbaum notes that human dignity 
that is closely related to the notion of a basic capability, ‘something inherent in the person that exerts a claim that it should be 
developed.’  
ibid 31. 
139 Martha Craven Nussbaum, Creating Capabilities: the Human Development Approach (n 43) 20-21.  
140 Venkatapuram, Health Justice: An Argument from the Capabilities Approach (n 45) 115. 
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economic growth as argued by some scholars, from the capabilities approach, 
the issue is whether the products or R&D results as incentivised by patent, 
ultimately enhance the opportunities and choices that individuals have with 
regards to their health capabilities.141  
 5.5.1 Access to Medicines as a Right to Health: Enhancing Health 
Capabilities 
The argument for the enhancement of Nigerians’ health capabilities through 
access to medicines resonates with the right to health discussion in Chapter 
IV.142 As mentioned in the chapter,143 the normative objective and content of the 
right to health144 which recognise the inherent human entitlement, freedom and 
capability of a person to be able to attain a state of physical and mental well-
being, also presupposes that it is the duty of the government to make available 
the necessary goods (medicines), health facilities and healthy conditions and 
environment for the realisation of the right to health.145 Thus, the enhancement 
of Nigerian’s health capabilities is also a human rights obligation of the state. 
This obligation on the state corresponds with the capabilities approach, 
especially as propounded by Nussbaum, that it is constitutionally imperative for 
the state and society to provide certain basic social and human entitlements to 
every individual to enhance their human capabilities – in the case of health, the 
capability to be healthy.146 Medicines it is argued, can be a means through 
                                                          
141 Wong (n 4) 24. 
142 See PART I of Chapter IV.  
143 See subsection 4.3.  
144 In Article 12 of the ICESCR and in Article 25 (1) of the 1948 UDHR. 
145 Committee on Economic, Social and Cultural Rights, General Comment 14: The Right to the Highest Attainable Standard of 
Health (Twenty-second session, UN Doc. E/C.12/2000/4 2000). 
146 Nussbaum argues for example that  
[t]he basic intuition from which the capability approach begins […] is that certain human abilities exert a moral 
claim that they should be developed […] Human beings are creatures such that, provided with the right 
educational and material support, they can become fully capable of all these human functions. . . . When these 
capabilities are deprived of the nourishment that would transform them into the high-level capabilities that 
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which people can enhance their health capabilities thus accessing affordable 
medicines is significant in this regard. This duty on the Nigerian state is to 
create the opportunities and provide the health facilities for its citizens to 
exercise the choice to be in good health. Human rights therefore complement 
human development and capabilities by placing an obligation on states to 
account for the attainment of human development and building people’s 
capabilities to be healthy. In consequence, both human rights and the 
capabilities approach promote health and well-being, and reinforce each other 
by promoting the expansion of people’s capabilities as an objective of human 
rights – to be protected, respected and realised by the state.  
Particularly to women in this study, human rights therefore serve as a legal 
basis to promote the development of their health capabilities and by extension, 
their human development through access to affordable life-saving drugs.  
 5.6 Towards a Human Development Paradigm of the Patent System in 
Nigeria 
Patents intersect with human development and health capabilities on two levels: 
first, as a barrier to accessing medicines and consequently human 
development, and as a means to facilitating R&D which is significant to the 
enhancement of the capability to be healthy.  
                                                                                                                                                                          
figure on the list, they are fruitless, cut off, in some way but a shadow of themselves. They are like actors who 
never get to go on the stage, or a musical score that is never performed. 
Martha C Nussbaum, ‘Human Capabilities, Female Human Beings’ in Martha C Nussbaum and Jonathan Glover (eds), Women, 
Culture, and Development: A Study of Human Capabilities (Oxford University Press 1995) 88.  
Nussbaum goes ahead to articulate a specific list of capabilities which includes the ‘[b]eing able to have good health, including 
reproductive health,’ and argues that the list is ‘the certain basic functional capabilities at which societies should aim for their 
citizens, and which quality of life measurements should measure.’ibid 82 
Nussbaum also argues that the list provides the ‘philosophical underpinning for an account of basic constitutional principles that 
should be respected and implemented by the governments of all nations’ and the basis ‘for central constitutional principles’ that 
ever citizen can demand from their governments as a matter of right.’ Nussbaum, Women and Human Development: The 
Capabilities Approach (n 42) 5, 12. 
See also Adusei (n 45) 258.  
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In the first instance, a potential drawback of patents is their effect on access to 
drugs and the consequential impact on the expansion of health capabilities. 
Discussed in Chapter III147 and stated earlier,148 a patent right could create a 
barrier to accessing the medicines needed to be in good health, which is 
important to the realisation of human development. Pointing out the effect of an 
IP owner’s right to freedoms, Gollin adds that the ‘the exclusivity of IP rights 
restricts the freedom of choice of those who seek access to an innovation.’149 
Through excessive pricing and other protectionist practices patent rights can 
diminish the capability of end users of the patented product to effectively access 
medicinal treatments for health purposes.150 In this light, patients who lack 
access to essential patented drugs would also lack the freedom and capability 
to use the drug as to ameliorate their health conditions as they wish. Given that 
patent protection grants monopoly rights that may have a significant effect on 
access to essential medicines, there is therefore a need to ensure that patent 
rights do not negatively impact on access. For access to pharmaceuticals 
therefore, it is the duty of the Nigerian authorities and policy makers to ensure 
that patent law does not hinder access to essential medicines, especially for 
women, as medicines are instrumental means to improve the capabilities to be 
                                                          
147 In subsection 3.7 and the sub subsections. 
148 In subsection 5.4.1. 
149 Michael A Gollin, Driving Innovation: Intellectual Property Strategies for a Dynamic World (Cambridge University Press 2008) 
343.  
150 As discussed in Chapter III, subsection 3.7.1.1 and 3.7.2, the main barrier to ensuring that individuals with chronic diseases can 
access essential medications is pricing in many developing countries. Thus even if the developing country were to provide a 
healthcare system capable of supporting the procurement and provision of essential medicines, implementation may constitute a 
problem if the medicines are not affordably priced and the government cannot subsidise the medicine. With regards to the pricing 
policies of pharmaceutical companies, the high prices of patented medicines are described as a ‘gateway’ barrier for accessing 
pharmaceuticals. Brent Savoie, 'Thailand’s Test: Compulsory Licensing in an Era of Epidemiologic Transition' (2007) 48 Virginia 
Journal of International Law 211, 222. 
In a similar regard, it is widely acknowledged that patent rights do not provide sufficient incentive to meet the need for the 
development of new products to fight diseases where the potential paying market is small or uncertain. World Health 
Organization, 'Intellectual Property and Access to Medicines: Papers and Perspectives' (World Health Organization 2010) 6. 
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healthy. Rather, patent law should be tailored to promote research and 
dissemination of knowledge, and used as a tool to facilitate R&D, alongside the 
relevant patent right exceptions through an appropriately designed policy and 
an efficient administration system.  
In a related manner, within the patent system itself, it is recognised that patent 
law can serve as means to the availability of medicines by encouraging the 
research and production of drugs, thus promoting the means to human 
development and improving well-being in general. These medicines, as 
incentivised by patent rights, could in turn, create the opportunities and means 
to be healthy and further contribute to increasing people’s freedom to choose by 
enlarging their choices. In this vein, a patent can play a more positive role in 
expanding people’s choices and capabilities to be in good health. Chon 
succinctly captures the human development dimension of IP in general thus: 
The model of development of freedom centres human capability through the 
provision of basic needs in the areas of education, health, and nutrition, because 
these lead to the ‘enhancement of human freedom, which is both the main object 
and the primary means of development’ (Sen 1999) […] Simply put, the growth 
model of development prioritizes the innovation mandate of intellectual property, 
while the freedom model of development emphasizes its multi-dimensional 
aspects. In the latter paradigm, intellectual property not only stimulates innovation 
but also protects knowledge goods that enhance human capabilities, which in turn 
build national capacity for innovation.151 
It is however argued that the development goals of patents in enhancing 
capabilities should not end with the availability of the products of innovation. 
There is a need to ensure that the actual societal benefits of the invention are 
                                                          
151 Chon, ‘Substantive Equality in International Intellectual Property Norm-Setting and Interpretation’ (n 80) 476; Barbosa, von 
Hase and Chon (n 46) 77. 
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realised. It is therefore important that the instrumental role of patents in 
guaranteeing the capability of users to be in a state of improved health is not 
merely focused on the R&D or incentive benefit of making the drugs available. 
To emphasise further, the technological innovation and economic development 
advantage of the patent system should not serve as an end to development; 
patent policy should also contribute substantially to sustainable human 
development. Patents are not only an incentive instrument for innovation, 
pharmaceutical R&D, or a ‘power tool’ for economic development, but also a 
means to improving the welfare of individuals in society. The human 
development paradigm is therefore important in assessing the development 
goal of patents to health through access to medicines, by drawing attention to 
the benefit of a patent system to humans (consumers), as well as the benefit 
resulting from innovation, economic growth and national GDP.   
Approaching development in patent law from a human development perspective 
goes further in examining how individuals can actually benefit from patent 
protection and how it helps to build their capabilities. As Gollin remarks, ‘the IP 
system, in driving the innovation cycle, serves at least in part as an instrument 
of individual freedom and choice.’152 Within the national context of Nigeria, it is 
argued that patent law should contribute to the overall function and 
development of humans, including public health. Thus, the Nigerian 
government, apart from promoting the availability of medicines by enacting a 
patent policy, also has an imperative duty to ensure that women and indeed 
every individual in Nigeria are guaranteed actual access to them.  
                                                          
152 Gollin (n 149) 343.  
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Approaching the welfare benefits of having a patent system charged with 
enhancing the human development of women and all its people, can provide the 
Nigerian government and policy makers with considerable room to facilitate 
access to patented pharmaceuticals. One way is to ensure that the central 
development goal of enhancing the people’s human development and building 
human capabilities, informs the design and implementation of patent rights. As 
Chon argues, ‘focusing on capabilities helps us think about goals for the system 
as a whole. Should IP take into account health measures? education 
measures? […] in addition to or instead of pure innovation measures?’153  
While there may be several ways of enhancing health capabilities and 
improving human welfare, in this thesis, the flexibilities are identified as a 
significant means of providing opportunities for people to enhance their basic 
capabilities. The Nigerian government and the appropriate authorities can 
exercise greater flexibility in the use of the patents-related health safeguards 
and exceptions in accordance with the public health interest goals of facilitating 
access to medicines for human development reasons. The proactive use of the 
TRIPS flexibilities in the event that the excessive use of pharmaceutical patent 
rights poses a threat to accessing medicines is one of the many ways in which 
Nigeria can improve the quality of life for all its citizens as defined by their 
capabilities. The utilisation of the TRIPS flexibilities, as will be comprehensively 
discussed in the next chapter, are to; promote access to cheaper drug options 
(compulsory licensing or parallel imports); foster generic competition; or 
facilitate incremental pharmaceutical R&D through the research and 
experimental use exceptions and early working (Bolar) exemption,154  and also 
                                                          
153 As cited in Wong (n 4) 32. 
154 Some of these flexibilities are further considered in the next chapter. 
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the use of internal controls such as price control mechanisms could in effect, 
counter-balance the adverse effects of patents on accessibility to affordable 
essential medicines.  
Moreover, the human development and capabilities approach is a useful 
framework for considering the design and implementation of patent exceptions 
and flexibilities identified Chapter VI. As this human development paradigm 
views the expansion of human capabilities and opportunities to exercise 
genuine choices as important goals of development, the Nigerian authorities 
can create an environment in which people can fully develop their potential to 
expand their choices using TRIPS-compliant flexibilities. The authorities can 
seek to build the capability of women, and all Nigerians, to lead long and 
healthy lives, through having access to vital resources, such as medicines, that 
are needed to live healthy.  This is through fully incorporating and adapting the 
flexibilities, proactively enforcing their use to promote health and curtailing the 
adverse effect of patent rights on access to medicines. It is therefore argued 
that approaching the incorporation and enforcement of the flexibilities from a 
human development and capability perspective, can be a justifiable reason to 
increase access to medicines in Nigeria. From the capabilities perspective, the 
goal of the government should be more than just to create an opportunity for 
people to have medicines by granting patents as incentives for incremental 
innovation. While these medicines can improve human wellbeing, approaching 
the patent system from a capabilities perspective should consider the relevance 
of the pharmaceuticals to enhancing human capabilities, and provide the most 
effective means of ensuring that patients who need the medicines can actually 
access them to build their health capabilities.  
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As Frishmann argues on the ways in which IP can be used to promote the 
capabilities, '[…] some social investments in capabilities are, or maybe or 
should be, made through legal structures that allocate freedoms to access and 
use resources that are necessary to participation in certain types of activities.'155  
In the context of promoting health capabilities of Nigerians, this observation 
highlights the need to ensure that the patent system is designed not only to 
protect IP and increase the development of innovative products, but also to take 
into account national development priorities and opportunities for people to 
access medicines, and use them to strengthen their health capabilities. The use 
of the flexibilities would ensure that the legal text of Nigerian's patent regime is 
construed and applied in a way that caters not only to the interest of 
pharmaceuticals patent holders but also to the basic health needs of those who 
require access to essential medicines. The flexibilities can provide additional 
opportunities for Nigeria to broaden access to important and life-saving 
medicines and to promote development without the need to strip away the rights 
of patentees.156   
 Equally important, the Nigerian courts and relevant authorities can interpret and 
enforce patent law in a manner that recognises the prominence of the human 
right to health and the right to development and the need to enhance health 
capabilities, in the event that the patent rights threaten access to medicines.157 
As argued in the preceding chapter,158 the right to health and life to be healthy 
should be weighed against the patent holder’s rights and where there are 
exigent health implications, the right to health should trump patent rights. This 
                                                          
155 Brett M Frischmann, 'Capabilities, Spillovers, and Intellectual Progress: Toward a Human Flourishing Theory for Intellectual 
Property' (2014) Cardozo Legal Studies Research Paper No. 442, 21. Available at SSRN: https://ssrn.com/abstract=2500196 or 
http://dx.doi.org/10.2139/ssrn.2500196 capabilities. Accessed 2 March 2017. 
156 Chon, 'Intellectual Property and the Development Divide’ (n 32) 2880. 
157 See the Endorois case above in subsection 5.4.1. 
158 See subsection 4.7.4, 4.9.2 and 4.10 of Chapter III. 
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argument can also be approached from a capabilities, human development, and 
right to development perspective.159  Prioritising access to medicines to improve 
health capability can provide another moral justification and legal basis for 
Nigeria to limit the exercise of patent rights to cater to human development 
needs of all Nigerians. 
The integration of human development considerations into the design, 
implementation and interpretation of patents has the value of ensuring that the 
Nigerian authorities take into account the development-related interests of 
Nigerians. The goal of any reform, redesign and repositioning of the patent 
system should be to guarantee that the people have opportunities to access 
medicines to enhance the quality of their lives. Likewise, strengthening patent 
exceptions and limitations should not be seen as a mere regulatory exercise of 
bringing the Nigerian laws into conformity with its TRIPS obligations. Rather, 
strengthening the flexibilities should be seen as a crucial way whereby health 
capabilities can be supported.  Approaching it from this perspective will ensure 
that the system is designed to serve and promote this development objective.  
To the best of this author’s knowledge, there is no judicial or WTO case on 
human development and IP rights. The argument to integrate human 
development principles into the norm-making and interpretation of patent 
policies, therefore, finds support in Paragraph 4 of the Doha Declaration which 
urges the interpretation and implementation of TRIPS in a manner that supports 
and promotes public health through access to medicines. 
                                                          
159 Also, the state can approach the issue of facilitating better access to patented pharmaceuticals to build the Nigerians human 
development potentials as part of its right to development duties to promote and protect health. See the discussion in subsection  
5.4. 
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5.7 Conclusion: Enhancing Women’s Human Capabilities through Access 
to Medicines in Nigeria 
It has been argued that pharmaceutical patents have significant implications for 
access to medicines and, by extension, human development. The reason for 
this is that access to affordable medicines is critical to the attainment of a good 
standard of life, which is fundamental to the realisation of a high level of human 
development. From a rights perspective, it is the duty of the Nigerian 
government to provide the necessary health care facilities and medicines to 
guarantee people the right to health. It can be said that providing a patent 
system to foster pharmaceutical research and production of drugs is one of the 
many ways in which Nigeria can facilitate the availability of health enhancing 
and medicinal resources. However, it is not enough that the patent right 
contributes to pharmaceutical innovation; there is a need to ensure that society 
can leverage these resources as a means of achieving social objectives, 
including the expansion of health capabilities. A fair balance between the 
private and social benefits of innovation requires the consideration of a 
development-oriented patent policy framework which ensures not only that new 
technologies are created but also that people are able to access them. In the 
context of patent rights as a barrier to accessibility to vital medicines, it is also 
the obligation of the Nigerian government to ensure that the patent law which 
should promote the R&D of pharmaceuticals does not obstruct specifically, 
women’s access, to the medicines and consequently, their potential for human 
development.  
The nexus between the right to health, building human development through 
access to medicines for human capacity and development requires a renewed 
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approach to the consideration of patent law. It goes without saying therefore 
that, while patents can be essential to innovation, and that, within international 
IP fora, providing patent protection is seen to facilitate economic growth and 
development, approaching the issue of development in light of patents 
assesses whether the IPR is essential to development by evaluating the role it 
plays in the achievement of human development. From a human development 
and capabilities perspective, it is imperative that the Nigerian government and 
relevant authorities ensure that the results of innovation reach those who need 
them. Given the adverse effects of the marketing practices of pharmaceutical 
firms on access to medicines, it is advisable for Nigeria to control activities of 
the pharmaceutical companies and the marketing techniques that acerbate the 
problems of access to drugs. Specifically, thinking in terms of capabilities, the 
Nigerian government and policy makers can broadly utilise the TRIPS 
flexibilities to guarantee women and everyone in Nigeria, access to patented 
medicines and facilitate the availability of cheaper generic medicines. As will be 
discussed in the next chapter, this can be do by incorporating the necessary 
TRIPS flexibilities and utilising the patent law exemption in the interests of 
health and access to affordable, essential medicines thus enhancing women’s 
human development potential.  
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CHAPTER VI: TRANSLATING TRIPS AND ITS FLEXIBILITIES 
FOR ACCESS TO MEDICINES AND THE RIGHT TO HEALTH IN 
NIGERIA 
 
6.1 Introduction 
As discussed in Chapters III, IV and V of this thesis,1 patent rights could impact 
the ability to access to medicines, the right to health, and consequently, human 
development. To address some of the adverse effects of patent rights and the 
TRIPS Agreement on accessing affordable and essential medicines, members 
of the World trade Organization (WTO) can take advantage of the legal 
exceptions within the TRIPS Agreement to promote and facilitate the availability 
and access to cheaper medicines for their citizens.2 The aim of this chapter is to 
assess the extent to which the TRIPS-inherent flexibilities, as clarified by the 
Doha Declaration, could serve as effective measures for states, especially 
developing countries, to promote and improve the state of health of their people 
through access to affordable pharmaceuticals. The chapter starts therefore, with 
a critical analysis of the flexibilities in TRIPS as a policy tool for facilitating 
access to life-saving medicines and thereby promoting the realisation of the right 
to health and advancing human development. With a specific focus on Nigeria, 
this chapter examines the flexibilities with the view of recommending ways in 
which the Nigerian Government can utilise the flexibilities in the context of 
pharmaceutical patents to particularly enhance women’s access to affordable 
and essential medicines. In so doing the chapter also questions the 
                                                          
1 See subsections 3.7, 4.5, 4.6 and 5.4 and 5.6 of Chapters III, IV and V respectively. 
2 This was mentioned in subsection 3.7.2 of Chapter III. 
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effectiveness of the health-related safeguards in the TRIPS Agreement, 
especially for Nigerian society.  
This chapter also generates insights into other developing and developed 
countries’ use of the flexibilities, the judicial authorities laid down by the courts 
and the WTO’s Dispute Resolution Panel to illustrate how a well-designed 
intellectual property (IP) policy and patent system can contribute to the 
performance of the flexibilities in a practical context. This chapter further 
examines how other WTO-member countries have handled their health crises 
using the flexibilities, including the challenges they encountered, to suggest how 
Nigeria can formulate its patent policy and system to expedite the availability of 
lower-priced medicines and also increase local production of pharmaceuticals 
whilst conforming to its international trade obligation. 
In light of the foregoing aims, the first part of this chapter highlights the current 
implementation status of the TRIPS Agreement, including the flexibilities, in 
Nigeria and the practical measures undertaken so far to maximise their benefits. 
The second part analyses the legal framework of the flexibilities and also points 
to the issues and problems that have arisen with regards to their implementation 
in a practical context and the subsequent need for clarification at Doha in 2001. 
The third part analyses some of the flexibilities in greater detail, and also draws 
on practical examples from other states that have relied on the health-related 
patent exceptions in a practical context to facilitate access to medicines. Having 
provided the legal and moral justifications to promote women’s access to 
medicines in the preceding chapters,3 this part argues that the flexibilities 
provide important avenues for Nigeria to meet its human rights obligations to 
                                                          
3 See Chapter III, IV and V of this thesis. 
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health and development and foster better access to drugs. It is argued, 
however, that effective use of the flexibilities in Nigeria depends upon its 
adaptation and interpretation in national laws in a manner that is better suited to 
the country’s national development and public health objectives. 
Due to space constraints, the analytical focus in this chapter is on four flexibility 
provisions in the TRIPS Agreement: the patentability flexibility and exceptions in 
Article 27; the limits to a patent right in Article 30; and compulsory licensing and 
non-commercial (government use) flexibilities in Article 31.  
 
PART I: AN OVERVIEW OF THE STATUS OF THE TRIPS 
AGREEMENT IN NIGERIA 
6.2 The Introduction of the TRIPS Agreement for Patent Rights in Nigeria 
As would be recalled from Chapter II,4 Nigeria became a signatory to TRIPS in 
2005 but is yet to domesticate or implement the TRIPS Agreement into its 
national laws as required under Section 12(1) of the 1999 Nigerian Constitution.5 
At the time of writing, the ratification process had been initiated by the Federal 
Executive Council (FEC), and now awaits ratification and implementation by the 
Nigerian National Assembly.6  
                                                          
4 See subsection 2.6.3 of Chapter II. 
5 Section 12 of the 1999 Nigerian Constitution states that all treaties must be passed into law and domesticated by the Nigerian 
National Assembly to have national effect. Hence the ratification process of the WTO TRIPS Agreement is subject to a national 
legislative act to be binding. 
6 In 2013, 2014 and 2015, the author of this thesis visited the trade department of the Ministry of Trade and Investment (formerly 
the Ministry of Trade and Commerce) in Nigeria and was told that there is a bill on the floor of the NASS that seeks to update the 
Patent and Design Act of 1970 to reflect Nigeria’s WTO TRIPS obligation. I was able to view a draft copy of the ‘Request for 
Approval for the Ratification and Acceptance of the Protocol Amending the WTO Agreement on Trade-Related Aspect of 
Intellectual Property Rights (TRIPS), agreed at Geneva, Switzerland, on 6th December, 2005.’ Since the commencement of this 
research, I have visited the relevant departments responsible for this amendment and ratification on three different occasions in 
the span of three years (in 2013, 2014 and 2015) but I could not find the draft TRIPS ratification instrument itself. No one at the 
Ministry of Trade and Investment, legal drafting department of the Ministry of Justice (responsible for drafting bills in Nigeria), or 
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6.2.1 The Nigerian Intellectual Property Commission (NIPCOM) Draft Bill 
The Nigerian IP regime is still under review and the legislative framework for a 
new consolidated IP legislation is at an advanced stage in Nigeria.7 Since 2002, 
attempts have been made to revise the IP laws in line with the international 
obligations of the TRIPS Agreement.8 Accordingly, the then Minister of 
Commerce (now the Minister of Trade and Investment) set up a committee to 
establish an administrative body to initiate this process.9 The Nigerian 
Intellectual Property Commission was, thereafter, inaugurated to administer IP 
laws.10 The Commission was charged with the responsibility for designing the 
necessary framework and fashioning the process for IP reform.11 The 
Committee in its report took into account the urgent need to comprehensively 
review and update substantive IP legislation in conformity to recent 
developments and the obligations and requirements of the TRIPS Agreement.12 
The Committee made several recommendations for this purpose including the 
harmonisation of IP regulations and an institutional framework for a proposed 
Intellectual Property Commission and drafted the Nigerian Intellectual Property 
Commission (NIPCOM) Bill of 2007 to this effect.13  
                                                                                                                                                                          
Patent Registry Office had a copy of the draft instrument or knew the whereabouts of the draft ratification instrument. To the best 
of my knowledge, as of December 2015, the draft ratification instrument is still under review but progress remains uncertain even 
to all the people responsible for the ratification.  
7 World Trade Organization, ‘Trade Policy Review Nigeria’ (Wt/Tpr/S/147, World Trade Organization 13 April 2005) ix; World Trade 
Organization, ‘Trade Policy Review Nigeria’ (WT/TPR/G/247 World Trade Organization 24 May 2011) 25. 
8 George M Sikoyo, Elvin Nyukuri and Judi W Wakhungu, Intellectual Property Protection in Africa: Status of Laws, Research and 
Policy Analysis in Ghana, Kenya, Nigeria, South Africa and Uganda (African Centre for Technology Studies Ecopolicy Series no 16 
2006) 26. 
9 ibid 26-27. 
10 ibid 
11 ibid 
12 ibid 27. 
13 ibid 
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The draft bill, compatible with the standards set out in the TRIPS Agreement, 
was presented to the Nigerian National Assembly as part of the intellectual 
property law reform process.14 It contains comprehensive provisions for the 
establishment of an administrative organ and harmonisation of all IP-related 
matters including patents and copyright.15 As such the bill contains detailed 
provisions on all the IP rights including copyright, trademarks, service marks, 
patent and designs, plant varieties, animal breeders’ and farmers’ rights. The bill 
also proposed to model the Nigerian IP system according to international 
standards and enhance domestic IP practices for the protection and 
administration of IP.16 The integration of the regulation and enforcement of IP 
under one administrative organ would reduce administrative costs, allow for 
better collaboration and ensure an efficient management of IP with fewer 
bureaucratic hurdles.17 Although the NIPCOM Bill was drafted before the 
ratification process to domesticate the TRIPS Agreement was initiated in Nigeria 
by the Federal Executive Council (FEC), the bill contains important provisions, 
including many of the TRIPS flexibilities options for enhancing access to 
medicines. The Draft Bill was the subject of an extensive review and 
consultation with various stakeholders; however, the bill has been before the 
legislative House of Assembly since 2007.18 Progress for enactment has been 
slow, partly due to lack of political and legislative will, administrative challenges 
                                                          
14 Adebambo Adewopo, According to Intellectual Property: A Pro-Development Vision of the Law and the Nigerian Intellectual 
Property Law and Policy Reform in the Knowledge Era (Nigerian Institute of Advanced Legal Studies 2012) 49. In late 2006, the 
previously unsuccessful Industrial Property Bill was reviewed and built upon by the draft Nigerian Intellectual Property 
Commission (NIPCOM) Bill. The bill sought to integrate the Patent, Designs and Trademark Registry and Nigerian Copyright 
Commission as a single administrative organ to form the Nigerian IP Commission (NIPCOM). The NIPCOM bill was prepared as part 
of the Federal Government’s reform agenda. Sikoyo, Nyukuri and Wakhungu (n 8) 26-27.  
15 Adewopo (n 14) 49; Okechukwu Timothy Umahi, ‘Proactive Legal Reforms through Nigerian Universities and Nigerian Bar 
Association Push: A Case for Intellectual Property Commission (NIPCOM) Bill’ 3. Available at <SSRN: 
http://ssrn.com/abstract=2012652> accessed 15 January 2014.  
16 ibid 
17 Umahi (n 15) 9. 
18 Adewopo, According to Intellectual Property: A Pro-Development Vision of the Law and the Nigerian Intellectual Property Law 
and Policy Reform in the Knowledge Era (n 14) 50; Umahi (n 15) 7.  
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and changes in government.19 Within the context of patents and its related 
flexibilities, and access to medicines, the provisions in the current patents 
legislation in Nigeria,20 the Draft Bill, and TRIPS Agreement are further 
examined.  
In summary, Nigeria is yet to adequately domesticate or implement the TRIPS 
Agreement to take advantage of some of the TRIPS-inherent flexibilities. From 
the perspectives of health, it is submitted that Nigeria should domesticate and 
broadly interpret the flexibilities to realise, fulfil, protect and promote women’s 
right to health and promote their human development in Nigeria. Since it is 
inevitable that the country, as a member of the WTO, has to adopt all the 
treaties and Agreements of the international trade system, including the TRIPS 
Agreement, Nigeria should effectively implement and adapt the Agreement and 
its flexibilities in the interests of its people’s health.  
Against the background of the foregoing, the following section analyses the legal 
framework of the flexibilities guaranteed by the TRIPS Agreement and the Doha 
Declaration as measures for protecting public health and promoting access to 
medicines. This section will focus on the implementation challenges and the 
process leading up to the clarification at Doha. 
 
 
 
 
                                                          
19 ibid 
20 The Patent and Designs Act of 1970 (PDA), Cap 344 of Laws of the Federation of Nigeria 1990. 
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PART II: REVISITING TRIPS FLEXIBILITIES AND SOLUTIONS 
FOR PUBLIC HEALTH 
6.3 TRIPS Agreement and Flexibilities: Framing the Global Debate 
As noted in Chapter III,21 the introduction of the TRIPS Agreement ushered in a 
new regime of global intellectual property (IP).22 In light of scientific and 
technological breakthroughs for life-threatening diseases in the pharmaceutical 
and medical sectors, a major concern was raised about the impact of patent 
protection contained in the TRIPS Agreement.23 Amidst millions dying each day 
from diseases that are treatable with existing medicines, the initial issue was 
how to make sure that the implementation of the TRIPS Agreement would not 
prevent the availability of, and access to, medicines for poor people in 
developing countries, but instead promote R&D.24 Consequently, the focus has 
shifted to the legal remedies contained in the Agreement that could be used by 
states to improve access to affordable patented medicines in the interests of the 
public.25  
6.3.2 The Flexibilities 
The legal exceptions and patent-related flexibilities in the TRIPS Agreement are 
classified into two main categories: the time-based extension by way of 
                                                          
21 This was mentioned in subsection 3.6.1 of Chapter III.  
22 Sell and Paresh observe that the introduction of the Agreement brought fundamental changes to the rules and normative 
setting of global intellectual property. Susan K Sell and Aseem Prakash, ‘Using Ideas Strategically: The Contest between Business 
and NGO Networks in Intellectual Property Rights’ (2004) 48(1) International Studies Quarterly 143, 154.  
23 Sisule F Musungu, Susan Villanueva and Roxana Blasetti, Utilizing TRIPS Flexibilities for Public Health Protection through South-
South Regional Frameworks (South Centre 2004) 1-2. Problems arose due to the prohibitive cost of patented drugs, especially 
treatments for ARV and other opportunistic infections, as well as a lack of research into neglected diseases as discussed in 
previous chapters. Haochen Sun, ‘The Road to Doha and Beyond: Some Reflections on the TRIPS Agreement and Public Health’ 
(2004) 15 European Journal of International Law 123, 123-127.  
24 Bryan Christopher Mercurio, ‘Resolving the Public Health Crisis in the Developing World: Problems and Barriers of Access to 
Essential Medicines’ (2007) 5(1) Northwestern Journal of International Human Rights 1-4. 
25 West African Health Organization (WAHO), ‘Development of a Harmonised TRIPS Policy for Adoption by ECOWAS Member 
States that Employ TRIPS Flexibilities to Improve Access to Medicines in the Region’ (West African Health Organization 2013) 17. 
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transition periods for developing26 and least developed countries (LDC)27 to 
implement the Agreement; and the substantive patent rights exemptions and 
flexibilities that can be utilised for the promotion of public health and facilitation 
of access to medicines.28 The substantive flexibilities are further categorised into 
a) the objectives and principles of the TRIPS in Articles 7 and 829 which 
emphasises the balance of IP rights between the IP producers and users on the 
one hand, and promotes the social welfare and public health goals of IP on the 
other, and; b) specific exceptions to patent rights that WTO Member states can 
adopt to enhance access to medicines.  
From the standpoint of health, the flexibilities with particular relevance to patents 
are contained in the following Articles of the TRIPS Agreement.30 Article 1(1) 
which allows Members the discretion to adapt and determine the appropriate 
method for implementing the provisions of the Agreement in their domestic laws; 
Article 6 which gives considerable freedom for members to define their own 
appropriate exhaustion regimes, thus allowing a wide mandate for the legal use 
of parallel imports;31 Article 8 which empowers members to formulate and 
amend their IP laws and regulations in a manner that takes into account public 
health, nutrition and other issues of public interest, including the adoption of 
necessary measures; and Article 27 which allows members to exclude certain 
inventions from patentability where preventing the invention from commercial 
exploitation  where it is necessary to safeguard and protect humans, health, 
animals, plant life or the environment. Other flexibilities are found in Article 30 
                                                          
26 Until 2005. 
27 Until 2033. 
28 Musungu, Villanueva and Blasetti (n 23) 5. 
29 The importance of the Articles to public health and human development was analysed in Chapter II, subsection 2.5.4, and 
Chapter V subsection and sub-subsections of 5.3. 
30 Some of the flexibilities are considered in detail in the next section of this chapter.  
31 TK Mirabile, ‘AIDS, Africa and Access to Medicines’ (2002) 11 Michigan State University-DCL Journal of International Law 175, 
212. 
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which grants members the latitude to provide limited exceptions to the exclusive 
rights conferred by patents, provided such exceptions do not unreasonably 
conflict with the normal exploitation of the patent or prejudice the legitimate 
interests of the patent right holder; and Article 31 which provide for the grant and 
use of compulsory licences and government use or authorisation of a patented 
invention in certain circumstances including the promotion public health and 
control of anti-competitive practices.32 Some of these flexibilities were reaffirmed 
by the Doha Declaration in 2001, as will be examined shortly.33  
The flexibilities, as a means of fostering access to affordable drugs have gained 
support in several international policy regulations and fora. For example, in 
2001, the World Health Organisation (WHO) expounded on the strategic use of 
compulsory licensing, differential pricing through parallel imports as well as price 
control as mechanisms to ensure affordable access to patented medicines.34 
Furthermore, the WHO and WTO published a report describing the role of the 
flexibilities in health policies.35 Legal remedies as tools for public health were 
also stressed in the resolution of the World Health Assembly (WHA) and the 
Report of the Commission on Intellectual Property Rights, Innovation and Public 
Health.36 Specifically, Resolution WHA56.27 urged states to adapt their national 
laws and implement the full use of the flexibilities in the interests of public 
health.37 A trilateral study by the WHO, World Intellectual Property Organization 
(WIPO) and WTO in 2013, reiterated the importance of implementing and using 
                                                          
32 See summary at Sisule F Musungu and Cecilia Oh, The Use of Flexibilities in TRIPS by Developing Countries: Can they Promote 
Access to Medicines? (South Centre 2006) xv-xxxiii.  
33 See the next subsection 6.4 in this Chapter. 
34 Jeffrey Sachs, ‘Macroeconomics and Health: Investing in Health for Economic Development’ (World Health Organization 2001) 
87-91, 127. The WHO however, emphasised the use of voluntary licensing by countries, the pharmaceutical industry, generic 
producers and other donor organisations to negotiate pricing and licensing for drug production in developing countries. ibid 89. 
35 World Health Organization (WHO) and World Trade Organization (WTO), WTO Agreements and Public Health: A Joint Study by 
the WHO and WTO Secretariat (World Health Organization and World Trade Organization 2002).  
36 World Health Assembly, ‘Intellectual Property Rights, Innovation and Public Health’ (WHA56.27 Agenda item 14.9 2003); World 
Health Organization (WHO), Public Health, Innovation and Intellectual Property Rights: Report of the Commission on Intellectual 
Property Rights, Innovation and Public Health (World Health Organization 2006).  
37 World Health Assembly (n 36). 
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the flexibilities as policy options for states to pursue public health objectives and 
enhance access to medicines.38 These resolutions and reports give significant 
impetus to developing countries to apply and enforce the IP exemptions and 
provisions limiting the exercise of patent rights to protect and to promote their 
people’s public health interests.39  
6.4 Enhancing the Use of the Flexibilities: The Doha Declaration 
Over the years, the exact scope and interpretation of the flexibilities in the 
TRIPS Agreement has been the subject of acrimonious debates over 
interpretation and application in practice.40One of the most notable disputes 
relating to patent rights and access to medicines in developing countries leading 
up to the Doha Declaration was the challenge against the South African 
Medicines and Related Substance Control Amendment Act no 90 of 1997 
(Medicines Act) by large multinational pharmaceutical corporations.41 Prior to 
this, South Africa, a member of the WTO, was experiencing a crippling scourge 
of HIV/AIDS.42 Many South Africans did not have access to essential 
                                                          
38 Hans G Bartels and others, Promoting Access to Medical Technologies and Innovation: Intersections between Public Health, 
Intellectual Property and Trade (World Health Organization, World Intellectual Property Organization and World Trade 
Organization 2013) 11-18. 
39 See also the World Health Organization, Global Strategy and Plan of Action on Public Health, Innovation and Intellectual 
Property (World Health Organization 2011). The Declaration’s importance for clarification has been tested in the decisions of 
national Courts. In Novartis Pharma AG c/ Monte Verde S.A. s/ varios propiedad industrial e intelectual Causa No. 5.619/05 (Arg.), 
Cámara Federal de Apelaciones [CFed.] [Federal Appeals Court], 1/2/2011, the Argentinian Court of Appeal had to determine 
whether Argentine Law No 24,766 (the confidentiality Act) which regulates the protection of test data, did not offer an effective 
data protection and was thus inconsistent with the provisions of Article 39(3) of the TRIPS Agreement. Novartis argued that Article 
39.3 mandates a data exclusivity protection with regards to its product Gleevec®. The court confirmed that the country’s law and 
TRIPS implementation regime was consistent with the provisions of the TRIPS Agreement and that the granting of data exclusivity 
rights is disallowed. In its ruling, the court relied on the Doha Declaration as an interpretive tool and held that the Declaration 
allowed for a ‘flexible interpretation of that provision.’ The court further used the right to health as a balancing factor by noting 
that the ‘WTO Members are not only obliged to comply with the TRIPS Agreement, but also to respect their commitment 
regarding human rights.’ As interpreted and quoted in Christophe Geiger, Research Handbook on Human Rights and Intellectual 
Property (Edward Elgar Publishing 2015) 212; Carlos Correa and Duncan Matthews, ‘The Doha Declaration 10 Years on and its 
Impact on Access to Medicines and the Right to Health’ (United Nations Development Programme 2011) 19. Also available at  
undp.org/content/dam/undp/library/hivaids/Discussion_Paper_Doha_Declaration_Public_Health.pdf accessed 16 January 2016. 
40 International debate by developing countries and developed countries centred on the exact scope and utilisation of the 
flexibilities to address public health needs. Musungu, Villanueva and Blasetti (n 23) xii. 
 
42 At that time, South Africa had one of the highest rates of HIV/AIDS infections in the world. William W Fisher III and Cyrill P 
Rigamonti, ‘The South Africa AIDS Controversy: A Case Study in Patent Law and Policy’ [2005] Harvard Law School, The Law and 
Business of Patents 3. Also available at  
336 
 
336 
 
antiretroviral (ARV) drugs and vaccines.43 This problem was aggravated by the 
pricing policies of the pharmaceutical companies who held patents on most of 
the ARV drugs.44 In consideration of the health crisis, the shortage of drugs and 
the high prices of essential medicines in the public sector, the government 
amended the Medicines and Related Substance Act of 1965 in 1997,45 to make 
medicines more available and affordable and improve the public health of its 
citizens.46 For this purpose, the Act, among other things, gave the government 
power to override patent rights in pharmaceuticals for public health reasons, 
issue compulsory licences and make provisions for the parallel importation of 
patented and cheaper medicines.47 In particular, the Act was amended to 
include a new Section 15C to make medicines cheaper and more available from 
other lower-priced options abroad, through parallel importation.  
This legislative policy, particularly Section 15C, was strongly condemned by 
some interest groups, particularly, the pharmaceutical companies who sought to 
set aside the implementation of the amended Act on the grounds that the Act 
was unconstitutional. They also argued that its provisions sought to deprive the 
owners of their property rights without compensation, contrary to section 25 of 
the South African Constitution.48 They further argued that the amended Act was 
a violation of their rights as prescribed in Article 28 of the TRIPS Agreement.49 
                                                                                                                                                                          
<https://cyber.harvard.edu/people/tfisher/South%20Africa.pdf> accessed 15 January 2016; Duncan Matthews, Intellectual 
Property, Human Rights and Development: The Role of the NGO’s and Social Movements (Edward Elgar Publishing 2011) 94. 
43 Fisher III and Rigamonti (n 42) 2. With an estimated average annual income of $2,600, many South Africans could not afford to 
pay for the necessary treatment which was about $1,000 a month. ibid 2. 
44 ibid 2-3. 
45 Medicines and Related Substances Control Amendment Act, No. 90 of 1997 (Medicines Act). 
46 Amir Attaran and Lee Gillespie-White, ‘Do Patents for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa?’ (2010) 
286 Journal of the American Medical Association 1886, 1888.  
47 Section 15C, Medicines and Related Substances Control Act 101 of 1965 after amendment by the Medicines and Related 
Substances Control Amendment Act (Act 90 of 1997). Matthews, Intellectual Property, Human Rights and Development: The Role 
of the NGO’s and Social Movements (n 42) 98. 
48 Carolyn Deere, The Implementation Game: The TRIPS Agreement and the Global Politics of Intellectual Property Reform in 
Developing Countries (Oxford University Press 2008) 222-229. 
49 Pharmaceutical Manufacturers' Association of South Africa et al v President of the Republic of South Africa (1998) Case No 
4183/98, Notice of Motion in the High Court of South Africa (Transvaal Provincial Division) Paragraphs 2-9. 
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The case received the backing of the United States (US) which threatened 
sanctions against South Africa unless the amended provisions were repealed.50 
In May 2000, the case was voluntarily withdrawn by the pharmaceutical 
companies after it attracted considerable international criticism and concern 
about the effect of IP on access to medicines.51  
The outcome of this significant case galvanised attention on the effect of IP 
rights on access to medicines, their impact on human survival in general and the 
actions of pharmaceutical companies in particular.52 According to Professor 
Fisher III and Rigamonti, the case ‘[…] touches upon the more fundamental 
question of to what extent WTO Member States – in this context, primarily 
developing countries – should be free to take legislative measures to deal with 
public health crises and to what extent the patent protection of pharmaceuticals 
required under TRIPS should limit the range of options available.’53 Importantly 
however, the outcome of this case helped to clarify the scope of the flexibilities 
that can be used by developing countries. Significantly, the strong opposition by 
the pharmaceutical industry to the legislative decision exposed some of the 
inadequacy of the flexibilities contained in TRIPS as a leveraging measure for 
access to medicines and the challenges inherent in implementing the 
flexibilities.54 The dispute around the practical implementation and utilisation of 
compulsory licensing and parallel imports as flexibility options also triggered a 
                                                          
50 The United States Government, applied pressure on South Africa to repeal the Act by placing the country on its infamous 301 
‘Watch List’ and suspending trade relations with South Africa. Due to public outrage, the US withdrew the trade pressures. Joo-
Young Lee, A Human Rights Framework for Intellectual Property, Innovation and Access to Medicines (Ashgate Publishing Ltd 2015) 
24. 
51 Ellen FM ‘t Hoen, The Global Politics of Pharmaceutical Monopoly Power: Power Drugs Access, Innovation and the Application of 
the WTO Doha Declaration on TRIPS and Public (AMB Publishers 2009) 21-22. The withdrawal was largely a result of pressure, 
campaigning and public advocacy by several international NGO’s including Médecins Sans Frontières (MSF), Oxfam, and Treatment 
Action Campaign (TAC) that raised awareness and brought global attention to the issues of access to medicines. The campaigns 
raised concerns about the role that patent on pharmaceuticals, and actions of patent holders can play in excerbating the problems 
of access to medicines. For more discussion on the role of the NGO’s in this case and other access to medicines campaign, see 
Matthews, Intellectual Property, Human Rights and Development: The Role of the NGO’S and Social Movements (n 42) 99-100. 
52 James Harrison, The Human Rights Impact of the World Trade Organisation (Hart 2007) 158. 
53 Fisher III and Rigamonti (n 42) 13.  
54 ibid  
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global debate on what should be allowed in the interpretation and application of 
the TRIPS flexibilities, to respond to health crises.55 The focal point of 
discussions in this regard was how to ensure an adequate balance of promoting 
public health through the flexibilities, while at the same time, preserving patents 
as important incentives for research and development (R&D) of 
pharmaceuticals.56  
In another instance, in 2000, the US brought an action before the WTO Dispute 
Settlement Body (DSB)57 against Brazil over Article 68 of the 1996 Brazilian 
Industrial Property Law which enumerates conditions for compulsory licensing.58 
The legislative measure by Brazil was aimed at increasing the provision of, and 
access to medicines, especially for people living with HIV/AIDS, in light of the 
patent protection of pharmaceutical products.59 The US complaint to the DSB 
was on the grounds that the ‘local working’ requirement for local production in 
Brazil in Article 68, violated the exclusive rights conferred to patent owners in 
Articles 27(1) and 28(1) of the TRIPS Agreement.60 The US argued that Article 
68 discriminated against, and curtailed the enjoyment of, the exclusive rights of 
US patent owners in Brazil whose products were not locally manufactured but 
imported into Brazil.61 Brazil, on the other hand, argued that the provision of the 
                                                          
55 Pranitha Maharaj and Benhjamine Roberts, ‘Tripping Up: AIDS, Pharmaceuticals and Intellectual Property in South Africa’ in 
Caren Grown, Elissa Braunstein and Anju Malhotra (eds), Trading Women's Health and Rights: Trade Liberalization and 
Reproductive Health in Developing Economies (Zed Books 2006) 228; Fisher III and Rigamonti (n 42) 14.  
56 Fisher III and Rigamonti (n 42) 14. 
57 Brazil — Measures Affecting Patent Protection (WT/DS199/1 G/L/385 IP/D/23 8 June 2000 (00-2254). 
58 Law No. 9,279 of May 14, 1996, effective May 1997 (Industrial Property Law Act).  
59 Matthews, Intellectual Property, Human Rights and Development: The Role of the NGO’S and Social Movements (n 42) 130. 
60 Brazil — Measures Affecting Patent Protection (WT/DS199/1 G/L/385 IP/D/23 8 June 2000 (00-2254). See More at WTO, ‘WTO | 
Dispute Settlement - The Disputes - DS199’ (Wto.org 2016)  
available at <https://www.wto.org/english/tratop_e/dispu_e/cases_e/ds199_e.htm> accessed 19 February 2016. 
61 ibid. The said Article 68 of the Industrial Property Law, No. 9.279, of May 14, 1996 as amended by Law 10.196 of February 14, 
2001 provides that: 
The titleholder shall be subject to having the patent licensed on a compulsory basis if he exercises his rights 
derived therefrom in an abusive manner, or by means thereof engages in abuse of economic power, proven 
pursuant to law in an administrative or judicial decision. 
The Article further lists the conditions for compulsory licenses including non-exploitation of the object or working of the patent 
within the territory of Brazil for ‘failure to manufacture or incomplete manufacture of the product,’ insufficient commercialisation 
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Act is TRIPS compliant and Article 27(1) should be considered in light of Article 
2(1) of TRIPS which incorporates provisions of the Paris Convention permitting 
local working of patents.62 The US complaint was later withdrawn and the 
dispute mutually settled by a bilateral agreement between the two countries 
after Brazil agreed to furnish advance notice if a licence was to be issued under 
Article 68 for patents held by US companies and any dispute is subject to 
discussion through a ‘Consultative Mechanism.’63  
Similar to the South African situation, this US complaint attracted considerable 
criticism and discussions globally on the impact of patent on affordable 
medicines for people in developing countries and the challenge to efforts by 
governments to ensure cost-effective medicinal solutions to their health crises, 
especially HIV/AIDS.64 These conflicts generated further international debate on 
the interpretation, use and scope of the TRIPS flexibilities particularly with 
regard to access to affordable essential medicines.65  
In the run-up to the Fourth Session of the WTO Ministerial Conference held in 
Doha, Qatar in 2001, the African Group, supported by other developing 
countries and civil societies, requested the Council for TRIPS to reconsider the 
issue of IP protection and access to essential medicines especially for people in 
                                                                                                                                                                          
to satisfy local demands, abuse of patent rights and further allows third parties to import the products and processes under patent 
protection to exploit the patent. Article 68 (1)-(5). 
62 Article 5A Paris Convention. Matthews, Intellectual Property, Human Rights and Development: The Role of the NGO’S and Social 
Movements (n 42) 133-134; Brazil also argued that the requirement for local working conditions only applied to issuances where it 
was necessary to curtail the abuse of patent rights and economic dominant position and power. ibid 134. 
63 Joint Notification of Mutually Agreed Solution (WT/DS199/4, July 19, 2001); WTO Reporter, ‘United States Drops WTO Case 
against Brazil over HIV/AIDS Patent Law’ (The Bureau of National Affairs Inc. 2001).  
Also available at<http://www.cptech.org/ip/health/c/brazil/bna06262001.html> accessed 3 November 2014; Matthews, 
Intellectual Property, Human Rights and Development: The Role of the NGO’S and Social Movements (n 42) 137-138; WTO, ‘Dispute 
Settlement: DS199, Brazil — Measures Affecting Patent Protection DS199’ (Wto.org 2016); The Consumer Project on Technology 
(CPTech) ‘Compulsory Licenses’ available at <http://www. http://www.cptech.org/ip/health/cl/recent-examples.html> accessed 
28 January 2016; Matthews Intellectual Property, Human Rights and Development: The Role of the NGO’S and Social Movements (n 
42); James Packard Love, ‘Recent Examples of the Use of Compulsory Licenses on Patents’ (2007) Knowledge Ecology International 
KEI.  
64 Duncan Matthews writes extensively on the campaign and activism of several NGO’s and other interest groups in the outcome 
of this Dispute Complaint. See Matthews, Intellectual Property, Human Rights and Development: The Role of the NGO’S and Social 
Movements (n 42) 133-146. 
65 ibid; Musungu and Oh (n 32) 1. 
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developing countries.66 In particular, the African Group, which includes Nigeria, 
made proposals for separate declarations with regards to access to essential 
medicines in the light of health crises such as AIDS in Africa.67 At the same 
time, there were various publicity campaigns for a solution to health problems 
within the context of IP rights by a large number of activist, international 
organisations and civil society’s around the globe.68 
To clarify the challenges that arose out of the impact of patent rules on 
affordable essential medicines, and the related use of the TRIPS flexibilities,69 
the ‘Declaration on the TRIPS Agreement and Public Health’ (Doha 
Declaration), was adopted by WTO Members in 2001 to interpret and give 
credence to the exceptions contained in the TRIPS Agreement.70 Significantly, 
to reiterate the right of WTO members to use the flexibilities, the Doha 
Declaration recognised the deficiencies of TRIPS for health and subsequently 
                                                          
66 Correa and Matthews (n 39) 7. 
67 Ellen FM ‘t Hoen, ‘TRIPS, Pharmaceutical Patents, and Access to Essential Medicines: A Long Way From Seattle to Doha.’ [2002] 
Chicago Journal of International Law 39, 50. 
For example, Zimbabwe as head of the Africa Group stated: 
We propose that Members issue a special declaration on the TRIPS Agreement and access to medicines at the 
Ministerial Conference in Qatar, affirming that nothing in the TRIPS Agreement should prevent Members from 
taking measures to protect public health. 
ibid; Patrick L Osewe, Yvonne K Nkrumah and Emmanuel K Sackey, Improving Access to HIV/AIDS Medicines in Africa: Trade-Related 
Aspects of Intellectual Property Rights Flexibilities (World Bank 2008) 4. See press release and summary of discussions at WTO, 
‘WTO: NEWS - TRIPS Council Discussion on Affordable Medicines - Press 232’ (Wto.org 2001.) Available at 
<https://www.wto.org/english/news_e/pres01_e/pr233_e.htm> accessed 20 February 2016; WTO, ‘WTO | News - 2001 News 
Items - TRIPS Council on Access to Medicines’ (Wto.org, 2001) Available at 
<https://www.wto.org/english/news_e/news01_e/trips_drugs_010620_e.htm> accessed 20 February 2016. 
68 Fisher III and Rigamonti (n 42) 15; Matthews, Intellectual Property, Human Rights and Development: The Role of the NGO’S and 
Social Movements (n 42) 133-146. 
69 For a detailed negotiating history of and commentary on the TRIPS Agreement including the process leading to the adoption of 
the Doha Declaration, see United Nations Conference on Trade and Development (UNCTAD) and  International Centre for Trade 
and Sustainable Development (ICTSD), Resource Book on TRIPS and Development (Cambridge University Press 2005). (Hereafter 
UNCTAD and ICTSD).  
70 WTO Ministerial Conference: The Declaration on the TRIPS Agreement and Public Health (Adopted on 14 November 2001 
WT/MIN(01)/DEC/W/2) (Hereinafter called the Doha Declaration for brevity). It is important to note however that the Ministerial 
Declaration is principally an interpretative instrument of the obligations contained in TRIPS, thus its binding effect is persuasive to 
the provisions contained therein and any dispute arising out of the TRIPS Agreement. Alan O Sykes, ‘TRIPS, Pharmaceuticals, 
Developing Countries, and the Doha 'Solution' [2002] Chicago John M Olin Law & Economics Working Paper No. 140, (2D Series) 
10. 
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sought to clarify the TRIPS health-related reliefs so that developing countries 
could effectively utilise them to improve their health situation.71  
The Doha Declaration did not aim to create new safeguard policies for public 
health but set out to confirm and expatiate the flexibility options that members 
could adopt and implement in the interests of public health and access to 
drugs.72 Accordingly, ‘[…] we affirm the right of the WTO Members to use, to the 
full, the provisions in the TRIPS Agreement, which provide flexibility for this 
purpose.’73 In this connection, the Declaration also affirms that the TRIPS 
Agreement should not prevent countries from promoting their public health 
objectives.74 Thus in recognising the gravity of the public health problems and 
diseases affecting developing and least-developed countries such as 
HIV/AIDS,75 the Doha Declaration acknowledged that developing countries 
could enforce the IP exceptions and flexibilities in TRIPS, as public health 
safeguards to promote access to medicinal treatments.76  
Furthermore, Paragraph 4 of the Doha Declaration makes reference to the 
‘implementation’ and ‘interpretation’ of the Agreement. It establishes a standard 
for the interpretation of the Agreement in the light of public health so that, in the 
event of ambiguity, dispute resolution panels and the Appellant Body could 
interpret the implementation of the Agreement in a manner that gives support to 
WTO members’ right to protect their citizen’s health and enhance their 
                                                          
71 Sun (n 23) 136; Duane Nash, ‘South Africa’s Medicines and Related Substance Control Amendment Act of 1977’ (2000) 15(24) 
Berkeley Technology Law Journal 485, 495. 
72 Correa and Matthews (n 39) 7; Haochen Sun, ‘A Wider Access to Patented Drugs under the TRIPS Agreement’ (2003) 21 Boston 
University International Law Journal 101, 104. 
73 The Doha Declaration Paragraph 3. 
74 This health consideration was declared as follows by the Ministers of the 142 Members of the WTO (at that time): 
We agree that the TRIPS Agreement does and should not prevent Members from taking measures to protect 
public health. Accordingly, while reiterating our commitment to the TRIPS Agreement, we affirm that the 
Agreement can and should be interpreted in a manner supportive of WTO Members right to protect public 
health in particular, access to medicines for all. 
The Doha Declaration Paragraph 4. 
75 The Doha Declaration Paragraph 1.  
76 The Doha Declaration Paragraph 4.  
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accessibility to medicines.77 Although the Declaration is not a formal 
interpretative authority of the TRIPS Agreement from a legal point of view, its 
provisions explicate the use of the flexibilities in the interest of access to 
medicines.78  
More specifically, the Doha Declaration addresses the issues aforementioned by 
clarifying that each WTO Member has the right to issue and use compulsory 
licencing to improve access to medicines and, at each Member’s discretion, 
determine the grounds for the granting of the licences.79 Thus the Declaration 
leaves room for more flexibility in the determination of the justifications for the 
interpretation and implementation of compulsory licences. The Declaration also 
reaffirms that members are allowed the discretion to determine the scope of 
what constitutes ‘national emergency’ and ‘other circumstances of extreme 
urgency.’80 Furthermore, it clarifies that ‘public health crises’ are understood to 
represent a ‘national emergency’ and ‘other circumstances of extreme urgency’, 
which could be a short or long term problem.81 To remove any doubt, HIV/AIDS, 
malaria and tuberculosis health crises are explicitly recognised as a case of 
such an emergency or urgency.82 Paragraphs 5(d) of the Declaration clarifies 
that members can adopt an appropriate principle of exhaustion of rights and are 
                                                          
77 The Doha Declaration Paragraph 4. Carlos M Correa, Implications of the Doha Declaration on the TRIPS Agreement and Public 
Health (EDM series 12, World Health Organization 2002) viii. Also available at 
<http://apps.who.int/medicinedocs/en/d/Js2301e/10.2.2.html> accessed 3 February 2016. The European Commission, for 
instance, stated that in a report that: 
In the case of disputes (e.g. in the context of WTO dispute settlement procedures) Members can avail 
themselves of the comfort provided by this Declaration. Panellists are likely to take account of the provisions of 
the TRIPS Agreement themselves as well as of this complementary Declaration, which, although it was not meant 
to affect Members’ rights and obligations, expresses the Members’ views and intentions. Hence, the Declaration 
is part of the context of the TRIPS Agreement, which, according to the rules of treaty interpretation, has to be 
taken into account when interpreting the Agreement. 
European Commission, WTO Ministerial Declaration on the TRIPS Agreement and Public Health (European Commission, 19 
November 2001) 2.  
78 Correa and Matthews (n 39) 18.  
79 The Doha Declaration Paragraph 5(b). 
80 The Doha Declaration Paragraph 5(c). 
81 The Doha Declaration Paragraph 5(c). 
82 ibid 
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free to determine the rules and regime for ‘such exhaustion without challenge.’ 
Likewise, the Doha Declaration acknowledges the difficulties that developing 
countries would face in using the compulsory licences with little or insufficient 
manufacturing capacity and therefore direct the Council for TRIPS to expedite a 
solution for access to generic medicines by poor countries with limited drug 
manufacturing capacity by 2002.83 
Finally, the Declaration ‘reaffirmed the commitment of developed-country 
Members to provide incentives to their enterprises and institutions to promote 
and encourage technology transfer to least-developed country [LCD] Members 
pursuant to Article 66.2. […]’ and extended the transitional period for LCD under 
Articles 66.1 to implement and enforce sections 5 (patents) and 7 (test data) of 
part II of the TRIPS Agreement until 1 January 2016 ‘without prejudice to the 
right of least-developed country Members to seek’ further extensions.84 
6.4.1 The Relevance of the Doha Declaration to the Rights to Health, Life 
and Accessibility of Medicines 
The Doha Declaration significantly brought about some positive changes to the 
effort of developing countries to gain access to medicines.85 
The adoption of the Doha Declaration signalled an important achievement for 
developing countries to safeguard their people’s human rights and ameliorate 
the impact of IP and patent protection of pharmaceuticals on access to 
affordable essential medicines and alleviate urgent disease burdens.86 More 
                                                          
83 The Doha Declaration Paragraph 6.  
84 The Doha Declaration Paragraph 7. 
85 Médecins Sans Frontières, One Step Forward, Two Steps Back?: Issues for the 5th WTO Ministerial Conference (Médecins Sans 
Frontières 2003) 2. 
86 Joint United Nations Programme on HIV/AIDS (UNAIDS), DOHA+10 TRIPS Flexibilities and Access to Antiretroviral Therapy: 
Lessons from the Past, Opportunities for the Future (Joint United Nations Programme on HIV/AIDS (UNAIDS) 2011) 3. (Hereafter 
UNAIDS for brevity); Correa and Matthews (n 39) 8. 
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importantly, the Doha Declaration has given additional support to Members of 
the WTO to facilitate the availability of cost-effective medicines under patents in 
the interest of the rights to health and life of their citizens as identified in Chapter 
III.87 Furthermore, the Doha Declaration has also helped to focus international 
attention on the problems of availability and access to medicines as a result of 
IP rights on essential medicines.88 Civil societies and NGO’s have relied on the 
principles and provisions of the Declaration to advocate for access to medicines 
and procure ARV for HIV/ADS treatment programmes.89  
The commitment to the principles and importance of the Doha Declaration is 
also referenced in bilateral and multilateral agreements. For instance, the EU-
Colombia-Peru FTA, in making reference to the importance of the exceptions 
and flexibilities in TRIPS to guarantee access to medicines, emphasises that 
parties to the FTA can amend or formulate their laws to the allowed use of the 
flexibilities as clarified in the Declaration.90 A ten year plus report by the Joint 
United Nations Programme on HIV/AIDS (UNAIDS) also indicates that the Doha 
Declaration has been instrumental in influencing policy change at both 
international and national levels, and that significant success has been recorded 
                                                          
87 See the articulation of the rights to health and life in Chapter III. Although the Doha Declaration has significantly clarified the 
legal scope and rights of members to adapt and utilise the TRIPS flexibilities to protect public health, the solutions proffered are 
still the subject of scepticism as a result of implementation and administrative difficulties, external pressures to undermine the 
flexibilities and lack of manufacturing capacity to utilise the flexibilities. Another significant problem for some developing countries 
is the lack of legal expertise and appropriate specialist technical assistance or capacity to assess and enforce the TRIPS legal 
exceptions. See more at Sangeeta Shashikant, ‘More Countries Use Compulsory License, but New Problems Emerge’ (2005) Third 
World Network Info Service on Health Issues No 2. Also available at 
<http://www.twn.my/title2/health.info/twninfohealth004.htm> accessed 7 Sept 2015; Deere (n 48) 103; Correa and Matthew (n 
39)19-30; Musungu, Villanueva and Blasetti (n 23) 20-21; Peter Drahos, ‘Developing Countries and International Intellectual 
Property Standard-Setting’ (2005) 5 The Journal of World Intellectual Property 765, 776. 
88 Correa and Matthews (n 39) 12. 
89 UNAIDS (n 86) 4.  
90 Accordingly, ‘[…] in interpreting and implementing the rights and obligations under this Title, the Parties shall ensure 
consistency with this Declaration.’ Article 197(1), Trade Agreement between the European Union and its Member States, of the 
One Part, and Colombia and Peru, of the Other Part (Official EN Journal of the European Union Volume 55 21 December 2012). 
Also available at  
<http://trade.ec.europa.eu/doclib/docs/2011/march/tradoc_147704.pdf> accessed 16 July 2016. The importance of Doha was 
also stated in Article 147(b) of the Economic Partnership Agreement between the CARIFORUM States, of the one part, and the 
European Community and its Member States, of the other part (Official EN Journal of the European Union 30 October 2008) 
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in the use of the TRIPS flexibilities to facilitate access to essential drugs since 
the Declaration.91 While the Declaration cannot authoritatively repudiate the 
express provisions of the TRIPS Agreement, it helps in interpreting the 
provisions of the Agreement, especially when there is an issue of ambiguity in 
the TRIPS provisions.92  
The Doha Declaration holds promise for enhancing the accessibility to health 
treatments in Nigeria. Fundamentally, the reaffirmed flexibility of the TRIPS 
Agreement in the Doha Declaration is crucial to the realisation of women’s 
access to medicines as a right to health and the expansion of their human 
development prospects.93 However, to maximise the use of the flexibilities to 
address public health issues with regards to patent rights in Nigeria, there must 
also be a proactive effort to fully incorporate and adapt the flexibilities and the 
willingness to utilise the flexibilities to satisfy public health needs. Other 
countries have recognised and incorporated the flexibilities as measures to 
promote public health. Within the context of legislative policy for example, 
Cambodia, citing the Doha Declaration, implemented a new patent legislation 
that excludes patents for pharmaceuticals until 2016.94 The European 
Parliament endorsed a commitment to the Doha Declaration in its Resolution on 
the TRIPS Agreement and access to medicines,95 and asked the European 
Council to ‘support the developing countries which use the so-called flexibilities 
built into the TRIPS Agreement and recognized by the Doha Declaration in order 
                                                          
91 UNAIDS (n 86) 3, 37. 
92 Correa and Matthews (n 39) 23. 
93 Correa and Matthews (n 39) 12; Daya Shanker, ‘Access to Medicines, Article 30 of TRIPS in the Doha Declaration and an 
Anthropological Critique of International Treaty Negotiations’ SSRN Electronic Journal 2. Available at 
<http://ssrn.com/abstract=391540> accessed 7 March 2015. 
94 Article 136, Law on the Patents, Utility Model Certificates and Industrial Designs, Kingdom of Cambodia. In its preparation for its 
accession to the WTO at Cancun, Cambodia started adapting its legislation to WTO requirements. 
95 European Parliament Resolution of 12 July 2007 on the TRIPS Agreement and Access to Medicines (TA(2007)0353, 12 July 2007) 
paragraphs 1, 11. Also available at  
<http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+TA+P6-TA-2007-0353+0+DOC+XML+V0//EN> accessed 16 
July 2016. 
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to be able to provide essential medicines at affordable prices under their 
domestic health programmes’96  
Developing countries, including Cameroon97 and Ghana, have explored the 
TRIPS flexibilities, as clarified by the Doha Declaration, to enhance access to 
the medicines to ameliorate their citizens’ health.98 Zimbabwe was one of the 
first countries to issue compulsory licences in 2002 for ARV medications after 
the Doha Declaration.99 In 2002, the Zimbabwean Government issued a notice 
(General Notice No. 240 of 2002) to declare an HIV/AIDS crisis and authorise 
the exercise of statutory compulsory licensing option.100 The public health crisis 
was declared for an initial period of six months but was subsequently extended 
to 2008.101 Notably, the Zimbabwe’s health declaration exceeded the grounds in 
Article 31 and broadly authorised the ‘making’ and ‘importation’ of drugs, hence 
also allowing parallel importation of generic HIV/AIDS medicines to effectively 
enable the government or third parties to source medicines from other 
countries.102 Following the declaration, a compulsory licence was issued to 
                                                          
96 ibid paragraph 8. See also a similar commitment in Motion for a European Parliament Resolution: on Strategy for the Protection 
and Enforcement of Intellectual Property Rights in Third Countries (2014/2206(INI, 13 May 2015) paragraph 13. Also available at  
<http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+REPORT+A8-2015-0161+0+DOC+XML+V0//EN> accessed 
16 July 2016. 
97 According to MSF, Cameroon has been able to access the other affordable international prices for ARVs because its Ministry of 
Health has authorised the importation of generic versions of patented drugs available at lower prices than the originator brands. 
As a result, the national procurement agency paid about US$277 for its first-line treatment combination at one of the lowest 
prices available internationally at that time. MSF, One Step Forward, Two Steps Back?: Issues for the 5Th WTO Ministerial 
Conference (n 85) 3. 
98 Nigerian Law Intellectual Property Watch, ‘10 Examples of the Use of Compulsory Licenses for AIDS-Related Pharmaceuticals in 
Africa’ (Nigerian Law Intellectual Property Watch 2013) available at <http://nlipw.com/10-examples-of-the-use-of-compulsory-
licenses-in-africa-2/> accessed 20 February 2016.  
A request was made for compulsory licence by Essential Inventions in Cameroon (2005). See Essential inventions, ‘Cameroon 
Request for Compulsory License’ (2016) <http://www.essentialinventions.org/docs/cameroon/> accessed 28 January 2016. See 
the letter for request at  
<http://www.essentialinventions.org/docs/cameroon/clcameroon8jan05en.html> accessed 16 February 2015. 
The flexibility measure as utilised by Ghana is further considered in subsection 6.9.  
99 Musungu and Oh (n 32) xv-xvi, 38-41; UNAIDS (n 86) 17. 
100 UNAIDS (n 86) 17; Dorothy Mushayavanhu, ‘The Realisation of Access to HIV and AIDS-Relate Medicines in Southern African 
Countries: Possibilities and Actual Realisation of International Law Obligations’ in Frans Viljoen and Susan Precious (eds), Human 
Rights Under Threat: Four Perspectives in HIV, AIDS and the Law in Southern Africa (PULP 2007) 153. 
101 Mushayavanhu (n 100) 153; UNAIDS (n 86) 17. The extension was expedient in light of the realisation that a six months’ 
timeframe was not enough to curb the scourge of the HIV/AIDS epidemic in the country, and the fact that the necessary medicines 
could not be secured within the six months period. ibid 153. 
102 See Section 2(b) of the General Notice No. 240 of 2002 (ch 20:3). 
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Varichem Pharmaceuticals (Pvt) Lit in 2003 to import and ‘produce antiretroviral 
or HIV/AIDS related drugs and supply three-quarters of its produced drugs to 
state-owned institutions.’103  
Zambia followed suit in 2004, making an emergency declaration with reference 
to the TRIPS and the Doha Declaration for public health emergencies to issue 
compulsory licences for its HIV/AIDS crises.104 Interestingly, however, Zambia’s 
declaration, unlike Zimbabwe’s, indicated that it would only locally produce the 
ARV’s and HIV-related drugs for the domestic market and also prohibited 
exports.105 Zambia later issued a compulsory licence to Pharmaco Ltd to 
manufacture the ARV’s locally.106 It is uncertain if the local production condition 
served its intended purpose since there were issues relating to manufacturing 
capacity.107  
It can be argued that the Doha Declaration sought to act as a balancing 
mechanism between promoting trade and development through patent rights at 
the same time as promoting public health, since the key provisions in TRIPS 
were nebulous in guaranteeing the use of the flexibilities in TRIPS as health 
safeguards. Consequently, the Doha Declaration reiterates the need to balance 
the protection of IP rights and the social welfare objective of the TRIPS 
                                                          
103 UNAIDS (n 86) 17. Subsequently, other companies were also authorised to import antiretrovirals from India. 
104 See Preamble to the Statutory Instrument 83 of 2004. In Zambia, the national state of emergency was declared in Statutory 
Instrument 83 of 2004 known as the ‘Patents (Manufacture of Patented Antiretroviral Drugs) (Authorization), Regulations, 2004’ 
Regulation 3; UNAIDS (n 86) 17. 
105 See the Declaration pursuant to Statutory Instrument 83 of 2004. UNAIDS (n 86) 17; Mushayavanhu (n 100) 156. 
 Mozambique also relied on a similar local production condition in 2004 to issue a compulsory licence for HIV generic medications. 
106 The Ministry of Commerce, Trade and Industry on September 21 2004 issued compulsory license No. CL.01/2004 for the 
production of lamivudine, stavudine and nevirapine ARV. The licence was granted to Pharco Ltd., a local producer, to produce a 
triple fixed-dose combination of the ARVs. A maximum royalty rate of 2.5% applied to the compulsory license. The Consumer 
Project on Technology (CPTech), ‘Compulsory License For Antiretrovirals, Zambia’ (Cptech.org)  
<http://www.cptech.org/ip/health/c/zambia/zcl.html> accessed 28 January 2016.  
107 Mushayavanhu (n 100) 156; Poku Adusei, Patenting of Pharmaceuticals and Development in Sub-Saharan Africa: Laws, 
Institutions, Practices, and Politics (Springer 2013) 142. 
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Agreement as prescribed in Article 7 of the Agreement,108 in the interests of 
public health through ‘access to essential medicines for all.’109 Some scholars 
further argue that the affirmations of the flexibilities in the Declaration 
significantly highlight the primacy of public health and access to medicines over 
the private interests of IP rights owners.110 Of equal significance is the role of 
the Doha Declaration in echoing the human development goal of patents and 
the TRIPS Agreement as discussed in Chapter V.111 Paragraph 5(a) of the Doha 
Declaration states that:  
In applying the customary rules of interpretation of public international law, each 
provision of the TRIPS Agreement shall be read in the light of the object and 
purpose of the Agreement as expressed, in particular, in its objectives and 
principles.112  
From a human development standpoint, this provision affirms that members can 
interpret the TRIPS flexibilities in a manner that takes into cognisance the public 
welfare and development aspect of TRIPS, as enshrined in the objective and 
principles contained in Articles 7 and 8 of the Agreement. This point supports 
the earlier discussion in Chapter II that a patent has a social welfare purpose 
and also, the argument in Chapter V that the TRIPS Agreement underlies a 
development objective.113 In this vein, the flexibilities could serve as additional 
measures to ensure that the rights granted to patent holders, and the obligations 
to the WTO do not interfere with the Nigerian Government’s duty to the right to 
                                                          
108 The Doha Declaration, Paragraphs 5. See the discussions of Article 7 in subsection 2.5.6 of Chapter II. See also, James Thuo 
Gathii, 'The Legal Status of the Doha Declaration on TRIPS and Public Health under the Vienna Convention on the Law of Treaties' 
(2002) 15(2) Harvard Journal of Law & Technology 291, 300-303. 
109 The Doha Declaration, Paragraph 4. Correa and Matthews (n 39) 8.  
110 ’t Hoen, ‘TRIPS, Pharmaceutical Patents, and Access to Essential Medicines: A Long Way from Seattle to Doha’ (n 67) 39; 
Arthritic Flexibilities for Accessing Medicines: Analysis of WTO Action Regarding Paragraph 6 of the Doha Declaration on the TRIPS 
Agreement and Public Health’ (2004) 14 Ind Intl & Comp L Rev 613, 625, 627. 
111 See subsection 4.4 of Chapter V.  
112 (Emphasis added.) 
113 See subsections 2.4 and subsection 2.5.5 of Chapter II. 
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health and development. It is imperative that Nigeria effectively utilise the TRIPS 
flexibilities within the maximum limit allowed in the Doha Declaration to facilitate 
better access to affordable medicines, to enhance the women’s and all its 
people’s human capabilities to meet the obligation to the right to health with 
regards to the patent protection of pharmaceuticals. To utilise the flexibilities 
effectively however, they must be incorporated into the national law of the 
country.  
6.4.1.1 The Importance of Adopting the TRIPS Flexibilities and the Doha 
Declaration in Nigeria 
Nigeria, as stated above,114 has yet to incorporate all the flexibilities into national 
law in spite of the fact that their benefits can only be utilised if they are 
appropriately incorporated into domestic law.115 The country’s lackadaisical 
approach to the implementation of the flexibilities is surprising since it is part of 
the African Group that actively sought to place the discussion of the effect of 
IPRs on access to treatments for the needy in developing countries on the 
agenda for the WTO Ministerial Conference. This half-hearted approach to the 
incorporation of the flexibilities is in direct contradiction to the government’s duty 
to secure the enjoyment of human rights to health and development, including 
the guarantees of access to affordable medicines in Nigeria through every 
reasonably available means such as the flexibilities. While there may be many 
reasons why the TRIPS flexibilities have not yet been transposed in Nigeria, 
with the right political will and legislative approach, the government and 
legislative authorities can effectively incorporate the flexibilities. Although 
implementation of TRIPS and the flexibilities only requires the actions of the law-
                                                          
114 See subsection 6.2 above. 
115 Musungu, Villanueva and Blasetti (n 23) 24. 
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making body in Nigeria and the executive’s assent, the process of making the 
law would require the necessary legal and technical proficiency to tailor the 
flexibilities to the national circumstances and development public policy 
objectives of the country. Even if the local expertise and skilled capacity to 
assess, adapt and utilise the flexibility provisions are absent, the state could 
employ or train specialists in this area, after all, the country as previously stated, 
is one of the richest in Africa by GDP per capita.  
Incorporating the flexibilities into the domestic laws of Nigeria is however, the 
first step towards guaranteeing women access to medicines in the country. In 
addition to making all the requisite TRIPS flexibilities available in Nigeria to take 
advantage of them, the government, law and policy makers have an obligation 
to ensure that the available opportunities to protect public health and promote 
accessibility to medicines are not curtailed in the future. This point needs 
emphasis in the light of bilateral agreements, regional Free Trade Agreements 
(FTAs) and multilateral treaties that could truncate the broader use of the 
flexibilities, impose onerous conditions for use, extend the terms of 
pharmaceutical patent rights or impose higher standards that exceed the 
minimum obligations required by the TRIPS Agreement.116  
Often known as ‘TRIPS-plus’, these bilateral and multilateral treaties and 
agreements negotiated outside the purview of the WTO could in effect, also 
prevent, limit or undermine the effective use of the flexibilities as measures to 
facilitate better access to pharmaceuticals.117  Correa explains that ‘[t]hese new 
free trade agreements negotiated outside the World Trade Organisation (WTO), 
                                                          
116 Correa and Matthews (n 39) 21. See more discussion at Susan Sell, ‘Industry Strategies for Intellectual Property and Trade: The 
Quest for TRIPS and Post-TRIPS Strategies’ (2002) 10 Cardozo Journal of International and Comparative Law 79, 79–108; Susan K 
Sell, ‘TRIPS-Plus Free Trade Agreements and Access to Medicines’ (2007) 28(1) Liverpool Law Review 41-75; Susan Sell, ‘TRIPS was 
Never Enough: Vertical Forum Shifting, FTAS, ACTA, and TPP’ (2011) 18 Journal of Intellectual Property Law 447-478. 
117 Musungu, Villanueva and Blasetti (n 23) 3, 30. 
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require even higher levels of intellectual property protection for medicines than 
those mandated by the TRIPS Agreement, and in some cases go beyond that 
required in the developing countries that are promoting them.’118 Although some 
TRIPS-Plus agreements and treaties permit the use of flexibilities such as 
compulsory licensing and non-commercial (government use), they deter 
member states from resorting to them freely or restrict their use to a limited 
number of situations.119  
Examples of TRIPS-plus provisions include the increase of patent terms beyond 
twenty years to make up for delays in the patent examination and application 
process.120 Instances can be found in regional and bilateral trade arrangements 
such as the Chile-USA FTA,121 US-Jordan FTA122 and the US-CAFTA123 that 
                                                          
118 Carlos Maria Correa, ‘Implications of Bilateral Free Trade Agreements on Access to Medicines’ (2006) 84 Bulletin of the World 
Health Organization 399. Carlos Correa writes that in 2006, the US had initiated over eleven bilateral and regional free trade 
Agreements with over twenty three countries with many more under negotiation. A common feature of these agreements is 
TRIPS-Plus standards that exceed IP protection beyond the terms allowed in TRIPS. These could reduce access to medicines in 
developing countries more than in developed countries. ibid 399-400. 
119 The US-Australia FTA, similarly to other US FTA’s with Jordan, Singapore and Vietnam, limits the terms for the use of 
compulsory licensing to defined cases of anti-competition and antitrust remedies, public non-commercial use, national 
emergencies and other circumstances of extreme urgency. Pedro Roffe and Christoph Spennemann, ‘The Impact of FTAS on Public 
Health Policies and TRIPS Flexibilities’ (2006) 1 International Journal of Intellectual Property Management 80.  
120 Pedro Roffe, ‘Bilateral Agreements and a TRIPS-Plus World: The Chile-USA Free Trade Agreement’ [2004] Quaker International 
Affairs Programme 23.  
Also available at http://law-wss-01.law.fsu.edu/gpc2007/materials/roffe_ottowa2004.pdf. 
121 For example, the Chile-US FTA expands the protection of pharmaceutical products and protection of test data and undisclosed 
information beyond the TRIPS provisions. ibid 1-2.  
122 One of the many extensions of such arrangements outside the TRIPS Agreement negotiated between US and Jordan is under 
Article 4.23 (a) of the US–Jordan FTA which states that ‘[w]ith respect to pharmaceutical products that are subject to a patent: (a) 
Each Party shall make available an extension of the patent term to compensate the patent owner for unreasonable curtailment of 
the patent term as a result of the marketing approval process.’ This provision is in contrast to Article 17 of the 1999 Jordanian 
Patent Law which provides that ‘the term of protection shall be twenty years beginning from the date of filing the application for 
registration pursuant to the provisions of this law.’ Mohammed El Said, Public Health Related TRIPS-Plus Provisions in Bilateral 
Trade Agreements: A Policy Guide for Negotiators and Implementers in the WHO Eastern Mediterranean Region (World Health 
Organization, Regional Office for the Eastern Mediterranean 2010) 144.  
123 The United States (US) and Central America Free Trade Agreement (CAFTA) in Article 15.10 (a) and (b) of the Agreement 
contains prohibitions or limits grounds for reliance on data submitted for marketing approvals of drugs for a particular period. 
According to Article 15.10 (a) for example, 
If a Party requires, as a condition of approving the marketing of a new pharmaceutical or agricultural chemical 
product, the submission of undisclosed data concerning safety or efficacy, the Party shall not permit third 
persons, without the consent of the person who provided such information, to market a product on the basis of 
(1) such information or (2) the approval granted to the person who submitted such information for at least five 
years for pharmaceutical products and ten years for agricultural chemical products from the date of approval in 
the Party. 
 And under Article 15.10 (b), third parties (e.g generic producers) shall not rely on data submitted for marketing approvals in 
‘another territory.’ Frederick M Abbott, ‘The Doha Declaration on the TRIPS Agreement and Public Health and the Contradictory 
Trend in Bilateral and Regional Free Trade Agreements’ (2004) Quaker United Nations Office, Occasional Paper 14, 6-7.  
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expand the terms of IP protection beyond TRIPS provisions or limit the grounds 
for use of the flexibilities. Jordan, Saudi Arabia and Oman joined the WTO with 
TRIPS-plus obligations attached to their accession process.124 Others prevent 
marketing approval for generic drugs when the patent is still in existence or 
provide data exclusivity for pharmaceutical test data which could delay the 
introduction of cheaper generic drugs; expand the subject matter of patentability 
and impose the grant of patent rights for second or new indications of 
pharmaceuticals.125 Some TRIPS-plus agreements prohibit parallel imports or 
the exports of drugs obtained under compulsory licence or impose stringent 
export rules.126 Such bilateral agreements and treaties take precedence over the 
intellectual property rights (IPRs) contained in TRIPS, or limit the scope of the 
Doha Declaration and benefits of the TRIPS flexibilities.127 An evaluation report 
by Oxfam in 2006 concludes that developed countries have reneged on their 
commitment to the Doha Declaration by circumventing, weakening or 
undermining the flexibility provisions through bilateral and regional trade 
treaties.128 The report also states that the Doha Declaration has not been 
interpreted in a favourable light by pharmaceutical companies.129 Accordingly, 
pharmaceutical companies, especially those in developed countries, have 
changed tactics, from lobbying to bullying, in a bid to pursue stronger IP rules 
                                                          
124 Mohammed El Said, Public Health Related TRIPS-Plus Provisions in Bilateral Trade Agreements: A Policy Guide for Negotiators 
and Implementers in the WHO Eastern Mediterranean Region (n 122) 94-95. See also, the Report of the Working Party on the 
Accession of the Hashemite Kingdom of Jordan (WT/ ACC/JOR/33 and WT/MIN(99)/9, World Trade Organization 1999) paragraph 
192. 
125 Mohammed El Said, Public Health Related TRIPS-Plus Provisions in Bilateral Trade Agreements: A Policy Guide for Negotiators 
and Implementers in the WHO Eastern Mediterranean Region (n 122) 133-141, 157-158. 
126 Correa and Matthews (n 39) 21; MSF, One Step forward, Two Steps Back? - Issues for the 5th WTO Ministerial Conference (n 85) 
3. 
127 Mohammed El Said, Public Health Related TRIPS-Plus Provisions in Bilateral Trade Agreements: A Policy Guide for Negotiators 
and Implementers in the WHO Eastern Mediterranean Region (n 122) 46. See some examples in Frederick M Abbott, ‘The Doha 
Declaration on the TRIPS Agreement and Public Health and the Contradictory Trend in Bilateral and Regional Free Trade 
Agreements’ [2004] Quaker United Nations Office (QUNO), Occasional Paper No. 14, 3-13. 
128 Rohit Malpani and Mohga Kamal-Yanni, Patents Versus Patients Five Years After The Doha Declaration (Oxfam International 
2006) 1-6,13-18. 
129 ibid 20. 
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that could effectively affect the accessibility to medicines.130 This they do by 
lobbying their governments to impose TRIPS-plus rules and sanctions to seek 
stringent IP protection, enforce their patent rights by relying on TRIPS-plus rules 
and challenging the use of the flexibilities as health safeguards.131  
Consequently, Nigerian policy makers should ensure that any treaty or 
agreement they enter into does not contradict the state’s duty to guarantee the 
realisation and enjoyment of women’s human rights, including the facilitation of 
access to affordable medicines. Increasingly, scholars and treaty monitoring 
committees of the UN have called on states to assess and consider the impact 
of their trade agreements and treaty obligations on the cost and access to 
medications, and their obligations to human rights laws, particularly the right to 
health.132 Accordingly, it is important that the Nigerian government considers its 
duty to the right to health when negotiating or implementing the TRIPS 
Agreement or TRIPS-plus IPRs provision to secure women’s rights to the 
attainment of the highest standard of physical and mental health and human 
development through access to cost-effective life-saving health treatments.  
In addition, with respect to pharmaceuticals reproduction through the use of the 
compulsory licence and other research-related exemptions, a robust and viable 
pharmaceutical sector (particularly generic producers) is vital for the effective 
                                                          
130 ibid 20-21. 
131 ibid 21-22. 
132 Lisa Forman, 'From TRIPS-Plus to Rights-Plus? Exploring Right to Health Impact Assessment of Trade-Related Intellectual 
Property Rights Through the Thai Experience’ (2012) 7(2) Asian Journal of WTO and International Health Law and Policy 347-375. 
See for example, UN Committee on Economic, Social and Cultural Rights, Concluding Observations of the Committee on Economic, 
Social and Cultural Rights: Morocco (E/C.12/MAR/CO/3 4 September 2006 September 4, 2006) paragraph 29; UN Committee on 
Economic, Social and Cultural Rights, Concluding Observations of the Committee on Economic, Social and Cultural Rights: Ecuador 
(E/C.12/1/Add.100 7 June 2004) paragraphs 30 and 50; UN Committee on Economic, Social and Cultural Rights, Draft concluding 
observations of the Committee on Economic, Social and Cultural Rights: Costa Rica (U.N Doc. E/C.12/CRI/CO/4 2008) paragraphs 27 
and 48. 
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use of the flexibilities.133 Several factors are essential to local pharmaceutical 
manufacturing and production. They include: the availability of skilled and 
technical personnel; access to capital and investment; adequate infrastructure 
and drugs production capacity; adequate regulatory environment; access to 
effective and relevant technologies; and the availability of active raw materials 
and input materials.134 Absence of any of these may constitute a barrier to local 
production of affordable medicines in Nigeria through the use of the 
flexibilities.135  
In sum, before Nigeria can take full advantage of the TRIPS exceptions to 
increase access to affordable medicines, these and many more issues need to 
be addressed for a substantial impact. Consequently, appropriate policies, 
considerable capital, sustainable public funds and technical assistance are 
needed to promote the growth of the pharmaceutical sector, increase medicines 
production capacity and address other manufacturing issues so that Nigerians 
can adequately benefit from the flexibilities.136  
 
 
 
                                                          
133 KM Gopakumar, ‘Product Patents and Access to Medicines in India: A Critical Review of The Implementation of TRIPS Patent 
Regime’ (2010) 3(2) The Law and Development Review 325, 327, 338. 
134 Frederick M Abbott, Trends in Local Production of Medicines and Related Technology Transfer (World Health Organization 2011) 
2; Musungu, Villanueva and Blasetti (n 23) 26.  
135 Warren Kaplan and Richard Laing, Local Production of Pharmaceuticals: Industrial Policy and Access to Medicines an Overview of 
Key Concepts, Issues and Opportunities for Future Research (The International Bank for Reconstruction and Development and The 
World Bank 2005) 2. 
136 Commission on Intellectual Property Rights (CIPR), Integrating Intellectual Property Rights and Development Policy: Report of 
the Commission on Intellectual Property Rights (Commission on Intellectual Property Rights 2002) 31. (Hereafter CIPR)This point is 
the focus of the next chapter. 
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PART III: THE PUBLIC HEALTH EXCEPTIONS AND 
FLEXIBILITIES IN TRIPS: TRANSLATING THE PROVISIONS TO 
NIGERIA  
 6.5 Incorporating the Flexibilities in Nigeria 
This part further examines some flexibilities in detail and recommends ways in 
which the Nigerian state can take advantage of the TRIPS-compliant exceptions 
to facilitate access to essential medicines for its people, particularly its women.  
As we have seen,137 effective utilisation of the flexibilities is dependent on some 
conditions: a) the incorporation of the flexibilities options into domestic 
legislation as a sine qua non condition to the utilisation of the safeguards; b) the 
availability of a viable domestic pharmaceutical manufacturing capacity;138 and 
c) supplementary policies and the political will to utilise the flexibilities in a 
nuanced manner to bring the provisions to fruition.139 This study examines the 
extent to which Nigeria has satisfied the above-mentioned conditions under the 
current national patents law, and the efforts made to incorporate some of the 
flexibilities in the NIPCOM draft Bill of 2007. Specifically, the relevant provisions 
of the Bill are comparatively analysed with the existing provisions of the current 
Patents and Designs Act of 1970 (PDA) in force, to determine the extent to 
which such measures effectively respond to the TRIPS flexibilities to address 
public health needs in Nigeria.  
 
                                                          
137 In subsection 6.4.1. 
138 In the absence of an adequate domestic manufacturing sector, states have the option of importing from other countries; 
however the advantage of a vibrant and dynamic local pharmaceutical industry for generic reproduction outweighs the requisite 
conditions and risk of importing counterfeits and substandard pharmaceutical products. 
139 Gopakumar (n 133) 327. 
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6.6 Patentability Standards and Limitations on the Grant of ‘New or 
Second Uses’ of Old Patents as Health Flexibilities 
Article 27(1) of the TRIPS Agreement is a general provision applicable to the 
patentable subject matter before the grant of patents. The Article states that the 
‘patents shall be available for any inventions, whether products or processes, in 
all fields of technology,’ on grounds of novelty, inventiveness and industrial 
application. While this provision does not provide a definition for inventions or 
specify what constitutes ‘new’, ‘inventiveness’ and ‘industrial applicability,’ WTO 
members have the flexibility to determine their domestic standard for 
patentability, and also interpret this provision in a manner that facilitates access 
to medicines to all and protects public health in accordance with the clarification 
in Paragraph 4 of the Doha Declaration.140 Scholars suggest that this deliberate 
patentability latitude is an opportunity for developing countries to determine the 
exact scope of what constitutes an invention and thus members can exclude 
new uses of old pharmaceuticals from patentability criteria under their domestic 
laws.141 A new pharmaceutical use is either a ‘first pharmaceutical use’ (another 
medical indication) or a ‘second pharmaceutical use’ (second medical 
indication).142 The former instance is a new pharmaceutical use of a known 
substance, e.g., a first pharmaceutical application for an existing patent (which 
had no prior pharmaceutical use), while the latter is a modified use of an existing 
pharmaceutical or further discovery of a new therapeutic value for a previously 
known drug.143 
                                                          
140 Osewe, Nkrumah and Sackey (n 67) 12. 
141 Musungu, Villanueva and Blasetti (n 23) 14; Osewe, Nkrumah and Sackey (n 67) 12. 
142 Musungu, Villanueva and Blasetti (n 23) 14. 
143 Musungu, Villanueva and Blasetti (n 23) 14; Musungu and Oh (n 32) 60. 
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In some jurisdictions, patents are granted for a new version of an old drug, often 
on the ground that it has improved the efficacy of the old drug.144 An example of 
this is AstraZeneca’s heartburn pill, Prilosec, which was extended by a slight 
modification of the chemical structure and subsequently renamed Nexium.145 
Shortly before the patent for Prilosec expired, AstraZeneca applied for an 
extension to the US Food and Drug Agency (FDA) on the grounds that Nexium 
was more effective than Prilosec.146 In effect, Prilosec, now Nexium, maintained 
its exclusivity thereby thwarting generics and the availability of cheaper versions 
of the drug.147  
Opponents of the patent standard allowing the new or second use of an existing 
patented article, argue that it does not confer enough significant therapeutic 
advantage over generic versions to warrant the grant of a patent monopoly 
right.148 Accordingly, the problem with allowing the grant of patents for modified 
versions of old drugs is that it serves the anti-competitive purpose of stifling 
generic reproduction of the drugs and consequently delays their introduction 
after the expiration of the patent term. In other words, it is a mere guise to 
extend the period of protection, exclusivity and monopoly, block the entry of 
                                                          
144 Carlos M Correa Intellectual Property Rights, the WTO and Developing Countries: The TRIPS Agreement and Policy Options (Zed 
Books Ltd 1999) 228. 
145 Gardiner Harris, ‘Prilosec's Maker Switches Users to Nexium, Thwarting Generics' [2002] The Wall Street Journal 
<http://www.wsj.com/articles/SB1023326369679910840> accessed 25 January 2016. 
AstraZeneca also got approval from FDA for a light modification of an anti-asthmatic drug (budesonide). The National Institute for 
Health Care Management Research and Educational Foundation (NIHCM), Changing Patterns of Pharmaceutical Innovation: A 
Research Report (The National Institute 2002) 6. Also available at <www.nihcm.org/pdf/innovations.pdf> accessed 27 July 2016; 
also see ‘The Application for Extension of Patent Term under 35 U.S.C 4’ 156. Available at  
<http://www.fda.gov/ohrms/dockets/dailys/04/sep04/090304/04e-0397-app0001-03-vol1.pdf> accessed 15 July 2016. 
146 Some commentators, including Ronald Grisant, claim that there is not much difference between Nexium and Prilosec. 
Apparently, both are proton pump inhibitors (PPI). Grisant explains that, ‘Prilosec is the original proton pump inhibitor that 
functions by disabling the protein in your stomach that pumps hydrogen ions (H+ ions) into gastric juices. Basically the PPIs can 
increase the pH of the stomach from 1 to 5. That means acid production is effectively ceased by these drugs.’ Ronald Grisanti, 
‘Nexium Prilosec Epiphany’ (Functional Medicine University) 
<http://www.functionalmedicineuniversity.com/public/888.cfm> accessed 25 January 2016.  
147 Harris (n 145). 
148 Sudip Chaudhuri, Chan Park and KM Gopakumar, Five Years into the Product Patent Regime: India’s Response (United Nations 
Development Programme 2010) 100-102. Also available at:  
<http://apps.who.int/medicinedocs/documents/s17761en/s17761en.pdf> accessed 27 July 2016; Carlos M Correa, 
‘Pharmaceutical Innovation, Incremental Patenting and Compulsory Licensing’ (2011) South Centre Research Paper 41, 32. 
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cheaper generics and hinder legitimate competition, which could in turn impact 
on accessibility to the medicines.149 Known as the practice of ‘evergreening,’ 
Gervais reiterates the criticism that, 
[i]t has become the common practice in the pharmaceutical industry to repackage a 
molecule (active ingredient) with known salts, metabolites, etc., in some cases with 
little if any advantage, to claim a new patent, one of the forms of “Evergreening” 
(prolonging of rent from otherwise out-of-patent branded medications).’150  
Although patents for such new use medical purposes or subsequent indications 
may be useful as rewards for incremental ingenuity and the promotion of the 
economic interest of patent holders for the minor improvement, it may not serve 
the overarching purpose of incentivising or indeed, promoting genuine R&D of 
essential pharmaceuticals. With respect to public health, extending patent terms 
could also impact on accessibility to affordable drugs. As examined in Chapter 
III,151 a patent’s monopoly right could potentially affect accessibility to 
medicines, where an already existing patent is extended on the grounds that it is 
a new improvement or second medical use, it may not necessarily confer benefit 
to public health, and it could, in fact, reduce affordable accessibility in the long 
run. Thus, where the patentability standard is too lax, there is a high possibility 
that many patents will be issued for minor incremental medicinal modifications 
with monopoly implications for the generic availability of affordable drugs and 
access to medicines.152 Also, patentees could take advantage of lax 
patentability provisions to surreptitiously extend their patent terms. This is 
particularly problematic in countries that lack proper substantive examination 
                                                          
149 Chaudhuri, Park and Gopakumar (n 148); Thomas A Faunce and Joel Lexchin, ‘Linkage' Pharmaceutical Evergreening in Canada 
and Australia’ (2007) 4 Australia and New Zealand Health Policy 1-2. 
150 Daniel Gervais, ‘Patentability Criteria as TRIPS Flexibilities, Examples of India and China’ in Ruth L Okediji and Margo A Bagley 
(eds), Patent Law in Global Perspective (Oxford University Press 2014) 562. 
151 See subsection 3.7.1 of Chapter III.  
152 Musungu and Oh (n 32) 59. 
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process or expertise to ensure that the purported second indication is actually 
novel and inventive, and in the case of medicines, capable of conferring an 
incremental therapeutic benefit.  
The approaches to the issue of new uses or indications for known inventions 
vary across countries. The US, for example, favours the new use patent 
approach in 35 United States Code (U.S.Code) § 101 which permits the 
patentability of ‘new and useful improvements’ of useful process, machine, 
manufacture, or composition of matter.’153 Also, U.S.Code § 156 permits the 
extension of patent terms on specific grounds.154 A research report indicates 
that this liberal standard may not facilitate the production of drugs that provide 
significant clinical benefit.155 For instance, out of a total of 1085 new drugs 
applications approved by US FDA between 1987 and 2000, only 361 were found 
to be new chemical entities (NCEs).156 Conversely, in accordance with Article 
53(c) of the European Patent Convention (EPC) (2000), Article 54(4) and 54(5) 
provide exceptions to the general rule in that a patent can only be granted to 
(absolutely) novel product claims or substance for use in a method. Article 54(4) 
does not exclude from patentability any substance or composition for use in a 
method of treatment that is comprised in the state of art provided such use is not 
part of the state of the art.157 Also, a substance or composition for a known ‘first 
medical use’ or purpose-limited product claim is permitted for a second and 
                                                          
153 Musungu and Oh (n 32) 60-61. 
154 See The United States Patent and Trademark Office United States Code Title 35 – ‘Patents.’ Appendix L - Patent Laws. Available 
at <http://www.uspto.gov/web/offices/pac/mpep/mpep-9015-appx-l.html#d0e300751> accessed 14 Dec 2014. The patentability 
of known products for a new specific usage is allowed in Europe. Musungu and Oh (n 32) 35. 
155 The National Institute for Health Care Management Research and Educational Foundation (NIHCM) (n 145) 3. The report 
demonstrated that the FDA approved 674 Medicines (sixty five percent) containing active ingredients that were already existing in 
the market. ibid 3.  
156 Estimate for drugs approved by the Centre for Drug Evaluation and Research. ibid 
157 Article 54(4) states: 
Paragraphs 2 and 3 shall not exclude the patentability of any substance or composition, comprised in the state of 
the art, for use in a method referred to in Article 53(c), provided that its use for any such method is not 
comprised in the state of the art. 
Lee (n 50) 111.  
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subsequent medical use in a method according to Article 54(5), provided the 
indicated medical use satisfies the criteria of novelty and inventiveness and has 
not been disclosed in the prior art.158  
Although not specifically required by the TRIPS Agreement, very few developing 
countries have explicitly excluded the possibility of patenting new or subsequent 
improvements and medical uses of known processes or products in their 
national legislation.159 Studies in 2010 and 2011 reveal for example that, at least 
twelve developing countries have specifically placed a limit on the grant of a 
new use for known products, however, the patenting of second uses and 
indications of pharmaceutical products and methods are allowed under the 
national laws of at least forty five developing countries including Nigeria.160 
Many patent laws in developing countries merely list the patentability criteria of 
novelty, industrial applicability and inventiveness, without specifying whether the 
patentability provisions exclude or extend to the availability of patents for new 
uses of known substances.161 This lack of clarification could effectively allow 
further use of known patents.162 
The measures undertaken by India when amending its national legislation in 
accordance with the TRIPS obligations are commendable in preventing the 
practice of ‘evergreening’. In line with its constitutional protection of the right to 
life and health objectives, Section 3(d) of the 1970 India Patents Act (as 
                                                          
158 Article 54(5) states: 
Paragraphs 2 and 3 shall also not exclude the patentability of any substance or composition referred to 
in paragraph 4 for any specific use in a method referred to in Article 53(c), provided that such use is not 
comprised in the state of the art.  
For a critique of the provision, see Sigrid Sterckx and Julian Cockbain, ‘Purpose-Limited Pharmaceutical Product Claims under the 
Revised European Patent Convention: A Camouflaged Attack on Generic Substitution?’ [2010] Intellectual Property Quarterly 88-
107. 
159 Deere (n 48) 78-79; Correa and Matthews (n 39) 20-21. 
160 Correa and Matthews (n 39) 20-21; Deere (n 48) 78-79. 
161 Musungu and Oh (n 32) 35; Deere (n 48) 79. 
162 ibid 
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amended), when setting out specific criteria for the grant of a patent, excludes 
the new forms of known substances.163 The section states that there is no 
patentability for: 
‘the mere discovery of a new form of a known substance which does not result in 
the enhancement of the known efficacy of that substance or the mere discovery of 
any new property or new use for a known substance or of the mere use of a known 
process, machine or apparatus unless such known process results in a new 
product or employs at least one new reactant.’ 
For emphasis, the section further exempts sixteen categories of inventions from 
patentability because they are not considered inventions for the purpose of 
enhancing efficacy.164 From a public health perspective, India did not rely solely 
on the patentability criteria in TRIPS but provided a broad exemption which 
excludes new forms of known compounds and substances, or mere discoveries 
including new purposes for any known substance,165 thus limiting the scope of 
patents to novel efficacious medical treatments. 
 A recent ruling by the Indian Supreme Court in the case of Novartis’s 
application for a new version of the drug, Glivec (known as Gleevec in other 
countries) gave impetus to this provision and drew support from opponents of 
                                                          
163 Section 3(d) of the Patents (Amendment) Act, 2005 (Act No. 15 of 2005). Studies of patenting trend in India however indicate 
that patent claims for compositions and formulations are for a new use of a known substance that are not patentable under 
section 3(d) of the India Patents Act and sometimes disguised to obtained patents. Chaudhuri, Park and Gopakumar (n 148) 100-
102; Correa ‘Pharmaceutical Innovation, Incremental Patenting and Compulsory Licensing’ (n 148) 10-11. For example, study by 
Sudip Chaudhuri, Chan Park and KM Gopakumar in 2010 indicated that significant claims for patents (sixteen patents, or nineteen 
percent of the study sample) ‘of patents reviewed were formulated as composition claims but were in fact ‘new use’ or ‘method of 
treatment’ claims ‘in disguise.”’ Chaudhuri, Park and Gopakumar (n 148) 100.  
164 The section provides that: 
For the purposes of this clause, salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, 
mixtures of isomers, complexes, combinations, and other derivatives of known substance shall be considered to 
be the same substance, unless they differ significantly in properties with regard to efficacy. 
 Gopakumar (n 133) 334. 
165 KM Gopakumar points out that this exclusion is based on a known substance which does not result ‘in the enhancement of 
known efficacy’; hence novel forms of existing products may be patented as long as they are not “mere” discoveries. Gopakumar 
(n 133) 334. 
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new uses of existing drugs and modification of old versions.166 Novartis 
approached the court to challenge the India patent office’s decision not to 
register a product patent for a specific compound, the beta crystalline form of 
‘imatinib mesylate’ used to treat chronic myeloid leukaemia (CML), on the 
grounds that the refusal was discriminatory, unconstitutional and a violation of 
India’s WTO commitment to the TRIPS Agreement.167 The high court of Madras 
upheld the decision by the patent office, rejected Novartis argument on the 
grounds of vagueness and arbitrariness168 and clarified that the meaning of 
efficacy under section 3(d) is understood as ‘the therapeutic effect’ of a drug in 
the pharmaceutical field.169 The high court, commenting on the issue of 
constitutionality with regards to section 3(d) of the Patent Act, explained that the 
amended provision was an ‘[…] inbuilt measure to guide the Statutory Authority 
                                                          
166 Prior to 2005, Glivec was the subject of a suit involving EMR. The Economic Times, ‘Novartis Gets EMR For Glivec’ The Times of 
India (New Delhi 11 November 2003).  
Available at <http://articles.economictimes.indiatimes.com/2003-12-24/news/27545132_1_gipap-emr-novartis-india> accessed 
21 February 2016. See also Médecins Sans Frontières (MSF) ‘HIV/AIDS Treatment in Developing Countries: The Battle for Long-
Term Survival has Just Begun’ (Campaign for Access to Medicines Médecins Sans Frontières 2009) 5. 
167 Novartis AG v Union of India (UOI) and Ors (2007) A.I.R 24751 (Mandras H.C). In January 2006, the Indian Controller of patent 
and Designs examined the mailbox application for Glivec, (imatinib mesylate, a beta crystalline form of the free base imatinib, and 
rejected the application based on the fact that the claim by Novartis did not meet the required standard of novelty and 
inventiveness or improved efficacy under section 3(d) of the patent Act.)  
See also Lee (n 50) 112-113; CR Sukumar, ‘Novartis Loses Patent Claim on Cancer Drug Patents Controller Upholds Natco 
Contention’ [2005] The Hindu Business Line. <http://www.thehindubusinessline.com/todays-paper/tp-corporate/novartis-loses-
patent-claim-on-cancer-drug-patents-controller-upholds-natco-contention/article1722947.ece> accessed 26 January 2016; 
Shamnad Basheer, ‘First Mailbox Opposition (Gleevec) Decided in India (March 11)’ (Spicy IP 2006). Available at 
<http://spicyip.com/2006/03/first-mailbox-opposition-gleevec.html> accessed 26 January 2016.  
168 Novartis AG v Union of India (UOI) and Ors, paragraph 12, 14,  
169 Novartis AG v Union of India (UOI) and Ors, paragraph 13. The crystalline form of imatinib mesylate was already included in 
Novartis earlier US Patent on the free base imatinb (US patent No 5521184, 1993) hence it was considered a prior art, devoid of 
novelty and inventiveness.  
The Patent Controller Patent reasoned that: 
I do not agree with the contention of the Applicant that the 1993 patent discloses only the free base. The 1993 
patent discloses mathanesulphonic acid as one of the salt forming groups and also the 1993 patent specification 
states that the required acid additions salts are obtained in a customary manner. Further, claims 6 to 23 of the 
1993 patent claim a pharmaceutically acceptable salt of the base compound. The patent term extension 
certificate for the 1993 patent issued by the US Patent Office specifically mentions imatinib mesylate (GleevecR) 
as the product. All these points clearly prove that imatinib mesylate is already known from the prior art 
publications.  
In the Matter of an Application for Patent No. 1602/MAS/98 ( 26 January 26 2006). Available at  
<http://www.scribd.com/doc/416824/Patent-office-Order-India-Glivec> accessed 5 June 2015. 
See also Basheer (n 167); Linda L Lee, ‘Trials and TRIPS-Ulations: Indian Patent Law and Novartis AG V. Union of India’ (2008) 23 
Berkeley Tech. L.J. 281, 281-313, 304.  
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[patent office] in exercising its power under the Act.’170 Reiterating the point that 
there is no vagueness in the provisions of Section 3(d), the court added that 
‘[w]e have also found that the amended section does not suffer from the vice of 
vagueness, ambiguity and arbitrariness. The Statutory Authority would be 
definitely guided in deciding whether a discovery is an invention or not by the 
materials to be placed before him by the patent applicant.’171 On the issue of 
compatibility with TRIPS, the High Court declined to rule on the issue and 
instead suggested that the WTO’s Dispute Settlement mechanism is the 
appropriate forum to entertain such an issue.172 
Novartis appealed and the Supreme Court in April 2013 also upheld the patent 
office’s decision in ruling that the beta crystalline failed the test of efficacy in 
Section 3(d) of the Patents Act.173 The court further clarified that ‘efficacy’ 
means therapeutic efficacy; i.e. a patent applicant must not only show that a 
new form of known compound is different from an old form but also that the 
modification will result in an improvement in the treatment of the patient.174 The 
patent claim by Novartis therefore, failed under the test of invention and 
patentability as provided in clauses (j), (ja) of section 2(1) and section 3(d) of the 
                                                          
170 Novartis AG v Union of India (UOI) and Ors, paragraph 18. 
171 Novartis AG v Union of India (UOI) and Ors, paragraph 14. The court also pointed out that the legislative aim of the section was 
to ‘prevent evergreening; to provide easy access to the citizens of this country to life saving drugs and to discharge their 
Constitutional obligation of providing good health care to its citizens.’ ibid Paragraph 12, and 19.  
172 Novartis AG v Union of India (UOI) and Ors paragraph 6; Lee (n 50) 300. See also Martin Adelman and others, Global Issues in 
Patent Law (West Academic 2010) 43-47. 
173 The denial of the application was also affirmed by the Intellectual Property Appellant Board (IPAB), a tribunal empowered to 
handle appeals from the patent office. See Intellectual Property Appellate Board Order No. 100 of 26 June 2006.  
<http://static1.1.sqspcdn.com/static/f/129694/3554588/1247202859077/Gleevec+IPAB+decision+26+June+2009.pdf?token=Gw7
IKoP19DmPKpg85uNRWIZCBaw%3D> accessed 26 January 2016. 
174 Novartis AG v. Union of India (UOI) and Ors Civil Appeal No. 2706-2716 of 2013, paragraphs 189, 190, 191 and 195. 
Novartis argued that its invention showed thirty percent more biodiversity (the level at which the drug is available in the human 
body), but the supreme court ruled the invention was anticipated based on the grounds that it could not distinguish between its 
new salt form and its old salt form (which was marketed) in terms of enhanced bioavailability.  
The court further clarified on the issue of incremental innovation in paragraph 191 that: 
We have held that the subject product, the beta crystalline form of Imatinib Mesylate, does not qualify the test 
of Section 3(d) of the Act but that is not to say that Section 3(d) bars patent protection for all incremental 
inventions of chemical and pharmaceutical substances. It will be a grave mistake to read this judgment to mean 
that section 3(d) was amended with the intent to undo the fundamental change brought in the patent regime by 
deletion of section 5 from the Parent Act. That is not said in this judgment. 
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India Patents Act.175 The decision of the court importantly laid a precedent for 
the interpretation of the intricate aspects of Section 3(d) with regards to the 
therapeutic use of known substances.176 It can be said that this judgment gives 
consumers an opportunity to pay for expensive patented drugs only when they 
result from novel innovations that confer substantial efficacy benefit to health or 
are the genuine and significant therapeutic advancements of old versions in 
limited circumstances.177 The court also made allowance for the availability of 
cheaper generic options at the expiration of a patent term by barring any 
extension does not satisfy the criterion of Section 3(d) of the Patents Act. 
Significantly, the therapeutic benefit of medicines to the public’s interest was 
taken into account in this case.  
The ruling highlights the need to strike a balance between promoting R&D on 
the one hand and innovation with affordability that will lead to cures rather than 
merely repackaging known compounds on the other.178 This case also 
demonstrates how India approached the issue of balancing the interest of 
patentee’s to promote innovation and the public health objective of facilitating 
access to medicines. The verdict came at a time when the price of the patented 
drug was vastly higher than that of the generic version; as news reports 
estimated that Gleevec (or Glivec) can cost up to $70,000 a year, while the 
                                                          
175 ibid paragraphs 191-195.  
176 Yogesh Pai, ‘Promoting Diversity in Pharmaceutical Innovation and Access: India's Experience in the Post TRIPS World’ in Irene 
Calboli and Srividhya Ragavan (eds), Diversity in Intellectual Property: Identities, Interests, and Intersections (Cambridge University 
Press 2015) 80-82.  
177 Frederick M Abbot, ‘Insider View: The Judgment in Novartis v. India: What the Supreme Court of India Said’ Intellectual 
Property Watch. Available at <http://www.ip-watch.org/2013/04/04/the-judgment-in-novartis-v-india-what-the-supreme-Court-
of-india-said/> accessed 3 February 2015. 
178 The court’s decision, however, received severe criticism from pharmaceutical industries. They contended that the decision is a 
huge setback for future innovation and research investment, especially for India. ibid; M Allirajan, ‘SC Decision on Glivec is 
Negative Credit for Branded Drug Firms: Moody’s’ The Times of India (India, 4 April 2013). For example, the Chairman of Novartis 
announced that the company would redirect its research and development program away from India to more receptive 
environments after the decision. Frederick M Abbott and Jerome H Reichman, ‘The Doha Round's Public Health Legacy: Strategies 
for the Production and Diffusion of Patented Medicines under the Amended TRIPS Provisions’ (2007) 10 Journal of International 
Economic Law 921, 959. 
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cheaper generic version cost about $2,500 a year.179 The court’s decision, 
therefore, gave support to India to continue making and supplying the medicines 
to other parts of the world which rely on the generic industry in India, thus 
facilitating access to affordable medicines to treat life-threatening diseases such 
as cancer, tuberculosis, HIV/AIDS and other opportunistic infections. 
6.6.1 New Use Patents Provision in Nigeria 
In Nigeria, Section 1(1)(a) of the Patents and Designs Act (PDA) of 1970 sets 
out the patentability standard in a threefold test.180 Specifically, these 
indispensable thresholds for the grant of patents are: novelty, utility or industrial 
applicability, and inventive step or non-obviousness.181 The monopoly and 
exclusive rights accruable from the patent are only granted if these 
predetermined objectives and standards are met. These criteria are consistent 
with the text in Article 27(1) of the TRIPS Agreement; however, the 1970 PDA 
further makes explicit provision for the patentability of new discoveries or 
improvements of an existing patented invention, provided the new invention 
satisfies the patentability requirements of novelty, inventiveness and industrial 
applicability. In this regard, Section 1(1) (b) of the PDA stipulates that 
patentability is allowed if an invention: ‘[…] constitutes an improvement upon a 
patented invention and also are new, results from inventive activity and is 
capable of industrial application.’ 
Similarly, the Nigerian Intellectual Property Commission (NIPCOM) Draft Bill of 
2007 in Article 105 contains the same provision of ‘improvement’ and new uses 
                                                          
179 Gardiner Thomas and Katie Thomas, ‘Top Court in India Rejects Novartis Drug Patent’ The New York Times (New Delhi, 1 April 
2013) Available at 
<http://www.nytimes.com/2013/04/02/business/global/top-Court-in-india-rejects-novartis-drug-patent.html?_r=0> accessed 21 
February 2016.  
180 The Act states that patents will be granted to an invention ‘[…] if it is new, results from inventive activity and is capable of 
industrial application.’ 
181 John H Barton, 'Non-Obviousness' (2003) 43(3) IDEA - The Journal of Law and Technology, 475, 476. 
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for known patents and but does not specifically define the term and criterion of 
‘improvement.’ What these provisions mean is that the improvement of an 
existing invention that is deemed novel, inventive, and capable of industrial 
application is another criterion that will be considered for patentability.182 
From a public health perspective, the patentability standard to which this 
provision applies does not indicate whether the improvement is for a new use of 
a known substance or a second indication of a patented product, but it appears 
to allow for modified versions of older drugs, thereby potentially permitting 
hindrance to the timely entry of cheaper generic medicines. Scholars such as 
Musungu and Oh support this view and raise the concern that patenting 
provisions for new use or second indications limit access to medicines when 
new combinations, formulations and new chemical entries are granted 
secondary patent protection and used for anti-competitive purposes to extend 
terms of patents.183 Moreover, the criterion of ‘improvement ‘of a prior invention 
is too lax, not well-defined and the extent of such improvement, whether slight or 
significant, is not specified. All the law requires is that it is novel, of inventive 
standard and industrially applicable. In essence, patents could be granted to any 
modified drug in Nigeria, no matter how slight the modification, as long as the 
new improvement meets the patentability criteria of inventiveness or is capable 
of industrial application. This is also without a proper investigation of whether 
the improved product and new version will substantially enhance health 
outcomes.  The significance of an improved drug is less sustainable when an 
old medicine is used to treat the same disease or sickness but administered 
through a different dosage or form. 
                                                          
182 Cecilia Oh, ‘Domestic Legislation and Court Decisions on Intellectual Property Rights and Public Health in Nigeria’ (Nigerian Law 
Intellectual Property Watch 2011) 2 <http://www.local-pharma 
production.net/fileadmin/dateien/Country_studies/Country_analysis_-_Nigeria.pdf> accessed on 6 September 2015. 
183 Musungu and Oh (n 32) 62-63. 
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The problem of extending improvements on existing patents is not restricted to 
the aforementioned circumstances. The absence of a substantive examination 
process before granting patents is another problematic feature of the patent 
system in Nigeria. Section 4 of the PDA provides that the Registrar will only 
examine the form, not the subject matter, of patentability.184 In particular, the 
applications are also granted without a consideration of the prior grant of similar 
inventions or inquiry as to whether the description and claims in the patent 
application satisfy the patentability criteria of Section 1 of the PDA or standard of 
improvement of a known invention.185 This limited administrative capacity and 
practice is a worrisome gap that potentially affects the quality of patents granted. 
The absence of an examination process could in effect, expand the scope of 
patentability to admit any and every frivolous incremental modification of existing 
versions, which could consequently impact on access to essential, cost-
effective, generic drugs. The Nigerian system is comparatively different from the 
substantive examination process adopted in most developed countries. In the 
UK for example, all patent applications are substantively examined to check 
whether the invention is new and inventive enough, and provides a useful 
application to merit the grant of a patent.186 The examination is also to ensure 
that the application is in line with other legal requirements including disclosure 
and enablement.187 The advantage of this latter system is that innovations 
                                                          
184 Section 4(1) states that:  
[t]he Registrar shall examine every patent application as to its conformity with section 3(1), (3) and (4) of this Act.  
185 Section 4 (2) provides that: 
            Where the examination mentioned in subsection (1) of this subsection shows that a patent application satisfies 
the requirements of section 3(1) and (3) of this Act, the patent shall be granted as applied for without further 
examination and, in particular, without examination of the questions- 
(a) whether the subject of the application is patentable under section 1 of this Act;  
             (b) whether the description and claims satisfy the requirements of section 3(2) of this Act; and (c) whether a prior 
application, or an application benefiting from a foreign priority, has been made in Nigeria in respect of the same 
invention, and whether a patent has been granted as a result of such an application. 
186 More information at the official site of Intellectual Property Office website. ‘Patenting Your Invention - GOV.UK’ (2016) 
<https://www.gov.uk/patent-your-invention/request-your-search-and-examination> accessed 20 January 2016. 
187 ibid 
368 
 
368 
 
registered for patents are examined to ensure that that they are truly novel, 
inventive, industrially relevant, and are adequately disclosed. The issue with the 
current system of patent registration in Nigeria is that it risks allowing the 
patenting of almost any invention, as long as it satisfies the formal requirements 
of the law. As pointed out by Yankey, the main problem of this registration 
system is that it secures the patenting of unmeritorious inventions.188 Thus 
inventions which may not confer the purported techno-economic and social 
benefits to society or unduly hinder follow-on innovations are protected.  
Nonetheless, Section 4(4) of the PDA provides that the grant of a patent is 
‘without guarantee of its validity,’ at the ‘risk of the patentee’ and may be set 
aside at any time. Furthermore, under Section 9 of the PDA, any person, 
including a public officer, can apply to the court to set aside patents on the 
grounds that the subject matter is not patentable; the description of the invention 
does not conform to the statutory criteria in Section 1(2) of the PDA; or there is 
an existing patent. It is argued however, that this provision unnecessarily shifts 
the duty of patent examination and the validity of patent claim onto an already 
overburdened judicial system. If a patent application was properly examined 
before it was issued it would save the time and cost of litigation. On that note, it 
is extremely important to examine patent applications before the grant. A proper 
examination could prevent the issuance of questionable and trivial patents that 
grant unwarranted market monopoly rights to inventors which would in turn, 
hamper competition and unduly increase costs.189 This assessment measure 
would not only ensure that truly innovative patents are given protection; it would 
also save potential inventors the substantial administrative processing cost of 
                                                          
188 G Sipa-Adjah Yankey, International Patents and Technology Transfer to Less Developed Countries: The Case of Ghana and 
Nigeria (Avebury 1987) 249, 253. 
189 Federal Trade Commission, ‘To Promote Innovation: The Proper Balance of Competition and Patent Law and Policy’ (Federal 
Trade Commission 2003) 5. 
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filing for a patent and consequently the cost of conducting expensive litigation to 
assert their claims.  
6.7 Making Patentability Exclusions, Public and Morality Exceptions to 
Encourage Access to Medicines 
Most analyses of the effective utilisation of the flexibilities as a means to health 
have focused more on limiting the exclusive rights of the patent holder; less 
attention has been directed to the issue of grant in the first place.190 The TRIPS 
Agreement allows countries considerable discretion regarding their approach to 
the patenting of certain products or processes contrary to public order and policy 
or morality. The TRIPS Agreement allows members some flexibility as to what 
they can exclude on these grounds, thus the provision gives a certain amount of 
leeway for Nigeria to define and apply a patentability criteria in line with public 
health interest and priorities and also, achieving its human development 
objectives. In the context of promoting women’s right to health in Nigeria, this 
flexibility is particularly important to improving access to medicines. 
Consequently, the country could adapt this provision by excluding inventions or 
methods that can impact adversely on health or stifle further pharmaceutical 
research, such as the patentability of human genetic materials, with its 
implications for access to cost-effective treatments.  
Article 27(2) of the TRIPS Agreement is subject to two conditions: first, the 
patentability of an invention may be excluded to prevent the commercial 
exploitation of the invention if it necessary to protect public order and morality. 
Since patent offices generally cannot prevent the commercialisation of a 
product, the non-patentability exemption may not necessarily prevent the 
                                                          
190 Musungu and Oh (n 32) 58.  
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commercialisation. Therefore, it appears that another competent authority may 
be required to prevent the commercialisation of the invention, even if it is not 
under a patent if the purpose is to protect morality and the public.191 The role of 
the patent officials, however, is to decline the issuance of patent protection in 
accordance with the patentability criteria. 
The second condition prohibits exclusions which are not based on Article 27(2) 
merely because it is not permissible under national domestic laws.192 The WTO 
overview to some extent attempts to define this by stating that the provision is 
for inventions whose commercial exploitation is prohibited to protect human, 
animal and plant life and not because the national law excludes an exploitation 
of the invention. 
These provisions for exclusion of patentability (ordre public and morality) under 
TRIPS are rather ambiguous and raise questions of practical enforcement in 
light of global differences in moral principles and norms. According to Correa, 
‘the notion of morality and ordre public are vague and their content will be 
dependent on national perceptions by patent offices and judges.’193 In other 
words, the provisions are so nebulous that it risks being the subject of 
protectionist abuse where members unduly restrict patentability on the grounds 
of their perceived notions of morality and public order; hence its use may be 
susceptible to frequent challenge by other members.194 Nevertheless, It appears 
that the interpretation of what constitutes morality will depend on national policy 
                                                          
191 Carlos M Correa, Intellectual Property Rights, the WTO and Developing Countries: The TRIPS and Policy Options (Zed Books 
2000) 63. 
192 ibid 63. 
193 ibid 62. 
194 M Bruce Harper, ‘TRIPS Article 27.2: An Argument for Caution’ (1997) 21(2) William & Mary Environmental Law and Policy 
Review 381, 383-384.  
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concerning what conduct will be contrary to the core values of a society.195 It is 
clear, however, that states have the authority to refuse patent registration on the 
grounds that it will encroach on public health and societal moral values.  
The disputes that have arisen in the breast cancer field illuminate many of the 
issues around patenting in modern pharmaceutical science and its implications 
for public policy, especially women’s access to medicinal treatments.196 The 
patent conflict that has accompanied the development and dissemination of 
treatment and diagnostic methods for breast cancer clearly illustrates the nexus 
between patent rights and the objective of ensuring an effective health regime 
for women. These disputes centre on patent rights for specific molecules with 
medical significance for the prevention, diagnosis, and treatment of breast 
cancer.  
A well-known controversy in this regard is the patenting of the human gene in 
the US case of Association for Molecular Pathology v Myriad Genetics Inc.197 
The dispute was over the validity of Myriad’s patents for the discovery of the 
location and sequencing of BRCA1198 and BRCA2 genes relating to breast and 
ovarian cancer.199 Myriad had successfully isolated the DNA sequences and 
methods to diagnose a propensity for cancer which, in turn, enabled the 
company to conduct tests for the detection of the mutation and methods to 
                                                          
195 Correa Intellectual Property Rights, the WTO and Developing Countries: The TRIPS And Policy Options (n 191) 62-63.  
196 For more discussions see Eileen M Kane, ‘Molecules and Conflict: Cancer, Patents, and Women’s Health’ (2007) 15(2) Journal of 
Gender, Social Policy & the Law 305-335.  
197 Association for Molecular Pathology et al v Myriad Genetics Inc. et al  (2013) 569 U.S. 12-398. In Europe, diagnostic patent right 
was granted to Myriad but the scope of the right was narrower than the patent granted in the USA. Similarly, the High Court of 
Australia (High Court) in 2015 unanimously revoked Myriad’s three patent claims on isolated BRCA1 DNA, although the court 
adopted a different reasoning for its decision. D'Arcy v Myriad Genetics Inc (2015) HCA 35. 
198 According to the National Cancer Institute, ‘BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These 
proteins help repair damaged DNA and, therefore, play a role in ensuring the stability of the cell’s genetic material. When either of 
these genes is mutated, or altered, such that its protein product either is not made or does not function correctly, DNA damage 
may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to cancer.’ 
National Cancer Institute, ‘BRCA1 & BRCA2: Cancer Risk & Genetic Testing’ (National Cancer Institute, 2016) 
<http://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#q1> accessed 21 February 2016.  
199 Surya Mani Tripathi, Neeraj Parnami and Santosh Kumar Pati, ‘Biotechnology and Intellectual Property Rights (IPRs)’ in Chander 
Parkash Malik, Chitra Wadhwani and Bhavneet Kaur (eds), Crop breeding and biotechnology (Pointer Publishers 2009) 250. 
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identify drugs using isolated DNA sequences.200 The patents by Myriad gave it 
exclusive rights to isolate an individual’s BRCA1 and BRCA2 genes, 
synthetically create BRCA cDNA and conduct the mutation test.201 Because of 
the exclusive right, Myriad charged up to US$250-500 to screen for the 
occurrence of the mutation.202 Myriad’s monopoly enabled it to own patent 
testing which could only take place in their labs203 and control the test process, 
which also deprived women of other cheaper alternatives. Myriad also 
challenged the test offered by other labs without its licence or and where a 
licence was given, strict conditions were attached to it.204 The patent effectively 
limited other researchers from conducting research into other treatments and 
medicines for women using the process, thereby stifling incremental innovation.  
In the case before the US Courts, the petitioners argued that the patents were 
essentially a monopoly over the laws of nature and approached the court to 
invalidate the patents on the grounds of 35 U. S. C. §101.205 On June 13, 2013, 
the US Supreme Court in a unanimous decision ruled that Myriad’s patents for 
naturally occurring DNA segments was a monopoly for a product of nature and, 
                                                          
200 Mutations in those genes can dramatically increase a woman's chance of developing breast or ovarian cancer. Thereafter, 
Myriad introduced BRCAnalysis® the first commercial genetic test to detect mutations in the breast cancer genes. Kane (n 196) 
329.  
201 Association for Molecular Pathology v Myriad Genetics, Inc. 569 U.S. 2013 (Opinion of the Court) 10–18. Available at 
<https://supreme.justia.com/cases/federal/us/569/12-398/> accessed 27 January 2016. Also available at 
https://supreme.justia.com/cases/federal/us/569/12-398/case.pdf. 
202 Yahong Li, ‘Human Gene Patenting and its Implications for Medical Research’ in Peter K Yu (ed), Intellectual Property and 
Information Wealth: Issues and Practices in the Digital Age (Greenwood Publishing Group 2007) 374. It also cost US$2400- 
US$3500 to conduct test linked to cancer in the US using BRCA1 and BRCA2. ibid 363. Myriad also granted the National IH and the 
National Cancer Institute NCI at-cost licences (about $1200 per test). Kane (n 196) 329; Bryn Williams-Jones, ‘History of a Gene 
Patent: Tracing the Development and Application of Commercial BRCA Testing’ [2006] Health Law Journal 123,136. 
203 Myriad’s enforcement of its patent rights requires any licensees to submit clinical samples directly to the Myriad laboratory for 
testing, a result that has been criticised on scientific grounds because it unduly limits the development of multiple technical 
approaches to genetic testing. Kane (n 196) 329.  
204 Kane (n 196) 329. For example, it was reported that researchers at the University of Pennsylvania who offered BRCA testing 
received cease and desist letters from Myriad, threatening litigation unless they took out a license to the Myriad patents. 
Williams-Jones (n 202) 136. 
205 Association for Molecular Pathology v Myriad Genetics (n 197) 1 (Slip Opinion). 
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therefore, invalid for patent protection even if it has been isolated from nature.206 
Delivering the majority judgement, Justice Clarence Thomas said: 
Had Myriad created an innovative method of manipulating genes while searching 
for the BRCA1 and BRCA2 genes, it could possibly have sought a method patent. 
But the processes used by Myriad to isolate DNA were well understood by 
geneticists at the time of Myriad’s patents “were well understood, widely used, and 
fairly uniform insofar as any scientist engaged in the search for a gene would likely 
have utilized a similar approach,[…]” 207  
However, the court held the cDNA patent was eligible because it is not naturally 
occurring.208  
This case illustrates some of the issues that can arise with regards to granting 
patents for claims that could impact on public policy and morality. This case 
demonstrates some of the healthcare effects that an improvidently granted 
patent can create in limiting research into diseases affecting women and 
increasing the cost of access to health care.209 This problem supports the 
argument that patent monopoly could impact access to health care and the 
development of a competitive market; hence it is important that the TRIPS 
flexibility excluding patents for certain pharmaceutical methods, therapeutic and 
medical processes on a public policy basis is given maximum consideration by 
                                                          
206 ibid (Opinion of the Court) 8–18. In a similar US related case of Prometheus v Mayo Collaborative Services Prometheus holds 
patents for methods of determining the optimal dosages of two drugs use to treat irritable bowel disorders. Mayo had purchased 
and used Prometheus’s tests but later announced it would use and sell a test it had developed ‘in-house’. Prometheus then filed 
against Mayo for infringement. Mayo argued that Prometheus’s patents were invalid as they fail the “machine or transformation” 
test. 
207 ibid (Opinion of the Court) 17.  
208 Association for Molecular Pathology v Myriad Genetics (Opinion of the Court) 10–18. The cDNA patent is for synthetically 
created DNA known as complementary DNA (cDNA), which contains the same protein-coding information found in a segment of 
natural DNA but omits portions within the DNA segment that do not code for proteins. ibid 1 (Opinion of the Court). 
209 Kane (n 196) 329-335.  
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the Nigerian government, lawmakers and the judiciary to expedite access to 
affordable medicines and health care.210  
The exact provision and interpretation of public order and morality under the 
national laws of other WTO members varies according to their public values.211 
For instance, Article 1(3) of the UK Patent Act 1977 states that ‘a patent shall 
not be granted […] for an invention the publication or exploitation of which would 
be generally expected to encourage offensive, immoral or anti-social 
behaviour.’212 Under the Guidelines for Examination of the European Patent 
Office for example, ordre public is linked to security considerations, such as riots 
or public disorder, and inventions which may lead to criminal or other generally 
offensive behaviour.213 In the European Patent Office (EPO), an application for a 
patent may be rejected on the grounds of morality or public order in some 
exceptional cases.214 Article 53 of the European Patent Convention (EPC) 
excludes the commercial exploitation of inventions which are contrary to 'ordre 
public' or morality215 
                                                          
210 This is especially imperative in the issue of patenting biological material and the human genome. (It is noteworthy that a 
comprehensive discussion of the broader policy implication of gene patenting or bio-scientific research is outside the scope of this 
thesis; however, it is touched upon because of the argument that patenting genes could block the downstream research on that 
particular DNA or gene sequence and its consequential impact on public health.) For more discussion, see Myles W Jackson, The 
Genealogy of a Gene: Patents, HIV/AIDS, and Race (MIT Press 2015).  
211 See various examples in Section 2 of the Ghana Patent Law 2003 (Act 657); Article 35 of the Japan Patent Act (Act No. 121 of 13 
April 1959, as amended up to 2006); Section 13 (2)(3) of the Singapore Patents Act (Revised Edition 2005, as amended up to the 
Statutes (Miscellaneous Amendments) Act 2014); Article 5 of the Patent Law of the People’s Republic of China (as amended up to 
the Decision of December 27, 2008, regarding the Revision of the Patent Law of the People’s Republic of China); Article 32 of the 
Patent Act of the republic of South Korea (Act No. 950 of December 31, 1961, as amended up to Act No. 6411 of February 3, 
2001); Section 25 of the South Africa Patents Act 1978 (Act No. 57 of 1978, as amended). All these laws contain provisions on 
exclusion of patentability on morality, public policy and interest grounds. 
212 Paragraph 3(b) - 3(e) of Schedule A2 to the Patents Act 1977 also identifies types of inventions whose commercial exploitation 
would be contrary to public policy or morality and should not be granted a patent, similar to types of invention which are listed in 
the Biotech Directive. Essentially biological processes for the production of plants and animals which are not micro-biological or 
other technical processes are excluded from patentability by virtue of Paragraph 3(f) of Schedule A2 to the Patents Act 1977. 
213 Part C Chapter IV, 3.1. 
214 Correa, Intellectual Property Rights, the WTO and Developing Countries: The TRIPS and Policy Options (n 191) 63.  
215 Article 53 states: European patents shall not be granted in respect of:  
(a) inventions the commercial exploitation of which would be contrary to "ordre public" or morality; such exploitation shall 
not be deemed to be so contrary merely because it is prohibited by law or regulation in some or all of the Contracting 
States.  
See also ibid 63.  
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Likewise Article 6 of the EC Biotechnology Directive216 exempts from 
patentability, processes modifying the germ line genetic diversity, processes of 
cloning humans and uses of human embryos for industrial or commercial 
processes from patent protection based on ordre public or morality grounds.217 
The jurisprudence of the EPO offers illustration into the interpretation of the 
provisions of morality and public order, particularly in cases with implication for 
medical research.218 The opinion of public majority or public abhorrence test 
was given consideration in Howard Florey/Relaxin.219 A group challenged the 
validity of a patent for the hormone Relaxin. They argued that the isolation of 
mRNA from the tissue of a pregnant woman and patenting of the human gene 
which relaxes the uterus during childbirth to reduce the need for caesarean 
section in difficult pregnancies and offends Article 53(a) of EPC on grounds of 
morality and human dignity and fail to satisfy the criteria of patentability. 
                                                                                                                                                                          
The EPO often employs two methods of analysis: the ‘balancing of interest at stake’ test; and ‘the public opinion of a vast majority 
of people’ to assess cases bordering on morality and public interest. ibid  
216 Article 6 asserts that  
Inventions shall be considered unpatentable where their commercial exploitation would be contrary to ordre 
public or morality; however, exploitation shall not be deemed to be so contrary merely because it is prohibited by 
law or regulation. 
2. On the basis of paragraph 1, the following, in particular, shall be considered unpatentable: 
(a) processes for cloning human beings; 
(b) processes for modifying the germ line genetic identity of human beings; 
(c) uses of human embryos for industrial or commercial purposes; 
(d) processes for modifying the genetic identity of animals which are likely to cause them suffering without any 
substantial medical benefit to man or animal, and also animals resulting from such processes.  
Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the Legal Protection of Biotechnological 
Inventions. (Official Journal of the European Communities L 213 , 30 July 1998) 
217 This list of exceptions to patentability is not exhaustive (Rule 28 EPC). See European Patent Office, ‘Patents on Biotechnology 
European Law and Practice’ (European Patent Office 2014). Li (n 202) 353. 
218 In the EU’s Transgenic animals/Harvard ‘Oncomouse’ case (T0019/90 (Oncomouse) of 3.10.1990.), the balancing of public 
interests approach was adopted by the EPO to consider the advantages of endangering genetically modified transgenic mice 
engineered to develop tumours, thereby subjecting them to excessive inconvenience. The EPO Technical Board of Appeal Board 
subsequently weighed the balance benefits to humans and animals by subjecting the animal to suffering and concluded that ‘a 
likelihood - but no more than a likelihood - that such suffering is necessary to "trigger" the operation of Rule 23 (d) EPC’ ((Harvard/ 
Oncomouse (2005) OJEPO, 229, T 0315/03 paragraph 6.2.) Therefore a substantial medical benefit had to be demonstrated if 
there is any likelihood that the animal will be subjected to such suffering. (Paragraphs 10.5, 10.6 and 10.9.) See more at 
Intellectual Property Office, ‘Examination Guidelines for Patent Applications Relating to Biotechnological Inventions in the 
Intellectual Property Office’ (Intellectual Property Office 2013) 39. 
219 Howard Florey/Relaxin (Oppositions by Fraktion der Grunen In Europaischen Parlament; Lannoye), Application No. 83 307 553.4 
Opposition Division, 8 December, 1994 [1995] E.P.O.R. 541, paragraph 6.3; Li (n 217) 333; Correa, Intellectual Property Rights, the 
WTO and Developing Countries: The TRIPS and Policy Options, (n 191) 65-66; Charlotte Waelde and others, Contemporary 
Intellectual Property: Law and Policy (Oxford University press 2016) 491; Antony Taubman, ‘The International Patent System and 
Biomedical Research: Reconciling Aspiration, Policy and Practice’ (2008) 10 The AAPS Journal 526, 533-534. 
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Although the EPO Opposition Division upheld the grant of the patent in question, 
it applied the public majority test ruled that the [p]atenting of the DNA would 
indeed be abhorrent to the overwhelming majority of the public if it were true that 
the invention involved the patenting of human life, an abuse of pregnant women, 
a return to slavery and the piecemeal sale of women to industry' and in this case 
Relaxin was not.220 While the EPO allowed the patenting of the DNA, it however, 
affirmed that patents would not be granted to inventions that are regarded as 
universally outrageous, although it is not clear which inventions would be so 
regarded as outrageous. 221 Though the public stands to benefit from the 
innovative advancement of genomic research and novel practice in the isolation 
of gene sequences, it is useful to provide clarity and limit the instances in which 
patents are granted for important genes and life forms, particularly where the 
commercial exploitation would negatively impact on pharmaceutical research, 
patient access and medical care. This is because patents on genomics imply 
                                                          
220 On the issue of the patent in question, the EPO Opposition Division pointed out that  
DNA is not 'life', but a chemical substance which carries genetic information and can be used as an intermediate 
in the production of proteins which may be medically useful. The patenting of a single human gene has nothing 
to do with the patenting of human life. Even if every gene in the human genome were cloned (and possibly 
patented), it would be impossible to reconstitute a human being from the sum of its genes. The opponents 
apparently do not object to the patenting and exploitation for medical purposes of other human substances such 
as proteins (even the H2-relaxin protein). However, no moral distinction can be seen in principle between the 
patenting of genes on the one hand and other human substances on the other, especially in view of the fact that 
only through gene cloning have many important human proteins (for example, erythropoeitin and the 
interferons) become available in sufficient amounts to be medically applied. 
ibid paragraph 6.3.4. The decision was upheld on appeal in Relaxin/Howard Florey Institute (Boards of Appeal, European Patent 
Office T0272/95, 23 October 2002). 
221 In a 2008 landmark ruling on stem cell cultures, the Enlarged Board of Appeal (EBoA) in WARF/ Embryonic Stem Cell Patents 
(G0002/06 (Use of embryos/WARF) of 25.11.2008) came to the conclusion that under the EPC, a patent cannot be granted for an 
invention which involves the commercial use and destruction of human embryos. The EBoA also considered the exploitation of the 
invention within the context of Article 53(a) EPC which excludes inventions from patentability if their commercial exploitation is 
against ordre public or morality, Rule 28(c) and the TRIPS Agreement in ruling that, 'this use involving destruction is thus an 
integral and essential part of the industrial or commercial exploitation of the claimed invention, and thus violates the prohibition 
of Rule 28(c) (formerly 23d(c)) EPC.' ibid paragraph 29. The EBoA however stressed that the decision does not cover all questions 
of patenting human stem cell, accordingly, it is important to point out that it is not the fact of the patenting itself that is 
considered to be against ordre public or morality, but it is the performing of the invention, which includes a step (the use involving 
its destruction of a human embryo) that has to be considered to contravene those concepts.' (paragraph 41). Similarly, the 
European Court of Justice in Oliver Brüstle v Greenpeace eV, (C-34/10) judgment of 18 October 2011 ruled that Article 6(2)(c) of 
the EU directive excludes from patentability, inventions which requires the destruction of human embryonic stem cells. The patent 
in question is a process for transforming hES cells (derived from an existing cell line) into nerve cells. Greenpeace sought to have 
the patent revoked on the grounds that the patent for the hES cells are excluded from patentability by virtue of the morality 
provision in the Article (6) and (2) of the Biotech Directive. The ECJ held that 'on the same grounds as those set out in paragraphs 
32 to 35 above, an invention must be regarded as unpatentable, even if the claims of the patent do not concern the use of human 
embryos, where the implementation of the invention requires the destruction of human embryos.' paragraph 49. 
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that it is the property of the company and the monopoly could in effect, hinder 
further medicinal research and innovation.222 On the other hand, even if 
researchers negotiated licences for the patents, the royalty payments could 
increase the cost of R&D which shifts the burden to the public.223 A survey by 
Professor Merz found that many of the respondents claimed they abandoned 
their research because of gene patents.224 This leads scholars Heller and 
Eisenberg to call this the problem ‘tragedy of the anti-commons’ for biomedical 
research.225 Accordingly, while patents could attract further incentives for R&D, 
the exclusive IPR could paradoxically restrict the use of biomedical materials 
and data and further stifle the R&D of life-saving health products.226 With 
regards to licensing agreements, the scholars noted that deadlocks and delays 
in negotiations of licences to use research tools and information, plus the high 
transaction costs of bargaining for multiple licences, could block creative 
research, particularly, academic research.227 The result of this problem is either 
                                                          
222 Jon F Merz and others, ‘Diagnostic Testing Fails the Test: The Pitfalls of Patents are Illustrated by the Case of Hemochromatosis’ 
[2014] 415 Nature 577, 580.  
223 Mrinalini Gupta, ‘India: Are Gene Patents a Hindrance to Innovation?’ [2013] Mondaq. Available at 
<http://www.mondaq.com/india/x/247166/Life+Sciences+Biotechnology/Are+Gene+pat+ents+a+hindrance+to+Innovati+on> 
accessed 27 January 2016. 
224 Merz and others (n 222) 580; Li (n 202) 363. Other studies suggest however, that biomedical research in general may not 
significantly be affected by gene patents (with only 1% reporting having to delay a project, and none abandoning projects due to 
patents). Timothy Caulfield and others, ‘Evidence and Anecdotes: An Analysis of Human Gene Patenting Controversies’ (2006) 24 
Nature Biotechnology 1-8; United States Patent and Trademark Office, ‘Report on Confirmatory Genetic Diagnostic Test Activity’ 
(United States Patent and Trademark Office 2015) 18. Other commentators are also sceptical of the argument that awarding 
patents to subject matters of biotechnology may be tantamount to granting a property right over life. Accordingly, a patent right 
only confers market monopoly right to exclude competitors and ' does not provide any means of curbing the way the invention 
might be exploited beyond limiting the impact or scope of the monopoly. A patent is not a means to regulate or control 
developments in science, medicines, or industry.' Waelde and others (n 219) 519. While patent is indeed a right that only entitles 
holders to exclude others from unauthorised access, the exercise of that right by the patent holders could in effect, constitute a 
potential barrier to innovation and patient access, for example, through licensing and infringement claims. Such market exclusivity 
rights and monopolies could consequentially limit patient access and increase prices. Peter Border, 'Biomedical Patents' (2012) 
Parliamentary Office of Science and Technology POSTNotes 401, 4. Available at  
<http://researchbriefings.parliament.uk/ResearchBriefing/Summary/POST-PN-401> accessed 17 July 2016. 
225 Michael A Heller and Rebecca S Eisenberg, ‘Can Patents Deter Innovation? The Anticommons in Biomedical Research’ (1998) 
280 Science 698. 
226 ibid 698.  
227 ibid 700-701. There are however, other mechanisms and flexibilities which can be used to ease the way and ensure cost 
effective licensing arrangements such as patent pool, a licensing arrangement where two or more patent holders offer a joint 
license for their patents to each other or third parties. Third parties can seek a compulsory licensing where the patent holder 
refused to negotiate the licence on reasonable terms or work the patent. Border (n224) 4; Waelde and others (n 219) 521. 
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less availability of health treatments228 or higher costs of the scarce end-
product.229 Hence, the need to control and where possible, exempt certain 
important biological materials or inventions that could impact on the availability 
and accessibility of essential medicines and medical services.  
Articles 27(3)(a)(b) TRIPS further exempts the patenting of plants, animals other 
than micro-organisms including diagnostic and therapeutic surgical methods 
from patentability.230 The objective behind the exclusion of medical, surgical and 
therapeutic processes from patentability itself is to protect methods of medical 
treatments to ensure that everyone gets adequate and proper healthcare by 
medical practitioners without limiting the means of providing it. An example is 
the BRCA1 and BRCA2 breast cancer treatment test and diagnostic patent 
monopoly by Myriad, aforementioned.231 While innovative medical instruments 
and diagnostic methods/processes could have positive effects on medical 
research and treatments, monopoly rights for them could impede the R&D of 
new medicines or increase licensing/royalty fees and 'cost of healthcare', and 
therefore, access.232 Further, given the medical value in plant-derived 
pharmaceuticals and chemical substances from plants, excluding patents for 
plants themselves becomes necessary to facilitate the development of new 
products based on plants and plant derivatives.233 It is worth noting that this 
                                                          
228 Heller and Eisenberg (n 225) 700-701. 
229 ibid 
230 27(3) of the TRIPS Agreement states: 
 Members may also exclude from patentability:  
(a) diagnostic, therapeutic and surgical methods for the treatment of humans or animals;  (b) plants and animals 
other than micro-organisms, and essentially biological processes for the production of plants or animals other 
than non-biological and microbiological processes. 
 However, Members shall provide for the protection of plant varieties either by patents or by an effective sui generis system or by 
any combination thereof. The provisions of this subparagraph shall be reviewed four years after the date of entry into force of the 
WTO Agreement.  
231 See subsection 6.7. 
232 E Richard Gold and others, 'Are Patents Impeding Medical Care and Innovation?' (2010) 7 PLoS Med 1, 3; Li (n 202) 362-364.  
233 Office of Industries U.S. International Trade Commission, Review of Global Competitiveness in the Pharmaceutical Industry 
(DIANE Publishing 2016) 4-12. 
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non-patentability exception does not however, extend to plant varieties, devices 
or products.234  
6.7.1 Patentable Subject Matter Exclusions in Nigeria 
The Patent and Designs Act (PDA) of 1970 in Section 1(4) extensively excludes 
from patentability, plants and animal varieties or, essentially, biological 
processes for the production of plants or animals, and other microbiological 
processes and their products.235 This protection conforms to the patentability 
criteria of Article 27(3)(b) TRIPS.236 Notably absent from this exclusion is a 
consideration of inventions that could affect humans and health, although 
Section 1(4)(b) of the PDA further prohibits the patenting of inventions that are 
by themselves contrary to public order or morality. In consonance with TRIPS, 
Section 1(5) of the PDA exempts principles and discoveries of a scientific nature 
from patentability. However, other permissible important patentability exclusions 
that are relevant to public health such as ‘diagnostic, therapeutic and surgical 
methods for treatment of humans and animals’ found in Article 27(2) of the 
TRIPS Agreement 237 are not clearly included in the provisions of the Nigerian 
1970 PDA. Also, Article 27(2) of TRIPS allows the exemption of inventions ‘to 
avoid serious prejudice to the environment,’ which is notably absent under the 
current Nigerian PDA.  
                                                          
234 Correa, Intellectual Property Rights, the WTO and Developing Countries: The TRIPS and Policy Options (n 191) 6.7. 
235 Section 1 (4) PDA states that: Patents cannot be validly obtained in respect of-  
             (a) plant or animal varieties, or essentially biological processes for the production of plants or animals (other than 
microbiological processes and their products); or (b) inventions the publication or exploitation of which would be 
contrary to public order or morality (it being understood for the purposes of this paragraph that the exploitation 
of an invention is not contrary to public order or morality merely because its exploitation is prohibited by law). 
 (5) Principles and discoveries of a scientific nature are not inventions for the purposes of this Act. 
236 Article 27(2) allows Members to exclude  
[f]rom patentability inventions, the prevention within their territory of the commercial exploitation of which is 
necessary to protect ordre public or morality, including to protect human, animal or plant life or health or to 
avoid serious prejudice to the environment, provided that such exclusion is not made merely because the 
exploitation is prohibited by their law. 
237 Article 27(3)states:  
 Members may also exclude from patentability: 
  (a) diagnostic, therapeutic and surgical methods for the treatment of humans or animals. 
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Likewise, there is no clarification or even an illustrative category of what would 
constitute ordre public and policy or morality, leaving the determination open to 
the patent registration authorities or the courts. Nigeria’s approach to issues of 
patentability is unlike India’s patent law which specifically excludes inventions 
that offend public order or morality or ‘[…] which causes serious prejudice to 
human, animal or plant life or health or to the environment’ in section 3(d) of the 
Patent Act.238 Conversely, since there is no definition of what constitutes 
morality or public order, the Nigerian courts in the interests of the right to health, 
can interpret the provisions of the 1970 PDA to secure the protection of public 
health and improve access to medicines, like the above stated case of Myriad.  
On the other hand, the earlier mentioned NIPCOM Draft Bill 2007239 in Article 
105 Bill specifically excepts the publication and exploitation of inventions on 
morality, and public order grounds and the exemption patenting of human, 
animals, plant life, and protection of health or anything ‘which are likely to be 
seriously prejudicial to the environment’ under Article 105.240 Article 105(5)(6) 
further excludes ‘diagnostic, therapeutic and surgical methods for treatment of 
humans and animals’ and principles and discoveries from patentability 
respectively. If passed into law, this provision could exempt the patenting of 
pharmaceutical inventions and medical equipment which are detrimental to the 
physical and mental health of women in Nigeria on the grounds of public policy 
and morality. 
                                                          
238 Section 3(b) excludes from patentability,  
an invention the primary or intended use or commercial exploitation of which could be contrary to public order 
or morality or which causes serious prejudice to human, animal or plant life or health or to the environment. 
239 See subsection 6.2.1 above. 
240 Furthermore, the bill explicitly states that computer programs which are of a scientific and mathematical nature may not be 
granted patent protection. 
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 In comparison to other countries however, the provisions in the NIPCOM Bill 
are inadequate for this purpose. There are no clearly stated categories or 
instances where an invention could be considered injurious to human health on 
the grounds of morality or protection of public order, leaving the provision vague 
and ambiguous. Rule 28 on Exceptions to patentability under Article 53(a) of the 
EPC and India’s Manual of Patent Office Practice and Procedure provide 
examples of inventions that are excluded on grounds of public morality and 
order, including the protection of humans and health. In India, examples of 
inventions that are injurious to health include pesticides or methods of 
adulteration of food.241 Interestingly, India’s IPAB in the previously stated case 
of Novartis AG v Union of India (UOI) and Ors also considered the possible 
health consequences of the grant of a patent to Novartis’s drug on the grounds 
of securing public order before rejecting the application. In reasoning, the IPAD 
emphasised that  
[…] we also observe that a grant of product patent on this application can create a 
havoc to the lives of poor people and their families affected with the cancer for 
which this drug is effective.  This will have disastrous effect on the society as well.  
[…] we observe that the Appellant’s alleged invention won’t be worthy of a reward 
of any product patent on  the basis of its impugned application for not only for not 
satisfying the requirement of section 3(d) of the Act,  but also for its possible 
disastrous consequences on such grant as stated above, which also is being 
attracted by the provisions of section 3(b) of the Act which prohibits grant of patent 
on inventions, exploitation of which could create public disorder among other 
things.242   
                                                          
241 India: Manual of Patent Office Practice and Procedure (The Office of Controller General of Patents, Designs & Trademarks, 
2010) 81-81. Also available at  
<http://www.wipo.int/wipolex/en/text.jsp?file_id=201589> accessed 16 September 2015. 
242 As cited in Novartis Ag vs Union Of India & Ors (2013) CIVIL APPEAL Nos. 2706-2716 of 2013 (Arising out of SLP(C) Nos. 20539-
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These legislative and judicial activisms are worth emulating by lawmakers in 
Nigeria. This development is important to adequately secure Nigerians’ human 
rights to health and life and enhance their human development by safeguarding 
their public health interests. The fatal effect of the 1996 meningitis drug trial by 
Pfizer in Kano, Nigeria, is a useful reminder of the need to safeguard Nigerians 
health interests in all aspects. During a clinical trial, 1000 children were given an 
experimental new oral antibiotic trovafloxacin (Trovan), and another 100 were 
given a substandard anti-meningitis treatment ceftriaxone.243 Five children 
eventually died from Trovan complications and six from ceftriaxone.244 Although 
this is not a patent-related case, the disastrous consequences of that drug trial 
raise public policy, morality and health issues. Moreover, the absence of a 
substantive patent examination system may mean that a similarly disastrous 
drug with devastating consequences for human health might be granted patent 
protection. Although this thesis is on promoting women’s access to medicines, 
through the lens of human rights, it is imperative that these medicines are safe 
for consumption, in addition to being available and affordable.  
Having analysed two flexibilities as to the methods of implementing the TRIPS 
obligations, two flexibilities with regards to the substantive standards of TRIPS 
are now examined.  
6.8 The Compulsory Licensing of Patented Pharmaceutical Inventions: 
Securing Accessibility to Affordable Medicines 
The use of Article 31 of the TRIPS Agreement as a means to addressing health 
challenges is one of the more common ways in which the TRIPS flexibilities 
have been utilised. The Article, which permits the state to use or approve the 
                                                          
243 Jacqui Wise ‘Pfizer Accused of Testing New Drug without Ethical Approval’ (2001) 322 British Medical Journal 194. 
244 ibid 
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use of an invention ‘without authorisation of the rights holder,’ is another way for 
the Nigerian authorities and third parties to circumvent a patent right, facilitate 
generic competition and exploit a patented medicine in the public interest.245 In 
many jurisdictions, the non-voluntary or compulsory licence is granted by the 
relevant administrative or judicial authority to a third party to use the patent 
without the voluntary consent of the patent rights holder.246 Consequently, the 
patent holder is informed of the licence and adequate remuneration is paid.247  
Compulsory licensing has the advantage of ensuring an alternative supply of 
patented medicines, often at a reduced and cheaper price.248 Particularly as 
regards the adverse effect of a patent’s monopoly on the right to accessibility to 
cheaper pharmaceuticals, compulsory licensing is an important mechanism for 
driving down the prices of drugs by facilitating competition in the market and 
creating an avenue for one or more generic producers to produce the same 
drug, thereby benefitting consumers, promoting social welfare and enhancing 
the enjoyment of the right to health.249 The grant of a licence to one or more 
third parties to use a patented method or product can also enhance access, 
which could lead to incremental R&D in the relevant field and enable the 
development of new follow-on innovations.250 Thus, in addition to expediting 
access to existing technology and drugs, compulsory licences can reduce the 
                                                          
245 Article 31 of TRIPS. 
246 WTO ‘WTO: Intellectual Property (TRIPS) - TRIPS and Public Health: Compulsory Licensing of Pharmaceuticals and TRIPS’ (2016) 
<https://www.wto.org/english/tratop_e/trips_e/public_health_faq_e.htm> accessed 28 January 2016; Musungu, Villanueva and 
Blasetti (n 23) 12. 
247 Osewe, Nkrumah and Sackey (n 67) 15. 
248 Correa, Implications of the Doha Declaration on the TRIPS Agreement and Public Health (n 77) 15. 
249 UNCTAD and ICTSD (n 69) 487-488; Carlos M Correa, Trade Related Aspects of Intellectual Property Rights: A Commentary on 
the TRIPS Agreement (OUP 2007) 313; CIPR (n 136) 45.  
250 Correa, Trade Related Aspects of Intellectual Property Rights: A Commentary on the TRIPS Agreement (n 249) 313. 
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adverse effect of a patent’s monopoly right and positively impact on R&D as well 
as ensuring the ‘future flow of innovations.’251  
A joint study by the WTO and WHO has identified this flexibility as a balancing 
mechanism by which the TRIPS Agreement aims to promote innovation, R&D of 
new drugs and also ensure the availability of lower priced medicines.252 WTO 
members have the discretion to determine the grounds for the utility of this 
licensing flexibility subject to some conditions in the TRIPS Agreement.253 
Notably however, Article 31 lists some permissible illustrative grounds for 
compulsory licensing such as: the use to ameliorate health conditions, ensuring 
an adequate supply of medicines in the event of national health emergencies or 
other circumstances of extreme urgency and as a remedy for an anti-
competitive practice.254 Other possible grounds for the issue of compulsory 
licences are when the rights holder has refused to deal or to grant a voluntary 
licence for a reasonable commercial arrangement by the applicant;255 where the 
working of a new invention is dependent on existing patents; and ensuring the 
working of a patent.256  
Significantly, as earlier discussed in subsection 6.4, the Doha Declaration has 
also reaffirmed the rights of members to adapt, interpret and fully utilise the 
flexibility options in the TRIPS Agreement to protect public health.257 Thus 
compulsory licensing can be broadly issued for the protection of the public 
                                                          
251 ibid 314. (Carlos Correa notes that the US has issued more than a hundred licences for various reasons including promotion of 
research in a relevant technical field, access to research results, technology information or know-how to other industry members 
etc). ibid 317. 
252 World Trade Organization and World Health Organization, WTO Agreements & Public Health: A Joint Study By The WHO And 
The WTO Secretariat (World Trade Organization and World Health Organization 2002) 99. 
253 Osewe, Nkrumah and Sackey (n 67) 15; Correa, Trade Related Aspects of Intellectual Property Rights: A Commentary on the 
TRIPS Agreement (n 249) 314.  
254 Article 31(b) TRIPS of the Agreement. 
255 The German Patent Law of 1996 in Section 24 (1) and the patent law of the Republic of China in Section 51 provide for the grant 
of compulsory licences on this basis.  
256 Article 31(1) TRIPS Agreement. 
257 See the Doha Declaration Paragraphs 4 and 5. 
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interest and enhancement of public health and nutrition.258 In this connection, 
Nigeria and other developing countries can incorporate, suitably adapt and 
utilise this flexibility to enhance their citizens’ human development and promote 
their rights to health, which includes the access to affordable life-saving 
medicines. Thus, the flexibility is relevant to enhancing women’s right to health 
and expanding their human development and capabilities opportunities in 
Nigeria.  
Another significant authority for the broad use of this flexibility measure in the 
interests of women’s rights to health in Nigeria is the earlier discussed Article 8 
of TRIPS,259 which allows states to adopt all means necessary for the protection 
of public health and nutrition. Furthermore, Nigeria and WTO Members can 
utilise this licencing procedure to advance development goals and the public 
and social welfare aspects of patents and the TRIPS Agreement as discussed in 
Chapter V260 With particular reference to the grant of compulsory licensing, 
since the Doha Declaration in Paragraph 5(b) reaffirmed the unquestionable 
rights of members to grant licences and ‘freedom to determine the grounds upon 
which such licences are granted,’ Nigeria and other WTO Members could 
compulsorily use or permit the use of a patented invention to control market 
monopoly practices by pharmaceutical companies, which can directly result in 
price increase and reduction of accessibility.  
In South Africa, for example, this avenue for health was exploited to address 
anti-competitive practices, with record success for access to affordable 
                                                          
258 Article 31(b) of the TRIPS Agreement. Musungu and Oh (n 32) 28-31. An example of such provision is Article L.613-61 of the 
French Patent Law which permits the responsible minister to grant ex-officio licenses in the event of insufficient quality and 
quantity or high cost of medicines. See Law No. 92-597 of I July 1992 on the intellectual property code (legislative part); Osewe, 
Nkrumah and Sackey (n 67) 15.  
259 See subsection 6.2.2 above and subsections 2.5.3 and 2.5.4 in Chapter II. 
260 See subsection 5.4 of Chapter V. 
386 
 
386 
 
medicines.261 It is also relevant in preventing acts that could impact indirectly on 
accessibility to essential medicines, for example, anti-competitive practices and 
abuse of patent rights which unduly restrain trade and affect the transfer of 
important health-related technologies.262 In another instance, licences were 
issued for anti-competitive purposes after an investigation of anti-trust practices 
and abuse of dominant market position by the relevant competition authorities in 
Italy.263 In 2006, a compulsory licence was also granted for GlaxoSmithKline‘s 
product sumatriptan succinate (for migraine headaches treatments), after an 
investigation into the refusal to licence and other anti-trust related grounds.264 
Where a compulsory licence is granted to remedy anti-competitive practices in 
an adjudicated judicial and administrative process, Article 31(k) can be relied 
                                                          
261 On 21 September, 2002, Treatment for Action instituted a complaint against GlaxoSmithKline and Boehringer Ingelheim to the 
South Africa's Competition Commission. (See Consumer Project on Technology, ‘TAC Statement on Competition Commission 
Announcement’ (2016). Available at  
<http://www.cptech.org/ip/health/sa/tac10162003.html> accessed 28 January 2016.) 
 The complaint was against the anti-competitive practices of charging excessive prices for ritonavir, lamivudine, lamivudine and 
nevirapine by the corporations. GSK and BI were subsequently found to have abused their dominant market positions in 
contravention of the Competition Act of 1998. On December 10, the Competition Commission reached a settlement with GSK, and 
the final terms of the settlement mandated the firms to: 
1) extend the voluntary licence granted to Aspen Pharmacare in October 2001 in respect of the public sector 
to include the private sector;  
2)  grant up to three more voluntary licences on terms no less favourable than those granted to Aspen 
Pharmacare;  
3)  permit the licensees to export the ARVs to sub-Saharan African countries;  
4) permit the importation of the drugs for distribution in South Africa if the licensee does not have 
manufacturing capability in South Africa;  
5) permit licensees to combine the relevant ARV with other antiretroviral medicines; and 
6) Charge royalties of no more than 5% of the net sales of the relevant ARVs. 
See Love (n 63). 
In another South African compulsory licensing-related example, in 2001, Cipla, an Indian company, made a formal request to the 
South African Department of Health to issue a compulsory licence for patented HIV drugs: nevirapine, lamivudine, zidovudine, 
stavudine, didanosine, efavirenz, indinavir and abacavin. Consumer Project on Technology ‘Compulsory Licenses’ 
<http://www.cptech.org/ip/health/cl/recent-examples.html#South> accessed 22 February 2016.  
262 Article 31(b) TRIPS of the Agreement. Correa Trade Related Aspects of Intellectual Property Rights: A Commentary on the TRIPS 
Agreement (n 249) 313. 
263 Italian authorities Autorità garante della concorrenza e del mercato (the AGCM) have granted compulsory licenses in a number 
of anti-trust and anti-competition related cases. 't Hoen, The Global Politics of Pharmaceutical Monopoly Power Drug Patents, 
Access, Innovation and the Application of the WTO Doha Declaration on TRIPS and Public Health (n 51) 44; Love (n 63). 
264 On 26 March 2007, the AGCM also issued a licence to Italian manufacturers to produce active pharmaceutical ingredients after 
an investigation of abuse of dominant position. Grounds for the compulsory licence include the refusal to grant a voluntary licence 
by Merck & Co. Inc; thus the AGCM requested that Merck ‘grant free licences to allow the manufacture and sale in Italy of the 
active ingredient Finasteride and related generic drugs two years before the 2009 expiration of the Complementary Protection 
Certificate.’ The licence further enables export to ‘other European countries.’ Love (n 63). See more at AGCM, ‘A364 - Merck - 
Active Ingredients (Conclusion of Investigation)’ (Agcm.it 2007) 
 <http://www.agcm.it/en/newsroom/press-releases/1096-a364-merck-active-ingredients-conclusion-of-investigation.html> 
accessed 22 February 2016.  
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upon to waive the condition of prior negotiation with the patent holder. It appears 
also that the state could employ the compulsory licence measure if the patent 
holder does not respond to voluntary negotiations within a reasonable time or 
the conditions for the voluntary licence are improperly restrictive.265 Since 
compulsory licences are issued for a particular purpose of exploiting a patented 
invention and addressing public health, the purpose of use can be weighed 
against the conditions offered by the patent holder and, when they are onerous, 
a compulsory licence may be the best option to utilise the invention. Arguably, 
what is required is that the negotiations are on reasonable terms.266 
The case of Brazil illustrates this point. After exhaustive unsuccessful attempts 
to negotiate with Roche Laboratories, the Brazilian Health Minister made an 
announcement on 22 August, 2001 that it would issue a compulsory licence for 
the manufacture of Nelfinavir, owned by Roche, for the treatment of AIDS, to Far 
Manguinhos, a Brazilian pharmaceutical producer.267 On August 31, the 
Government and Roche came to an understanding that Roche would sell the 
drug at an additional discount of forty percent and Brazil would not grant the 
compulsory licence. This approach also indicates the persuasive effect of the 
compulsory licence flexibility. The threat to issue the compulsory licence played 
an active part in ensuring access to affordable medicines. In another instance, in 
2005, the Brazilian government issued a decree for compulsory licences of the 
ARV drug Kaletra on the grounds of public health, following failed attempts to 
negotiate a price reduction of the drug with Abbott.268 The government also gave 
Abbot an option of reducing the price to avert the compulsory licence within a 
                                                          
265 Office of Industries U.S. International Trade Commission (n 233) 4-11. 
266 As per Article 31(b) of the TRIPS Agreement. 
267 The Consumer Project on Technology (CPTech) ‘Brazilian Statement on Compulsory License for Nelfinavir’ Available at 
<http://www.cptech.org/ip/health/c/brazil/nelf08222001.html> accessed 28 January 2016. 
268 Carlos and Matthews (n 39) 24.  
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specified timeframe.269 Subsequently an agreement to waive the licence was 
agreed upon by the government and Abbott, on the condition that the company 
would supply the drugs at a lower price.270 
Studies also indicate that the degree of achievement, and the efficacy of the 
TRIPS flexibilities as a means of increasing access to medicines, is largely 
attributed to the grant of compulsory licences.271 Practical examples of the use 
of compulsory licencing in other countries demonstrate the extent to which the 
flexibility can play a part in sustaining increased access to cost-effective 
medicines in Nigeria, especially in times of health crises. In April 2005, Guinea 
issued a licence for the importation of drugs to treat HIV-AIDS from generic 
sources;272 on 8 June, 2005, Eritrea, an LDC, granted a licence for generic 
production of HIV-AIDS medicines for non-commercial purposes.273 Similarly, 
the compulsory licensing option has been proactively explored by Latin 
American countries.274 Examples include the grant of a compulsory licence by 
Brazil in 2007, for the patented drug efavirenz (Sustiva), an essential HIV 
medication.275 Countries such as Argentina,276 Chile,277 and Ecuador278 have 
also explored the compulsory licensing option in the interest of the public’s 
                                                          
269 ibid 
270 ibid 
271 Musungu and Oh (n 32) 18-26.  
272 Nigerian Law Intellectual Property Watch (n 98). 
273 The Consumer Project on Technology (CPTech), ‘Eritrea’. Available at 
<http://www.cptech.org/ip/health/cl/Eritrea.png> accessed 28 January 2016; Love (n 63).  
274 Jerome Reichman, ‘Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options’ (2009) 37 Journal of 
Law, Medicine and Ethics 247, 250.  
275 On April 25, 2007, the Brazilian Minister of Health, José Gomes Temporão signed Decree 866, declaring the AIDS drug efavirenz 
to be of public interest. Subsequently, compulsory licensing of the patented antiretroviral drug Efavirenz was issued on May 4, 
2007. James Packard Love, ‘Recent Examples of the Use of Compulsory Licenses on Patents: Brazil’ (2016) 
<http://www.cptech.org/ip/health/c/brazil/> accessed 28 January 2016. See more in Amy S Nunn and others, ‘Evolution of 
Antiretroviral Drug Costs in Brazil in the Context of Free and Universal Access to AIDS Treatment’ (2007) 4(11) PLoS Med.  
276 The health Minister announced that the government would issue a compulsory licence for Tamiflu. It transpired that there was 
no patent for Tamiflu in Argentina. Love (n 63). 
277 Essential Inventions made a request for a compulsory licence to supply Glivec to Chile in 2004. Love (n 63).  
278 Acromax, a local manufacturer, petitioned the patent office to grant a compulsory licence for the fixed-dose combination of 
Lamivudine (3TC) and AZT (sold under the tradename Combivir by Glaxo) in 2003. The request was rejected; however, Glaxo 
subsequently granted Ecuador preferential prices on all their HIV-AIDS medicines. Love (n 63). 
389 
 
389 
 
access to medicines. In Asia, threats by Indonesia, Vietnam, India and South 
Korea to grant a compulsory licence, and possibly revoke the patent for 
oseltamivir (Tamiflu) resulted in an increased supply of influenza drugs.279 
Indonesia has issued three licences: two in 2004 for Lamivudine and Nevirapine 
as HIV/AIDS drugs and one in 2007 for HIV drug efavirenz.280 In another 
instance, India granted a licence for Bayer AG’s anti-cancer drug 'Nexavar' and 
authorised generic production at low cost.281 
The grant of compulsory licences in the interest of public health is also popular 
in developed countries.282 For instance, in 2001, the United States, facing a 
health crisis, threatened to use the flexibility on Bayer’s patented Ciprofloxacin 
(Cipro) for the treatment of anthrax.283 The Italian competition authority Autorità 
Garante della Concorrenza e del Mercato (AGCM), in 2005 and 2008, issued 
licences for Merck Sharp & Dohme (MSD)’s antibiotics that uses the active 
ingredients Imipenem/Cilastatina.284 French authorities also considered the use 
of a compulsory licence for the pill Ru 486 and subsequently amended its laws 
to allow broader use of the ex-officio licence for breast and ovarian cancer 
                                                          
279 Love (n 63). 
280 ibid. In 2004, intellectual property authorities issued compulsory licences for 5 patents in Taiwan and in 2005, another license 
was issued for patents needed to manufacture and sell the generic copies of Tamiflu. ibid  
281 International Centre for Trade and Sustainable Development, ‘India Grants First Compulsory License to Generic Drug Producer’ 
(2012) 16(10) Bridges. Available at <http://www.ictsd.org/bridges-news/bridges/news/india-grants-first-compulsory-license-to-
generic-drug-producer> accessed 14 March 2015. 
282 Hiroko Yamane, Interpreting TRIPS: Globalisation of Intellectual Property Rights and Access to Medicines (Hart Publishing 2011) 
42-43; Sudip Chaudhuri, ‘TRIPS and Changes in Pharmaceutical Patent Regime in India’ (2005) Indian Institute of Management 
Calcutta Working Paper No 535, 21-22. Canada has used compulsory licensing extensively. For instance, following significant policy 
and reform of the Patents Act of 1969, 613 compulsory licences were granted between 1969 and 1992. ibid 23-24.Sudip 
Chaudhuri, The WTO and India's Pharmaceuticals Industry: Patent Protection, TRIPS, and Developing Countries, (Oxford University 
Press 2005) 85; In Germany, there was a request for a compulsory licence by Roche which was cancelled after an agreement with 
Chiron. Love (n 63)  
283 The Consumer Project on Technology (Cptech), ‘Cipro Compulsory Licensing Dispute’ (cptech.org)) 
<http://www.cptech.org/ip/health/cl/cipro/> accessed 28 January 2016.  
The United States is one of the most active users of compulsory licensing under its antitrust legislation. The country has grant over 
100 compulsory licences for a number of purposes, including anti-competition. Carlos M Correa, ‘Intellectual Property Rights and 
the Use of Compulsory Licenses: Options for Developing Countries’ (1999) South Centre Trade-related Agenda, Development and 
Equity (T.R.A.D.E.) Working papers, 14-15. See examples of some licenses at The Consumer Project on Technology (CPTech) 
‘Compulsory Licensing in the United States’ (cptech.org) <http://www.cptech.org/ip/health/cl/recent-examples.html> accessed 28 
January 2016. 
284 Love (n 63)  
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genetic diagnostic testing patents due to excessive prices and licensing 
restrictions.285  
The examples above suggest that the compulsory licensing flexibility has been 
important to the effort to sustain access to essential medicines. Whether issued 
to third parties or for use by government authorities, evidently, the measure has 
facilitated access to affordable generic medicines and impacted policy 
approaches to public health issues.286 If appropriately used in Nigeria, the 
flexibility can significantly enhance women’s right to health and facilitate their 
access to affordable medicines.287  
6.8.1 Conditions for Granting Compulsory Licences in the TRIPS 
Agreement 
While Article 31 of the TRIPS Agreement defines the scope, procedural nature 
and conditions for the grant of compulsory licence, the Agreement allows 
considerable room for establishing the parameters and interpretation of the 
conditions for granting of the licence at the national level.288 However, members 
cannot make laws granting compulsory licence for frivolous reasons or 
automatically grant licences for no apparent justification.289 For this reason, 
Article 31(a) states that each authorisation for granting of a compulsory licence 
should be considered on its merits. This means that every licence shall be 
granted or authorised for government use taking into consideration the merits of 
                                                          
285 Carlos María Correa, Research Handbook on the Protection of Intellectual Property Under WTO Rules (Edward Elgar Publishing 
2010) 598. 
286 For example, in the Indian case of Bayer Corporation v Natco Pharma Ltd. Order No. 45/2013 (Intellectual Property Appellate 
Board, Chennai), the Intellectual Property Appellate Board (IPAB) reiterates that the significant point to be taken into account in 
the consideration of compulsory licensing procedure (in this case, section 84 of the India Patents Act of 1970 as amended in 2005) 
is whether the ‘public interest’ has been satisfied, and in this case, whether the patented drug was reasonably affordable to the 
public. Paragraphs 42 and 43 respectively. (The court held that ‘[a]fter all, the compulsory licence procedure itself is only in public 
interest.’)  
287 See Zita Lazzarini, ‘Making Access to Pharmaceuticals a Reality: Legal Options under TRIPS and the Case of Brazil,’ (2003) 6(1) 
Yale Human Rights and Development Law Journal 103, 125.  
288 With the exception of semi-conductor technology. 
289 Nuno Pires de Carvalho, The TRIPS Regime of Patent Rights (Kluwer Law International 2005) 317. 
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the application for the licence, the specific facts of each case, including the 
value of royalty to be paid. 
Although Pires de Carvalho argues that compulsory licences are to be granted 
only in exceptional circumstances, where serious reasons warrant it, this 
argument may not be supported by Article 31(b) of the TRIPS Agreement.290 
The Article stipulates that a licence may be granted for use where the proposed 
user has made efforts to obtain a voluntary licence from the rights owner. There 
is little to indicate that the proposed licensee is required to furnish exceptional 
reasons or serious grounds to apply for the compulsory licence. All that the 
TRIPS Agreement in Article 31(b) stipulates is that the proposed licensee made 
efforts to negotiate a voluntary licence from the patent holder on ‘reasonable 
commercial terms and conditions’ and that such conditions and authorisation 
had not been successful within a reasonable period. Admittedly, it is ideal to limit 
the granting compulsory licences to cogent and important reasons in the 
interests of a patent holder, however, arguing that the licence be limited to 
‘exceptional circumstances’ or ‘serious reasons’ may be taking the interpretation 
of the provision too far.  
The obligation for prior negotiation in Article 31(b) can be waived by members in 
the event of a national health crisis, an emergency or other extreme exigent 
circumstance; public non-commercial use; and remedying of an anti-competitive 
practice.291 In the event of derogation for reasons of national emergency and 
other circumstances of extreme urgency, the rights holder shall be duly notified 
as reasonably practicable.292 The precise definition of what will constitute 
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291 Article 31(b) of the TRIPS Agreement; Carlos M Correa, Trade Related Aspects of Intellectual Property Rights: A Commentary on 
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‘national emergency and other circumstances of extreme urgency’ for the 
purpose of a waiver of prior negotiation is vague and may be subject to 
ambiguous definitions. This has however, been clarified in Paragraph 5(c) of the 
Doha Declaration allowing members to define a national emergency or 
circumstances of extreme urgency, as earlier discussed.293 Thus compulsory 
licensing can be granted without prior negotiation in the case of a sudden and 
unexpected health crisis requiring immediate relief.294 This clarification extends 
the measure to the duration of the crises.295  
The rights and authorisation granted under a compulsory licence — as 
established under national law — are non-exclusive and non-assignable.296 This 
means that the licensee cannot transfer or grant a sub-licence, except with that 
part of the enterprise or goodwill that uses it.297 The patent holder retains the 
right to exploit and use the patented invention and voluntarily licence same to 
third parties.  
The exception in Article 31(h) also requires that adequate remuneration be paid 
to the right holder, having regards to the economic value of the authorisation. 
The TRIPS Agreement does not define what constitutes ‘adequate 
remuneration’ but it has been suggested that the Agreement leaves 
considerable room for it to be interpreted in line with the national objectives and 
laws of each member.298 
 
                                                          
293 See subsection 6.4 above.  
294 Correa, Implications of the Doha Declaration on the TRIPS Agreement and Public Health (n 77) 15-17. 
295 ibid 17.  
296 The TRIPS Agreement in Article 31(d) and (e). 
297 Correa, Trade Related Aspects of Intellectual Property Rights: A Commentary on the TRIPS Agreement (n 249) 321. 
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6.8.2 Challenges to the Use of Compulsory Licencing as a Health 
Safeguard Measure 
While the TRIPS Agreement allows members latitude to define their licence 
regimes299 and the Doha Declaration300 further paved the way for the practical 
use of the flexibilities by elaborating the terms of national emergencies, the 
larger question of what the phrase ‘other circumstances of extreme urgency’ 
encapsulates has been left to the qualified discretion of states to determine. 
Unvaryingly however, the liberal discretion of states to determine their licensing 
regime opens up the risk of being the subject of either additional standards or 
retaliatory measures by developed countries should developing countries 
attempt to define and utilise this measure. This is demonstrated by the US 
bilateral trade agreements and treaties with some developing countries to limit 
or exclude the circumstances for the granting of compulsory licensing.301 An 
example can be found in the 2001 US-Jordan FTA which provides very specific 
requirements for the use of compulsory licences.302 In the FTA, compulsory 
licencing is restricted only to remedy an anti-competitive practice, in the case of 
public non-commercial use, or in the case of ‘national emergency’ or situations 
of ‘extreme urgency,’ although Article 31 of the TRIPS Agreement or Doha 
Declaration gives a wider discretion.303 An Oxfam International report in 2007 
                                                          
299 Subject of course to the general standard and principles of the TRIPS Agreement. 
300 See subsection 6.4. 
301 Mohammed El Said, Public Health Related TRIPS-Plus Provisions in Bilateral Trade Agreements: A Policy Guide for Negotiators 
and Implementers in the WHO Eastern Mediterranean Region (n 122) 95-94; Keith E Maskus, ‘Reforming U.S. Patent Policy Getting 
the Incentives Right’ (The Council on Foreign Relations 2006) 29-30.  
The US also signed bilateral agreements with Sri Lanka and Albania which limit the circumstances for the grant and use of 
compulsory licenses. Correa, ‘Intellectual Property Rights and the Use of Compulsory Licenses: Options for Developing Countries’ 
(n 283) 1. 
302 Oxfam International, ‘All costs, No benefits: How TRIPS-plus Intellectual Property Rules in the US-Jordan FTA Affect Access to 
Medicines’ (Oxfam Briefing Paper (2007) 7. The US-Australia FTA, similarly to the US FTA’s with Jordan, Singapore and Vietnam, 
also limits the terms for the use of compulsory licensing to defined cases of anti-competition and antitrust remedies, public non-
commercial use, national emergencies and other circumstances of extreme urgency. Roffe and Spennemann (n 119) 80. See for 
example, Article 4 Paragraph 20 of the USA – Jordan FTA. Signed 24 October 2000. Available at <www.jordanusfta.com> accessed 
8 May 2015. 
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maintains that these TRIPS-plus rules may have contributed to an increase in 
the overall prices of medicines between 2001 and 2006, and would result in the 
delay or limited use of the TRIPS-guaranteed flexibilities to reduce the prices of 
new drugs in the future.304 Developed countries can also impose punitive 
measures through unilateral trade sanctions such as the US Trade Law ‘Special 
301’ mechanism, should countries exercise a broad discretion to define their 
licensing regimes or challenge the enforcement of compulsory licensing 
provisions.305 A case in point is the above mentioned US challenge to the local 
working provisions of Article 68 of Brazil’s Industrial Property Law before the 
WTO’s Dispute Settlement Body, as discussed earlier.306 Consequently, 
developing countries may choose not to issue the licences in the interests of 
exigent public health crises, to avoid retaliatory measures or the fear of 
jeopardising future investment and technology transfer opportunities.307 The end 
result may be higher prices of medicines such as the aforementioned case of 
Jordan, and therefore, less availability and access to medicines.  
In light of the above, Nigeria needs to desist from signing up to TRIPS-plus 
treaties and agreements that could restrict the use of this important compulsory 
licensing option to improve women’s better access to cheaper medicines. While 
these TRIPS-plus agreements and treaties hold the promise of technological, 
trade or market concessions, the human rights obligation of Nigeria, as pointed 
                                                          
304 Oxfam International, ‘All costs, No benefits: How TRIPS-plus Intellectual Property Rules in the US-Jordan FTA Affect Access to 
Medicines’ (n 302) 2. 
305 Jillian Clare Cohen-Kohler, Lisa Forman and Nathaniel Lipkus, ‘Addressing Legal and Political Barriers to Global Pharmaceutical 
Access: Options for Remedying the Impact of The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and 
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out earlier,308 exceed the purported economic growth, technological benefits and 
trading relations that might result from the treaties and agreements. As Oxfam 
International advised, the case of Jordan is an important lesson for countries to 
be careful when signing up to TRIPS-plus agreements that can undermine the 
broad use of the flexibilities to improve public health.309  
Also, the right to improve healthcare through Article 31 of the TRIPS Agreement, 
is subject to some qualifying conditions that could make the enforcement easier 
in principle than practice for developing countries.310 For instance, Article 31(f) 
requires that a licence shall be granted ‘predominantly for the supply of the 
domestic market of the member authorizing such use’ except to remedy anti-
competitive practice, as determined by a judicial or ant-competitive authority. 
Only a few developing countries such as Brazil, India, China, Mexico, Argentina 
and South Africa could boast of adequate pharmaceutical manufacturing 
capacity to adequately produce generic medicines under a compulsory 
licence.311 Moreover, even these countries also need drugs that cannot be 
locally produced.312 The requirement for domestic supply may have significant 
effect on countries with little or insufficient pharmaceutical manufacturing 
capacity.313 For these countries the best option would be to import from other 
countries, in which case, the other country has to exercise an equivalent 
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compulsory licence.314 The conditions for granting of compulsory licences in 
Article 31(f), however, constitutes a major problem for the countries with little or 
no manufacturing capacity to produce the drugs as they cannot rely on supply 
from other countries who wish to export the relevant pharmaceuticals under 
compulsory licence or government use.315 Thus effectively, Article 31(f) creates 
an encumbrance to this assistance since the use of the licence must be used 
‘predominantly’ in the domestic market of the authorising and manufacturing 
country.316 Matthews also observes that this provision brings an additional 
problem for countries lacking in administrative proficiency, technical and legal 
expertise to issue and use this flexibility measure.317 Invariably, the ability to 
meet health demands and address public health crises, and ensure access to 
medicines through export under a compulsory licence is constrained by this 
restricted exception. Nonetheless, a close reading of the language of Article 
31(f) suggests that a country can permit the ‘non-predominant’ part of the 
production for export under a compulsory licence.318 The Doha Declaration in 
Paragraph 6 has however, recognised and proffered a solution to the foregoing 
legal glitch regarding the requirement of domestic supply. 
6.8.3 The WTO Solution on the Implementation Challenges in Accordance 
with Paragraph 6 of the Doha Declaration 
Following the directive given to the TRIPS Council to expedite a solution for 
members with insufficient or lack of manufacturing infrastructures under 
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Paragraph 6 of the Doha Declaration,319 a temporary waiver of the obligations 
under Article 31(f) and (h) was negotiated by the WTO members meeting with 
the TRIPS Council, to allow the export of medicines under compulsory 
licensing.320 This Decision was endorsed by the General Council of the WTO of 
30 August, 2003, and is known as the ‘Implementation of Paragraph 6 of the 
Doha Declaration on the TRIPS Agreement and Public Health.’321 The 
chairperson of the WTO General Council also reiterated the public health 
purpose of the Decision to facilitate access to medicines.322  
 Although the Decision does not strictly create new TRIPS flexibilities, it contains 
essential waivers to allow countries to import generic medicines from another 
member country under a compulsory licence.323 The first waiver exempts the 
exporting country from the export restriction in Article 31(f), for the purposes of 
producing pharmaceutical products;324 the second waiver allows an exportation 
under compulsory licence to eligible members and developing or least-
developed countries in line with UN classification;325 and thirdly, the requirement 
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TRIPS Agreement and Public Health: A Solution to the Access to Essential Medicines Problem?’ (n 311) 83-84. 
324 Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health: Decision of the General 
Council of 30 August 2003 (General Council WT/L/540) Paragraph 2. 
325 ibid Paragraphs 2(ii) and 6. Essentially, only least-developed countries with little or no manufacturing capacities can take 
advantage of this Decision. Other countries wishing to utilise this system are required to prove that they lack the requisite 
manufacturing capacity. This proof is by indicating that they have no manufacturing capacity in the pharmaceutical sector or 
insufficient capacity to meet local needs and health crises. Peter K Yu, ‘Access to Medicines, BRICS Alliances, and Collective Action’ 
(2008) 34 American Journal of Law & Medicine 345, 346. 
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to pay adequate remuneration to the rights holder by the user (importing 
country) under Article 31(h) of TRIPS is waived.326 Only the exporting country is 
required to pay the requisite adequate remuneration to the patent holder.327 
Where the medicine is under a patent in the importing country, the importing 
country will authorise a compulsory licence to import the generic version of the 
patented medicines.328 However, where there is no patent protection for the 
medicine or for least-developed countries that may not have made provisions for 
the patent protection of pharmaceuticals under their domestic laws, the 
importing country need not issue a compulsory licence. Equally, the exporting 
country will issue a compulsory licence to export the patented medicines to the 
importing country.329 To utilise this Decision for export, the exporting country 
must make provisions for it under national laws, as patent law does not 
generally allow for production for export under compulsory licence.330 
After another protracted round of negotiation, the temporary waiver was 
amended to a permanent relief on the 6 December, 2005.331 The amendment 
contains a qualified condition on the grounds of approval by a two-thirds majority 
                                                          
326 Paragraph 3, Decision of the General Council of 30 August 2003.  
327 ibid  
328 ibid, Paragraph 2; Musungu and Oh (n 32) 69-70. 
329 Musungu and Oh (n 32) 69-70. The Decision sets out certain conditions for its use. First the eligible importing country is 
required to notify the WTO TRIPS Council of the intention to exercise the provisions of the Decision, and both countries must 
notify the Council of the grant of the compulsory licence to export and import the patented medicines. Paragraph 2, Decision of 
the General Council of 30 August 2003. If the importing country is not a LDC, there is an additional requirement to demonstrate 
the lack of or insufficient manufacturing capacity in a manner specified in the annex of the Decision. Both import and export 
countries are required to provide certain safeguard measures, such as anti-diversion mechanisms, to prevent the diversion or re-
importation of medicine under compulsory licence to unintended destinations and markets. This measure should be reasonable 
and proportionate to the ‘administrative capacities and to risk of trading diversion.’ Paragraph 4, Decision of the General Council 
of 30 August 2003; ibid. Correa writes extensively on the practical determination, implementation and interpretation of the 
provisions of the Decision. See Carlos Correa, Implementation of the WTO General Council Decision on Paragraph 6 of the Doha 
Declaration on the TRIPS Agreement and Public Health (WHO/EDM/PAR/2004.4, WHO Department of Essential Drugs and 
Medicines Policy (2004).See also Musungu and Oh (n 32) 69-70. 
330 Musungu and Oh (n 32) 69-70. 
331 ‘Amendment of the TRIPS Agreement, Decision of 6 December 2005’ (WTO doc. WT/L/64/, 8 December 2005); see also 
‘Intellectual Property: Members OK Amendment to Make Health Flexibility Permanent’ (WTO Press Releases Press/426, 6 
December 2005); Sisule Musungu, ‘Benchmarking Progress in Tackling the Challenges of Intellectual Property, and Access to 
Medicines in Developing Countries’ (2006) 84 Bulletin of the World Health Organization 367.  
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of WTO members.332 Once two-thirds have accepted the change, it will formally 
be incorporated into the TRIPS Agreement.333 The original deadline of 1 
December, 2007 was subsequently extended to 31 December, 2017.334  
Within the realm of the WTO, the Decision is another important means to 
promote public health objectives as the provisions can be interpreted and 
implemented to facilitate access to medicines for all.335 The success of this 
mechanism is exemplified in the first back-to-back export under a compulsory 
licensing by Canada to Rwanda under the Paragraph 6 Doha Declaration and 
WTO waiver to supply AIDS drugs.336 In 2007, Rwanda made a request to the 
WTO Council for TRIPS to import the HIV drug TriAvir (patented by 
GlaxoSmithKline) from Apotex, a Canadian company and that it would not 
enforce any patent right granted to the said drug.337 Having amended its law to 
allow export under compulsory licence,338 Canada also issued a compulsory 
licence to allow Apotex to utilise nine patents, including the manufacture and 
                                                          
332 Once two-thirds of members have formally accepted it, the amendment will take effect in those Members and will replace the 
2003 waiver for them. For each of the remaining members, the waiver will continue to apply until that Member accepts the 
amendment and it takes effect. 
Official website of the WTO, ‘WTO: Intellectual Property (TRIPS) and Public Health: Members Accepting Amendment’ (2016) 
available at 
<https://www.wto.org/english/tratop_e/trips_e/amendment_e.htm> accessed 23 January 2016. 
333 ibid 
334 By the General Council Decision of 30 November 2015 (document WT/L/965). 
335 Musungu and Oh (n 32) 72; Correa, Implementation of the WTO General Council Decision on Paragraph 6 of the Doha 
Declaration on the TRIPS Agreement and Public Health (n 329) 2, 12. 
336 Paige E Goodwin, ‘Right Idea, Wrong Result: Canada's Access to Medicines Regime’ (2008) 34(4) American Journal of Law & 
Medicine 567, 569.  
337 World Trade Organization, Notification under Paragraph 2(a) of the Decision of 30 August 2003 on the Implementation of 
Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health: Rwanda (Doc. IP/N/9/RWA/1, 19 July 2007). See 
more analysis at Holger Hestermeyer, ‘Canadian-Made Drugs for Rwanda: The First Application of the WTO Waiver on Patents and 
Medicines’ (2007) 11(28) The American Society of International Law. Available online at 
<https://www.asil.org/insights/volume/11/issue/28/canadian-made-drugs-rwanda-first-application-wto-waiver-patents-and> 
accessed 16 May 2016.  
338 See Sections 21.03- 21.2 of the Canada Patent Act (R.S.C., 1985, c. P-4).  
Canada had been at the forefront of efforts to facilitate access to pharmaceutical products to address public health problems 
afflicting many developing and least-developed countries through the use of the compulsory licensing mechanism to promote 
access to medicines. For example, Canada overrode Bayer’s patents on ciprofloxacin, and authorized generic manufacture for 
purposes of building a stockpile as protection against an attack of certain strains of anthrax.  
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export of TriAvir to Rwanda, and subsequently notified the TRIPS Council of the 
decision and licence.339 
Nigeria has not incorporated the provisions of the Council Decision of 2003 to 
allow exports under a compulsory licence into its national law. In contrast, some 
developing countries such as India have done so. India incorporated the 
provisions of the Decision into its amended Patents Act in 2005.340 Under 
Section 92A of the Patents Act,341 companies can apply for a compulsory 
licence to export patented medicines to countries that request it. An attempt has 
also been made to utilise this provision for the supply of medicines. In 2007, 
Natco Pharma Ltd filed an application to obtain a compulsory licence for two 
anti-cancer drugs, Sutent and Tarceva, under patent ownerships by Pfizer and 
Roche respectively.342 The application sought to manufacture and export the 
drugs to Nepal for public health reasons.343 Subsequently, the Indian patent 
office organised a hearing with the interested parties based on the application 
and objection to the hearing of the application by Natco.344 Citing the Doha 
Declaration, Natco argued for the right of developing countries to have access to 
affordable drugs. Natco contended that the generic versions of the drugs can be 
                                                          
339 World Trade Organization, Notification under Paragraph 2(c) of the Decision of 30 August 2003 on the Implementation of 
Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health: Canada (IP/N/10/CAN/1, 8 October 2007). 
340 Harshita Mathur, ‘Compulsory Licensing under Section 92A: Issues and Concerns’ (2008) 13 Journal of Intellectual Property 
Rights 464, 465. 
341 Section 92A(1) states that  
Compulsory licence shall be available for manufacture and export of patented pharmaceutical products to any 
country having insufficient or no manufacturing capacity in the pharmaceutical sector for the concerned product 
to address public health problems, provided compulsory licence has been granted by such country or such 
country has, by notification or otherwise, allowed importation of the patented pharmaceutical products from 
India. 
342 Mathur (n 340) 465; Yamane (n 282) 327. 
343 In Natco Pharm Ltd v Pfizer/Roche. Racha Bakhru, ‘India Grants First Compulsory Licence Under Patents Act’ 3 Intellectual 
Property Magazine 46, available at  
<www.rouse.com/media/126620/india_grants_first_compulsory_licence.pdf> accessed 17 September 2016; Yamane (n 282) 327.  
344 Yamane (n 282) 327; Shamnad Basheer, ‘Natco Vs Roche/Pfizer: Hearing on the Right to Hearing’ (Spicy IP, 2008) 
<http://spicyip.com/2008/03/natco-vs-rochepfizer-hearing-on-right.html> accessed 23 January 2016; Shamnad Basheer, ‘Natco Vs 
Pfizer: Joe Mathew Reports on Compulsory Licensing Decision’ (Spicy IP, 2008)  
<http://spicyip.com/2008/07/natco-vs-pfizer-joe-mathew-reports-on.html> accessed 23 January 2016. 
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manufactured at one-fifth the cost of the original patented drug.345 Although the 
application for compulsory licence was later withdrawn by Natco Pharma Ltd, 
the case could have laid a significant precedent that could clarify the procedural 
modalities for the grant and issue of compulsory licences to export drugs. India 
is one of the main suppliers of essential medicines to developing countries, thus 
a decision in this regard could open up practical avenues for the supply of 
affordable drugs by generic producers. Nonetheless, the application generated a 
positive outcome. Pfizer established a donor programme to deliver free patient 
assistance to two leading cancer hospitals in Nepal.346 
The progressive action by India to adopt the Decision is a positive policy action 
for enhancing the availability of and access to affordable medicines around the 
world that Nigeria could perhaps imitate, to assist other African countries and 
indeed, other developing countries around the world. Nigeria could also make 
provisions allowing the use of compulsory licenses from foreign sources.  
6.8.4 Compulsory Licensing Provisions in Nigeria 
Section 11 of the Nigerian PDA 1970 makes provision for the granting of 
compulsory licences for patented inventions.347 First Schedule, Part I to the PDA 
1970 enumerates the grounds for the procedures and grants of a compulsory 
licence by the court. According to Paragraph 1 of the First Schedule, any 
interested person can make an application for compulsory licensing on the 
following grounds, namely: 
a) the patented article is not being worked in Nigeria  
                                                          
345 Mathur (n 242) 465. 
346 Yamane (n 282) 327. 
347 Section 11 PDA states:  
The provisions of the First Schedule to this Act shall have effect in relation to compulsory licences and the use of 
patents for the service of government agencies.  
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b)  the degree of working the patented invention does not meet the reasonable 
demands for the product 
c) the working of the patented article is hindered or prevented by the 
importation of the patented invention 
d) and, refusal by the rights holder to licence the invention on reasonable terms 
has unduly and substantially affected industrial and commercial activities in 
Nigeria.348  
Under Paragraph 13, First Schedule, Part I to the PDA, a compulsory licence on 
the authority of the Minister is also made available for patented inventions that 
are essential for the defence or economy of Nigeria or public health and the 
licence can be satisfied through importation.349  
With regards to the current Nigerian PDA, an application for a compulsory 
licence can only be made after a period of four years from the date of filing an 
application for patent or three years after the patent grant.350 This period 
obviously limits the timeframe within which a licence can be sought. It may be 
argued that this period of undisturbed monopoly is to secure the interest of the 
patent holder to exploit the invention since obtaining marketing approval or 
                                                          
348 The text reads further that 
If an invention protected by a patent in Nigeria cannot be worked without infringing rights derived from a patent 
granted on an earlier application or benefiting from an earlier foreign priority, a compulsory licence may be 
granted to the patentee of the later patent to the extent necessary for the working of his invention if the 
invention-  
(a) Serves industrial purposes different from those served by the it, invention which is the subject of the earlier 
patent; or  
(b) constitutes substantial technical progress in relation to that last mentioned invention.  
349 First Schedule, Part I Paragraph 13 states:  
The Minister by order in the Federal Gazette may provide that, for certain patented products and processes (or 
for certain categories thereof) declared by the order to be of vital importance for the defence or the economy of 
Nigeria or for public health, compulsory licences may be granted before the expiration of the period mentioned 
in paragraph 1 above and may permit importation. 
350 First Schedule, Part I paragraph 1 states:  
Subject to this Part, at any time after the expiration of a period of four years after the filing of a patent application 
or three years after the grant of a patent, whichever period last expires, a person may apply to the Court for the 
grant of a compulsory licence […] 
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patent could take a period of about four to nine years.351 However, the TRIPS 
Agreement does not place an obligation on members to provide such a cooling 
period and there is no justifiable reason why a licence cannot be granted to 
provide affordable access to medicines when it is expedient to do so, for 
example, in health crises, until a minimum period of time has elapsed. Some 
countries, such as India, make an exception to a similar period in cases of 
national emergency, extreme emergency and public non-commercial use.352 In 
the absence of such provisions under Nigeria’s PDA, applicants have to wait 
until four years after filing date, or three years after the grant of a patent has 
elapsed to apply for a licence.  
Further, Paragraph 1, First Schedule to the PDA confers a duty on the court to 
grant, manage and maintain compulsory licences. Thus the PDA makes the 
court responsible for the grant of a compulsory licence.353 In Paragraph 5 (a), for 
example, the court assesses and must be satisfied that the patentee has failed 
to grant a voluntary licence before a compulsory licence is issued to an 
applicant. In Paragraph 8, the court decides whether to grant the licence and 
also determines the terms and royalties on which to grant the licence. It is also 
the duty of the court to cancel or vary the terms of the licence under Paragraph 
11. In light of the already overburdened Nigerian judicial system,354 this 
enormous duty on the court raises the issue of delay especially in situations of 
health crises and emergencies. These obvious gaps and issues limit the 
effectiveness of the flexibility as a mechanism for ameliorating health situations 
in Nigeria.  
                                                          
351 Gopakumar (n 133) 340. 
352 ibid 
353 Paragraph 5(b) offers guarantees satisfactory to the court to work the relevant invention sufficiently to remedy the deficiencies 
(or to satisfy the requirements) which gave rise to his application. 
354 Daily Editor, ‘Nigerian Judiciary Overburdened – CJN – News’ (Independent Newspapers Limited 2015) 
<http://dailyindependentnig.com/2015/02/nigerian-judiciary-overburdened-cjn/> accessed 22 February 2016. 
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Provisions of the NIPCOM Draft Bill 2007 have attempted to remedy this 
position. The First Schedule Part I of the Bill provides for similar grounds for the 
grant of a compulsory licence but further expands the scope and procedural 
requirements on which the licence may be granted. Apart from the reasonable 
non-working, insufficient working and refusal to provide a licence for commercial 
purpose, the Bill prescribes additional specific grounds for anti-competitive 
practices and abuse of intellectual property rights; the public interests; a public 
health national emergency; nutrition; and the development of vital sectors 
including ‘that of ensuring access to medicines for all.’355 Fundamentally, the bill 
ensures that compulsory licensing is made available for patented inventions that 
are either not available to the public at affordable prices, or are of insufficient 
quality or quantity.356 These extensive grounds for the granting of compulsory 
licences are indicative of the progressive steps taken by the Nigerian legislature 
to address the problems of access to medicines; however, the NIPCOM Bill falls 
short of other standard requirements, such as providing an option for export to 
other developing countries with insufficient manufacturing facilities as is the 
case in India.  
6.9 Public Non-commercial Use of Patents (Government Use) 
The public non-commercial or government use of a patented invention is 
another effective means, akin to compulsory licensing, that WTO members can 
employ to safeguard public health and curb monopoly abuses of patent rights. 
Article 31(b) of the TRIPS Agreement recognises the public and non-commercial 
use of patents ‘by or for the government’s without obtaining the voluntary licence 
                                                          
355 Part 1, First Schedule (1) (a)-(j). 
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of the patent holder.357 While the non-commercial use measure is similar to 
compulsory licensing, it is distinguishable by the nature and purpose of use.358 
The TRIPS Agreement stipulates that government use is restricted to ‘public 
non-commercial’ use, while compulsory licence extends to both private and 
commercial use of an invention, although the conditions set out in Article 31 
generally apply to both compulsory licence and government use.359  
The most significant advantage of this exception over compulsory licensing is 
that it permits skipping procedural requirements, such as the waiver of 
negotiations and prior voluntary consent; hence it makes enforcement simpler 
and faster. In some jurisdictions, some patent laws allow government authorities 
to make use of a patented invention without the need to issue a compulsory 
licence for this purpose.360 Thus, it is a useful flexibility for Nigeria and other 
WTO members to fast-track the availability and affordability of medicines, 
especially in emergency situations. Importantly, it is a measure for Nigeria to 
meet its human rights to health obligations, circumvent pharmaceutical patent 
holder’s rights and encourage the generic availability of essential and affordable 
medicines, particularly for women, in Nigeria. Its other advantages are very 
similar to compulsory licences mentioned above,361 i.e working a patent, 
promoting R&D, controlling anti-competition and the remedying of the adverse 
effect of patent monopolies, and facilitating access to cheaper medicines, 
amongst many others. While the government does not negotiate with the holder 
                                                          
357 Gopakumar (n 133) 341.  
358 Musungu and Cecilia Oh (n 32) 20-21. 
359 ibid 21. As per Article 31(b) TRIPS of the Agreement. 
360 Musungu and Oh (n 32) 35. 
361 See subsection 6.8 above. 
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on a voluntary basis to issue a licence in this regard, the patent holder is still 
entitled to compensation and may sue the government for remuneration. 362  
Current state practice in several countries indicates that the provision for 
government use is broadly defined to cover general public interest such as 
national security, nutrition, health and development of vital sectors.363 In the US 
for example, the provisions of 35 U.S.Code 28 comprehensively permits the 
government or its authorised person to use patents on the basis of virtually any 
public use.364 Using this non-commercial flexibility measure, the Malaysian 
government also approved the importation of generic ARV medicines on the 
authority of section 84 (1) of the Patents Act of 1983,365 which empowers the 
government or its authorised third party to exploit a patented invention in the 
event of a national emergency.366 It is worth noting that the use was resorted to 
after price negotiations between the government and the patent holders were 
unsuccessful.367 This government use authorisation in Malaysia is indicative of 
the alternative steps to be taken when licensing negotiations have resulted in a 
deadlock.  
An important question often raised with regards to government use is the scope 
and interpretation of the term ‘public non-commercial use’ since it is not 
precisely defined in the TRIPS Agreement.368 It appears that governments are 
given considerable latitude to determine the grounds and circumstances for 
such government use. Undoubtedly, therefore, domestic public consumption in 
                                                          
362 As per Article 31(b) of the TRIPS Agreement.  
363 For example, Section 65 of the Singapore Patent Act 1994 (No. 21 of 1994, as amended). 
364 Musungu and Oh (n 32) 36-37. 
365 As amended as of 15 May, 2002 
366 Sections 49-51 and 84 of the Patents Act No. 291 of 1983, as last amended in 2006, provides for the grant of compulsory licence 
and government use. ibid 
367 Zimbabwe’s declaration of a public health emergency to facilitate access to HIV/AIDS drugs is another example of government 
use.  
368 It appears that the exact scope and definition of ‘public non-commercial use’ is at the discretion of Members. 
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the interests of improving access to medicines will come under this provision. 
But for developing countries that rely on imported drugs due to a lack of or 
insufficient manufacturing capacity, this provision may not offer sufficient 
incentives for pharmaceutical manufacturers since the purpose of production is 
restricted to non-commercial usage, particularly in poor countries. In that case, 
the generic manufacturers may not earn economic incentives through 
commercial means. Another issue is whether the government can resell drugs 
through private channels after it has acquired the use for non-commercial 
purposes. Arguably, although not expressly stated, it appears that nothing in the 
agreement prevents governments from distributing drugs through private means 
to recover the cost of drug production and distribution to its people.369 
A significant achievement for public health has been recorded in the utilisation of 
the non-commercial TRIPS-compliant safeguard by government authorities. In 
Ghana, for instance, the Minister for Health declared an emergency situation on 
HIV/AIDS and issued a government use licence for the importation of generic 
HIV-AIDS medicines on October 26, 2005.370 Thailand also applied provisions of 
Article 31 of TRIPS Agreement to regulate prices of medicines.371 From 2006-
2007 the government has issued three licences for AIDS and cardiovascular 
drug treatments under the public non-commercial use provisions of the patent 
law.372  
 
                                                          
369 Gopakumar (n 133) 341. 
370 See the Notice at the Consumer Project on Technology (CPTech)’s official website  
<http://www.cptech.org/ip/health/cl/Ghana.png> accessed 28 January 2016; Nigerian Law Intellectual Property Watch (n 98). 
371 In 2006, the Department of Disease Control issued a compulsory licence for Efavirenz, an HIV/AIDS drug. On January 24, 2007, 
another licence was issued for Kaletra, another HIV/AIDS medication. The next day, a licence was issued for Plavix, a heart disease 
medication. Pier DeRoo, ‘Public Non-Commercial Use' Compulsory Licensing for Pharmaceutical Drugs in Government Health Care 
Programs’ (2011) 32 Michigan Journal of International Law 347, 359; Love (n 63) 
372 Kristina M Lybecker and Elisabeth Fowler, ‘Compulsory Licensing in Canada and Thailand: Comparing Regimes to Ensure 
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6.9.1 Government Use of Patent in Nigeria 
For the government’s authorisation and use of patents in Nigeria, the relevant 
provision is found in Part II of the First Schedule to the PDA 1970. Paragraph 15 
of the Schedule allows the use of patented articles or inventions for the service 
of government agencies.373 Under Paragraph 15, ‘any’ minister is conferred the 
discretionary powers to take over, and authorise a third party or his agent to 
use, patented inventions in the interests of the public.374 This provision broadly 
allows the government to use, sell, purchase or make any patented invention or 
grant a licence to a third party, after which the patent holder is notified of this 
action.375 The determination of the public interest is at the discretion of the 
Minister or his/her authority who can exercise this flexibility option to expedite 
access to affordable medicines. Moreover, Paragraph 23, Part II of the First 
Schedule, to the PDA explicitly clarifies that ‘articles’ includes-(a) any drugs or 
pharmaceutical preparations, substances or materials.’ Paragraph 20, Part II of 
the First Schedule further provides a list of possible situations where the 
government might use the patented article in the event of an emergency. They 
include, among others: use for ‘the maintenance of supplies and services 
essential to the life of the community’; or ‘for securing a sufficiency of supplies 
and services essential to the well-being of the community.’376 It appears that, on 
                                                          
373 First Schedule, Part II Paragraph 15 reads: 
Notwithstanding anything in this Act, where a Minister is satisfied that it is in the public interest to do so, he may 
authorise any person to purchase, make, exercise or vend any patented article or invention for the service of a 
Government agency in the Federal Republic. 
374 According to paragraph 16,  
     The authority of a Minister under paragraph 15 of this Schedule may be given-  
     (a) before or after the relevant patent has been granted;  
     (b) before or after the doing of the acts in respect of which the authority is given; and  
     (c) to any person whether or not he is authorised directly or indirectly by the patentee to   
      make, use, exercise or vend the relevant article or invention. 
375 First Schedule, Part II, Paragraph 18. 
376 Others are: d) the promotion of productivity of industry, commerce and agriculture; (e) fostering and directing exports and 
reducing imports; or (f) ensuring that the whole resources of the community are available for use, and are used in a manner best 
calculated to serve the interests of the community. First Schedule, Part II, Paragraph 20, 
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the authority of Paragraph 15 of the First Schedule, the Minister can extend the 
scope of these circumstances.  
Since medicinal supplies, as discussed in Chapter III, are essential to the rights 
to health and life377 the non-commercial use flexibility can be utilised as an 
effective means to secure access to essential and cheaper medicines for 
women in Nigeria. A proactive use of this flexibility by the state is exemplified in 
Mozambique. The Mozambique health authorities in 2004, relied on its domestic 
government use provision to declare a health emergency and issue a 
compulsory licensing to Pharco Mozambique Lda for the local production of 
HIV/AIDS drugs to increase the availability and access to the medicines.378 An 
issue with the government use provision in Nigeria, however, is that the 
authorising power to exercise this use is vested in any government Minister. 
This provision may give rise to a great degree of uncertainty and unnecessary 
bureaucratic challenges regarding the actual government agency to execute this 
provision.  
Paragraph 15, Part II of the First Schedule to the NIPCOM Draft Bill 2008 
provides the basis for government use of patents. Importantly, the term ‘public 
interest’ is explicitly defined in Paragraph 15 to include: ‘national security, 
nutrition, health, environmental protection or the development of other vital 
sectors of the national economy […].’ Notably, the power to authorise use by the 
government is vested in one Minister (the Minister responsible for intellectual 
                                                          
377 See the argument in subsections 4.4 and 4.4.1 of Chapter IV. 
378 In April 5, 2004, Mozambique's Deputy Minister of Industry and Commerce issued a compulsory licence for Pharco 
Mozambique Lda, a local producer to override the patent rights and to manufacture lamivudine, stavudine and nevirapine as a 
fixed-dose combination. Royalties were not to exceed two percent of sales. (Article 70 of the Industrial Policy Code (Decree No 
18/99 of 4 May) was amended for this purpose.) The Consumer Project on Technology (CPTech) ‘Compulsory Licenses’  
 <http://www.cptech.org/ip/health/cl/recent-examples.html#Mozambique> accessed 28 January 2016.  
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property). This could curb unnecessary bureaucratic challenges in the issuance 
and use of the flexibility.  
6.9.3.4 Are Compulsory Licensing and Government Use the Most 
Significant Flexibility Options for Enhancing Access to Medicines in 
Nigeria? 
Activism by civil societies NGO’s, as well as scholarly analysis and literature on 
the flexibilities seem to focus mostly on compulsory licensing or non-commercial 
use by governments, as a means to ease the tension between patent 
monopolies and health.379 Clearly, compulsory licensing and non-commercial 
use are particularly favoured as a means of addressing health objectives, 
probably because it is adequate as a short-term measure of making drugs more 
affordable to consumers, working a patent and controlling abuses of patent 
rights.380 The question that needs to be asked is whether compulsory licence 
and government use are the only ideal solutions for the long-term goal of 
securing the objectives of the right to health by ensuring access to medicines. In 
other words, while the high price of patented pharmaceutical drugs dominates 
the argument for access to medicines, assuming the high cost of drugs is no 
longer an issue associated with patent monopoly, would the problems 
associated with patents as possible barriers to accessing medicines still 
constitute a challenge? The answer is, yes, because the problems of access to 
medicines extend beyond pricing to include lack of research into neglected 
diseases; re-engineering of old patents for new patents and, in some cases, 
                                                          
379 Lissett Ferreira, ‘Access to Affordable HIV/AIDS Drugs: The Human Rights Obligations of Multinational Pharmaceutical 
Corporations’ (2002) 71(3) Fordham Law Review 1138. 
380 Tenu Avafia, Jonathan Berger and Trudi Hartzenberg, ‘The Ability of Select Sub-Saharan African Countries to Utilise TRIPS 
Flexibilities and Competition Law to Ensure a Sustainable Supply of Essential Medicines: A Study of Producing and Importing 
Countries’ (ICTSD, UNCTAD and Tralac 2006).  
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impediments to follow-on research, all of which can impinge on the availability 
of, and access to, medicines. 
Undoubtedly, the compulsory licensing safeguard is important and can be 
significant to expediting access to cheaper medicines in Nigeria. It is argued, 
however, that Nigeria should not concentrate only on issuing compulsory 
licensing as the dominant means of ensuring the availability and access to 
affordable medicines. In the event of national emergencies, health crises or 
instances where patent encroaches on access to medicines, a compulsory 
licence is a flexibility best suited to facilitate quicker access to inexpensive drugs 
and control anti-competitive practices. However, a broader solution for access to 
medicines should extend beyond just making medicines available at a cheaper 
price, working patents or controlling anti-competitive practices. Without a doubt, 
the broad use of a compulsory licence for all the aforementioned purposes will 
enhance better access to medicines. However, considering the fact that 
compulsory licensing/government use is an exception rather than the rule, and 
its grant is subject to conditions, Nigeria is better off concentrating on other 
means of enhancing overall health objectives through the use of the flexibilities. 
Rather than focusing on a small fraction of the intended recipients in the event 
of compulsory licences, Nigeria should ensure sustainable access to medicines 
by exploiting other flexibilities such as the exclusion of patentability; limits on 
data exclusivity; and early working and experimental use exceptions, which 
have greater implications for R&D to boost the availability of medicines in the 
longer term. 
That said, it is imperative that the Nigerian government and appropriate 
authorities broadly use and interpret the compulsory licence and non-
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commercial government use provisions in compliance with the country’s’ human 
rights obligations to fulfil and promote the right to health, and facilitate access to 
medicines.  
In closing, Nigeria is better off utilising the TRIPS-compliant flexibilities in a 
manner that will ensure long-term success, such as making sure the local 
pharmaceutical industry is well developed to meet the health demands of the 
population. When other flexibilities are utilised in ways that can develop local 
pharmaceutical capacity, the benefits to be derived from compulsory licensing 
through generic sources are correspondingly enhanced.  
In this light, the following flexibility option can be explored as a more sustainable 
and lasting measure to encourage R&D for the availability and accessibility of 
pharmaceuticals in Nigeria.  
6.10 Exploring the Early Working Exceptions and Flexibility Limiting 
Patent Rights for Pharmaceuticals Research and Experimental Use, to 
Encourage Access to Medicines in Nigeria  
Generally, the rights conferred on patent holders by Article 28(1) of the TRIPS 
Agreement are not absolute in the sense that the state can limit the rights in the 
public interest.381 Article 30 of the TRIPS Agreement also provides for the 
limitation of the patent owner’s rights, which can be utilised by members to 
promote access to affordable generic medicines, and permit the use of patented 
inventions for research and experimental purposes without the consent of the 
right holder. Article 30 states:  
Members may provide limited exceptions to the exclusive rights conferred by a 
patent, provided that such exceptions do not unreasonably conflict with a normal 
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exploitation of the patent and do not unreasonably prejudice the legitimate interests 
of the patent owner, taking account of the legitimate interests of third parties. 
A plain reading of this test suggests that Members are given considerable 
discretion within specified conditions to interfere with and limit the exclusive 
rights conferred by a patent. From an access to medicines and human right 
perspective, Nigeria can rely on this provision to limit the effect of a patent’s 
monopoly on access and facilitate the availability of and access to medicines 
within the stated conditions in TRIPS. 
Although the TRIPS Agreement does not define the nature, scope and extent of 
the ‘limited exception,’ Article 30 makes it clear that the exception is subject to a 
three-way test: the limitation a) must not unreasonably restrain the normal 
enjoyment of the patent right; b) must not unreasonably prejudice the legal 
rights of patentees; and c) must take into consideration the legitimate interests 
of third parties.382 Again, the scope and wording of conditions for the exceptions 
in Article 30 appear to be vague and the TRIPS Agreement does not elaborate 
on how these conditions can be satisfied.383 Nonetheless, it has been argued 
that they are independent conditions, yet each must relate to the other.384 This 
interpretation of the conditions was adopted and expounded by the WTO Panel 
in the Canada-Patent Protection of Pharmaceutical Products (Canada-Patent 
Dispute) dispute settlement case, although the Panel unduly narrowed down the 
scope of the Article.385  
                                                          
382 Musungu and Oh (n 32) 34. 
383 Holger Hestermeyer, Human Rights and the WTO: The Case of Patents and Access to Medicines (Oxford University Press 2007) 
235.  
384 ibid 
385 See Canada - Patent Protection of Pharmaceutical Products - Complaint by the European Communities and their Member States: 
Report of the Panel (WT/DS114IR, March 17 2000) (Hereafter the Canada-Patent Dispute). Robert Howse, ‘The Canadian Generic 
Medicines Panel: A Dangerous Precedent in Dangerous Times’ (2005) 3(4) The Journal of World Intellectual Property 493, 496-507. 
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In this case, the EU instituted a complaint against Canada to challenge the 
legality of some provisions of Canada’s Patent Act such as Section 55(2)(1), 
relating to the development and submission of information for marketing 
approval of pharmaceutical products without the consent of the patentee, as a 
breach of Article 28(1) TRIPS.386 The EU also alleged that Section 55(2)(2) and 
55(2)(3) of the Canadian Patent Act (together with the Manufacturing and 
Storage of Patented Medicines Regulations), which allows the testing of 
medicines six months before expiration of the patent and makes provision for 
production and stockpiling of the generic version for immediate release after 
patent expiration without the owner’s consent, was also in violation of the patent 
holder’s right under Article 28(1) and Article 33 of the TRIPS Agreement.387 
Canada counter-argued that its patent laws duly conformed to its obligation 
under the TRIPS Agreement as each of the provisions is in accordance with the 
‘limited exceptions’ to the patent holder’s rights within the meaning of Article 30 
of the TRIPS.388 Among other things, the dispute panel was invited to determine 
the scope and extent of the ‘limited exceptions to the exclusive rights of a 
patent’ and whether a limitation or violation of the patent holder’s rights can be 
justified under Article 30.389  
In its decision, the panel elaborated on the objective, scope and meaning of the 
provision in Article 30 of the TRIPS Agreement. The Dispute Panel, in clarifying 
the three-fold criteria and scope of Article 30390 stated that ‘[t]he three conditions 
                                                          
386 Paragraph 3.1, Canada-Patent Dispute. 
387 ibid 
388 Paragraph 3.2, Canada-Patent Dispute. 
389 Argument by the EU in paragraph 4.6 Canada-Patent Dispute. In sum, the Panel found that the regulatory review exception of 
Section 55.2(1) is a ‘limited exception’ within the meaning of Article 30 of the TRIPS Agreement. 
390 The panel clarified the criteria as follows: 
(1) the exception must be ‘limited’;  
(2) the exception must not ‘unreasonably conflict with normal exploitation of the patent’;  
(3) the exception must not ‘unreasonably prejudice the legitimate interests of the patent owner, taking 
account of the legitimate interests of third parties.’  
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are cumulative, each being a separate and independent requirement that must 
be satisfied. Failure to comply with any one of the three conditions results in the 
Article 30 exception being disallowed.’391 The panel defined the terms ‘limited’ 
and ‘exception’ separately and took the position that ‘limited exception’ within 
the context of Article 30 connotes ‘a narrow exception — one which makes only 
a small diminution of the rights in question’392 and it is measured by the extent to 
which the patentee’s rights have been curtailed.393 On this basis, the Panel 
found that the stockpiling provision for generic production was not justifiable 
within the permissible limitations envisaged by Article 30 of TRIPS.394 
Accordingly, there was no limit to the quantity of production for the purposes of 
stockpiling, thus it constituted ‘a curtailment of the exclusionary rights granted to 
the patent holders.’395  
The panel, however, found that Canada’s regulatory review proviso was justified 
under the limited exception condition in Article 30 of TRIPS. The panel justified 
this limitation on the grounds that the scope of the curtailment of the patentee’s 
rights was confined to the conduct necessary to satisfy the requirements of the 
regulatory approval process, thus it will not hamper the rights holders as it will 
be ‘small and narrowly bonded.’396 Accordingly, since the testing requirement is 
for the purposes of obtaining government’s regulatory approval, as long as it 
was for that reason and not commercial purposes, it was permissible under 
Article 30.397 In so doing, the panel gave authority for the Canadian government 
to allow the generic producers to conduct clinical trials and tests on a patented 
                                                                                                                                                                          
Paragraph 7.20. 
391 Paragraph 7.20, Canada-Patent Dispute. 
392 Paragraph 7.30, Canada-Patent Dispute. 
393 Paragraph 7.32, Canada-Patent Dispute. 
394 Paragraph 7.36, Canada-Patent Dispute. 
395 Paragraph 7.34-7.36, Canada-Patent Dispute. 
396 Paragraph 7.45, Canada-Patent Dispute. 
397 Paragraph 7.45, Canada-Patent Dispute. 
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product as a reasonable precondition for securing regulatory approval of a 
generic substitute for use upon determination of the patent production of drugs, 
before the expiration of the patent.  
Nevertheless, the panel left many of questions open. For instance, although the 
problems of accessing affordable essential medicines vis-à-vis patent rights 
were raised several times in the submission of parties in the dispute, the panel 
did not comprehensively elaborate on the use of the ‘limited exception’ in Article 
30 of TRIPS within the specific context of access to affordable medicines.398 
Thus the opportunity to create a precedent for the use of Article 30 as a 
measure to facilitate access to affordable drug therapies by limiting the rights of 
the patent holder was lost.399  
Additionally, it also appears that the ‘limited’ condition, as elaborated by the 
panel, further narrowed down the scope of the exclusion of rights in Article 30 of 
TRIPS. The panel adopted a narrow view by stating that the word ‘exception’ in 
Article 30 implies a limit on the extent of the derogation, which is further 
narrowed down by the term ‘limited’.400 Therefore, the limitation in Article 30 ‘is 
                                                          
398 For example, Canada argued that the legitimate interests of third parties under Article 30 of TRIPS took into account the need 
to ‘[…] protect public health - a value recognized in Article 8.1 of the TRIPS Agreement - through promoting access to cost-effective 
generic medicines following patent expiry and, in this connection, they took into account the legitimate interests of individuals, 
private insurers and public sector entities that financed health care in maintaining access to affordable medicines.’ 
Paragraph 4.0 Canada-Patent Dispute. 
399 The panel, however, mentioned the importance of granting exclusive patent rights to holders when considering what ‘‘normal 
exploitation’ signifies thus:  
The normal practice of exploitation by patent owners, as with owners of any other intellectual property right, is 
to exclude all forms of competition that could detract significantly from the economic returns anticipated from a 
patent's grant of market exclusivity. The specific forms of patent exploitation are not static, of course, for to be 
effective exploitation must adapt to changing forms of competition due to technological development and the 
evolution of marketing practices. Protection of all normal exploitation practices is a key element of the policy 
reflected in all patent laws. Patent laws establish a carefully defined period of market exclusivity as an 
inducement to innovation, and the policy of those laws cannot be achieved unless patent owners are permitted 
to take effective advantage of that inducement once it has been defined. 
 Paragraph 7.55 Canada-Patent Dispute. 
400 The panel provided an interpretation of what “limited” means in Article 30 thus:  
The word "exception" by itself connotes a limited derogation, one that does not undercut the body of rules from 
which it is made. When a treaty uses the term "limited exception", the word "limited" must be given a meaning 
separate from the limitation implicit in the word "exception" itself. The term "limited exception" must therefore 
be read to connote a narrow exception - one which makes only a small diminution of the rights in question.  
417 
 
417 
 
to be determined by reference to the limitation of the exclusive rights granted 
under Article 28 of the TRIPS Agreement rather than by the economic impact of 
the exception, which is examined under the other conditions of Article 30 of the 
TRIPS Agreement.’ Scholarly analysis of this decision indicates disappointment 
that the panel unnecessarily whittled down the permissible scope of the 
exception for health and access to medicines and limited the discretion given to 
members to define their national objectives.401 For example, an interpretation of 
the narrow scope of the panel’s decision will not permit the use of the exception 
to produce and stockpile a large quantity of medicines for distribution to a large 
part of the population in the interest of public health. Hestermeyer rightly argues 
that the panel’s narrow interpretation ‘would not permit an exception under 
Article 30 that could meaningfully enhance access to medicine in the developing 
world, such as a governmental non-commercial use permitting the Government 
to produce the medicine and to provide it to large parts of the population.’402  
The panel should have considered this limited exception in light of the general 
principles and objectives of the TRIPS Agreement as prescribed in Articles 7 
and 8, instead of relying on the literal definitions of ‘limited’ and ‘exception’ to 
determine the extent to which the state could derogate the patentee’s rights.403 
The TRIPS Agreement is more than an instrument that confers rights to the 
patent holder; it is a regulator of rights and obligations of patent holders and 
users. It can be said that the flexibility provisions of Article 30 TRIPS Agreement 
                                                                                                                                                                          
Paragraph 7.30 Canada-Patent Dispute.  
401 Hestermeyer, Human Rights and the WTO: The Case of Patents and Access to Medicines (n 383) 235; Howse (n 385) 496-507; 
Denis Borges Barbosa, Margaret Chon and Andres Moncayo von Hase, ‘Slouching Towards Development in International 
Intellectual Property’ (2007) 1 Michigan State Law Review 71, 113; Peter K Yu, ‘The Objectives and Principles of the TRIPS 
Agreement’ (2009) 46 Houston Law Review, 5. 
402 Hestermeyer, Human Rights and the WTO: The Case of Patents and Access to Medicines (n 383) 239. 
403 According to Hestermeyer, ‘the panel's reliance on the narrow scope of exceptions is in direct contradiction both to a 
statement by the Appellate Body that the mere characterization as an exception does not in and of itself justify a narrower 
interpretation of a provision and to the principle of in dubio mitius.’ ibid 234. 
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corresponds with the objectives and principles in Articles 7 and 8 of the 
Agreement by ensuring that the protection of private patent rights is balanced 
against the public interest.404 It is argued that one of the purposes of Article 30 is 
to give the state a greater flexibility to limit the patent owner’s rights, when it is 
expedient to do so to achieve the balance of rights and obligation between 
‘producers and users of technological knowledge and in a manner conducive to 
social and economic welfare, and to a balance of rights and obligations.’405 It is 
worth noting that the panel in the Canada-Patent Dispute case stated that the 
aim of Article 30 is not to ‘renegotiate the basic balance of the Agreement.’406 
However, it is argued that states can determine this ‘balance’ by granting patent 
rights and also making exemptions to allow the broader use of a patented 
invention for public policy and health purposes under Article 30 of TRIPS.407 
Moreover, the Doha Declaration in Paragraph 5(a) gives countries latitude in the 
interpretation and implementation of the TRIPS Agreement in light of its 
objectives and principles; thus countries can reasonably determine the ambit of 
the exceptions in Article 30. 408 
Suffice to say that the panel’s decision in allowing the testing process for 
regulatory approval, and thus justifying the early working (Bolar) exception in 
                                                          
404 See the argument in subsection 2.5.4 of Chapter II and subsection 5.4 of Chapter V. 
405 See paragraph 7.23, Canada-Patent Dispute.  
Canada held the view that Articles 7 and 8 should be read together with Article 30 of the TRIPS Agreement since ‘one of the key 
goals of the TRIPS Agreement was a balance between the intellectual property rights created by the Agreement and other 
important socio-economic policies of WTO Member governments.’ 
406 Paragraph 7.26 Canada-Patent Dispute. The Panel attempted to draw a compromise between Canada and the EU’s arguments 
by allowing certain adjustments under Article 30 but restrained any purported ‘renegotiation of the basic balance of the 
Agreement’ enshrined in the principles and objectives of TRIPS Agreement. Yu, ‘The Objectives and Principles of the TRIPS 
Agreement’ (n 401) 5. 
407 Correa, Implications of the DOHA Declaration on the TRIPS Agreement and Public Health (n 77) 29. It is important to point out 
that the legal interpretation of WTO law by the WTO Panel or its Appellant Body does not bind all Members of WTO and it is not a 
binding stare decisis for disputes between different parties, even if it is on the same issue and question of law. WTO, 'Disputes - 
Dispute Settlement CBT - Legal Effect of Panel and Appellate Body Reports and DSB Recommendations and Rulings - Legal Status 
of Adopted/Unadopted Reports in Other Disputes - Page 1' (Wto.org) 
 Available at <https://www.wto.org/english/tratop_e/dispu_e/disp_settlement_cbt_e/c7s2p1_e.htm> accessed 10 June 2016.  
408 The historical negotiation of Article 30 of the TRIPS Agreement and possible interpretations of the text are extensively analysed 
in the UNCTAD and ICTSD (n 69). 
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Canada’s law as compatible with the provisions of Article 30 of TRIPS, confirms 
the utility of the provisions as a flexibility measure to ensure access to affordable 
medicines, particularly generic pharmaceuticals.409 
On the authority of Article 30 of TRIPS, Nigeria can promote its public health 
objectives including the facilitation of scientific research, and dissemination of 
knowledge and education, by limiting the rights of patent holders, to ensure that 
incremental R&D is not impeded by patent protection.410 The state can also 
make exceptions to patent holder’s rights for public health purposes, including 
the promotion of technology transfer and the prevention of anti-competition 
practices. This Nigeria can do by allowing generic producers or third party 
researchers to access and use the patented invention within the specific 
exemptions that the state deems fit to specify (within the confines of the 
conditions in the Article). Since a cardinal aim of a patent as per Article 7 TRIPS 
is to contribute to promoting technological innovation for social welfare which will 
include access to innovative medicines, and foster pharmaceutical R&D and 
dissemination of knowledge, the Article 30 exception can be invoked to 
complement this objective.  
There is currently no internationally agreed list of exceptions to patent rights 
based on Article 30 of TRIPS. However, it is generally accepted that states can 
rely on Article 30 of TRIPS to adopt some exceptions to patents rights, such as 
providing for early working (Bolar-type) exemptions,411 experimental and 
                                                          
409 Chapter III in subsection 3.7.1.1 demonstrated that generic drugs are generally much less expensive than the patented versions 
and competition from several generic producers can deliver greater access benefits to consumers. As soon as a medicine’s 
patented term expires, generic producers can compete and also reproduce the drug, which can lead to a significant price drop. US 
Federal Trade Commission, Generic Drug Entry Prior to Patent Expiration: An FTC Study (DIANE publishing) 9. 
410 Musungu and Oh (n 32) 55. 
411 Also called the Bolar exception after the case of Roche Products, Inc. v Bolar Pharmaceutical Col., Inc. 733 F.2d 858 (Fed. Cir. 
1984). In that case, Roche an MNC had a patent for the drug flurazepam. A year before expiration of the patent term, Bolar 
Pharmaceuticals, a generic company, began experimentation of the drug. Thereafter, Bolar commenced a process to produce the 
drug by submitting an FDA application for approval. Roche instituted a suit for infringement. Bolar argued that experimental use 
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research use purposes, and research testing of a drug before the expiration of 
the patent term under national law.412  
6.10.1 Early Working (Bolar-Type) Exemptions 
The so-called Bolar-type exemption,413 or early working exclusion, allows 
generic medicines producers to make a request to the appropriate health 
registration or regulatory authorities to undertake testing or marketing approval 
of the generic versions of a product before the patent expiration.414 This 
flexibility option is relevant to Nigeria’s obligation towards its women’s right to 
health by improving access to medicines. For health purposes, this flexibility has 
the advantage of securing access to affordable medicines, and facilitating 
competition amongst many drug producers almost as soon as the patent term 
expires.415 This exemption is also important to expediting the effectiveness of 
compulsory licences since generic producers can test and register their products 
for the purposes of satisfying a compulsory licence.416 Therefore, when a 
domestic law makes provision for the early working of a patent for this purpose, 
a generic producer can commence pharmaceutical testing or clinical 
experimentation to obtain regulatory approval without seeking the consent of the 
                                                                                                                                                                          
should not be considered an infringement moreover; the production was for sale at the end of the patent. The US Court of 
Appeals for the Federal Circuit rejected Bolar’s contention. The court held that the experimental use was for commercial and 
business purposes because Bolar intended to sell its generic product in competition with Roche’s Dalmane after the expiration of 
the patent term, thus the experimental use exception did not apply. Thus the court denied Bolar’s right to develop the drug and 
seek regulatory approval. Thereafter, the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Watxman 
Act) overruled this decision by allowing the use of patented products for regulatory purposes before the expiration of the patent 
to facilitate swift generic entry. Sudip Chaudhuri, The WTO and India's Pharmaceuticals Industry: Patent Protection, TRIPS, And 
Developing Countries (n 282) 76-78. 
412 Musungu, Villanueva and Blasetti (n 23) 17.  
413 Also called the safe harbour exemption in some countries. 
414 Sebastian Haunss, Conflicts In the Knowledge Society: The Contentious Politics of Intellectual Property (Cambridge University 
Press 2013) 148; Peter Groves, A Dictionary of Intellectual Property Law (Edward Elgar Publishing 2011) 33; Waelde and others (n 
219) 491; Carlos Correa, Integrating Public Health Concerns into Patent Legislation in Developing Countries (South Centre 2000) 68-
69. 
415 Kenneth C Shadlen, ‘The Politics of Patents and Drugs in Brazil and Mexico: The Industrial Bases of Health Policies’ in Kenneth C 
Shadlen and others (eds), Intellectual Property, Pharmaceuticals and Public Health: Access to Drugs in Developing Countries 
(Edward Elgar Publishing 2011) 185; Carlos Correa, Integrating Public Health Concerns into Patent Legislation in Developing 
Countries (n 414) 69. 
416 Sisule F Musungu, ‘The TRIPS Agreement and Public Health’ in Abdulqawi Yusuf and Carlos María Correa (eds), Intellectual 
Property and International Trade: The TRIPS Agreement (Kluwer Law International 2008) 435. 
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patentee.417 The WTO panel decision in the Canada-EU Patent case is relevant 
as a useful test case for Nigeria to adopt in interpreting the Bolar-type exception 
in accordance with Article 30 flexibility to promote the generic availability of 
medicines during the subsistence of patent, for use immediately after the patent 
expiration. 
The Bolar-type exemption appears to be much more popular in the national laws 
of developed countries than it is in developing countries.418 For instance, the US 
in U.S.Code 271(e)(i) (or Hatch-Waxman exemption) exempts from infringement 
certain acts relating to the research, development and testing of drugs and 
medicinal products for purposes of Food and Drugs Administration (FDA) 
regulatory approval.419 One purpose of this provision, among others, is to 
establish a framework to enable generic competitors to enter the market after 
patent expiration and to encourage research activities.420 The scope of this 
exemption was considered by the US Courts in Merck KGaA v Integra 
Lifesciences I, Ltd.421 The US Supreme Court held that the exemption ‘provides 
a wide berth for the use of patented drugs in activities related to the federal 
regulatory process.’422 The court further clarified that ‘reasonably related’ in the 
text of U.S.Code § 271(e)(i)423 and the scope of the provision extends to all 
reasonable uses of patented compounds in preclinical studies for the purpose of 
                                                          
417 Carlos Correa, Integrating Public Health Concerns into Patent Legislation in Developing Countries (n 414) 68-69. 
418 Musungu and Oh (n 32) 56-57.  
419 Peter Groves, A Dictionary of Intellectual Property Law (Edward Elgar Publishing 2011) 33. 
420 Biswajit Dhar and KM Gopakuma, ‘The Case of the Generic Industry In India’ in Ricardo Melendez-Ortiz and Pedro Roffe (eds), 
Intellectual Property and Sustainable Development: Development Agendas in a Changing World (Edward Elgar Publishing 2009) 
110. 
421 545 U.S. 193 (2005).  
422 ibid paragraph 202.  
423 In 35 U.S.C. § 271(e)(1), 
[i]t shall not be an act of infringement to make, use, offer to sell, or sell within the United States or import into 
the United States a patented invention (other than a new animal drug or veterinary biological product […] which 
is primarily manufactured using recombinant DNA, recombinant RNA, hybridoma technology, or other processes 
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and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs or 
veterinary biological products. 
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development or submission of information for regulatory approval under the 
FDA, even when it is subsequently not submitted to the FDA.424 Fundamentally, 
the court broadly interpreted the provision to lay precedence for the use of a 
patented invention by a third party to conduct testing and trials when the patent 
still subsists. This indicates a positive effect for the manufacture, use and 
access to affordable drugs.  
6.10.2 Experimental and Research Use Exemption 
It is generally argued that patent protection plays an important part in 
encouraging pharmaceutical innovation.425 Chapter III illustrates,426 however, 
that a patent monopoly of technological innovations could be damaging to 
technological progress, because generally, no one can use a patented idea 
without the permission of the patentee as part of the exclusive rights under 28 of 
the TRIPS Agreement.427  
Another way to ensure that the monopoly rights conferred by patents do not 
endanger further creativity and innovation in Nigeria is to make exemptions for 
the use of patented invention for research purposes.428 Hence, despite the rights 
conferred by patents, the experimental and research use exception allows third 
parties and the government to leverage on the invention for scientific and 
pharmaceutical research and academic purposes without infringing the 
patentee’s rights. This exemption is particularly relevant for research-based 
institutions, universities, and scientific/pharmaceutical companies and even 
                                                          
424 The court added that there must be a ‘reasonable basis for believing that a patented compound may work, through a particular 
biological process, to produce a particular physiological effect.’ 545 U.S. 202-206. 
425 Burcu Kiliç, Boosting Pharmaceutical Innovation in the Post-TRIPS Era: Real-Life Lessons for the Developing World (Edward Elgar 
2014) 40. 
426 See subsection 3.6.2.1 of Chapter III. 
427 Edwin Cameron and Jonathan Berger, ‘Public Health: Principle, Politics and Paradox’ in Proceedings of the British Academy, 
Volume 131, 2004 Lectures (OUP and British Academy 2004) 335-334.  
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traditional medicines practitioners/native healers wishing to utilise the patented 
idea to develop new inventions, test or build new knowledge and improve the 
existing innovation (or drug) which can be beneficial to the availability of 
essential medicines.429 Exceptions for research purposes could commonly apply 
to test, trials, procedures and all aspects of experimentation and research use of 
the patented invention. Generally, these exemptions do not cover instances 
where the main purpose of research is for commercialisation; however, if the 
research activity aims to improve or build on a patented invention for 
commercialisation, some laws may exempt such activities from patent 
infringements.430  
Studies indicate that most countries have enacted specific domestic legislation 
for research and experimental use of patents.431 India, for example, specifically 
provides such exceptions for scientific and experimental use.432 Within Africa, 
some states, including the Organisation Africaine de la Propriété Intellectuelle 
(OAPI) Members, in accordance with their obligations under the Bangui 
Agreement, have enacted this exception into their domestic laws.433  
Nonetheless, it is observed that not many developing countries have made the 
necessary legislative adjustment to accommodate the full use of the early 
                                                          
429 Evans Misati and Kiyoshi Adachi, ‘The Research and Experimentation Exceptions in Patent Law: Jurisdictional Variations and the 
WIPO Development Agenda’ (2010) 1 UNCTAD- ICTSD Project on IPRs and Sustainable Development 2.  
430 UNCTAD and ICTSD (n 69) 437. For example, under Article 27(b) of the Community Patent Convention 1975, if an activity is 
done for experimental use with the purpose of improving or leveraging on an invention, even if it is done for commercial 
purposes, such acts are exempted from infringement cases. The Research or Experimental Use Exception: A Comparative Analysis: 
Prepared for Health Canada (Centre for Intellectual Property Policy 2004) 5. 
431 Sisule Musungu and Cecilia Oh’s study demonstrated that derogation of patent rights for research and experimental purposes 
has gained popularity in the laws of the Latin American, Asian and Caribbean countries. The report however recorded lower 
provisions in African countries at 59%. Musungu and Oh (n 32) 56.  
432 The India Patents Act of 1970 Section 107A reads: 
Certain acts not to be considered as infringement—For the purposes of this Act, (a) any act of making, 
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country other than India, that regulates the manufacture, construction, use, sale or import of any product. 
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working and experimental or scientific use exception under domestic 
legislation.434 What does this say about the zeal to promote cheaper access to 
medicine through generic means in the countries that have not made these 
specific provisions?435 However, some African countries, such as South Africa436 
and Zimbabwe,437 make the provision for early working under their national 
laws. These legislative actions are worth following by other African countries.  
6.10.3 Early Working, Research and the Experimental Use Exemption in 
Nigeria 
The Nigerian PDA of 1970 in Section 6(3) states that: 
The rights under a patent- 
(a) shall extend only to acts done for industrial or commercial purposes;  
Although not expressly stated, it can be said that this provision makes an 
exemption for private non-commercial use of a patented invention, although this 
provision has not been elaborated by the PDA or Nigerian courts. While the law 
does not specifically mention the early working and scientific use exclusion, it 
may also be argued that a broad interpretation of Section 6(3) gives credence to 
                                                          
434 The study by Musungu and Oh in 2006 reports that many African developing countries did not make provisions for early 
working and few national laws in Latin American and African countries provide for the early working exception. The national 
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437 Section 24(5) of the Zimbabwe Patents Act (Chapter 26:03, as amended up to Act No. 20/1994)  
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The rights granted in subsection (4) shall not be construed as prohibiting any person from making, constructing, 
using or selling the patented invention solely for uses reasonably related to the development and submission of 
information required under any law that regulates the manufacturing, construction, use or sale of any product. 
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the exclusion of patent rights for research, experimental use, and furtherance of 
innovation purposes in Nigeria, in so far as it is not for industrial or commercial 
purposes.438 Nevertheless, the provisions on exemptions would benefit from 
further clarification and definitions of the exact scope and terms of use of a 
patent without infringing the patentee’s rights. For example, Trinidad and 
Tobago’s Patent Act 1996 (as amended) makes a similar provision for non-
industrial and commercial use of patents as Nigeria,439 yet the Act was 
expanded and provides that ‘acts done for experimental purposes relating to the 
subject matter of the relevant patented invention’, shall not be the subject of 
patent infringement. This additional requirement is worthy of emulation as a 
crucial step to scaling up the research, production and availability of medicines 
in Nigeria to enhance accessibility to pharmaceuticals. In the interest of 
women’s right to health, such amendment could enhance the access to 
affordable generic medicines from alternative sources and also facilitate 
incremental R&D leading to opportunities for the enhancement of human 
development.440  
It is imperative for Nigerian patent law to make explicit provisions for early 
working or experimental use of patented inventions. This is because uncertainty 
about the extent to which researchers can impinge on the patent holder’s rights 
for research purposes, or the extent to which generic producers can seek for 
preparatory approval, could discourage generic producers or researchers from 
                                                          
438 The PDA does not explicitly define what industrial and commercial purposes mean, however, a literal interpretation of 
commercial would mean that the exclusive monopoly rights granted to a patent holder would relate only to acts that are directly 
or indirectly for financial gain. Sisule F Musungu, ‘Access to Art and other Essential Medicines in sub-Saharan Africa: Intellectual 
Property and Relevant Legislations’ (United Nations Development Programme (UNDP) Regional Service Centre for Eastern and 
Southern Africa 2007) 27. 
439 Patents Act of 1996 (Amended by 54 of 2000) in Section 42 states:  
The rights conferred by a patent shall not extend to— (a) acts done privately and for non-commercial purposes.  
Sisule Musungu and Cecilia Oh (n 32) 32. 
440 See also Kenya’s patent law in Article 58(1) Kenya Industrial Property Act (2001) (as amended). 
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working in the area where the invention is patented for risk of being sued for 
infringement. Besides discouraging researchers from conducting important 
medicinal research and scientific inquiries, it could also hinder follow-on 
pharmaceutical innovation and R&D and open the door to needless patent 
litigation. 
The NIPCOM Draft Bill of 2007 in Article 112(3) on the other hand, provides an 
extensive list of exceptions to the rights of the patent holder. The provision 
excludes from patent rights infringement, private and non-commercial uses of 
patents, including for purposes of experimental and scientific research and 
testing, regulatory approval and the use of an invention for the preparation of 
medicines and teaching purposes. As revealed in Chapter II,441 since patents 
are also granted on the justification that the disclosure will encourage the 
diffusion of knowledge and further improvement by inventors, the R&D 
exception is an important avenue for putting this justification to use in Nigeria. 
Fundamentally, an enactment of the NIPCOM Bill provision will serve as an 
incentive to local and foreign generic producers to engage in clinical trials and 
testing without the challenge of litigation for patent infringements. The view is 
further expressed that while the bill provides sufficient grounds for the excluding 
the patentee’s rights for the purposes of clarity, the legislation should provide 
illustrative grounds for the use of the exceptions specifically for purposes of 
expediting access to cost-effective essential medicines.442  
                                                          
441 See the arguments in subsection 2.3.2 of Chapter II and Subsection 3.6.2.1 of Chapter III. 
442 By way of example, the Australian Patents Act of 1990 in Section 119C provides several descriptive grounds for the exception of 
patent rights for experimental purposes. The Act (as amended by Act No. 59, 2015) provides as follows: 
(2) For the purposes of this section, experimental purposes relating to the subject matter of the invention include, 
but are not limited to, the following: 
determining the properties of the invention; 
determining the scope of a claim relating to the invention; 
improving or modifying the invention; 
determining the validity of the patent or of a claim relating to the invention; 
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6.11 Conclusion: Utilising the TRIPS Flexibilities to promote the right to 
health and Facilitate Women’s Access to Medicines in Nigeria 
From the foregoing, the flexibilities in the TRIPS Agreement, as reaffirmed in the 
Doha Declaration, signify an important milestone for WTO members, especially 
the developing countries, to offset the adverse effect of patent rights on access 
to patented medicines and also facilitate the availability and access to essential 
drugs. It is, therefore, imperative that Nigeria’s human rights response to the 
issue of women’s access to medicine include the full implementation and 
exercise of many opportunities that the flexibilities offer in ameliorating the price 
and other counter effects of patent rights.  
The implementation, use and enforcement of the flexibilities should also be 
approached from a human development paradigm. As argued in Chapter V, 
having access to medicines can play a significant role in enhancing the 
opportunities, choices and quest for women and all Nigerians to live long and 
healthy lives, and also pursue other development objectives. Thinking in terms 
of enhancing the human capabilities as analysed in the previous chapter, the 
Nigerian government can seek to build up the health capabilities of its 
population and enhance their human development through the instrumentality of 
the flexibilities. Importantly, therefore, the regulatory and institutional reform of 
the patent system to promote access to medicines should be approached in light 
of the human development needs of Nigerians and the right to development 
obligation of the state. Furthermore, since the guarantee, realisation, promotion 
and protection of the right to development, as discussed in Chapter V, is also 
dependent on creating opportunities for the citizens to build their human 
                                                                                                                                                                          
determining whether the patent for the invention would be, or has been, infringed by the doing of an act. 
Under section 119A of the Patents Act 1990, several acts for obtaining regulatory approval of pharmaceuticals are 
exempted. 
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development potentials and enhance their standards of living, the state should 
consider the implementation, utilisation and design of the flexibilities as a 
necessary action to protect health and fulfil its right to development obligations.   
The flexibilities in national laws though significant, however, offer only a partial 
solution to the issue of providing access to affordable medicines in Nigeria. It 
also requires the government’s commitment, strong policy determination to 
actually utilise the health reliefs, administrative competence and technical 
proficiency to effectively exercise the flexibilities.  It is also linked to several 
other factors, such as a well-established pharmaceutical industrial capacity and 
other support systems and policies. Thus efforts to make essential medicines 
more accessible should extend beyond the implementation of the flexibilities 
under national law, though significant should not be underestimated.  
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CHAPTER VII: CONCLUSION AND FINAL RECOMMENDATIONS 
Having made a case for women’s access to essential medicines from a human 
rights perspective in the previous chapters, this chapter concludes and draws 
the thesis together by making recommendations for reforms of the structures 
and systems necessary to promote women’s access to high quality medicines 
for the enhancement of their human development and health capabilities.  
7.1 General Summary of the Thesis 
This thesis considered the issue of women’s accessibility to medicines in Nigeria 
within the context of patent law and the argument that the international IP 
provisions in the TRIPS Agreement can contribute to the conundrum of 
accessibility in developing countries. The thesis argued from a public 
perspective in Chapter II that the patent system and the rights conferred to 
inventors underlay a social welfare objective and the benefit of the system to 
society would be maximised if it could access and utilise patented inventions 
such as pharmaceuticals. Likewise, it argued that the TRIPS Agreement was 
negotiated with the objective that it would stimulate local innovation, promote 
socio-economic welfare and facilitate technological development. These 
objectives are codified in the Preambles and Article 7 of the Agreement. The 
issue, however, remains that the patent rules contained therein can be used to 
cause barriers to accessing affordable essential life-saving drugs and vaccines 
for the poor in Nigeria and other developing countries, with significant 
implications for their human rights and human development potential. It is 
acknowledged that while several factors influence the problems of access to 
medicines, pharmaceutical patents rights can contribute to the problems of 
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unavailability and also, interfere with access to essential medicines at an 
affordable cost.  
Against this backdrop, Chapter III analysed the debate that while patent law is 
essential to incentivising R&D, the rights could create problems for, and impact 
on public health. This considered debate presents the patent dilemma: on the 
one side, a patent is seen to facilitate research activities and increase the 
transfer of valuable technologies; on the other side, however, a pharmaceutical 
patent’s monopoly right could prevent competition and reduce affordable access 
to the patented invention, which has human rights and human development 
implications.1 These views have provoked discussions on whether the purported 
benefits of patents in encouraging innovation, research and novel drug 
discovery and its consequential development benefits, outweigh the adverse 
cost to public health and access to life-saving medicines. The central question 
this dilemma poses is how to balance the cost and benefit of patents to society. 
It was argued that the challenge for the Nigerian government, particularly, within 
the context of women’s access to medicines, will be to ensure that patent rights, 
which should promote new inventions for public benefit, do not hamper 
affordable access to the fruits of these inventions, especially medicines that are 
essential to human lives and their wellbeing.  
It is acknowledged that accessibility to medicines is important to the wellbeing of 
everyone in Nigeria; however, this study particularly focused on Nigerian 
women, regardless of age. Although the result of this study is structured to have 
wider benefit implications for everyone in Nigeria, the issue of access was 
approached within the context of women’s socio-economic realities and 
                                                          
1 It was argued that although these issues are not inherent in patent law, they are a result of the manner in which patent holders 
utilise and enforce their rights.  
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inequalities. Since the problem of access to affordable essential medicines viz 
patent rights is associated and more challenging for the poorest in developing 
countries, and women and children make up the majority of the poor, it is most 
likely that they have even less access to medicines. Consequently, their socio-
economic status, experience and perspective offer an additional support to 
argue for policy interventions to improve access to medicines in Nigeria.  
In making the argument for increased accessibility to health treatments in 
Nigeria, the thesis made the case for women’s access through the lens of 
human rights to health, life and development. Essentially, human rights provides 
the jurisprudential justification and legal force in which this study argues for the 
consideration, interpretation and circumvention of patent rights in favour of 
increased access to medicines in Nigeria. The thesis argues in Chapter IV that it 
is the primary responsibility of Nigeria to meet the basic healthcare needs of the 
citizens. For women, this also includes providing an appropriate healthcare 
delivery system, timely and adequate health interventions such as medicines, 
and making proactive efforts to address other health determinants and gender 
inequalities. Fulfilling this human rights obligation also requires the state to 
ensure that the exercise of patent rights does not hamper access to affordable 
medicines as a constituent of the right to health and life. Equally, it is argued 
that human rights principles can serve as a basis for the resolution of the conflict 
between private patent rights and public healthcare in favour of health and 
human welfare where the proprietary rights undermine access to important 
health treatment. Moreover, human rights norms provide the legal basis for a 
broader interpretation and implementation of the flexibilities in favour of 
accessing affordable pharmaceuticals.  
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To further enrich the argument for increased accessibility to affordable and high- 
quality medicines in Nigeria, this study argues that access to medicines is not 
only an essential component of health and wellbeing, it is also helpful for the 
purpose of enhancing people’s choices, opportunities, and basic freedoms to 
achieve their basic health goals and development. Thus facilitating women’s 
access to medicines should form part of the development goals of the Nigerian 
government. It is also important that this development objective is approached 
from a people-centred human development paradigm, not one based solely on 
economic growth. Furthermore, it is argued in Chapter V that while a patent is 
important to securing the goals of human development, it could also impact 
adversely on access to medicines and therefore, the opportunities and choices 
for human development. It is the duty of the Nigerian government to ensure that 
patent protection which promotes technological developments and 
pharmaceutical R&D does not hamper women’s human development. 
In Chapter VI, this study centrally points to the flexibilities that can be used by 
Nigeria to address and counter-balance the impact of patents on essential 
pharmaceuticals and enhance women’s access to medicines. They include 
among others: government use and compulsory licenses to allow government 
authorities or third parties to use an invention without the consent of the owner; 
patentability standards and limitations on the grant of ‘new or second uses’ of 
old patents; public policy, order and morality exclusions; research/experimental 
use and early-working exemptions to facilitate the research and production of 
medicines and other limited exceptions.2 These flexibilities have been confirmed 
by the Doha Declaration in 2001.  
                                                          
2 Another important flexibility which was not considered in detail in this thesis is the exhaustion of rights flexibility and parallel 
imports to allow the importation and resale of a patented product. 
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Significantly, the Declaration affirmed that members can interpret and implement 
the TRIPS Agreement in a way that supports the right to public health and 
facilitates access to medicines for all. Despite the reaffirmations of the 
flexibilities at Doha in the interests of public health, other challenges relating to 
legal and regulatory conditions, lack of technical knowledge, limited resources, 
insufficient manufacturing capacity and absence of basic infrastructure, raise 
questions about the extent to which the flexibilities can address the problems of 
access to medicines within the context of patent law. These doubts also arise in 
light of TRIPS-plus sanctions that threaten and limit the ability of developing 
countries to invoke health safeguards in the interests of public health. 
Notwithstanding, it is argued that the available flexibilities provide important 
mechanisms to promote and increase the availability of affordable medicines for 
women in Nigeria. Consequently, this thesis argues for a broad-based 
incorporation and adaptation of the flexibilities into the patent law and other 
relevant policies of Nigeria and also, the implementation and interpretation 
thereof in the interests of public health.  
 
7.2 Nigeria and Access to Medicines: The Way Forward 
In Nigeria, addressing the conundrum of access to medicines requires manifold 
intensive intervention from within the country. In proposing ways to address the 
challenges of access to medicines in Nigeria, two central recommendations run 
throughout this study. First is a proposal for the reform of the substantive and 
procedural provisions of the patents law and system; second is the improvement 
of human welfare, social, economic conditions and other national support 
systems. While the second aspect is highlighted as important for promoting and 
enhancing access to medicines, this thesis essentially focuses on the first. 
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7.2.1 Reforming the Patent System in Nigeria 
First, this thesis recommends a reform of the legislative and regulatory 
framework of the patent system in Nigeria to better facilitate the availability of, 
and access to affordable medicines in the interests of the citizens’ human rights 
and human development. While there are many ways of doing this, this thesis 
specifically recommends that the obviously obsolete patent law is amended to 
bring it into compliance with its obligations under the TRIPS Agreement. In line 
with the human rights duties of the Nigerian State, this amendment should be 
approached with the pro-development objective of encouraging important and 
innovative pharmaceutical R&D, at the same time as promoting the production 
of generic medicines for domestic consumption to enhance the availability of, 
and access to, cheaper essential medicines. In conforming to Nigeria’s TRIPS 
obligations, the patent law should be designed in a way that promotes important 
R&D, while minimising any interference with access to high quality and 
affordable new pharmaceuticals, incremental R&D and generic manufacturing or 
re-entry after the expiration of a patent term. 
It is particularly identified that the flexibilities can play an important role in this 
respect. The fundamental element is the language of the law in prescribing the 
protection and the exceptions to the right, including the derogation for public 
use. As Article 8 of the TRIPS Agreement, supported by Paragraph 4 of the 
Doha Declaration allows members the discretion to ‘adopt necessary measures’ 
consistent with the general provisions of the Agreement in cases where it is 
expedient to protect public health and promote the interests of the public, this 
thesis highly recommends the full incorporation of all TRIPS flexibilities 
provisions, as well as tailoring the rules to ensure women and indeed, all 
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Nigerians access to essential medicines. This would enable the government and 
citizens to take advantage of the health safeguards and exceptions to actively 
promote the availability of, and accessibility of affordable life-saving medicinal 
treatments. Where the flexibilities already exist under the national law, they 
should be suitably adjusted to safeguard public health and improve access to 
affordable medicines without unnecessary delays. The incorporation and 
amendment of the patent law in the public interest should take into cognisance 
the importance of the flexibilities to the objectives and aims of the rights to 
health, life, human development and access to medicines as articulated in 
Chapters IV and V of this thesis.  
7.3.1 Promoting the Use of the TRIPS-compliant Flexibilities to Enhance 
Women’s Rights to Health and Human Development in Nigeria 
The following specific recommendations are made for the calibration of some of 
the flexibilities to circumstances of public interest for the enhancement of 
women’s access to cost-effective life-saving medicines and human 
development. Specific recommendations are made in the section on how to 
amend the Nigerian Patents and Designs Act (PDA) of 1970 to provide and 
make effective use of the health safeguards.  
7.3.1.1 Recommendation I: Amending the Patentability Criteria in Nigeria, 
in the Interests of Access to Medicines  
Chapter VI3 identified that the Nigeria PDA of 1970 allows the ‘improvement’ of 
an already patented article which would permit the patenting of the new use of 
an existing medicine and new therapeutic indication of a known drug, in so far it 
meets the threshold of newness, industrial applicability and inventiveness. It is 
                                                          
3 See subsection 6.6.1 of Chapter VI.  
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also argued that the problem with this provision is that it could be used as a 
legal strategy by patent holders to slightly modify and extend the patent term of 
drugs on the brink of expiration, thereby obstructing the availability of cheaper 
generic drugs. In light of these issues it is recommended that Nigeria, as per its 
human rights responsibilities, enact patent requirements that will protect 
pharmaceutical R&D that are significantly ‘innovative,’ improve the quality of 
patents granted and reduce the anti-competitive costs and effect to public 
health.  
There are two identified ways of tightening the legal scope and standards of 
patent protection in Nigerian law. Firstly, increase the threshold of the innovation 
patentability standard to explicitly exclude or limit the patenting of new medical, 
or subsequently indicated use of a patented product and/or process.4 Secondly, 
clarify the term and standard of ‘improvement’ to exclude certain types of 
innovations that do not substantially indicate enhanced ‘efficacy.’  
In the first instance, Nigeria could exclude new or known uses from patentability 
to limit the scope of a newly discovered use or second use of a known medical 
substance that does not substantially indicate ‘efficacy.’ For instance, Members 
of the Andean Community of Nations5 provide a particularly broad exemption for 
new uses of patents thus:  
Products or processes already patented and included in the state of the art […] 
may not be the subject of new patents on the sole ground of having been put to a 
new use different from that originally contemplated by the initial patent.6  
                                                          
4 KM Gopakumar, 'Product Patents and Access to Medicines in India: A Critical Review of the Implementation of TRIPS Patent 
Regime' (2010) 3(2) The Law and Development Review 325, 332.  
5 Article 21 Decision 486 of the Andean Community Commission, 2000 (Decision 486). The Andean Community (Comunidad 
Andina) is a customs union comprising of Bolivia, Colombia, Ecuador, and Peru.  
6 Decision 486 of the Andean Community Commission, 2000 (Decision 486). 
437 
 
437 
 
Perhaps, Nigeria could take a cue from this strict non-patentability of new uses 
of known patents.  
Although the current PDA succinctly provides a patentability standard that is 
broadly consistent with TRIPS, similar to other countries such as India’s,7 and 
the European Union,8 the PDA could also specifically limit the grant of patents to 
new or further use of some pharmaceutical products, processes or substances. 
Nigeria can take a hint from Section 3(d) of India’s Patent Act and restrict certain 
clearly listed categories of known substances from patent protection and 
specifically prohibit frivolous claims of anything contrary to well established 
natural law.9  
Also, the policy makers can clarify the provision on ‘improvement upon patented 
inventions’ in the PDA to clearly differentiate between novel inventions and 
substantial new indication, and ne inventions that are only minor incremental 
modifications of existing medicines to avoid an ambiguous interpretation of the 
section. The clarification of the term ‘improvement’ should ensure that the new 
uses are genuine therapeutic enhancements of older versions by clearly 
defining the degree of such ‘improvement.’ The provision should state that only 
significant improvement which substantially meets the patentability criteria of 
novelty, inventiveness and industrial applicability is allowed. For this purpose, 
patent law should only allow substantial new development which will ensure that 
only efficacious innovative drugs that contain new active ingredients and provide 
significant medicinal benefits are protected. The PDA should exclude minor 
                                                          
7 Criteria for patentability are defined in Section 2(j) Indian Patent Act in three-fold standards of novelty, inventive step and 
industrial application. 
8 The European Patent Convention (EPC) puts forth four criteria of patentability; and an invention is patentable if, (i) it is novel 
(Article 54 EPC), (ii) involves an inventive step (Article 56 EPC), (iii) is capable of industrial application (Article 57 EPC), and (iv) is 
not excluded by Article 52(2) and (3) EPC. 
9 See section 3(d) of the Patents (Amendment) Act cited in subsection 6.6 of Chapter VI 
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incremental enhancements, no matter how novel and innovative unless the 
modification substantially changes the general therapeutic nature of the 
invention. Narrowing the definition of novelty or limiting the scope of 
‘improvements,’ could reduce the patenting of minor increments and frivolous 
extension of patent terms which could in turn impact on the accessibility to 
affordable generic medicines. Restricting patentability will also make allowance 
for the early entry of generic drugs that could facilitate competition, reduce 
prices of drugs and promote better access to affordable medicines.  
In addition, to lessen the possibility of ‘evergreening’ where patent terms are 
prolonged based on minor amendments as discussed in Chapter VI,10 it is 
important to extend the administrative duties of the Nigerian patents registration 
officials beyond mere registration of patent applications. For this purpose, there 
is a need for a patent examination system that will guard against the problems 
inherent in a registration system where patents are relatively easy to file and 
much harder to challenge. The European Patent Office for example, carries out 
a substantive examination of all patent applications.11 In this vein, the proper 
examination and assessment of patents in Nigeria might be another means to 
guard against the practice of extending the protection period of a patent and 
blocking generics entry and avoiding the registration of low quality patents, 
which could have anti-competitive effects and unjustifiably increase the price of 
the end products.12 Realistically, this is not to suggest a thorough investigative 
examination system. Even in developed countries like the US for example, 
                                                          
10 See subsection 6.6 and 6.6.1 of Chapter VI 
11 European Office, ‘Part C – Guidelines for Procedural Aspects of Substantive Examination - Guidelines for Examination’ (Epo.org 
2016) available at <http://www.epo.org/law-practice/legal-texts/html/guidelines/e/c.htm> accessed 12 Jan 2015. In the US also, 
patents are granted based on proper examination of patent validity. The United States Patent and Trademark Office USPTO 
registration officials examine patent applications to determine if the requirements of the law are satisfied before granting patents. 
United States Patent and Trademark Office, ‘General Information Concerning Patents’ available at the official website of the 
USPTO at <https://www.uspto.gov/patents-getting-started/general-information-concerning-patents>accessed 17 July 2016. 
12 See the discussion in subsection 6.6.1 of Chapter VI 
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patents are examined based on the ‘preponderance of evidence’, that is with 
due consideration of the evidence and persuasive argument of the applicant 
rather than by clear and convincing evidence.13  
It is also important to provide adequate funding for the patent officials to 
efficiently examine the quality of patent applications, particularly with regards to 
preventing the grant of frivolous pharmaceutical patents. Without sufficient 
resources, it would be nearly impossible to effectively and accurately examine 
and screen trivial and questionable patent claims. The Patent and Designs 
Registry is a unit in the Commercial Law Department of the Ministry of Industry, 
Trade and Investment. This means that the Patent Registry is dependent on the 
policy decisions, administrative powers and budget allocation of the Ministry. 
The registry has no control over the funds it generates from patent applications 
which could enable it to administer the affairs of patents effectively.14 Lack of 
control over the resources it generates or insufficient resource allocation may 
also mean that registry staff are not regularly trained in up-to-date patent 
practices and regulation. In terms of administrative control of matters relating to 
patents, its powers are limited to the formal examination, grant of patent and 
administration of patent rights.15 Patent support services such as registration of 
patent-related technology transfer and foreign direct investment, monitoring of 
patent licensing and promotion of innovation, are entrusted to the National 
Office of Industrial Property (NOPTAP).16 NOPTAP is also actively engaged in 
                                                          
13 Federal Trade Commission, ‘To Promote Innovation: The Proper Balance of Competition and Patent Law and Policy’ (Federal 
Trade Commission 2003) 9; Gopakumar (n 4) 344. 
14 Copyright is administered by an independent commission. The Nigerian Copyright commission that is responsible for the 
management and regulation of all matters relating to copyright in Nigeria. More information at 'Copyright Act: Establishment of 
the Nigerian Copyright Commission' (Nigerian Law Intellectual Property Watch) <http://nlipw.com/copyright-act-establishment-of-
the-nigerian-copyright-commission/> accessed 27 April 2016. 
15 This is in addition to other functions such as regulating the filings of trademarks and industrial designs.  
16 NOTAP is an independent government parastatal in Nigeria. Emeka Chinalu Orji, ‘Nigeria: Country Presentation on IP’ (WIPO-JPO 
Study Programme Programme on IP Asset- 25 November 2009). 
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raising public awareness and training the public in knowledge about patents as 
well as assisting inventors in patenting their inventions.17 This ought to be one of 
the main functions of the Patents and Designs Office. With limited funding, 
however, it may be impracticable to undertake this important responsibility. Thus 
it is highly recommended that the patent office is adequately funded, particularly 
if it is to undertake the substantive examination of patents.  
It is also imperative that the patent officials receive regular, up-to-date scientific, 
legal and technical training to build their capacities to assess patent claims and 
reject applications with insignificant improvements. An additional or alternative 
arrangement would be to put in place a system where independent individuals 
who possess the necessary legal, scientific and technical expertise are 
registered to carry out assessments and examination of patent applications at 
the patent office. Currently, the sole system in place allows the registration of 
agents who only guide or advise inventors through the patent application 
process.18 Many developed countries, as well as international organisations, are 
increasingly offering capacity training to developing countries’ patent offices,19 
although scholars are sceptical that the intention is only to serve the overarching 
purpose of ensuring swift TRIPS implementation and entrenching stronger IP 
                                                                                                                                                                          
 A visit to the patent registry revealed that there is little collaboration between the patent office and NOTAP. The registrar 
indicated that it is also limited by budgetary constraints in carrying out some promotional activities.  
17 ibid 
18 Federal Ministry of Trade And Investment, ‘Trademarks, Patents and Designs Registry, Commercial Law Department: Federal 
Ministry of Trade and Investment’ (2016) available at <http://www.iponigeria.com/#/> accessed 25 January 2016. It is unclear if 
these agents must be qualified patent attorneys. In some jurisdictions such as Australia, Canada and the US, only authorised 
practitioners can act before the patent office, although applicants (inventors) in some jurisdictions such as US can generally 
represent themselves. See more at 'Become a Registered Attorney: Professional Standards Board' (Psb.gov.au 2015) 
<https://www.psb.gov.au/become-a-registered-attorney> accessed 2 October 2015. See also 'Canada: Patent Rules (SOR/96-423) 
(Version of Document Current to 2011)' available at  
<http://www.wipo.int/wipolex/en/details.jsp?id=9360> accessed 2 October 2015.  
19 The WIPO, for example, offers technical assistance to developing countries and international patent examination. WIPO, ‘Patent 
Information Services for Developing Countries’ (Wipo.int 2015) 
<http://www.wipo.int/patentscope/en/data/developing_countries.html> accessed 15 February 2015. See more at Tom Pengelly, 
‘Technical Assistance for the Formulation and Implementation of Intellectual Property Policy in Developing Countries and 
Transition Economies’ (2005) ICTSD Programme on IPRs and Sustainable Development Issue Paper no 1; Poku Adusei, Patenting of 
Pharmaceuticals and Development in Sub-Saharan Africa: Laws, Institutions, Practices, and Politics (Springer 2013) 97-100. 
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standards.20 The World Intellectual Property Organization (WIPO), the World 
Trade Organization (WTO) and some non-governmental organizations (NGO’s) 
also render advice and legal or technical assistance to developing countries and 
Nigeria can take advantage of the technical skills and legal support opportunities 
they offer.21 It is however, vital that the goal of guaranteeing and protecting 
public health and promoting the Nigerian people’s human development is clearly 
identified as the main objective of any technical and capacity building 
assistance.  
To detect pre-grant defective claims, it is also imperative to put in place a 
procedure for public scrutiny of patent applications before and after they are 
granted. The public should also be given the opportunity to check frivolous 
claims and challenge same; however, this should be without prejudice to the 
patent applicant. Furthermore, it is suggested that the administrative procedure 
for the pre or post grant review or challenge of patents be made simple and 
transparent. To realise this mission, the patent legislation should formulate a 
process for opposing patent applications and grants that do not meet the 
patentability criteria or claims with modifications of existing products within a 
specific time frame, without the need for recourse to the judicial system. The law 
should specify the means of addressing such oppositions without delay.  
It is important to reiterate that any amendment of the patent law with regards to 
patentability is guided by the state’s human rights obligations to guarantee the 
                                                          
20 These scholars highlight the underhanded nature of technical assistance and capacity building from international organizations 
and developed countries. Carolyn Deere, The Implementation Game: The TRIPS Agreement and the Global Politics of Intellectual 
Property Reform in Developing Countries (Oxford University Press 2008) 19; Sudip Chaudhuri, The WTO and India's 
Pharmaceuticals Industry: Patent Protection, TRIPS, and Developing Countries (Oxford University Press 2005) 106-107.  
21 Peter Drahos, ‘Developing Countries and International Intellectual Property Standard-Setting’ (2005) 5 The Journal of World 
Intellectual Property 765, 776. See for example WIPO’s technical and legal assistance to developing countries in World Intellectual 
Property Organization, ‘WIPO’S Legal and Technical Assistance to Developing Countries for the Implementation of the TRIPS 
Agreement from January 1, 1996, to December 31, 2000’ (World Intellectual Property Organization 2001); World Trade 
Organization, 'WTO: Intellectual Property (TRIPS) - Technical Cooperation' (Wto.org 2015) 
<https://www.wto.org/english/tratop_e/trips_e/intel9_e.htm> accessed 2 October 2016. 
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enjoyment of the right to health via the accessibility of affordable medical 
treatments that are safe and of good quality, in an acceptable manner.  
7.3.1.2 Recommendation II: Amending the Public Morality and Public Order 
Provisions to Safeguard Access to Medicines in Nigeria 
In view of public health objectives and the goal of securing women’s right to 
health, enacting an appropriate scope of patentability in Nigeria is crucial to 
accessing medicines. Where the terms are too rigid and narrow, they risk 
restricting the innovation climate of the country, whereas, when the provisions 
are too lax, they admit ambiguity in terms of interpretation and enforcement. 
Chapter VI reveals that the patentability exceptions with regards to public order 
and morality in Nigeria’s patent law are too ambiguous, which could defeat the 
main purpose of having the provision.22 Chapter VI also indicates that the TRIPS 
Agreement in Article 27(2) clearly relates the concept of ordre public and 
morality to the protection of humans, animals and health; however, the Nigerian 
patent law is yet to explicitly link the probation of patentability on grounds of 
public order and morality with its citizens’ health.23 Therefore, it is important that 
the current patent regime in Nigeria is reformed to specify the grounds for the 
interpretation of the concept ordre public in the interests of public health and 
access to medicines. This clarification is imperative in the face of increasing 
monopoly over biotechnology, traditional medicinal plants properties and genetic 
material which could affect medical research and consequently, the availability 
of and access to medicines. This reform should be done in Nigeria to avoid the 
monopolisation of inventions in crucial areas that could affect humans, 
especially their health, animals and the environment. 
                                                          
22 See also the discussion in 6.7.1 of Chapter VI. 
23 See discussion in subsection 6.7 of Chapter VI. 
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This reform should also reflect a comprehensive patentability standard which 
includes provisions to specifically exclude diagnostic, therapeutic and surgical 
methods in order to promote access to health treatments. This approach is 
substantiated by the recommendations of the IPR Commission for developing 
countries, particularly those without research capabilities, to ‘strictly exclude 
diagnostic, therapeutic and surgical methods from patentability, including new 
uses of known products.’24  
Similar to the consideration above, while it is important for Nigeria’s national 
legislation to contain all the TRIPS flexibility provisions, a proficient patent 
examination system and administration is necessary to judge and decide 
whether to grant or deny a patent on the basis of moral, and public interest 
grounds to prevent any consequential adverse effect on health, plants and 
animals and the environment. 
7.3.1.3 Recommendation III: Adapting and Utilising the Compulsory 
Licensing Medium and Government Use Flexibilities to Promote Access to 
Affordable and Essential Medicines in Nigeria 
While the Nigerian government has put in place national legislation for the 
granting of compulsory licensing and government use that could ensure the 
availability of cheaper generic drugs options as revealed in Chapter VI,25 more 
needs to be done to put this flexibility option to significant use. From a public 
health perspective, it is worth stating that the grounds for issuing compulsory 
licensing in Nigeria are quite limited. In any case, compulsory licensing revolves 
around working the patented invention and the public interests of security, 
                                                          
24 Commission on Intellectual Property Rights, Integrating Intellectual Property Rights and Development Policy: Report of the 
Commission on Intellectual Property Rights (Commission on Intellectual Property Rights 2002) 50.  
25 See discussion in subsection 6.8.4 of Chapter VI. 
444 
 
444 
 
economy and health, without elaborating on additional public health 
circumstances when it can be used. While the public interest grounds in 
Nigeria’s patent law is similar to that of other nations such as India,26 the 
circumstances and basis for issuance are restricted to limited circumstances. 
The patent law does illustratively list other possible grounds for granting 
compulsory licences, such as the adequate supply of cheaper medicines and 
use in the event of health emergencies.27 Furthermore, it was observed in 
Chapter VI28 that although the provisions for anti-competition practices can be 
inferred, the PDA ought to expressly provide for the grant of a compulsory 
licence to remedy these practices. For instance, the Indian Patent Act of 1970 
spells out analogous but more extensive grounds for granting compulsory 
licenses for a dependent patent, instances where reasonable public 
requirements have been satisfied, unaffordable price of the invention for the 
public; the non-working of the patent in India, circumstances of national and 
extreme emergency, and public non-commercial use.29 Importantly, India’s 
Patent Act provides for the grant of compulsory licensing for health relief 
specifically and also makes provision for granting of compulsory licences for 
purposes of export to countries with limited or no manufacturing capacity.30 In 
comparison to India, the current Nigerian PDA does not contain provisions 
pertaining to national or extreme emergency to expeditiously invoke a 
                                                          
26  Section 84 of the Indian Patents Act, 1970, as amended by Act No. 15 of 2005, states the grounds for grant of compulsory 
licence as follows: 
     (a) that the reasonable requirements of the public with respect to the patented invention have not been satisfied, or 
      (b) that the patented invention is not available to the public at a reasonably affordable price, or 
      (c) that the patented invention is not worked in the territory of India. 
27 However, the Minister is conferred a broad discretion on the applicability of the licensing provisions in Paragraph 13 First 
Schedule, Part I to the PDA. According to the provision, the  
Minister by order in the Federal Gazette may provide that, for certain patented products and processes (or for 
certain categories thereof) declared by the order to be of vital importance for the defence or the economy of 
Nigeria or for public health, compulsory licences may be granted before the expiration of the period […]. 
28 See subsection 6.8.4 of Chapter VI. 
29 Section 84, 87, 91 and 92 of the India Patents Act, 1970, as amended by Act No. 15 of 2005. 
30 Section 92A of the India Patents Act, 1970.  
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compulsory licence in events of health crises, nor is there a provision for exports 
under a licence.  
In another example, Belgium went further than the provision allowed in Article 
31 of TRIPS in making provisions for compulsory licensing by relying on the 
basis of Articles 8 and 30 of TRIPS to make specific provisions for a compulsory 
licence in the interests of public health and availability of medicines,31 including 
specific fast-tracked measures for health crises.32 Article 31 bis § 1 of the 
Belgium Patent Act 1984 expressly states that ‘in the interest of health, the King, 
by decree established after consultation with the Council of Ministers, can grant 
a licence, for the exploitation and application of an invention protected by 
patent.’33 For this purpose, the products for compulsory licences include:  
a) A medicine, a medical device, a product or medical device used for performing 
a diagnosis, a derived or combinable therapeutic product;  
b) The process or product necessary for the manufacture of one or more products 
indicated under a);  
c) A diagnostic method applied outside of the human or animal body. 
This provision explicitly includes medicines as one of the grounds to exploit the 
compulsory licensing flexibility, which will include affordable access to 
medicines.34 For effective utility, the compulsory licensing provisions in the 
current PDA should be reviewed to include additional public health-friendly 
grounds as bases for the grant. It is suggested that Nigerian patent law could 
                                                          
31 Jerome H Reichman ‘Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options’ (2009) 7 Journal of 
Law, Medicine and Ethics 247, 343; Geertrui Van Overwalle and Esther van Zimmeren, ‘Reshaping Belgian Patent Law: The 
Revision of the Research Exemption and the Introduction of a Compulsory License for Public Health' (2006) 64 IIP Forum (Japanese 
Journal) 42. 
(The translated version is available at  
 <https://www.iip.or.jp/e/e_publication/pdf/vol64_overwalle_and_zimmeren.pdf> accessed 1 June 2015) 5.  
32 In the case of health emergencies, the Minister responsible for public health is obliged to take additional measures to accelerate 
or bypass the procedure for grant of compulsory licensing in Article 31 BIS § 6 paragraph 5 of the Belgium Patent Act. Van 
Overwalle and van Zimmeren ibid 7: K Outterson and AS Kesselheim, ‘Market-Based Licensing for HPV Vaccines in Developing 
Countries’ (2008) 27 Health Affairs 130, 136-137.  
33 Emphasis added. 
34 For detailed analysis of the provision, see Van Overwalle and van Zimmeren (n 31) 
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emulate the foregoing countries (India and Belgium) and expressly list 
illustrative public health grounds for the issuance of compulsory licences. The 
grounds for utilisation of the flexibilities should be broadly specified, for example, 
allowing the importation and export of medicines under compulsory licences.  
It may also be that the provision of compulsory licensing in Nigeria is 
deliberately left open so that it can be broadly interpreted. If this is the case, the 
judiciary and relevant authorities should widely interpret and enforce the 
provisions on compulsory licences in the interest of improving access to 
medicines in Nigeria, to promote women’s and all Nigeria’s human rights 
through accessibility to life-saving health treatments.  
The procedural grounds for the grant and use of compulsory licences or 
government use would benefit from additional reforms to make the provision 
straightforward, simpler, transparent, fast and easier to administer. Equally, the 
Nigerian legislature should fully exploit the flexibilities by establishing a clear 
decision-making process for determining the basis for the grant of compulsory 
licences and government use, including the option for export to other countries. 
The responsible government agencies should also ensure that the legal 
conditions for the grant are satisfied to avoid triggering expensive and 
unnecessary litigation from patent owners in a bid to thwart the derivable 
benefits. Where discretion can be exercised, in the case of health emergencies 
for example, the interest of the public’s right to health should supersede private 
patent rights considerations.  
The decision-making process for the adequate utility of these flexibilities lies 
with at least four government agencies in Nigeria and their duties would often 
overlap. The Ministry of Health is responsible for determining health challenges 
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and procuring medicines; the regulatory agency, the National Agency for Food 
and Drugs Administration and Control (NAFDAC) controls the importation, 
export, distribution and use of drugs; the Ministry of Justice is tasked with the 
domestic implementation and reform of the law; and the Ministry of Industry, 
Trade and Investment is concerned with the administration of patent rights and 
the implementation of the TRIPS Agreement in general. The courts also play a 
role in the granting and regulation of compulsory licences. Therefore, the 
effective enforcement of the flexibilities depends on the coordinated, 
collaborative and individual responsibility of these agencies and the courts. It is 
important to clarify and assign specific roles and responsibilities to each 
organisation involved in the process of ensuring access to medicines through 
compulsory licensing and government use. The determination and designation 
of responsibility of each authority should be clearly stated to avoid multiplicity, 
unnecessary overlap, administrative delays and negation of duties.  
The legal text, in articulating the terms for use of the flexibilities in Nigeria, 
should also state the compensation procedure, and provide an opportunity for 
the patent holder to request a hearing on the use of the flexibilities on his 
patents, except where it is expedient not to do so e.g, in emergency or urgent 
circumstances.35 The grievance procedure should be in the form of a quasi-
judicial review of the complaint and thereafter, recourse to judicial redress. The 
creation of an independent public administrative body with quasi-judicial powers 
to determine and manage the utilisation of compulsory licences and non-
commercial use by the Nigerian government towards addressing exigent public 
health concerns would be another way of ensuring efficient utilisation of these 
                                                          
35 For example, in India, the Comptroller of Patent Office hears both parties in an application for the use of compulsory licence. Blu 
Tirohl, Law for Artists: Copyright, The Obscene and all the Things in Between (Routledge 2014) 167. 
448 
 
448 
 
flexibilities.36 This administrative body would reduce the burden on the court and 
expedite the licensing process for use.37 Such an arrangement could promote 
transparency by determining the guidelines or the payment of compensation to 
avoid ambiguity and deadlock in the negotiation of royalties.38 Adopting this 
recommendation has important implications for future practice in terms of setting 
up the guidelines for remuneration, procedures, the terms of licence granting 
and rights of appeal. Another advantage of this approach is that such a body 
would have quasi-judicial decision-making powers to ensure speedy 
adjudication, thereby saving the cost of expensive legislation.  
Importantly, the Nigerian government and policy makers must ensure that the 
compulsory licences issued and government use are in the interests of the 
public for example, ameliorating health and not a profit making venture for 
opportunistic generic manufacturers. The prescription of the law on the grounds 
of exercising the safeguard should also guide the review process and check any 
implementation of the flexibilities done in bad faith. It is important that the review 
and legal redress does not defeat the purpose of the flexibilities; therefore, the 
panel or court should exercise discretion in favour of health to refuse or grant a 
stay on the execution of the flexibilities pending the outcome of the complaint. It 
is also imperative that there is prior notification to the patent holders before 
issuing compulsory licences to maintain a patent-friendly environment, except 
where it is not expedient to do so in emergency situations. In the case of a 
deadlock in negotiations, the overall public health consideration should override 
                                                          
36 For example, the Belgium Patent Act in Article 35(1) prescribes the setting up of a compulsory licensing commission with the 
specific allocated task of handling issues related to compulsory licensing.  
37 In this connection, the United Nations Development Programme (UNDP) Human Development report and the IPR Commission 
have also endorsed the establishment of a multi-agency committee to be responsible for the decision-making, execution and 
management of compulsory licensing and government use. The Commission on Intellectual Property Rights, ‘Integrating 
Intellectual Property Rights and Development Policy: Report of the Commission on Intellectual Property Rights’ 44. 
38 Commission on Intellectual Property Rights ibid.  
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the private interest of the patentee; however, compensation should be paid for 
the inconvenience caused. 
Nigeria’s authorities should resist TRIPS-plus pressures and desist from rules in 
FTAs that would limit, undermine, exclude or affect the implementation of the 
flexibilities with regards to the right to health. The Nigerian legislators can do this 
by specifically enacting laws that prevent the introduction of TRIPS-plus rules 
which would thwart public health objectives. The previously discussed principles 
of the right to health and life in Chapter IV and human development goals in 
Chapter V39 should guide the assessment of TRIPS-Plus rules which directly or 
indirectly impose additional IP requirements. 
The responsibility of the Nigerian government to improve access to 
pharmaceuticals through the instrumentality of compulsory licences and the 
non-commercial use option do not end with laws. Successful implementation of 
the compulsory licensing and government use legal remedies for example, 
would depend upon important factors such as the availability of a functioning 
pharmaceutical industry and an effective administrative control system to 
monitor the impact of patents on access to medicines and swiftly engage the 
use of the flexibilities. 
7.3.1.4 Recommendation IV: Maximising the Benefits of the Exemptions to 
Patent Rights Flexibility in Nigeria 
The experimental and research use exemption is strongly recommended as a 
means of encouraging research by the budding generic production and 
research-intensive pharmaceutical industry in Nigeria to expedite the access to 
medicines by women and indeed, everyone else in Nigeria. With respect to 
                                                          
39 See the discussion in Part I of Chapter IV and subsection 5.7 of Chapter V.  
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pharmaceutical patents, the early working provision is important for facilitating 
regulatory approval before the commercialisation, availability and production of 
generic medicines at the end of a patent term by generic manufacturers and 
researchers.  
Nigerian patent law does not expressly make an exemption for research 
purposes as revealed in Chapter VI, though this can be inferred.40 To avoid 
ambiguity, it is recommended that the provision with regards to the exemption of 
patent rights specifically allows experimentation and early working, as well as 
academic uses of the patent for commercial use after the patent expiration. This 
should be expressly stated in the national patent law and other research and 
development policies. Making research exemptions to patent rights could 
facilitate the availability of additional new drugs and the Bolar-type exceptions 
could expedite the availability of cheaper medicinal alternatives immediately 
after a patent’s expiration. The existence of an alternative source may promote 
competition and drive down prices of drugs which will benefit women and all 
Nigerian consumers. 
The law in Nigeria should expressly state that the exemption covers both 
generic and novel drugs researches and discoveries. Furthermore, it is 
recommended that the experimental use and Bolar-type provision is without limit 
of its territorial scope. That is, the exception can also be broadly defined to 
facilitate approvals for generics production for export to other countries with 
insufficient or no manufacturing sector as per Paragraph 6 of the Doha 
Declaration.  
                                                          
40 See subsection 6.10.3 of Chapter VI. 
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7.4 Towards Guaranteeing the Right to Health through Access to Essential 
Medicines in Nigeria: Adopting an All-encompassing Approach 
Although this thesis fundamentally endorses the implementation and use of the 
flexibilities to enhance women’s access to medicines in Nigeria, it is 
acknowledged that finding a solution to access problems requires a multifaceted 
response. First, it is important that women’s right to health and access to 
medicines as a constituent of the right is respected, fulfilled, guaranteed and 
protected in Nigeria.  
7.4.1 Incorporating a Human Rights Perspective to Secure Women’s 
Access to Medicines and Health in the Light of Patent Rights in Nigeria 
Access to medicines as a matter of right has the potential to contribute to an 
improvement in Nigerian women’s wellbeing and by extension, children that rely 
on women for child-care. For a concerted effect however, the Nigerian 
government must domesticate the relevant international human rights provisions 
such as the International Covenant on Economic, Social and Cultural Rights 
(ICESCR), the International Covenant on Civil and Political Rights (ICCPR), and 
the Universal Declaration of Human Rights (UDHR), and promote their use by 
the courts and other relevant authorities to assuage the adverse effect of 
patents, especially in cases where it undermines the right to health and leads to 
unreasonably high costs of medicines.41  
There is a corresponding duty on the Nigerian government to ensure that 
access to affordable medicines as a human right to health entitlement is not 
                                                          
41 For example, the General Comment No.17 in Paragraph 35 enjoins State parties ‘to prevent unreasonably high costs for access to 
essential medicines.’ See UN Committee on Economic, Social and Cultural Rights (CESCR), General Comment No. 17: The Right of Everyone 
to Benefit from the Protection of the Moral and Material Interests Resulting from any Scientific, Literary or Artistic Production of Which He 
or She is the Author (Art. 15, Para. 1 (c) of the Covenant) (12 January 2006, E/C.12/GC/17, 2006).  
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impeded by other laws and regulations or actions of third parties such as patent 
holders’ rights. Since the quintessence of the right to health is access to the 
relevant medicines, health facilities, and conditions,42 it is a duty of the Nigerian 
state to fulfil and promote the right to health at all levels of state activities, 
including national health policies, and to ensure that provisions of trade 
agreements are not enforced in ways that restrict access to medicines. As noted 
by the CESCR, if the country ‘[…] adopts legislation or policies that are 
manifestly incompatible with pre-existing domestic or international legal 
obligation relating to the right to health,’ it is in violation of the duty to guarantee 
and protect the right to health.43 Many members of the WTO (including Nigeria) 
are State parties and have ratified the ICECSR.44 As Desierto argues, State 
Parties to both the TRIPS Agreement and human rights covenants and 
instruments have an obligation under the ICECSR to ensure their commitment 
under the WTO does not contradict the enjoyment of rights under the 
covenant.45  
While access to medical care and healthy working conditions is a non-justiciable 
constitutional duty on the state, it is imperative that the right to healthcare is 
recognised as an enforceable human rights claim in the Constitution of Nigeria. 
Perhaps it is not out of place to suggest that the Nigerian legislature should take 
a cue from South Africa and purposely provide for the right to healthcare and 
specifically mention affordable medicine as a justiciable right in the 
                                                          
42 Stephen P Marks, ‘The Emergence and Scope of the Right to Health’ in José M Zuniga, Stephen P Marks, and Lawrence O Gostin (eds), 
Advancing the Human Right to Health (OUP 2013) 9. 
43 UN Committee on Economic, Social and Cultural Rights (CESCR), General Comment No. 14: The Right to the Highest Attainable Standard 
of Health (Article 12 of the Covenant) (Adopted at the Twenty-second Session of the Committee on Economic, Social and Cultural Rights, on 
11 August 2000 E/C.12/2000/4) paragraph 48. 
44 Ping Xiong, An International Law Perspective on the Protection of Human Rights in the TRIPS Agreement: An Interpretation of the TRIPS 
Agreement in Relation to the Right to Health (Martinus Nijhoff Publishers 2012) 255. Nigeria signed and ratified the ICESCR on 29th October 
1993. 
45 Diane Desierto, Public Policy in International Economic Law: The ICESCR in Trade, Finance, and Investment (OUP Oxford 2015) 284. Note 
however that the provisions of ICECSR are not applicable to all relations between the WTO members that are not signatories to the human 
rights instruments. Diane Desierto ibid 205. 
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Constitution.46 Human rights scholars argue that a claim can only be justly called 
a right if it is recognised as such, or it is capable of attracting some form of legal 
sanction and remedy.47 Devoid of legal enforcement, the provisions on access 
to healthcare facilities including medicines in the 1999 Constitution would be 
mere moral aspirations, bereft of legal rights that can attract binding sanctions 
for violations.48 While the right to health in the African Charter can be relied 
upon to exert a duty on the state, it is still important that the right to access 
adequate healthcare including medicines in the Nigerian Constitution is secured 
as an enforceable human right. If this right is contained in the Constitution, it will 
supersede any other right contained in other laws, such as a patentee’s right 
under patent law, when it contradicts the constitutional provisions.49 Until then, it 
can only be hoped that the judiciary and government respect the rights to health 
under the African Charter and fulfil their duty to provide adequate medical and 
healthcare facilities as contained in Section 17(1)(c)(d) of the Constitution.50  
 
7.4.2 The Role of the Nigerian Judiciary in Promoting Access 
The judiciary in Nigeria can play an important strategic role in ensuring that the 
enforcement and judicial interpretation of patents provisions and claims do not 
conflict with rights to health and access to medicines. It is recommended that 
human rights and human development principles also influence the courts’ 
decision-making processes. Furthermore, the judiciary should play a central part 
                                                          
46 The Rights to healthcare are contained in three sections of the South African Constitutions, Act 108 of 1996, in Section 27 including the 
rights to reproductive health of women, and basic healthcare for children. Unlike the Nigerian constitution, these rights can be enforced in 
Court and the Constitution requires the state to ‘respect, protect, promote and fulfil these rights alongside those from international 
treaties.' See Hans V. Hogerzeil, Melanie Samson and Jaume Vidal Casanova, ‘Ruling for Access Leading Court Cases in Developing Countries 
on Access to Essential Medicines as part of the Fulfilment of the Right to Health’ (World Health Organization Department of Essential Drugs 
and Medicines Policy 2004) 30. 
47 Obiajulu Nnamuchi, ‘Kleptocracy and its Many Faces: The Challenges of Justiciability of the Right to Health Care in Nigeria' (2008) 52 
Journal of African Law 1, 5. 
48 ibid 
49 The Constitution is the grundnorm  in the Country. This means no other law, judicial decision or policy can override its specific provisions.  
50 This suggestion is made bearing in mind the rigid and rigorous process of Nigeria in amending the constitution.  
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in interpreting the flexibilities in the interests of public health and laying down 
precedents that promote human rights to health and access to medicines, as 
exemplified in the Indian case of F. Hoffmann-La Roche Ltd and Anr. v Cipla 
Ltd.51 It is also suggested that there is a need for regular training and capacity 
building to inform and educate judicial officers, as well as patent officials, and 
regulatory authorities on the relationship between patent rights and access to 
medicines, especially ways in which IP impacts on access to medicines and the 
necessary interventions available to mitigate this effect. 
Furthermore, other external factors and infrastructural development must be put 
in place to address and improve the availability and access to affordable and 
safe quality essential medicines. Some recommendations, although not the core 
focus of this thesis, are made in the following. 
7.4.3 Social Welfare Improvement, Other Policy and Infrastructural 
Reforms to Enhance Access to Medicines in Nigeria 
A thorough analysis of the legal and infrastructural environment of Nigeria 
reveals that the solution for access to medicines extends beyond the patent 
system. A workable welfare system that puts into place an effective framework 
for the distribution of medicines at affordable rates; a national insurance 
scheme; and a robust healthcare system to guarantee regular access to 
medicines are interventions that could contribute in bolstering access to 
medicine in Nigeria.  
Addressing social factors, traditional practices, and cultural barriers is equally 
relevant in effectively enhancing women’s health and rectifying the issue of 
                                                          
51 148 (2008) DLT 598, MIPR 2008 (2) 35. In delivering the judgment in the case, the Judge ruled with regards to the ‘right of the 
general public to access life-saving drugs which are available and for which such access would be denied if the injunction were 
granted.’ Judgment delivered by Ravindra Bhat, J. This case was discussed in Chapter IV, subsection 4.9.2.  
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women’s access to medicines in Nigeria. In Chapter III, it was identified that 
women face social, cultural and traditional discrimination.52 It is the responsibility 
of the government to ensure that women are protected from adverse socio-
cultural and traditional practices, violence and bias that endanger their health 
and general well-being. Nigeria should, therefore, seek to constitutionally 
guarantee, initiate policies on and reaffirm women’s basic human rights for 
freedom from all discriminatory practices that can impinge on their health. 
Furthermore, national laws and policies must be backed up by practical efforts 
to safeguard and promote women’s fundamental human rights, including the 
right to health.53 Progressively, the disadvantaged and vulnerable in society, 
such as women and children, should receive special attention with regards to 
their healthcare needs as part of improving and securing their welfare and 
wellbeing. 
Other infrastructural factors should be reviewed to facilitate the availability and 
accessibility to medicines such as: good transportation and distribution systems 
to ensure adequate distribution of medicines. Also, technical rules, export/ 
import duties, tariffs and taxes that could increase the price of medicines or 
undermine the practical exploitation of the flexibilities should be reviewed and 
amended accordingly.  
As briefly mentioned in chapter III, there is currently no price control mechanism 
or policy on pharmaceutical products in Nigeria.54 To make the prices of 
medicines and health products more affordable to women and Nigerians in 
                                                          
52 In subsections 3.4, and sub-subsections 3.4.1, 3.4.2 and 3.4.3 of Chapter III. 
53 As Mann argues, ‘preventing human rights abuses […] to the extent that it involves protecting the vulnerable, must be 
understood as a challenge to the political and societal status quo.’ Jonathan Mann, ‘Health and Human Rights: If Not Now, Then 
When?’ (1997) 2 Health &Humam Rights 113, 117 
54 Charles Wambebe and Nelson Ochekpe, ‘Pharmaceutical Sector Profile: Nigeria’ (United Nations Industrial Development 
Organization (UNIDO) 2011) 34. 
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general, the Nigerian policy-makers in addition to incorporating and 
implementing the flexibilities, need to set up a price control mechanism and 
regulatory authority to curb the high market prices of medicines and 
pharmaceuticals. There are many price control options that can be employed to 
regulate drug prices. Price control intervention can be in the form of regulating 
the price of individual drugs, placing a limit on total spending, promoting 
competition from generic manufacturers and cheap sources, among many other 
mechanisms.55 The price control policy or the designated regulatory authority 
can also fix ceiling prices of essential drugs or formulation packs of drugs to 
regulate the cost.56 The previously analysed compulsory licence as a flexibility 
can also play an important role in controlling the price of medicines.57 However, 
it must be stated here that the degree of price control should not be so strong as 
to distort incentives in the drug market or result in a lower supply of medicines.58  
It is noteworthy that the quest for access to medicines in Nigeria cannot be 
adequately addressed by over-dependence on foreign products. As mentioned 
in Chapter VI,59 other external factors such as a fully functional and capable 
domestic pharmaceutical base must be in place to facilitate the use of the 
flexibilities. It is advised that Nigeria continually strive to promote and develop a 
viable local pharmaceutical industry to cater for the national medicinal needs of 
                                                          
55 Jakkrit Kuanpoth, Patent Rights in Pharmaceuticals in Developing Countries: Major Challenges for the Future (Edward Elgar 
Publishing 2010)136. Under a functional social insurance scheme, the government can also regulate prices directly by negotiating 
with and purchasing the drugs from the manufacturers. 
56 In India for example, the government regulatory agency National Pharmaceutical Pricing Authority (NPPA) under the authority of 
India’s medicines price control legislation, the 2013 Drugs (Prices Control) Order, fixes price ceilings on essential medicines based 
on mark-up cost or input cost or market-based mechanisms. ibid 136. See more at http://www.nppaindia.nic.in/. 
More recently, the NPPA fixed the price ceiling of 530 essential drugs, leading to an estimated forty percent reduction in the cost 
of over 120 drugs. The Economic Times, '126 Drugs Cheaper by Over 40% as Govt Fixes Ceiling - The Economic Times' (The 
Economic Times, 2016)  
<http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/126-drugs-cheaper-by-over-40-as-govt-
fixes-ceiling/articleshow/51255840.cms> accessed 28 April 2016. 
57 See subsection 6.8 of Chapter VI. 
58 Kuanpoth (n 54) 137. 
59 See subsections 6.4.1.1 and 6.5 of Chapter VI. 
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its populace. With a rich biodiversity, medicinal and herbal plants,60 Nigeria’s 
pharmaceutical sector has the potential to grow to a size that could cater for the 
healthcare needs of the people.  
In light of the problems of research for neglected diseases as identified in 
Chapter III,61 alternative, collaborative and supplementary research mechanisms 
of incentivising the R&D of neglected diseases such as public-private 
partnerships (PPPs), Prize Funds, Advanced Market Commitments (AMC), 
medicines patent pools, patent buyout schemes and open source medicine 
initiatives, should be encouraged and explored in Nigeria.62 
These avenues provide the means for pooling resources, data, and expertise to 
promote pharmaceutical R&D, licensing and drug production, towards the public 
health objectives of providing the necessary treatments, especially for 
populations afflicted by poverty 
One of the issues that became clear during the study for this thesis and cannot 
be ignored, is that the general healthcare system in Nigeria needs to be 
reformed and improved to enhance access to essential medicines.  
Lastly, it is also important that the Nigerian Intellectual Property Commission 
(NIPCOM) Bill of 2007 with the suggested recommendations in this thesis be 
passed into law with immediate effect.  
                                                          
60 Nigeria is a country that is rich in biodiversity and endowed with a variety of medicinal plants such as neem (Azadirachta india), 
africa nutmeg (monodora myristica) bitter leaf (vernomia amygdaline) for treating diseases and infections, catharan thusreuses 
(rosy periwinkle) for leukaemia treatment and many other traditional medicinal and herbal plants. Emma-Okafor, and others, 
‘Biodiversity Conservation for Sustainable Agriculture in Tropical Rainforest of Nigeria’ (2009) 2(7) New York Science Journal 82. 
Studies indicate that a significant number of drugs are produced from plant extracts and natural products. See SMK Rates, 'Plants 
as Source of Drugs' (2001) 39 Toxicon 603. With the abundance of plants and herbs, and bio-genetic resources of Nigeria, the 
prospects for drug discovery research are great and should be further explored by drug manufacturers and promoted by the 
government. Bala Yauri Muhammad and Ahmed Awaisu, ‘The Need for Enhancement of Research, Development, and 
Commercialization of Natural Medicinal Products in Nigeria: Lessons from The Malaysian Experience’ (2008) 5(2) African Journal of 
Traditional, Complementary and Alternative medicines (AJTCAM) 120 - 130.  
61 See subsections 3.6.3 and 3.6.3.1 of Chapter III. 
62 This was mentioned in 3.6.3.1 of Chapter III. 
458 
 
458 
 
It is worth stressing that the quest for access to medicines requires a broad-
based national effort by government, the pharmaceuticals sector, research 
institutes and universities, private and public individuals and organisations, 
judicial authorities, regulatory control authorities and, significantly, a robust 
health care system. Most importantly, a good and stable democratic governance 
system, regulatory structure and political will-power to effectively and 
convincingly monitor the effect of patents on public health and utilise the 
flexibilities in this regard are paramount in the context of access to medicines.  
It goes without saying that the proposals in this thesis are illustrative of the many 
ways in which Nigeria can effectively address the problems of access to 
medicines for women and indeed, everyone in Nigeria.
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